<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6775655\results\search\tropicalVirus\results.xml">
   <result pre="urban mosquitoes in densely populated tropical regions. For dengue, chikungunya," exact="Zika" post="and yellow fever viruses, sylvatic (forest) transmission cycles also"/>
   <result pre="data on sylvatic cycles involving non-human primates and dengue, chikungunya," exact="Zika" post="and yellow fever viruses in Africa, dengue viruses in"/>
   <result pre="exist in sylvatic cycles. Keywords Sylvatic Primates Enzootic Arboviruses Mosquitoes" exact="Chikungunya" post="Dengue Zika Yellow fever Funding National Institute of Allergy"/>
   <result pre="in sylvatic cycles. Keywords Sylvatic Primates Enzootic Arboviruses Mosquitoes Chikungunya" exact="Dengue" post="Zika Yellow fever Funding National Institute of Allergy and"/>
   <result pre="sylvatic cycles. Keywords Sylvatic Primates Enzootic Arboviruses Mosquitoes Chikungunya Dengue" exact="Zika" post="Yellow fever Funding National Institute of Allergy and Infectious"/>
   <result pre="cycles. Keywords Sylvatic Primates Enzootic Arboviruses Mosquitoes Chikungunya Dengue Zika" exact="Yellow fever" post="Funding National Institute of Allergy and Infectious Diseases1R21AI128407-01KellyPatrick John"/>
   <result pre="the population. Some arboviruses, like dengue (DENV), chikungunya (CHIKV) and" exact="Zika" post="(ZIKV), have become fully adapted to urban cycles and"/>
   <result pre="for sampling sylvatic Aedes�?; however, humans must be vaccinated against" exact="YFV" post="and using malaria prophylaxis. Further, some would consider this"/>
   <result pre="With regard to sylvatic cycles in NHPs, the DENV, YFV," exact="ZIKV" post="and Spondweni (SPONV) are flaviviruses belonging to the family"/>
   <result pre="a particular problem with the multiple serotypes of DENV. Additionally," exact="DENV" post="and ZIKV (Flaviviridae) possess similar antigenic surface epitopes (Flavivirus"/>
   <result pre="problem with the multiple serotypes of DENV. Additionally, DENV and" exact="ZIKV" post="(Flaviviridae) possess similar antigenic surface epitopes (Flavivirus E protein)"/>
   <result pre="38]. Alphaviruses have similar problems where, for example, methods targeting" exact="CHIKV" post="antibodies to the E2EP3 protein (anti-E2EP3) cross-react with non-CHIKV"/>
   <result pre="or ONNV. Fortuitously, anti-E2EP3 can be used to differentiate between" exact="CHIKV" post="infections and Flavivirus infections with 93% accuracy [39]. It"/>
   <result pre="[32, 33]. Natural dengue virus infections in NHPs and mosquitoes" exact="Dengue" post="virus infections are responsible for more deaths and illness"/>
   <result pre="diathesis and circulatory failure (severe dengue or dengue haemorrhagic fever)." exact="Dengue" post="virus is a Flavivirus (Fig. 2) and exists in"/>
   <result pre="Flavivirus (Fig. 2) and exists in four ecologically distinct serotypes." exact="Dengue" post="virus infections in NHPs and sylvatic mosquitoes in Asia"/>
   <result pre="fever virus in the early 20th century, the possibility of" exact="DENV" post="occurring in a sylvatic cycle in Southeast Asia was"/>
   <result pre="found that NHPs from dengue-free areas could be infected with" exact="DENV" post="and mosquitoes that fed on them could subsequently transmit"/>
   <result pre="virus. In contrast, NHPs from dengue-endemic areas were resistant to" exact="DENV" post="challenge because they had already been exposed to the"/>
   <result pre="arboreal animals on the Malaysian peninsula were a reservoir for" exact="DENV" post="and that infections were maintained by mosquitoes that do"/>
   <result pre="did not test for reactivity with arboviruses closely related to" exact="DENV" post="and, although the specificity of the results were questioned,"/>
   <result pre="not excluded [51]. Conclusive proof of a sylvatic cycle of" exact="DENV" post="involving NHPs in the forests of Malaysia was provided"/>
   <result pre="positive for antibodies by HAI, their sera failed to neutralise" exact="DENV" post="indicating the presence of cross-reacting antibodies against, for example,"/>
   <result pre="against, for example, Japanese encephalitis virus (JEV). Attempts to isolate" exact="DENV" post="from mosquitoes, animal sera and tissues (liver, lung, spleen"/>
   <result pre="a single NHP in 1968, representing the first recovery of" exact="DENV" post="from a vertebrate other than man and later in"/>
   <result pre="isolation Experimental infections showed that NHPs could be infected with" exact="DENV" post="although these animals showed no overt clinical signs. An"/>
   <result pre="the forest canopy in the Malaysian peninsula with all four" exact="DENV" post="serotypes circulating between NHPs and mosquitoes (most likely those"/>
   <result pre="and mosquitoes (most likely those in the Ae. niveus group)." exact="Dengue" post="virus infections in NHPs in Southeast Asia Later serosurveys"/>
   <result pre="widespread in Southeast Asia. Later, IgG, IgM, neutralising antibody and" exact="DENV" post="RNA were demonstrated in cynomolgus macaques (Macaca fascicularis) in"/>
   <result pre="[42]. However, sequence analysis of the genes coding for the" exact="DENV" post="non-structural protein (NS1) and envelope (E) in isolates from"/>
   <result pre="macaques showed they were the same as the circulating human/urban" exact="DENV" post="strain. Infections were, then, most likely part of the"/>
   <result pre="2) [56]. Further analysis revealed a highly focal epizootic of" exact="DENV" post="had occurred in the population (Table 2) [57], which"/>
   <result pre="nearby Luzon Island in the Philippines were IgM positive to" exact="DENV" post="and all of them were IgG positive by ELISA"/>
   <result pre="2) [59] suggesting a subacute primary infection or a reinfection." exact="Dengue" post="virus infections in NHPs and sylvatic mosquitoes in Africa"/>
   <result pre="NHPs and sylvatic mosquitoes in Africa Early evidence of a" exact="DENV" post="sylvatic cycle in Africa can be found in a"/>
   <result pre="suggested that there might also be a sylvatic cycle of" exact="DENV" post="in Africa. In 1982, DENV-2 was isolated from a"/>
   <result pre="(Table 2) [61] indicated there had been an amplification of" exact="DENV" post="infections in local NHPs without a concurrent outbreak in"/>
   <result pre="these mosquitoes may be involved in a sylvatic cycle of" exact="DENV" post="[60]. Ultimately, Rodhain [60] concluded that the studies he"/>
   <result pre="DENV-2 existing in Senegal which involved AGMs in particular [29]." exact="Dengue" post="virus infections in NHPs in Africa The recent findings"/>
   <result pre="suggests the presence of sylvatic cycles is widespread in Africa." exact="Dengue" post="virus infections in NHPs in the Americas In the"/>
   <result pre="(Macaca mulatta) from Puerto Rico had serological evidence of prior" exact="DENV" post="infection (Table 2) [65]. As there was no evidence"/>
   <result pre="thereby raising the possibility of ‘spillback infection’ (Table 2) [67]." exact="Dengue" post="virus infections in sylvatic mosquitoes in the Americas There"/>
   <result pre="to exist in Asia and Africa (Malaysia and Senegal), where" exact="DENV" post="has been isolated from forest mosquitoes that feed on"/>
   <result pre="across Africa. There is no good evidence yet for sylvatic" exact="DENV" post="circulation in NHPs in the Americas. Natural chikungunya virus"/>
   <result pre="virus infection in NHPs and mosquitoes Prior to 2004, the" exact="CHIKV" post="was only known to produce localised outbreaks of disease"/>
   <result pre="Asia. Subsequently, there has been a near global spread of" exact="CHIKV" post="to La Réunion, India, Asia and Europe reaching the"/>
   <result pre="severe manifestations can include neurological disease, myocarditis and death. The" exact="CHIKV" post="is an Alphavirus (Fig. 2), which occurs as three"/>
   <result pre="Alphavirus (Fig. 2), which occurs as three different genotypes [47]." exact="Chikungunya" post="virus infections in NHPs and sylvatic mosquitoes in Africa"/>
   <result pre="Africa McIntosh et al. [22] investigated possible sylvatic cycles of" exact="CHIKV" post="in 1962 in Rhodesia (Zimbabwe) and discovered all the"/>
   <result pre="recent epizootic although none of the 42,000 mosquitoes tested contained" exact="CHIKV" post="and no sentinel NHPs seroconverted [69]. The study indicated"/>
   <result pre="no active infection and NHPs were not currently maintaining sylvatic" exact="CHIKV" post="although other arboviruses could be isolated from mosquitoes suggesting"/>
   <result pre="that time [69]. In the forest canopies of Uganda (including" exact="Zika" post="forest) in 1969, CHIKV was isolated from sylvatic mosquitoes"/>
   <result pre="the forest canopies of Uganda (including Zika forest) in 1969," exact="CHIKV" post="was isolated from sylvatic mosquitoes Aedes africanus (9/102 pools;"/>
   <result pre="of reports of laboratory confirmed natural infections of NHPs with" exact="CHIKV" post="in countries around the world Year Reference Country Primate"/>
   <result pre="neutralization; VI, viral isolation In Senegal, between 1972 and 1983," exact="CHIKV" post="was isolated from multiple species of NHP (Table 2)"/>
   <result pre="species of NHP (Table 2) [30]. Over the same period," exact="CHIKV" post="was detected in forest-dwelling mosquitoes using multiple tests. Between"/>
   <result pre="a known focus of sylvatic arbovirus circulation due to previous" exact="CHIKV" post="isolation in mosquitoes and NHPs) identified CHIKV by multiple"/>
   <result pre="due to previous CHIKV isolation in mosquitoes and NHPs) identified" exact="CHIKV" post="by multiple tests in 15/50 species of mosquitoes captured"/>
   <result pre="were involved in the maintenance of the sylvatic cycle of" exact="CHIKV" post="with Ae. furcifer most likely to contribute to any"/>
   <result pre="species and that species other than NHPs may be involved." exact="Chikungunya" post="virus infections in NHPs in Africa High seroprevalences have"/>
   <result pre="3) [10, 71]. Of note, immediately after an outbreak of" exact="CHIKV" post="in people in the region from 2010 to 2012"/>
   <result pre="indicate the presence of high herd immunity and that ongoing" exact="CHIKV" post="circulation in a sylvatic cycle would be unlikely. There"/>
   <result pre="not the only vertebrate hosts involved and alternate reservoirs of" exact="CHIKV" post="were possible [10]. In Africa, then, there is strong"/>
   <result pre="across the continent. There is widespread evidence of exposure to" exact="CHIKV" post="in a variety of NHPs across the continent in"/>
   <result pre="Gabon (Table 3) [26] and Kenya (Table 3) [25], and" exact="CHIKV" post="has been isolated from multiple species of NHPs [22,"/>
   <result pre="3) [72]. The brown lemurs (E. fulvus) were negative for" exact="CHIKV" post="by PCR and it was thought the seropositive animals"/>
   <result pre="as a result of the presence of a sylvatic cycle." exact="Chikungunya" post="virus infections in NHPs and sylvatic mosquitoes in Asia"/>
   <result pre="sylvatic mosquitoes in Asia There are sparse data on sylvatic" exact="CHIKV" post="in Asia. In rural Thailand in the 1960’s, CHIKV"/>
   <result pre="sylvatic CHIKV in Asia. In rural Thailand in the 1960’s," exact="CHIKV" post="was first isolated from a Culex tritaeniorhynchus and antibodies"/>
   <result pre="tritaeniorhynchus and antibodies were reported in NHPs (Table 3) [73]." exact="Chikungunya" post="virus infections in NHPs in Asia Further serological investigations"/>
   <result pre="included 642 NHPs, and only 16 (2.5%) had antibodies to" exact="CHIKV" post="(Table 3) [74]. The first isolation of CHIKV from"/>
   <result pre="antibodies to CHIKV (Table 3) [74]. The first isolation of" exact="CHIKV" post="from NHPs in Asia was in Malaysia, from wild"/>
   <result pre="nemestrina leonine) were found to be seropositive before and after" exact="CHIKV" post="activity in people in the region suggesting macaques could"/>
   <result pre="people in the region suggesting macaques could become infected by" exact="CHIKV" post="independently of people (Table 3) [55]. Finally, on the"/>
   <result pre="(Malaysia) wild and semi-captive orangutans (Pongo pygmaeus) were seronegative to" exact="CHIKV" post="[58] indicating that sylvatic CHIKV may not infect this"/>
   <result pre="(Pongo pygmaeus) were seronegative to CHIKV [58] indicating that sylvatic" exact="CHIKV" post="may not infect this species or the virus might"/>
   <result pre="virus might not have spread to islands in the region." exact="Chikungunya" post="virus infections in NHPs in the Americas The CHIKV"/>
   <result pre="region. Chikungunya virus infections in NHPs in the Americas The" exact="CHIKV" post="was introduced into the Americas in 2013 and 2014"/>
   <result pre="virus establishing a sylvatic cycle in New World NHPs, as" exact="YFV" post="had done previously. Investigations of sylvatic cycles have been"/>
   <result pre="and 2017 and found to have very low seropositivity to" exact="CHIKV" post="with very low antibody titres (Table 3) [77]. Two"/>
   <result pre="interpreting serology in the presence of cross-reactivity. None had detectable" exact="CHIKV" post="RNA by RT-PCR indicating an absence of active infection"/>
   <result pre="of active infection [77]. Summary In Africa (Uganda and Senegal)," exact="CHIKV" post="has been isolated from forest mosquitoes and NHPs and"/>
   <result pre="is unclear if NHPs are the only vertebrate host of" exact="CHIKV" post="or if there is a role for other vertebrates"/>
   <result pre="has not been demonstrated as there is no evidence of" exact="CHIKV" post="in forest-dwelling mosquitoes and CHIKV infections are not common"/>
   <result pre="there is no evidence of CHIKV in forest-dwelling mosquitoes and" exact="CHIKV" post="infections are not common or widespread in NHPs. Similarly,"/>
   <result pre="of susceptible mosquitoes, NHPs and people. [77–80]. Natural infections of" exact="Zika" post="virus in NHPs and mosquitoes The ZIKV is endemic"/>
   <result pre="Natural infections of Zika virus in NHPs and mosquitoes The" exact="ZIKV" post="is endemic in Africa and Asia [47] but caused"/>
   <result pre="defects in babies born to women infected while pregnant. The" exact="ZIKV" post="is a Flavivirus (Fig. 2) and there are three"/>
   <result pre="Flavivirus (Fig. 2) and there are three distinct genotypes [47]." exact="Zika" post="virus infections in NHPs and sylvatic mosquitoes in Africa"/>
   <result pre="virus infections in NHPs and sylvatic mosquitoes in Africa The" exact="ZIKV" post="was first identified in 1947 in the Zika (syn."/>
   <result pre="Africa The ZIKV was first identified in 1947 in the" exact="Zika" post="(syn. Ziika) forest of Uganda (Table 4) [21] when,"/>
   <result pre="of Uganda (Table 4) [21] when, as part of a" exact="YFV" post="surveillance project, the ZIKV was isolated from a sentinel"/>
   <result pre="[21] when, as part of a YFV surveillance project, the" exact="ZIKV" post="was isolated from a sentinel rhesus macaque (Macaca mulatta)"/>
   <result pre="a sentinel rhesus macaque (Macaca mulatta) and the local sylvatic" exact="YFV" post="vector, Ae. africanus. This provided evidence of a sylvatic"/>
   <result pre="species (Table 4) [81] and led to the isolation of" exact="ZIKV" post="from Ae. africanus (14/27 pools; 51.8%) and Aedes apicoargenteus"/>
   <result pre="100%) [81]. Due to the extensive arboviral investigations and periodic" exact="YFV" post="and CHIKV activity in the NHPs and mosquitoes, researchers"/>
   <result pre="Due to the extensive arboviral investigations and periodic YFV and" exact="CHIKV" post="activity in the NHPs and mosquitoes, researchers began to"/>
   <result pre="researchers began to suggest the possibility of cross-protection (immunisation) between" exact="YFV" post="and ZIKV (and possibly CHIKV) in NHPs. It was"/>
   <result pre="to suggest the possibility of cross-protection (immunisation) between YFV and" exact="ZIKV" post="(and possibly CHIKV) in NHPs. It was also suggested"/>
   <result pre="ability to transmit virus [81]. In 1968 in Senegal, the" exact="ZIKV" post="was first isolated from Ae. luteocephalus from the Saboya"/>
   <result pre="Ae. luteocephalus from the Saboya forest and in 1980 the" exact="ZIKV" post="was also isolated from NHPs (Table 4) [8, 9,"/>
   <result pre="of reports of laboratory confirmed natural infection of NHPs with" exact="ZIKV" post="in countries around the world Year Reference Country Primate"/>
   <result pre="PCR, polymerase chain reaction; SN, serum neutralization; VI, viral isolation" exact="Zika" post="virus infections in sylvatic mosquitoes in Africa Subsequent investigations"/>
   <result pre="in remote forest areas, away from human habitation, transmission of" exact="ZIKV" post="is primarily sylvatic involving NHPs, although the possibility of"/>
   <result pre="the possibility of vertical transmission could not be excluded [83]." exact="Zika" post="virus infections in NHPs in Africa As the recent"/>
   <result pre="Zika virus infections in NHPs in Africa As the recent" exact="ZIKV" post="pandemic developed, serological evidence of natural infections of ZIKV"/>
   <result pre="recent ZIKV pandemic developed, serological evidence of natural infections of" exact="ZIKV" post="were described in a wide variety of NHPs from"/>
   <result pre="Uganda, Nigeria, Gambia and Tanzania (Table 4) [45, 47, 84–86]." exact="Zika" post="virus infections in NHPs and sylvatic mosquitoes in Asia"/>
   <result pre="In Asia, there have been only limited studies of possible" exact="ZIKV" post="vectors [87, 88] despite the widespread but benign circulation"/>
   <result pre="vectors [87, 88] despite the widespread but benign circulation of" exact="ZIKV" post="in people for decades [89]. Marchette et al. [90]"/>
   <result pre="mangrove swamps and freshwater swamps, they only managed to isolate" exact="ZIKV" post="from urban Ae. aegypti. Interestingly, the authors state &quot;there"/>
   <result pre="occurs naturally in wild monkeys in Malaysia (our unpublished data)�?." exact="Zika" post="virus infections in NHPs in Asia The only published"/>
   <result pre="NHPs in Asia The only published data on NHPs revealed" exact="ZIKV" post="seropositive individuals in a small focus of captive and"/>
   <result pre="to represent ‘spillback’ from infected people (Table 4) [58, 91]." exact="Zika" post="virus infections in NHPs in the Americas In the"/>
   <result pre="in Brazil was suspected to be the reason for several" exact="ZIKV" post="RT-PCR-positive NHPs found in 2016 and 2017 during the"/>
   <result pre="93]. This finding rekindled speculation that a sylvatic cycle of" exact="ZIKV" post="could become established. More extensive studies around Brazil, however,"/>
   <result pre="established. More extensive studies around Brazil, however, failed to identify" exact="ZIKV" post="RNA by PCR and found only low seroprevalences and"/>
   <result pre="established sylvatic cycles (Table 4) [77]. Summary Sylvatic cycles of" exact="ZIKV" post="exist in Africa (Uganda and Senegal) with virus having"/>
   <result pre="are limited data for this region. Currently, sylvatic cycles of" exact="ZIKV" post="have not been conclusively demonstrated in the Americas; however,"/>
   <result pre="The history and role of NHPs in the epidemiology of" exact="YFV" post="around the world is well documented [3, 6, 60,"/>
   <result pre="60, 94] and the early investigations into the epidemiology of" exact="YFV" post="led to the development of the concepts of arboviral"/>
   <result pre="sylvatic cycles in NHPs that we have today [13, 94]." exact="Yellow fever" post="outbreaks continue in Africa and South America and can"/>
   <result pre="in Africa and South America and can be extensive. Most" exact="YFV" post="infections in people are subclinical but signs can range"/>
   <result pre="abdominal pain, jaundice, hepatitis, haemorrhagic diatheses and death [47]. The" exact="YFV" post="is the archetypal Flavivirus and exists in seven genotypes"/>
   <result pre="is the archetypal Flavivirus and exists in seven genotypes [6]." exact="Yellow fever" post="infection in NHPs and mosquitoes in Africa YFV originated"/>
   <result pre="[6]. Yellow fever infection in NHPs and mosquitoes in Africa" exact="YFV" post="originated in Africa in a sylvatic cycle involving a"/>
   <result pre="opok, Ae. vittatus and the Aedes simpsoni complex) [3, 82]." exact="Yellow fever" post="infection in NHPs and mosquitoes in the Americas The"/>
   <result pre="fever infection in NHPs and mosquitoes in the Americas The" exact="YFV" post="was introduced into people in the Americas during the"/>
   <result pre="(Ateles spp.) and owl monkeys (Aotus spp.). Transmission of the" exact="YFV" post="in the NHPs was established by infection of local"/>
   <result pre="dying from infections. Indeed, today nearly all human outbreaks of" exact="YFV" post="in South America and Africa result from ‘spillover’ infection"/>
   <result pre="South American NHPs are now a well-known warning sign of" exact="YFV" post="amplification and the heralding of a yellow fever outbreak"/>
   <result pre="a yellow fever outbreak in local people [3, 6, 82]." exact="Yellow fever" post="infection in NHPs and mosquitoes in Asia Yellow fever"/>
   <result pre="82]. Yellow fever infection in NHPs and mosquitoes in Asia" exact="Yellow fever" post="is notably absent from Asia despite there being large"/>
   <result pre="been found to be highly susceptible to experimental infections with" exact="YFV" post="[6]. Possible reasons for the absence of observed disease"/>
   <result pre="reviewed [3] and include the lack of opportunity for the" exact="YFV" post="to spread with the lack of major trade routes"/>
   <result pre="routes between West Africa and Asia and the fact that" exact="YFV" post="has not been documented in nearby East Africa. It"/>
   <result pre="dengue, which is a very common disease in Asia. Additionally," exact="DENV" post="antibodies in NHP hosts and people might provide cross-protection"/>
   <result pre="in NHP hosts and people might provide cross-protection against the" exact="YFV" post="and there might be direct viral competition between the"/>
   <result pre="Spondweni virus Spondweni virus (SPONV) (Flavivirus) is closely related to" exact="ZIKV" post="and is the agent of Spondweni fever in people"/>
   <result pre="fever in people in Africa, which is readily confused with" exact="Zika" post="[103]. It has been isolated from several species of"/>
   <result pre="and which might occur in sylvatic cycles with NHPs. Abbreviations" exact="CHIKV" post="chikungunya virus CFT complement fixation test DENV dengue virus"/>
   <result pre="with NHPs. Abbreviations CHIKV chikungunya virus CFT complement fixation test" exact="DENV" post="dengue virus ELISA enzyme-linked immunosorbent assay HAI haemagglutination inhibition"/>
   <result pre="reaction SN serum neutralization SPOV Spondweni virus VI viral isolation" exact="ZIKV" post="Zika virus Publisher's Note Springer Nature remains neutral with"/>
   <result pre="SN serum neutralization SPOV Spondweni virus VI viral isolation ZIKV" exact="Zika" post="virus Publisher's Note Springer Nature remains neutral with regard"/>
   <result pre="circulation dynamics in SenegalAm J Trop Med Hyg.201592889710.4269/ajtmh.13-061725404071 9.AlthouseBMVasilakisNSallAADialloMWeaverSCHanleyKAPotential for" exact="Zika" post="virus to establish a sylvatic transmission cycle in the"/>
   <result pre="Trop Med Hyg.2010831249125810.4269/ajtmh.2010.10-029021118930 19.DudleyDMAliotaMTMohrELWeilerAMLehrer-BreyGWeisgrauKLet al.A rhesus macaque model of Asian-lineage" exact="Zika" post="virus infectionNat Commun.201671220410.1038/ncomms1220427352279 20.CornetMSaluzzoJFHervyJPDigoutteJPGermainMChauvancyMFet al.Dengue 2 au Sénégal oriental:"/>
   <result pre="of dengue virus infectionJ Infect Dis.2017215Suppl. 2899510.1093/infdis/jiw649 38.PriyamvadaLHudsonWAhmedRWrammertJHumoral cross-reactivity between" exact="Zika" post="and dengue viruses: implications for protection and pathologyEmerg Microbes"/>
   <result pre="J Trop Med Hyg.2016941095109910.4269/ajtmh.15-026227001754 66.MoralesMAFabbriCMZuninoGEKowalewskiMMLuppoVCEnríaDAet al.Detection of the mosquito-borne flaviviruses," exact="West Nile," post="dengue, Saint Louis encephalitis, Ilheus, Bussuquara, and yellow fever"/>
   <result pre="and rats in three Indian Ocean islands after the 2006" exact="CHIKV" post="outbreakVet Res.2014455210.1186/1297-9716-45-5224885529 73.HalsteadSBUdomsakdiSVertebrate hosts of chikungunya virusBull World Health"/>
   <result pre="evidence for infection of urban and peri-urban nonhuman primates with" exact="Zika" post="and chikungunya viruses in BrazilmSphere20183e00523-1710.1128/mSphere.00523-1729404420 78.HiggsSVanlandinghamDChikungunya virus and its"/>
   <result pre="transmission and chikungunya virus emergenceCurr Opin Virol.20161614315010.1016/j.coviro.2016.02.00726986235 81.McCraeAWKiryaBGYellow fever and" exact="Zika" post="virus epizootics and enzootics in UgandaTrans R Soc Trop"/>
   <result pre="in mosquitoes in southeastern Senegal, 2011PLoS ONE20149e10944210.1371/journal.pone.010944225310102 84.BuechlerCRBaileyALWeilerAMBarryGLBreitbachMEStewartLMet al.Seroprevalence of" exact="Zika" post="virus in wild African green monkeys and baboonsmSphere20172e00392-1610.1128/mSphere.00392-1628289727 85.BuenoMGMartinezNAbdallaLDuarte"/>
   <result pre="African green monkeys and baboonsmSphere20172e00392-1610.1128/mSphere.00392-1628289727 85.BuenoMGMartinezNAbdallaLDuarte Dos SantosCNChameMAnimals in the" exact="Zika" post="virus life cycle: what to expect from megadiverse Latin"/>
   <result pre="what we should investigate urgentlyInt J Infect Dis.201648859010.1016/j.ijid.2016.05.01427208633 87.MishraBBeheraBThe mysterious" exact="Zika" post="virus: adding to the tropical flavivirus mayhemJ Postgrad Med.20166224925410.4103/0022-3859.19100627763483"/>
   <result pre="Trop Dis.201711e000593310.1371/journal.pntd.000593329145400 89.PetterssonJHBohlinJDupont-RouzeyrolMBrynildsrudOBAlfsnesKCao-LormeauVMet al.Re-visiting the evolution, dispersal and epidemiology of" exact="Zika" post="virus in AsiaEmerg Microbes Infect.201877910.1038/s41426-018-0082-529739925 90.MarchetteNJGarciaRRudnickAIsolation of Zika virus"/>
   <result pre="epidemiology of Zika virus in AsiaEmerg Microbes Infect.201877910.1038/s41426-018-0082-529739925 90.MarchetteNJGarciaRRudnickAIsolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm J Trop"/>
   <result pre="pygmaeus) in Sabah, MalaysiaJ Wildl Dis.200339738310.7589/0090-3558-39.1.7312685070 92.FavorettoSAraujoDOliveiraDDuarteNMesquitaFZanottoPet al.First detection of" exact="Zika" post="virus in neotropical primates in Brazil: a possible new"/>
   <result pre="Brazil: a possible new reservoirbioRxiv.201610.1101/049395 93.TerzianACBZiniNSacchettoLRochaRFParraMCPDel SartoJLet al.Evidence of natural" exact="Zika" post="virus infection in neotropical non-human primates in BrazilSci Rep.201881603410.1038/s41598-018-34423-630375482"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6778435\results\search\tropicalVirus\results.xml">
   <result pre="coronavirus (Li et al., 2005), poliovirus (Hwang et al., 2008)," exact="West Nile" post="Virus, dengue and yellow fever viruses (Zou et al.,"/>
   <result pre="Spectrometry Reviews25345048210.1002/mas.2007116429408 Zou et al. (2009)ZouGPuig-BasagoitiFZhangBQingMChenLPankiewiczKWFelczakKYuanZShiPY2009A single-amino acid substitution in" exact="West Nile" post="virus 2K peptide between NS4A and NS4B confers resistance"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6779206\results\search\tropicalVirus\results.xml">
   <result pre="virus from patients and sequenced its genome. The sequences of" exact="DENV" post="isolated from Guangdong and other countries screened since 2005"/>
   <result pre="number of indigenous cases significantly exceeded that of imported cases." exact="Dengue" post="virus 1 is the most important serotype and caused"/>
   <result pre="evolution since 2005 among the four lineages was present. The" exact="DENV" post="isolated from Guangdong was closely related to those causing"/>
   <result pre="of sufficient epidemiological data and evidence on the local mosquito-borne" exact="DENV" post="emphasizes the importance of studying the molecular evolutionary features"/>
   <result pre="tree for dengue prevention and control in Guangdong. page-count: INTRODUCTION" exact="Dengue" post="virus (DENV), a mosquito-borne flavivirus, is transmitted primarily by"/>
   <result pre="with the highest morbidity and great harm.5 The genome of" exact="DENV" post="is a single-stranded, positive-sense RNA, and its single open"/>
   <result pre="and NS5, are also present in its structure.9 Four distinct" exact="DENV" post="serotypes (DENV1, DENV2, DENV3, and DENV4) have been identified,"/>
   <result pre="III (Malaysia), genotype IV (South Pacific), and genotype V (America/Africa).10" exact="Dengue" post="genotypes are phylogenetically distinct clusters of viruses, often associated"/>
   <result pre="biological sequences.13 Alignment of the nucleic acid sequences of the" exact="DENV" post="followed by its phylogenetic analysis and subsequent generation of"/>
   <result pre="epidemiology of the disease worldwide.14–16 The E protein of the" exact="DENV" post="is responsible for its tropism and virulence.17 The gene"/>
   <result pre="analysis of the coding region can help assign the correct" exact="DENV" post="genotype and infer the relationships within genotypes and lineages"/>
   <result pre="of dengue have occurred in the past 30 years.22 The" exact="DENV" post="found in these areas may have different origins. There"/>
   <result pre="over the previous 10 years. Although three serotypes of the" exact="DENV" post="(DENV1, DENV2, and DENV3) were identified, DENV1 was found"/>
   <result pre="laboratory diagnosis and clinical signs. Sample collection and epidemiological data." exact="Dengue" post="virus RNA samples (n = 29) were obtained from"/>
   <result pre="by the Health Care Center of Guangdong International Travel. Twenty-five" exact="DENV" post="strains were isolated by the Guangdong CDC on C6/36"/>
   <result pre="each city), the distribution of imported cases and indigenous cases," exact="DENV" post="serotype data confirmed by laboratory, and other information. We"/>
   <result pre="(TaKaRa Bio, Shiga, Japan) was used for the transcription of" exact="DENV" post="RNA. Type-specific primers (Table 1) were used to confirm"/>
   <result pre="with up to four serotypes emerging in recent years. Each" exact="DENV" post="serotype was identified. Dengue virus 1 was the major"/>
   <result pre="serotypes emerging in recent years. Each DENV serotype was identified." exact="Dengue" post="virus 1 was the major cause of the outbreak"/>
   <result pre="and Shanwei were included in the collection areas (Figure 1E)." exact="Dengue" post="virus 1 was the major causative agent of this"/>
   <result pre="between Lineages II and III. Interestingly, concerning the recent severe" exact="DENV" post="epidemic, since 2006 or 2007 (the previous circulation), Lineages"/>
   <result pre="to clarify the relationship between Guangdong and other countries concerning" exact="DENV" post="outbreaks. For this, we illustrated the origin of molecular"/>
   <result pre="DENV1 in Guangdong was determined from its long-term epidemic history." exact="Dengue" post="virus 1 was first detected in Zhongshan, Guangdong Province."/>
   <result pre="the leading serotype, which triggered massive outbreaks in Guangzhou.33 Thereafter," exact="DENV" post="was circulated continuously across multiple geographies in Guangdong, and"/>
   <result pre="present, imported and local cases are equally responsible for the" exact="DENV" post="outbreaks, which have occurred with a complex pattern wherein"/>
   <result pre="only city in Guangdong Province in which no cases of" exact="DENV" post="were detected since 2005, indicating the criticality of the"/>
   <result pre="since 2005, indicating the criticality of the occurrence of the" exact="DENV" post="epidemic in this region.36,37 Analyses of the epidemiological trends"/>
   <result pre="Analyses of the epidemiological trends suggest that the severity of" exact="DENV" post="outbreaks has increased since 2012. The rising number of"/>
   <result pre="outbreak in 2014, which marked the top of the periodical" exact="DENV" post="infections and transmission. With an increase in the number"/>
   <result pre="dominant in recent years.38–40 Previous studies indicated that although three" exact="DENV" post="serotypes (DENV1, DENV2, and DENV3) were identified, DENV1 was"/>
   <result pre="However, several lineages from different origins were responsible for the" exact="DENV" post="outbreak in 2014. Moreover, strains belonging to genotype V"/>
   <result pre="et al. used the term &quot;in situ evolution�? to characterize" exact="DENV" post="in Singapore through phylogenetic analysis. Results of the analysis"/>
   <result pre="the correlation between its genetic and evolutionary aspects, suggesting that" exact="DENV" post="had lurked locally and reappeared after some time.46 Rajarethinam"/>
   <result pre="Guangdong since 2005. Another possible transmission and evolution pattern of" exact="DENV" post="broke out in parts (switch of the lineage), followed"/>
   <result pre="2007 to 2012, it was observed that the prevalence of" exact="DENV" post="was low and it frequently interchanged between the three"/>
   <result pre="Guangdong. Castonguay-Vanier et al.57 also described the active circulation of" exact="DENV" post="in Laos and the concurrent multiple introductions of new"/>
   <result pre="evidence on the local mosquito vector regarding its harboring of" exact="DENV" post="during epidemic and nonepidemic periods which can support the"/>
   <result pre="et al.64 regarding the epidemiological characteristics and genetic diversity of" exact="DENV" post="in Guangdong in 2014. Nevertheless, since 2012, with an"/>
   <result pre="Nevertheless, since 2012, with an extremely high incidence of cases," exact="DENV" post="spread more rapidly and affected a wider range of"/>
   <result pre="pH, the specific interaction between DI and DIII of the" exact="DENV" post="E protein is destroyed, resulting in its conformational change"/>
   <result pre="III has an immunoglobulin-like structure and a functional region where" exact="DENV" post="binds to a cellular receptor. Drumond et al.70 predicted"/>
   <result pre="certainty. However, it is highly recommended that we detect the" exact="DENV" post="in local mosquito vectors urgently. At the same time,"/>
   <result pre="Center for Disease Control and Prevention for providing with 25" exact="DENV" post="strains and their epidemiological data. This study was partly"/>
   <result pre="2007Epidemic situation of dengue fever in Guangdong province, China, 1990–2005." exact="Dengue" post="Bull31: 1–9. 23.WuWet al.2011Molecular epidemiology of dengue viruses in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6780377\results\search\tropicalVirus\results.xml">
   <result pre="Contemporary Strategies and Current Trends in Designing Antiviral Drugs against" exact="Dengue" post="Fever via Targeting Host-Based Approaches https://orcid.org/0000-0001-7313-4729AhammadFoysal1Tengku Abd RashidTengku Rogayah2https://orcid.org/0000-0001-7783-8950MohamedMaizan3TanbinSuriyea1Ahmad"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Dengue" post="virus (DENV) is an arboviral human pathogen transmitted through"/>
   <result pre="that can prevent or treat infections resulting from this pathogen." exact="DENV" post="utilizes numerous host molecules and factors for transcribing the"/>
   <result pre="utilized by the pathogens, targeting these factors may result in" exact="DENV" post="inhibitors, and will play an important role in attenuating"/>
   <result pre="the progress made in the development of host-based approaches for" exact="DENV" post="viral infections, focusing on host cellular mechanisms and factors"/>
   <result pre="host-dependent antiviral therapeutics. dengue virus (DENV) antiviral drugs drug targets" exact="DENV" post="host factors host metabolism DENV inhibitors arthropod-borne viruses 1."/>
   <result pre="(DENV) antiviral drugs drug targets DENV host factors host metabolism" exact="DENV" post="inhibitors arthropod-borne viruses 1. Introduction Dengue is an important"/>
   <result pre="host factors host metabolism DENV inhibitors arthropod-borne viruses 1. Introduction" exact="Dengue" post="is an important arthropod-borne viral infectious disease caused by"/>
   <result pre="viral serotypes. The antigenically distinct but closely related serotypes of" exact="DENV" post="belong to the genus Flavivirus, family Flaviviridae. Its rapid"/>
   <result pre="more than 70 small-enveloped viruses related to Japanese encephalitis (JEV)," exact="Zika" post="viruses (ZIKV), West Nile (WNV), yellow fever virus (YFV),"/>
   <result pre="small-enveloped viruses related to Japanese encephalitis (JEV), Zika viruses (ZIKV)," exact="West Nile" post="(WNV), yellow fever virus (YFV), DENV, or tick-borne encephalitis"/>
   <result pre="tick-borne encephalitis (TBEV), and other medically-important arboviruses [3]. Most importantly," exact="DENV" post="is endemic in 112 countries, and incidence of infection"/>
   <result pre="is estimated that ~400 million individuals suffer annually because of" exact="DENV" post="infection [5]. DENV infection results in varying degrees of"/>
   <result pre="~400 million individuals suffer annually because of DENV infection [5]." exact="DENV" post="infection results in varying degrees of clinical signs and"/>
   <result pre="(DSS) [6]. However, specific therapeutics are presently not available for" exact="DENV" post="infections [7], necessitating an improved approach for re-mediating this"/>
   <result pre="we will explore the host factors or targets that influence" exact="DENV" post="replication, focusing on the factors that can potentially be"/>
   <result pre="believed that it was not only dengue, but that the" exact="Chikungunya" post="virus was also responsible for the epidemics [10,11]. The"/>
   <result pre="(1919) and Siler et al. (1926) subsequently confirmed that the" exact="DENV" post="transmission process was akin to the &quot;jungle cycle�? of"/>
   <result pre="(Japan) and Dr. S. Hotta (Hawaii) isolated and identified the" exact="DENV" post="strains DENV-1 and DENV-2 [19]. In 1953, the DENV-3"/>
   <result pre="Philippines and Thailand [20]. 1.2. Vector and Non-Vector Transmission of" exact="Dengue" post="In most cases, DENV transmission is accomplished by the"/>
   <result pre="1.2. Vector and Non-Vector Transmission of Dengue In most cases," exact="DENV" post="transmission is accomplished by the primary vectors, whereby A."/>
   <result pre="[6]. Other species that act as secondary vectors for carrying" exact="DENV" post="include Aedes scutellaris, Aedes africanus (subgenus Stegomyia) and Aedes"/>
   <result pre="dengue vectors for carrying dengue infectious virus [22,23]. The non-mosquito" exact="DENV" post="transmission route is infrequent and accidental, but it has"/>
   <result pre="congenitally, through mucocutaneous exposure, and through bone marrow transplants [24]." exact="DENV" post="infection of healthcare workers usually occurs as a result"/>
   <result pre="locations in tropical Africa and Asia, probable rates of sylvatic" exact="DENV" post="transmission to humans are unknown, but appeared to be"/>
   <result pre="of new-world non-human primates were found to be resistant to" exact="DENV" post="infection, and no cases of sylvatic DENV transmission were"/>
   <result pre="be resistant to DENV infection, and no cases of sylvatic" exact="DENV" post="transmission were recorded. Similarly, no evidence of enzootic circulation"/>
   <result pre="of Bolivia, where A. aegypti is absent, recommend that sylvatic" exact="DENV" post="transmission may happen in the region [44]. Cross-species transmission"/>
   <result pre="transmission may happen in the region [44]. Cross-species transmission of" exact="DENV" post="in rural areas of Africa and Asia from non-human"/>
   <result pre="[47,48]. DENV-infected small A. aegypti bite humans and thus initiate" exact="DENV" post="transmission. These mosquitos lay eggs and rest indoors in"/>
   <result pre="feed on several persons, thus rapidly accelerating the transmission of" exact="DENV" post="[49]. After transmission into the human host and following"/>
   <result pre="2. Targeting Host as an Antiviral Approach The significance of" exact="DENV" post="and its mechanism of interaction with host factors must"/>
   <result pre="host factors must be fully understood for proper morphogenesis of" exact="DENV" post="for targeting host processes as an antiviral therapy. The"/>
   <result pre="protein kinase IIb (CAM K2B) [55,56]. On the other hand," exact="West Nile" post="virus (WNV) replication is associated with intracellular membrane rearrangements,"/>
   <result pre="pathways, as well as membrane re-modelling of the host [57,58]." exact="DENV" post="is not exceptional from the other viruses—it also depends"/>
   <result pre="machinery to complete its life cycle. In order to understand" exact="DENV" post="host dependent factors, a genome-wide screen to explain DENV"/>
   <result pre="understand DENV host dependent factors, a genome-wide screen to explain" exact="DENV" post="host dependency for their life cycle in Drosophila melanogaster"/>
   <result pre="has been published [59]. Later, different conservative genome-wide screens of" exact="DENV" post="identified different host-dependent factors responsible for their replication, where"/>
   <result pre="factors, and anti-inflammatory pathways are most commonly found to influence" exact="DENV" post="replication and infection. Different host and viral factors play"/>
   <result pre="an immunopathogenic response. From the hypothesis, we can understand that" exact="DENV" post="serotypes are propagated in endemic areas, and pre-existing immunity"/>
   <result pre="severe dengue cases in the frame of all the four" exact="DENV" post="serotypes. Prior to evaluation, sometimes targeting the factors is"/>
   <result pre="Targeting intracellular metabolic pathways and their pharmacological inhibition can reduce" exact="DENV" post="RNA synthesis and infectious virion production [60], which may"/>
   <result pre="and infectious virion production [60], which may serve as successful" exact="DENV" post="antiviral strategies. For example, lipid and glucose metabolic pathways"/>
   <result pre="cycle of DENV. Both steps in the replication cycles of" exact="DENV" post="can be inhibited by different pharmacological agents, and the"/>
   <result pre="mechanisms by which specific glucose and lipids are generated during" exact="DENV" post="infection, as well as its trafficking to the relevant"/>
   <result pre="blocks, and other important molecules required for viral replication. In" exact="DENV" post="infection, a major change occurs in the central carbon"/>
   <result pre="is up-regulated and glucose consumption is increased in DENV-infected cells." exact="DENV" post="activates the glycolytic pathway for viral metabolic requirements and"/>
   <result pre="case cancer cells and human cytomegalovirus (HCMV) cells [3,4,5,6]. As" exact="DENV" post="activates the host glycolytic pathway for generating their necessary"/>
   <result pre="necessary building blocks, pharmacologic regulation of glycolysis significantly blocks infectious" exact="DENV" post="production. Krystal and colleagues reported that glycolysis inhibition through"/>
   <result pre="d-glucose (2DG) treatment can result in a significant reduction in" exact="DENV" post="replication [5]. 3.2. Targeting the Host Lipid Biosynthesis Pathway"/>
   <result pre="Targeting the Host Lipid Biosynthesis Pathway As an enveloped virus," exact="DENV" post="stimulates the lipid biosynthesis pathway for essential membrane formation."/>
   <result pre="A (AcCoA) for generating most distinct membrane lipids (Figure 2)." exact="DENV" post="stimulates fatty acid biosynthesis by the help of the"/>
   <result pre="autophagy that transports lipids for β-oxidation. Several studies indicate that" exact="DENV" post="infection induces pro-viral autophagy [62,63,64,65,66]. The lipids accumulated in"/>
   <result pre="energy and plays a key role in lipophagy, thus assisting" exact="DENV" post="replication. Additionally, NADPH that arises through β-oxidation utilizes a"/>
   <result pre="FASN and it may stimulate the fatty acid synthesis for" exact="DENV" post="replication. In DENV-infected cells, both fatty acid synthesis and"/>
   <result pre="decarboxylase, an enzyme required for cholesterol biosynthesis [60], can decrease" exact="DENV" post="production in host cells. 3.3. Targeting the Host Nucleoside"/>
   <result pre="DHODH inhibitor), an anti-metabolite in cancer and immune-suppression, can inhibit" exact="DENV" post="type 1,2,3 (DENV-1,2,3) serotypes. However, it cannot inhibit DENV"/>
   <result pre="inhibit DENV type 1,2,3 (DENV-1,2,3) serotypes. However, it cannot inhibit" exact="DENV" post="type 2 (DENV-2) variants because of resistance against brequinar,"/>
   <result pre="vitro study of the compound shows a great potency against" exact="DENV" post="serotypes, but the compound did not show any efficacy"/>
   <result pre="Targeting the enzymes that play a key role in supplying" exact="DENV" post="nucleoside can therefore be effective for antiviral therapeutics. 4."/>
   <result pre="at the cellular level play a key role in the" exact="DENV" post="virus entry process, but attachment factors and receptors are"/>
   <result pre="reported as potential treatment candidates. Targeting host factors involved in" exact="DENV" post="attachment can thus have a beneficial antiviral potential. 4.1."/>
   <result pre="the family of glycosaminoglycans (GAGs). It initiates interactions between the" exact="DENV" post="envelope protein and the host cell (Figure 3). HS"/>
   <result pre="heads exhibits a strong inhibitory effect on infections caused by" exact="DENV" post="[74]. Chondroitin sulfate, a curdlan sulfate that inhibits all"/>
   <result pre="DENV [74]. Chondroitin sulfate, a curdlan sulfate that inhibits all" exact="DENV" post="serotypes, has been found in baby hamster kidney 21"/>
   <result pre="infectivity (Figure 3) [73,89]. Although the role of DC-SIGN in" exact="DENV" post="entry remains controversial [90,91,92], many authors posit that DENV"/>
   <result pre="in DENV entry remains controversial [90,91,92], many authors posit that" exact="DENV" post="is handed over to another unidentified co-receptor for movement"/>
   <result pre="Findings yielded by a large number of studies indicate that" exact="DENV" post="can recognize cell surface DC-SIGN, as well as move"/>
   <result pre="viral attachment, resulting in entry into the cell [89,93]. As" exact="DENV" post="can pass to clathrin-coated structures (CCS) through virus receptor"/>
   <result pre="complexes [22], receptors that mediate DC-SIGN are potential targets for" exact="DENV" post="antiviral treatment. Several compounds, such as glycomimetic DC-SIGN ligand"/>
   <result pre="(Table 1), were found to act as strong inhibitors of" exact="DENV" post="infection in DC-transfected cells. These findings can potentially be"/>
   <result pre="efficiency of a wide spectrum of antiviral therapies to block" exact="DENV" post="virus uptake. 4.3. Other Possible Receptors Viral attachment to"/>
   <result pre="of higher affinity receptors may then be recruited to permit" exact="DENV" post="entry because of the diverse tissue tropism of the"/>
   <result pre="because of the diverse tissue tropism of the virus [94]." exact="DENV" post="uses two pathways to enter DCs, whereby infection can"/>
   <result pre="of antibodies grant an alternative entry pathway of DENV, where" exact="DENV" post="enters monocytes, macrophages, and dendritic cells through the activating"/>
   <result pre="monocytes, macrophages, and dendritic cells through the activating FcɣRs [95]." exact="DENV" post="can enter cells via cellular attachment molecules’ TIM and"/>
   <result pre="responsible for the engulfment and removal of apoptotic cells. Since" exact="DENV" post="is a virus that exposes PtdSer in its membrane,"/>
   <result pre="and GRP-78 are known as a receptor complex, which allows" exact="DENV" post="entry into human cells from hepatic, neural, and monocytic"/>
   <result pre="class B type I (SCARB1), also known as SR-BI, promotes" exact="DENV" post="infections, necessitating further research in order to elucidate the"/>
   <result pre="into the host, as well as for replication and assembly." exact="DENV" post="dominates some processes to manipulate the host cell proteins"/>
   <result pre="as furin and signalase, have been used to cleave the" exact="DENV" post="RNA genome co- and post-translationally and were translated as"/>
   <result pre="protease required for virus polyprotein formation is a basis of" exact="DENV" post="replication, it can be a strong target for antiviral"/>
   <result pre="of the host cell, where it assists in cleaving the" exact="DENV" post="prM proteins, resulting in the formation of mature active"/>
   <result pre="the virion M protein that plays an important role during" exact="DENV" post="infections [99,103]. The signal peptidase on endoplasmic reticulum (ER)"/>
   <result pre="target. 5.2. Targeting Host Kinases Host kinases are involved in" exact="DENV" post="assembly and secretion. Protein kinase inhibits the dengue replication"/>
   <result pre="MAP kinase-activated protein kinase 5 (MAPKAPK5) kinase activity and inhibit" exact="DENV" post="propagation [108]. GNF-2 and imatinib inhibit DENV but are"/>
   <result pre="activity and inhibit DENV propagation [108]. GNF-2 and imatinib inhibit" exact="DENV" post="but are mediated by cellular Abl kinases [109]. Many"/>
   <result pre="AR-12 inhibits PI3K/JAKT pathway by expressing GRP-78 for all four" exact="DENV" post="serotypes. Sunitinib and erlotinib, as well as isothiazolo[5,4-b] pyridines"/>
   <result pre="pyridazine, are inhibitors of AAK1 and GAK pathways that inhibit" exact="DENV" post="replication, whereas U0126 inhibits the ERK pathway to reduce"/>
   <result pre="N-linked oligosaccharides of the viral prM and E glycoproteins [110]." exact="DENV" post="structural protein prM and E glycoproteins are translocated into"/>
   <result pre="reticulum chaperones (calnexin or calreticulin) for proper folding [113]. As" exact="DENV" post="prME heterodimer formation is not influenced by the inhibition"/>
   <result pre="been shown that the folding, stability, secretion, and activity of" exact="DENV" post="glycoproteins in the ER depends on the trimming of"/>
   <result pre="celgosivir have shown to causing an improved survival rate in" exact="DENV" post="infected mouse. The efficacy analyses were performed in patients"/>
   <result pre="to decrease mortality in an &quot;antibody-dependent enhancement�? model of secondary" exact="DENV" post="infection [117]. It is also noteworthy that α-glucosidase substrate"/>
   <result pre="cell signals are generated to block the dissemination of DENV." exact="DENV" post="causes acute disease without persistent infection. All virus strains"/>
   <result pre="strategies that bypass the innate and adaptive immune response. Therefore," exact="DENV" post="does not escape the host defense mechanism. Innate immunity"/>
   <result pre="Hence, a better understanding of the host immune response during" exact="DENV" post="infection and the evasion mechanisms would have great importance"/>
   <result pre="potential antiviral production. 6.1. Targeting Host Immune Factors Involved in" exact="DENV" post="Sensing Viral pathogenic factors can be recognized through the"/>
   <result pre="lectin domain family 5 member A (CLEC5A) does not block" exact="DENV" post="infection [122]. Other important molecules such as toll-like receptors"/>
   <result pre="as toll-like receptors (TLR3) also sense dsRNA and can restrict" exact="DENV" post="replication in different cell lineages [123,124,125]. DENV produces excess"/>
   <result pre="and can restrict DENV replication in different cell lineages [123,124,125]." exact="DENV" post="produces excess IFN-I (essential for DENV-induced production) through toll-like"/>
   <result pre="toll-like receptors 7 (TLR7) in plasmacytoid-DC, which can also restrict" exact="DENV" post="replication in different cell lineages, as TLR3 [126]. Additionally,"/>
   <result pre="TLR3 [126]. Additionally, increasing inflammatory and humoral responses that decrease" exact="DENV" post="replication have been found, such as when TLR3 and"/>
   <result pre="into rhesus macaques aided in enhanced antiviral mechanisms during primary" exact="DENV" post="infection [127]. Gene expression analysis indicates that RIG-I and"/>
   <result pre="beta (IFN-β) promoters, resulting in impaired replication of DENV. Additionally," exact="DENV" post="with double or single RIG-I/MDA5-deficient fibroblasts triggers both responses"/>
   <result pre="detection of antibodies via RNA sensors (for examples RIG-I) enhanced" exact="DENV" post="infection by tissue-resident mast cells that produce type IFN-I,"/>
   <result pre="MDA5, and TLR3 sensors (major PRRs recognize innate responses to" exact="DENV" post="infection), contributing to impairing DENV replication in vitro [130]."/>
   <result pre="PRRs recognize innate responses to DENV infection), contributing to impairing" exact="DENV" post="replication in vitro [130]. Activation of these major pattern"/>
   <result pre="[130]. Activation of these major pattern recognition receptors (PRRs) by" exact="DENV" post="generates a strong type of IFN-I response during human"/>
   <result pre="reported [131]. Extant evidence (experimented upon mice) further indicates that" exact="DENV" post="primary infection utilizes the interferon α/β receptor (IFNAR)-dependent (including"/>
   <result pre="the latter antiviral process—aiding virus propagation and disease control. In" exact="DENV" post="primary infection, cells typically utilize both mechanisms [132,133]. Anti-CLEC5A"/>
   <result pre="primary infection, cells typically utilize both mechanisms [132,133]. Anti-CLEC5A blocks" exact="DENV" post="by releasing pro-inflammatory cytokines and does not affect IFN-I"/>
   <result pre="IFN-I production in the infected cells [134]. As CLEC5A blocks" exact="DENV" post="infections, future studies are necessary to enhance CLEC5A activation."/>
   <result pre="(IFN)-γ, all of which are responsible for primary and secondary" exact="DENV" post="infection in humans, are excessively elevated and have been"/>
   <result pre="Cytokines are not responsible in causing any primary and secondary" exact="DENV" post="infections in humans. Cytokine IFN-γ production in the host"/>
   <result pre="production in the host cell plays protective roles during primary" exact="DENV" post="infection. In primary DENV infections, production of IL-12 and"/>
   <result pre="cell plays protective roles during primary DENV infection. In primary" exact="DENV" post="infections, production of IL-12 and IL-18 proinflammatory cytokines precede"/>
   <result pre="oxide production that assists the host in resistance against primary" exact="DENV" post="infection [145], which was previously found to inhibit DENV"/>
   <result pre="primary DENV infection [145], which was previously found to inhibit" exact="DENV" post="replication [146]. Sustained IFN-γ production is necessary during the"/>
   <result pre="can be a potential target for the host to control" exact="DENV" post="replication and resistance to infection. Enhanced proinflammatory cytokine TNF-α"/>
   <result pre="contain higher amounts of TNF-α after ex vivo stimulation with" exact="DENV" post="antigens [148]. Hence, the blocking of enhanced proinflammatory cytokine"/>
   <result pre="is indicative of a more severe disease form during primary" exact="DENV" post="infections [138]. Experiments have shown that DENV primary infections"/>
   <result pre="form during primary DENV infections [138]. Experiments have shown that" exact="DENV" post="primary infections were less severe in MIF−/− mice, and"/>
   <result pre="proinflammatory cytokines TNF-α and MIF during the host response to" exact="DENV" post="infection favors more severe disease [152]. The chemokine system"/>
   <result pre="chemokine system that plays a protective and pathologic role during" exact="DENV" post="infections produces CXCL10 and activates CXCR3 (C-X-C chemokine receptor"/>
   <result pre="(C-X-C chemokine receptor type 3) to improve host resistance against" exact="DENV" post="infection [7]. Clinical studies in endemic areas indicated the"/>
   <result pre="in endemic areas indicated the presence of a correlation between" exact="DENV" post="outcome and the level of CCL2, 3, 4 concentrations"/>
   <result pre="2 and type 4 (CCR2−/−and CCR4−/−) knockout mice with primary" exact="DENV" post="infection. However, no difference in viral load has been"/>
   <result pre="CCR2 and CCR4 cause infection rather than providing protection against" exact="DENV" post="infection [154]. Cellular populations are also important for DENV"/>
   <result pre="against DENV infection [154]. Cellular populations are also important for" exact="DENV" post="infection. For example, cluster of differentiation 8 (CD8+) T"/>
   <result pre="leakage by stabilization of endothelial cell development is important for" exact="DENV" post="infection prevention [201]. The MIF inhibitor ISO-1 reduces permeability"/>
   <result pre="endothelial stabilization [205]. 6.4. Targeting Immune Factor Progress Disease after" exact="DENV" post="Infection Platelet-activating factor receptors (PAFR) released from macrophages, which"/>
   <result pre="advantages over synthetic drug design [207] and also tested as" exact="DENV" post="inhibitors. Interferon type I [129], human heme oxygenase I,"/>
   <result pre="helicase with zinc linger 2 [194] are other examples of" exact="DENV" post="inhibitors that have been experimentally studied to ascertain their"/>
   <result pre="arise in the way of host inhibition processes that interrupt" exact="DENV" post="replication along with infections. Host metabolic pathways serve as"/>
   <result pre="DENV. For example, the primary glycolysis is conservatively required by" exact="DENV" post="and exogenous glucose, and glutamine deprivation decreases DENV production,"/>
   <result pre="required by DENV and exogenous glucose, and glutamine deprivation decreases" exact="DENV" post="production, which could lead to the development of novel"/>
   <result pre="to the role of lipid and fatty acid metabolism during" exact="DENV" post="infection, and the extant findings indicate that modulating lipid"/>
   <result pre="biosynthesis pathways of the host supply necessary nucleosides required for" exact="DENV" post="replication. Hence, targeting the host nucleoside biosynthesis pathways can"/>
   <result pre="biosynthesis pathways can assist in blocking the essential functions of" exact="DENV" post="as another avenue for antiviral drug development. In the"/>
   <result pre="continue the viral life cycle. This process can occur in" exact="DENV" post="through the interaction between viral surface proteins and host"/>
   <result pre="genome release into the cytoplasm. If the early steps of" exact="DENV" post="infection cycle can be blocked by targeting host attachment"/>
   <result pre="development of antiviral drugs. Without utilizing host proteins and enzymes," exact="DENV" post="would be unable to propagate rapidly in host cells."/>
   <result pre="cells. Numerous host proteins are found to be essential in" exact="DENV" post="replication. For example, host proteases aid in the RNA"/>
   <result pre="genome cleavage and polyprotein formation, while host kinases help in" exact="DENV" post="assembly, and glucosidase is used in DENV maturation and"/>
   <result pre="kinases help in DENV assembly, and glucosidase is used in" exact="DENV" post="maturation and folding. Every single step mentioned utilizes host"/>
   <result pre="proteins and enzymes, which are the most important factors for" exact="DENV" post="multiplications. Hence, targeting one of these can reduce DENV"/>
   <result pre="for DENV multiplications. Hence, targeting one of these can reduce" exact="DENV" post="production and may lead to an effective antiviral drug."/>
   <result pre="drug. The inflammatory response is activated in host cells during" exact="DENV" post="infection to clear the pathogen from the host immune"/>
   <result pre="immune system. Whenever the host senses the presence of the" exact="DENV" post="virus, activation of innate and inflammatory pathways occurs as"/>
   <result pre="discussed in this work can yield more comprehensive knowledge about" exact="DENV" post="and related host factors that can be utilized in"/>
   <result pre="1.BuchmeierM.J.PetersC.J.de LaT.J.F.V.Arenaviridae: The Virus and Their ReplicationFields Virol.200717921827 2.TelesF.R.R.PrazeresD.M.F.Lima-FilhoJ.L.Trends in" exact="Dengue" post="DiagnosisRev. Med. Virol.20051528730210.1002/rmv.46115672450 3.OliveiraE.R.A.Mohana-BorgesR.de AlencastroR.B.HortaB.A.C.The Flavivirus Capsid Protein: Structure,"/>
   <result pre="Function and Perspectives towards Drug DesignVirus Res.201722711512310.1016/j.virusres.2016.10.00527751882 4.MillerN.Recent Progress in" exact="Dengue" post="Vaccine Research and DevelopmentCurr. Opin. Mol.2010123138 5.FontaineK.A.SanchezE.L.CamardaR.LagunoffM.Dengue Virus Induces"/>
   <result pre="and Requires Glycolysis for Optimal ReplicationJ. Virol.2015892358236610.1128/JVI.02309-1425505078 6.WhiteheadS.S.BlaneyJ.E.DurbinA.P.MurphyB.R.Prospects for a" exact="Dengue" post="Virus VaccineNat. Rev. Microbiol.2007551852810.1038/nrmicro169017558424 7.HalsteadS.B.Antibody, Macrophages, Dengue Virus Infection,"/>
   <result pre="6.WhiteheadS.S.BlaneyJ.E.DurbinA.P.MurphyB.R.Prospects for a Dengue Virus VaccineNat. Rev. Microbiol.2007551852810.1038/nrmicro169017558424 7.HalsteadS.B.Antibody, Macrophages," exact="Dengue" post="Virus Infection, Shock, and Hemorrhage: A Pathogenetic CascadeRev. Infect."/>
   <result pre="of dengue feverInfect. Dis.1907444047510.1093/infdis/4.3.440 14.ClelandJ.B.BradleyB.MacDonaldW.Further Experiments in the Etiology of" exact="Dengue" post="FeverJ. Hyg.19191821725410.1017/S002217240000747620474685 15.NishiuraH.HalsteadS.B.Natural History of Dengue Virus (DENV) 1"/>
   <result pre="in the Etiology of Dengue FeverJ. Hyg.19191821725410.1017/S002217240000747620474685 15.NishiuraH.HalsteadS.B.Natural History of" exact="Dengue" post="Virus (DENV) 1 and DENV 4 InfectionsJ. Infect. Dis.20071951007101310.1086/51182517330791"/>
   <result pre="FeverJ. Hyg.19191821725410.1017/S002217240000747620474685 15.NishiuraH.HalsteadS.B.Natural History of Dengue Virus (DENV) 1 and" exact="DENV" post="4 InfectionsJ. Infect. Dis.20071951007101310.1086/51182517330791 16.SilerJ.F.HallM.W.HitchensA.P.Dengue: Its History, Epidemiology, Mechanism"/>
   <result pre="19.KonishiE.KunoG.In Memoriam: Susumu Hotta (1918–2011)Emerg. Infect. Dis.20131984384510.3201/eid1905.IM098623697347 20.MessinaJ.P.BradyO.J.ScottT.W.ZouC.PigottD.M.DudaK.A.SimmonsC.P.Global Spread of" exact="Dengue" post="Virus Types: Mapping the 70 Year HistoryTrends Microbiol.20142213814610.1016/j.tim.2013.12.01124468533 21.EbiK.L.NealonJ.Dengue"/>
   <result pre="Causes, Complications, and Vaccine StrategiesJ. Immunol. Res.2016201611410.1155/2016/680309827525287 24.ChenL.H.MaryE.Non-Vector Transmission of" exact="Dengue" post="and Other Mosquito-Borne FlavivirusesDengue Bull.2005291831 25.WazieresD.EliteA.S.ClinicalM.J.Nosocomial transmission of dengue"/>
   <result pre="transmission of dengue from a needlestick injuryLancet199835149810.1016/S0140-6736(05)78686-4 26.HirschJ.F.DeschampsC.LhuillierM.Transmission MŽtropolitaine d’une" exact="Dengue" post="Par Inoculation Accidentelle HospitalièreAnn. Med. Intern.1990141629 27.LanggartnerJ.AudebertF.SchölmerichJ.GlückT.Dengue Virus Infection"/>
   <result pre="29.WagnerD.De WithK.HuzlyD.HufertF.WeidmannM.BreisingerS.EppingerS.KernW.V.BauerT.M.Nosocomial Acquisition of DengueEmerg. Infect. Dis.2004101872187310.3201/eid1010.03103715504282 30.BerberianG.FarinaD.RosanovaM.T.HidalgoS.EnriaD.MitchenkoA.MorenoJ.SánchezI.S.Dengue Perinatal; Perinatal" exact="Dengue" post="InfectionArch. Argent. Pediatr.201110923223621660390 31.Rigau-PérezJ.G.VorndamA.V.ClarkG.G.The Dengue and Dengue Hemorrhagic Fever"/>
   <result pre="Infect. Dis.2004101872187310.3201/eid1010.03103715504282 30.BerberianG.FarinaD.RosanovaM.T.HidalgoS.EnriaD.MitchenkoA.MorenoJ.SánchezI.S.Dengue Perinatal; Perinatal Dengue InfectionArch. Argent. Pediatr.201110923223621660390 31.Rigau-PérezJ.G.VorndamA.V.ClarkG.G.The" exact="Dengue" post="and Dengue Hemorrhagic Fever Epidemic in Puerto Rico, 1994–1995Am."/>
   <result pre="30.BerberianG.FarinaD.RosanovaM.T.HidalgoS.EnriaD.MitchenkoA.MorenoJ.SánchezI.S.Dengue Perinatal; Perinatal Dengue InfectionArch. Argent. Pediatr.201110923223621660390 31.Rigau-PérezJ.G.VorndamA.V.ClarkG.G.The Dengue and" exact="Dengue" post="Hemorrhagic Fever Epidemic in Puerto Rico, 1994–1995Am. J. Trop."/>
   <result pre="in Puerto Rico, 1994–1995Am. J. Trop. Med. Hyg.200164677410.4269/ajtmh.2001.64.6711425166 32.ChenL.H.WilsonM.E.Transmission of" exact="Dengue" post="Virus without a Mosquito Vector: Nosocomial Mucocutaneous Transmission and"/>
   <result pre="et Quo Vadis?Viruses201131562160810.3390/v309156221994796 34.HolmesE.C.TwiddyS.S.The Origin, Emergence and Evolutionary Genetics of" exact="Dengue" post="VirusInfect. Genet. Evol.20033192810.1016/S1567-1348(03)00004-212797969 35.DialloM.BaY.SallA.A.DiopO.M.NdioneJ.A.MondoM.GiraultL.MathiotC.Amplification of the Sylvatic Cycle of"/>
   <result pre="Dengue VirusInfect. Genet. Evol.20033192810.1016/S1567-1348(03)00004-212797969 35.DialloM.BaY.SallA.A.DiopO.M.NdioneJ.A.MondoM.GiraultL.MathiotC.Amplification of the Sylvatic Cycle of" exact="Dengue" post="Virus Type 2, Senegal, 1999-2000: Entomologic Findings and Epidemiologic"/>
   <result pre="Entomologic Findings and Epidemiologic ConsiderationsEmerg. Infect. Dis.2003936236710.3201/eid0903.02021912643833 36.HervyJ.P.LegrosF.RocheJ.C.MontenyN.DiacoB.Circulation Du Virus" exact="Dengue" post="2 Dans Plusieurs Milieux Boisés des Savanes Soudaniennes de"/>
   <result pre="and yellow feverComp. Immunol. Microbiol. Infect. Dis.19911491910.1016/0147-9571(91)90036-D1905605 38.RobinY.CornetM.HemeG.Le GonidecG.Isolation of" exact="Dengue" post="Virus from Senegal/Isolement Du Virus de La Dengue Au"/>
   <result pre="GonidecG.Isolation of Dengue Virus from Senegal/Isolement Du Virus de La" exact="Dengue" post="Au SenegalAnn. Virol. E1980131149154 39.RocheJ.C.CordellierR.HervyJ.P.DigoutteJ.P.MontenyN.Isolement de 96 Souches de"/>
   <result pre="Au SenegalAnn. Virol. E1980131149154 39.RocheJ.C.CordellierR.HervyJ.P.DigoutteJ.P.MontenyN.Isolement de 96 Souches de Virus" exact="Dengue" post="2 à Partir de Moustiques Capturés En Cote-d’ivoire et"/>
   <result pre="IVW.C.BennettK.E.Gorrochótegui-EscalanteN.Barillas-MuryC.V.Fernández-SalasI.MuñozM.D.L.Farfán-AléJ.A.OlsonK.E.BeatyB.J.Flavivirus Susceptibility in Aedes AegyptiArch. Med. Res.20023337938810.1016/S0188-4409(02)00373-912234528 42.YuwonoJ.SuharyonoW.KoimanI.TsuchiyaY.TagayaI.Seroepidemiological Survey on" exact="Dengue" post="and Japanese Encephalitis Virus Infections in Asian MonkeysSouth. Asian"/>
   <result pre="J. Trop. Med. Public Health198415194200 43.RosenL.Observations on the Epidemiology of" exact="Dengue" post="in PanamaAm. J. Epidemiol.195868455810.1093/oxfordjournals.aje.a119948 44.RobertsD.PeytonE.PinheiroF.BalderramaF.Associations of Arbovirus Vectors with"/>
   <result pre="45.GermainM.MouchetJ.CordellierR.ChippauxA.CornetM.HerveJ.P.SureauP.FabreJ.RobinY.Epidemiology of yellow fever in AfricaMed. Infect. Dis.197886977 46.RudnickA.L.B.E.R.T.Ecology of" exact="Dengue" post="VirusAsian J. Infect. Dis.19782156160 47.FreierJ.E.RosenL.Vertical Transmission of Dengue Viruses"/>
   <result pre="46.RudnickA.L.B.E.R.T.Ecology of Dengue VirusAsian J. Infect. Dis.19782156160 47.FreierJ.E.RosenL.Vertical Transmission of" exact="Dengue" post="Viruses by Aedes MediovittatusAm. J. Trop. Med. Hyg.19883921822210.4269/ajtmh.1988.39.2183407842 48.collab:"/>
   <result pre="by Aedes MediovittatusAm. J. Trop. Med. Hyg.19883921822210.4269/ajtmh.1988.39.2183407842 48.collab: WHODengue and" exact="Dengue" post="Haemorrhagic Fever. 1990–1994Relev. Epidemiol. Hebd.199570334335 49.GublerD.J.Dengue and Dengue Hemorrhagic"/>
   <result pre="WHODengue and Dengue Haemorrhagic Fever. 1990–1994Relev. Epidemiol. Hebd.199570334335 49.GublerD.J.Dengue and" exact="Dengue" post="Hemorrhagic Fever, 1996Epidemiol. Bull.1996171214 50.TaiA.W.BenitaY.PengL.F.KimS.SakamotoN.XavierR.J.ChungR.T.A functional genomic screen identifies"/>
   <result pre="ONE20116e2497010.1371/journal.pone.002497021949814 58.KrishnanM.N.NgA.SukumaranB.GilfoyF.D.UchilP.D.SultanaH.BrassA.L.AdametzR.TsuiM.QianF.et al.RNA Interference Screen for Human Genes Associated with" exact="West Nile" post="Virus InfectionNature200845524224510.1038/nature0720718690214 59.SessionsO.M.BarrowsN.J.Souza-NetoJ.A.RobinsonT.J.HersheyC.L.RodgersM.A.RamirezJ.L.DimopoulosG.YangP.L.PearsonJ.L.et al.Discovery of Insect and Human Dengue"/>
   <result pre="West Nile Virus InfectionNature200845524224510.1038/nature0720718690214 59.SessionsO.M.BarrowsN.J.Souza-NetoJ.A.RobinsonT.J.HersheyC.L.RodgersM.A.RamirezJ.L.DimopoulosG.YangP.L.PearsonJ.L.et al.Discovery of Insect and Human" exact="Dengue" post="Virus Host FactorsNature20094581047105010.1038/nature0796719396146 60.JordanT.X.RandallG.Flavivirus Modulation of Cellular MetabolismCurr. Opin."/>
   <result pre="Regulates Lipid MetabolismCell Host Microbe2010842243210.1016/j.chom.2010.10.00621075353 64.KhakpoorA.PanyasrivanitM.WikanN.SmithD.R.A Role for Autophagolysosomes in" exact="Dengue" post="Virus 3 Production in HepG2 CellsJ. Gen. Virol.2009901093110310.1099/vir.0.007914-019264601 65.LeeY.R.HuH.Y.KuoS.H.LeiH.Y.LinY.S.YehT.M.LiuC.C.LiuH.S.Dengue"/>
   <result pre="in Vivo StudyJ. Biomed. Sci.2013206510.1186/1423-0127-20-6524011333 66.MateoR.NagamineC.M.SpagnoloJ.MéndezE.RaheM.GaleM.YuanJ.KirkegaardK.Inhibition of Cellular Autophagy Deranges" exact="Dengue" post="Virion MaturationJ. Virol.2013871312132110.1128/JVI.02177-1223175363 67.JordanT.X.RandallG.Flaviviruses and AutophagyAutophagy, Infection, and the"/>
   <result pre="&amp;amp; Sons, Inc.Hoboken, NJ, USA201581100 68.RothwellC.LeBretonA.Young NgC.LimJ.Y.H.LiuW.VasudevanS.LabowM.GuF.GaitherL.A.Cholesterol Biosynthesis Modulation Regulates" exact="Dengue" post="Viral ReplicationVirology200938981910.1016/j.virol.2009.03.02519419745 69.WangQ.Y.BushellS.QingM.XuH.Y.BonaviaA.NunesS.ZhouJ.PohM.K.Florez de SessionsP.NiyomrattanakitP.et al.Inhibition of Dengue Virus"/>
   <result pre="Modulation Regulates Dengue Viral ReplicationVirology200938981910.1016/j.virol.2009.03.02519419745 69.WangQ.Y.BushellS.QingM.XuH.Y.BonaviaA.NunesS.ZhouJ.PohM.K.Florez de SessionsP.NiyomrattanakitP.et al.Inhibition of" exact="Dengue" post="Virus through Suppression of Host Pyrimidine BiosynthesisJ. Virol.2011856548655610.1128/JVI.02510-1021507975 70.LiuS.NeidhardtE.A.GrossmanT.H.OcainT.ClardyJ.Structures"/>
   <result pre="for the Productive Infection of Human Dendritic Cells by Mosquito-Cell-Derived" exact="Dengue" post="VirusesEMBO Rep.2003472372810.1038/sj.embor.embor86612783086 73.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) Mediates Dengue Virus Infection"/>
   <result pre="Cells by Mosquito-Cell-Derived Dengue VirusesEMBO Rep.2003472372810.1038/sj.embor.embor86612783086 73.TassaneetrithepB.BurgessT.H.Granelli-PipernoA.TrumpfhellerC.FinkeJ.SunW.EllerM.A.PattanapanyasatK.SarasombathS.BirxD.L.et al.DC-SIGN (CD209) Mediates" exact="Dengue" post="Virus Infection of Human Dendritic CellsJ. Exp. Med.200319782382910.1084/jem.2002184012682107 74.HungJ.J.HsiehM.T.YoungM.J.KaoC.L.KingC.C.ChangW.An"/>
   <result pre="Exp. Med.200319782382910.1084/jem.2002184012682107 74.HungJ.J.HsiehM.T.YoungM.J.KaoC.L.KingC.C.ChangW.An External Loop Region of Domain III of" exact="Dengue" post="Virus Type 2 Envelope Protein Is Involved in Serotype-Specific"/>
   <result pre="78 (BiP) as a Liver Cell Expressed Receptor Element for" exact="Dengue" post="Virus Serotype 2Arch. Virol.200414991592710.1007/s00705-003-0263-x15098107 76.MeertensL.CarnecX.LecoinM.P.RamdasiR.Guivel-BenhassineF.LewE.LemkeG.SchwartzO.AmaraA.The TIM and TAM Families"/>
   <result pre="Virol.200414991592710.1007/s00705-003-0263-x15098107 76.MeertensL.CarnecX.LecoinM.P.RamdasiR.Guivel-BenhassineF.LewE.LemkeG.SchwartzO.AmaraA.The TIM and TAM Families of Phosphatidylserine Receptors Mediate" exact="Dengue" post="Virus EntryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 77.IchiyamaK.Gopala ReddyS.B.ZhangL.F.ChinW.X.MuschinT.HeinigL.SuzukiY.NanjundappaH.YoshinakaY.RyoA.et al.Sulfated Polysaccharide, Curdlan"/>
   <result pre="Curdlan Sulfate, Efficiently Prevents Entry/Fusion and Restricts Antibody-Dependent Enhancement of" exact="Dengue" post="Virus Infection In Vitro: A Possible Candidate for Clinical"/>
   <result pre="Negl. Trop. Dis.20137e218810.1371/journal.pntd.000218823658845 78.KatoD.EraS.WatanabeI.AriharaM.SugiuraN.KimataK.SuzukiY.MoritaK.HidariK.I.P.J.SuzukiT.Antiviral Activity of Chondroitin Sulphate E Targeting" exact="Dengue" post="Virus Envelope ProteinAntivir. Res.20108823624310.1016/j.antiviral.2010.09.00220851716 79.ChenY.MaguireT.HilemanR.FrommJ.EskoJ.LinhardtR.MarksR.Dengue Virus Infectivity Depends Envelope"/>
   <result pre="Med.1997386687110.1038/nm0897-8669256277 80.LeeE.PavyM.YoungN.FreemanC.LobigsM.Antiviral Effect of the Heparan Sulfate Mimetic, PI-88, against" exact="Dengue" post="and Encephalitic FlavivirusesAntivir. Res.200669313810.1016/j.antiviral.2005.08.00616309754 81.HungS.L.LeeP.L.ChenH.W.ChenL.K.KaoC.L.KingC.C.Analysis of the Steps Involved"/>
   <result pre="and Encephalitic FlavivirusesAntivir. Res.200669313810.1016/j.antiviral.2005.08.00616309754 81.HungS.L.LeeP.L.ChenH.W.ChenL.K.KaoC.L.KingC.C.Analysis of the Steps Involved in" exact="Dengue" post="Virus Entry into Host CellsVirology199925715616710.1006/viro.1999.963310208929 82.HidariK.I.P.J.TakahashiN.AriharaM.NagaokaM.MoritaK.SuzukiT.Structure and Anti-Dengue Virus"/>
   <result pre="Biophys. Res. Commun.2008376919510.1016/j.bbrc.2008.08.10018762172 83.VervaekeP.AlenM.NoppenS.ScholsD.OresteP.LiekensS.Sulfated Escherichia Coli K5 Polysaccharide Derivatives Inhibit" exact="Dengue" post="Virus Infection of Human Microvascular Endothelial Cells by Interacting"/>
   <result pre="Activity of Carbohydrate-Binding Agents and the Role of DC-SIGN in" exact="Dengue" post="Virus InfectionVirology2009387677510.1016/j.virol.2009.01.04319264337 86.TalaricoL.B.DamonteE.B.Interference in Dengue Virus Adsorption and Uncoating"/>
   <result pre="the Role of DC-SIGN in Dengue Virus InfectionVirology2009387677510.1016/j.virol.2009.01.04319264337 86.TalaricoL.B.DamonteE.B.Interference in" exact="Dengue" post="Virus Adsorption and Uncoating by CarrageenansVirology200736347348510.1016/j.virol.2007.01.04317337028 87.Reyes-del ValleJ.Salas-BenitoJ.Soto-AcostaR.del AngelR.M.Dengue"/>
   <result pre="Cell BiologyJ. Leukoc. Biol.2002271921931 89.LiuP.RidillaM.PatelP.BettsL.GallichotteE.ShahidiL.ThompsonN.L.JacobsonK.Beyond Attachment: Roles of DC-SIGN in" exact="Dengue" post="Virus InfectionTraffic20171821823110.1111/tra.1246928128492 90.FlipseJ.WilschutJ.TrafficJ.S.Molecular mechanisms involved in antibody-dependent enhancement of"/>
   <result pre="91.LozachP.Y.BurleighL.StaropoliI.Navarro-SanchezE.HarriagueJ.VirelizierJ.L.ReyF.A.DesprèsP.Arenzana-SeisdedosF.AmaraA.Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Non-Integrin (DC-SIGN)-Mediated Enhancement of" exact="Dengue" post="Virus Infection Is Independent of DC-SIGN Internalization SignalsJ. Biol."/>
   <result pre="of a Putative Coreceptor on Vero Cells That Participates in" exact="Dengue" post="4 Virus InfectionJ. Virol.2002757818782710.1128/JVI.75.17.7818-7827.200111483725 95.BoonnakK.SlikeB.M.BurgessT.H.MasonR.M.WuS.-J.SunP.PorterK.RudimanI.F.YuwonoD.PuthavathanaP.et al.Role of Dendritic Cells"/>
   <result pre="Virol.2002757818782710.1128/JVI.75.17.7818-7827.200111483725 95.BoonnakK.SlikeB.M.BurgessT.H.MasonR.M.WuS.-J.SunP.PorterK.RudimanI.F.YuwonoD.PuthavathanaP.et al.Role of Dendritic Cells in Antibody-Dependent Enhancement of" exact="Dengue" post="Virus InfectionJ. Virol.2008823939395110.1128/JVI.02484-0718272578 96.BhattacharyyaS.ZagórskaA.LewE.D.ShresthaB.RothlinC.V.NaughtonJ.DiamondM.S.LemkeG.YoungJ.A.T.Enveloped Viruses Disable Innate Immune Responses"/>
   <result pre="Protein 90 and Heat Shock Protein 70 Are Components of" exact="Dengue" post="Virus Receptor Complex in Human CellsJ. Virol.2005794557456710.1128/JVI.79.8.4557-4567.200515795242 99.ElshuberS.AllisonS.L.HeinzF.X.MandlC.W.Cleavage of"/>
   <result pre="BHK-21 Cells by Tick-Borne Encephalitis VirusJ. Gen. Virol.20038418319110.1099/vir.0.18723-012533715 100.ArakakiT.L.FangN.X.FairlieD.P.YoungP.R.MartinJ.L.Catalytically Active" exact="Dengue" post="Virus NS3 Protease Forms Aggregates That Are Separable by"/>
   <result pre="dengue virus diseasesFEBS J.20072742986300210.1111/j.1742-4658.2007.05831.x17509079 102.GouveaI.E.IzidoroM.A.JudiceW.A.S.CezariM.H.S.CaliendoG.SantagadaV.dos SantosC.N.D.QueirozM.H.JulianoM.A.YoungP.R.et al.Substrate Specificity of Recombinant" exact="Dengue" post="2 Virus NS2B-NS3 Protease: Influence of Natural and Unnatural"/>
   <result pre="Res.201714317618510.1016/j.antiviral.2017.03.02628389141 106.ChuJ.J.H.YangP.L.C-Src Protein Kinase Inhibitors Block Assembly and Maturation of" exact="Dengue" post="VirusProc. Natl. Acad. Sci. USA20071043520352510.1073/pnas.061168110417360676 107.de WispelaereM.LaCroixA.J.YangP.L.The Small Molecules"/>
   <result pre="Sci. USA20071043520352510.1073/pnas.061168110417360676 107.de WispelaereM.LaCroixA.J.YangP.L.The Small Molecules AZD0530 and Dasatinib Inhibit" exact="Dengue" post="Virus RNA Replication via Fyn KinaseJ. Virol.2013877367738110.1128/JVI.00632-1323616652 108.AnwarA.HosoyaT.LeongK.M.OnogiH.OkunoY.HiramatsuT.KoyamaH.SuzukiM.HagiwaraM.Garcia-BlancoM.A.The Kinase"/>
   <result pre="Replication via Fyn KinaseJ. Virol.2013877367738110.1128/JVI.00632-1323616652 108.AnwarA.HosoyaT.LeongK.M.OnogiH.OkunoY.HiramatsuT.KoyamaH.SuzukiM.HagiwaraM.Garcia-BlancoM.A.The Kinase Inhibitor Sfv785 Dislocates" exact="Dengue" post="Virus Envelope Protein from the Replication Complex and Blocks"/>
   <result pre="Complex and Blocks Virus AssemblyPLoS ONE20116e2324610.1371/journal.pone.002324621858043 109.ClarkM.J.MiduturuC.SchmidtA.G.ZhuX.PittsJ.D.WangJ.PotisoponS.ZhangJ.WojciechowskiA.Hann ChuJ.J.et al.GNF-2 Inhibits" exact="Dengue" post="Virus by Targeting Abl Kinases and the Viral e"/>
   <result pre="the Viral e ProteinCell Chem. Biol.20162344345210.1016/j.chembiol.2016.03.01027105280 110.CourageotM.P.FrenkielM.P.Dos SantosC.D.DeubelV.DesprèsP.Alpha-Glucosidase Inhibitors Reduce" exact="Dengue" post="Virus Production by Affecting the Initial Steps of Virion"/>
   <result pre="Expression, And ReplicationAnnu. Rev. Microbiol.19904464968810.1146/annurev.mi.44.100190.0032452174669 112.WhitbyK.PiersonT.C.GeissB.LaneK.EngleM.ZhouY.DomsR.W.DiamondM.S.Castanospermine, a Potent Inhibitor of" exact="Dengue" post="Virus Infection In Vitro and In VivoJ. Virol.2005798698870610.1128/JVI.79.14.8698-8706.200515994763 113.HebertD.N.FoellmerB.HeleniusA.Calnexin"/>
   <result pre="Protective Efficacy of Celgosivir in a Lethal Mouse Model for" exact="Dengue" post="Virus Infection Informs Dosing Regimen for a Proof of"/>
   <result pre="a Proof of Concept Clinical TrialAntivir. Res.201296323510.1016/j.antiviral.2012.07.00822867971 116.RathoreA.P.ParadkarP.N.WatanabeS.TanK.H.SungC.ConnollyJ.E.LowJ.OoiE.E.VasudevanS.G.Celgosivir Treatment Misfolds" exact="Dengue" post="Virus NS1 Protein, Induces Cellular pro-Survival Genes and Protects"/>
   <result pre="Mouse ModelAntivir. Res.20119245346010.1016/j.antiviral.2011.10.00222020302 117.PerryS.T.BuckM.D.PlummerE.M.PenmastaR.A.BatraH.StavaleE.J.WarfieldK.L.DwekR.A.ButtersT.D.AlonziD.S.et al.An Iminosugar with Potent Inhibition of" exact="Dengue" post="Virus Infection in VivoAntivir. Res.201398354310.1016/j.antiviral.2013.01.00423376501 118.ChangJ.SchulW.ButtersT.D.YipA.LiuB.GohA.LakshminarayanaS.B.AlonziD.ReinkensmeierG.PanX.et al.Combination of α-Glucosidase"/>
   <result pre="al.Combination of α-Glucosidase Inhibitor and Ribavirin for the Treatment of" exact="Dengue" post="Virus Infection in Vitro and in VivoAntivir. Res.201189263410.1016/j.antiviral.2010.11.00221073903 119.GoldbergM.F.SainiN.K.PorcelliS.A.Evasion"/>
   <result pre="to Win the WarCurr. Top. Microbiol. Immunol.200731616719217969448 123.TsaiY.T.ChangS.Y.LeeC.N.KaoC.L.Human TLR3 Recognizes" exact="Dengue" post="Virus and Modulates Viral Replication in VitroCell. Microbiol.20091160461510.1111/j.1462-5822.2008.01277.x19134117 124.ChattopadhyayS.SenG.C.dsRNA-activation"/>
   <result pre="effectsJ. Interferon Cytokine20143442743610.1089/jir.2014.003424905199 125.LiangZ.WuS.LiY.HeL.WuM.JiangL.FengL.ZhangP.HuangX.Activation of Toll-Like Receptor 3 Impairs the" exact="Dengue" post="Virus Serotype 2 Replication through Induction of IFN-β in"/>
   <result pre="Induction of IFN-β in Cultured Hepatoma CellsPLoS ONE20116e2334610.1371/journal.pone.002334621829730 126.SariolC.A.MartínezM.I.RiveraF.RodríguezI.V.PantojaP.AbelK.AranaT.GiavedoniL.HodaraV.WhiteL.J.et al.Decreased" exact="Dengue" post="Replication and an Increased Anti-Viral Humoral Response with the"/>
   <result pre="Anti-Viral Chemokine Production and IFN-Mediated Protection in Response to Antibody-Enhanced" exact="Dengue" post="Virus InfectionPLoS ONE20127e3405510.1371/journal.pone.003405522479521 130.NasirudeenA.M.A.WongH.H.ThienP.XuS.LamK.P.LiuD.X.RIG-I, MDA5 and TLR3 Synergistically Play"/>
   <result pre="and TLR3 Synergistically Play an Important Role in Restriction of" exact="Dengue" post="Virus InfectionPLoS Negl. Trop. Dis.20115e92610.1371/journal.pntd.000092621245912 131.KuraneI.InnisB.L.NimmannityaS.NisalakA.MeagerA.EnnisF.A.High Levels of Interferon"/>
   <result pre="Levels of Interferon Alpha in the Sera of Children with" exact="Dengue" post="Virus InfectionAm. J. Trop. Med. Hyg.19934822222910.4269/ajtmh.1993.48.2228447527 132.PerryS.T.BuckM.D.LadaS.M.SchindlerC.ShrestaS.STAT2 mediates innate"/>
   <result pre="InfectionAm. J. Trop. Med. Hyg.19934822222910.4269/ajtmh.1993.48.2228447527 132.PerryS.T.BuckM.D.LadaS.M.SchindlerC.ShrestaS.STAT2 mediates innate immunity to" exact="Dengue" post="virus in the absence of STAT1 via the type"/>
   <result pre="of primary dengue virus infection in miceJ. Immunol.20051753946395410.4049/jimmunol.175.6.394616148142 134.GomesA.L.V.WeeL.J.K.KhanA.M.GilL.H.V.G.MarquesE.T.A.Calzavara-SilvaC.E.TanT.W.Classification of" exact="Dengue" post="Fever Patients Based on Gene Expression Data Using Support"/>
   <result pre="Gene Expression Data Using Support Vector MachinesPLoS ONE20105e1126710.1371/journal.pone.001126720585645 135.RothmanA.L.Immunity to" exact="Dengue" post="Virus: A Tale of Original Antigenic Sin and Tropical"/>
   <result pre="to Cell Surface Heparan SulfateJ. Immunol.20061773185319210.4049/jimmunol.177.5.318516920957 139.BozzaF.A.CruzO.G.ZagneS.M.AzeredoE.L.NogueiraR.M.AssisE.F.BozzaP.T.KubelkaC.F.Multiplex Cytokine Profile from" exact="Dengue" post="Patients: MIP-1beta and IFN-Gamma as Predictive Factors for SeverityBMC"/>
   <result pre="Infect. Dis.200888610.1186/1471-2334-8-8618578883 140.BrasierA.R.ScottT.W.MorrisonA.C.KochelT.J.SprattH.M.BazanI.ForsheyB.M.GarciaJ.VictorS.S.RochaC.et al.A Three-Component Biomarker Panel for Prediction of" exact="Dengue" post="Hemorrhagic FeverAm. J. Trop. Med. Hyg.20128634134810.4269/ajtmh.2012.11-046922302872 141.TolfvenstamT.LindblomA.SchreiberM.J.LingL.ChowA.OoiE.E.HibberdM.L.Characterization of Early"/>
   <result pre="Med. Hyg.20128634134810.4269/ajtmh.2012.11-046922302872 141.TolfvenstamT.LindblomA.SchreiberM.J.LingL.ChowA.OoiE.E.HibberdM.L.Characterization of Early Host Responses in Adults with" exact="Dengue" post="DiseaseBMC Infect. Dis.20111120910.1186/1471-2334-11-20921810247 142.FagundesC.T.CostaV.V.CisalpinoD.AmaralF.A.SouzaP.R.S.SouzaR.S.RyffelB.VieiraL.Q.SilvaT.A.AtrasheuskayaA.et al.IFN-γ Production Depends on IL-12"/>
   <result pre="IL-12 and IL-18 Combined Action and Mediates Host Resistance to" exact="Dengue" post="Virus Infection in a Nitric Oxide-Dependent MannerPLoS Negl. Trop."/>
   <result pre="InfectionPLoS Negl. Trop. Dis.20126e166310.1371/journal.pntd.000166322666512 144.PacsaA.S.AgarwalR.ElbishbishiE.A.ChaturvediU.C.NagarR.MustafaA.S.Role of Interleukin-12 in Patients with" exact="Dengue" post="Hemorrhagic FeverFEMS Immunol. Med. Microbiol.20002815115510.1111/j.1574-695X.2000.tb01470.x10799806 145.Neves-SouzaP.C.AzeredoE.L.ZagneS.M.Valls-de-SouzaR.ReisS.R.CerqueiraD.I.NogueiraR.M.KubelkaC.F.Inducible nitric oxide synthase"/>
   <result pre="145.Neves-SouzaP.C.AzeredoE.L.ZagneS.M.Valls-de-SouzaR.ReisS.R.CerqueiraD.I.NogueiraR.M.KubelkaC.F.Inducible nitric oxide synthase (iNOS) expression in monocytes during acute" exact="Dengue" post="Fever in patients and during in vitro infectionBMC Infect."/>
   <result pre="infectionBMC Infect. Dis.200556410.1186/1471-2334-5-6416109165 146.CharnsilpaW.TakhampunyaR.EndyT.P.MammenM.P.LibratyD.H.UbolS.Nitric Oxide Radical Suppresses Replication of Wild-Type" exact="Dengue" post="2 Viruses in VitroJ. Med. Virol.200577899510.1002/jmv.2041816032750 147.GuntherV.J.PutnakR.EckelsK.H.MammenM.P.SchererJ.M.LyonsA.SunW.A human challenge"/>
   <result pre="Responses in Peripheral Blood Mononuclear Cells Obtained Prior to Secondary" exact="Dengue" post="Virus Infections in Thai SchoolchildrenJ. Infect. Dis.20021851697170310.1086/34082212085313 149.AtrasheuskayaA.PetzelbauerP.FredekingT.M.IgnatyevG.Anti-TNF Antibody"/>
   <result pre="SchoolchildrenJ. Infect. Dis.20021851697170310.1086/34082212085313 149.AtrasheuskayaA.PetzelbauerP.FredekingT.M.IgnatyevG.Anti-TNF Antibody Treatment Reduces Mortality in Experimental" exact="Dengue" post="Virus InfectionFEMS Immunol. Med. Microbiol.200335334210.1111/j.1574-695X.2003.tb00646.x12589955 150.ShrestaS.ShararK.L.PrigozhinD.M.BeattyP.R.HarrisE.Murine Model for Dengue"/>
   <result pre="Experimental Dengue Virus InfectionFEMS Immunol. Med. Microbiol.200335334210.1111/j.1574-695X.2003.tb00646.x12589955 150.ShrestaS.ShararK.L.PrigozhinD.M.BeattyP.R.HarrisE.Murine Model for" exact="Dengue" post="Virus-Induced Lethal Disease with Increased Vascular PermeabilityJ. Virol.200680102081021710.1128/JVI.00062-0617005698 151.ZellwegerR.M.PrestwoodT.R.ShrestaS.Supplemental"/>
   <result pre="Liver Sinusoidal Endothelial Cells in a Mouse Model of Severe" exact="Dengue" post="DiseaseCell Host Microbe2010712813910.1016/j.chom.2010.01.00420153282 152.Assunção-MirandaI.AmaralF.A.BozzaF.A.FagundesC.T.SousaL.P.SouzaD.G.PachecoP.Barbosa-LimaG.GomesR.N.BozzaP.T.et al.Contribution of Macrophage Migration Inhibitory"/>
   <result pre="al.Contribution of Macrophage Migration Inhibitory Factor to the Pathogenesis of" exact="Dengue" post="Virus InfectionFASEB J.20102421822810.1096/fj.09-13946919776337 153.KyleJ.L.HarrisE.Global Spread and Persistence of DengueAnnu."/>
   <result pre="Receptors CCR1, CCR2 and CCR4 in the Pathogenesis of Experimental" exact="Dengue" post="Infection in MicePLoS ONE.20105e1568010.1371/journal.pone.001568021206747 155.RennesonJ.GuabirabaR.MailletI.A detrimental role for invariant"/>
   <result pre="via hypothalamic AMP-activated protein kinaseJ. Biol. Chem.2004279199701997610.1074/jbc.M40216520015028725 158.MackenzieJ.M.KhromykhA.A.PartonR.G.Cholesterol Manipulation by" exact="West Nile" post="Virus Perturbs the Cellular Immune ResponseCell Host Microbe2007222923910.1016/j.chom.2007.09.00318005741 159.Martínez-GutierrezM.CastellanosJ.E.Gallego-GómezJ.C.Statins"/>
   <result pre="Virus Perturbs the Cellular Immune ResponseCell Host Microbe2007222923910.1016/j.chom.2007.09.00318005741 159.Martínez-GutierrezM.CastellanosJ.E.Gallego-GómezJ.C.Statins Reduce" exact="Dengue" post="Virus Production via Decreased Virion AssemblyIntervirology20115420221610.1159/00032189221293097 160.PohM.K.ShuiG.XieX.ShiP.Y.WenkM.R.GuF.U18666A, an Intra-Cellular"/>
   <result pre="Decreased Virion AssemblyIntervirology20115420221610.1159/00032189221293097 160.PohM.K.ShuiG.XieX.ShiP.Y.WenkM.R.GuF.U18666A, an Intra-Cellular Cholesterol Transport Inhibitor, Inhibits" exact="Dengue" post="Virus Entry and ReplicationAntivir. Res.20129319119810.1016/j.antiviral.2011.11.01422146564 161.Soto-AcostaR.Bautista-CarbajalP.SyedG.H.SiddiquiA.Del AngelR.M.Nordihydroguaiaretic Acid (NDGA)"/>
   <result pre="161.Soto-AcostaR.Bautista-CarbajalP.SyedG.H.SiddiquiA.Del AngelR.M.Nordihydroguaiaretic Acid (NDGA) Inhibits Replication and Viral Morphogenesis of" exact="Dengue" post="VirusAntivir. Res.201410913214010.1016/j.antiviral.2014.07.00225017471 162.HyrinaA.MengF.McArthurS.J.EivemarkS.NabiI.R.JeanF.Human Subtilisin Kexin Isozyme-1 (SKI-1)/Site-1 Protease (S1P)"/>
   <result pre="Virus AgentsPLoS ONE201712e017448310.1371/journal.pone.017448328339489 163.MazzuccoM.B.TalaricoL.B.VatanseverS.CarroA.C.FascioM.L.D’AccorsoN.B.GarcíaC.C.DamonteE.B.Antiviral Activity of an N-Allyl Acridone against" exact="Dengue" post="VirusJ. Biomed. Sci.2015222910.1186/s12929-015-0134-225908170 164.HoffmannH.-H.KunzA.SimonV.A.PaleseP.ShawM.L.Broad-Spectrum Antiviral That Interferes with de"/>
   <result pre="Novo Pyrimidine BiosynthesisProc. Natl. Acad. Sci. USA20111085777578210.1073/pnas.110114310821436031 165.DiamondM.S.ZachariahM.HarrisE.Mycophenolic Acid Inhibits" exact="Dengue" post="Virus Infection by Preventing Replication of Viral RNAVirology200230421122110.1006/viro.2002.168512504563 166.FurutaY.TakahashiK.ShirakiK.SakamotoK.SmeeD.F.BarnardD.L.GowenB.B.JulanderJ.G.MorreyJ.D.T-705"/>
   <result pre="of Sulfated Galactomannans against Yellow Fever Virus (BeH111 Strain) and" exact="Dengue" post="1 Virus (Hawaii Strain)Antivir. Res.20036020120810.1016/S0166-3542(03)00175-X14638396 168.TalaricoL.B.PujolC.A.ZibettiR.G.M.FaríaP.C.S.NosedaM.D.DuarteM.E.R.DamonteE.B.The Antiviral Activity of"/>
   <result pre="(Hawaii Strain)Antivir. Res.20036020120810.1016/S0166-3542(03)00175-X14638396 168.TalaricoL.B.PujolC.A.ZibettiR.G.M.FaríaP.C.S.NosedaM.D.DuarteM.E.R.DamonteE.B.The Antiviral Activity of Sulfated Polysaccharides against" exact="Dengue" post="Virus Is Dependent on Virus Serotype and Host CellAntivir."/>
   <result pre="Antiviral Activity of Carbohydrate-Binding Agents against the Four Serotypes of" exact="Dengue" post="Virus in Monocyte-Derived Dendritic CellsPLoS ONE20116e2165810.1371/journal.pone.002165821738755 170.LiangY.De WispelaereM.CarocciM.LiuQ.WangJ.YangP.L.GrayN.S.Structure-Activity Relationship"/>
   <result pre="Multivalent Inhibitor of the DC-SIGN Dependent Uptake of HIV-1 and" exact="Dengue" post="VirusBiomaterials2014354175418410.1016/j.biomaterials.2014.01.01424508075 172.KouretovaJ.HammamyM.Z.EppA.HardesK.KallisS.ZhangL.HilgenfeldR.BartenschlagerR.SteinmetzerT.Effects of NS2B-NS3 Protease and Furin Inhibition on"/>
   <result pre="Dengue VirusBiomaterials2014354175418410.1016/j.biomaterials.2014.01.01424508075 172.KouretovaJ.HammamyM.Z.EppA.HardesK.KallisS.ZhangL.HilgenfeldR.BartenschlagerR.SteinmetzerT.Effects of NS2B-NS3 Protease and Furin Inhibition on" exact="West Nile" post="and Dengue Virus ReplicationJ. Enzym. Inhib. Med. Chem.20173271272110.1080/14756366.2017.130652128385094 173.HotokezakaH.SakaiE.KanaokaK.SaitoK.MatsuoK.I.KitauraH.NakayamaK.U0126"/>
   <result pre="of NS2B-NS3 Protease and Furin Inhibition on West Nile and" exact="Dengue" post="Virus ReplicationJ. Enzym. Inhib. Med. Chem.20173271272110.1080/14756366.2017.130652128385094 173.HotokezakaH.SakaiE.KanaokaK.SaitoK.MatsuoK.I.KitauraH.NakayamaK.U0126 and PD98059,"/>
   <result pre="osteoclast-like cellsJ. Biol. Chem.2002277473664737210.1074/jbc.M20828420012237315 174.SreekanthG.P.ChuncharuneeA.SirimontapornA.PanaamponJ.NoisakranS.YenchitsomanusP.T.LimjindapornT.SB203580 Modulates P38 MAPK Signaling and" exact="Dengue" post="Virus-Induced Liver Injury by Reducing MAPKAPK2, HSP27, and ATF2"/>
   <result pre="178.PuS.Y.XiaoF.SchorS.BekermanE.ZaniniF.Barouch-BentovR.NagamineC.M.EinavS.Feasibility and Biological Rationale of Repurposing Sunitinib and Erlotinib for" exact="Dengue" post="TreatmentAntivir. Res.2018155677510.1016/j.antiviral.2018.05.00129753658 179.ChenH.H.ChenC.C.LinY.S.ChangP.C.LuZ.Y.LinC.F.ChenC.L.ChangC.P.AR-12 Suppresses Dengue Virus Replication by down-Regulation"/>
   <result pre="Repurposing Sunitinib and Erlotinib for Dengue TreatmentAntivir. Res.2018155677510.1016/j.antiviral.2018.05.00129753658 179.ChenH.H.ChenC.C.LinY.S.ChangP.C.LuZ.Y.LinC.F.ChenC.L.ChangC.P.AR-12 Suppresses" exact="Dengue" post="Virus Replication by down-Regulation of PI3K/AKT and GRP78Antivir. Res.201714215816828238876"/>
   <result pre="Res.2014111829210.1016/j.antiviral.2014.09.00425241249 181.ChangJ.SchulW.YipA.XuX.GuoJ.T.BlockT.M.Competitive Inhibitor of Cellular α-Glucosidases Protects Mice from Lethal" exact="Dengue" post="Virus InfectionAntivir. Res.20119236937110.1016/j.antiviral.2011.08.00321854808 182.GuB.MasonP.WangL.NortonP.BourneN.MoriartyR.MehtaA.DespandeM.ShahR.BlockT.Antiviral Profiles of Novel Iminocyclitol Compounds"/>
   <result pre="Profiles of Novel Iminocyclitol Compounds against Bovine Viral Diarrhea Virus," exact="West Nile" post="Virus, Dengue Virus and Hepatitis B VirusAntivir. Chem. Chemother.200718495910.1177/09563202070180010517354651"/>
   <result pre="Iminocyclitol Compounds against Bovine Viral Diarrhea Virus, West Nile Virus," exact="Dengue" post="Virus and Hepatitis B VirusAntivir. Chem. Chemother.200718495910.1177/09563202070180010517354651 183.LiangP.H.ChengW.C.LeeY.L.YuH.P.WuY.T.LinY.L.WongC.H.Novel Five-Membered"/>
   <result pre="of N -Alkylated Deoxynojirimycin (DNJ) Derivatives for the Treatment of" exact="Dengue" post="Virus InfectionJ. Med. Chem.2012556061607510.1021/jm300171v22712544 186.PlummerE.BuckM.D.SanchezM.GreenbaumJ.A.TurnerJ.GrewalR.KloseB.SampathA.WarfieldK.L.PetersB.et al.Dengue Virus Evolution under"/>
   <result pre="Heme Oxygenase 1 Is a Potential Host Cell Factor against" exact="Dengue" post="Virus ReplicationSci. Rep.201663217610.1038/srep3217627553177 188.YuJ.S.WuY.H.TsengC.K.LinC.K.HsuY.C.ChenY.H.LeeJ.C.Schisandrin A Inhibits Dengue Viral Replication"/>
   <result pre="Cell Factor against Dengue Virus ReplicationSci. Rep.201663217610.1038/srep3217627553177 188.YuJ.S.WuY.H.TsengC.K.LinC.K.HsuY.C.ChenY.H.LeeJ.C.Schisandrin A Inhibits" exact="Dengue" post="Viral Replication via Upregulating Antiviral Interferon Responses through STAT"/>
   <result pre="Antiviral Interferon Responses through STAT Signaling PathwaySci. Rep.201774517110.1038/srep4517128338050 189.YuJ.S.TsengC.K.LinC.K.HsuY.C.WuY.H.HsiehC.L.LeeJ.C.Celastrol Inhibits" exact="Dengue" post="Virus Replication via Up-Regulating Type I Interferon and Downstream"/>
   <result pre="Innate Immunity to Restrict the Replication of Hepatitis C and" exact="Dengue" post="VirusFront. Microbiol.2017866810.3389/fmicb.2017.0066828473813 193.ChiangC.BeljanskiV.YinK.Sequence-specific modifications enhance the broad-spectrum antiviral response"/>
   <result pre="broad-spectrum antiviral response activated by RIG-I agonistsJ. Virol.2015898011802510.1128/JVI.00845-1526018150 194.ShafeeN.AbuBakarS.Zinc Accelerates" exact="Dengue" post="Virus Type 2-Induced Apoptosis in Vero CellsFEBS Lett.2002524202410.1016/S0014-5793(02)02991-512135735 195.CorrêaG.LindenbergC.D.A.Fernandes-SantosC.GandiniM.PaivaF.P.Coutinho-SilvaR.KubelkaC.F.The"/>
   <result pre="CellsFEBS Lett.2002524202410.1016/S0014-5793(02)02991-512135735 195.CorrêaG.LindenbergC.D.A.Fernandes-SantosC.GandiniM.PaivaF.P.Coutinho-SilvaR.KubelkaC.F.The Purinergic Receptor P2X7 Role in Control of" exact="Dengue" post="Virus-2 Infection and Cytokine/Chemokine Production in Infected Human MonocytesImmunobiology201622179480210.1016/j.imbio.2016.02.00326969484"/>
   <result pre="and Cytokine/Chemokine Production in Infected Human MonocytesImmunobiology201622179480210.1016/j.imbio.2016.02.00326969484 196.MelloC.D.S.ValenteL.M.M.WolffT.Lima-JuniorR.S.FialhoL.G.MarinhoC.F.AzeredoE.L.Oliveira-PintoL.M.PereiraR.D.C.A.SianiA.C.et al.Decrease in" exact="Dengue" post="Virus-2 Infection and Reduction of Cytokine/Chemokine Production by Uncaria"/>
   <result pre="Antiviral Activities of Uncaria Tomentosa on Human Monocytes Infected with" exact="Dengue" post="Virus-2Int. Immunopharmacol.2008846847610.1016/j.intimp.2007.11.01018279801 198.WagstaffK.M.HarrichD.HeatonS.M.SivakumaranH.JansD.A.Ivermectin Is a Specific Inhibitor of Importin"/>
   <result pre="α/β-Mediated Nuclear Import Able to Inhibit Replication of HIV-1 and" exact="Dengue" post="VirusBiochem. J.201244385185610.1042/BJ2012015022417684 199.PanX.B.HanJ.C.CongX.WeiL.BST2/Tetherin Inhibits Dengue Virus Release from Human"/>
   <result pre="Inhibit Replication of HIV-1 and Dengue VirusBiochem. J.201244385185610.1042/BJ2012015022417684 199.PanX.B.HanJ.C.CongX.WeiL.BST2/Tetherin Inhibits" exact="Dengue" post="Virus Release from Human Hepatoma CellsPLoS ONE20127e5103310.1371/journal.pone.005103323236425 200.TrungD.T.WillsB.Systemic Vascular"/>
   <result pre="from Human Hepatoma CellsPLoS ONE20127e5103310.1371/journal.pone.005103323236425 200.TrungD.T.WillsB.Systemic Vascular Leakage Associated with" exact="Dengue" post="Infections—The Clinical PerspectiveSpringerBerlin/Heidelberg, Germany2010 201.GrögerM.PasteinerW.IgnatyevG.MattU.KnappS.AtrasheuskayaA.BukinE.FriedlP.ZinklD.Hofer-WarbinekR.et al.Peptide Bβ15-42 Preserves Endothelial"/>
   <result pre="Function in ShockPLoS ONE20094e539110.1371/annotation/9ae032a2-c48d-46d9-9f8f-d3f401714e4219401765 202.ChuangY.C.LeiH.Y.LiuH.S.LinY.S.FuT.F.YehT.M.Macrophage Migration Inhibitory Factor Induced by" exact="Dengue" post="Virus Infection Increases Vascular PermeabilityCytokine20115422223110.1016/j.cyto.2011.01.01321320786 203.KubelkaC.AzeredoE.GandiniM.PintoL.Metalloproteinases Are Produced during"/>
   <result pre="Dengue Virus Infection Increases Vascular PermeabilityCytokine20115422223110.1016/j.cyto.2011.01.01321320786 203.KubelkaC.AzeredoE.GandiniM.PintoL.Metalloproteinases Are Produced during" exact="Dengue" post="Fever and MMP9 Is Associated with SeverityThe British Infection"/>
   <result pre="in Endothelial CellsPLoS ONE20127e4193210.1371/journal.pone.004193222860034 205.CostaV.V.FagundesC.T.SouzaD.G.TeixeiraM.M.Inflammatory and Innate Immune Responses in" exact="Dengue" post="InfectionAm. J. Pathol.20131821950196110.1016/j.ajpath.2013.02.02723567637 206.SouzaD.FagundesC.Essential Role of Platelet-Activating Factor Receptor"/>
   <result pre="206.SouzaD.FagundesC.Essential Role of Platelet-Activating Factor Receptor in the Pathogenesis of" exact="Dengue" post="Virus InfectionProc. Natl. Acad. Sci. USA2009106141381414310.1073/pnas.090646710619666557 207.RahmanS.M.AtikullahM.IslamM.N.MohaimenulM.AhammadF.IslamM.S.SahaB.RahmanM.H.Anti-inflammatory, antinociceptive and"/>
   <result pre="repository hosts. Figure 2 Host metabolic pathways are necessary for" exact="DENV" post="replication: As an enveloped virus, DENV requires fatty acids"/>
   <result pre="pathways are necessary for DENV replication: As an enveloped virus," exact="DENV" post="requires fatty acids for replication and virion envelopment, resulting"/>
   <result pre="into the endoplasmic reticulum (ER) and subsequently assemble with the" exact="DENV" post="virus. Glucose uptake in DENV-infected cells may increase through"/>
   <result pre="(GLUT-1) and hexokinase II (HK-II), the first enzyme of glycolysis." exact="DENV" post="infection alters glucose metabolism allosterically by up-regulation of glycolytic"/>
   <result pre="lipid [60,61]. Experimentally limiting glucose and fatty acid synthesis during" exact="DENV" post="infection, along with limiting glutamine levels, can help prevent"/>
   <result pre="with limiting glutamine levels, can help prevent infections. Figure 3" exact="DENV" post="receptors in human cells: DENV recognizes various types of"/>
   <result pre="help prevent infections. Figure 3 DENV receptors in human cells:" exact="DENV" post="recognizes various types of receptors present in the host"/>
   <result pre="Heparan sulfate was identified as the first molecule responsible for" exact="DENV" post="entry into mammalian cells, while sulfated glycosaminoglycans—ubiquitous molecules on"/>
   <result pre="the cell surface—were found to play a role in mediating" exact="DENV" post="attachment. CLEC4L (C-type lectin domain family 4, member L),"/>
   <result pre="that have a high affinity towards high-mannose ligands involved in" exact="DENV" post="entry into target cells, where C-type lectin domain family"/>
   <result pre="which are part of the receptor complex, assist in the" exact="DENV" post="binding. Lipid receptors phosphatydil serine (PtdSer), T-cell immunoglobulin and"/>
   <result pre="Another receptor, SR-BI, is also responsible for lipoprotein-associated interaction with" exact="DENV" post="and allows the virus to enter the host [76]."/>
   <result pre="to enter the host [76]. microorganisms-07-00296-t001_Table 1Table 1 List of" exact="DENV" post="inhibitors isolated by targeting host process. LLC-MK2 = rhesus"/>
   <result pre="I, IMP dehydrogenase = Inosine-5′-monophosphate dehydrogenase. Host Process Inhibitor(s) Target" exact="DENV" post="Types Cell Line(s) Tested Refs. Glycolytic pathway 2-deoxy- d-glucose"/>
   <result pre="acid biosynthesis DENV-4 Huh-7 cell [161] Orlistat Fatty acid biosynthesis" exact="DENV" post="-4, -2 HepG2 and HEK293T/17 Cell [161] PF-429242 Fatty"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783508\results\search\tropicalVirus\results.xml">
   <result pre="pathophysiology. Finally, Beaver et al., have reviewed evidence of how" exact="Zika" post="virus (ZIKV) evolution can explain the observed patterns of"/>
   <result pre="responses against African isolates differ from those observed against Asian" exact="ZIKV" post="lineages, and discuss how this could explain observed pathogenic"/>
   <result pre="and discuss how this could explain observed pathogenic differences among" exact="ZIKV" post="strains. From ancient germline infections to modern epidemics, outbreaks"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6783930\results\search\tropicalVirus\results.xml">
   <result pre="italic;} VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 6783930 doi: 10.3390/v11090878viruses-11-00878 : Review Chasing Intracellular" exact="Zika" post="Virus Using Proteomics ScaturroPietro1*KastnerAnna Lena1https://orcid.org/0000-0002-0166-1367PichlmairAndreas12*[1], lena.kastner@tum.de[2], *Correspondence: pietro.scaturro@tum.de (P.S.);"/>
   <result pre="(e.g., dengue virus), but can also cause fulminant outbreaks (e.g.," exact="West Nile" post="virus, Japanese encephalitis virus and Zika virus). Intense research"/>
   <result pre="fulminant outbreaks (e.g., West Nile virus, Japanese encephalitis virus and" exact="Zika" post="virus). Intense research efforts in the past decades uncovered"/>
   <result pre="proteomic approaches in flavivirus biology with a special focus on" exact="Zika" post="virus, and their basic and translational potential and implications"/>
   <result pre="in understanding and characterizing host responses to arboviral infections. flaviviruses" exact="Zika" post="virus proteomics interactome AP-LC-MS/MS phosphoproteomics Label-free Quatification arboviruses DENV"/>
   <result pre="flaviviruses Zika virus proteomics interactome AP-LC-MS/MS phosphoproteomics Label-free Quatification arboviruses" exact="DENV" post="WNV 1. Introduction Viruses are highly adapted intracellular pathogens"/>
   <result pre="Zika virus proteomics interactome AP-LC-MS/MS phosphoproteomics Label-free Quatification arboviruses DENV" exact="WNV" post="1. Introduction Viruses are highly adapted intracellular pathogens that"/>
   <result pre="strike in a naïve population. One such pathogen is the" exact="Zika" post="virus, a positive stranded RNA virus belonging to the"/>
   <result pre="newborns in southern America could be linked to the ongoing" exact="Zika" post="virus (ZIKV) outbreak in this otherwise naïve population [2,3]."/>
   <result pre="(ZIKV) outbreak in this otherwise naïve population [2,3]. In adults," exact="ZIKV" post="is predominantly asymptomatic or causes mild, flu-like symptoms, although"/>
   <result pre="impairment and infertility [3,4,5]. Following vertical transmission upon maternal infection," exact="ZIKV" post="can cause fetal demise or Guillain-Barré syndrome, a neuro-inflammatory"/>
   <result pre="the peripheral nervous system [6,7]. However, the limited knowledge on" exact="ZIKV" post="pathogenesis and the sudden spread of this pathogen sparked"/>
   <result pre="a molecular level. These studies are of particular interest, since" exact="ZIKV" post="combines many unique features of flaviviruses that are normally"/>
   <result pre="Indeed, similarly to other members of the Flaviviridae family like" exact="Dengue" post="(DENV), Yellow fever (YFV), Japanese encephalitis virus (JEV) and"/>
   <result pre="to other members of the Flaviviridae family like Dengue (DENV)," exact="Yellow fever" post="(YFV), Japanese encephalitis virus (JEV) and West Nile virus"/>
   <result pre="Dengue (DENV), Yellow fever (YFV), Japanese encephalitis virus (JEV) and" exact="West Nile" post="virus (WNV), ZIKV is also transmitted by mosquitoes. Furthermore,"/>
   <result pre="(YFV), Japanese encephalitis virus (JEV) and West Nile virus (WNV)," exact="ZIKV" post="is also transmitted by mosquitoes. Furthermore, analogously to JEV,"/>
   <result pre="ZIKV is also transmitted by mosquitoes. Furthermore, analogously to JEV," exact="WNV" post="and tick-borne encephalitis virus (TBEV), Zika virus infections are"/>
   <result pre="Furthermore, analogously to JEV, WNV and tick-borne encephalitis virus (TBEV)," exact="Zika" post="virus infections are associated with neurological diseases, although ZIKV"/>
   <result pre="(TBEV), Zika virus infections are associated with neurological diseases, although" exact="ZIKV" post="is the only Flaviviridae member with documented ability to"/>
   <result pre="its unique properties and the urgent need to further understand" exact="ZIKV" post="biology, a number of laboratories started to use large-scale"/>
   <result pre="are efforts during public health responses as recently shown by" exact="ZIKV" post="and Ebola virus epidemics [22,23,24]. Furthermore, NGS can be"/>
   <result pre="therapy. This is particularly true for epidemic viruses such as" exact="Zika" post="virus, which since 2016 has left a devastating impact"/>
   <result pre="virus as a whole. 3.1. ZIKV–Host Interactions 3.1.1. Interactions of" exact="ZIKV" post="Capsid with Host Proteins Systematic studies are of paramount"/>
   <result pre="to investigate the cellular interactome of each of the 10" exact="ZIKV" post="proteins (Figure 2a). A discrete number of previously reported"/>
   <result pre="approach in SK-N-BE2 neuroblastoma cells [34], we identified in the" exact="ZIKV" post="capsid interactome a strong enrichment in nuclear and nucleolar-resident"/>
   <result pre="Pex19, that have been previously reported as cellular targets of" exact="Dengue" post="(DENV) and West Nile virus (WNV) (Figure 2b) [35,36,37]."/>
   <result pre="been previously reported as cellular targets of Dengue (DENV) and" exact="West Nile" post="virus (WNV) (Figure 2b) [35,36,37]. Interestingly, among the capsid-specific"/>
   <result pre="interactors, a completely new set of proteins associating with the" exact="ZIKV" post="capsid was identified. Among these, a poorly characterized nucleolar"/>
   <result pre="were identified as specific capsid interactors, suggesting the propensity of" exact="ZIKV" post="capsid to interact with RNA-binding proteins. Importantly the functional"/>
   <result pre="RNA-binding proteins. Importantly the functional relevance of some of these" exact="ZIKV" post="capsid interactors was underlined by knock-down studies, confirming a"/>
   <result pre="members of the DDX family and ZC3HAV1, among the specific" exact="ZIKV" post="capsid interactors using BioID- and AP-LC-MS/MS in 293T cells,"/>
   <result pre="ZC3HAV1 led to a 4- to 8-fold increase in ZIKV," exact="DENV" post="and WNV virus titers. Interestingly, the antiviral activity of"/>
   <result pre="to a 4- to 8-fold increase in ZIKV, DENV and" exact="WNV" post="virus titers. Interestingly, the antiviral activity of ZC3HAV1 has"/>
   <result pre="and the exon-junction complex (EJC) as targets of the WNV," exact="DENV" post="and ZIKA virus capsids [42,46]. While the antiviral activity"/>
   <result pre="depletion of the cellular PYM1 pool upon recruitment by the" exact="WNV" post="capsid to protect viral RNA from decay. Similarly, direct"/>
   <result pre="of the regulator of nonsense transcripts 1 (UPF1) among the" exact="ZIKV" post="capsid interactors and the upregulation of several NMD substrate"/>
   <result pre="interactors and the upregulation of several NMD substrate mRNAs upon" exact="ZIKV" post="infection both in Huh7 and hNPC. Furthermore, depletion of"/>
   <result pre="In addition to proteins recruited by several flavivirus capsids, the" exact="ZIKV" post="capsid is the only one reported to specifically associate"/>
   <result pre="diverge regulation or expression of specific transcripts. 3.1.2. Interactions of" exact="ZIKV" post="NS4B with the Host Another interesting ZIKV protein that"/>
   <result pre="3.1.2. Interactions of ZIKV NS4B with the Host Another interesting" exact="ZIKV" post="protein that appears to have both conserved and unique"/>
   <result pre="elongation as proposed recently [47]. In addition to mitochondrial proteins," exact="ZIKV" post="NS4B appears to bind cellular proteins involved in protein"/>
   <result pre="specific binders of arthropod-borne flaviviruses in neuronal cells (such as" exact="DENV" post="and ZIKV), a subset of proteins exhibited ZIKV specificity"/>
   <result pre="(such as DENV and ZIKV), a subset of proteins exhibited" exact="ZIKV" post="specificity (TMEM41b, CEND1, CLN6), suggesting that similarly to capsid,"/>
   <result pre="and specifically associates with mTOR. These results support reports associating" exact="ZIKV" post="infection or NS4B overexpression to defective neurogenesis via suppression"/>
   <result pre="Viral Proteins In addition to capsid and NS4B, several novel" exact="ZIKV" post="NS5 binders were recently identified in these proteomics surveys."/>
   <result pre="observed upon gene silencing (2-fold increase and 2-fold decrease for" exact="ZIKV" post="and JEV infectivity, respectively) [41,54]. Further mechanistic studies suggest"/>
   <result pre="[53]. Furthermore, among the novel cellular targets identified in the" exact="ZIKV" post="NS4A interactome is ANKLE2, a protein previously shown to"/>
   <result pre="of anti-viral activity. However, in light of cumulative evidence on" exact="ZIKV" post="and WNV, it is tempting to speculate that this"/>
   <result pre="of WNV, for instance, interacts with NS4B (WNV, [58]). Likewise," exact="DENV" post="NS1 associates with an unprocessed viral precursor NS4A-2k-NS4B (DENV,"/>
   <result pre="an unprocessed viral precursor NS4A-2k-NS4B (DENV, [59]) and NS4B of" exact="DENV" post="has been reported to bind NS3 (DENV, [60]). Proteomic"/>
   <result pre="the mode of action of therapeutic drugs. 3.1.4. Interactions of" exact="ZIKV" post="Viral RNA with the Host In addition to PPI,"/>
   <result pre="reported the identification of 79 proteins specifically associated with the" exact="DENV" post="gRNA [64]. Among these, proteins earlier involved in PPI"/>
   <result pre="Importantly, depletion of RBMX and NONO by RNAi significantly reduced" exact="DENV" post="titers, confirming their functional relevance in DENV replication. Similar"/>
   <result pre="RNAi significantly reduced DENV titers, confirming their functional relevance in" exact="DENV" post="replication. Similar studies were also performed using an alternative"/>
   <result pre="the use of 5′-end biotinylated antisense oligonucleotides specific to the" exact="DENV" post="gRNA and very stringent cut-off criteria. Interestingly this approach"/>
   <result pre="Only one study to date reported the systematic analysis of" exact="ZIKV" post="and DENV gRNA-associated proteins, using the ChIRP-MS (comprehensive identification"/>
   <result pre="study to date reported the systematic analysis of ZIKV and" exact="DENV" post="gRNA-associated proteins, using the ChIRP-MS (comprehensive identification of RNA-binding"/>
   <result pre="[66]. This approach identified 464 RNA-binding proteins (RBPs) associated with" exact="DENV" post="or ZIKV gRNAs [67], confirming association with previously reported"/>
   <result pre="approach identified 464 RNA-binding proteins (RBPs) associated with DENV or" exact="ZIKV" post="gRNAs [67], confirming association with previously reported flavivirus RBPs"/>
   <result pre="as well as four newly performed surveys using all four" exact="DENV" post="serotypes, identified Vigilin and RRBP1 (ribosome-binding protein 1) as"/>
   <result pre="linked to flavivirus infection. Interestingly, both of these proteins promote" exact="DENV" post="infection and gRNA stability, positively modulating translation and replication"/>
   <result pre="replication of the gRNA. 3.2. Global Proteome Expression Affected by" exact="ZIKV" post="Infection Several studies systematically investigated the impact of flavivirus"/>
   <result pre="analysis to study the impact of a Brazilian isolate of" exact="ZIKV" post="on human neurospheres [70]. This approach revealed 199 downregulated"/>
   <result pre="human neuronal progenitors, confirmed specific downregulation of neuronal factors upon" exact="ZIKV" post="infection, as well as activation of general antiviral response"/>
   <result pre="[51], this study also identified shared targets deregulated both by" exact="ZIKV" post="infection and NS4B expression (e.g., MAP2, -6, DPYSL3, -5,"/>
   <result pre="-5, CNTN2). Recently, additional reports investigated further the impact of" exact="ZIKV" post="infection on human mesenchymal stem cells using the MudPIT"/>
   <result pre="[73]. Using this method to systematically compare African and Asian" exact="ZIKV" post="isolate representatives, revealed differential responses especially in the context"/>
   <result pre="transcriptomic analysis of ZIKA virus infected neuronal cells is that" exact="ZIKV" post="infection has a profound effect on expression of proteins"/>
   <result pre="of infected patients. 3.3. Phosphorylation and Other PTMs Modulated by" exact="ZIKV" post="Initial studies by the Cao group focused on the"/>
   <result pre="Similarly, to JEV and WNV, 1216 proteins were modulated upon" exact="ZIKV" post="infection, and analysis of enriched cellular functions affected by"/>
   <result pre="ZIKV infection, and analysis of enriched cellular functions affected by" exact="ZIKV" post="infection identified cellular assembly and organization, cell-cycle regulation, as"/>
   <result pre="diseases. In line with earlier reports, also in case of" exact="ZIKV" post="the ATM, AKT/mTOR and ERK/MAPK signaling cascades were significantly"/>
   <result pre="map kinases (e.g., EIF4EBP1, BAZ1B, TWIST) were significantly dephosphorylated upon" exact="ZIKV" post="infection. In this respect, these data complement on a"/>
   <result pre="effects appear to be ZIKV-specific, at least when compared to" exact="DENV" post="infection in hNPC [71], suggesting an important role in"/>
   <result pre="neuronal progenitors. Phosphoproteomic analysis also supports a prominent role of" exact="Zika" post="virus on neurogenesis. p38 MAPK and downstream targets (HSPBI"/>
   <result pre="screen. This work identified several host proteins differentially mono-ubiquitylated upon" exact="DENV" post="infection, unraveling the ER-resident protein AUP1 as differentially ubiquitin-modified"/>
   <result pre="Emergence in the Western HemisphereJ. Virol.2016904864487510.1128/JVI.00252-1626962217 2.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–2015: A retrospective"/>
   <result pre="to Male Infertility in MiceCell201716854210.1016/j.cell.2017.01.00928129543 5.KodatiS.PalmoreT.N.SpellmanF.A.CunninghamD.WeistropB.SenH.N.Bilateral posterior uveitis associated with" exact="Zika" post="virus infectionLancet201738912512610.1016/S0140-6736(16)32518-127939402 6.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika Virus Infection during Pregnancy in"/>
   <result pre="Virus Associated with MicrocephalyN. Engl. J. Med.201637495195810.1056/NEJMoa160065126862926 8.PiersonT.C.DiamondM.S.The emergence of" exact="Zika" post="virus and its new clinical syndromesNature201856057358110.1038/s41586-018-0446-y30158602 9.PichlmairA.KandasamyK.AlvisiG.MulhernO.SaccoR.HabjanM.BinderM.StefanovicA.EberleC.A.GoncalvesA.et al.Viral immune"/>
   <result pre="Flaviviridae host factors through genome-scale CRISPR screensNature201653515916310.1038/nature1863127383987 15.SavidisG.McDougallW.M.MeranerP.PerreiraJ.M.PortmannJ.M.TrincucciG.JohnS.P.AkerA.M.RenzetteN.RobbinsD.R.et al.Identification of" exact="Zika" post="Virus and Dengue Virus Dependency Factors using Functional GenomicsCell"/>
   <result pre="through genome-scale CRISPR screensNature201653515916310.1038/nature1863127383987 15.SavidisG.McDougallW.M.MeranerP.PerreiraJ.M.PortmannJ.M.TrincucciG.JohnS.P.AkerA.M.RenzetteN.RobbinsD.R.et al.Identification of Zika Virus and" exact="Dengue" post="Virus Dependency Factors using Functional GenomicsCell Rep.20161623224610.1016/j.celrep.2016.06.02827342126 16.SessionsO.M.BarrowsN.J.Souza-NetoJ.A.RobinsonT.J.HersheyC.L.RodgersM.A.RamirezJ.L.DimopoulosG.YangP.L.PearsonJ.L.et al.Discovery"/>
   <result pre="factorsNature20094581047105010.1038/nature0796719396146 17.DukhovnyA.LamkiewiczK.ChenQ.FrickeM.Jabrane-FerratN.MarzM.JungJ.U.SklanE.H.A CRISPR Activation Screen Identifies Genes That Protect against" exact="Zika" post="Virus InfectionJ. Virol.201993e00211-1910.1128/JVI.00211-1931142663 18.LiY.MuffatJ.Omer JavedA.KeysH.R.LungjangwaT.BoschI.KhanM.VirgilioM.C.GehrkeL.SabatiniD.M.et al.Genome-wide CRISPR screen for"/>
   <result pre="Zika Virus InfectionJ. Virol.201993e00211-1910.1128/JVI.00211-1931142663 18.LiY.MuffatJ.Omer JavedA.KeysH.R.LungjangwaT.BoschI.KhanM.VirgilioM.C.GehrkeL.SabatiniD.M.et al.Genome-wide CRISPR screen for" exact="Zika" post="virus resistance in human neural cellsProc. Natl. Acad. Sci."/>
   <result pre="Proteomics DataAnnu. Rev. Biomed. Data Sci.2018120723410.1146/annurev-biodatasci-080917-013516 31.TaguwaS.MaringerK.LiX.Bernal-RubioD.RauchJ.N.GestwickiJ.E.AndinoR.Fernandez-SesmaA.FrydmanJ.Defining Hsp70 Subnetworks in" exact="Dengue" post="Virus Replication Reveals Key Vulnerability in Flavivirus InfectionCell20151631108112310.1016/j.cell.2015.10.04626582131 32.CastelloA.FischerB.EichelbaumK.HorosR.BeckmannB.M.StreinC.DaveyN.E.HumphreysD.T.PreissT.SteinmetzL.M.et"/>
   <result pre="in innate immunityTrends Immunol.20133461061910.1016/j.it.2013.05.00223827258 34.ScaturroP.StukalovA.HaasD.A.CorteseM.DraganovaK.PlaszczycaA.BartenschlagerR.GotzM.PichlmairA.An orthogonal proteomic survey uncovers novel" exact="Zika" post="virus host factorsNature201856125325710.1038/s41586-018-0484-530177828 35.BalinskyC.A.SchmeisserH.GanesanS.SinghK.PiersonT.C.ZoonK.C.Nucleolin interacts with the dengue virus"/>
   <result pre="VirusJ. Virol.201892e01042-1810.1128/JVI.01042-1830209172 40.CoyaudE.RanadheeraC.ChengD.GoncalvesJ.DyakovB.J.A.LaurentE.M.N.St-GermainJ.PelletierL.GingrasA.C.BrumellJ.H.et al.Global Interactomics Uncovers Extensive Organellar Targeting by" exact="Zika" post="VirusMol. Cell Proteom.2018172242225510.1074/mcp.TIR118.000800 41.ShahP.S.LinkN.JangG.M.SharpP.P.ZhuT.SwaneyD.L.JohnsonJ.R.Von DollenJ.RamageH.R.SatkampL.et al.Comparative Flavivirus-Host Protein Interaction"/>
   <result pre="41.ShahP.S.LinkN.JangG.M.SharpP.P.ZhuT.SwaneyD.L.JohnsonJ.R.Von DollenJ.RamageH.R.SatkampL.et al.Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of" exact="Dengue" post="and Zika Virus PathogenesisCell201817519311945.e1810.1016/j.cell.2018.11.02830550790 42.LiM.JohnsonJ.R.TruongB.KimG.WeinbrenN.DittmarM.ShahP.S.Von DollenJ.NewtonB.W.JangG.M.et al.Identification of antiviral"/>
   <result pre="al.Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and" exact="Zika" post="Virus PathogenesisCell201817519311945.e1810.1016/j.cell.2018.11.02830550790 42.LiM.JohnsonJ.R.TruongB.KimG.WeinbrenN.DittmarM.ShahP.S.Von DollenJ.NewtonB.W.JangG.M.et al.Identification of antiviral roles for"/>
   <result pre="zinc-finger antiviral proteinPLoS Pathog.201814e100716610.1371/journal.ppat.100716630016363 46.FontaineK.A.LeonK.E.KhalidM.M.TomarS.Jimenez-MoralesD.DunlapM.KayeJ.A.ShahP.S.FinkbeinerS.KroganN.J.et al.The Cellular NMD Pathway Restricts" exact="Zika" post="Virus Infection and Is Targeted by the Viral Capsid"/>
   <result pre="Cell20161966367110.1016/j.stem.2016.07.01927524440 52.HeatonN.S.MoshkinaN.FenouilR.GardnerT.J.AguirreS.ShahP.S.ZhaoN.ManganaroL.HultquistJ.F.NoelJ.et al.Targeting Viral Proteostasis Limits Influenza Virus, HIV, and" exact="Dengue" post="Virus InfectionImmunity201644465810.1016/j.immuni.2015.12.01726789921 53.De MaioF.A.RissoG.IglesiasN.G.ShahP.PozziB.GebhardL.G.MammiP.ManciniE.YanovskyM.J.AndinoR.et al.The Dengue Virus NS5 Protein"/>
   <result pre="Influenza Virus, HIV, and Dengue Virus InfectionImmunity201644465810.1016/j.immuni.2015.12.01726789921 53.De MaioF.A.RissoG.IglesiasN.G.ShahP.PozziB.GebhardL.G.MammiP.ManciniE.YanovskyM.J.AndinoR.et al.The" exact="Dengue" post="Virus NS5 Protein Intrudes in the Cellular Spliceosome and"/>
   <result pre="the Cellular Spliceosome and Modulates SplicingPLoS Pathog.201612e100584110.1371/journal.ppat.100584127575636 54.KovanichD.SaisawangC.SittipaisankulP.RamphanS.KalpongnukulN.SomparnP.PisitkunT.SmithD.R.Analysis of the" exact="Zika" post="and Japanese Encephalitis Virus NS5 InteractomesJ. Proteome. Res.2019183203321810.1021/acs.jproteome.9b0031831199156 55.HafirassouM.L.MeertensL.Umana-DiazC.LabeauA.DejarnacO.Bonnet-MadinL.KummererB.M.DelaugerreC.RoingeardP.VidalainP.O.et"/>
   <result pre="InteractomesJ. Proteome. Res.2019183203321810.1021/acs.jproteome.9b0031831199156 55.HafirassouM.L.MeertensL.Umana-DiazC.LabeauA.DejarnacO.Bonnet-MadinL.KummererB.M.DelaugerreC.RoingeardP.VidalainP.O.et al.A Global Interactome Map of the" exact="Dengue" post="Virus NS1 Identifies Virus Restriction and Dependency Host FactorsCell"/>
   <result pre="FactorsCell Rep.2017213900391310.1016/j.celrep.2017.11.09429281836 56.LinD.L.InoueT.ChenY.J.ChangA.TsaiB.TaiA.W.The ER Membrane Protein Complex Promotes Biogenesis of" exact="Dengue" post="and Zika Virus Non-structural Multi-pass Transmembrane Proteins to Support"/>
   <result pre="56.LinD.L.InoueT.ChenY.J.ChangA.TsaiB.TaiA.W.The ER Membrane Protein Complex Promotes Biogenesis of Dengue and" exact="Zika" post="Virus Non-structural Multi-pass Transmembrane Proteins to Support InfectionCell Rep.20192716661674.e410.1016/j.celrep.2019.04.05131067454"/>
   <result pre="Rep.20192716661674.e410.1016/j.celrep.2019.04.05131067454 57.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MunozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A Screen of FDA-Approved Drugs for Inhibitors of" exact="Zika" post="Virus InfectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 58.YounS.LiT.McCuneB.T.EdelingM.A.FremontD.H.CristeaI.M.DiamondM.S.Evidence for a genetic and"/>
   <result pre="between nonstructural proteins NS1 and NS4B that modulates replication of" exact="West Nile" post="virusJ. Virol.2012867360737110.1128/JVI.00157-1222553322 59.PlaszczycaA.ScaturroP.NeufeldtC.J.CorteseM.CerikanB.FerlaS.BrancaleA.PichlmairA.BartenschlagerR.A novel interaction between dengue virus nonstructural"/>
   <result pre="replication organellePLoS Pathog.201915e100773610.1371/journal.ppat.100773631071189 60.Chatel-ChaixL.FischlW.ScaturroP.CorteseM.KallisS.BartenschlagerM.FischerB.BartenschlagerR.A Combined Genetic-Proteomic Approach Identifies Residues within" exact="Dengue" post="Virus NS4B Critical for Interaction with NS3 and Viral"/>
   <result pre="Viral ReplicationJ. Virol.2015897170718610.1128/JVI.00867-1525926641 61.RobyJ.A.PijlmanG.P.WiluszJ.KhromykhA.A.Noncoding subgenomic flavivirus RNA: Multiple functions in" exact="West Nile" post="virus pathogenesis and modulation of host responsesViruses2014640442710.3390/v602040424473339 62.ChavaliP.L.StojicL.MeredithL.W.JosephN.NahorskiM.S.SanfordT.J.SweeneyT.R.KrishnaB.A.HosmilloM.FirthA.E.et al.Neurodevelopmental"/>
   <result pre="of host responsesViruses2014640442710.3390/v602040424473339 62.ChavaliP.L.StojicL.MeredithL.W.JosephN.NahorskiM.S.SanfordT.J.SweeneyT.R.KrishnaB.A.HosmilloM.FirthA.E.et al.Neurodevelopmental protein Musashi-1 interacts with the" exact="Zika" post="genome and promotes viral replicationScience2017357838810.1126/science.aam924328572454 63.CharleyP.A.WiluszJ.Sponging of cellular proteins"/>
   <result pre="RNAsCurr. Opin. Virol.20149141810.1016/j.coviro.2014.09.00125233339 64.ViktorovskayaO.V.GrecoT.M.CristeaI.M.ThompsonS.R.Identification of RNA Binding Proteins Associated with" exact="Dengue" post="Virus RNA in Infected Cells Reveals Temporally Distinct Host"/>
   <result pre="Factor RequirementsPLoS Negl. Trop. Dis.201610e000492110.1371/journal.pntd.000492127556644 65.PhillipsS.L.SoderblomE.J.BradrickS.S.Garcia-BlancoM.A.Identification of Proteins Bound to" exact="Dengue" post="Viral RNA in Vivo Reveals New Host Proteins Important"/>
   <result pre="cellsPLoS ONE20149e9330510.1371/journal.pone.009330524671231 69.PastorinoB.Boucomont-ChapeaublancE.PeyrefitteC.N.BelghaziM.FusaiT.RogierC.TolouH.J.AlmerasL.Identification of cellular proteome modifications in response to" exact="West Nile" post="virus infectionMol. Cell Proteom.200981623163710.1074/mcp.M800565-MCP20019395707 70.GarcezP.P.NascimentoJ.M.de VasconcelosJ.M.Madeiro da CostaR.DelvecchioR.TrindadeP.LoiolaE.C.HigaL.M.CassoliJ.S.VitoriaG.et al.Zika"/>
   <result pre="al.Quantitative Label-Free Phosphoproteomics Reveals Differentially Regulated Protein Phosphorylation Involved in" exact="West Nile" post="Virus-Induced Host Inflammatory ResponseJ. Proteome Res.2015145157516810.1021/acs.jproteome.5b0042426485063 76.SouzaB.S.SampaioG.L.PereiraC.S.CamposG.S.SardiS.I.FreitasL.A.FigueiraC.P.ParedesB.D.NonakaC.K.AzevedoC.M.et al.Zika virus"/>
   <result pre="membrane topology. (b) Capsid interactors reported to bind exclusively to" exact="Zika" post="virus (ZIKV)-C are surrounded by the light blue circle,"/>
   <result pre="the orange circle were reported as shared interactors of ZIKV," exact="West Nile" post="virus (WNV) and Dengue (DENV)-C. The respective sub-cellular localization"/>
   <result pre="as shared interactors of ZIKV, West Nile virus (WNV) and" exact="Dengue" post="(DENV)-C. The respective sub-cellular localization is indicated. (c) NS4B"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784050\results\search\tropicalVirus\results.xml">
   <result pre="pmcid: 6784050 doi: 10.3390/v11090867viruses-11-00867 : Review Vector Competence: What Has" exact="Zika" post="Virus Taught Us? https://orcid.org/0000-0002-9182-216XAzarSasha R.123*https://orcid.org/0000-0001-8016-8556WeaverScott C.123*[1], [2], [3], *Correspondence:"/>
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract The unprecedented outbreak of" exact="Zika" post="virus (ZIKV) infection in the Americas from 2015 to"/>
   <result pre="other arboviruses, and discuss potential avenues of standardization going forward." exact="Zika" post="virus mosquitoes vector competence arbovirus Aedes aegypti Flaviviruses 1."/>
   <result pre="virus mosquitoes vector competence arbovirus Aedes aegypti Flaviviruses 1. Introduction" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus (arbovirus) of the"/>
   <result pre="infection produces minimal disease [2,3]. Seroprevalence analyses also indicate that" exact="ZIKV" post="has circulated in Southeast Asia as early as the"/>
   <result pre="to the related flaviviruses yellow fever (YFV) and dengue (DENV)," exact="ZIKV" post="demonstrates evidence of an African enzootic, or sylvatic transmission"/>
   <result pre="as patas or African green monkeys [7,8,9,10,11]. Beginning in 2007," exact="Zika" post="began to emerge outside of endemic areas in a"/>
   <result pre="States of Micronesia, and in Gabon [12,13]. Following these outbreaks," exact="ZIKV" post="spread across the South Pacific, causing epidemics in French"/>
   <result pre="outbreaks taking place in the South Pacific, the capacity for" exact="ZIKV" post="to cause some of the unique clinical outcomes and"/>
   <result pre="the World Health Organization to declare the ongoing transmission of" exact="ZIKV" post="in the Americas to be a public health emergency"/>
   <result pre="[21]. Substantial efforts were rapidly undertaken for the development of" exact="ZIKV" post="vaccines and therapeutics [23], culminating in several vaccine candidates"/>
   <result pre="of clinical licensure; as such, the best methodologies for combating" exact="ZIKV" post="outbreaks remain public education and mosquito abatement. The breadth"/>
   <result pre="public education and mosquito abatement. The breadth of the 2015–2017" exact="ZIKV" post="outbreak was unprecedented in the amount of information that"/>
   <result pre="various populations of potential vector mosquitoes to multiple strains of" exact="ZIKV" post="using various experimental approaches. Collectively, these efforts are best"/>
   <result pre="the finding that susceptibility to infection, and ability to transmit" exact="ZIKV" post="varies widely across disparate geographic strains of several mosquito"/>
   <result pre="geographic strains of several mosquito species, and disparate strains of" exact="ZIKV" post="also vary greatly in their ability to be transmitted"/>
   <result pre="of multiple arboviruses [27]. Despite this typical variability, the principal" exact="ZIKV" post="vector, Aedes aegypti, has often proved relatively refractory to"/>
   <result pre="considerations intrinsic to vector competence analyses, utilizing the body of" exact="ZIKV" post="literature as an example, and making comparisons with previously"/>
   <result pre="York in 2013 [42], as well as the outbreaks of" exact="CHIKV" post="in Italy and France in 2017 [43,44,45]), or in"/>
   <result pre="of Arboviral Evolution on Vector Competence Upon the introduction of" exact="ZIKV" post="into the Americas, two hypotheses gained considerable traction as"/>
   <result pre="the outbreak and the observation of sequelae such as congenital" exact="Zika" post="syndrome (CZS) and Guillain–Barré syndrome: i) ZIKV underwent an"/>
   <result pre="such as congenital Zika syndrome (CZS) and Guillain–Barré syndrome: i)" exact="ZIKV" post="underwent an adaptive evolutionary process that enhanced urban transmission"/>
   <result pre="vector competence evaluations allow for the direct examination of whether" exact="ZIKV" post="had adapted for more efficient transmission by urban vectors"/>
   <result pre="transmission by urban vectors such as Ae. aegypti. Given that" exact="ZIKV" post="exists as two distinct lineages, African and Asian, with"/>
   <result pre="Ae. aeygpti populations were more efficiently infected by African lineage" exact="ZIKV" post="compared to Asian lineage or American outbreak strains [29,52,53,54],"/>
   <result pre="variation in terms of infectivity and transmissibility within the African" exact="ZIKV" post="clade in a single population of mosquitoes (Ae. aegypti,"/>
   <result pre="which was associated with an A188V mutation in Asian lineage" exact="ZIKV" post="strains just before the South Pacific and American outbreaks"/>
   <result pre="the vector competence literature. For example, the NY99 genotype of" exact="West Nile" post="virus (WNV) that was introduced in the United States"/>
   <result pre="the house sparrow (Passer domesticus), developed resistance to NY99 lineage" exact="WNV" post="viremia over time, which taken in the context of"/>
   <result pre="as viral stocks frozen for greater than one week) of" exact="ZIKV" post="PRVABC59 (human isolate, Puerto Rico, 2015, hereafter referred to"/>
   <result pre="that even a short-term freeze adversely affected the ability of" exact="ZIKV" post="to disseminate compared to fresh virus, although this phenotype"/>
   <result pre="phenomenon is not limited to ZIKV; previous work on a" exact="YFV" post="isolate from a human patient in Peru (1899/81) was"/>
   <result pre="combinations, this finding is not universal. In an analysis of" exact="ZIKV" post="(strain TS17-2016), two populations of Ae. aegypti (Townsville and"/>
   <result pre="(7.7 log10 50% tissue culture infectious dose (TCID50)/mL) or frozen" exact="ZIKV" post="(7.2 log10 TCID50/mL). Even considering the negligible difference in"/>
   <result pre="necessity for subsequent cell culture passage (discussed below). Although several" exact="ZIKV" post="full-length infectious clones (FLIC) exist, for the purposes of"/>
   <result pre="The first of these was based on the Asian lineage" exact="ZIKV" post="FSS13025 (human isolate, Cambodia, 2010), hereafter referred to as"/>
   <result pre="genetic diversity from the cloning strategy employed [71]. Likewise, the" exact="ZIKV" post="infectious clone system based on the 2015 isolate from"/>
   <result pre="wild-type demonstrating polymorphisms at a frequency of over 1%, while" exact="ZIKV" post="ICD demonstrated only a single nucleotide with a polymorphism"/>
   <result pre="the infectious clone system made for the American outbreak strain" exact="ZIKV" post="PRVABC59 (human isolate, Puerto Rico, 2015), hereafter referred to"/>
   <result pre="PRVABC59 (human isolate, Puerto Rico, 2015), hereafter referred to as" exact="ZIKV" post="FLICPR, performed comparably to the parental isolate in various"/>
   <result pre="infectivity, and animal pathogenesis. However, when examined for genetic diversity," exact="ZIKV" post="FLICPR proved less rich in single nucleotide polymorphism (SNP)"/>
   <result pre="[74]. While this phenomenon has not been directly tested for" exact="ZIKV" post="(i.e., identical strains with differing passages being subsequently analyzed"/>
   <result pre="being subsequently analyzed for vector competence), the initial description of" exact="ZIKV" post="from the late 1940s utilized multiple mouse brain passages,"/>
   <result pre="the late 1940s utilized multiple mouse brain passages, which adapted" exact="ZIKV" post="from merely sickening the animals to producing neurologic symptoms"/>
   <result pre="mosquito infectivity was demonstrated via the comparative analysis of four" exact="ZIKV" post="strains (MR766, ZIKV-PR, ZIKV-FLR (Columbia, 2015), and ZIKV-PAN (Panama,"/>
   <result pre="identified in Vero passage 3 viral stocks as well as" exact="ZIKV" post="FLICPR that were not present in the original patient’s"/>
   <result pre="serum [76]. These mutations were associated with the attenuation of" exact="ZIKV" post="infection of AG129 (mice lacking receptors for α/β/γ interferons),"/>
   <result pre="gains in both cell lines [77]. Work on SLEV and" exact="WNV" post="utilized serial passages in C6/36 mosquito cells that bypassed"/>
   <result pre="case of vector competence work conducted in the context of" exact="ZIKV" post="for example, the use of the MR766 prototype strain"/>
   <result pre="DENV, YFV, CHIKV, and ZIKV. Unsurprisingly, the vast majority of" exact="ZIKV" post="vector competence literature focuses on Ae. aegypti (reviewed [27,81,82,83])."/>
   <result pre="analyses is that there is substantial variation in susceptibility to" exact="ZIKV" post="across Ae. aegypti populations, with variations within populations observed"/>
   <result pre="However, given the explosive spread and breadth of the 2015–2016" exact="ZIKV" post="outbreaks, coupled with recent evidence of vector-adaptive mutations facilitating"/>
   <result pre="ZIKV outbreaks, coupled with recent evidence of vector-adaptive mutations facilitating" exact="CHIKV" post="adaption to a novel vector (CHIKV E1 A226V [84],"/>
   <result pre="albopictus transmission), substantial effort has been expended on alternative vectors." exact="ZIKV" post="transmission competence has been demonstrated in Ae. albopictus [28,66,87,88,89],"/>
   <result pre="the ability of this mosquito to become infected and transmit" exact="ZIKV" post="[97,98,99,100,101], with no robust field evidence supporting its role"/>
   <result pre="are not conducted with mosquito species in the range of" exact="ZIKV" post="circulation, e.g., Ae. notoscriptus and Ae. camptorhynchus, which were"/>
   <result pre="to determine if Australian mosquitoes have the potential to transmit" exact="ZIKV" post="[91,92]. Likewise, Sabethes cyaneus has never been implicated as"/>
   <result pre="other sylvatic Sabethes spp. mosquitoes to assess the potential for" exact="ZIKV" post="to spill back into a sylvatic cycle in the"/>
   <result pre="Beach, Florida, which also demonstrated an overall decrease in disseminated" exact="YFV" post="infections with colonization (F1 = 54.5%, F10 = 12%)"/>
   <result pre="highlight the functional importance of the Toll pathway in attenuating" exact="DENV" post="infection [113]. As an emerging field within the vector"/>
   <result pre="Serratia spp. have been demonstrated to increase the transmission of" exact="WNV" post="(by Cx. tarsalis) and DENV-2 (Ae. aegypti) [115,116]. Even"/>
   <result pre="aegypti with EILV 7 days prior to oral exposure to" exact="CHIKV" post="decreases the infection rate observed at 3 and 5"/>
   <result pre="reducing replication kinetics in C6/36 cells of SLEV, JEV, and" exact="WNV" post="whether the second virus was inoculated simultaneously (co-infection), or"/>
   <result pre="3, or 5 DPI [126]. This effect was reproduced with" exact="ZIKV" post="and DENV-2, and IT inoculation of NHUV into Ae."/>
   <result pre="prior to a ZIKV-infectious bloodmeal caused a significant decrease in" exact="ZIKV" post="infection and dissemination. The co-inoculation of both ZIKV and"/>
   <result pre="decrease in ZIKV infection and dissemination. The co-inoculation of both" exact="ZIKV" post="and NHUV to Ae. aegypti significantly decreased ZIKV transmission"/>
   <result pre="of both ZIKV and NHUV to Ae. aegypti significantly decreased" exact="ZIKV" post="transmission in saliva compared to mosquitoes solely inoculated with"/>
   <result pre="ZIKV transmission in saliva compared to mosquitoes solely inoculated with" exact="ZIKV" post="[127]. Similar observations have been made in Ae. aegypti"/>
   <result pre="with CFAV two days prior to oral exposure to either" exact="ZIKV" post="(PF2013, French Polynesia, 2013) or DENV-1 (KDH0026A, Thailand, 2010),"/>
   <result pre="[128]. Although there were no differences in the rate of" exact="DENV" post="infection between CFAV-infected and mock-infected mosquitoes, both the rate"/>
   <result pre="mosquitoes, both the rate of dissemination and the titer of" exact="DENV" post="present in the head were significantly lower in CFAV-infected"/>
   <result pre="cytopathic effects in C6/36 cells as a confounding element). Strikingly," exact="ZIKV" post="infection and dissemination rates were unaffected by prior CFAV"/>
   <result pre="as has Ae. notoscriptus for infection (however, not transmission) with" exact="ZIKV" post="strain MR766 [92]. Likewise, the vector competence of various"/>
   <result pre="Likewise, the vector competence of various Culex spp. mosquitoes for" exact="WNV" post="is highly dependent on oral doses [131,132]. Despite these"/>
   <result pre="interpreted with caution, as the data from many of these" exact="ZIKV" post="analyses suggest that this virus requires oral doses that"/>
   <result pre="30%) [135]. Similar work in nonhuman primate models of both" exact="DENV" post="and ZIKV infection have shown direct oral infection of"/>
   <result pre="Similar work in nonhuman primate models of both DENV and" exact="ZIKV" post="infection have shown direct oral infection of Ae. aegypti"/>
   <result pre="most important epidemic arboviruses such as ZIKV, DENV, YFV, and" exact="CHIKV" post="[9,60,152], it is not surprising that substantial efforts have"/>
   <result pre="initial infection, and its effect disappeared by 10 days of" exact="ZIKV" post="extrinsic incubation. Nevertheless, the observed decrease in the EIP"/>
   <result pre="For example, an analysis of field-derived Ae. aegypti exposed to" exact="ZIKV" post="and reared at 16 °C, 20 °C, 24 °C,"/>
   <result pre="within the 28–34 °C range (19–23%) [130]. Compared to ZIKV," exact="CHIKV" post="demonstrated an increased infectivity of Ae. aegypti Liverpool when"/>
   <result pre="were maintained at 18 °C compared to 28 °C, while" exact="YFV" post="demonstrated increased infectivity in field-derived Ae. albopictus when the"/>
   <result pre="of natural mosquito populations. 6. Conclusions and Recommendations While the" exact="ZIKV" post="epidemic led to substantial strides in understanding vector competence,"/>
   <result pre="major public health challenge [61,162,163]. Given the major investments in" exact="ZIKV" post="vector competence assessments, it would behoove arbovirologists to capitalize"/>
   <result pre="vector competence assessments, it would behoove arbovirologists to capitalize on" exact="ZIKV" post="findings to begin discussions on how best to approach"/>
   <result pre="from the development and utilization of animal models. In this," exact="ZIKV" post="provides an excellent example of the difficulties associated with"/>
   <result pre="variability in how these studies are conducted across labs. The" exact="ZIKV" post="epidemic in the Americas illustrates how, despite the large"/>
   <result pre="Hyg.19565044244810.1016/0035-9203(56)90090-613380987 4.PetterssonJ.H.BohlinJ.Dupont-RouzeyrolM.BrynildsrudO.B.AlfsnesK.Cao-LormeauV.M.GauntM.W.FalconarA.K.de LamballerieX.EldholmV.et al.Re-visiting the evolution, dispersal and epidemiology of" exact="Zika" post="virus in AsiaEmerg. Microbes Infect.201877910.1038/s41426-018-0082-529739925 5.WikanN.SmithD.R.Zika virus: History of"/>
   <result pre="a Southeast Asian perspectiveAsian Pac. J. Trop. Med.2017101510.1016/j.apjtm.2016.11.01328107856 7.AlthouseB.M.VasilakisN.SallA.A.DialloM.WeaverS.C.HanleyK.A.Potential for" exact="Zika" post="Virus to Establish a Sylvatic Transmission Cycle in the"/>
   <result pre="virus in the Americas: Early epidemiological and genetic findingsScience201635234534910.1126/science.aaf503627013429 17.LoweR.BarcellosC.BrasilP.CruzO.G.HonorioN.A.KuperH.CarvalhoM.S.The" exact="Zika" post="Virus Epidemic in Brazil: From Discovery to Future ImplicationsInt."/>
   <result pre="Public Health2018159610.3390/ijerph15010096 18.PassosS.R.L.Borges Dos SantosM.A.Cerbino-NetoJ.BuonoraS.N.SouzaT.M.L.de OliveiraR.V.C.VizzoniA.Barbosa-LimaG.VieiraY.R.Silva de LimaM.et al.Detection of" exact="Zika" post="Virus in April 2013 Patient Samples, Rio de Janeiro,"/>
   <result pre="Patient Samples, Rio de Janeiro, BrazilEmerg. Infect. Dis.2017232120212110.3201/eid2312.17137528953451 19.YactayoS.StaplesJ.E.MillotV.CibrelusL.Ramon-PardoP.Epidemiology of" exact="Chikungunya" post="in the AmericasJ. Infect. Dis.2016214S441S44510.1093/infdis/jiw39027920170 20.MussoD.BossinH.MalletH.P.BesnardM.BroultJ.BaudouinL.LeviJ.E.SabinoE.C.GhawcheF.LanteriM.C.et al.Zika virus in"/>
   <result pre="Anatomy of a completed outbreakLancet Infect. Dis.201818e172e18210.1016/S1473-3099(17)30446-229150310 21.PiersonT.C.DiamondM.S.The emergence of" exact="Zika" post="virus and its new clinical syndromesNature201856057358110.1038/s41586-018-0446-y30158602 22.KongW.LiH.ZhuJ.Zika virus: The"/>
   <result pre="therapeutics: Landscape analysis and challenges aheadBMC Med.2018168410.1186/s12916-018-1067-x29871628 24.DurbinA.Wilder-SmithA.An update on" exact="Zika" post="vaccine developmentsExpert Rev. Vaccines20171678178710.1080/14760584.2017.134530928633549 25.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against Zika"/>
   <result pre="on Zika vaccine developmentsExpert Rev. Vaccines20171678178710.1080/14760584.2017.134530928633549 25.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 26.WahidB.AliA.RafiqueS.IdreesM.Current status of therapeutic and vaccine"/>
   <result pre="Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 26.WahidB.AliA.RafiqueS.IdreesM.Current status of therapeutic and vaccine approaches against" exact="Zika" post="virusEur. J. Intern. Med.201744121810.1016/j.ejim.2017.08.00128797534 27.Souza-NetoJ.A.PowellJ.R.BonizzoniM.Aedes aegypti vector competence studies:"/>
   <result pre="Vector Competency of Aedes albopictus Populations from the Americas for" exact="Zika" post="VirusAm. J. Trop. Med. Hyg.20179733033910.4269/ajtmh.16-096928829735 29.RoundyC.M.AzarS.R.RossiS.L.HuangJ.H.LealG.YunR.Fernandez-SalasI.VitekC.J.PaploskiI.A.KitronU.et al.Variation in Aedes"/>
   <result pre="Med. Hyg.20179733033910.4269/ajtmh.16-096928829735 29.RoundyC.M.AzarS.R.RossiS.L.HuangJ.H.LealG.YunR.Fernandez-SalasI.VitekC.J.PaploskiI.A.KitronU.et al.Variation in Aedes aegypti Mosquito Competence for" exact="Zika" post="Virus TransmissionEmerg. Infect. Dis.20172362510.3201/eid2304.16148428287375 30.AzarS.R.RossiS.L.HallerS.H.YunR.HuangJ.H.PlanteJ.A.ZhouJ.OlanoJ.P.RoundyC.M.HanleyK.A.et al.ZIKV Demonstrates Minimal Pathologic"/>
   <result pre="of Aedes aegypti and Aedes albopictus and Vectorial Capacity for" exact="Chikungunya" post="VirusJ. Infect. Dis.2016214S453S45810.1093/infdis/jiw28527920173 36.MacdonaldG.Epidemiologic models in studies of vector-borne"/>
   <result pre="Entomol.2016531029104710.1093/jme/tjw09627354440 42.ChristoffersonR.C.A Reevaluation of the Role of Aedes albopictus in" exact="Dengue" post="TransmissionJ. Infect. Dis.20152121177117910.1093/infdis/jiv17425784727 43.CalbaC.Guerbois-GallaM.FrankeF.JeanninC.Auzet-CaillaudM.GrardG.PigaglioL.DecoppetA.WeicherdingJ.SavaillM.C.et al.Preliminary report of an autochthonous"/>
   <result pre="in Italy: 2007–2017J. Travel Med.201825tay00410.1093/jtm/tay004 45.LindhE.ArgentiniC.RemoliM.E.FortunaC.FaggioniG.BenedettiE.AmendolaA.MarsiliG.ListaF.RezzaG.et al.The Italian 2017 Outbreak" exact="Chikungunya" post="Virus Belongs to an Emerging Aedes albopictus-Adapted Virus Cluster"/>
   <result pre="Trop. Med. Hyg.201611014114426711697 48.GrubaughN.D.LadnerJ.T.KraemerM.U.G.DudasG.TanA.L.GangavarapuK.WileyM.R.WhiteS.ThezeJ.MagnaniD.M.et al.Genomic epidemiology reveals multiple introductions of" exact="Zika" post="virus into the United StatesNature201754640140510.1038/nature2240028538723 49.MillerB.R.MonathT.P.TabachnikW.J.EzikeV.I.Epidemic yellow fever caused"/>
   <result pre="by an incompetent mosquito vectorTrop. Med. Parasitol.1989403963992623418 50.WeaverS.C.Emergence of Epidemic" exact="Zika" post="Virus Transmission and Congenital Zika Syndrome: Are Recently Evolved"/>
   <result pre="Med. Parasitol.1989403963992623418 50.WeaverS.C.Emergence of Epidemic Zika Virus Transmission and Congenital" exact="Zika" post="Syndrome: Are Recently Evolved Traits to Blame?MBio20178e02063-1610.1128/mBio.02063-16 51.WangL.ValderramosS.G.WuA.OuyangS.LiC.BrasilP.BonaldoM.CoatesT.Nielsen-SainesK.JiangT.et al.From"/>
   <result pre="to Blame?MBio20178e02063-1610.1128/mBio.02063-16 51.WangL.ValderramosS.G.WuA.OuyangS.LiC.BrasilP.BonaldoM.CoatesT.Nielsen-SainesK.JiangT.et al.From Mosquitos to Humans: Genetic Evolution of" exact="Zika" post="VirusCell Host Microbe20161956156510.1016/j.chom.2016.04.00627091703 52.CalvezE.O’ConnorO.PolM.RoussetD.FayeO.RichardV.TarantolaA.Dupont-RouzeyrolM.Differential transmission of Asian and African"/>
   <result pre="Zika VirusCell Host Microbe20161956156510.1016/j.chom.2016.04.00627091703 52.CalvezE.O’ConnorO.PolM.RoussetD.FayeO.RichardV.TarantolaA.Dupont-RouzeyrolM.Differential transmission of Asian and African" exact="Zika" post="virus lineages by Aedes aegypti from New CaledoniaEmerg. Microbes"/>
   <result pre="aegypti from New CaledoniaEmerg. Microbes Infect.2018715910.1038/s41426-018-0166-230254274 53.SmithD.R.SpragueT.R.HollidgeB.S.ValdezS.M.PadillaS.L.BellancaS.A.GoldenJ.W.CoyneS.R.KuleshD.A.MillerL.J.et al.African and Asian" exact="Zika" post="Virus Isolates Display Phenotypic Differences Both In Vitro and"/>
   <result pre="LunaS.M.FauverJ.R.FoyB.D.PereraR.BlackW.C.KadingR.C.et al.Vector Competence of American Mosquitoes for Three Strains of" exact="Zika" post="VirusPLoS Negl. Trop. Dis.201610e000510110.1371/journal.pntd.000510127783679 55.LiuY.LiuJ.DuS.ShanC.NieK.ZhangR.LiX.F.ZhangR.WangT.QinC.F.et al.Evolutionary enhancement of Zika"/>
   <result pre="of Zika VirusPLoS Negl. Trop. Dis.201610e000510110.1371/journal.pntd.000510127783679 55.LiuY.LiuJ.DuS.ShanC.NieK.ZhangR.LiX.F.ZhangR.WangT.QinC.F.et al.Evolutionary enhancement of" exact="Zika" post="virus infectivity in Aedes aegypti mosquitoesNature201754548248610.1038/nature2236528514450 56.MoudyR.M.MeolaM.A.MorinL.L.EbelG.D.KramerL.D.A Newly Emergent"/>
   <result pre="infectivity in Aedes aegypti mosquitoesNature201754548248610.1038/nature2236528514450 56.MoudyR.M.MeolaM.A.MorinL.L.EbelG.D.KramerL.D.A Newly Emergent Genotype of" exact="West Nile" post="Virus Is Transmitted Earlier and More Efficiently by Culex"/>
   <result pre="MosquitoesAm. J. Trop. Med. Hyg.20077736537010.4269/ajtmh.2007.77.36517690414 57.EbelG.D.CarricabaruJ.YoungD.BernardK.A.KramerL.D.Genetic and phenotypic variation of" exact="West Nile" post="virus in New York, 2000–2003Am. J. Trop. Med. Hyg.20047149350010.4269/ajtmh.2004.71.49315516648"/>
   <result pre="J. Trop. Med. Hyg.20047149350010.4269/ajtmh.2004.71.49315516648 58.CiotaA.T.KramerL.D.Vector-virus interactions and transmission dynamics of" exact="West Nile" post="virusViruses201353021304710.3390/v512302124351794 59.DuggalN.K.Bosco-LauthA.BowenR.A.WheelerS.S.ReisenW.K.FelixT.A.MannB.R.RomoH.SwetnamD.M.BarrettA.D.et al.Evidence for co-evolution of West Nile Virus"/>
   <result pre="dynamics of West Nile virusViruses201353021304710.3390/v512302124351794 59.DuggalN.K.Bosco-LauthA.BowenR.A.WheelerS.S.ReisenW.K.FelixT.A.MannB.R.RomoH.SwetnamD.M.BarrettA.D.et al.Evidence for co-evolution of" exact="West Nile" post="Virus and house sparrows in North AmericaPLoS Negl. Trop."/>
   <result pre="virus reside within the E2 envelope glycoproteinJ. Virol.2002766387639210.1128/JVI.76.12.6387-6392.200212021373 66.CiotaA.T.BialosukniaS.M.ZinkS.D.BrecherM.EhrbarD.J.MorrissetteM.N.KramerL.D.Effects of" exact="Zika" post="Virus Strain and Aedes Mosquito Species on Vector CompetenceEmerg."/>
   <result pre="Trop. Med. Hyg.19883959760210.4269/ajtmh.1988.39.5973207178 70.Hall-MendelinS.PykeA.T.MooreP.R.RitchieS.A.MooreF.A.J.van den HurkA.F.Characterization of a Western Pacific" exact="Zika" post="Virus Strain in Australian Aedes aegyptiVector Borne Zoonotic Dis.20181831732210.1089/vbz.2017.223229694294"/>
   <result pre="aegyptiVector Borne Zoonotic Dis.20181831732210.1089/vbz.2017.223229694294 71.ShanC.XieX.MuruatoA.E.RossiS.L.RoundyC.M.AzarS.R.YangY.TeshR.B.BourneN.BarrettA.D.et al.An Infectious cDNA Clone of" exact="Zika" post="Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral"/>
   <result pre="Antiviral InhibitorsCell Host Microbe20161989190010.1016/j.chom.2016.05.00427198478 72.TsetsarkinK.A.KenneyH.ChenR.LiuG.ManukyanH.WhiteheadS.S.LaassriM.ChumakovK.PletnevA.G.A Full-Length Infectious cDNA Clone of" exact="Zika" post="Virus from the 2015 Epidemic in Brazil as a"/>
   <result pre="and Characterization of Recombinant Virus Generated from a New World" exact="Zika" post="Virus Infectious CloneJ. Virol.201791e01765-1610.1128/JVI.01765-1627795432 74.CiotaA.T.LovelaceA.O.NgoK.A.LeA.N.MaffeiJ.G.FrankeM.A.PayneA.F.JonesS.A.KauffmanE.B.KramerL.D.Cell-specific adaptation of two flaviviruses"/>
   <result pre="serial passage in mosquito cell cultureVirology200735716517410.1016/j.virol.2006.08.00516963095 75.MoserL.A.BoylanB.T.MoreiraF.R.MyersL.J.SvensonE.L.FedorovaN.B.PickettB.E.BernardK.A.Growth and adaptation of" exact="Zika" post="virus in mammalian and mosquito cellsPLoS Negl. Trop. Dis.201812e000688010.1371/journal.pntd.000688030418969"/>
   <result pre="mosquito cellsPLoS Negl. Trop. Dis.201812e000688010.1371/journal.pntd.000688030418969 76.DuggalN.K.McDonaldE.M.Weger-LucarelliJ.HawksS.A.RitterJ.M.RomoH.EbelG.D.BraultA.C.Mutations present in a low-passage" exact="Zika" post="virus isolate result in attenuated pathogenesis in miceVirology2019530192610.1016/j.virol.2019.02.00430763872 77.VasilakisN.DeardorffE.R.KenneyJ.L.RossiS.L.HanleyK.A.WeaverS.C.Mosquitoes"/>
   <result pre="alternationProc. Natl. Acad. Sci. USA20081056970697510.1073/pnas.071213010518458341 79.AliotaM.T.DudleyD.M.NewmanC.M.MohrE.L.GellerupD.D.BreitbachM.E.BuechlerC.R.RasheedM.N.MohnsM.S.WeilerA.M.et al.Heterologous Protection against Asian" exact="Zika" post="Virus Challenge in Rhesus MacaquesPLoS Negl. Trop. Dis.201610e000516810.1371/journal.pntd.000516827911897 80.HuangY.S.HiggsS.VanlandinghamD.L.Arbovirus-Mosquito"/>
   <result pre="Disease Pathogenesis of ArbovirusesFront. Microbiol.2019102210.3389/fmicb.2019.0002230728812 81.Gutierrez-BugalloG.PiedraL.A.RodriguezM.BissetJ.A.Lourenco-de-OliveiraR.WeaverS.C.VasilakisN.Vega-RuaA.Vector-borne transmission and evolution of" exact="Zika" post="virusNat. Ecol. Evol.2019356156910.1038/s41559-019-0836-z30886369 82.BoyerS.CalvezE.Chouin-CarneiroT.DialloD.FaillouxA.B.An overview of mosquito vectors of"/>
   <result pre="Zika virusNat. Ecol. Evol.2019356156910.1038/s41559-019-0836-z30886369 82.BoyerS.CalvezE.Chouin-CarneiroT.DialloD.FaillouxA.B.An overview of mosquito vectors of" exact="Zika" post="virusMicrobes Infect.20182064666010.1016/j.micinf.2018.01.00629481868 83.EpelboinY.TalagaS.EpelboinL.DusfourI.Zika virus: An updated review of competent"/>
   <result pre="mosquitoesNat. Commun.20145408410.1038/ncomms508424933611 86.TsetsarkinK.A.WeaverS.C.Sequential adaptive mutations enhance efficient vector switching by" exact="Chikungunya" post="virus and its epidemic emergencePLoS Pathog.20117e100241210.1371/journal.ppat.100241222174678 87.Chouin-CarneiroT.Vega-RuaA.VazeilleM.YebakimaA.GirodR.GoindinD.Dupont-RouzeyrolM.Lourenco-de-OliveiraR.FaillouxA.B.Differential Susceptibilities of"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="VirusPLoS Negl. Trop. Dis.201610e000454310.1371/journal.pntd.000454326938868 88.Di LucaM.SeveriniF.TomaL.BoccoliniD.RomiR.RemoliM.E.SabbatucciM.RizzoC.VenturiG.RezzaG.et al.Experimental studies of"/>
   <result pre="LucaM.SeveriniF.TomaL.BoccoliniD.RomiR.RemoliM.E.SabbatucciM.RizzoC.VenturiG.RezzaG.et al.Experimental studies of susceptibility of Italian Aedes albopictus to" exact="Zika" post="virusEuro Surveill.20162110.2807/1560-7917.ES.2016.21.18.30223 89.WongP.S.LiM.Z.ChongC.S.NgL.C.TanC.H.Aedes (Stegomyia) albopictus (Skuse): A potential vector"/>
   <result pre="virusEuro Surveill.20162110.2807/1560-7917.ES.2016.21.18.30223 89.WongP.S.LiM.Z.ChongC.S.NgL.C.TanC.H.Aedes (Stegomyia) albopictus (Skuse): A potential vector of" exact="Zika" post="virus in SingaporePLoS Negl. Trop. Dis.20137e234810.1371/journal.pntd.000234823936579 90.GendernalikA.Weger-LucarelliJ.Garcia LunaS.M.FauverJ.R.RuckertC.MurrietaR.A.BergrenN.SamarasD.NguyenC.KadingR.C.et al.American"/>
   <result pre="90.GendernalikA.Weger-LucarelliJ.Garcia LunaS.M.FauverJ.R.RuckertC.MurrietaR.A.BergrenN.SamarasD.NguyenC.KadingR.C.et al.American Aedes vexans Mosquitoes are Competent Vectors of" exact="Zika" post="VirusAm. J. Trop. Med. Hyg.2017961338134010.4269/ajtmh.16-096328719283 91.DucheminJ.B.MeeP.T.LynchS.E.VedururuR.TrinidadL.ParadkarP.Zika vector transmission risk"/>
   <result pre="Mosquito Species Incriminates Aedes aegypti as the Potential Vector of" exact="Zika" post="Virus in AustraliaPLoS Negl. Trop. Dis.201610e000495910.1371/journal.pntd.000495927643685 93.DiagneC.T.DialloD.FayeO.BaY.FayeO.GayeA.DiaI.FayeO.WeaverS.C.SallA.A.et al.Potential of"/>
   <result pre="of selected Senegalese Aedes spp. mosquitoes (Diptera: Culicidae) to transmit" exact="Zika" post="virusBMC Infect. Dis.20151549210.1186/s12879-015-1231-226527535 94.KarnaA.K.AzarS.R.PlanteJ.A.YunR.VasilakisN.WeaverS.C.HansenI.A.HanleyK.A.Colonized Sabethes cyaneus, a Sylvatic New"/>
   <result pre="New World Mosquito Species, Shows a Low Vector Competence for" exact="Zika" post="Virus Relative to Aedes aegyptiViruses20181043410.3390/v10080434 95.Elizondo-QuirogaD.Medina-SanchezA.Sanchez-GonzalezJ.M.EckertK.A.Villalobos-SanchezE.Navarro-ZunigaA.R.Sanchez-TejedaG.Correa-MoralesF.Gonzalez-AcostaC.AriasC.F.et al.Zika Virus in"/>
   <result pre="BrazilEmerg. Microbes Infect.20176e6910.1038/emi.2017.5928790458 97.AmraouiF.Atyame-NtenC.Vega-RuaA.Lourenco-de-OliveiraR.VazeilleM.FaillouxA.B.Culex mosquitoes are experimentally unable to transmit" exact="Zika" post="virusEuro Surveill.20162110.2807/1560-7917.ES.2016.21.35.30333 98.HartC.E.RoundyC.M.AzarS.R.HuangJ.H.YunR.ReynoldsE.LealG.NavaM.R.VelaJ.StarkP.M.et al.Zika Virus Vector Competency of Mosquitoes,"/>
   <result pre="Culex quinquefasciatus and Culex pipiens pipiens from North America for" exact="Zika" post="VirusAm. J. Trop. Med. Hyg.2017961235124010.4269/ajtmh.16-086528500817 100.Lourenco-de-OliveiraR.MarquesJ.T.SreenuV.B.Atyame NtenC.AguiarE.VarjakM.KohlA.FaillouxA.B.Culex quinquefasciatus mosquitoes"/>
   <result pre="Hyg.2017961235124010.4269/ajtmh.16-086528500817 100.Lourenco-de-OliveiraR.MarquesJ.T.SreenuV.B.Atyame NtenC.AguiarE.VarjakM.KohlA.FaillouxA.B.Culex quinquefasciatus mosquitoes do not support replication of" exact="Zika" post="virusJ. Gen. Virol.20189925826410.1099/jgv.0.00094929076805 101.MainB.J.NicholsonJ.WinokurO.C.SteinerC.RiemersmaK.K.StuartJ.TakeshitaR.KrasnecM.BarkerC.M.CoffeyL.L.Vector competence of Aedes aegypti, Culex"/>
   <result pre="Aedes aegypti, Culex tarsalis, and Culex quinquefasciatus from California for" exact="Zika" post="virusPLoS Negl. Trop. Dis.201812e000652410.1371/journal.pntd.000652429927940 102.GuoX.X.LiC.X.DengY.Q.XingD.LiuQ.M.WuQ.SunA.J.DongY.D.CaoW.C.QinC.F.et al.Culex pipiens quinquefasciatus: A"/>
   <result pre="Dis.201812e000652410.1371/journal.pntd.000652429927940 102.GuoX.X.LiC.X.DengY.Q.XingD.LiuQ.M.WuQ.SunA.J.DongY.D.CaoW.C.QinC.F.et al.Culex pipiens quinquefasciatus: A potential vector to transmit" exact="Zika" post="virusEmerg. Microbes Infect.20165e10210.1038/emi.2016.10227599470 103.Costa-da-SilvaA.L.IoshinoR.S.AraujoH.R.KojinB.B.ZanottoP.M.OliveiraD.B.MeloS.R.DurigonE.L.CapurroM.L.Laboratory strains of Aedes aegypti are"/>
   <result pre="Infect.20165e10210.1038/emi.2016.10227599470 103.Costa-da-SilvaA.L.IoshinoR.S.AraujoH.R.KojinB.B.ZanottoP.M.OliveiraD.B.MeloS.R.DurigonE.L.CapurroM.L.Laboratory strains of Aedes aegypti are competent to Brazilian" exact="Zika" post="virusPLoS ONE201712e017195128187183 104.KunoG.Early history of laboratory breeding of Aedes"/>
   <result pre="to Infection by the American and Southeast Asian Genotypes of" exact="Dengue" post="Type 2 VirusVector Borne Zoonotic Dis.2001115916810.1089/15303660131697776912680353 106.GarganT.P.BaileyC.L.HigbeeG.A.GadA.SaidS.E.The effect of"/>
   <result pre="has entomopathogenic and in vitro anti-pathogen activitiesPLoS Pathog.201410e100439810.1371/journal.ppat.100439825340821 115.DodsonB.L.HughesG.L.PaulO.MatacchieroA.C.KramerL.D.RasgonJ.L.Wolbachia enhances" exact="West Nile" post="virus (WNV) infection in the mosquito Culex tarsalisPLoS Negl."/>
   <result pre="arthropod cells with medically important flavivirusesJ. Gen. Virol.2014952796280810.1099/vir.0.068031-025146007 127.RomoH.KenneyJ.L.BlitvichB.J.BraultA.C.Restriction of" exact="Zika" post="virus infection and transmission in Aedes aegypti mediated by"/>
   <result pre="variation in viremia on mosquito susceptibility, infectiousness, and R0 of" exact="Zika" post="in Aedes aegyptiPLoS Negl. Trop. Dis.201812e000673310.1371/journal.pntd.000673330133450 131.GoddardL.B.RothA.E.ReisenW.K.ScottT.W.Vector Competence of"/>
   <result pre="aegyptiPLoS Negl. Trop. Dis.201812e000673310.1371/journal.pntd.000673330133450 131.GoddardL.B.RothA.E.ReisenW.K.ScottT.W.Vector Competence of California Mosquitos for" exact="West Nile" post="VirusEmerg. Infect. Dis.200281385139110.3201/eid0812.02053612498652 132.SardelisM.R.TurellM.J.DohmD.J.O’GuinnM.L.Vector Competence of Selected North American"/>
   <result pre="Competence of Selected North American Culex and Coquillettidia Mosquitos for" exact="West Nile" post="VirusEmerg. Infect. Dis.200171018102210.3201/eid0706.01061711747732 133.FourcadeC.MansuyJ.M.DutertreM.DelpechM.MarchouB.DelobelP.IzopetJ.Martin-BlondelG.Viral load kinetics of Zika virus"/>
   <result pre="for West Nile VirusEmerg. Infect. Dis.200171018102210.3201/eid0706.01061711747732 133.FourcadeC.MansuyJ.M.DutertreM.DelpechM.MarchouB.DelobelP.IzopetJ.Martin-BlondelG.Viral load kinetics of" exact="Zika" post="virus in plasma, urine and saliva in a couple"/>
   <result pre="French West IndiesJ. Clin. Virol.2016821410.1016/j.jcv.2016.06.01127389909 134.LanciottiR.S.KosoyO.L.LavenJ.J.VelezJ.O.LambertA.J.JohnsonA.J.StanfieldS.M.DuffyM.R.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg."/>
   <result pre="of Temperature on the Vector Efficiency of Aedes aegypti for" exact="Dengue" post="2 virusAm. J. Trop. Med. Hyg.19873614315210.4269/ajtmh.1987.36.1433812879 137.KonishiE.Size of blood"/>
   <result pre="Culicidae) from the Torres Strait Compared with Mainland Australia for" exact="Dengue" post="2 and 4 VirusesJ. Med. Entomol.20034095095610.1603/0022-2585-40.6.95014765675 150.HuangY.S.LyonsA.C.HsuW.W.ParkS.L.HiggsS.VanlandinghamD.L.Differential outcomes of"/>
   <result pre="Dengue 2 and 4 VirusesJ. Med. Entomol.20034095095610.1603/0022-2585-40.6.95014765675 150.HuangY.S.LyonsA.C.HsuW.W.ParkS.L.HiggsS.VanlandinghamD.L.Differential outcomes of" exact="Zika" post="virus infection in Aedes aegypti orally challenged with infectious"/>
   <result pre="infectious protein mealsPLoS ONE201712e018238610.1371/journal.pone.018238628796799 151.VogelsC.B.GoertzG.P.PijlmanG.P.KoenraadtC.J.Vector competence of European mosquitoes for" exact="West Nile" post="virusEmerg. Microbes Infect.20176e9610.1038/emi.2017.8229116220 152.WeaverS.C.CharlierC.VasilakisN.LecuitM.Zika, Chikungunya, and Other Emerging Vector-Borne"/>
   <result pre="Viremia and Antibody ResponsesJ. Infect. Dis.199717632233010.1086/5140489237696 165.Pérez-GuzmánE.X.PantojaP.Serrano-CollazoC.HassertM.A.Ortiz-RosaA.RodríguezI.V.GiavedoniL.HodaraV.ParodiL.CruzL.et al.Time elapsed between" exact="Zika" post="and Dengue infections improves the immune response against Dengue"/>
   <result pre="Antibody ResponsesJ. Infect. Dis.199717632233010.1086/5140489237696 165.Pérez-GuzmánE.X.PantojaP.Serrano-CollazoC.HassertM.A.Ortiz-RosaA.RodríguezI.V.GiavedoniL.HodaraV.ParodiL.CruzL.et al.Time elapsed between Zika and" exact="Dengue" post="infections improves the immune response against Dengue without viremia"/>
   <result pre="between Zika and Dengue infections improves the immune response against" exact="Dengue" post="without viremia enhancement in rhesus macaquesBioRxiv62109410.1101/621094 166.DuongV.LambrechtsL.PaulR.E.LyS.LayR.S.LongK.C.HuyR.TarantolaA.ScottT.W.SakuntabhaiA.et al.Asymptomatic humans"/>
   <result pre="studies in Iquitos, PeruPLoS Negl. Trop. Dis.201913e000709010.1371/journal.pntd.000709030742621 168.MorrisonT.E.DiamondM.S.Animal Models of" exact="Zika" post="Virus Infection, Pathogenesis, and ImmunityJ. Virol.201791e00009e0001710.1128/JVI.00009-1728148798 169.ReynoldsE.S.HartC.E.HermanceM.E.BriningD.L.ThangamaniS.An Overview of"/>
   <result pre="169.ReynoldsE.S.HartC.E.HermanceM.E.BriningD.L.ThangamaniS.An Overview of Animal Models for Arthropod-Borne VirusesComp. Med.20176723224128662752 170.RossiS.L.VasilakisN.Modeling" exact="Zika" post="Virus Infection in MiceCell Stem Cell2016194610.1016/j.stem.2016.06.00927392219 171.GormanM.J.CaineE.A.ZaitsevK.BegleyM.C.Weger-LucarelliJ.UccelliniM.B.TripathiS.MorrisonJ.YountB.L.DinnonK.H.3rdet al.An Immunocompetent"/>
   <result pre="in MiceCell Stem Cell2016194610.1016/j.stem.2016.06.00927392219 171.GormanM.J.CaineE.A.ZaitsevK.BegleyM.C.Weger-LucarelliJ.UccelliniM.B.TripathiS.MorrisonJ.YountB.L.DinnonK.H.3rdet al.An Immunocompetent Mouse Model of" exact="Zika" post="Virus InfectionCell Host Microbe20182367268510.1016/j.chom.2018.04.00329746837 172.RossiS.L.TeshR.B.AzarS.R.MuruatoA.E.HanleyK.A.AugusteA.J.LangsjoenR.M.PaesslerS.VasilakisN.WeaverS.C.Characterization of a Novel Murine"/>
   <result pre="Host Microbe20182367268510.1016/j.chom.2018.04.00329746837 172.RossiS.L.TeshR.B.AzarS.R.MuruatoA.E.HanleyK.A.AugusteA.J.LangsjoenR.M.PaesslerS.VasilakisN.WeaverS.C.Characterization of a Novel Murine Model to Study" exact="Zika" post="VirusAm. J. Trop. Med. Hyg.2016941362136910.4269/ajtmh.16-011127022155 173.VasilakisN.CardosaJ.HanleyK.A.HolmesE.C.WeaverS.C.Fever from the forest:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6784101\results\search\tropicalVirus\results.xml">
   <result pre="VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 6784101 doi: 10.3390/v11090798viruses-11-00798 : Article Updated Phylogeny of" exact="Chikungunya" post="Virus Suggests Lineage-Specific RNA Architecture https://orcid.org/0000-0001-7487-266Xde Bernardi SchneiderAdriano1†https://orcid.org/0000-0003-1126-0513OchsenreiterRoman2†https://orcid.org/0000-0002-7548-8624HostagerReilly1https://orcid.org/0000-0001-7132-0800HofackerIvo L.23JaniesDaniel4https://orcid.org/0000-0003-0925-5205WolfingerMichael"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Chikungunya" post="virus (CHIKV), a mosquito-borne alphavirus of the family Togaviridae,"/>
   <result pre="Americas from lineages from two continents: Asia and Africa. Historically," exact="CHIKV" post="circulated as at least four lineages worldwide with both"/>
   <result pre="recent patterns of emergence and the current status of the" exact="CHIKV" post="spread, updated analyses of the viral genetic data and"/>
   <result pre="needed. Here, we performed phylogenetic and comparative genomics screens of" exact="CHIKV" post="genomes, taking advantage of the public availability of many"/>
   <result pre="a single one. In parallel, we performed thermodynamic modeling of" exact="CHIKV" post="untranslated regions (UTRs), which revealed evolutionarily conserved structured and"/>
   <result pre="duplication events in recently emerged American isolates of the Asian" exact="CHIKV" post="lineage and propose the existence of a flexible 3’UTR"/>
   <result pre="propose the existence of a flexible 3’UTR architecture among different" exact="CHIKV" post="lineages. RNA virus evolution epidemics phylogeography secondary structure 1."/>
   <result pre="viral diseases. Dramatic (re)emergences of arthropod-borne viruses (arboviruses), such as" exact="Chikungunya" post="(CHIKV), West Nile, Zika, and Dengue, have increased in"/>
   <result pre="Dramatic (re)emergences of arthropod-borne viruses (arboviruses), such as Chikungunya (CHIKV)," exact="West Nile," post="Zika, and Dengue, have increased in frequency and intensity,"/>
   <result pre="which the vector can complete its life cycle and transmit" exact="CHIKV" post="[2,3]. Here, we investigate the RNA architecture of CHIKV"/>
   <result pre="transmit CHIKV [2,3]. Here, we investigate the RNA architecture of" exact="CHIKV" post="untranslated regions (UTRs) that underlies their ability to adapt"/>
   <result pre="provide an updated large-scale phylogeny summarizing the geographic spread of" exact="CHIKV" post="lineages. CHIKV is a mosquito-borne virus that belongs to"/>
   <result pre="updated large-scale phylogeny summarizing the geographic spread of CHIKV lineages." exact="CHIKV" post="is a mosquito-borne virus that belongs to the Alphavirus"/>
   <result pre="believed to have a marine origin [4,5]. The presence of" exact="CHIKV" post="in sylvatic mosquitoes, such as Aedes africanus, Aedes furcifer,"/>
   <result pre="in Central or East Africa [6,7]. The first isolation of" exact="CHIKV" post="was in 1952 in the Newala district of Tanganyika,"/>
   <result pre="a British territory that is now part of Tanzania [8,9]." exact="CHIKV" post="has caused multiple outbreaks in all continents except Antarctica,"/>
   <result pre="recently in Europe and Central and South America. In total," exact="CHIKV" post="has been present in over 100 countries [6,10,11,12]. CHIKV"/>
   <result pre="total, CHIKV has been present in over 100 countries [6,10,11,12]." exact="CHIKV" post="infects multiple human tissues, causing a febrile illness which"/>
   <result pre="La Réunion, and after, higher morbidity has been associated with" exact="CHIKV" post="infection, including neurological issues, such as visual and hearing"/>
   <result pre="CHIKV, and are capable of transmission to humans [19]. 1.1." exact="Chikungunya" post="Lineages CHIKV is a virus for which four major"/>
   <result pre="are capable of transmission to humans [19]. 1.1. Chikungunya Lineages" exact="CHIKV" post="is a virus for which four major lineages have"/>
   <result pre="Despite these notions, the origin and the history of how" exact="CHIKV" post="spreads inside of Africa remains elusive. This gap in"/>
   <result pre="is due to undersampling and confounding factors such as co-circulating" exact="Dengue" post="and Yellow Fever viruses. The co-circulation of viruses diminishes"/>
   <result pre="single lineage. 1.2. Conserved RNA Structure as Evolutionary Trait The" exact="CHIKV" post="genome consists of a single-stranded, (+)-sense RNA of approximately"/>
   <result pre="of direct repeats (DRs) at the sequence level [2,33]. Distinctive" exact="CHIKV" post="lineages also differ in their 3’UTR architecture, in particular"/>
   <result pre="structures. The knowledge of structured RNAs in alphavirus UTRs, and" exact="CHIKV" post="in particular, is limited. This limitation results from the"/>
   <result pre="data have raised the possibility of revising the lineages of" exact="CHIKV" post="as a whole, reevaluating the historical global spread of"/>
   <result pre="set out to structurally characterize the UTRs of all known" exact="CHIKV" post="lineages, and found evidence for lineage-specific structured and unstructured"/>
   <result pre="&quot;Middle Africa�?. 2.2. Phylogenetic Tree Search Two complete ORFs of" exact="CHIKV" post="were extracted from the complete viral sequences for the"/>
   <result pre="evidence supports the hypothesis. According to recently published phylogenies of" exact="CHIKV" post="[20,22,45], viruses from the Western African clade form a"/>
   <result pre="Western African clade form a sister group to all other" exact="CHIKV" post="clades. Given these results and the absence of co-circulating"/>
   <result pre="the absence of co-circulating Western African strains with any other" exact="CHIKV" post="lineage, we selected this clade as the outgroup for"/>
   <result pre="South American (ECSA-MASA), from the phylogenetic tree generated from all" exact="CHIKV" post="sequences. We created a csv table including all locations"/>
   <result pre="location [52,53]. In order to evaluate the historical spread of" exact="CHIKV" post="using a parsimonious ancestral reconstruction, the tree must be"/>
   <result pre="selected a root for each clade based on the complete" exact="CHIKV" post="phylogeny. For each individual clade, the sister taxon to"/>
   <result pre="the Supplementary Materials GitHub repository. 2.4. Conserved RNA Structures in" exact="CHIKV" post="3’UTR Evolutionary conservation of functional RNAs is typically achieved"/>
   <result pre="to find homologous RNAs in large RNA sequence databases. All" exact="CHIKV" post="3’UTRs were processed and curated from full genomes by"/>
   <result pre="using the RNAplot utility [58]. 3. Results 3.1. Phylogeny of" exact="Chikungunya" post="Indicates Multiple Lineages In Africa No significant recombination events"/>
   <result pre="IQ-Tree resulted in a best-scoring heuristic maximum likelihood tree for" exact="CHIKV" post="with 590 genomic sequences (Figure 1). Deep ancestral branches"/>
   <result pre="had lower SH-aLRT support/ultrafast bootstrap values. The phylogenetic hypothesis for" exact="CHIKV" post="with branch values is available online as Supplementary Materials"/>
   <result pre="outbreak did not generate a new endemic region for the" exact="CHIKV" post="lineage (Table 1). 3.2. Spread of Major Chikungunya Epidemic"/>
   <result pre="for the CHIKV lineage (Table 1). 3.2. Spread of Major" exact="Chikungunya" post="Epidemic Lineages Our reconstruction of the spread of the"/>
   <result pre="structurally conserved sequence element (CSE) required for replication [2] in" exact="CHIKV" post="3’UTR. Chen et al. [34] proposed distinct direct repeat"/>
   <result pre="of presently available sequence data (i.e., 196 complete and truncated" exact="CHIKV" post="3’UTRs), and conclusively infer hitherto unresolved structural properties of"/>
   <result pre="available 3’UTR sequences with CMs and HMMs revealed that different" exact="CHIKV" post="lineages have evolved distinct patterns of structured and unstructured"/>
   <result pre="functional RNAs has led to a varied 3’UTR architecture among" exact="CHIKV" post="strains. This is particularly pronounced in the AUL and"/>
   <result pre="of SL-b and UR (Figure 4). 4. Discussion Studies on" exact="CHIKV" post="phylogenetics have provided phylogenomic means of understanding disease spread"/>
   <result pre="evolutionary forces should act on coding and non-coding regions. 4.1." exact="Chikungunya" post="Virus Nomenclature It is critical to emphasize the significance"/>
   <result pre="viral classification: the evolutionary independence of evolving lineages. Assessing each" exact="CHIKV" post="taxon as an individual, and bearing in mind the"/>
   <result pre="the concept of phylogenetic independence, we cannot conclusively state that" exact="CHIKV" post="sequences isolated in the Americas are divergent enough from"/>
   <result pre="or more lineages regardless of geography. 4.2. Lineage Diversity in" exact="Chikungunya" post="Virus Multiple waves of CHIKV infection have occurred over"/>
   <result pre="geography. 4.2. Lineage Diversity in Chikungunya Virus Multiple waves of" exact="CHIKV" post="infection have occurred over the past two decades, with"/>
   <result pre="Malaysia), Southern Asia (India) and the Americas [20]. Clades of" exact="CHIKV" post="observed in the analyses are consistent with those found"/>
   <result pre="America. Asian Urban and IOL are the main lineages of" exact="CHIKV" post="in Asia [69,70]. Moreover, Asian Urban has since emerged"/>
   <result pre="to the lack of sampling in Africa which obscures the" exact="Chikungunya" post="virus dynamics between the distinct regions within Africa. The"/>
   <result pre="As more isolates are sequenced, a more nuanced history of" exact="CHIKV" post="evolution will emerge which will aid in our understanding"/>
   <result pre="in mammalian cells [34]. Interestingly, molecular evolution experiments with engineered" exact="CHIKV" post="3’UTRs in mosquito and mammalian cells suggest that improved"/>
   <result pre="in this study confirms the previously reported repeat organization in" exact="CHIKV" post="3’UTR sequences. It is now possible to conclusively associate"/>
   <result pre="are conserved among all lineages. Importantly, the organization of all" exact="CHIKV" post="3’UTRs follows a common pattern characterized by an alternating"/>
   <result pre="consensus folding algorithms. This suggests that these regions of the" exact="CHIKV" post="genome exist in a predominantly unpaired state, rendering them"/>
   <result pre="cellular HuR and La proteins [76,77]. While HuR binding in" exact="CHIKV" post="appears impaired [78], stabilization of viral RNA through host"/>
   <result pre="present at multiple loci within the unstructured repeat of all" exact="CHIKV" post="3’UTR sequences, supporting the biological role of intrinsic lack"/>
   <result pre="the 3’UTRs of Eastern equine encephalitis virus (EEEV) [80] and" exact="CHIKV" post="[81,82]. The miRNA binding site reported by Dubey et"/>
   <result pre="structured Y-shaped element (SL-Y) characterized here. Whether or not the" exact="CHIKV" post="genome encodes for endogenous viral miRNAs, as observed in"/>
   <result pre="individual outbreaks and therefore only represent a fraction of the" exact="CHIKV" post="population. In contrast to other arboviruses, such as flaviviruses"/>
   <result pre="what extent secondary structure conservation is a driving force of" exact="CHIKV" post="UTR evolution. This is underlined by a weak support"/>
   <result pre="negative z-scores. One of the most striking features of the" exact="CHIKV" post="3’UTR is presence of multiple copies of the unstructured"/>
   <result pre="regions. Our findings indicate that the evolutionary forces acting on" exact="CHIKV" post="3’UTR manifest as a process that can rapidly rearrange"/>
   <result pre="elements, as observed in a recently emerged partial duplication of" exact="CHIKV" post="strains isolated from the Caribbean [66]. Consequently, our predictions"/>
   <result pre="picture of the 3’UTR phylogeny in the context of diverged" exact="CHIKV" post="lineages, we computed a separate phylogeny based exclusively on"/>
   <result pre="intuitively. On a broader scale, our data provide evidence that" exact="CHIKV" post="CDS and 3’UTRs show coherent evolutionary patterns, with leads"/>
   <result pre="to environmental change, e.g., by means of recombination [32]. Still," exact="CHIKV" post="3’UTRs do not exhibit the high degree of plasticity"/>
   <result pre="available online at https://www.mdpi.com/1999-4915/11/9/798/s1, Figure S1: Maximum likelihood tree of" exact="CHIKV" post="3’UTRs. Scripts and data sets are available via GitHub"/>
   <result pre="phylogenetic study provides new insights on the global expansion of" exact="Chikungunya" post="virusJ. Virol.201690106001061110.1128/JVI.01166-1627654297 8.RossR.The Newala epidemic: III. The virus: Isolation,"/>
   <result pre="Southern Province, Tanganyika Territory, in 1952–1953: An additional note on" exact="Chikungunya" post="virus isolations and serum antibodiesTrans. R. Soc. Trop. Med."/>
   <result pre="serum antibodiesTrans. R. Soc. Trop. Med. H19575123824010.1016/0035-9203(57)90022-6 10.RezzaG.NicolettiL.AngeliniR.RomiR.FinarelliA.PanningM.CordioliP.FortunaC.BorosS.MaguranoF.et al.Infection with" exact="Chikungunya" post="virus in Italy: An outbreak in a temperate regionLancet20073701840184610.1016/S0140-6736(07)61779-618061059"/>
   <result pre="and the significance for EuropeEurosurveillance2014192075910.2807/1560-7917.ES2014.19.13.2075924721539 12.TeixeiraM.G.AndradeA.M.Maria da ConceiçãoN.C.CastroJ.S.OliveiraF.L.GoesC.S.MaiaM.SantanaE.B.NunesB.T.VasconcelosP.F.East/Central/South African genotype" exact="Chikungunya" post="virus, Brazil, 2014Emerg. Infect. Dis.20152190610.3201/eid2105.14172725898939 13.WeaverS.C.LecuitM.Chikungunya virus and the"/>
   <result pre="and hurdles to vaccine developmentPLoS Negl. Trop. D201913e000691910.1371/journal.pntd.000691930653504 15.BorgheriniG.PoubeauP.StaikowskyF.LoryM.MoullecN.L.BecquartJ.P.WenglingC.MichaultA.PaganinF.Outbreak of" exact="Chikungunya" post="on Reunion Island: Early clinical and laboratory features in"/>
   <result pre="virus: Mapping the 64-year historyInt. J. Infect. Dis.201758697610.1016/j.ijid.2017.03.00628288924 19.DialloM.ThonnonJ.Traore-LamizanaM.FontenilleD.Vectors of" exact="Chikungunya" post="virus in Senegal: Current data and transmission cyclesAm. J."/>
   <result pre="murine and nonhuman primate modelsmBio20189e02449-1710.1128/mBio.02449-1729511072 22.VolkS.M.ChenR.TsetsarkinK.A.AdamsA.P.GarciaT.I.SallA.A.NasarF.SchuhA.J.HolmesE.C.HiggsS.et al.Genome-Scale Phylogenetic Analyses of" exact="Chikungunya" post="Virus Reveal Independent Emergences of Recent Epidemics and Various"/>
   <result pre="Various Evolutionary RatesJ. Virol.2010846497650410.1128/JVI.01603-0920410280 23.WhiteS.K.MavianC.SalemiM.MorrisJ.G.Jr.ElbadryM.A.OkechB.A.LednickyJ.A.DunfordJ.C.A new &quot;American�? subgroup of African-lineage" exact="Chikungunya" post="virus detected in and isolated from mosquitoes collected in"/>
   <result pre="in Haiti, 2016PLoS ONE201813e019685710.1371/journal.pone.019685729746539 24.LiX.F.JiangT.DengY.Q.ZhaoH.YuX.D.YeQ.WangH.J.ZhuS.Y.ZhangF.C.QinE.D.et al.Complete genome sequence of a" exact="Chikungunya" post="virus isolated in Guangdong, ChinaJ. Virol.2012868904890510.1128/JVI.01289-1222843862 25.HydeJ.L.ChenR.TrobaughD.W.DiamondM.S.WeaverS.C.KlimstraW.B.WiluszJ.The 5’ and"/>
   <result pre="RNAs–non-coding is not non-functionalVirus Res.20152069910710.1016/j.virusres.2015.01.01625630058 26.CasalP.E.ChouhyD.BolattiE.M.PerezG.R.StellaE.J.GiriA.A.Evidence for homologous recombination in" exact="Chikungunya" post="VirusMol. Phylogenet. Evol.201585687510.1016/j.ympev.2015.01.01625701772 27.RobyJ.A.PijlmanG.P.WiluszJ.KhromykhA.A.Noncoding subgenomic flavivirus RNA: Multiple functions"/>
   <result pre="VirusMol. Phylogenet. Evol.201585687510.1016/j.ympev.2015.01.01625701772 27.RobyJ.A.PijlmanG.P.WiluszJ.KhromykhA.A.Noncoding subgenomic flavivirus RNA: Multiple functions in" exact="West Nile" post="virus pathogenesis and modulation of host responsesViruses2014640442710.3390/v602040424473339 28.VillordoS.M.CarballedaJ.M.FilomatoriC.V.GamarnikA.V.RNA Structure"/>
   <result pre="29.ChapmanE.G.MoonS.L.WiluszJ.KieftJ.S.RNA structures that resist degradation by Xrn1 produce a pathogenic" exact="Dengue" post="virus RNAeLife20143e0189210.7554/eLife.0189224692447 30.MacFaddenA.O’DonoghueZ.SilvaP.A.ChapmanE.G.OlsthoornR.C.SterkenM.G.PijlmanG.P.BredenbeekP.J.KieftJ.S.Mechanism and structural diversity of exoribonuclease-resistant RNA"/>
   <result pre="in flaviviral RNAsNat. Commun.2018911910.1038/s41467-017-02604-y29317714 31.De Bernardi SchneiderA.WolfingerM.T.Musashi binding elements in" exact="Zika" post="and related Flavivirus 3’ UTRs: A comparative study in"/>
   <result pre="UTRs: A comparative study in silicoSci. Rep.20199691110.1038/s41598-019-43390-531061405 32.FilomatoriC.V.BardossyE.S.MerwaissF.SuzukiY.HenrionA.SalehM.C.AlvarezD.E.RNA recombination at" exact="Chikungunya" post="virus 3’UTR as an evolutionary mechanism that provides adaptabilityPLoS"/>
   <result pre="travelers—United States, 2014–2016Am. J. Trop. Med. Hyg.20189819219710.4269/ajtmh.17-066829182144 61.HapuarachchiH.BandaraK.SumanadasaS.HapugodaM.LaiY.L.LeeK.S.TanL.K.LinR.T.NgL.F.BuchtG.et al.Re-emergence of" exact="Chikungunya" post="virus in South-east Asia: virological evidence from Sri Lanka"/>
   <result pre="Gen. Virol.2010911067107610.1099/vir.0.015743-019955565 62.Da CostaA.C.ThézéJ.KomninakisS.C.V.Sanz-DuroR.L.FelintoM.R.L.MouraL.C.C.de Oliveira BarrosoI.M.SantosL.E.C.de Lemos NunesM.A.MouraA.A.et al.Spread of" exact="Chikungunya" post="virus east/central/south African genotype in northeast BrazilEmerg. Infect. Dis.201723174210.3201/eid2310.17030728930031"/>
   <result pre="63.SouzaT.M.A.AzeredoE.L.Badolato-CorrêaJ.DamascoP.V.SantosC.Petitinga-PaivaF.NunesP.C.G.BarbosaL.S.CipitelliM.C.Chouin-CarneiroT.et al.First report of the East-Central South African genotype of" exact="Chikungunya" post="virus in Rio de Janeiro, BrazilPLoS Curr.2017910.1371/currents.outbreaks.4200119978d62ccaa454599cd2735727 64.HardyR.W.RiceC.M.Requirements at"/>
   <result pre="detectionBiocomp 2010World ScientificLondon, UK20106979 66.StaplefordK.A.MoratorioG.HenningssonR.ChenR.MatheusS.EnfissiA.Weissglas-VolkovD.IsakovO.BlancH.MounceB.C.et al.Whole-Genome Sequencing Analysis from the" exact="Chikungunya" post="Virus Caribbean Outbreak Reveals Novel Evolutionary Genomic ElementsPLoS Negl."/>
   <result pre="reconsideredSyst. Zool197827172610.2307/2412809 68.PetersonA.T.Defining viral species: Making taxonomy usefulVirol. J.20141113110.1186/1743-422X-11-13125055940 69.YangC.F.SuC.L.HsuT.C.ChangS.F.LinC.C.HuangJ.C.ShuP.Y.Imported" exact="Chikungunya" post="Virus Strains, Taiwan, 2006–2014Emerg. Infect. Dis.201622198110.3201/eid2211.16040427767908 70.MahaM.S.SusilariniN.K.Nur Ika HariastutiS.Chikungunya"/>
   <result pre="AzevedoR.d.S.da SilvaD.E.A.da SilvaE.V.P.da SilvaS.P.et al.Emergence and potential for spread of" exact="Chikungunya" post="virus in BrazilBMC Med.20151310210.1186/s12916-015-0348-x25976325 72.YactayoS.StaplesJ.E.MillotV.CibrelusL.Ramon-PardoP.Epidemiology of Chikungunya in the"/>
   <result pre="for spread of Chikungunya virus in BrazilBMC Med.20151310210.1186/s12916-015-0348-x25976325 72.YactayoS.StaplesJ.E.MillotV.CibrelusL.Ramon-PardoP.Epidemiology of" exact="Chikungunya" post="in the AmericasJ. Infect. Dis.2016214S441S44510.1093/infdis/jiw39027920170 73.StraussJ.H.StraussE.G.The Alphaviruses: Gene Expression,"/>
   <result pre="Biol. Chem.2012287362293623810.1074/jbc.M112.37120322915590 79.ChavaliP.L.StojicL.MeredithL.W.JosephN.NahorskiM.S.SanfordT.J.SweeneyT.R.KrishnaB.A.HosmilloM.FirthA.E.et al.Neurodevelopmental protein Musashi 1 interacts with the" exact="Zika" post="genome and promotes viral replicationScience2017357838810.1126/science.aam924328572454 80.TrobaughD.W.GardnerC.L.SunC.HaddowA.D.WangE.ChapnikE.MildnerA.WeaverS.C.RymanK.D.KlimstraW.B.RNA viruses can hijack"/>
   <result pre="innate immunityNature201450624510.1038/nature1286924352241 81.DubeyS.K.ShrinetJ.SunilS.Aedes aegypti microRNA, miR-2944b-5p interacts with 3’UTR of" exact="Chikungunya" post="virus and cellular target vps-13 to regulate viral replicationPLoS"/>
   <result pre="of nonself RNAScience201434378378710.1126/science.124846524482115 Figure 1 Maximum-likelihood phylogenetic tree of 590" exact="Chikungunya" post="virus genomic sequences highlighting the geographic locations (tree branches)"/>
   <result pre="depicted in gray. Figure 2 Worldwide spread of major epidemic" exact="Chikungunya" post="clades: Asian Urban American (AUL-Am), ECSA Indian Ocean Lineage"/>
   <result pre="alignments and base-pair probability plots (dot plots) of the structured" exact="CHIKV" post="3’UTR elements SL-Y, CSE, SL-a, and SL-b. Colored squares"/>
   <result pre="Figure 4 Schematic of the 3’UTR architecture of all major" exact="CHIKV" post="strains. The phylogeny on the left is derived from"/>
   <result pre="viruses-11-00798-t001_Table 1Table 1 Comparison between literature and proposed nomenclature of" exact="Chikungunya" post="lineages and epidemic clades based on the updated phylogeny."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6787251\results\search\tropicalVirus\results.xml">
   <result pre="pmcid: 678725112677 doi: 10.1038/s41467-019-12677-6 : Article Oligomeric state of the" exact="ZIKV" post="E protein defines protective immune responses http://orcid.org/0000-0002-9249-2844MetzStefan W.swmetz@med.unc.edu1ThomasAshlie1BrackbillAlex2ForsbergJohn2MileyMichael J.2LopezCesar"/>
   <result pre="copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The current leading" exact="Zika" post="vaccine candidates in clinical testing are based on live"/>
   <result pre="virus platforms, which have safety issues, especially in pregnant women." exact="Zika" post="subunit vaccines, however, have shown poor performance in preclinical"/>
   <result pre="tested do not display critical quaternary structure epitopes present on" exact="Zika" post="E protein homodimers that cover the surface of the"/>
   <result pre="recombinant E protein homodimers that are recognized by strongly neutralizing" exact="Zika" post="specific monoclonal antibodies. In mice, the dimeric antigen stimulate"/>
   <result pre="are similar to epitopes recognized by human antibodies following natural" exact="Zika" post="virus infection. The monomer antigen stimulates low levels of"/>
   <result pre="low levels of E-domain III targeting neutralizing antibodies. In a" exact="Zika" post="challenge model, only E dimer antigen stimulates protective antibodies,"/>
   <result pre="surface when designing subunit vaccines. Many human antibodies that neutralize" exact="Zika" post="virus recognize quaternary epitopes on the envelope (E) protein."/>
   <result pre="protein. Here, Metz et al. engineer stable recombinant homodimers of" exact="Zika" post="virus E protein and show that it induces neutralizing"/>
   <result pre="in mice that recognize similar epitopes as human antibodies from" exact="Zika" post="infected people. Subject terms Antibodies Protein vaccines Viral infection"/>
   <result pre="infected people. Subject terms Antibodies Protein vaccines Viral infection Introduction" exact="Zika" post="virus (ZIKV) is an enveloped single stranded RNA virus"/>
   <result pre="by mosquito vectors. As a member of the flavivirus genus," exact="ZIKV" post="shares many structural features with other medically important flaviviruses"/>
   <result pre="protective human antibodies bind to these higher order protein structures1." exact="ZIKV" post="infection during pregnancy can result in neurodevelopmental defects (congenital"/>
   <result pre="ZIKV infection during pregnancy can result in neurodevelopmental defects (congenital" exact="Zika" post="syndrome). This has stimulated work on subunit vaccines, as"/>
   <result pre="of these antigens in preclinical studies2,7,8. Here, we investigate if" exact="ZIKV" post="rE dimers are better subunit vaccine antigens than monomers."/>
   <result pre="the dimer is recognized by strongly neutralizing mAbs isolated from" exact="ZIKV" post="patients and the dimer, not the monomer, stimulates strongly"/>
   <result pre="were similar to epitopes recognized by human antibodies following natural" exact="Zika" post="virus infection. These results highlight the importance of mimicking"/>
   <result pre="and are applicable to developing second generation subunit vaccines against" exact="Zika" post="as well as other medically important flaviviruses like dengue"/>
   <result pre="important flaviviruses like dengue and yellow fever. Results Expression of" exact="ZIKV" post="rE monomers and homodimers Here, to investigate if ZIKV"/>
   <result pre="of ZIKV rE monomers and homodimers Here, to investigate if" exact="ZIKV" post="rE dimers are better subunit vaccine antigens than monomers,"/>
   <result pre="dimers are better subunit vaccine antigens than monomers, we expressed" exact="ZIKV" post="rE variants (aa1–402) that are monomers (rEM) or stable"/>
   <result pre="or stable dimers (rED) under physiological conditions. We generated stable" exact="ZIKV" post="rED proteins as previously described for DENV E protein"/>
   <result pre="We generated stable ZIKV rED proteins as previously described for" exact="DENV" post="E protein by introducing a disulfide bridge (A264C) in"/>
   <result pre="mAbs C8 and C10 (Fig. 1c). Fig. 1 Expression pf" exact="ZIKV" post="rE monomers and rE homodimers. a The soluble ZIKV"/>
   <result pre="pf ZIKV rE monomers and rE homodimers. a The soluble" exact="ZIKV" post="rE-monomer (rEM, aa1–404) was expressed and purified from mammalian"/>
   <result pre="was expressed and purified from mammalian cells. The soluble stable" exact="ZIKV" post="rE-homodimer (rED) was generated by an A264C substitution, resulting"/>
   <result pre="weights of ~49 kDa (monomer) and ~98 kDa (dimer). c Binding of" exact="ZIKV" post="specific (A9E, G9E, and ZKA-230) and flavivirus cross-reactive (4G2,"/>
   <result pre="and flavivirus cross-reactive (4G2, 1M7, C8, and C10) mAbs to" exact="ZIKV" post="rEM and rED was analyzed. Binding of mAbs that"/>
   <result pre="deviation. Source data are provided as a Source Data file" exact="ZIKV" post="rED, but not rEM, induces neutralizing antibodies After confirming"/>
   <result pre="in the absence of alumn, these antibodies failed to neutralize" exact="ZIKV" post="(Fig. 2d). In contrast, non-adjuvanted rED elicited ZIKV-neutralizing antibodies"/>
   <result pre="potently neutralizing compared with the rEM stimulated antibodies. Fig. 2" exact="ZIKV" post="rED induces neutralizing antibody responses. a Mice were primed"/>
   <result pre="neutralizing antibody responses. a Mice were primed with 5 µg of" exact="ZIKV" post="rEM or rED (+/−alum) and boosted with similar doses"/>
   <result pre="deviation. Source data are provided as a Source Data file" exact="ZIKV" post="rED stimulates antibodies that target complex epitopes We next"/>
   <result pre="by rEM and rED antigens recognized different epitopes on the" exact="ZIKV" post="E protein. Many flavivirus type-specific antibodies recognize relatively simple"/>
   <result pre="rED+alum). The antibody binding patterns were also reflected in the" exact="ZIKV" post="neutralization assays. The majority of neutralizing antibodies in the"/>
   <result pre="that target epitopes distinct from simple EDIII epitopes. Fig. 3" exact="ZIKV" post="rED stimulates antibodies that target complex epitopes on the"/>
   <result pre="Method for depleting EDIII-binding antibodies from mouse immune sera. Recombinant" exact="ZIKV" post="E-domain III (EDIII, His-tagged) was coupled to nickel beadsi"/>
   <result pre="(A9E and G9E) from a person who was infected with" exact="ZIKV" post="in 201623. These antibodies map to complex epitopes on"/>
   <result pre="epitopes on domain I (A9E) and domain II (G9E) of" exact="ZIKV" post="E protein23. Moreover, antibody blockade assays using these mAbs"/>
   <result pre="mAbs also are targeted by antibodies in immune serum from" exact="Zika" post="patients but not dengue patients23. We used a blockade"/>
   <result pre="binds to a E dimer-dependent epitope that is conserved between" exact="DENV" post="and ZIKV. Sera from mice immunized with rEM did"/>
   <result pre="not block binding of A9E, G9E, and C10 mAbs to" exact="ZIKV" post="(Fig. 3d). In contrast, sera from mice immunized with"/>
   <result pre="ZIKV. These results demonstrate that the rED antigen and natural" exact="ZIKV" post="infections stimulate antibodies that target similar complex epitopes on"/>
   <result pre="antibodies and directs the antibody response to simple epitopes on" exact="ZIKV" post="EDIII. ZIKV rED induces protective antibodies in mice Next,"/>
   <result pre="directs the antibody response to simple epitopes on ZIKV EDIII." exact="ZIKV" post="rED induces protective antibodies in mice Next, we investigated"/>
   <result pre="vaccinated with rEM+alum and rED+alum could protect mice from lethal" exact="ZIKV" post="challenge. We immunized wild-type mice as previously described (Fig."/>
   <result pre="to ZIKV. Ifnar1−/− mice were challenged with 1000 FFU of" exact="ZIKV" post="H/PF/2013, 1 day post serum transfer. Mice were monitored"/>
   <result pre="post serum transfer. Mice were monitored for weight loss and" exact="ZIKV" post="induced disease, and mice were bled at days 0"/>
   <result pre="G9E was used as a positive control for protection against" exact="ZIKV" post="infection23. Mice that received G9E or serum from rED+alum"/>
   <result pre="against replicating virus in these animals (Fig. 4c). Fig. 4" exact="ZIKV" post="rED induce protective antibodies in mice. a Wild-type mice"/>
   <result pre="Ifnar1−/− mice 24 h prior to challenge with 1000 FFU of" exact="ZIKV" post="by subcutaneous footpad inoculation (n = 5 for rEM and rED"/>
   <result pre="Discussion The magnitude, sudden onset and severe clinical manifestations of" exact="ZIKV" post="epidemics highlight the need for safe and effective vaccines"/>
   <result pre="replication. It has been difficult to formulate tetravalent live attenuated" exact="DENV" post="vaccines that stimulate balanced and effective responses to each"/>
   <result pre="the surface of infectious virus particles. Here we demonstrate that" exact="ZIKV" post="rEM and rED subunit antigens induce antibody responses that"/>
   <result pre="induce antibody responses that differ in functionality and domain focus." exact="ZIKV" post="rE monomers stimulated an EDIII biased, poorly neutralizing IgG"/>
   <result pre="stimulated an EDIII biased, poorly neutralizing IgG response. In contrast," exact="ZIKV" post="rE dimers induced strongly neutralizing and protective antibodies that"/>
   <result pre="are needed to compare the immunogenicity, efficacy and safety of" exact="ZIKV" post="rE-dimer, inactivated virus and VLP vaccines. The strategy we"/>
   <result pre="virus and VLP vaccines. The strategy we describe here for" exact="ZIKV" post="E protein may also be applicable for developing subunit"/>
   <result pre="cells (ThermoFisher) were cultured in EXPI293 expression medium (Life Technologies)." exact="ZIKV" post="strain H/PF/2013 was grown in Vero cells and titered"/>
   <result pre="titered by focus-forming assay using flavivirus mAb E6026,27. Production of" exact="ZIKV" post="rE antigens The recombinant ZIKV E (H/PF/2013; aa1–404) monomers"/>
   <result pre="flavivirus mAb E6026,27. Production of ZIKV rE antigens The recombinant" exact="ZIKV" post="E (H/PF/2013; aa1–404) monomers (rEM) and stable E dimers"/>
   <result pre="samples were flash frozen and stored at −80 °C. Production of" exact="ZIKV" post="EDIII proteins ZIKA virus EDIII (H/PF/2013, aa302–403) was expressed"/>
   <result pre="and grown to and OD600 = 0.6 at 37 °C, shaking at 225 rpm." exact="ZIKV" post="EDIII expression was stimulated by adding 50 mM IPTG and"/>
   <result pre="Next, cells were pelleted and lysed by high pressure homogenization." exact="ZIKV" post="EDIII proteins were purified from the lysate by Ni2+-affinity"/>
   <result pre="acid, 50% methanol). Protein confirmations were analyzed by antigen-capture ELISA." exact="ZIKV" post="rEM and rED were captured on Ni2+-coated ELISA plates"/>
   <result pre="the Care and Use of Laboratory Animals). For evaluation of" exact="ZIKV" post="rE immunogenicity, mice were immunized subcutaneously in the flank"/>
   <result pre="of rE-induced antibodies, heat-inactivated immune sera were passively transferred to" exact="ZIKV" post="susceptible A129 mice. Serum samples (days 70 through 112)"/>
   <result pre="into A129 mice, via intraperitoneal route 1 day prior to" exact="ZIKV" post="challenge. The ZIKV-neutralizing mAb G9E23 was used as a"/>
   <result pre="positive control (200 µg/mouse, n = 3). Mice were challenged with 1000 FFU of" exact="ZIKV" post="(H/PF/2013) by subcutaneous footpad inoculation. Mice were weighed daily"/>
   <result pre="Mice losing 30% of their starting weight were humanely euthanized." exact="ZIKV" post="rE-induced antibody evaluation ZIKV-specific IgG responses were measured by"/>
   <result pre="evaluation ZIKV-specific IgG responses were measured by antigen-capture ELISA. Briefly," exact="ZIKV" post="was captured on 1M7 (2 ng per µl)-coated ELISA plates"/>
   <result pre="and incubated for 45 min at 37 °C with the amount of" exact="ZIKV" post="previously determined to infect ~15% of the cells. Cells"/>
   <result pre="software. Depletion of EDIII-binding IgG from mouse serum Bacterially expressed" exact="ZIKV" post="EDIII proteins (C-terminal 6 × His-tag) were conjugated to Ni-NTA Magnetic"/>
   <result pre="for subsequent IgG ELISA and neutralization assays. The percentage of" exact="ZIKV" post="EDIII-binding antibodies was calculated by dividing the EDIII-depleted IgG"/>
   <result pre="IgG titers by the control-depleted IgG titers. The percentage of" exact="ZIKV" post="EDIII neutralizing antibodies was calculated by dividing the EDIII-depleted"/>
   <result pre="blocking, plates were washed in PBS + 0.2% Tween and incubated with" exact="ZIKV" post="H/PF/2013 for 1 h at 37 °C. The plates were washed"/>
   <result pre="and developed with AP-substrate and absorbance was measured at 405 nm." exact="ZIKV" post="RNA qRT-PCR analysis Viral RNA was isolated from 30 µl"/>
   <result pre="60 °C) × 40 cycles. RNA was isolated from a known quantity of" exact="ZIKV" post="H/PF/2013 to generate a standard curve. Reporting summary Further"/>
   <result pre="grant W81-XWH-18-2-0035 (PI A. de Silva) and the European Union" exact="Zika" post="Plan Research Consortium. Author contributions S.W.M. and A.T. performed"/>
   <result pre="majority of experiments. A.B., J.F., and M.J.M. expressed and purified" exact="ZIKV" post="monomer and dimer proteins. C.A.L., H.M.L., and S.T. performed"/>
   <result pre="dengue virus infectionsAdv. Exp. Med. Biol.20181062637610.1007/978-981-10-8727-1_529845525 2.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 3.BlockOKet al.A tetravalent recombinant dengue domain"/>
   <result pre="allows stable dimerization of secretory and virus-associated E proteins of" exact="Dengue" post="and Zika viruses in mammalian cellsSci. Rep.2017796610.1038/s41598-017-01097-528424472 10.RouvinskiAet al.Covalently"/>
   <result pre="dimerization of secretory and virus-associated E proteins of Dengue and" exact="Zika" post="viruses in mammalian cellsSci. Rep.2017796610.1038/s41598-017-01097-528424472 10.RouvinskiAet al.Covalently linked dengue"/>
   <result pre="virus (DENV) type 2 envelope protein domain 3 type-specific and" exact="DENV" post="complex-reactive critical epitope residuesJ. Gen. Virol.20159628829310.1099/vir.0.070813-025351518 13.ZhouYet al.The mechanism"/>
   <result pre="epitope monoclonal antibodies isolated from dengue patients are protective against" exact="Zika" post="virusmBio201671123113110.1128/mBio.01123-16 16.FibriansahGet al.A potent anti-dengue human antibody preferentially recognizes"/>
   <result pre="Vaccines2010913714710.1586/erv.09.13920109025 20.QuPet al.Insect cell-produced recombinant protein subunit vaccines protect against" exact="Zika" post="virus infectionAntivir. Res.20181549710310.1016/j.antiviral.2018.04.01029665376 21.YangMDentMLaiHSunHChenQImmunization of Zika virus envelope protein"/>
   <result pre="subunit vaccines protect against Zika virus infectionAntivir. Res.20181549710310.1016/j.antiviral.2018.04.01029665376 21.YangMDentMLaiHSunHChenQImmunization of" exact="Zika" post="virus envelope protein domain III induces specific and neutralizing"/>
   <result pre="protein domain III induces specific and neutralizing immune responses against" exact="Zika" post="virusVaccine2017354287429410.1016/j.vaccine.2017.04.05228669618 22.FlipseJSmitJMThe complexity of a dengue vaccine: a review"/>
   <result pre="Dis.201593749376710.1371/journal.pntd.0003749 23.Collins, M. H. et al. Human antibody response to" exact="Zika" post="targets type-specific quaternary structure epitopes. JCI Insight410.1172/jci.insight.124588 (2019). 24.MartinJHermidaLDengue"/>
   <result pre="2013. Genome Announc.210.1128/genomeA.00500-14 (2014). 27.BrienJDLazearHMDiamondMSPropagation, quantification, detection, and storage of" exact="West Nile" post="virusCurr. Protoc. Microbiol.20133115D 13 1115D 13 18 28.MetzSWet al.In"/>
   <result pre="18 28.MetzSWet al.In vitro assembly and stabilization of dengue and" exact="Zika" post="virus envelope protein homo-dimersSci. Rep.20177452410.1038/s41598-017-04767-628674411 29.HenchalEAMcCownJMBurkeDSSeguinMCBrandtWEEpitopic analysis of antigenic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789597\results\search\tropicalVirus\results.xml">
   <result pre="6789597 doi: 10.3390/ph12030101pharmaceuticals-12-00101 : Review Antiviral Agents in Development for" exact="Zika" post="Virus Infections BazMariana*BoivinGuy*[], *Correspondence: Mariana.Baz@crchudequebec.ulaval.ca (M.B.); Guy.Boivin@crchul.ulaval.ca (G.B.); Tel.:"/>
   <result pre="Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract In 1947," exact="Zika" post="virus (ZIKV), a mosquito-borne flavivirus was identified in Uganda"/>
   <result pre="alarm due to its increased virulence and rapid dissemination. Importantly," exact="ZIKV" post="infections have been associated with severe neurological complications such"/>
   <result pre="still no approved specific antiviral drug for the treatment of" exact="ZIKV" post="infections. Herein, we review several anti ZIKV candidates including"/>
   <result pre="the treatment of ZIKV infections. Herein, we review several anti" exact="ZIKV" post="candidates including drugs targeting both the virus (structural proteins"/>
   <result pre="both the virus (structural proteins and enzymes) and cellular elements." exact="Zika" post="virus antiviral agents small molecules virus targets host targets"/>
   <result pre="molecules virus targets host targets repurposing pre-clinical studies 1. Introduction" exact="Zika" post="virus (ZIKV) is a member of the Flaviviridae family"/>
   <result pre="clusters [1]. Mosquito-borne flaviviruses such as ZIKV, dengue virus (DENV)," exact="West Nile" post="virus (WNV), yellow fever virus (YFV), and Japanese encephalitis"/>
   <result pre="the last decade since their global incidence has grown dramatically." exact="ZIKV" post="(strain MR 766) was first isolated in 1947 [3]"/>
   <result pre="from serum samples of a Rhesus monkey during investigation on" exact="YFV" post="in the Zika forest of Uganda. In 1948, the"/>
   <result pre="of a Rhesus monkey during investigation on YFV in the" exact="Zika" post="forest of Uganda. In 1948, the virus was isolated"/>
   <result pre="in the same forest [4]. The first human cases of" exact="ZIKV" post="infections were reported in Africa in the 1950s [5]"/>
   <result pre="Cook Islands in 2013 and 2014 [6]. In May 2015," exact="ZIKV" post="spread across the Pacific Ocean and was introduced in"/>
   <result pre="subnational areas, and became a public health problem worldwide [8]." exact="ZIKV" post="infection is usually asymptomatic or produces a relatively mild"/>
   <result pre="recovery [6]. However, during the 2015 epidemics in South America," exact="ZIKV" post="became a global health threat, showing increased virulence, rapid"/>
   <result pre="newborns and a remarkable increase in Guillain–Barré syndrome cases [8,9]." exact="ZIKV" post="is transmitted to people primarily through the bite of"/>
   <result pre="different tissues including reproductive tissues and organs [12,13,14]. In males," exact="ZIKV" post="can infect testes, the prostate, and seminal vesicles [14,15],"/>
   <result pre="cells from the placenta [14,16]. Therefore, direct human–to–human transmission of" exact="ZIKV" post="can occur perinatally [17], sexually [18,19], and through breastfeeding"/>
   <result pre="is no vaccine or drug licensed to prevent or treat" exact="ZIKV" post="infections. The aim of this review article is to"/>
   <result pre="anti-ZIKV agents. 2. Genome and Replicative Cycle The genome of" exact="ZIKV" post="(strain MR 766) comprises a 10.8-kb single-stranded positive-sense RNA"/>
   <result pre="modulation of host defense mechanism [35]. The replicative cycle of" exact="ZIKV" post="is similar to other known flaviviruses (Figure 2). Briefly,"/>
   <result pre="the tyrosine-protein kinase receptor AXL, Tyro3, DC-SIGN, and TIM-1, facilitate" exact="ZIKV" post="viral entry [37]. The viral genome is released into"/>
   <result pre="extracellular space. 3. Potential Therapeutic Options for the Treatment of" exact="ZIKV" post="Infection So far, no specific antiviral is approved for"/>
   <result pre="far, no specific antiviral is approved for the treatment of" exact="ZIKV" post="infections. Acetaminophen is usually used to control fever and"/>
   <result pre="infection in children and teenagers [11]. The current search for" exact="ZIKV" post="antiviral options is being conducted through several different approaches"/>
   <result pre="drugs and therapeutic candidates have been discovered or repurposed with" exact="ZIKV" post="activity both in vitro and in pre-clinical studies and"/>
   <result pre="host cell replication. Consequently, they have been extensively evaluated against" exact="ZIKV" post="in cell culture and in animal models. Eyer et"/>
   <result pre="µM for their ability to inhibit cytopathic effects (CPE) of" exact="ZIKV" post="on Vero cells. They found that five of these"/>
   <result pre="and 2’-C-methyluridine (2-CMU), significantly reduced cell death compared to non-treated" exact="ZIKV" post="infected cells with 50% effective concentration (EC50) values ranging"/>
   <result pre="2’-C-methylated nucleosides on the in vitro activity of purified recombinant" exact="ZIKV" post="RdRp [46]. In addition, the viral polymerase inhibitor 7-deaza-2-CMA"/>
   <result pre="and safe for short-term therapy of acute flaviviral diseases, including" exact="WNV" post="[49], and thus represents one of the most promising"/>
   <result pre="ability of favipiravir to inhibit several geographically and temporally different" exact="ZIKV" post="strains in in vitro assays [51,52]. The genetic barrier"/>
   <result pre="pyrimidine synthesis inhibitor such as NITD008 exhibited antiviral activity against" exact="ZIKV" post="in vitro (EC50 = 0.28–0.95 µM) and in A129"/>
   <result pre="active site of NS5 [56] and was shown to inhibit" exact="ZIKV" post="infection and replication in human hepatocellular carcinoma (Huh-7) cells,"/>
   <result pre="varied among different cell types [58]. Interestingly, sequence analysis of" exact="ZIKV" post="isolated from infected cells treated with sofosbuvir showed higher"/>
   <result pre="of viral RNA synthesis [62]. It was found to inhibit" exact="ZIKV" post="replication in Vero cells with EC50 values in the"/>
   <result pre="strain [64]. In addition, treatment of AG129 mice infected with" exact="ZIKV" post="(Malaysian strain, P-6-740) twice daily (BID) with an intramuscular"/>
   <result pre="[65]. Hercik et al. reported the crystal structure of the" exact="ZIKV" post="methyltransferase in complex with the pan-methyltransferase inhibitor sinefungin, an"/>
   <result pre="affinity toward the enzyme for better selectivity and inhibition of" exact="ZIKV" post="replication [68]. However, when this drug was used as"/>
   <result pre="µM) and binding activity (KD of ∼5–10 μM) against the" exact="Zika" post="NS2B-NS3 protease from testing 71 HCV NS3/NS4A inhibitors that"/>
   <result pre="protease, and some of them have been found to inhibit" exact="ZIKV" post="protease activity. Lim et al. evaluated 22 polyphenol compounds"/>
   <result pre="and one natural phenol (curcumin) which were shown to inhibit" exact="Zika" post="NS2B-NS3 protease by binding to a pocket on the"/>
   <result pre="the active site and allosterically affect the structure-activity property of" exact="Zika" post="NS2B-NS3 protease. The EC50 from the flavonoids ranged between"/>
   <result pre="identified eight clinically approved drugs with inhibitory activity on the" exact="ZIKV" post="NS2B-NS3 protease [77]. In addition, the authors further validated"/>
   <result pre="triphosphatase (RTPase) activities. NS3 inhibitors can be used to impede" exact="ZIKV" post="infection. Suramin, an anti-parasitic drug used to treat trypanosomal"/>
   <result pre="but both the release of genomes and the infectivity of" exact="ZIKV" post="were reduced, suggesting that this drug also affects virus"/>
   <result pre="virus biogenesis probably by interfering with glycosylation and maturation of" exact="ZIKV" post="during traffic through the secretory pathway [85]. 3.2. Host-Targeting"/>
   <result pre="group and others demonstrated the inhibitory activity of ribavirin against" exact="ZIKV" post="strains of different geographic origins in several cell lines"/>
   <result pre="type I IFN signaling and are thus highly sensitive to" exact="ZIKV" post="infection with a lethal outcome [89]. Recent studies have"/>
   <result pre="the purine synthesis and immunosuppressive compound, was shown to abolish" exact="ZIKV" post="replication in HeLa (cervical cancer cells) and JEG3 (human"/>
   <result pre="the synthesis of pyrimidines have also been shown to affect" exact="ZIKV" post="replication. Pascoalino et al. screened a library of 725"/>
   <result pre="action. The entire library was screened at 20 µM against" exact="ZIKV" post="infecting Huh7 cells. The authors identified the 6-azauridine (EC50"/>
   <result pre="identified lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitor, whose activity against" exact="ZIKV" post="was confirmed through a dose-response assay (EC50 = 20.7"/>
   <result pre="antiflaviviral activity of lovastatin was also demonstrated against HCV and" exact="DENV" post="[94,95]. In addition, Sarkey et al., demonstrated that a"/>
   <result pre="nerve diseases such as Guillain–Barré syndrome (GBS), a consequence of" exact="ZIKV" post="infection [96]. Retallack et al. performed the screening of"/>
   <result pre="cytopathic effect in glial cells with low toxicity and reduced" exact="ZIKV" post="infection of U87 cells at an EC50 of 2"/>
   <result pre="chloroquine was able to partially reverse morphological changes induced by" exact="ZIKV" post="in mouse neurospheres [101]. In vitro, chloroquine reduces the"/>
   <result pre="cells, and inhibits virus production and cell death promoted by" exact="ZIKV" post="infection without cytotoxic effects [101]. Saliphenylhalamide (SaliPhe), a viral"/>
   <result pre="vacuolar ATPase and prevents the acidification of endosomes, also inhibits" exact="ZIKV" post="replication in human retinal pigment epithelial (RPE) cells, which"/>
   <result pre="retinal pigment epithelial (RPE) cells, which are natural targets for" exact="ZIKV" post="infection [102] with an EC50 of 1 μM [103]."/>
   <result pre="fully elucidated [104]. In glioblastoma SNB-19 cells, the EC50 against" exact="ZIKV" post="was 0.37 μM based on the measurement of intracellular"/>
   <result pre="[105]. PHA-690509, is an investigational cyclin-dependent kinase inhibitor which inhibited" exact="ZIKV" post="infection with an EC50 value of 1.72 μM [105]."/>
   <result pre="against cell death in multiple neural cell types or inhibit" exact="ZIKV" post="replication. Among them, seliciclib (a purine analog) and RGB-286147"/>
   <result pre="replication. Among them, seliciclib (a purine analog) and RGB-286147 inhibited" exact="ZIKV" post="infection at sub-micromolar concentrations [105]. Studies from Costa et"/>
   <result pre="sub-micromolar concentrations [105]. Studies from Costa et al. showed that" exact="ZIKV" post="has tropism for the central nervous system (CNS) and"/>
   <result pre="neurons, inducing neurodegeneration, neuroinflammation, and ophthalmologic disorders [106]. Neurodegeneration in" exact="ZIKV" post="disease possibly occurs due to the excitotoxicity of glutamate."/>
   <result pre="ifenprodil were found to prevent neuronal cell death caused by" exact="ZIKV" post="under in vitro conditions without reducing viral titers [106]."/>
   <result pre="[106]. Blocking hyperactivation of NMDAR would therefore reduce rates of" exact="Zika" post="virus-induced cell death and help ameliorate neuronal symptoms during"/>
   <result pre="could be used safely to reduce neurological complications associated with" exact="ZIKV" post="infection. 4. Who Benefits from ZIKV Therapies? In immunocompetent"/>
   <result pre="neurological complications associated with ZIKV infection. 4. Who Benefits from" exact="ZIKV" post="Therapies? In immunocompetent individuals, ZIKV infection is asymptomatic or"/>
   <result pre="infection. 4. Who Benefits from ZIKV Therapies? In immunocompetent individuals," exact="ZIKV" post="infection is asymptomatic or produces a relatively mild illness"/>
   <result pre="acetaminophen, anti-histamines, and fluids. However, due to the ability of" exact="ZIKV" post="to infect fetuses and cause severe neurological disease, there"/>
   <result pre="Many FDA approved drugs have been tested for efficacy against" exact="ZIKV" post="and can be repurposed for treating ZIKV infection in"/>
   <result pre="for efficacy against ZIKV and can be repurposed for treating" exact="ZIKV" post="infection in humans. In order to reach the fetus,"/>
   <result pre="vaccine and antiviral drugs for the prevention or treatment of" exact="ZIKV" post="infections. However, there is still no approved vaccine or"/>
   <result pre="physical propertiesTrans. R. Soc. Trop. Med. Hyg.19524652153410.1016/0035-9203(52)90043-612995441 4.HaddowA.J.WilliamsM.C.WoodallJ.P.SimpsonD.I.GomaL.K.Twelve Isolations of" exact="Zika" post="Virus from Aedes (Stegomyia) Africanus (Theobald) Taken in and"/>
   <result pre="MicronesiaN. Engl. J. Med.20093602536254310.1056/NEJMoa080571519516034 7.ZanlucaC.MeloV.C.MosimannA.L.SantosG.I.SantosC.N.LuzK.First report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem. Inst. Oswaldo Cruz201511056957210.1590/0074-0276015019226061233 8.HamelinM.E.BazM.AbedY.CoutureC.JoubertP.BeaulieuE.BelleroseN.PlanteM.MallettC.SchumerG.et al.Oseltamivir-resistant pandemic"/>
   <result pre="of selected Senegalese Aedes spp. mosquitoes (Diptera: Culicidae) to transmit" exact="Zika" post="virusBMC Infect. Dis.20151549210.1186/s12879-015-1231-226527535 11.MussoD.GublerD.J.Zika VirusClin. Microbiol. Rev.20162948752410.1128/CMR.00072-1527029595 12.GourinatA.C.O’ConnorO.CalvezE.GoarantC.Dupont-RouzeyrolM.Detection of"/>
   <result pre="Zika virusBMC Infect. Dis.20151549210.1186/s12879-015-1231-226527535 11.MussoD.GublerD.J.Zika VirusClin. Microbiol. Rev.20162948752410.1128/CMR.00072-1527029595 12.GourinatA.C.O’ConnorO.CalvezE.GoarantC.Dupont-RouzeyrolM.Detection of" exact="Zika" post="virus in urineEmerg. Infect. Dis.201521848610.3201/eid2101.14089425530324 13.CoffeyL.L.PesaventoP.A.KeeslerR.I.SingapuriA.WatanabeJ.WatanabeR.YeeJ.Bliss-MoreauE.CruzenC.ChristeK.L.et al.Zika Virus Tissue"/>
   <result pre="persistence in multiple tissuesPLoS Pathog.201713e100621910.1371/journal.ppat.100621928278237 17.BesnardM.LastereS.TeissierA.Cao-LormeauV.MussoD.Evidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Eurosurveillance20141910.2807/1560-7917.ES2014.19.13.20751 18.ImperatoP.J.The"/>
   <result pre="of a Virus, Mosquitoes, and Human Travel in Globalizing the" exact="Zika" post="EpidemicJ. Commun. Health20164167467910.1007/s10900-016-0177-7 19.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.TeshR.B.Probable non-vector-borne transmission"/>
   <result pre="EpidemicJ. Commun. Health20164167467910.1007/s10900-016-0177-7 19.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.TeshR.B.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 20.Dupont-RouzeyrolM.BironA.O’ConnorO.HuguonE.DesclouxE.Infectious Zika viral particles"/>
   <result pre="non-vector-borne transmission of Zika virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 20.Dupont-RouzeyrolM.BironA.O’ConnorO.HuguonE.DesclouxE.Infectious" exact="Zika" post="viral particles in breastmilkLancet2016387105110.1016/S0140-6736(16)00624-3 21.CalvetG.AguiarR.S.MeloA.S.O.SampaioS.A.de FilippisI.FabriA.AraujoE.S.M.de SequeiraP.C.de MendoncaM.C.L.de OliveiraL.et"/>
   <result pre="breastmilkLancet2016387105110.1016/S0140-6736(16)00624-3 21.CalvetG.AguiarR.S.MeloA.S.O.SampaioS.A.de FilippisI.FabriA.AraujoE.S.M.de SequeiraP.C.de MendoncaM.C.L.de OliveiraL.et al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="in Brazil: A case studyLancet Infect. Dis.20161665366010.1016/S1473-3099(16)00095-526897108 22.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
   <result pre="viral polyproteinProc. Natl. Acad. Sci. USA1990878898890210.1073/pnas.87.22.88982147282 26.WenglerG.CzayaG.FarberP.M.HegemannJ.H.In vitro synthesis of" exact="West Nile" post="virus proteins indicates that the amino-terminal segment of the"/>
   <result pre="for the activation of flaviviral NS3 proteases from dengue and" exact="West Nile" post="virusNat. Struct. Mol. Biol.20061337237310.1038/nsmb107316532006 33.Munoz-JordanJ.L.Sanchez-BurgosG.G.Laurent-RolleM.Garcia-SastreA.Inhibition of interferon signaling by"/>
   <result pre="dengue virusProc. Natl. Acad. Sci. USA2003100143331433810.1073/pnas.233516810014612562 34.RoosendaalJ.WestawayE.G.KhromykhA.MackenzieJ.M.Regulated cleavages at the" exact="West Nile" post="virus NS4A-2K-NS4B junctions play a major role in rearranging"/>
   <result pre="genome organization, expression, and replicationAnnu. Rev. Microbiol.19904464968810.1146/annurev.mi.44.100190.0032452174669 37.HamelR.DejarnacO.WichitS.EkchariyawatP.NeyretA.LuplertlopN.Perera-LecoinM.SurasombatpattanaP.TalignaniL.ThomasF.et al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 38.Van HemertF.BerkhoutB.Nucleotide"/>
   <result pre="in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 38.Van HemertF.BerkhoutB.Nucleotide composition of the" exact="Zika" post="virus RNA genome and its codon usageVirol. J.2016139510.1186/s12985-016-0551-127278486 39.LindenbachB.D.RiceC.M.Molecular"/>
   <result pre="Res.200359236114696326 40.BatistaM.N.BragaA.C.S.CamposG.R.F.SouzaM.M.MatosR.P.A.LopesT.Z.CandidoN.M.LimaM.L.D.MachadoF.C.AndradeS.T.Q.et al.Natural Products Isolated from Oriental Medicinal Herbs Inactivate" exact="Zika" post="VirusViruses2019114910.3390/v11010049 41.HaddadJ.G.KoishiA.C.GaudryA.Nunes Duarte Dos SantosC.ViranaickenW.DespresP.El KalamouniC.Doratoxylon apetalum, an Indigenous"/>
   <result pre="Medicinal Plant from Mascarene Islands, Is a Potent Inhibitor of" exact="Zika" post="and Dengue Virus Infection in Human CellsInt. J. Mol."/>
   <result pre="from Mascarene Islands, Is a Potent Inhibitor of Zika and" exact="Dengue" post="Virus Infection in Human CellsInt. J. Mol. Sci.201920238210.3390/ijms20102382 42.collab:"/>
   <result pre="42.collab: Tychan Pte Ltd.Safety and Tolerability of an Antibody Against" exact="Zika" post="Virus (Tyzivumab) in ZIKV Infected Patients. ClinicalTrials.gov. NCT number:"/>
   <result pre="and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in" exact="ZIKV" post="Infected Patients. ClinicalTrials.gov. NCT number: NCT03776695. 2018 Dec. NCT03776695Available"/>
   <result pre="antibodies targeting different epitopes of E protein confer protection against" exact="Zika" post="virus in a neonatal mouse modelEmerg. Microbes Infect.2019874975910.1080/22221751.2019.161488531130109 44.De"/>
   <result pre="RNA chain terminatorsHandb. Exp. Pharmacol.2009538410.1007/978-3-540-79086-0_319048197 45.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RuzekD.Nucleoside Inhibitors of" exact="Zika" post="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 46.HercikK.KozakJ.SalaM.DejmekM.HrebabeckyH.ZbornikovaE.SmolaM.RuzekD.NenckaR.BouraE.Adenosine triphosphate analogs can efficiently inhibit"/>
   <result pre="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 46.HercikK.KozakJ.SalaM.DejmekM.HrebabeckyH.ZbornikovaE.SmolaM.RuzekD.NenckaR.BouraE.Adenosine triphosphate analogs can efficiently inhibit the" exact="Zika" post="virus RNA-dependent RNA polymeraseAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 47.ZmurkoJ.MarquesR.E.ScholsD.VerbekenE.KapteinS.J.NeytsJ.The Viral Polymerase Inhibitor"/>
   <result pre="Polymerase Inhibitor 7-Deaza-2’-C-Methyladenosine Is a Potent Inhibitor of In Vitro" exact="Zika" post="Virus Replication and Delays Disease Progression in a Robust"/>
   <result pre="infectionsAntivir. Res.2009829510210.1016/j.antiviral.2009.02.19819428599 51.BazM.GoyetteN.GriffinB.D.KobingerG.P.BoivinG.In vitro susceptibility of geographically and temporally distinct" exact="Zika" post="viruses to favipiravir and ribavirinAntivir. Ther.20172261361810.3851/IMP318028694390 52.CaiL.SunY.SongY.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors"/>
   <result pre="52.CaiL.SunY.SongY.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of" exact="Zika" post="virus replicationArch. Virol.20171622847285310.1007/s00705-017-3436-828597088 53.DelangL.AbdelnabiR.NeytsJ.Favipiravir as a potential countermeasure against"/>
   <result pre="virusesAntivir. Res.2018153859410.1016/j.antiviral.2018.03.00329524445 54.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 55.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies"/>
   <result pre="Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 55.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to Combat" exact="Zika" post="Virus: Current Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 56.ReznikS.E.AshbyC.R.Jr.Sofosbuvir: An"/>
   <result pre="PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 56.ReznikS.E.AshbyC.R.Jr.Sofosbuvir: An antiviral drug with potential efficacy against" exact="Zika" post="infectionInt. J. Infect. Dis.201755293010.1016/j.ijid.2016.12.01127988410 57.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug sofosbuvir inhibits"/>
   <result pre="Zika infectionInt. J. Infect. Dis.201755293010.1016/j.ijid.2016.12.01127988410 57.Bullard-FeibelmanK.M.GoveroJ.ZhuZ.SalazarV.VeselinovicM.DiamondM.S.GeissB.J.The FDA-approved drug sofosbuvir inhibits" exact="Zika" post="virus infectionAntivir. Res.201713713414010.1016/j.antiviral.2016.11.02327902933 58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved"/>
   <result pre="58.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug sofosbuvir inhibits" exact="Zika" post="virus replicationSci. Rep.201774092010.1038/srep4092028098253 59.PeralesC.DomingoE.Antiviral Strategies Based on Lethal Mutagenesis"/>
   <result pre="and Error ThresholdCurr. Top. Microbiol. Immunol.201639232333926294225 60.LazearH.M.GoveroJ.SmithA.M.PlattD.J.FernandezE.MinerJ.J.DiamondM.S.A Mouse Model of" exact="Zika" post="Virus PathogenesisCell Host Microbe20161972073010.1016/j.chom.2016.03.01027066744 61.MangiaA.PiazzollaV.Overall efficacy and safety results"/>
   <result pre="5S179S18510.1016/j.dld.2014.09.02625458780 62.EyerL.ZouharovaD.SirmarovaJ.FojtikovaM.StefanikM.HaviernikJ.NenckaR.de ClercqE.RuzekD.Antiviral activity of the adenosine analogue BCX4430 against" exact="West Nile" post="virus and tick-borne flavivirusesAntivir. Res.2017142636710.1016/j.antiviral.2017.03.01228336346 63.WarrenT.K.WellsJ.PanchalR.G.StuthmanK.S.GarzaN.L.Van TongerenS.A.DongL.RettererC.J.EatonB.P.PegoraroG.et al.Protection against"/>
   <result pre="BCX4430Nature201450840240510.1038/nature1302724590073 64.JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.et al.Efficacy of the broad-spectrum antiviral compound BCX4430 against" exact="Zika" post="virus in cell culture and in a mouse modelAntivir."/>
   <result pre="in a mouse modelAntivir. Res.2017137142210.1016/j.antiviral.2016.11.00327838352 65.StephenP.BazM.BoivinG.LinS.X.Structural Insight into NS5 of" exact="Zika" post="Virus Leading to the Discovery of MTase InhibitorsJ. Am."/>
   <result pre="Versatile Tools for SAM-Dependent MethyltransferasesACS Chem. Biol.20161158359710.1021/acschembio.5b0081226540123 68.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of" exact="Zika" post="virus methyltransferase inhibition by sinefunginArch. Virol.20171622091209610.1007/s00705-017-3345-x28357511 69.Robert-GeroM.LawrenceF.LedererE.Potential Clinical Use"/>
   <result pre="of novel small molecule inhibitors against NS2B/NS3 serine protease from" exact="Zika" post="virusAntivir. Res.2017139495810.1016/j.antiviral.2016.12.01628034741 71.BahramsoltaniR.SodagariH.R.FarzaeiM.H.AbdolghaffariA.H.GoosheM.RezaeiN.The preventive and therapeutic potential of natural"/>
   <result pre="the Natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses" exact="West Nile" post="Virus, Zika Virus, and Dengue VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived"/>
   <result pre="Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus," exact="Zika" post="Virus, and Dengue VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived anti-hepatitis B"/>
   <result pre="Gallate against the Flaviviruses West Nile Virus, Zika Virus, and" exact="Dengue" post="VirusFront. Microbiol.20178131410.3389/fmicb.2017.0131428744282 73.WuY.H.Naturally derived anti-hepatitis B virus agents and"/>
   <result pre="virus and their structure activity relationshipBiotechnol. Lett.20173941542110.1007/s10529-016-2261-627885509 75.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
   <result pre="ONE201712e018063210.1371/journal.pone.018063228700665 76.LiZ.BrecherM.DengY.Q.ZhangJ.SakamuruS.LiuB.HuangR.KoetznerC.A.AllenC.A.JonesS.A.et al.Existing drugs as broad-spectrum and potent inhibitors for" exact="Zika" post="virus by targeting NS2B-NS3 interactionCell Res.2017271046106410.1038/cr.2017.8828685770 77.YuanS.ChanJ.F.den-HaanH.ChikK.K.ZhangA.J.ChanC.C.PoonV.K.YipC.C.MakW.W.ZhuZ.et al.Structure-based discovery"/>
   <result pre="interactionCell Res.2017271046106410.1038/cr.2017.8828685770 77.YuanS.ChanJ.F.den-HaanH.ChikK.K.ZhangA.J.ChanC.C.PoonV.K.YipC.C.MakW.W.ZhuZ.et al.Structure-based discovery of clinically approved drugs as" exact="Zika" post="virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus"/>
   <result pre="drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit" exact="Zika" post="virus infection in vitro and in vivoAntivir. Res.2017145334310.1016/j.antiviral.2017.07.00728712942 78.AguilarJ.S.RiceM.WagnerE.K.The"/>
   <result pre="high throughput assay formatBiochem. Biophys. Res. Commun.201445353954410.1016/j.bbrc.2014.09.11325281902 85.AlbulescuI.C.KovacikovaK.TasA.SnijderE.J.van HemertM.J.Suramin inhibits" exact="Zika" post="virus replication by interfering with virus attachment and release"/>
   <result pre="Virol.200616374810.1002/rmv.48316287208 88.SidwellR.W.HuffmanJ.H.KhareG.P.AllenL.B.WitkowskiJ.T.RobinsR.K.Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamideScience197217770570610.1126/science.177.4050.7054340949 89.KamiyamaN.SomaR.HidanoS.WatanabeK.UmekitaH.FukudaC.NoguchiK.GendoY.OzakiT.SonodaA.et al.Ribavirin inhibits" exact="Zika" post="virus (ZIKV) replication in vitro and suppresses viremia in"/>
   <result pre="STAT1-deficient miceAntivir. Res.201714611110.1016/j.antiviral.2017.08.00728818572 90.TongX.SmithJ.BukreyevaN.KomaT.ManningJ.T.KalkeriR.KwongA.D.PaesslerS.Merimepodib, an IMPDH inhibitor, suppresses replication of" exact="Zika" post="virus and other emerging viral pathogensAntivir. Res.2018149344010.1016/j.antiviral.2017.11.00429126899 91.RauschK.HackettB.A.WeinbrenN.L.ReederS.M.SadovskyY.HunterC.A.SchultzD.C.CoyneC.B.CherryS.Screening Bioactives"/>
   <result pre="Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against" exact="Zika" post="VirusCell Rep.20171880481510.1016/j.celrep.2016.12.06828099856 92.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MunozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A Screen of FDA-Approved Drugs for"/>
   <result pre="Rep.20171880481510.1016/j.celrep.2016.12.06828099856 92.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MunozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A Screen of FDA-Approved Drugs for Inhibitors of" exact="Zika" post="Virus InfectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 93.PascoalinoB.S.CourtemancheG.CordeiroM.T.GilL.H.Freitas-JuniorL.Zika antiviral chemotherapy: Identification of"/>
   <result pre="chloroquineAm. J. Perinatol.1991817417810.1055/s-2007-9993712029276 101.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v8120322 102.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika Virus"/>
   <result pre="Damage and Fetal DemiseCell20161651081109110.1016/j.cell.2016.05.00827180225 103.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit" exact="Zika" post="virus infection in vitro and differentially affect cellular signaling,"/>
   <result pre="broad antiviral effectsPLoS Pathog.20128e100297610.1371/journal.ppat.100297623133371 105.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
   <result pre="SartoJ.L.RochaR.F.SilvaF.R.DoriaJ.G.OlmoI.G.MarquesR.E.Queiroz-JuniorC.M.FoureauxG.AraujoJ.M.S.et al.N-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by" exact="Zika" post="Virus InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of Zika virus"/>
   <result pre="Induced by Zika Virus InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of" exact="Zika" post="virus (ZIKV) genome. ZIKV genomic RNA is capped but"/>
   <result pre="InfectionmBio2017810.1128/mBio.00350-1728442607 Figure 1 Detailed structure of Zika virus (ZIKV) genome." exact="ZIKV" post="genomic RNA is capped but lacks poly A tail."/>
   <result pre="NS2A, NS2B, NS3, NS4A, 2K, NS4B, and NS5). Figure 2" exact="Zika" post="virus life cycle. ZIKV, an enveloped RNA virus, enters"/>
   <result pre="pharmaceuticals-12-00101-t001_Table 1Table 1 The table shows the structural and nonstructural" exact="ZIKV" post="proteins from the 5’ to the 3’ untranslated regions."/>
   <result pre="reductase inhibitor √ X Azithromycin Unknown mechanisms of action against" exact="ZIKV" post="√ X Chloroquine Inhibition of pH-dependent steps of viral"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789600\results\search\tropicalVirus\results.xml">
   <result pre="Medicine and Infectious Disease2414-6366MDPI pmcid: 6789600 doi: 10.3390/tropicalmed4030104tropicalmed-04-00104 : Review" exact="Zika" post="Vaccine Development—Current Progress and Challenges for the Future https://orcid.org/0000-0003-0305-5608MaslowJoel"/>
   <result pre="an employee of GeneOne Life Science, a developer of a" exact="Zika" post="vaccine. epub: 2019-7-7collection: 2019-943104received: 2019-6-11accepted: 2019-7-11(C) , 2019Licensee MDPI,"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus is an emergent pathogen that gained significant importance"/>
   <result pre="infection causing microcephaly, blindness, and other congenital neurologic complications. Numerous" exact="Zika" post="virus vaccines were developed, with nine different vaccines representing"/>
   <result pre="II. Here we review the current landscape and challenges confronting" exact="Zika" post="virus vaccine development. Zika virus flavivirus emerging infectious disease"/>
   <result pre="the current landscape and challenges confronting Zika virus vaccine development." exact="Zika" post="virus flavivirus emerging infectious disease vaccine sample size 1."/>
   <result pre="flavivirus emerging infectious disease vaccine sample size 1. Introduction The" exact="Zika" post="virus, discovered in Uganda in 1947 [1], was shown"/>
   <result pre="and on French Polynesia in 2014 [4]. Starting in mid-2015," exact="Zika" post="virus infection achieved epidemic status, spreading rapidly through South"/>
   <result pre="and the Caribbean Islands [5]. It was soon recognized that" exact="Zika" post="virus infection occurring during pregnancy caused microcephaly and other"/>
   <result pre="the primary reason for the World Health Organization (WHO) labelling" exact="Zika" post="as an international threat in early 2016. Beginning in"/>
   <result pre="by the time the first vaccines entered clinical trials, the" exact="Zika" post="epidemic had started to wane creating significant challenges to"/>
   <result pre="paper, we provide a brief update of current progress in" exact="Zika" post="virus vaccine development and explore the challenges to vaccine"/>
   <result pre="explore the challenges to vaccine assessment and eventual licensure. 2." exact="Zika" post="Vaccine Target Population Zika virus infection presents with a"/>
   <result pre="vaccine assessment and eventual licensure. 2. Zika Vaccine Target Population" exact="Zika" post="virus infection presents with a symptom complex consisting of"/>
   <result pre="that only 19% of survey participants reported symptoms consistent with" exact="Zika" post="virus infection [3], a figure that has been cited"/>
   <result pre="[3], a figure that has been cited to suggest that" exact="Zika" post="virus infection is asymptomatic in as many as 80%"/>
   <result pre="those with evidence of prior infection had symptoms consistent with" exact="Zika" post="virus infection [11]. A more recent meta-analysis of 23"/>
   <result pre="studies [12]. In adults, the most common reported complication of" exact="Zika" post="virus infection is a Guillain–Barré-like illness that had a"/>
   <result pre="30% children born to mothers infected during pregnancy [16,17,18,19,20,21]. Additionally," exact="Zika" post="can directly invade the placenta and has been associated"/>
   <result pre="placenta and has been associated with prolonged maternal viremia [22,23,24]." exact="Zika" post="virus can also be transmitted through sexual contact, first"/>
   <result pre="is unknown and could not be differentiated from mosquito-borne transmission." exact="Zika" post="virus carriage in the male urogenital tract is common"/>
   <result pre="may persist in some to 9 months [27]. In mice," exact="Zika" post="virus infection causes testicular atrophy and significantly decreases spermatic"/>
   <result pre="function and fertility rates [28,29,30]. In one study of a" exact="Zika" post="virus DNA vaccine, the adverse effects in the male"/>
   <result pre="system were prevented by vaccination [30]. The question of whether" exact="Zika" post="virus can adversely affect human reproductive potential and, if"/>
   <result pre="effects would be age-related is unknown. Females may also excrete" exact="Zika" post="virus RNA for extended times. A prospective study of"/>
   <result pre="extended times. A prospective study of five women showed that" exact="Zika" post="RNA was detected in vaginal fluid for as long"/>
   <result pre="in three of the five [31]. Murine studies showed that" exact="Zika" post="virus caused infection of the ovaries of non-immunosuppressed C57Bl/6"/>
   <result pre="rapidly cleared virus from the genital tract [33]. Thus, while" exact="Zika" post="virus infection is mildly symptomatic and self-limited for the"/>
   <result pre="been put on hold due to the decreasing incidence of" exact="Zika" post="infection rates, as discussed in the next section. 3."/>
   <result pre="discussed in the next section. 3. Changing Epidemiology of the" exact="Zika" post="Virus Outbreak In late 2015 and through mid-2016, global"/>
   <result pre="was predictive of the subsequent epidemiology in the Americas. The" exact="Zika" post="virus outbreaks in Yap Island and French Polynesia were"/>
   <result pre="rapid resolution over a span of 3–4 months [3,9]. The" exact="Zika" post="epidemic in the Americas was characterized by a longer"/>
   <result pre="South and Central America (https://www.paho.org/). The almost complete disappearance of" exact="Zika" post="has created significant barriers to ongoing vaccine studies as"/>
   <result pre="reasonable sample sizes [6]. The WHO removed the designation of" exact="Zika" post="a virus of global concern in 2018 as case"/>
   <result pre="representatives from industry, and regulators to discuss the approach to" exact="Zika" post="virus vaccine development in an era of waning incidence"/>
   <result pre="vaccine development in an era of waning incidence [7]. Although" exact="Zika" post="virus remains endemic in Asia, Africa, and Central and"/>
   <result pre="rapid response to new reports suggesting increased disease activity. 4." exact="Zika" post="Vaccine Candidates in Development Vaccine development against the Zika"/>
   <result pre="4. Zika Vaccine Candidates in Development Vaccine development against the" exact="Zika" post="virus began in earnest in late 2015 following the"/>
   <result pre="of a 1953 study to define the ultrastructural characteristics of" exact="Zika" post="virus, that found intramuscular vaccination of mice with infectious"/>
   <result pre="Poland et al. provide a comprehensive listing of almost 40" exact="Zika" post="virus vaccines in development as of 2017 [37]. Diamond"/>
   <result pre="[37]. Diamond et al. discuss potential immunoreactive epitopes on the" exact="Zika" post="envelope and provide further information on those vaccines that"/>
   <result pre="II (Table 1). GLS-5700, a DNA vaccine encoding for the" exact="Zika" post="virus prME genes designed as a consensus based on"/>
   <result pre="virus prME genes designed as a consensus based on available" exact="Zika" post="virus sequences through December 2015 [43], was the first"/>
   <result pre="shown to develop B and T-cell immune responses against the" exact="Zika" post="virus envelope and protected against development of neurologic disease"/>
   <result pre="that included the JEV prM signal sequence followed by the" exact="Zika" post="envelope (E) gene (VRC5283) or a similar construct with"/>
   <result pre="and subcutaneously vaccinated mice were only partially protected against the" exact="Zika" post="Brazil strain [46]. A subsequent study in non-human primates"/>
   <result pre="following challenge with either Brazilian or Puerto Rican strains of" exact="Zika" post="virus [47]. ZPIV safety and immunogenicity was tested in"/>
   <result pre="and immunogenicity was tested in three clinical trials to assess" exact="Zika" post="vaccine responses relative to dose level, vaccination schedule, or"/>
   <result pre="day 57. Passive transfer of purified IgG derived from 10" exact="Zika" post="immunized participants to groups of 5 Balb/C mice per"/>
   <result pre="that incorporates the prM-E genes of a Micronesian strain of" exact="Zika" post="virus was created incorporating with or without four-point mutations"/>
   <result pre="strain PRVABC59 selected as without passage-related mutations, protected against lethal" exact="Zika" post="virus challenge in AG129 mice when administered with alum"/>
   <result pre="administered with alum adjuvant [49]. A measles-vectored vaccine encoding the" exact="Zika" post="virus prME was shown to lessen viremia in pregnant"/>
   <result pre="knockout mice (AG129 or IFNAR -/-) develop lethal infection following" exact="Zika" post="virus infection and have been used as a more"/>
   <result pre="human challenge trials raises unique medical and ethical considerations. For" exact="Zika" post="virus trials, one must balance the relative benign and"/>
   <result pre="transmission risks. As reviewed above, published studies provide estimates that" exact="Zika" post="virus infection is relatively asymptomatic and self-limited for the"/>
   <result pre="above, a Guillain–Barre-like syndrome occurs in approximately 1 of 5000" exact="Zika" post="virus infections [13], whereas other neurologic complications such as"/>
   <result pre="a sexual partner and the potential for infection during pregnancy." exact="Zika" post="virus commonly persists in the male urogenital tract for"/>
   <result pre="[27]. Some have considered limiting studies to non-pregnant females as" exact="Zika" post="virus colonization of the female genital tract may be"/>
   <result pre="female genital tract may be temporally limited. The fact that" exact="Zika" post="virus is known to cause testicular atrophy in mice"/>
   <result pre="challenge strain is as yet undetermined. 7. Summary In summary," exact="Zika" post="vaccine development continues with multiple candidate vaccines in clinical"/>
   <result pre="a developer of DNA-based vaccines including a vaccine against the" exact="Zika" post="virus. Abbreviations WRAIR Walter Reed Army Institute of Research"/>
   <result pre="4.collab: European Centre for Disease Prevention and ControlRapid risk assessment:" exact="Zika" post="virus infection outbreak, French PolynesiaProceedings of the ECDCStockholm, Sweden14"/>
   <result pre="Americas—Yet another arbovirus threatN. Engl. J. Med.201637460160410.1056/NEJMp160029726761185 6.CohenJ.Steep drop in" exact="Zika" post="cases undermines vaccine trialScience20183611055105610.1126/science.361.6407.105530213891 7.VanniceK.S.CassettiM.C.EisingerR.W.HombachJ.KnezevicI.MarstonH.D.Wilder-SmithaA.CavaleridM.KrauseeP.R.Demonstrating vaccine effectiveness during a"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 8.Cao-LormeauV.M.RocheC.TeissierA.RobinE.BerryA.-L.MalletH.P.SallA.A.MussoD.Zika virus, French Polynesia, South Pacific, 2013Emerg."/>
   <result pre="South Pacific, 2013Emerg. Infect. Dis.2014201086108710.3201/eid2011.141380 9.MalletH.P.VialA.L.MussoD.Bilan de l’épidémie à virus" exact="Zika" post="survenue en Polynésie française entre octobre 2013 et mars"/>
   <result pre="aux connaissances acquises après l’évènementBulletin Épidémiologique Hebdomadaire201620–21367373 10.MussoD.NhanT.RobinE.RocheC.BierlaireD.ZisouK.Shan YanA.Cao-LormeauV.M.BroultJ.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
   <result pre="virus seroprevalence, French Polynesia, 2014–2015Emerg. Infect. Dis.20172366967210.3201/eid2304.16154928084987 12.HabyM.M.PinartM.EliasV.ReveizL.Prevalence of asymptomatic" exact="Zika" post="virus infection: A systematic reviewBull. World Health Org.201896402D413D10.2471/BLT.17.20154129904223 13.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissieraA.LarreP.et"/>
   <result pre="reviewBull. World Health Org.201896402D413D10.2471/BLT.17.20154129904223 13.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissieraA.LarreP.et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 14.BautistaL.E.Zika"/>
   <result pre="dysfunction in fetuses and newborns following the 2013 to 2014" exact="Zika" post="virus epidemic in French PolynesiaEuro Surv.201621223010.2807/1560-7917.ES.2016.21.13.3018127063794 17.BrasilP.PereiraJ.P.MoreiraM.E.NogueiraR.M.R.DamascenoL.WakimotoM.RabelloR.S.ValderramosS.G.HalaiU.-A.SallesT.S.et al.Zika virus"/>
   <result pre="18.collab: European Centre for Disease Prevention and ControlRapid risk assessment:" exact="Zika" post="virus epidemic in the Americas: Potential association with microcephaly"/>
   <result pre="fetuses and infants of US women with evidence of possible" exact="Zika" post="virus infection during pregnancyJAMA201717596810.1001/jama.2016.19006 20.LealM.C.MunizL.F.FerreiraT.S.A.SantosC.M.AlmeidaL.C.Van Der LindenV.RamosR.C.F.RodriguesL.C.NetoS.S.C.Hearing loss in"/>
   <result pre="LindenV.RamosR.C.F.RodriguesL.C.NetoS.S.C.Hearing loss in infants with microcephaly and evidence of congenital" exact="Zika" post="virus infection—Brazil, November 2015–May 2016MMWR20166591791910.15585/mmwr.mm6534e327585248 21.VenturaC.V.MaiaM.TravassosS.B.MartinsT.T.PatriotaF.NunesM.E.AgraC.TorresV.L.van der LindenV.RamosR.C.et al.Risk"/>
   <result pre="associated with the ophthalmoscopic findings identifed in infants with presumed" exact="Zika" post="virus congenital infectionJAMA Ophthalmol.201613491291810.1001/jamaophthalmol.2016.178427228275 22.DriggersR.W.HoC.Y.KorhonenE.M.KuivanenS.JääskeläinenA.J.SmuraT.RosenbergA.HillA.DeBiasiR.L.VezinaG.et al.Zika virus infection with"/>
   <result pre="brain abnormalitiesN. Engl. J. Med.201610.1056/NEJMoa1601824 23.Meaney-DelmanD.OduyeboT.PolenK.N.D.WhiteJ.L.BinghamA.M.SlavinskiS.A.Heberlein-LarsonL.St. GeorgeK.RakemanJ.L.HillsS.et al.Prolonged detection of" exact="Zika" post="virus RNA in pregnant womenObstet. Gynecol.201612872473010.1097/AOG.000000000000162527479770 24.Oliveira MeloA.S.MalingerG.XimenesR.SzejnfeldP.O.Alves SampaioS.Bispo"/>
   <result pre="iceberg?Ultrasound Obstet. Gynecol.2016476710.1002/uog.1583126731034 25.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.RobertB.TeshR.B.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 26.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent Zika virus sexual"/>
   <result pre="non-vector-borne transmission of Zika virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 26.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent" exact="Zika" post="virus sexual transmission and prolonged viral RNA shedding in"/>
   <result pre="in miceNature201654043844210.1038/nature2055627798603 30.GriffinB.D.MuthumaniK.WarnerB.M.MajerA.HaaganM.AudetJ.SteinD.R.RanadheeraC.RacineT.De La VegaM.-A.et al.DNA vaccination protects mice against" exact="Zika" post="virus-induced damage to the testesNat. Commun.201781574310.1038/ncomms1574328589934 31.ReyesY.BowmanN.M.Becker-DrepsS.CentenoE.CollinsM.H.LiouG.A.BucardoF.Prolonged shedding of"/>
   <result pre="Zika virus-induced damage to the testesNat. Commun.201781574310.1038/ncomms1574328589934 31.ReyesY.BowmanN.M.Becker-DrepsS.CentenoE.CollinsM.H.LiouG.A.BucardoF.Prolonged shedding of" exact="Zika" post="virus RNA in vaginal secretions, NicaraguaEmerg. Infect. Dis.20192580881010.3201/eid2504.18097730882329 32.CaineE.A.ScheafferS.M.BroughtonD.E.SalazarV.GoveroJ.PoddarS.OsulaA.HalabiJ.Skaznik-WikielM.E.DiamondM.S.et"/>
   <result pre="DC, USA2017 36.ReaganR.L.BrueknerA.L.Comparison by electron microscopy of the Ntaya and" exact="Zika" post="virusesTex. Rep. Biol. Med.19531134735113077401 37.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against Zika"/>
   <result pre="and Zika virusesTex. Rep. Biol. Med.19531134735113077401 37.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 38.DiamondM.S.LedgerwoodJ.E.PiersonT.C.Zika virus vaccine development: Progress in"/>
   <result pre="39.MaslowJ.N.Vaccines for emerging infectious diseases: Lessonso from MERS coronavirus and" exact="Zika" post="virusHum. Vaccin. Immunother.2017122918293010.1080/21645515.2017.135832528846484 40.DurbinA.Wilder-SmithA.An update on Zika vaccine developmentsExpert"/>
   <result pre="MERS coronavirus and Zika virusHum. Vaccin. Immunother.2017122918293010.1080/21645515.2017.135832528846484 40.DurbinA.Wilder-SmithA.An update on" exact="Zika" post="vaccine developmentsExpert Rev. Vaccin.20171678178710.1080/14760584.2017.1345309 41.GaudinskiM.R.HouserK.V.MorabitoK.M.HuZ.YamshchikovG.RothwellR.S.BerkowitzN.MendozaF.SaundersJ.G.NovikL.et al.Safety, tolerability, and immunogenicity"/>
   <result pre="developmentsExpert Rev. Vaccin.20171678178710.1080/14760584.2017.1345309 41.GaudinskiM.R.HouserK.V.MorabitoK.M.HuZ.YamshchikovG.RothwellR.S.BerkowitzN.MendozaF.SaundersJ.G.NovikL.et al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: Randomised, open-label,"/>
   <result pre="vaccine—Preliminary ReportN. Engl. J. Med.2017201710.1056/NEJMoa1708120 43.MuthumaniK.GriffinB.D.AgarwalS.KudchodkarS.ReuschelE.L.ChoiH.KraynyakK.A.DuperretE.K.KeatonA.A.ChungC.et al.In vivo protection against" exact="ZIKV" post="infection and pathogenesis through passive antibody transfer and active"/>
   <result pre="vaccineNPJ Vaccin.201611602110.1038/npjvaccines.2016.21 44.DowdK.A.KoS.-Y.MorabitoK.M.YangE.S.PelcR.S.DeMasoC.R.CastilhoL.R.AbbinkP.BoydM.NityanandamR.et al.Rapid development of a DNA vaccine for" exact="Zika" post="virusScience201635423724010.1126/science.aai913727708058 45.ModjarradK.LinL.GeorgeS.L.StephensonK.E.EckelsK.H.De La BarreraR.A.JarmanR.G.SondergaardE.TennantJ.AnselJ.L.et al.Preliminary aggregate safety and immunogenicity"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="randomised, double-blind, placebo-controlled clinical trialsLancet20183911012010.1016/S0140-6736(17)33106-9 46.LaroccaR.A.AbbinkP.PeronJ.P.S.de AZanottoP.M.IampietroM.J.Badamchi-ZadehA.BoydM.Ng’ang’aD.KirilovaM.NityanandamR.et al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 47.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of"/>
   <result pre="47.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113310.1126/science.aah615727492477 48.RichnerJ.M.HimansuS.BultlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.CiaramellaG.et al.Modified mRNA vaccines"/>
   <result pre="challenge in rhesus monkeysScience20163531129113310.1126/science.aah615727492477 48.RichnerJ.M.HimansuS.BultlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.CiaramellaG.et al.Modified mRNA vaccines protect against" exact="Zika" post="virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 49.BaldwinW.R.LivengoodJ.A.GieblerH.A.StovallJ.L.BoroughsK.L.SonnbergS.BohningK.J.DietrichE.A.OngY.T.DanhH.K.et al.Purified inactivated Zika vaccine candidates afford"/>
   <result pre="mRNA vaccines protect against Zika virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 49.BaldwinW.R.LivengoodJ.A.GieblerH.A.StovallJ.L.BoroughsK.L.SonnbergS.BohningK.J.DietrichE.A.OngY.T.DanhH.K.et al.Purified inactivated" exact="Zika" post="vaccine candidates afford protection against lethal challenge in miceSci."/>
   <result pre="miceSci. Rep.201881650910.1038/s41598-018-34735-730405178 50.NürnbergerC.BodmerB.S.FiedlerA.H.GabrielG.MühlebachM.D.A measles virus-based vaccine candidate mediates protection against" exact="Zika" post="virus in an allogeneic mouse pregnancy modelJ. Virol.20199310.1128/JVI.01485-18 51.MorrisonT.E.DiamondM.S.Animal"/>
   <result pre="in an allogeneic mouse pregnancy modelJ. Virol.20199310.1128/JVI.01485-18 51.MorrisonT.E.DiamondM.S.Animal models of" exact="Zika" post="virus infection, pathogenesis, and immunityJ. Virol.20179110.1128/JVI.00009-17 52.MinerJ.J.CaoB.GoveroJ.SmithA.M.FernandezE.CabreraO.H.GarberC.NollM.KleinR.S.NoguchiK.K.et al.Zika virus"/>
   <result pre="and fetal demiseCell201616511110.1016/j.cell.2016.05.008 53.BarcellosC.XavierD.R.PavãoA.BoccoliniC.S.PinaM.F.PedrosoF.P.M.RomeroD.RomãoR.A.Increased hospitalizations for neuropathies as indicators of" exact="Zika" post="virus infection, according to Health Information System data, BrazilEmerg."/>
   <result pre="Azevedo MarquesE.T.Jr.PenaL.J.Guillain-Barré syndrome, acute disseminated encephalomyelitis and encephalitis associated with" exact="Zika" post="virus infection in Brazil: Detection of viral RNA and"/>
   <result pre="during late infectionAm. J. Trop. Med. Hyg.2017971405140910.4269/ajtmh.17-010629140242 55.ShahS.K.KimmelmanJ.LyerlyA.D.LynchH.F.McCutchanF.MillerF.G.PalaciosR.Pardo-VillamizarC.ZorrillaC.Ethical Considerations for" exact="Zika" post="Virus Human Challenge TrialsNational Institutes of Health, National Institute"/>
   <result pre="for controlled human infectionJ. Infect. Dis.2017216Suppl. 10S971S97510.1093/infdis/jix49129267920 tropicalmed-04-00104-t001_Table 1Table 1" exact="Zika" post="vaccines in clinical development. Vaccine Type/Vaccine Name Developer Development"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789833\results\search\tropicalVirus\results.xml">
   <result pre="Reporter MR766-Based Flow Cytometry Neutralization Test for Rapid Detection of" exact="Zika" post="Virus-Neutralizing Antibodies in Serum Specimens https://orcid.org/0000-0002-7734-7737FrumenceEtiennehttps://orcid.org/0000-0002-0915-8635ViranaickenWildrisshttps://orcid.org/0000-0001-6325-4866GadeaGilleshttps://orcid.org/0000-0001-8926-4050DesprèsPhilippe*[], *Correspondence: philippe.despres@univ-reunion.fr; Tel.:"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is an emerging arthropod-borne virus of major"/>
   <result pre="is an emerging arthropod-borne virus of major public health concern." exact="ZIKV" post="infection is responsible for congenital Zika disease and other"/>
   <result pre="major public health concern. ZIKV infection is responsible for congenital" exact="Zika" post="disease and other neurological defects. Antibody-mediated virus neutralization is"/>
   <result pre="In the present study, we assessed whether our GFP reporter" exact="ZIKV" post="derived from African viral strain MR766 could be useful"/>
   <result pre="immune sera from adult mice that received ZIKBeHMR-2. The chimeric" exact="ZIKV" post="clone ZIKBeHMR-2 comprises the structural protein region of epidemic"/>
   <result pre="valid format for measuring ZIKV-neutralizing antibodies in serum specimens. arbovirus" exact="Zika" post="virus GFP reporter ZIKV flow cytometry neutralization test mouse"/>
   <result pre="ZIKV-neutralizing antibodies in serum specimens. arbovirus Zika virus GFP reporter" exact="ZIKV" post="flow cytometry neutralization test mouse immune sera humoral immune"/>
   <result pre="plaque-reduction neutralization test flow cytometry neutralization test 1. Introduction Mosquito-borne" exact="Zika" post="virus (ZIKV) is an emerging flavivirus initially reported in"/>
   <result pre="emerging flavivirus initially reported in Africa in 1947 [1]. Recently," exact="ZIKV" post="became a public health concern with recent epidemics occurring"/>
   <result pre="Polynesia (2013), and South America (2015) [2]. During these outbreaks," exact="ZIKV" post="infection was reported to cause severe complications in humans,"/>
   <result pre="abnormalities in infants and Guillain-Barre syndrome in adults [3]. Also," exact="ZIKV" post="is capable of long-term persistence in human body fluids"/>
   <result pre="transmission of disease has been documented [4,5]. Laboratory diagnosis of" exact="ZIKV" post="infection is mainly based on RT-PCR method during the"/>
   <result pre="the acute phase of the disease [5,6,7,8]. Serological diagnosis of" exact="ZIKV" post="infection is obtained at least one week after the"/>
   <result pre="antigenic cross-reactivity making inconclusive serological tests especially in regions where" exact="ZIKV" post="and related flaviviruses, such as dengue viruses, co-circulate. To"/>
   <result pre="issue, the detection of antibodies that have neutralizing activity against" exact="ZIKV" post="can be achieved to confirm recent infection [8]. Plaque-reduction"/>
   <result pre="gene-based methods for neutralizing assays have been recently developed for" exact="ZIKV" post="[10,11,12]. Given that reporter systems afford the ability to"/>
   <result pre="expression inside the infected cells, we generated a GFP reporter" exact="ZIKV" post="entitled ZIKVGFP [13]. We demonstrated that ZIKVGFP is a"/>
   <result pre="that ZIKVGFP is a performing tool for the monitoring of" exact="ZIKV" post="replication in the host cell as well as the"/>
   <result pre="Biotech, Aidenbach, Germany). The recombinant ZIKVGFP derived from molecular clone" exact="ZIKV" post="MR766MC is described elsewhere [13]. ZIKVGFP and derived viral"/>
   <result pre="Cytometry Neutralization Test To generate a more reliable GFP reporter" exact="ZIKV" post="for flow cytometry neutralization test, recombinant ZIKVGFP was repeatedly"/>
   <result pre="1B). Thus, the MR766GFP variant is a suitable GFP reporter" exact="ZIKV" post="for the development of a FNT. 3.2. Comparison Between"/>
   <result pre="adult mice that received intraperitoneally 5 log PFU of chimeric" exact="ZIKV" post="clone ZIKBeHMR-2 developed high titers of ZIKV-neutralizing antibodies [23]."/>
   <result pre="of ZIKV-neutralizing antibodies [23]. ZIKBeHMR-2 is a chimeric clone of" exact="ZIKV" post="derived from historical African ZIKV strain MR766 in which"/>
   <result pre="is a chimeric clone of ZIKV derived from historical African" exact="ZIKV" post="strain MR766 in which the structural protein region was"/>
   <result pre="the structural protein region was replaced with that of epidemic" exact="ZIKV" post="strain BeH819015 of Asian lineage [23]. Noteworthy, the ZIKBeHMR-2"/>
   <result pre="aim, we took advantage of our previously developed GFP reporter" exact="ZIKV" post="(recombinant ZIKVGFP), which had been demonstrated to be a"/>
   <result pre="ZIKBeHMR-2, which contains the structural protein region of epidemic Brazilian" exact="ZIKV" post="strain BeH810915 into a MR766 backbone [23]. ZIKBeHMR-2 has"/>
   <result pre="in 96-well-plates. The neutralizing activity of anti-ZIKBeHMR-2 immune sera against" exact="ZIKV" post="was estimated within two days. There was a linear"/>
   <result pre="is a suitable method for the general measurement of antibody-mediated" exact="ZIKV" post="neutralization. Now, it is of paramount importance to estimate"/>
   <result pre="the detection of ZIKV-neutralizing antibodies using human serum specimens from" exact="Zika" post="patients. 5. Conclusions In the present study, we demonstrated"/>
   <result pre="demonstrated that viral clone MR766GFP is a suitable GFP reporter" exact="ZIKV" post="for the identification of ZIKV-neutralizing antibodies in serum specimens"/>
   <result pre="could provide a reliable platform for measuring antibodies that neutralize" exact="ZIKV" post="in a large number of serum specimens without the"/>
   <result pre="in the patent entitled &quot;Vaccine compositions comprising an attenuated mutant" exact="Zika" post="virus�? under the number WO2017220748A1 (priority date 2016-06-23). Acknowledgments"/>
   <result pre="the AmericasJ. Gen. Virol.20169726927310.1099/jgv.0.00038126684466 3.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 4.Runge-RanzingerS.MorrisonA.C.Manrique-SaideP.HorstickO.Zika"/>
   <result pre="Health20192452352910.1111/tmi.1321630771269 5.MussoD.GublerD.J.Zika VirusClin. Microbiol. Rev.20162948752410.1128/CMR.00072-1527029595 6.LanciottiR.S.KosoyO.L.LavenJ.J.VelezJ.O.LambertA.J.JohnsonA.J.StanfieldS.M.DuffyM.R.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg."/>
   <result pre="J.2013195334010.1016/j.tvjl.2012.08.01923036176 9.RoehrigJ.T.HombachJ.BarrettA.D.T.Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to" exact="Dengue" post="VirusesViral Immunol.20082112313210.1089/vim.2008.000718476771 10.MatsudaM.YamanakaA.YatoK.YoshiiK.WatashiK.AizakiH.KonishiE.TakasakiT.KatoT.MuramatsuM.et al.High-throughput neutralization assay for multiple flaviviruses"/>
   <result pre="using dengue virus type 1 reporter repliconSci. Rep.2018810.1038/s41598-018-34865-y 11.ShanC.XieX.RenP.LoeffelholzM.J.YangY.FuruyaA.DupuisA.P.KramerL.D.WongS.J.ShiP.-Y.A Rapid" exact="Zika" post="Diagnostic Assay to Measure Neutralizing Antibodies in PatientsEBioMedicine20171715716210.1016/j.ebiom.2017.03.00628283425 12.KoishiA.C.SuzukawaA.A.ZanlucaC.CamachoD.E.ComachG.Duarte"/>
   <result pre="a novel high-throughput image-based fluorescent neutralization test for detection of" exact="Zika" post="virus infectionPLoS Negl. Trop. Dis.201812e000634210.1371/journal.pntd.000634229543803 13.GadeaG.BosS.Krejbich-TrototP.ClainE.ViranaickenW.El-KalamouniC.MavinguiP.DesprèsP.A robust method for"/>
   <result pre="Dis.201812e000634210.1371/journal.pntd.000634229543803 13.GadeaG.BosS.Krejbich-TrototP.ClainE.ViranaickenW.El-KalamouniC.MavinguiP.DesprèsP.A robust method for the rapid generation of recombinant" exact="Zika" post="virus expressing the GFP reporter geneVirology201649715716210.1016/j.virol.2016.07.01527471954 14.El KalamouniC.FrumenceE.BosS.TurpinJ.NativelB.HarrabiW.WilkinsonD.A.MeilhacO.GadeaG.DesprèsP.et al.Subversion"/>
   <result pre="14.El KalamouniC.FrumenceE.BosS.TurpinJ.NativelB.HarrabiW.WilkinsonD.A.MeilhacO.GadeaG.DesprèsP.et al.Subversion of the Heme Oxygenase-1 Antiviral Activity by" exact="Zika" post="VirusViruses201811210.3390/v1101000230577437 15.ClainE.SinigagliaL.KoishiA.C.GorgetteO.GadeaG.ViranaickenW.Krejbich-TrototP.MavinguiP.DesprèsP.Nunes Duarte Dos SantosC.et al.Extract from Aphloia theiformis,"/>
   <result pre="Aphloia theiformis, an edible indigenous plant from Reunion Island, impairs" exact="Zika" post="virus attachment to the host cell surfaceSci. Rep.201881085610.1038/s41598-018-29183-230022045 16.HaddadJ.G.KoishiA.C.GaudryA.Nunes"/>
   <result pre="Medicinal Plant from Mascarene Islands, Is a Potent Inhibitor of" exact="Zika" post="and Dengue Virus Infection in Human CellsInt. J. Mol."/>
   <result pre="from Mascarene Islands, Is a Potent Inhibitor of Zika and" exact="Dengue" post="Virus Infection in Human CellsInt. J. Mol. Sci.201920232810.3390/ijms2010238231091703 17.ClainE.HaddadJ.G.KoishiA.C.SinigagliaL.RachidiW.DesprèsP.Duarte"/>
   <result pre="Medicinal Plant from Reunion Island, Inhibits the Early Stages of" exact="Dengue" post="and Zika Virus InfectionInt. J. Mol. Sci.201920186010.3390/ijms2008186030991717 18.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprèsP.El-KalamouniC.The Flavonoid"/>
   <result pre="from Reunion Island, Inhibits the Early Stages of Dengue and" exact="Zika" post="Virus InfectionInt. J. Mol. Sci.201920186010.3390/ijms2008186030991717 18.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprèsP.El-KalamouniC.The Flavonoid Isoquercitrin Precludes"/>
   <result pre="InfectionInt. J. Mol. Sci.201920186010.3390/ijms2008186030991717 18.GaudryA.BosS.ViranaickenW.RocheM.Krejbich-TrototP.GadeaG.DesprèsP.El-KalamouniC.The Flavonoid Isoquercitrin Precludes Initiation of" exact="Zika" post="Virus Infection in Human CellsInt. J. Mol. Sci.201819109310.3390/ijms19041093 19.VanwalscappelB.GadeaG.DesprèsP.A"/>
   <result pre="Virus ActivityInt. J. Mol. Sci.201920157410.3390/ijms20071574 20.VanwalscappelB.TadaT.LandauN.R.Toll-like receptor agonist R848 blocks" exact="Zika" post="virus replication by inducing the antiviral protein viperinVirology201852219920810.1016/j.virol.2018.07.01430036788 21.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The"/>
   <result pre="the antiviral protein viperinVirology201852219920810.1016/j.virol.2018.07.01430036788 21.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="Guidelines for planning animal research and testingLab. Anim.20185213514110.1177/002367721772482328771074 23.FrumenceE.ViranaickenW.BosS.Alvarez-MartinezM.-T.RocheM.ArnaudJ.-D.GadeaG.DesprèsP.A Chimeric" exact="Zika" post="Virus between Viral Strains MR766 and BeH819015 Highlights a"/>
   <result pre="Vero cells. The neutralizing ability of mouse serum specimens against" exact="ZIKV" post="was determined by flow cytometry neutralization test (FNT) on"/>
   <result pre="A549 cells. The neutralizing ability of mouse serum specimens against" exact="ZIKV" post="was determined by FNT on A549 cells. Samples of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6789886\results\search\tropicalVirus\results.xml">
   <result pre="italic;} Vaccines (Basel)Vaccines (Basel)vaccinesVaccines2076-393XMDPI pmcid: 6789886 doi: 10.3390/vaccines7030072vaccines-07-00072 : Article" exact="Zika" post="Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces"/>
   <result pre="Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of" exact="Dengue" post="Virus Infection Cabral-MirandaGustavo12*LimStephanie M.3https://orcid.org/0000-0003-3510-9148MohsenMona O.12PobelovIlya V.4RoestiElisa S.2HeathMatthew D.5SkinnerMurray A.5https://orcid.org/0000-0002-3740-4733KramerMatthias"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is a flavivirus similar to Dengue virus"/>
   <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract Zika virus (ZIKV) is a flavivirus similar to" exact="Dengue" post="virus (DENV) in terms of transmission and clinical manifestations,"/>
   <result pre="clinical manifestations, and usually both viruses are found to co-circulate." exact="ZIKV" post="is usually transmitted by mosquitoes bites, but may also"/>
   <result pre="and sexually. After 2015, when the most extensive outbreak of" exact="ZIKV" post="had occurred in Brazil and subsequently spread throughout the"/>
   <result pre="throughout the rest of South America, it became evident that" exact="ZIKV" post="infection during the first trimester of pregnancy was associated"/>
   <result pre="newborns. As a result, the development of a vaccine against" exact="ZIKV" post="became an urgent goal. A major issue with DENV"/>
   <result pre="against ZIKV became an urgent goal. A major issue with" exact="DENV" post="vaccines, and therefore likely also with ZIKV vaccines, is"/>
   <result pre="major issue with DENV vaccines, and therefore likely also with" exact="ZIKV" post="vaccines, is the induction of antibodies that fail to"/>
   <result pre="for ADE for other viral strains. Therefore, we generated a" exact="ZIKV" post="vaccine based on the EDIII domain displayed on the"/>
   <result pre="after a single injection. The antibodies were able to neutralise" exact="ZIKV" post="without enhancing infection by DENV in vitro. Thus, the"/>
   <result pre="antibodies were able to neutralise ZIKV without enhancing infection by" exact="DENV" post="in vitro. Thus, the here described vaccine based on"/>
   <result pre="VLPs was able to stimulate production of antibodies specifically neutralizing" exact="ZIKV" post="without potentially enhancing disease caused by DENV. vaccine Zika"/>
   <result pre="neutralizing ZIKV without potentially enhancing disease caused by DENV. vaccine" exact="Zika" post="virus envelop (E) protein domain III (EDIII) virus like"/>
   <result pre="(EDIII) virus like particles (VLPs) dioleoyl phosphatidylserine (DOPS) 1. Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus transmitted to humans"/>
   <result pre="Aedes mosquitoes [1,2]. In recent years, it was found that" exact="ZIKV" post="may also be transmitted among humans without participation of"/>
   <result pre="for example by blood transfusion, maternal–foetal transmission, and sexually [3,4,5,6]." exact="ZIKV" post="is not a new virus and was first identified"/>
   <result pre="new virus and was first identified in 1947 in the" exact="Zika" post="Forest of Uganda, Africa [1,7], with the first human"/>
   <result pre="in the 1950s. Before the outbreak in Brazil in 2015," exact="ZIKV" post="was not well known worldwide. Only thereafter, and when"/>
   <result pre="ZIKV was not well known worldwide. Only thereafter, and when" exact="ZIKV" post="infection became associated with microcephaly and cases of Guillain-Barré"/>
   <result pre="associated with microcephaly and cases of Guillain-Barré syndrome [8,9,10,11], did" exact="ZIKV" post="call attention of the public as well as health"/>
   <result pre="health authorities worldwide, and the World Health Organization (WHO) declared" exact="ZIKV" post="as a Public Health Emergency of International Concern in"/>
   <result pre="a Public Health Emergency of International Concern in 2016 [12]." exact="ZIKV" post="shares considerable genetic and structural similarity with other flaviviruses,"/>
   <result pre="considerable genetic and structural similarity with other flaviviruses, for example," exact="Dengue" post="virus (DENV) [13], which is also transmitted by Aedes"/>
   <result pre="it is well established that previous infection with a different" exact="DENV" post="serotype may predispose to a more serious disease such"/>
   <result pre="Most preclinical and clinical programs aimed to develop vaccines against" exact="ZIKV" post="have focused on attenuated or inactivated viruses as well"/>
   <result pre="contrast, the E-DIII domain may be the best target for" exact="ZIKV" post="vaccine development, as antibodies recognising this domain are largely"/>
   <result pre="models [36]. In this study, we developed a vaccine-candidate against" exact="ZIKV" post="by coupling E-DIII to CuMVttVLP and formulating the product"/>
   <result pre="efficiently and neutralise the virus without predisposing for ADE with" exact="DENV" post="infections. ZIKV and DENV are flaviviruses that circulate mostly"/>
   <result pre="neutralise the virus without predisposing for ADE with DENV infections." exact="ZIKV" post="and DENV are flaviviruses that circulate mostly in the"/>
   <result pre="virus without predisposing for ADE with DENV infections. ZIKV and" exact="DENV" post="are flaviviruses that circulate mostly in the same environmental"/>
   <result pre="new vaccine candidate warrants further development. 2. Experimental Section 2.1." exact="Zika" post="Virus (ZIKV) E-DIII Protein Production The cloning and production"/>
   <result pre="Virus (ZIKV) E-DIII Protein Production The cloning and production of" exact="ZIKV" post="envelope protein domain III was published recently [37]. Briefly"/>
   <result pre="III was published recently [37]. Briefly the E-DIII gene of" exact="Zika" post="virus Brazil-ZKV2015 strain was selected from GenBank, reference number"/>
   <result pre="8.0 and subsequently purified on a Ni Sepharose resin. The" exact="ZIKV" post="ED-III protein, after purification, was refolded by dialysis. First"/>
   <result pre="were subtracted from the titres of the vaccinated groups. 2.6." exact="Zika" post="Virus Neutralization Assay The test of neutralizing capacity of"/>
   <result pre="tested in two independent experiments. 2.7. Antibody-Dependent Enhancement Test with" exact="Dengue" post="Virus (DENV-2) The ADE test was performed using THP-1"/>
   <result pre="3. Results 3.1. Choosing the Target Epitope to Design a" exact="ZIKV" post="Vaccine The development of vaccines against flaviviruses represents a"/>
   <result pre="maximize neutralization and minimize cross-reactivity. It has been shown for" exact="DENV" post="that domain III of the envelope proteins (EDIII) is"/>
   <result pre="[37]. Furthermore, we have previously shown that the EDIII-domain of" exact="West Nile" post="virus (WNV), another flavivirus, induced highly neutralizing and protective"/>
   <result pre="displayed on VLPs [42]. We therefore expressed the EDIII of" exact="ZIKV" post="with a small linker containing a free Cys for"/>
   <result pre="we have performed a CPE-based neutralization assay using a representative" exact="ZIKV" post="strain inducing good CPE (Figure 4). As shown in"/>
   <result pre="vaccinated with VLP-EDIII+DOPS developed antibody responses able to neutralise the" exact="ZIKV" post="after two vaccinations (Day 42). In contrast, mice vaccinated"/>
   <result pre="to induce measurable levels of neutralizing antibodies. 3.4. Assessment of" exact="ZIKV" post="Antibody-Dependent Enhancement with DENV-2 Enhanced infection due to cross-reactive"/>
   <result pre="for DENV. DENV-2 is considered to be the most virulent" exact="DENV" post="serotype with a genetically diverse population and is most"/>
   <result pre="antibodies may cross-react with DENV, a key feature of a" exact="ZIKV" post="vaccine candidate is that it must not induce antibodies"/>
   <result pre="candidate is that it must not induce antibodies that enhance" exact="DENV" post="infection. As described in the schematic figure (Figure 6a,b)"/>
   <result pre="destroy the virus. However, as shown in Figure 6b, when" exact="ZIKV" post="is recognised by non-neutralizing antibodies, the antibody binding will"/>
   <result pre="As seen in Figure 6c,d, the qRT-PCR results demonstrate that" exact="ZIKV" post="specific serum antibodies induced by vaccination did not promote"/>
   <result pre="induced by vaccination did not promote the synthesis of more" exact="DENV" post="RNA as measured in the supernatants. Under none of"/>
   <result pre="not inducing ADE antibodies. 4. Discussion The widespread outbreak of" exact="ZIKV" post="in the Americas and its causal association with severe"/>
   <result pre="non-enhancing antibodies. Several studies have shown that immune responses to" exact="ZIKV" post="were similar to responses induced against other flaviviruses such"/>
   <result pre="were similar to responses induced against other flaviviruses such as" exact="DENV" post="or WNV. Specifically, it has been shown that neutralising"/>
   <result pre="antibodies may result in enhancement of infection or disease with" exact="ZIKV" post="or DENV [18,47]. Therefore, the issue of enhancement has"/>
   <result pre="result in enhancement of infection or disease with ZIKV or" exact="DENV" post="[18,47]. Therefore, the issue of enhancement has to be"/>
   <result pre="to be considered when developing vaccines against flavivirus, such as" exact="ZIKV" post="and DENV [14,15,16,17,18,19,20,21]. In this study we have shown"/>
   <result pre="considered when developing vaccines against flavivirus, such as ZIKV and" exact="DENV" post="[14,15,16,17,18,19,20,21]. In this study we have shown that a"/>
   <result pre="study we have shown that a VLPs vaccine candidate carrying" exact="ZIKV" post="E-DIII induced neutralizing antibodies, but no enhancement against DENV-2"/>
   <result pre="against DENV-2 was observed. The number of vaccine candidates against" exact="ZIKV" post="have increased recently and some of them have advanced"/>
   <result pre="non-neutralizing and cross-reactive antibodies that could enhance disease of either" exact="ZIKV" post="or DENV. Vaccines based on E-DIII are likely to"/>
   <result pre="and enhancing antibodies. Indeed, a recent publication has demonstrated that" exact="Zika" post="EDIII-domain fused to hepatitis B core Antigen (HBcAg) induces"/>
   <result pre="Antigen (HBcAg) induces potent neutralizing antibodies in mice without enhancing" exact="DENV" post="virus infection in vitro [49]. Immunogenicity of the candidate"/>
   <result pre="DENV virus infection in vitro [49]. Immunogenicity of the candidate" exact="ZIKV" post="vaccine was tested in Balb/C mice. We wanted to"/>
   <result pre="neutralizing titers. We have shown that complement alone can inactivate" exact="ZIKV" post="and DENV (unpublished) and, therefore, we did not study"/>
   <result pre="We have shown that complement alone can inactivate ZIKV and" exact="DENV" post="(unpublished) and, therefore, we did not study complement-dependent neutralization"/>
   <result pre="with other serotypes or genotypes could be enhanced by the" exact="ZIKV" post="antibodies. Therefore, studies investigating enhancement activity of flavivirus cross-reactive"/>
   <result pre="analysis and wrote the paper; S.M.L. and B.E.E.M.: performed the" exact="ZIKV" post="neutralization assay and cross-reactivity and ADE test with DENV;"/>
   <result pre="Aegypti and Aedes AlbopictusECDCStockholm, Sweden2016 3.TurmelJ.M.AbgueguenP.HubertB.VandammeY.M.MaquartM.Le Guillou-GuillemetteH.Leparc-GoffartI.Late sexual transmission of" exact="Zika" post="virus related to persistence in the semenLancet2016387250110.1016/S0140-6736(16)30775-927287833 4.MansuyJ.M.PasquierC.DaudinM.Chapuy-RegaudS.MoinardN.ChevreauC.IzopetJ.MengelleC.BujanL.Zika virus"/>
   <result pre="a patient returning from a non-epidemic areaLancet Infect. Dis.20161689489510.1016/S1473-3099(16)30153-0 5.FiorentinoD.G.MonteroF.J.The" exact="Zika" post="Virus and PregnancyCurr. Obstet. Gynecol. Rep.2016523423810.1007/s13669-016-0171-1 6.MussoD.StramerS.L.BuschM.P.Zika virus: A"/>
   <result pre="syndrome in Colombia: Epidemiological situation during 21 months of the" exact="Zika" post="virus outbreak, 2015–2017Arch. Public Health2017756510.1186/s13690-017-0233-529118981 10.BarbiL.CoelhoA.V.C.AlencarL.C.A.CrovellaS.Prevalence of Guillain-Barré syndrome"/>
   <result pre="virus outbreak, 2015–2017Arch. Public Health2017756510.1186/s13690-017-0233-529118981 10.BarbiL.CoelhoA.V.C.AlencarL.C.A.CrovellaS.Prevalence of Guillain-Barré syndrome among" exact="Zika" post="virus infected cases: A systematic review and meta-analysisBraz. J."/>
   <result pre="Infect. Dis.20182213714110.1016/j.bjid.2018.02.00529545017 11.StyczynskiA.R.MaltaJ.M.A.S.Krow-LucalE.R.PercioJ.NobregaM.E.VargasA.LanzieriT.M.LeiteP.L.StaplesJ.E.FischerM.X.et al.Increased rates of Guillain-Barre’ syndrome associated with" exact="Zika" post="virus outbreak in the Salvador metropolitan area, BrazilPLoS Negl."/>
   <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="Virus and Observed Increase in Neurological Disorders and Neonatal"/>
   <result pre="on 4 March 2019) 13.HuberRG.LimX.N.NgW.C.SimA.Y.L.PohH.X.ShenY.LimS.Y.SundstromK.B.SunX.AwJ.G.et al.Structure mapping of dengue and" exact="Zika" post="viruses reveals functional long-range interactionsNat. Commun.201910140810.1038/s41467-019-09391-830926818 14.DejnirattisaiW.SupasaP.WongwiwatW.RouvinskiA.Barba-SpaethG.DuangchindaT.Dengue virus sero-cross-reactivity"/>
   <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virusProc. Natl. Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 16.KawieckiA.B.ChristoffersonR.C.Zika Virus-Induced Antibody Response"/>
   <result pre="virusProc. Natl. Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 16.KawieckiA.B.ChristoffersonR.C.Zika Virus-Induced Antibody Response Enhances" exact="Dengue" post="Virus Serotype 2 Replication In VitroJ. Infect. Dis.20162141357136010.1093/infdis/jiw37727521359 17.Martín-AcebesM.A.Juan-CarlosS.de"/>
   <result pre="humansScience201032874574810.1126/science.118518120448183 19.StettlerK.BeltramelloM.EspinosaD.A.GrahamV.CassottaA.BianchiS.VanzettaF.MinolaA.JaconiS.MeleF.et al.Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infectionScience201635382382610.1126/science.aaf850527417494 20.CastanhaP.M.S.NascimentoE.J.M.BragaC.CordeiroM.T.CarvalhoO.V.MendonçaL.R.Dengue virus (DENV)-specific antibodies enhance Brazilian Zika"/>
   <result pre="by Zika virus infectionScience201635382382610.1126/science.aaf850527417494 20.CastanhaP.M.S.NascimentoE.J.M.BragaC.CordeiroM.T.CarvalhoO.V.MendonçaL.R.Dengue virus (DENV)-specific antibodies enhance Brazilian" exact="Zika" post="virus (ZIKV) infectionJ. Infect. Dis.201721578178510.1093/infdis/jiw63828039355 21.KhandiaR.MunjalA.DhamaK.KarthikK.TiwariR.MalikY.S.SinghR.K.ChaicumpaW.Modulation of Dengue/Zika Virus"/>
   <result pre="by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in" exact="Zika" post="Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of Zika vaccine development:"/>
   <result pre="Against Enhancement in Zika Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of" exact="Zika" post="vaccine development: Zika vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012"/>
   <result pre="Zika Virus InfectionFront. Immunol.2018959710.3389/fimmu.2018.0059729740424 22.BarrettA.D.T.Current status of Zika vaccine development:" exact="Zika" post="vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012 23.MakhlufH.ShrestaS.Development of Zika"/>
   <result pre="development: Zika vaccines advance into clinical evaluationNPJ Vaccines201832410.1038/s41541-018-0061-929900012 23.MakhlufH.ShrestaS.Development of" exact="Zika" post="Virus VaccinesVaccines20186710.3390/vaccines6010007 24.RichnerJ.M.DiamondM.S.Zika virus vaccines: Immune response, current status,"/>
   <result pre="Opin. Immunol.20185313013610.1016/j.coi.2018.04.02429753210 25.WahidB.AliA.RafiqueS.IdreesM.Current status of therapeutic and vaccine approaches against" exact="Zika" post="virusEur J. Intern. Med.201744121810.1016/j.ejim.2017.08.00128797534 26.Barba-SpaethG.DejnirattisaiW.RouvinskiA.VaneyM.C.MeditsI.SharmaA.Simon-LorièreE.SakuntabhaiA.Cao-LormeauV.M.HaouzA.et al.Structural basis of potent"/>
   <result pre="against Malaria for VLP-TRAP Based VaccinesDiseases2018610710.3390/diseases604010730469323 37.Cabral-MirandaG.CardosoA.R.FerreiraL.C.S.SalesM.G.F.BachmannM.F.Biosensor-based selective detection of" exact="Zika" post="virus specific antibodies in infected individualsBiosens. Bioelectron.201811310110710.1016/j.bios.2018.04.05829751200 38.Cabral-MirandaG.HeathM.D.MohsenM.O.GomesA.C.EngeroffP.FlaxmanA.LeorattiF.M.S.El-TurabiA.Reyes-SandovalA.SkinnerM.A.et al.Virus-Like"/>
   <result pre="Cell Immunogenicity and Protection against Plasmodium berghei/vivaxVaccines201751010.3390/vaccines502001028468322 39.BarzonL.PacentiM.BertoA.SinigagliaA.FranchinE.LavezzoE.BrugnaroP.PalùG.Isolation of infectious" exact="Zika" post="virus from saliva and prolonged viral RNA shedding in"/>
   <result pre="Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus," exact="Dengue" post="Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCRJ."/>
   <result pre="Clin. Microbiol.2002402323233010.1128/JCM.40.7.2323-2330.200212089242 42.SpohnG.JenningsG.T.MartinaB.E.KellerI.BeckM.PumpensP.OsterhausA.D.BachmannM.F.A VLP-based vaccine targeting domain III of the" exact="West Nile" post="virus E protein protects from lethal infection in miceVirol."/>
   <result pre="45.AbbinkP.LaroccaR.A.De La BarreraR.A.BricaultC.A.MoseleyE.T.BoydM.KirilovaM.LiZ.Ng’ang’aD.NanayakkaraO.et al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of"/>
   <result pre="Zika virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of" exact="Zika" post="Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive Dengue Virus Antibodies Augment"/>
   <result pre="46.ZhaoH.FernandezE.DowdK.A.SpeerS.D.PlattD.J.GormanM.J.GoveroJ.NelsonC.A.PiersonT.C.DiamondM.S.et al.Structural Basis of Zika Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive" exact="Dengue" post="Virus Antibodies Augment Zika Virus Infection of Human Placental"/>
   <result pre="Zika Virus-Specific Antibody ProtectionCell20161661016102710.1016/j.cell.2016.07.02027475895 47.ZimmermanM.G.QuickeK.M.O’NealJ.T.AroraN.MachiahD.PriyamvadaL.KauffmanR.C.RegisterE.AdekunleO.SwiebodaD.et al.Cross-Reactive Dengue Virus Antibodies Augment" exact="Zika" post="Virus Infection of Human Placental MacrophagesCell Host Microbe20182473174210.1016/j.chom.2018.10.00830439342 48.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development"/>
   <result pre="of Human Placental MacrophagesCell Host Microbe20182473174210.1016/j.chom.2018.10.00830439342 48.PolandG.A.KennedyR.B.OvsyannikovaI.G.PalaciosR.HoP.L.KalilJ.Development of vaccines against" exact="Zika" post="virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 49.YangM.LaiH.SunH.ChenQ.Virus-like particles that display Zika virus"/>
   <result pre="vaccines against Zika virusLancet Infect. Dis.201818e211e21910.1016/S1473-3099(18)30063-X29396004 49.YangM.LaiH.SunH.ChenQ.Virus-like particles that display" exact="Zika" post="virus envelope protein domain III induce potent neutralizing immune"/>
   <result pre="observational studyPLoS Negl. Trop. Dis.201812e000681710.1371/journal.pntd.000681730226880 55.GallichotteE.N.BaricT.J.NivarthiU.DelacruzM.J.GrahamR.WidmanD.G.YountB.L.DurbinA.P.WhiteheadS.S.de SilvaA.M.et al.Genetic Variation between" exact="Dengue" post="Virus Type 4 Strains Impacts Human Antibody Binding and"/>
   <result pre="and atomic force microscopy (AFM) images. (a) The conjugation of" exact="Zika" post="virus E-DIII protein was done by modifying the CuMVttVLP"/>
   <result pre="of a ZIKV-specific antibodies to prevent cpe. Cells infected with" exact="ZIKV" post="pre-incubated with sera from immunized mice showed no CPA"/>
   <result pre="+ virus). Cytopathic effect (CPE) was seen in serum without" exact="ZIKV" post="specific antibodies (Negative serum + Virus), comparable to cultures"/>
   <result pre="(Negative serum + Virus), comparable to cultures infected only with" exact="ZIKV" post="(Virus control). The panel &quot;Cell control�? shows uninfected cells."/>
   <result pre="control). The panel &quot;Cell control�? shows uninfected cells. Figure 5" exact="ZIKV" post="neutralising capacity assessment. The figure shows the titer of"/>
   <result pre="has been completely opsonised by neutralizing antibody (a) and when" exact="ZIKV" post="is recognised by non-neutralizing antibodies, the antibody binding will"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6792355\results\search\tropicalVirus\results.xml">
   <result pre="Tropical pmcid: 679235500229 doi: 10.1590/S1678-9946201961057 : Original Article Circulation of" exact="Chikungunya" post="virus East-Central-South Africa genotype during an outbreak in 2016-17"/>
   <result pre="medium, provided the original work is properly cited. Abstract ABSTRACT" exact="Chikungunya" post="virus (CHIKV) is an arbovirus that emerged in the"/>
   <result pre="arbovirus that emerged in the Americas in 2013. Infection with" exact="CHIKV" post="is symptomatic in most of the cases and patients"/>
   <result pre="in Bahia State. Here we report the circulation of the" exact="CHIKV" post="ECSA genotype in Piaui State, Northeast Brazil, during the"/>
   <result pre="in Brazil and supports its circulation in the Brazilian Northeast." exact="Chikungunya" post="virus Brazil ECSA genotype Arbovirus Togavirus Alphavirus Molecular surveillance"/>
   <result pre="Molecular surveillance Epidemiology E1 gene fig-count: table-count: equation-count: ref-count: INTRODUCTION" exact="Chikungunya" post="virus (CHIKV) is an arthropod-borne, enveloped, positive single-stranded RNA"/>
   <result pre="months to years in approximately 40% of the infected people7,8." exact="CHIKV" post="was isolated for the first time in 1952-53 in"/>
   <result pre="Indian Ocean (IOL), Asian and West African lineages10. Until 2004," exact="CHIKV" post="had caused small and sporadic outbreaks at the African"/>
   <result pre="of Health, between 2016 and 2018, 547,797 suggestive cases of" exact="CHIKV" post="were reported in the country, with 361,640 laboratory confirmed"/>
   <result pre="Maranhao and Tocantins (Figure 1). Until 2016, no cases of" exact="CHIKV" post="(imported or autochthonous) were reported in Piaui State. However,"/>
   <result pre="Piaui State. However, in 2016, the incidence rate of suggestive" exact="CHIKV" post="infections increased to 86.4 per 100.000 inhabitants, the lowest"/>
   <result pre="to 17.4 per 100.000 inhabitants. In addition, deaths caused by" exact="CHIKV" post="infection have been confirmed in Piaui State in 2016"/>
   <result pre="there has been an increase in the incidence rate of" exact="CHIKV" post="in Piaui State, the aim of the present study"/>
   <result pre="-70 °C. When available, results of the serological tests for" exact="DENV" post="and CHIKV performed by public health services were retrieved."/>
   <result pre="When available, results of the serological tests for DENV and" exact="CHIKV" post="performed by public health services were retrieved. The research"/>
   <result pre="Piaui, under the protocol Nº CAAE 46111615.0.0000.5214. Molecular investigation of" exact="Chikungunya" post="infection Viral RNA extractions were performed from serum of"/>
   <result pre="following the manufacturer’s instructions. Using specific primers previously described for" exact="CHIKV" post="E1 (DVRChk-F 5’ ACCGGCGTCTACCCATT CATGT 3’; DVRChk-R 5’ GGGCGGGTAGTCCATGTTGTAGA"/>
   <result pre="(DVRChk-F 5’ ACCGGCGTCTACCCATT CATGT 3’; DVRChk-R 5’ GGGCGGGTAGTCCATGTTGTAGA 3’)20 and" exact="CHIKV" post="E2 (JM1 5’ GCAGACGCAGAGAGGGCCAG 3’; JM2 5’ CGTGCTGCAAGGTAGTTCTC 3’;"/>
   <result pre="concatenated in frame and aligned to 74 concatenated sequences of" exact="CHIKV" post="genotypes retrieved from GenBank (http://www.ncbi.nlm.nih.gov) using CLUSTALW, implemented on"/>
   <result pre="as encephalitis. Of the 580 samples collected, serological tests for" exact="CHIKV" post="IgM were performed on 52.59% (305/580) samples, CHIKV IgG"/>
   <result pre="tests for CHIKV IgM were performed on 52.59% (305/580) samples," exact="CHIKV" post="IgG on 19.31% (112/580), DENV IgM on 75.69% (439/580)"/>
   <result pre="performed on 52.59% (305/580) samples, CHIKV IgG on 19.31% (112/580)," exact="DENV" post="IgM on 75.69% (439/580) and DENV IgG on 61.72%"/>
   <result pre="IgG on 19.31% (112/580), DENV IgM on 75.69% (439/580) and" exact="DENV" post="IgG on 61.72% (358/580). Of these, 70.16% (214/305) were"/>
   <result pre="on 61.72% (358/580). Of these, 70.16% (214/305) were positive for" exact="CHIKV" post="IgM, 14.12% (62/439) for DENV IgM and 36 (6.21%)"/>
   <result pre="70.16% (214/305) were positive for CHIKV IgM, 14.12% (62/439) for" exact="DENV" post="IgM and 36 (6.21%) were positive for both CHIKV"/>
   <result pre="for DENV IgM and 36 (6.21%) were positive for both" exact="CHIKV" post="and DENV IgM tests (Figure 2). Table 1 Demographic"/>
   <result pre="IgM and 36 (6.21%) were positive for both CHIKV and" exact="DENV" post="IgM tests (Figure 2). Table 1 Demographic and clinical"/>
   <result pre="Table 1 Demographic and clinical characteristics of suspected cases of" exact="CHIKV" post="infection during April/2016 to November/2017 in Piaui, Brazil, according"/>
   <result pre="infection during April/2016 to November/2017 in Piaui, Brazil, according to" exact="CHIKV" post="laboratory test results (RT-PCR). All Samples (n=580) Suspected cases"/>
   <result pre="number of patient samples collected and laboratory tested (RT-PCR) to" exact="CHIKV" post="during April/2016 to November/2017. RT-PCR for CHIKV From the"/>
   <result pre="tested (RT-PCR) to CHIKV during April/2016 to November/2017. RT-PCR for" exact="CHIKV" post="From the total of collected samples, RNA extraction were"/>
   <result pre="2017. Of the analyzed samples, 29.46% (33/112) were positive for" exact="CHIKV" post="by PCR, with 57.58% (19/33) from 2016 and 42.42%"/>
   <result pre="2016 and 42.42% (14/33) from 2017. Of the positive samples," exact="CHIKV" post="specific IgM tests were available for 36.36% (12/33) patients,"/>
   <result pre="available for 36.36% (12/33) patients, of which 50% (6/12) were" exact="CHIKV" post="IgM positive (Figure 2). 87.88% (29/33) of the PCR-positive"/>
   <result pre="CHIKV IgM positive (Figure 2). 87.88% (29/33) of the PCR-positive" exact="CHIKV" post="samples had DENV IgM tests performed, and 10.34% (3/29)"/>
   <result pre="(Figure 2). 87.88% (29/33) of the PCR-positive CHIKV samples had" exact="DENV" post="IgM tests performed, and 10.34% (3/29) of samples were"/>
   <result pre="of the CHIKV-positive samples with serological tests results presented both" exact="DENV" post="and CHIKV IgM antibodies. Of the 33 CHIKV-positive samples,"/>
   <result pre="CHIKV-positive samples with serological tests results presented both DENV and" exact="CHIKV" post="IgM antibodies. Of the 33 CHIKV-positive samples, one (3.03%)"/>
   <result pre="fever, vomiting, headache, myalgia and eye complications. The presence of" exact="CHIKV" post="IgM antibodies was detected in this sample, but DENV"/>
   <result pre="of CHIKV IgM antibodies was detected in this sample, but" exact="DENV" post="IgM and IgG were not detected. Among the PCR"/>
   <result pre="IgG were not detected. Among the PCR negative samples (79/112)," exact="CHIKV" post="IgM tests were performed on 39.34% (31/79) of the"/>
   <result pre="the patients. Of these, 70.97% (22/31) of the samples presented" exact="CHIKV" post="IgM antibodies (Figure 2). Nucleotide sequencing and phylogenetic analysis"/>
   <result pre="and 10,253 to 10,460 compared to the nucleotide sequence of" exact="CHIKV" post="strain BHI3745/H804709, isolated in Feira de Santana, Bahia (GenBank"/>
   <result pre="probability (PP) equal to 0.96). This group clustered with other" exact="CHIKV" post="isolates, circulating from 2014 to 2016, in Bahia16, Rio"/>
   <result pre="(PP=1) (Figure 3). Supplemental Figure 1 Maximum likelihood analysis of" exact="Chikungunya" post="virus. The maximum likelihood tree was inferred using 88"/>
   <result pre="Chikungunya virus. The maximum likelihood tree was inferred using 88" exact="Chikungunya" post="virus sequences (328 nt). The bootstrap values are represented"/>
   <result pre="African. Gwest African: Genotype West African. GAsian: Genotype Asian. CHIKV:" exact="Chikungunya" post="virus. Figure 3 Bayesian phylogenetic analysis of Chikungunya virus."/>
   <result pre="Asian. CHIKV: Chikungunya virus. Figure 3 Bayesian phylogenetic analysis of" exact="Chikungunya" post="virus. A subtree of the ECSA genotype, from the"/>
   <result pre="genotype, from the maximum clade credibility tree inferred using 88" exact="Chikungunya" post="virus sequences (328 nt) is shown. The posterior probability"/>
   <result pre="PI: Piaui. BR: Brazil. GECSA: Genotype East-Central South African. CHIKV:" exact="Chikungunya" post="virus. The isolates from CHIKV/PI/2016-2017 had the most recent"/>
   <result pre="DISCUSSION In this study, we performed a molecular investigation of" exact="CHIKV" post="infection in symptomatic patients in Piaui State, Northeast Brazil,"/>
   <result pre="Northeast Brazil, during 2016 and 2017. By using molecular tests," exact="CHIKV" post="infections were confirmed in 33 patients out of 112"/>
   <result pre="however, encephalopathies are the most common neurological disorders associated with" exact="CHIKV" post="infection36. On the other hand, symptoms such as fever,"/>
   <result pre="as fever, arthralgia, headache and myalgia are better described in" exact="CHIKV" post="infected patients. These symptoms were the most prevalent in"/>
   <result pre="E1 and E2 genes, phylogenetic analysis indicated that the Piaui" exact="CHIKV" post="isolates presented in this study were clustered within the"/>
   <result pre="common recent ancestor dating from 2015, suggesting the introduction of" exact="CHIKV" post="ECSA genotype into Piaui probably in that year. Studies"/>
   <result pre="also located in the Brazilian Northeast region, have suggested that" exact="CHIKV" post="was also introduced in these States in 2015. Moreover,"/>
   <result pre="States in 2015. Moreover, the interval between the introduction of" exact="CHIKV" post="in Piaui in 2015, and the report of its"/>
   <result pre="finding from Costa et al.33, who estimated the introduction of" exact="CHIKV" post="in Alagoas in mid-April 2015, but the virus was"/>
   <result pre="de Janeiro, Southeast Brazil, has shown that the introduction of" exact="CHIKV" post="ECSA genotype in the State may have taken place"/>
   <result pre="the surveillance system40. Altogether, these data corroborate our finding that" exact="CHIKV" post="may have been circulating in Piaui up to a"/>
   <result pre="CONCLUSION In conclusion, we provided the first genotype surveillance of" exact="CHIKV" post="cases during 2016/2017 in Piaui State, Northeast Brazil. Our"/>
   <result pre="Sergipe32 and Alagoas33,42. Our data also indicate the introduction of" exact="CHIKV" post="in Piaui in 2015, and its maintenance up to"/>
   <result pre="to evaluate the prevalence and impact of acute and chronic" exact="CHIKV" post="infections in the region. ACKNOWLEDGMENTS We would like to"/>
   <result pre="writing of this manuscript. References REFERENCES 1TangBLThe cell biology of" exact="Chikungunya" post="virus infectionCell Microbiol2012141354136322686853 2WeaverSCLecuitMChikungunya virus and the global spread"/>
   <result pre="of chikungunya virus infectionLancet Infect Dis200882318156079 5AyuSMLaiLRChanYFHatimAHairiNNAyobAet al.Seroprevalence survey of" exact="Chikungunya" post="virus in Bagan Panchor, MalaysiaAm J Trop Med Hyg2010831245124821118929"/>
   <result pre="J Trop Med Hyg2010831245124821118929 6SissokoDMoendandzeAMalvyDGiryCEzzedineKSoletJLet al.Seroprevalence and risk factors of" exact="Chikungunya" post="virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based"/>
   <result pre="meta-analysisTrans R Soc Trop Med Hyg201811230131630007303 8FeldsteinLRRowhani-RahbarAStaplesJEWeaverMRHalloranMEEllisEMPersistent arthralgia associated with" exact="Chikungunya" post="virus outbreak, US Virgin Islands, December 2014-February 2016Emerg Infect"/>
   <result pre="R Soc Trop Med Hyg195549283214373834 10VolkSMChenRTsetsarkinKAAdamsAPGarciaTISallAAet al.Genome-scale phylogenetic analyses of" exact="Chikungunya" post="virus reveal independent emergences of recent epidemics and various"/>
   <result pre="recent epidemics and various evolutionary ratesJ Virol2010846497650420410280 11SergonKNjugunaCKalaniROfulaVOnyangoCKonongoiLSet al.Seroprevalence of" exact="Chikungunya" post="virus (CHIKV) infection on Lamu Island, Kenya, October 2004Am"/>
   <result pre="2004Am J Trop Med Hyg20087833333718256441 12RenaultPSoletJSissokoDBalleydierELarrieuSFilleulLet al.A major epidemic of" exact="Chikungunya" post="virus infection on Réunion Island, France, 2005-2006Am J Trop"/>
   <result pre="Island, France, 2005-2006Am J Trop Med Hyg20077772773117978079 13RezzaGNicolettiLAngeliniRRomiRFinarelliACPanningMet al.Infection with" exact="Chikungunya" post="virus in Italy: an outbreak in a temperate regionLancet20073701840184618061059"/>
   <result pre="in the AmericasLancet201438351424506907 15NunesMRFariaNRVasconcelosJMGoldingNKraemerMUOliveiraLFet al.Emergence and potential for spread of" exact="Chikungunya" post="virus in BrazilBMC Med201513size: 102pages 16TeixeiraMGAndradeAMCostaMCCastroJSOliveiraFLGoesCSet al.East/Central/South African genotype"/>
   <result pre="Chikungunya virus in BrazilBMC Med201513size: 102pages 16TeixeiraMGAndradeAMCostaMCCastroJSOliveiraFLGoesCSet al.East/Central/South African genotype" exact="Chikungunya" post="virus, Brazil, 2014Emerg Infect Dis20152190690825898939 17collab: Brasilcollab: Ministério da"/>
   <result pre="de Vigilância em SaúdeMonitoramento dos casos de dengue, febre de" exact="Chikungunya" post="e doença aguda pelo vírus Zika até a Semana"/>
   <result pre="de dengue, febre de Chikungunya e doença aguda pelo vírus" exact="Zika" post="até a Semana Epidemiológica 49 de 2018Bol Epidemiol201849114cited 2019"/>
   <result pre="de Vigilância em SaúdeMonitoramento dos casos de dengue, febre de" exact="Chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="casos de dengue, febre de Chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 49, 2016Bol Epidemiol201747110cited 2019 May"/>
   <result pre="de Vigilância em SaúdeMonitoramento dos casos de dengue, febre de" exact="Chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="casos de dengue, febre de Chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 50, 2017Bol Epidemiol201748113cited 2019 May"/>
   <result pre="Epidemiológica 50, 2017Bol Epidemiol201748113cited 2019 May 27http://portalarquivos2.saude.gov.br/images/pdf/2018/janeiro/10/2017-046-Publicacao.pdf 20KumarCVJohnsonAMGopalDVMolecular characterization of" exact="Chikungunya" post="virus from Andhra Pradesh, India &amp;amp; phylogenetic relationship with"/>
   <result pre="African isolatesIndian J Med Res200712653454018219080 21PorterKRTanRIstaryYSuharyonoWSutaryoWidjajaSet al.A serological study of" exact="Chikungunya" post="virus transmission in Yogyakarta, Indonesia: evidence for the first"/>
   <result pre="2019 Sep 9http://tree.bio.ed.ac.uk/software/figtree/ 31CunhaMSCruzNVSchnellrathLCMedagliaMLCasottoMEAlbanoRMet al.Autochthonous transmission of East/Central/South African genotype" exact="Chikungunya" post="virus, BrazilEmerg Infect Dis2017231737173928930027 32Costa-da-SilvaALIoshinoRSPetersenVLimaAFCunhaMPWileyMRet al.First report of naturally"/>
   <result pre="Dis2017231737173928930027 32Costa-da-SilvaALIoshinoRSPetersenVLimaAFCunhaMPWileyMRet al.First report of naturally infected Aedes aegypti with" exact="Chikungunya" post="virus genotype ECSA in the AmericasPLoS Negl Trop Dis201711e000563028614394"/>
   <result pre="ECSA in the AmericasPLoS Negl Trop Dis201711e000563028614394 33CostaACThézéJKomninakisSCSanz-DuroRLFelintoMRMouraLCet al.Spread of" exact="Chikungunya" post="virus East/Central/South African genotype in Northeast BrazilEmerg Infect Dis2017231742174428930031"/>
   <result pre="African genotype in Northeast BrazilEmerg Infect Dis2017231742174428930031 34LemantJBoissonVWinerAThibaultLAndréHTixierFet al.Serious acute" exact="Chikungunya" post="virus infection requiring intensive care during the Reunion Island"/>
   <result pre="Island outbreak in 2005-2006Crit Care Med2008362536254118679124 35CrosbyLPerreauCMadeuxBCossicJArmandCHerrmann-StorkeCet al.Severe manifestations of" exact="Chikungunya" post="virus in critically ill patients during the 2013-2014 Caribbean"/>
   <result pre="2013-2014 Caribbean outbreakInt J Infect Dis201648788027208636 36MehtaRGerardinPBritoCASoaresCNFerreiraMLSolomonTThe neurological complications of" exact="Chikungunya" post="virus: a systematic reviewRev Med Virol201828e197829671914 37CunhaMPSantosCALimaDFNetoSchanoskiASPourSZPassosSDet al.Outbreak of"/>
   <result pre="Chikungunya virus: a systematic reviewRev Med Virol201828e197829671914 37CunhaMPSantosCALimaDFNetoSchanoskiASPourSZPassosSDet al.Outbreak of" exact="Chikungunya" post="virus in a vulnerable population of Sergipe, Brazil: a"/>
   <result pre="surveyJ Clin Virol201797444929100064 38MachadoLCMorais-SobralMCCamposTLPereiraMRAlbuquerqueMFGilbertCet al.Genome sequencing reveals coinfection by multiple" exact="Chikungunya" post="virus genotypes in a recent outbreak in BrazilPLoS Negl"/>
   <result pre="de Vigilância em SaúdeMonitoramento dos casos de dengue, febre de" exact="Chikungunya" post="e febre pelo vírus Zika até a Semana Epidemiológica"/>
   <result pre="casos de dengue, febre de Chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52, 2015Bol Epidemiol201647110cited 2019 May"/>
   <result pre="2019 May 27http://portalarquivos2.saude.gov.br/images/pdf/2016/janeiro/15/svs2016-be003-dengue-se52.pdf 40SouzaTMVieiraYRDelatorreEBarbosa-LimaGLuizRLVizzoniAet al.Emergence of the East-Central-South-African genotype of" exact="Chikungunya" post="virus in Brazil and the city of Rio de"/>
   <result pre="occurred years before surveillance detectionSci Rep20199size: 2760pages 41SardiSISomasekarSNaccacheSNBandeiraACTauroLBCamposGSet al.Coinfections of" exact="Zika" post="and Chikungunya viruses in Bahia, Brazil, identified by metagenomic"/>
   <result pre="before surveillance detectionSci Rep20199size: 2760pages 41SardiSISomasekarSNaccacheSNBandeiraACTauroLBCamposGSet al.Coinfections of Zika and" exact="Chikungunya" post="viruses in Bahia, Brazil, identified by metagenomic next-generation sequencingJ"/>
   <result pre="next-generation sequencingJ Clin Microbiol2016542348235327413190 42TanabeELTanabeISSantosECMarquesJPBorgesAALimaMCet al.Report of East-Central South African" exact="Chikungunya" post="virus genotype during the 2016 outbreak in the Alagoas"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6794280\results\search\tropicalVirus\results.xml">
   <result pre="Rousettus aegyptiacusBMC Infect. Dis.2009915919785757 26.MessinaJPet al.Mapping global environmental suitability for" exact="Zika" post="viruseLife20165e1527227090089 27.PigottDavid MDeshpandeAniruddhaLetourneauIanMorozoffChloeReinerRobert CKraemerMoritz U GBrentShannon EBogochIsaac IKhanKamranBiehlMolly HBursteinRoyEarlLucasFullmanNancyMessinaJane"/>
   <result pre="potential in Africa: a multistage analysisThe Lancet20173901011326622672 28.BogochIIet al.Potential for" exact="Zika" post="virus introduction and transmission in resource limited countries in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6797215\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Infectious Diseases:"/>
   <result pre="can transmit yellow fever virus Aedes malayensis is a competent" exact="YFV" post="vector MiotElliott F.ConceptualizationFormal analysisInvestigationVisualizationWriting – original draftWriting – review"/>
   <result pre="for trade and tourism and therefore at high risk for" exact="YFV" post="introduction. Effective control of the main domestic mosquito vector"/>
   <result pre="Singapore has failed to prevent re-emergence of dengue, chikungunya and" exact="Zika" post="viruses in the last two decades, raising suspicions that"/>
   <result pre="from wild Ae. malayensis in Singapore was experimentally competent for" exact="YFV" post="to a similar level as Ae. aegypti controls. In"/>
   <result pre="We conclude that Ae. malayensis is a competent vector of" exact="YFV" post="and re-emphasize that vector control methods should be extended"/>
   <result pre="should be extended to target peridomestic vector species. Author summary" exact="Yellow fever" post="is a dreadful disease caused by a mosquito-borne virus"/>
   <result pre="and is one of the highest among arthropod-borne viruses (arboviruses)." exact="YFV" post="is endemic in 47 countries in Africa and South"/>
   <result pre="the past few years have seen a growing number of" exact="YFV" post="outbreaks (Democratic Republic of the Congo, Angola, Uganda, Brazil"/>
   <result pre="and return to non-endemic countries have raised the risk of" exact="YFV" post="introduction to unprecedented levels [6]. The Asia-Pacific region has"/>
   <result pre="unprecedented levels [6]. The Asia-Pacific region has remained free of" exact="YFV" post="until now but the risk of introduction has never"/>
   <result pre="been higher [6–8]. In 2016, eleven Chinese workers infected with" exact="YFV" post="in Angola who returned to China were the first"/>
   <result pre="Angola who returned to China were the first cases of" exact="YFV" post="diagnosed in travelers to Asia [7]. Over two billion"/>
   <result pre="vaccine production capacity would be insufficient to prevent a massive" exact="YFV" post="epidemic, while mosquito control programs would be overwhelmed [8]."/>
   <result pre="[9]. Re-emergence of dengue virus (DENV), chikungunya virus (CHIKV) and" exact="Zika" post="virus in Singapore in the last two decades [10–13]"/>
   <result pre="in urban parks of Singapore and is experimentally competent for" exact="DENV" post="and CHIKV [14]. Here, we evaluated the potential contribution"/>
   <result pre="parks of Singapore and is experimentally competent for DENV and" exact="CHIKV" post="[14]. Here, we evaluated the potential contribution of the"/>
   <result pre="the potential contribution of the peridomestic mosquito Ae. malayensis to" exact="YFV" post="transmission in Singapore. Vector competence assays in the laboratory"/>
   <result pre="survey provided evidence that indeed Ae. malayensis could contribute to" exact="YFV" post="transmission in Singapore. Methods Ethics statement This study used"/>
   <result pre="Virus Vector competence experiments were carried out with a low-passage" exact="YFV" post="isolate (YFV-S79 strain) belonging to the West African lineage,"/>
   <result pre="Senegal [15]. Prior to its use in the experiments, the" exact="YFV" post="isolate was passaged twice in newborn mouse brains and"/>
   <result pre="was produced during the last passage, as previously described for" exact="DENV" post="[16]. Virus titration was performed by standard focus-forming assay"/>
   <result pre="performed by standard focus-forming assay (FFA), as previously described for" exact="DENV" post="[16] with the exception of the primary antibody. A"/>
   <result pre="experiments 1 and 2 hereafter), mosquitoes were orally challenged with" exact="YFV" post="as previously described for DENV [16]. Briefly, eight-day-old females"/>
   <result pre="mosquitoes were orally challenged with YFV as previously described for" exact="DENV" post="[16]. Briefly, eight-day-old females deprived of sucrose for 24"/>
   <result pre="obtain a dose-response curve, three separate blood meals with increasing" exact="YFV" post="concentrations were prepared. In experiment 1, mosquitoes were exposed"/>
   <result pre="10 min at 98°C to extract viral RNA. Detection of" exact="YFV" post="RNA was performed using a two-step RT-PCR reaction to"/>
   <result pre="them. In each experiment, mosquitoes were exposed to three different" exact="YFV" post="infectious doses to establish a dose-response curve. Vector competence"/>
   <result pre="combined from two separate experiments. 10.1371/journal.pntd.0007783.t001Table 1 Test statistics of" exact="YFV" post="infection and dissemination rates. Infection and dissemination rates were"/>
   <result pre="by logistic regression. The model included the effect of the" exact="YFV" post="oral infectious dose (log10-transformed blood meal titer), the mosquito"/>
   <result pre="at low infectious doses, the two species had a similar" exact="YFV" post="susceptibility overall. The proportion of females with a disseminated"/>
   <result pre="blood meal only for the highest infectious dose (Fig 2)." exact="YFV" post="was detected in the saliva of 33.3% (3/9) of"/>
   <result pre="Fig 2 Peridomestic Ae. malayensis in Singapore are competent for" exact="YFV" post="transmission. Transmission potential is shown for the Ae. malayensis"/>
   <result pre="proportion of females with a disseminated infection that had infectious" exact="YFV" post="in their saliva 14 days post blood meal. Transmission"/>
   <result pre="is the proportion of all blood-fed females that had infectious" exact="YFV" post="in their saliva 14 days post blood meal. Vertical"/>
   <result pre="to vector competence, the ability of Ae. malayensis to transmit" exact="YFV" post="depends on its propensity to bite humans. To assess"/>
   <result pre="study indicates that peridomestic Ae. malayensis mosquitoes can contribute to" exact="YFV" post="transmission in Singapore based on two lines of evidence."/>
   <result pre="to earlier data demonstrating vector competence of this colony for" exact="DENV" post="and CHIKV [14], our results are the first experimental"/>
   <result pre="data demonstrating vector competence of this colony for DENV and" exact="CHIKV" post="[14], our results are the first experimental evidence, to"/>
   <result pre="knowledge, that peridomestic Ae. malayensis from Singapore can potentially transmit" exact="YFV" post="acquired from an infectious blood meal. Second, we captured"/>
   <result pre="attraction to humans make Ae. malayensis a potential vector of" exact="YFV" post="and other arboviruses that deserves increased attention from public"/>
   <result pre="health authorities. The level of Ae. malayensis vector competence for" exact="YFV" post="that we observed was in the same range as"/>
   <result pre="dose, but vary at a different dose. For example, the" exact="DENV" post="type 2 susceptibility of two field-derived populations of Ae."/>
   <result pre="mosquito populations. Likewise, in the present study, we observed similar" exact="YFV" post="OID50 values for Ae. aegypti and Ae. malayensis but"/>
   <result pre="aegypti and Ae. malayensis but Ae. aegypti had a lower" exact="YFV" post="OID10 value. In natural conditions, the oral infectious dose"/>
   <result pre="successful human-to-mosquito transmission of arboviruses [35,36]. Despite an efficient vaccine," exact="YFV" post="still remains an important public health concern in Africa"/>
   <result pre="an important public health concern in Africa and South America." exact="YFV" post="is maintained in sylvatic cycles between non-human primates and"/>
   <result pre="Although there is no evidence of a sylvatic cycle of" exact="YFV" post="in the Asia-Pacific region, the risk of spillover transmission"/>
   <result pre="region, the risk of spillover transmission exists. The lack of" exact="YFV" post="outbreaks in the Asia-Pacific region to date could be"/>
   <result pre="to cross-protective immunity conferred by other widespread flaviviruses such as" exact="DENV" post="and Japanese encephalitis virus, but it could also reflect"/>
   <result pre="virus, but it could also reflect relatively fewer opportunities for" exact="YFV" post="introduction until now. Rampant globalization now puts the Asia-Pacific"/>
   <result pre="now puts the Asia-Pacific region at an unprecedented risk of" exact="YFV" post="introduction [6–8]. Billions of immunologically naïve people, together with"/>
   <result pre="set of conditions that are theoretically favorable to a massive" exact="YFV" post="epidemic. On the other hand, a scenario whereby YFV"/>
   <result pre="massive YFV epidemic. On the other hand, a scenario whereby" exact="YFV" post="would establish a novel sylvatic cycle [40] seems unlikely"/>
   <result pre="mosquito species such as Ae. malayensis could facilitate introduction of" exact="YFV" post="into the Asia-Pacific region. In Singapore, strict and sustained"/>
   <result pre="on the ability of Ae. malayensis from Singapore to transmit" exact="DENV" post="and CHIKV [14], we reiterate the need to account"/>
   <result pre="ability of Ae. malayensis from Singapore to transmit DENV and" exact="CHIKV" post="[14], we reiterate the need to account for peridomestic"/>
   <result pre="Singap. 2008;37: 538–545. 18695764 12LeoYS, ChowALP, TanLK, LyeDC, LinL, NgLC." exact="Chikungunya" post="outbreak, Singapore, 2008. Emerging Infect Dis. 2009;15: 836–837. 10.3201/eid1505.08139019402989"/>
   <result pre="10.3201/eid1505.08139019402989 13Maurer-StrohS, MakT-M, NgY-K, PhuahS-P, HuberRG, MarzinekJK, et al.South-east Asian" exact="Zika" post="virus strain linked to cluster of cases in Singapore,"/>
   <result pre="Field Aedes aegypti Populations to a Low Infectious Dose of" exact="Dengue" post="Virus. PLoS ONE. 2014;9: e9297110.1371/journal.pone.009297124664142 35DuongV, LambrechtsL, PaulRE, LyS,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6798183\results\search\tropicalVirus\results.xml">
   <result pre="IFITM proteins mediate cellular resistance to influenza A H1N1 virus," exact="West Nile" post="virus, and dengue virus.Cell1391243–1254. 10.1016/j.cell.2009.12.01720064371 CalifanoD.FuruyaY.RobertsS.AvramD.McKenzieA. N. J.MetzgerD. W."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6804639\results\search\tropicalVirus\results.xml">
   <result pre="infants. More than 500,000 incident cervical cancer cases, caused by" exact="HPV" post="occurred in 2018, with a greater than 50% mortality"/>
   <result pre="these estimates 6, 7. Newly emerging viral pathogens Ebola and" exact="Zika" post="have gained prominent attention as they are each sexually"/>
   <result pre="Organization . Guidelines for the prevention of sexual transmission of" exact="Zika" post="virus: Executive summary. [cited 2019 Jun 17]. Available at:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6805996\results\search\tropicalVirus\results.xml">
   <result pre="demonstrate that neurotropism is not a recently acquired phenotype of" exact="Zika" post="virus (53). The effect of EV-D68 infection on organotypic"/>
   <result pre="therapy (52, 66–69). They have also been used to study" exact="Zika" post="virus and measles virus infections (53, 70, 71). Findings"/>
   <result pre="to be part of the neuropathology caused by the flaviviruses" exact="West Nile" post="virus and Zika virus and the alphavirus chikungunya virus"/>
   <result pre="the neuropathology caused by the flaviviruses West Nile virus and" exact="Zika" post="virus and the alphavirus chikungunya virus (75, 77–79). The"/>
   <result pre="and the alphavirus chikungunya virus (75, 77–79). The ability of" exact="West Nile" post="virus to infect astrocytes not only is a distinguishing"/>
   <result pre="doi:10.1016/0169-328x(94)90100-7.7531803 53.RosenfeldAB, DoobinDJ, WarrenAL, RacanielloVR, ValleeRB2017Replication of early and recent" exact="Zika" post="virus isolates throughout mouse brain development. Proc Natl Acad"/>
   <result pre="analysis between flaviviruses reveals specific neural stem cell tropism for" exact="Zika" post="virus in the mouse developing neocortex. EBioMedicine10:71–76. doi:10.1016/j.ebiom.2016.07.018.27453325 71.WelschJC,"/>
   <result pre="doi:10.1128/JVI.00618-19.31019048 72.QianX, NguyenHN, JacobF, SongH, MingGL2017Using brain organoids to understand" exact="Zika" post="virus-induced microcephaly. Development144:952–957. doi:10.1242/dev.140707.28292840 73.La MonicaN, MeriamC, RacanielloVR1986Mapping of"/>
   <result pre="responses engaged by astrocytes, microglia and resident dendritic cells against" exact="Chikungunya" post="neuroinfection. J Gen Virol96:294–310. doi:10.1099/vir.0.071175-0.25351727 79.SimoninY, LoustalotF, DesmetzC, FoulongneV,"/>
   <result pre="KimKS, DiamondMS, FredericksenBL2013Differential replication of pathogenic and nonpathogenic strains of" exact="West Nile" post="virus within astrocytes. J Virol87:2814–2822. doi:10.1128/JVI.02577-12.23269784 81.van MarleG, AntonyJ,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6812269\results\search\tropicalVirus\results.xml">
   <result pre="but described in limited areas, as the recent example of" exact="Zika" post="virus rapid expansion (Liu et al., 2019). Ticks are"/>
   <result pre="10:e0004574. 10.1371/journal.pntd.000457427035712 LiuZ. Y.ShiW. F.QinC. F. (2019). The evolution of" exact="Zika" post="virus from Asia to the Americas. Nat. Rev. Microbiol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6815955\results\search\tropicalVirus\results.xml">
   <result pre="viruses and other enveloped viruses, such as HIV, Ebola virus," exact="Zika" post="virus, West Nile virus, and Nipah virus, all of"/>
   <result pre="other enveloped viruses, such as HIV, Ebola virus, Zika virus," exact="West Nile" post="virus, and Nipah virus, all of which represent considerable"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6816401\results\search\tropicalVirus\results.xml">
   <result pre="&amp;amp; Francis pmcid: 6816401 pmid: 311166911621149 doi: 10.1080/21645515.2019.1621149 : Mini-Review" exact="West Nile" post="virus vaccines – current situation and future directions S."/>
   <result pre="altered, transformed, or built upon in any way.khvi-15-10-1621149.pdf Abstract ABSTRACT" exact="West Nile" post="virus (WNV) is a widely spread human pathogenic arthropod-borne"/>
   <result pre="decades, several vaccine candidates for the protection of humans from" exact="WNV" post="have been developed. Some technologies were transferred into clinical"/>
   <result pre="product. This review summarizes the current status of a human" exact="WNV" post="vaccine and discusses reasons for the lack of clinically"/>
   <result pre="and how it can be addressed during vaccine development. KEYWORDS" exact="West Nile" post="virus vaccines flavivirus antibodies table-count: ref-count: page-count: Introduction West"/>
   <result pre="West Nile virus vaccines flavivirus antibodies table-count: ref-count: page-count: Introduction" exact="West Nile" post="virus (WNV) is a single-stranded RNA virus which belongs"/>
   <result pre="includes several important human arthropod-borne pathogens, such as dengue (DENV)," exact="Zika" post="(ZIKV), tick-borne encephalitis (TBEV), Yellow fever (YFV) or Japanese"/>
   <result pre="pathogens, such as dengue (DENV), Zika (ZIKV), tick-borne encephalitis (TBEV)," exact="Yellow fever" post="(YFV) or Japanese encephalitis (JEV) viruses.1 WNV circulates in"/>
   <result pre="encephalitis (TBEV), Yellow fever (YFV) or Japanese encephalitis (JEV) viruses.1" exact="WNV" post="circulates in birds and is transmitted by many different"/>
   <result pre="among the severe cases.3 Since its first description in 1937" exact="WNV" post="has caused several outbreaks in Africa, Asia and South"/>
   <result pre="than 1,500 fatalities have been recorded until today. In addition," exact="WNV" post="led to countless severe infections among horses and caused"/>
   <result pre="among horses and caused the decline of local bird populations.5,6" exact="WNV" post="outbreaks occur in unpredictable magnitude and localization. In Europe,"/>
   <result pre="in unpredictable magnitude and localization. In Europe, a peak in" exact="WNV" post="circulation was experienced in 2018, in total, 1,503 cases"/>
   <result pre="In addition to countries such as Italy and Greece, where" exact="WNV" post="is endemic already for several years, the virus was"/>
   <result pre="increase in endemic areas over the last decades has made" exact="WNV" post="the arthropod-borne human pathogenic flavivirus with the largest distribution"/>
   <result pre="the arthropod-borne human pathogenic flavivirus with the largest distribution worldwide.9" exact="WNV" post="can be divided into five genetic lineages.10 Lineage 1"/>
   <result pre="capacity of this single-stranded RNA virus to mutate its genome.13" exact="WNV" post="vaccine development Since the (re-)emergence of WNV in the"/>
   <result pre="mutate its genome.13 WNV vaccine development Since the (re-)emergence of" exact="WNV" post="in the late 1990, substantial research has been invested"/>
   <result pre="licensed.14,15 For humans, no vaccine is yet available. To develop" exact="WNV" post="vaccines, different technological platforms were employed, including those from"/>
   <result pre="including those from the licensed vaccines for TBEV, JEV and" exact="YFV" post="(attenuated strains and chemically inactivated viruses) in addition to"/>
   <result pre="recombinant proteins, virus-like particles, RNA-replicons, chimeric flaviviruses, viral vectors expressing" exact="WNV" post="genes, DNA- and RNA vaccines. Several recent reviews have"/>
   <result pre="approaches, so they will not be discussed herein further detail.9,16–19" exact="WNV" post="immunization studies used different experimental setups, such as viral"/>
   <result pre="have led to critically important general conclusions: – protection from" exact="WNV" post="can be achieved by a large variety of immunization"/>
   <result pre="of all vaccine candidates described to be successful – E-protein-based" exact="WNV" post="vaccines are protective against genetic lineages 1 and 2"/>
   <result pre="flaviviruses using the yellow fever vaccine strain or an attenuated" exact="DENV" post="as backbones and a recombinant, insect-cell-derived E protein ectodomain.22–2610.1080/21645515.2019.1621149-T0001Table"/>
   <result pre="as backbones and a recombinant, insect-cell-derived E protein ectodomain.22–2610.1080/21645515.2019.1621149-T0001Table 1." exact="WNV" post="vaccine candidates in clinical testing until today. Candidate vaccine"/>
   <result pre="in 50% of individuals after two doses. I 20 Inactivated" exact="WNV" post="Inactivated using formaldehyde Neutralizing antibodies after three doses. I/II"/>
   <result pre="ChimeriVax-WN02 Recombinant yellow fever vaccine strain expressing the prM/E-fragment of" exact="WNV" post="Neutralizing antibodies (&amp;gt;90%) in younger and older age groups"/>
   <result pre="age groups after one dose II 22 rWN/DEN4Δ30 Recombinant attenuated" exact="DENV" post="expressing the prM/E-fragment of WNV Neutralizing antibodies in 89%"/>
   <result pre="II 22 rWN/DEN4Δ30 Recombinant attenuated DENV expressing the prM/E-fragment of" exact="WNV" post="Neutralizing antibodies in 89% of individuals after two doses."/>
   <result pre="antibodies in all individuals after three doses I 24–25 VRC" exact="WNV" post="DNA plasmid expressing the prM/E fragment Neutralizing antibodies (&amp;gt;90%)"/>
   <result pre="evaluated clinically. Firstly, two doses of a hydrogen peroxide inactivated" exact="WNV" post="vaccine led to detectable neutralizing antibodies in approx. 50%"/>
   <result pre="hydrogen peroxide and formaldehyde.20 Secondly, three doses of formaldehyde inactivated" exact="WNV" post="particles induced high titers of neutralizing antibodies.21 None of"/>
   <result pre="particles induced high titers of neutralizing antibodies.21 None of these" exact="WNV" post="vaccine trials reported any adverse events or safety concerns"/>
   <result pre="events or safety concerns which could impede further clinical testing." exact="WNV" post="induced disease is most severe in the elderly; hence,"/>
   <result pre="phase I trial using the DNA vaccine.22,26,29 Current absence of" exact="WNV" post="vaccine candidates in late stages of clinical development In"/>
   <result pre="clinical development In light of these successful developments, a human" exact="WNV" post="vaccine should already be on the market or at"/>
   <result pre="already several years ago.30 Today, there is still no human" exact="WNV" post="vaccine, and there is no candidate even close to"/>
   <result pre="above, it is possible to obtain protective immune responses to" exact="WNV" post="by using a variety of different immunization technologies. Existing"/>
   <result pre="immunization technologies. Existing flavivirus vaccines also use different approaches: the" exact="YFV" post="vaccine consists of an attenuated virus, whereas TBEV and"/>
   <result pre="unlikely to be responsible for the poor outcome of clinical" exact="WNV" post="vaccine development to date. Initial clinical trials have provided"/>
   <result pre="Initial clinical trials have provided good safety profiles for the" exact="WNV" post="candidate vaccines. The existing flavivirus vaccines against YFV and"/>
   <result pre="for the WNV candidate vaccines. The existing flavivirus vaccines against" exact="YFV" post="and TBEV are in use for decades and are"/>
   <result pre="a recently developed and (at least in some countries) licensed" exact="DENV" post="vaccine has caused substantial discussion on vaccine safety. The"/>
   <result pre="vaccine CYD-TDV was designed to protect against all four major" exact="DENV" post="serotypes and consists of the YFV vaccine virus genetically"/>
   <result pre="against all four major DENV serotypes and consists of the" exact="YFV" post="vaccine virus genetically modified to express the DENV prM/E"/>
   <result pre="of the YFV vaccine virus genetically modified to express the" exact="DENV" post="prM/E proteins. Large clinical efficacy trials revealed a small,"/>
   <result pre="but significant, increase in the risk for hospitalization due to" exact="DENV" post="in individuals naïve to the virus. In contrast, those"/>
   <result pre="observations still have to be determined. Achieving vaccine-mediated protection against" exact="DENV" post="is intrinsically challenging due to the need to equally"/>
   <result pre="debatable to what extent similar problems would occur with a" exact="WNV" post="vaccine. Nevertheless, the only WNV candidate vaccine that underwent"/>
   <result pre="problems would occur with a WNV vaccine. Nevertheless, the only" exact="WNV" post="candidate vaccine that underwent a phase II clinical trial"/>
   <result pre="specific time span. Given the detailed epidemiological information available for" exact="WNV" post="outbreaks in the USA since 1999, it might nevertheless"/>
   <result pre="might nevertheless be possible to identify hotspots with relatively high" exact="WNV" post="incidence, which could be suitable areas for efficacy trials,"/>
   <result pre="has been established. A key result from vaccination studies with" exact="WNV" post="is the capability of antibodies to mediate complete protection."/>
   <result pre="highly similar to other flaviviruses, and in the cases of" exact="YFV" post="or JEV, specific titers in neutralizing antibodies serve as"/>
   <result pre="non-human primates.36 However, non-human primates are much less susceptible to" exact="WNV" post="than they are to YFV, which complicates the establishment"/>
   <result pre="Likewise, the fact that most of the people infected with" exact="WNV" post="do not develop clinical symptoms makes the identification of"/>
   <result pre="larger scale trials. Nevertheless, it cannot be excluded that a" exact="WNV" post="vaccine could obtain market approval by using one of"/>
   <result pre="the vaccine leads to clear clinical and also socioeconomic benefits." exact="WNV" post="can induce severe, even fatal disease. It has caused"/>
   <result pre="alone and 181 deaths in Europe during 2018. Consequently, a" exact="WNV" post="vaccine would save lives and would avoid the suffering"/>
   <result pre="unacceptably high. Two published studies have addressed the cost-effectiveness of" exact="WNV" post="vaccination in the USA, one in 2006,38 the other"/>
   <result pre="the other one in 2017.39 Both investigations conclude that a" exact="WNV" post="vaccine is unlikely to save costs. As case numbers"/>
   <result pre="study participants. Many also rely on sophisticated, but expensive, technologies." exact="WNV" post="is constantly expanding its endemic area, and case numbers,"/>
   <result pre="different genetic variations that are associated with severe forms of" exact="WNV" post="disease, which could lead to more targeted vaccination approaches.40"/>
   <result pre="of an infection, as antibodies against one of the four" exact="DENV" post="serotypes can enhance infection with another serotype. The phenomenon"/>
   <result pre="pathogenesis of human dengue infections remains controversial.45 The emergence of" exact="ZIKV" post="in DENV endemic areas has led to investigations to"/>
   <result pre="human dengue infections remains controversial.45 The emergence of ZIKV in" exact="DENV" post="endemic areas has led to investigations to test potential"/>
   <result pre="might be responsible for some of the severe symptoms of" exact="ZIKV" post="infections, for example, fetal neurological malformations. ADE between DENV"/>
   <result pre="of ZIKV infections, for example, fetal neurological malformations. ADE between" exact="DENV" post="and ZIKV could be demonstrated in cell culture experiments"/>
   <result pre="infections, for example, fetal neurological malformations. ADE between DENV and" exact="ZIKV" post="could be demonstrated in cell culture experiments and in"/>
   <result pre="E-protein.46,47 However, recent epidemiological studies on the effect of pre-existing" exact="DENV" post="immunity on ZIKV infection in regions endemic for both"/>
   <result pre="epidemiological studies on the effect of pre-existing DENV immunity on" exact="ZIKV" post="infection in regions endemic for both viruses report correlations"/>
   <result pre="be addressed and excluded during vaccine development. Immunological cross-reactivity between" exact="WNV" post="and other flaviviruses in serological diagnosis is well described.50"/>
   <result pre="of few studies until now, mainly in the context of" exact="ZIKV" post="emergence. Plasma samples from convalescent human WNV- (but not"/>
   <result pre="human WNV- (but not TBEV-) infections were demonstrated to enhance" exact="ZIKV" post="infections both in vitro and in vivo.51,52 On the"/>
   <result pre="hand, no ADE was observed in mice previously infected with" exact="ZIKV" post="and then challenged with WNV. Depending on the ZIKV"/>
   <result pre="with ZIKV and then challenged with WNV. Depending on the" exact="ZIKV" post="strain used, these animals were even better protected against"/>
   <result pre="ZIKV strain used, these animals were even better protected against" exact="WNV" post="than those naïve to ZIKV.53 The complementary animal experiment"/>
   <result pre="naïve to ZIKV.53 The complementary animal experiment (ZIKV challenge after" exact="WNV" post="infection) has not yet been described. In addition, vaccine-induced"/>
   <result pre="studies. For existing flavivirus vaccines, e.g. the licensed TBEV or" exact="YFV" post="vaccines, the availability of large sets of human sera"/>
   <result pre="candidate for ZIKV, consisting of an RNA coding for a" exact="ZIKV" post="virus-like particle, contains four such point mutations and did"/>
   <result pre="for DENV.57 A similar strategy could be used for a" exact="WNV" post="vaccine. Mutant WNV E-proteins have been developed and shown"/>
   <result pre="similar strategy could be used for a WNV vaccine. Mutant" exact="WNV" post="E-proteins have been developed and shown to significantly diminish"/>
   <result pre="less conserved among flaviviruses. Using only the DIII domain of" exact="WNV" post="has been shown to fully protect mice from lethal"/>
   <result pre="data suggest that this antigen does not induce ADE for" exact="DENV" post="and ZIKV.59–61 Alternatively, a vaccine could predominantly induce protective"/>
   <result pre="could predominantly induce protective T-cell responses and thereby avoid ADE." exact="WNV" post="vaccine approaches based on T-cell epitopes have been described,"/>
   <result pre="the combination with neutralizing antibody-inducing antigens still seems necessary.62,63 Conclusions" exact="WNV" post="remains a significant threat to humans in many parts"/>
   <result pre="would be essential to encounter this global threat. Technologies for" exact="WNV" post="vaccines have been developed, they are protective and safe."/>
   <result pre="SejvarJJ, ZakiSR, LanciottiRS, BodeAV, CampbellGLVirology, pathology, and clinical manifestations of" exact="West Nile" post="virus disease. Emerg Infect Dis. 2005;11:1174–79. doi:10.3201/eid1108.050289b.16102303 4.LanciottiRS, EbelGD,"/>
   <result pre="Crabtree MB, et alComplete genome sequences and phylogenetic analysis of" exact="West Nile" post="virus strains isolated from the United States, Europe, and"/>
   <result pre="10.McMullenAR, AlbayrakH, MayFJ, DavisCT, BeasleyDW, BarrettADMolecular evolution of lineage 2" exact="West Nile" post="virus. J Gen Virol. 2013;94:318–25. doi:10.1099/vir.0.046888-0.23136360 11.BakonyiT, FerencziE, ErdélyiK,"/>
   <result pre="Bán E, Nowotny NExplosive spread of a neuroinvasive lineage 2" exact="West Nile" post="virus in Central Europe, 2008/2009. Vet Microbiol. 2013;165:61–70. doi:10.1016/j.vetmic.2013.03.005.23570864"/>
   <result pre="FiguerolaJ, KorakaP, MartinaB, MorenoA, NowotnyN, PardigonN, et alThe challenge of" exact="West Nile" post="virus in Europe: knowledge gaps and research priorities. Euro"/>
   <result pre="LH, Venter MGenetic determinants of virulence in pathogenic lineage 2" exact="West Nile" post="virus strains. Emerg Infect Dis. 2008;14:222–30. doi:10.3201/eid1402.070457.18258114 14.NgT, HathawayD,"/>
   <result pre="2008;14:222–30. doi:10.3201/eid1402.070457.18258114 14.NgT, HathawayD, JenningsN, ChampD, ChiangYW, ChuHJEquine vaccine for" exact="West Nile" post="virus. Dev Biol (Basel). 2003;114:221–27.14677692 15.El GarchH, MinkeJM, RehderJ,"/>
   <result pre="S, Andreoni C, Audonnet JC, Nordgren R, Juillard V. A" exact="West Nile" post="virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing"/>
   <result pre="Immunopathol. 2008;123:230–39. doi:10.1016/j.vetimm.2008.02.002.18372050 16.IyerAV, KousoulasKGA review of vaccine approaches for" exact="West Nile" post="virus. Int J Environ Res Public Health. 2013;10:4200–23. doi:10.3390/ijerph10094200.24025396"/>
   <result pre="Public Health. 2013;10:4200–23. doi:10.3390/ijerph10094200.24025396 17.UlbertS, MagnussonSETechnologies for the development of" exact="West Nile" post="virus vaccines. Future Microbiol. 2014;9(10):1221–32. doi:10.2217/fmb.14.67.25405890 18.AmannaIJ, SlifkaMKCurrent trends"/>
   <result pre="virus vaccines. Future Microbiol. 2014;9(10):1221–32. doi:10.2217/fmb.14.67.25405890 18.AmannaIJ, SlifkaMKCurrent trends in" exact="West Nile" post="virus vaccine development. Expert Rev Vaccines. 2014;13:589–608. doi:10.1586/14760584.2014.906309.24689659 19.ScherwitzlI1,"/>
   <result pre="trial to evaluate the safety and immunogenicity of an inactivated" exact="West Nile" post="virus Vaccine, HydroVax-001, in healthy adults. Vaccine. 2019;S0264–410X:31699–702. 21.BarrettPN,"/>
   <result pre="22.DayanGH, PugachevK, BevilacquaJ, LangJ, MonathTPPreclinical and clinical development of a" exact="YFV" post="17 D-based chimeric vaccine against West Nile virus. Viruses."/>
   <result pre="clinical development of a YFV 17 D-based chimeric vaccine against" exact="West Nile" post="virus. Viruses. 2013;5:3048–70. doi:10.3390/v5123048.24351795 23.DurbinAP, WrightPF, CoxA, KaguciaW, ElwoodD,"/>
   <result pre="S, Wong TImmunogenicity and protective efficacy of a recombinant subunit" exact="West Nile" post="virus vaccine in rhesus monkeys. Clin Vaccine Immunol. 2009;16:1332–37."/>
   <result pre="Clin Vaccine Immunol. 2009;16:1332–37. doi:10.1128/CVI.00119-09.19641099 25.CollerBA, PaiV, Weeks-LevyC, OgataSARecombinant subunit" exact="West Nile" post="virus vaccine for protection of human subjects. Patent application"/>
   <result pre="Enama ME, Nelson S, Nason M, Gu W, et alA" exact="West Nile" post="virus DNA vaccine utilizing a modified promoter induces neutralizing"/>
   <result pre="vaccine elicits humoral and cellular immunity and protects against lethal" exact="West Nile" post="virus infection in aged mice. J Virol. 2013;87:1926–36. doi:10.1128/JVI.02903-12.23221549"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidates. Vaccine. 2019;37:863–68. doi: 10.1016/j.vaccine.2018.12.04030639461 34.GruberMF, FarizoKM, PrattRD,"/>
   <result pre="after intradermal infection with a European lineage 1 strain of" exact="West Nile" post="virus. PLoS One. 2014;9:e112568. doi:10.1371/journal.pone.0112568.25392925 38.ZohrabianA, HayesEB, PetersenLRCost-effectiveness of"/>
   <result pre="Nile virus. PLoS One. 2014;9:e112568. doi:10.1371/journal.pone.0112568.25392925 38.ZohrabianA, HayesEB, PetersenLRCost-effectiveness of" exact="West Nile" post="virus vaccination. Emerg Infect Dis. 2006;12:375–80. doi:10.3201/eid1203.050782.16704772 39.ShankarMB, StaplesJE,"/>
   <result pre="doi:10.3201/eid1203.050782.16704772 39.ShankarMB, StaplesJE, MeltzerMI, FischerMCost effectiveness of a targeted age-based" exact="West Nile" post="virus vaccination program. Vaccine. 2017;35:3143–51. doi:10.1016/j.vaccine.2016.11.078.28456529 40.CahillME, ConleyS, DeWanAT,"/>
   <result pre="ConleyS, DeWanAT, MontgomeryRRIdentification of genetic variants associated with dengue or" exact="West Nile" post="virus disease: a systematic review and meta-analysis. BMC Infect"/>
   <result pre="UlbertS, PalùGLatest developments and challenges in the diagnosis of human" exact="West Nile" post="virus infection. Expert Rev Anti Infect Ther. 2015;13:327–42. doi:10.1586/14787210.2015.1007044.25641365"/>
   <result pre="De OliveraD, HaganJE, et alImpact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region. Science. 2019;363:607–10."/>
   <result pre="patterns and their consequences for the diagnosis and control of" exact="West Nile" post="disease. Int J Environ Res Public Health. 2013;10:6049–83. doi:10.3390/ijerph10116049.24225644"/>
   <result pre="DuehrJ, FrereJJ, BrownJA, NachbagauerR, FosterGA, KrysztofD, TortorellaD, et alEnhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356:175–80. doi:10.1126/science.aal4365.28360135"/>
   <result pre="SaizJC, Martín-AcebesMA, Jiménez de OyaNZika virus infection confers protection against" exact="West Nile" post="virus challenge in mice. Emerg Microbes Infect. 2017;6:e81. doi:10.1038/emi.2017.68.28928416"/>
   <result pre="TrainorNB, ChangGJA detailed mutagenesis study of flavivirus cross-reactive epitopes using" exact="West Nile" post="virus-like particles. J Gen Virol. 2007;88:1169–74. doi:10.1099/vir.0.82640-0.17374760 56.RockstrohA, BarzonL,"/>
   <result pre="doi:10.1016/j.cell.2017.02.017.28222903 58.ChabierskiS, BarzonL, PapaA, NiedrigM, BramsonJL, RichnerJM, PalùG, DiamondMS, UlbertSDistinguishing" exact="West Nile" post="virus infection using a recombinant envelope protein with mutations"/>
   <result pre="BürkiK, LiebertUG, UlbertSA DNA vaccine encoding the E protein of" exact="West Nile" post="virus is protective and can be boosted by recombinant"/>
   <result pre="60.MartinaBE, KorakaP, van den DoelP, van AmerongenG, RimmelzwaanGF, OsterhausADImmunization with" exact="West Nile" post="virus envelope domain III protects mice against lethal infection"/>
   <result pre="HeJ, YangM, BaiF, ChenQA plant-produced vaccine protects mice against lethal" exact="West Nile" post="virus infection without enhancing Zika or dengue virus infectivity."/>
   <result pre="protects mice against lethal West Nile virus infection without enhancing" exact="Zika" post="or dengue virus infectivity. Vaccine. 2018;36:1846–52. doi:10.1016/j.vaccine.2018.02.073.29490880 62.KimS, LiL,"/>
   <result pre="an immundominant peptide elicit protective T cell immunity against lethal" exact="West Nile" post="virus infection. J Immunol. 2010;184:4423–30. doi:10.4049/jimmunol.0903955.20212098 63.AnticoliS, ManfrediF, ChiozziniC,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6822705\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Microbiology :"/>
   <result pre="Medical microbiology : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Medicine and health sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and Life Sciences : Genetics :"/>
   <result pre=": Invertebrates : Arthropoda : Insects: Mosquitoes Twenty years of" exact="West Nile" post="virus spread and evolution in the Americas visualized by"/>
   <result pre="source are credited.ppat.1008042.pdf Abstract It has been 20 years since" exact="West Nile" post="virus first emerged in the Americas, and since then,"/>
   <result pre="virus. After its first detection in New York in 1999," exact="West Nile" post="virus quickly spread across the continent, causing an epidemic"/>
   <result pre="(nextstrain.org/WNV/NA). Nextstrain utilizes a growing database of more than 2,000" exact="West Nile" post="virus genomes and harnesses the power of phylogenetics for"/>
   <result pre="Nextstrain, we use virus genomics to investigate the emergence of" exact="West Nile" post="virus in the U S, followed by its rapid"/>
   <result pre="links provided within this paper are constantly updated as new" exact="West Nile" post="virus genomes are shared publicly, helping to stay current"/>
   <result pre="the research. Overall, our review showcases how genomics can track" exact="West Nile" post="virus spread and evolution, as well as potentially uncover"/>
   <result pre="publish, or preparation of the manuscript. fig-count: table-count: page-count: Background" exact="West Nile" post="virus (WNV; family Flaviviridae; genus Flavivirus) is globally distributed"/>
   <result pre="total human infections in the continental US [5]. At present," exact="WNV" post="is considered one of the most important zoonotic diseases"/>
   <result pre="important zoonotic diseases of concern to the US population [6]." exact="WNV" post="is also a significant animal pathogen, having caused over"/>
   <result pre="the American Crow (Corvus brachyrhynchos) population following the introduction of" exact="WNV" post="[9]. The impact of WNV has not been limited"/>
   <result pre="population following the introduction of WNV [9]. The impact of" exact="WNV" post="has not been limited to the US, as more"/>
   <result pre="threat across the Americas [11–13]. In the two decades since" exact="WNV" post="became established in the US, limited progress has been"/>
   <result pre="Thus, renewed investment in understanding the fundamental aspects of endemic" exact="WNV" post="transmission and innovative research directions are needed to mitigate"/>
   <result pre="directions are needed to mitigate the public health burden of" exact="WNV" post="for the next 20 years. For example, advances in"/>
   <result pre="for example, were recently deployed to reconstruct the emergence of" exact="Zika" post="virus in the Americas [16–18] and revealed the sources"/>
   <result pre="epidemiological and evolutionary processes during the emergence and establishment of" exact="WNV" post="in the Americas (nextstrain.org/WNV/NA) and discuss collaborative opportunities to"/>
   <result pre="evolved resistance to previous vaccines [32,33]. Moreover, recent epidemics of" exact="Zika" post="and Ebola have highlighted the need for not only"/>
   <result pre="the maximum likelihood phylogenetic analysis [35], through which the entire" exact="WNV" post="dataset currently presented on Nextstrain (n = 2,267 genomes"/>
   <result pre="under an hour on a modern computer. We created a" exact="WNV" post="Nextstrain resource in 2018 to convey the history of"/>
   <result pre="WNV Nextstrain resource in 2018 to convey the history of" exact="WNV" post="in the Americas and promote new research directions (nextstrain.org/WNV/NA;"/>
   <result pre="found at github.com/grubaughlab/WNV-nextstrain, which can be used to analyze any" exact="WNV" post="dataset offline. Additionally, we designed a new narrative function"/>
   <result pre="nature of such research, Nextstrain is constantly updated as new" exact="WNV" post="genomes are shared publicly. Thus, the live display links"/>
   <result pre="that had never before been observed in the Americas—WNV [21,36,39]." exact="WNV" post="was first isolated in Uganda in 1937 [40] and"/>
   <result pre="Australia, and the Middle East [41]. Despite its global distribution," exact="WNV" post="was not detected in the Americas before the outbreak"/>
   <result pre="the virus sequences isolated from New York in 1999 to" exact="WNV" post="sequences from around the world revealed that it was"/>
   <result pre="world revealed that it was most closely related to a" exact="WNV" post="isolate from the brain of a dead goose found"/>
   <result pre="Middle East [42] (Fig 1). Further genetic studies revealed that" exact="WNV" post="was likely introduced in 1998 [24,43] (Fig 1). Thus,"/>
   <result pre="WNV was likely introduced in 1998 [24,43] (Fig 1). Thus," exact="WNV" post="may have been circulating in the US for a"/>
   <result pre="detected during the summer of 1999. Fig 1 Emergence of" exact="WNV" post="in New York. Though WNV was first detected in"/>
   <result pre="1999. Fig 1 Emergence of WNV in New York. Though" exact="WNV" post="was first detected in New York in 1999, (A)"/>
   <result pre="the US [44]. The primary mechanism by which dengue and" exact="Zika" post="viruses spread around the world is the long-distance travel"/>
   <result pre="travel of infected humans (e.g., [16,45]). However, unlike these viruses," exact="WNV" post="is maintained in a transmission cycle between birds and"/>
   <result pre="humans, is the more plausible mechanism for the introduction of" exact="WNV" post="from the Middle East into the US. While migratory"/>
   <result pre="the US. While migratory birds might be important dispersers of" exact="WNV" post="worldwide [46–48], flyways between the Middle East and North"/>
   <result pre="located within the area of the 1999 New York City" exact="WNV" post="outbreak a plausible hypothesis. Although it is impossible to"/>
   <result pre="plausible hypothesis. Although it is impossible to determine exactly how" exact="WNV" post="was introduced, more detailed future investigations into the patterns"/>
   <result pre="was introduced, more detailed future investigations into the patterns of" exact="WNV" post="introductions worldwide may reveal new insights. Conquering a continent"/>
   <result pre="York in 1999 [37], surveillance of mosquitoes and birds showed" exact="WNV" post="spread along the eastern seaboard reaching Florida by 2001"/>
   <result pre="Pacific Northwest (Washington state) by 2002 [4,49]. Finally, in 2003," exact="WNV" post="was detected in Southern California [4,50], marking its successful"/>
   <result pre="across the continental US. The virus genomic data reveal that" exact="WNV" post="spread even faster across the US than the surveillance"/>
   <result pre="combining spatial and phylogenetic data, it is estimated that the" exact="WNV" post="&quot;wave�? moved from the East Coast to the West"/>
   <result pre="the first few years (1999–2003) [26]. Moreover, by the time" exact="WNV" post="was first detected in New York, the virus had"/>
   <result pre="Southeast by 2000 (Fig 2B). These data also suggest that" exact="WNV" post="was established in Texas by 2001 [26] (Fig 2C)"/>
   <result pre="by local surveillance systems [4,50]. The rapid geographical expansion of" exact="WNV" post="between 2001 and 2002 is consistent with a large"/>
   <result pre="in 2002) [4]. Fig 2 Genomics reveals rapid spread of" exact="WNV" post="across the continent. By reconstructing the ancestral traits using"/>
   <result pre="nodes of the phylogenetic tree to map the pattern of" exact="WNV" post="spread. The phylogenetic data show that WNV spread to"/>
   <result pre="the pattern of WNV spread. The phylogenetic data show that" exact="WNV" post="spread to new regions occurred about a year before"/>
   <result pre="(C) nextstrain.org/WNV/NA?c=num_date&amp;amp;d=map&amp;amp;dmax=2001-12-31&amp;amp;f_country=USA, (D) nextstrain.org/WNV/NA?c=num_date&amp;amp;d=map&amp;amp;dmax=2002-12-31&amp;amp;f_country=USA. During the initial rapid spread of" exact="WNV" post="in the US, the lack of geographic structure (i.e.,"/>
   <result pre="numerous national [24,26,51–54] and regional [51,55–58] phylogenetic studies suggests that" exact="WNV" post="encountered a highly conducive environment with few barriers after"/>
   <result pre="part to the large diversity of hosts and vectors that" exact="WNV" post="can utilize for transmission [1–3]. Among these, highly abundant"/>
   <result pre="and C. pipiens) [60–62] are the most important for maintaining" exact="WNV" post="transmission. Therefore, it is likely that a large population"/>
   <result pre="susceptible hosts and vectors already present in the Americas helped" exact="WNV" post="to quickly conquer a continent despite the varied landscapes"/>
   <result pre="and mosquitoes [64] may account for a large portion of" exact="WNV" post="dispersal, the rapid rates of spread, nonuniform diffusion pattern,"/>
   <result pre="movement of WNV-infected migratory birds. Indeed, the early spread of" exact="WNV" post="along the eastern seaboard aligns with a major bird"/>
   <result pre="patterns of passerines may account for the East to West" exact="WNV" post="expansion [27,48,68]. However, it is also possible that other"/>
   <result pre="virus mixing. For example, the impact of human behavior on" exact="WNV" post="spread [63], specifically through the unintentional transport of WNV-infected"/>
   <result pre="America, should be examined more thoroughly. Better understanding of how" exact="WNV" post="spreads long distances may be critical to inform future"/>
   <result pre="critical to inform future mitigation strategies. Aided by evolution? While" exact="WNV" post="continues to diversify, the direct role that evolution played"/>
   <result pre="the direct role that evolution played during the emergence of" exact="WNV" post="in the Americas is currently difficult to discern. Evolution"/>
   <result pre="in the Americas is currently difficult to discern. Evolution of" exact="WNV" post="and other mosquito-borne viruses is complicated due to their"/>
   <result pre="mosquito vectors and vertebrate hosts [69–73]. As a result, the" exact="WNV" post="evolutionary rate (approximately 4 × 10 −4 substitutions/site/year; S3"/>
   <result pre="the virus population has been detected since the emergence of" exact="WNV" post="in the Americas [24]. Yet, the displacement of initial"/>
   <result pre="WNV in the Americas [24]. Yet, the displacement of initial" exact="WNV" post="genotype (termed NY99) by locally derived genotypes (WN02 and"/>
   <result pre="the US (Fig 3). Fig 3 Displacement of the introduced" exact="WNV" post="by locally derived genotypes. (A) The WNV phylogenetic data"/>
   <result pre="of the introduced WNV by locally derived genotypes. (A) The" exact="WNV" post="phylogenetic data support three main genotypes in the US:"/>
   <result pre="genotype displacement is a single amino acid substitution in the" exact="WNV" post="envelope protein (E-V159A) that emerged around 2001 [25,51,76] (Fig"/>
   <result pre="the evidence that supports the hypothesis that rapid evolution of" exact="WNV" post="facilitated its westwardly spread is limited, and additional studies"/>
   <result pre="in the Americas. Becoming an entrenched virus Following its emergence," exact="WNV" post="quickly established endemicity and became one of the most"/>
   <result pre="2002, between 662 (in 2009) and 9,438 (in 2003) human" exact="WNV" post="cases have been reported every year in the US"/>
   <result pre="susceptible mosquito vectors and avian hosts, the data indicate that" exact="WNV" post="poses as an annual public health threat with no"/>
   <result pre="annual public health threat with no signs of remission. Though" exact="WNV" post="transmission is consistently detected throughout the continental US, its"/>
   <result pre="that influence mosquito and bird populations can be predictive of" exact="WNV" post="intensity [88–94], yet the contributions of these extrinsic factors"/>
   <result pre="genetic diversity [64,101], causing potential differences in their efficiency for" exact="WNV" post="transmission [95,102]. Combined with varied avian ecology and migratory"/>
   <result pre="bird flyways across the US [3,96], these data suggest that" exact="WNV" post="is maintained in regional transmission networks with unique selective"/>
   <result pre="selective pressures that influence the stability and emergence of new" exact="WNV" post="strains [87]. The slowed dispersal velocity and formation of"/>
   <result pre="initial rapid spread stage (Fig 2) reinforce the hypothesis that" exact="WNV" post="is now primarily maintained at local or regional levels"/>
   <result pre="Understanding such fundamental questions of the epidemiology and biology of" exact="WNV" post="strains between and within states may be important for"/>
   <result pre="combating this entrenched virus. An international concern The spread of" exact="WNV" post="north to Canada and as far south as Argentina"/>
   <result pre="far south as Argentina highlights that the growing burden of" exact="WNV" post="is not limited to the US. The first human"/>
   <result pre="WNV is not limited to the US. The first human" exact="WNV" post="case in Canada was reported in Ontario in 2002,"/>
   <result pre="Canadian provinces [10,103]. Surveillance between 2001 and 2004 showed that" exact="WNV" post="had spread to Central America and the Caribbean [12,13,104–107]."/>
   <result pre="Central America and the Caribbean [12,13,104–107]. Since then, evidence of" exact="WNV" post="transmission has been found across South America, including Colombia,"/>
   <result pre="America, including Colombia, Venezuela, Brazil, and Argentina [13,108–111]. Detection of" exact="WNV" post="antibodies in migratory birds suggests that this route may"/>
   <result pre="suggests that this route may be an important factor for" exact="WNV" post="dissemination throughout the Americas [106]; but as described above,"/>
   <result pre="still unclear if other mechanisms may influence the spread of" exact="WNV" post="to Central and South America. Although many partial WNV"/>
   <result pre="of WNV to Central and South America. Although many partial" exact="WNV" post="genomes (primarily envelope coding sequences) were generated from the"/>
   <result pre="dynamics [113]. To this end, there are currently only 11" exact="WNV" post="genomes available from Mexico [114,115], seven from the rest"/>
   <result pre="may be commonly moving across the US–Mexico border [114,115]. Moreover," exact="WNV" post="genetic data from the British Virgin Islands [119] and"/>
   <result pre="circulation in South America [116–118]. However, the paucity of complete" exact="WNV" post="genomes makes it difficult to understand the patterns of"/>
   <result pre="diversity outside of the US. Fig 4 International spread of" exact="WNV" post="following its emergence in the US. Following the emergence"/>
   <result pre="following its emergence in the US. Following the emergence of" exact="WNV" post="in the US, the virus was detected throughout the"/>
   <result pre="map depicting spread. However, the limited number of available near-complete" exact="WNV" post="genomes from each location and the long branches make"/>
   <result pre="found at nextstrain.org/WNV/NA?c=country&amp;amp;f_country=Argentina,Brazil,British-Virgin-Islands,Colombia,Mexico&amp;amp;p=grid. An important question is why large human" exact="WNV" post="outbreaks have not been detected in Latin American countries"/>
   <result pre="was recently detected in Brazil [118] and serological evidence of" exact="WNV" post="is prevalent in resident birds from Latin America [13,104–106],"/>
   <result pre="resident birds from Latin America [13,104–106], it is likely that" exact="WNV" post="is endemic throughout the Americas. Perhaps the presence of"/>
   <result pre="or may convey some level of cross-protection [12,122]. Alternatively, as" exact="WNV" post="may have initially outcompeted SLEV in the US [124],"/>
   <result pre="Central and South America may have at least temporarily slowed" exact="WNV" post="transmission in these regions. Given these uncertainties, initiatives to"/>
   <result pre="and equine serosurveys and dead bird and mosquito surveillance for" exact="WNV" post="in regions throughout the Americas are paramount for determining"/>
   <result pre="its true burden. Future role of genomics Given how much" exact="WNV" post="has thrived in the US, significant national investment will"/>
   <result pre="and collaborative efforts to fill in the many gaps in" exact="WNV" post="genomic sampling throughout the country, especially from the last"/>
   <result pre="the last 10 years (Fig 5), to better understand endemic" exact="WNV" post="transmission using virus genomics approaches [14]. Fortunately, the availability"/>
   <result pre="continually communicated to the public. Fig 5 Gaps in recent" exact="WNV" post="sampling hinder the usefulness of virus genomic analyses. Following"/>
   <result pre="decrease. The circle sizes represent the relative number of near-complete" exact="WNV" post="genomes available from each collection location (county) per 5-year"/>
   <result pre="(county) per 5-year period. There are currently (A) 728 available" exact="WNV" post="genomes from 37 states from 1999 to 2004, (B)"/>
   <result pre="genomes from 37 states from 1999 to 2004, (B) 789" exact="WNV" post="genomes from 22 from 2005 to 2009, (C) 541"/>
   <result pre="WNV genomes from 22 from 2005 to 2009, (C) 541" exact="WNV" post="genomes from 22 states from 2010 to 2014, and"/>
   <result pre="from 22 states from 2010 to 2014, and (D) 190" exact="WNV" post="genomes from 5 states from 2015 to 2019 (all"/>
   <result pre="(C) nextstrain.org/WNV/NA?c=num_date&amp;amp;d=map&amp;amp;dmax=2014-12-31&amp;amp;dmin=2010-01-01&amp;amp;f_country=USA&amp;amp;r=division, (D) nextstrain.org/WNV/NA?c=num_date&amp;amp;d=map&amp;amp;dmax=2019-12-31&amp;amp;dmin=2015-01-01&amp;amp;f_country=USA&amp;amp;r=division. Generating a well-distributed temporal and spatial" exact="WNV" post="genomic dataset can be used to determine which strains"/>
   <result pre="became locally established. This work will help to identify if" exact="WNV" post="outbreaks in Ames, Iowa, for example, are connected to"/>
   <result pre="Chicago, Illinois (approximately 560 km). Systematically searching for connections among" exact="WNV" post="outbreaks around the country may reveal endemic &quot;transmission networks,�?"/>
   <result pre="networks,�? which could be exploited for control and forecasting purposes." exact="WNV" post="control is primarily based on local interventions to temporarily"/>
   <result pre="control within a transmission network may reduce reintroductions and limit" exact="WNV" post="transmission beyond a single season. In addition, genomic epidemiology"/>
   <result pre="location to limit potential outbreaks [29]. After 20 years of" exact="WNV" post="in the Americas, it is time to recognize that"/>
   <result pre="it is time to recognize that alleviating the burden of" exact="WNV" post="for the next generation will likely depend on significant"/>
   <result pre="Supporting information S1 Fig Nextstrain as a tool to visualize" exact="WNV" post="evolution and spread. A depiction of the main interactive"/>
   <result pre="plotted as entropy and positioned by codon sequence). In the" exact="WNV" post="genome, the protein abbreviations are as follows: C ="/>
   <result pre="in on various features, can be found at nextstrain.org/WNV/NA?p=grid. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="in the epidemic suggests that there were few barriers to" exact="WNV" post="spread. An unrooted maximum likelihood WNV phylogenetic tree shows"/>
   <result pre="were few barriers to WNV spread. An unrooted maximum likelihood" exact="WNV" post="phylogenetic tree shows that there is little geographic structure"/>
   <result pre="form as the virus transitioned into its endemic phase. Additional" exact="WNV" post="sequencing throughout the US from the last 10 years"/>
   <result pre="Layout�?. A live display can be found at nextstrain.org/WNV/NA?l=unrooted&amp;amp;m=div&amp;amp;p=full. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="here for additional data file. S3 Fig Evolutionary rate of" exact="WNV" post="in the Americas. A root-to-tip plot showing the divergence"/>
   <result pre="root-to-tip plot showing the divergence (substitutions per site) of sequenced" exact="WNV" post="genomes (tips) from the inferred ancestral sequence (root) by"/>
   <result pre="Layout.�? A live display can be found at nextstrain.org/WNV/NA?c=num_date&amp;amp;d=tree&amp;amp;l=clock. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="additional data file. S4 Fig Multiple independent occurrences of genotype-defining" exact="WNV" post="mutations. WNV genotype SW03 is defined by two amino"/>
   <result pre="file. S4 Fig Multiple independent occurrences of genotype-defining WNV mutations." exact="WNV" post="genotype SW03 is defined by two amino acid substitutions,"/>
   <result pre="can be found at (A) nextstrain.org/WNV/NA?c=gt-NS4A_85 and (B) nextstrain.org/WNV/NA?c=gt-NS5_314. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="Click here for additional data file. S5 Fig Cocirculation of" exact="WNV" post="genotypes WN02 and SW03. Since the emergence of WN02"/>
   <result pre="found at (A) https://nextstrain.org/WNV/NA?c=lineage&amp;amp;f_authors=Hepp%20et%20al, (B) https://nextstrain.org/WNV/NA?c=lineage&amp;amp;f_authors=Duggal%20et%20al, and (C) https://nextstrain.org/WNV/NA?c=lineage&amp;amp;f_authors=Shabman%20et%20al. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="for additional data file. S6 Fig Establishment of persistent local" exact="WNV" post="transmission networks demonstrates endemicity. WNV is likely establishing persistent"/>
   <result pre="Fig Establishment of persistent local WNV transmission networks demonstrates endemicity." exact="WNV" post="is likely establishing persistent local transmission networks throughout the"/>
   <result pre="function. A live display can be found at nextstrain.org/WNV/NA?f_state=NY&amp;amp;d=tree. WNV," exact="West Nile" post="virus. (PDF) LINK Click here for additional data file."/>
   <result pre="1KramerLD, StyerLM, EbelGD. A global perspective on the epidemiology of" exact="West Nile" post="virus. Annu Rev Entomol. 2008;53: 61–81. 10.1146/annurev.ento.53.103106.09325817645411 2KomarN. West"/>
   <result pre="West Nile virus. Annu Rev Entomol. 2008;53: 61–81. 10.1146/annurev.ento.53.103106.09325817645411 2KomarN." exact="West Nile" post="virus: epidemiology and ecology in North America. Adv Virus"/>
   <result pre="America. Adv Virus Res. 2003;61: 185–234. 14714433 3ReisenWK. Ecology of" exact="West Nile" post="virus in North America. Viruses. 2013;5: 2079–2105. 10.3390/v509207924008376 4CDC."/>
   <result pre="Nile virus in North America. Viruses. 2013;5: 2079–2105. 10.3390/v509207924008376 4CDC." exact="West Nile" post="Virus Final Cumulative Maps and Data [Internet]. 10 Dec"/>
   <result pre="[cited 2019 May 5]. 5RoncaSE, MurrayKO, NolanMS. Cumulative incidence of" exact="West Nile" post="virus infection, continental United States, 1999–2016. Emerg Infect Dis."/>
   <result pre="2019. Available from: https://www.cdc.gov/media/releases/2019/s0506-zoonotic-diseases-shared.html. [cited 2019 May 13]. 7Aphis U." exact="West Nile" post="Virus Maps- States with Equine Cases [Internet]. Available from:"/>
   <result pre="25]. 8GeorgeTL, HarriganRJ, LaMannaJA, DeSanteDF, SaraccoJF, SmithTB. Persistent impacts of" exact="West Nile" post="virus on North American bird populations. Proc Natl Acad"/>
   <result pre="Sci U S A. 2015;112: 14290–14294. 10.1073/pnas.150774711226578774 9LaDeauSL, KilpatrickAM, MarraPP." exact="West Nile" post="virus emergence and large-scale declines of North American bird"/>
   <result pre="2007;447: 710–713. 10.1038/nature0582917507930 10Public Health Agency of Canada. Surveillance of" exact="West Nile" post="virus [Internet]. 26 Jun 2015. Available from: https://www.canada.ca/en/public-health/services/diseases/west-nile-virus/surveillance-west-nile-virus.html. [cited"/>
   <result pre="DudasG, TanAL, GangavarapuK, et al.Genomic epidemiology reveals multiple introductions of" exact="Zika" post="virus into the United States. Nature. 2017;90: 4864. 17MetskyHC,"/>
   <result pre="ThézéJ, de JesusJG, GiovanettiM, et al.Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the Americas. Nature. 2017; 10.1038/nature2240128538727"/>
   <result pre="21LanciottiRS, RoehrigJT, DeubelV, SmithJ, ParkerM, SteeleK, et al.Origin of the" exact="West Nile" post="virus responsible for an outbreak of encephalitis in the"/>
   <result pre="22HeppCM, CockingJH, ValentineM, YoungSJ, DamianD, Samuels-CrowKE, et al.Phylogenetic analysis of" exact="West Nile" post="Virus in Maricopa county, Arizona: Evidence for dynamic behavior"/>
   <result pre="23DuggalNK, ReisenWK, FangY, NewmanRM, YangX, EbelGD, et al.Genotype-specific variation in" exact="West Nile" post="virus dispersal in California. Virology. 2015;485: 79–85. 10.1016/j.virol.2015.07.00426210076 24Di"/>
   <result pre="GeogheganJL, DochertyDE, McLeanRG, ZodyMC, QuJ, et al.Fluid spatial dynamics of" exact="West Nile" post="virus in the United States: Rapid spread in a"/>
   <result pre="LanciottiRS, BraultAC, GuzmanH, SiirinM, et al.Phylogenetic analysis of North American" exact="West Nile" post="virus isolates, 2001–2004: Evidence for the emergence of a"/>
   <result pre="WidenSG, WoodTG, ReynaM, WilkersonL, DebbounM, et al.Terrestrial bird migration and" exact="West Nile" post="virus circulation, United States. Emerg Infect Dis. 2018;24: 2184–2194."/>
   <result pre="39JiaXY, BrieseT, JordanI, RambautA, ChiHC, MackenzieJS, et al.Genetic analysis of" exact="West Nile" post="New York 1999 encephalitis virus. Lancet. 1999;354: 1971–1972. 10.1016/s0140-6736(99)05384-210622305"/>
   <result pre="PetersenLR. Emerging flaviviruses: The spread and resurgence of Japanese encephalitis," exact="West Nile" post="and dengue viruses. Nat Med. 2004;10: S98–109. 10.1038/nm114415577938 42MayFJ,"/>
   <result pre="Med. 2004;10: S98–109. 10.1038/nm114415577938 42MayFJ, DavisCT, TeshRB, BarrettADT. Phylogeography of" exact="West Nile" post="virus: From the cradle of evolution in Africa to"/>
   <result pre="Lo PrestiA, RezzaG, DeloguM, et al.Phylogeography and epidemiological history of" exact="West Nile" post="virus genotype 1a in Europe and the Mediterranean basin."/>
   <result pre="basin. Infection, Genetics and Evolution. 2011;11: 646–653. 10.1016/j.meegid.2011.02.00321320643 44JohnstonBL, ConlyJM." exact="West Nile" post="virus—where did it come from and where might it"/>
   <result pre="763–775. 10.1016/j.tree.2016.07.00527507683 47Hernández-TrianaLM, JeffriesCL, MansfieldKL, CarnellG, FooksAR, JohnsonN. Emergence of" exact="West Nile" post="virus lineage 2 in Europe: A review on the"/>
   <result pre="27110.3389/fpubh.2014.0027125538937 48ReedKD, MeeceJK, HenkelJS, ShuklaSK. Birds, migration and emerging zoonoses:" exact="West Nile" post="virus, Lyme disease, influenza A and enteropathogens. Clin Med"/>
   <result pre="A and enteropathogens. Clin Med Res. 2003;1: 5–12. 15931279 49CDC." exact="West Nile" post="Virus Activity—United States, September 26-October 2, 2002, and Investigations"/>
   <result pre="Virus Activity—United States, September 26-October 2, 2002, and Investigations of" exact="West Nile" post="Virus Infections in Recipients of Blood Transfusion and Organ"/>
   <result pre="GuzmanH, VanlandinghamDL, Travassos da RosaAPA, ParsonsRE, et al.Limited evolution of" exact="West Nile" post="virus has occurred during its southwesterly spread in the"/>
   <result pre="52HerringBL, BernardinF, CagliotiS, StramerS, ToblerL, AndrewsW, et al.Phylogenetic analysis of" exact="WNV" post="in North American blood donors during the 2003–2004 epidemic"/>
   <result pre="53GrinevA, ChanceyC, VolkovaE, AñezG, HeiseyDAR, WinkelmanV, et al.Genetic variability of" exact="West Nile" post="virus in US blood donors from the 2012 epidemic"/>
   <result pre="54AnezG, GrinevA, ChanceyC, BallC, AkolkarN, LandKJ, et al.Evolutionary dynamics of" exact="West Nile" post="virus in the United States, 1999–2011: Phylogeny, selection pressure"/>
   <result pre="D’AntonM, NovakRJ, et al.Genetic variation among temporally and geographically distinct" exact="West Nile" post="virus isolates, United States, 2001, 2002. Emerg Infect Dis."/>
   <result pre="RuizMO, BrawnJD, LossSR, et al.Fine-scale genetic variation and evolution of" exact="West Nile" post="Virus in a transmission &quot;hot spot�? in suburban Chicago,"/>
   <result pre="BertolottiL, HamerGL, KitronUD, WalkerED, RuizMO, et al.Multi-year evolutionary dynamics of" exact="West Nile" post="virus in suburban Chicago, USA, 2005–2007. Philos Trans R"/>
   <result pre="2010;365: 1871–1878. 10.1098/rstb.2010.005420478882 58BertolottiL, KitronU, GoldbergTL. Diversity and evolution of" exact="West Nile" post="virus in Illinois and the United States, 2002–2005. Virology."/>
   <result pre="North American birds with the New York 1999 strain of" exact="West Nile" post="virus. Emerg Infect Dis. 2003;9: 311–322. 10.3201/eid0903.02062812643825 60TurellMJ, O’GuinnM,"/>
   <result pre="60TurellMJ, O’GuinnM, OliverJ. Potential for New York mosquitoes to transmit" exact="West Nile" post="virus. Am J Trop Med Hyg. 2000;62: 413–414. 10.4269/ajtmh.2000.62.41311037788"/>
   <result pre="61GoddardLB, RothAE, ReisenWK, ScottTW. Vector competence of California mosquitoes for" exact="West Nile" post="virus. Emerg Infect Dis. 2002;8: 1385–1391. 10.3201/eid0812.02053612498652 62SardelisMR, TurellMJ,"/>
   <result pre="competence of selected North American Culex and Coquillettidia mosquitoes for" exact="West Nile" post="virus. Emerg Infect Dis. 2001;7: 1018–1022. 10.3201/eid0706.01061711747732 63RappoleJH, ComptonBW,"/>
   <result pre="10.3201/eid0706.01061711747732 63RappoleJH, ComptonBW, LeimgruberP, RobertsonJ, KingDI, RennerSC. Modeling movement of" exact="West Nile" post="virus in the western hemisphere. Vector Borne Zoonotic Dis."/>
   <result pre="Population genetic data suggest a role for mosquito-mediated dispersal of" exact="West Nile" post="virus across the western United States. Mol Ecol. 2010;19:"/>
   <result pre="EdwardsE, BruR, HughesM, et al.Migrating birds as dispersal vehicles for" exact="West Nile" post="virus. Ecohealth. 2006;3: 79. 66DusekRJ, McLeanRG, KramerLD, UbicoSR, DupuisAP"/>
   <result pre="66DusekRJ, McLeanRG, KramerLD, UbicoSR, DupuisAP 2nd, EbelGD, et al.Prevalence of" exact="West Nile" post="virus in migratory birds during spring and fall migration."/>
   <result pre="808–815. 10.4269/ajtmh.2010.10-020020889869 68RappoleJH, DerricksonSR, HubálekZ. Migratory birds and spread of" exact="West Nile" post="virus in the western hemisphere. Emerg Infect Dis. 2000;6:"/>
   <result pre="72GrubaughND, FauverJR, RuckertC, Weger-LucarelliJ, Garcia-LunaS, MurrietaRA, et al.Mosquitoes transmit unique" exact="West Nile" post="virus populations during each feeding episode. Cell Rep. 2017;19:"/>
   <result pre="Rep. 2017;19: 709–718. 10.1016/j.celrep.2017.03.07628445723 73DeardorffER, FitzpatrickKA, JerzakGVS, ShiP-Y, KramerLD, EbelGD." exact="West Nile" post="virus experimental evolution in vivo and the trade-off hypothesis."/>
   <result pre="156–165. 10.1007/s00239-001-0064-311821909 75GranwehrBP, LiL, DavisCT, BeasleyDWC, BarrettADT. Characterization of a" exact="West Nile" post="virus isolate from a human on the Gulf Coast"/>
   <result pre="76EbelGD, CarricaburuJ, YoungD, BernardKA, KramerLD. Genetic and phenotypic variation of" exact="West Nile" post="virus in New York, 2000–2003. Am J Trop Med"/>
   <result pre="77MoudyRM, MeolaMA, MorinL-LL, EbelGD, KramerLD. A newly emergent genotype of" exact="West Nile" post="virus is transmitted earlier and more efficiently by Culex"/>
   <result pre="MeolaMA, MoudyRM, KramerLD. Temperature, viral genetics, and the transmission of" exact="West Nile" post="virus by Culex pipiens mosquitoes. PLoS Pathog. 2008;4: e100009210.1371/journal.ppat.100009218584026"/>
   <result pre="Bosco-LauthA, BowenRA, WheelerSS, ReisenWK, FelixTA, et al.Evidence for co-evolution of" exact="West Nile" post="virus and house sparrows in North America. PLoS Negl"/>
   <result pre="80AndersonJF, MainAJ, ChengG, FerrandinoFJ, FikrigE. Horizontal and vertical transmission of" exact="West Nile" post="virus genotype NY99 by Culex salinarius and genotypes NY99"/>
   <result pre="BarrettADT, HiggsS. Short report: Comparison of oral infectious dose of" exact="West Nile" post="virus isolates representing three distinct genotypes in Culex quinquefasciatus."/>
   <result pre="incubation rate is not accelerated in recent California strains of" exact="West Nile" post="virus in Culex tarsalis (Diptera: Culicidae). J Med Entomol."/>
   <result pre="LiL, GuzmanH, BuenoRJr, DennettJA, et al.Evolution of new genotype of" exact="West Nile" post="virus in North America. Emerg Infect Dis. 2011;17: 785–793."/>
   <result pre="86AñezG, GrinevA, ChanceyC, BallC, AkolkarN, LandKJ, et al.Evolutionary dynamics of" exact="West Nile" post="virus in the United States, 1999–2011: Phylogeny, selection pressure"/>
   <result pre="KoetznerCA, MaffeiJG, HalpinRA, et al.Evolutionary dynamics and molecular epidemiology of" exact="West Nile" post="virus in New York State: 1999–2015. Virus Evol. 2019;5:"/>
   <result pre="KramerLD, DiffenbaughNS, et al.Drought and immunity determine the intensity of" exact="West Nile" post="virus epidemics and climate change impacts. Proceedings of the"/>
   <result pre="KnightTM, ChaseJM. Inter-annual associations between precipitation and human incidence of" exact="West Nile" post="virus in the United States. Vector Borne Zoonotic Dis."/>
   <result pre="2007;710.1089/vbz.2006.059017867908 90ShamanJ, DayJF, StieglitzM. Drought-induced amplification and epidemic transmission of" exact="West Nile" post="virus in southern Florida. J Med Entomol. 2005;42: 134–141."/>
   <result pre="91WimberlyMC, LamsalA, GiacomoP, ChuangTW. Regional variation of climatic influences on" exact="West Nile" post="virus outbreaks in the United States. Am J Trop"/>
   <result pre="BrownWM, WalkerED, et al.Local impact of temperature and precipitation on" exact="West Nile" post="virus infection in Culex species mosquitoes in northeast Illinois,"/>
   <result pre="mosquito surveillance to predict vector-borne disease: Prospective forecasts of a" exact="West Nile" post="virus outbreak. PLoS Curr. 2017; 10.1371/currents.outbreaks.90e80717c4e67e1a830f17feeaaf85de28736681 94ChuangTW, WimberlyMC. Remote"/>
   <result pre="2017; 10.1371/currents.outbreaks.90e80717c4e67e1a830f17feeaaf85de28736681 94ChuangTW, WimberlyMC. Remote sensing of climatic anomalies and" exact="West Nile" post="virus incidence in the northern great plains of the"/>
   <result pre="2012;7: 1–10. 95CiotaAT, KramerLD. Vector-virus interactions and transmission dynamics of" exact="West Nile" post="virus. Viruses. 2013;5: 3021–3047. 10.3390/v512302124351794 96KilpatrickAM. Globalization, land use,"/>
   <result pre="3021–3047. 10.3390/v512302124351794 96KilpatrickAM. Globalization, land use, and the invasion of" exact="West Nile" post="virus. Science. 2011;334: 323–327. 10.1126/science.120101022021850 97DunphyBM, KovachKB, GehrkeEJ, FieldEN,"/>
   <result pre="temporal patterns implicating Culex tarsalis as the primary vector of" exact="West Nile" post="virus. Sci Rep. 2019;9: 663710.1038/s41598-019-43246-y31036953 98AndreadisTG. The contribution of"/>
   <result pre="of Culex pipiens complex mosquitoes to transmission and persistence of" exact="West Nile" post="virus in North America. Journal of American Mosquito Control"/>
   <result pre="MaddenM, MasourJ, YabsleyMJ, StallknechtDE. Factors affecting the geographic distribution of" exact="West Nile" post="virus in Georgia, USA: 2002–2004. Vector Borne Zoonotic Dis."/>
   <result pre="DrakeJM. Regional differences in the association between land cover and" exact="West Nile" post="virus disease incidence in humans in the United States."/>
   <result pre="of hybridization of Culex pipiens complex mosquitoes on transmission of" exact="West Nile" post="virus. Parasit Vectors. 2013;6: 30510.1186/1756-3305-6-30524499581 103GiordanoBV, KaurS, HunterFF. West"/>
   <result pre="West Nile virus. Parasit Vectors. 2013;6: 30510.1186/1756-3305-6-30524499581 103GiordanoBV, KaurS, HunterFF." exact="West Nile" post="virus in Ontario, Canada: A twelve-year analysis of human"/>
   <result pre="ONE. 2017;12: e018356810.1371/journal.pone.018356828829827 104DupuisAP 2nd, MarraPP, KramerLD. Serologic evidence of" exact="West Nile" post="virus transmission, Jamaica, West Indies. Emerg Infect Dis. 2003;9:"/>
   <result pre="circulation since July 2002. Emerging Infectious Diseases. 2003;910.3201/eid0912.03056414720402 106KomarN, ClarkGG." exact="West Nile" post="virus activity in Latin America and the Caribbean. Revista"/>
   <result pre="Dis. 2005;11: 1449–1452. 10.3201/eid1109.05012116229779 108MattarS, EdwardsE, LaguadoJ, GonzálezM, AlvarezJ, KomarN." exact="West Nile" post="virus antibodies in Colombian horses. Emerg Infect Dis. 2005;11:"/>
   <result pre="111Pauvolid-CorrêaA, MoralesMA, LevisS, FigueiredoLTM, Couto-LimaD, CamposZ, et al.Neutralising antibodies for" exact="West Nile" post="virus in horses from Brazilian Pantanal. Mem Inst Oswaldo"/>
   <result pre="p. 58295710.1101/582957 114MannBR, McMullenAR, GuzmanH, TeshRB, BarrettADT. Dynamic transmission of" exact="West Nile" post="virus across the United States-Mexican border. Virology. 2013;436: 75–80."/>
   <result pre="10.1016/j.virol.2012.10.02323141421 115DeardorffE, Estrada-FrancoJ, BraultAC, Navarro-LopezR, Campomanes-CortesA, Paz-RamirezP, et al.Introductions of" exact="West Nile" post="virus strains to Mexico. Emerg Infect Dis. 2006;12: 314–318."/>
   <result pre="10.3201/eid1202.05087116494762 116OsorioJE, CiuoderisKA, LoperaJG, PiedrahitaLD, MurphyD, LevasseurJ, et al.Characterization of" exact="West Nile" post="viruses isolated from captive American flamingoes (Phoenicopterus ruber) in"/>
   <result pre="LevisS, LanciottiRS. Complete genome sequences and phylogenetic analysis of two" exact="West Nile" post="virus strains isolated from equines in Argentina in 2006"/>
   <result pre="SilvaSP da, CruzACR, PantojaJA de S, et al.First isolation of" exact="West Nile" post="virus in Brazil. Mem Inst Oswaldo Cruz. 2019;114: e18033210.1590/0074-0276018033230672980"/>
   <result pre="10.1007/s10393-014-0910-624504904 120MannBR, McMullenAR, SwetnamDM, BarrettADT. Molecular epidemiology and evolution of" exact="West Nile" post="virus in North America. Int J Environ Res Public"/>
   <result pre="121BarreraR, HunspergerE, Muñoz-JordánJL, AmadorM, DiazA, SmithJ, et al.First isolation of" exact="West Nile" post="virus in the Caribbean. Am J Trop Med Hyg."/>
   <result pre="Med Hyg. 2008;78: 666–668. 18385366 122GublerDJ. The continuing spread of" exact="West Nile" post="virus in the western hemisphere. Clin Infect Dis. 2007;45:"/>
   <result pre="et al.Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nature"/>
   <result pre="Biotechnol. 2019;37: 160–168. 10.1038/s41587-018-0006-x30718881 127GublerDJ, CampbellGL, NasciR, KomarN, PetersenL, RoehrigJT." exact="West Nile" post="virus in the United States: Guidelines for detection, prevention,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6823455\results\search\tropicalVirus\results.xml">
   <result pre="pmcid: 682345552307 doi: 10.1038/s41598-019-52307-1 : Article Asian and African lineage" exact="Zika" post="viruses show differential replication and innate immune responses in"/>
   <result pre="To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract" exact="Zika" post="virus (ZIKV) infections in humans are considered to be"/>
   <result pre="human monocyte-derived dendritic cells (DCs) and macrophages. The epidemic Asian/American" exact="ZIKV" post="replicated well and induced relatively good antiviral responses in"/>
   <result pre="early proteasomal activation in phagocytic cells. Our data indicates that" exact="ZIKV" post="evolution has led to significant phenotypic differences in the"/>
   <result pre="ja Aatos Erkon Säätiö (Jane and Aatos Erkko Foundation) Introduction" exact="Zika" post="virus (ZIKV) belongs to the family of Flaviviridae, which"/>
   <result pre="which is a large group of viruses including e.g. Dengue," exact="West Nile," post="Japanese encephalitis, Tick-borne encephalitis and many other important human"/>
   <result pre="and many other important human pathogenic viruses. In most individuals" exact="ZIKV" post="infection is a self-limiting disease with fever, rash, arthritis,"/>
   <result pre="subclinical infection1. However, in 2015 there was increasing evidence that" exact="ZIKV" post="is linked to congenital infections leading to spontaneous abortions"/>
   <result pre="severe neonatal birth defects2,3. Indeed, it was observed that maternal" exact="ZIKV" post="infection can spread to the fetal brains causing the"/>
   <result pre="to reduced brain volume and development of microcephaly4,5. In addition," exact="ZIKV" post="infections have been associated with Guillain-Barré syndrome and likely"/>
   <result pre="appear in early childhood6. Due to the rapid spread of" exact="ZIKV" post="infections in the Americas and accumulating data on severe"/>
   <result pre="severe birth defects in children whose mothers had suffered a" exact="ZIKV" post="infection during pregnancy, WHO declared ZIKV infection as a"/>
   <result pre="mothers had suffered a ZIKV infection during pregnancy, WHO declared" exact="ZIKV" post="infection as a global health alert during the epidemic"/>
   <result pre="as a global health alert during the epidemic in 2015–20167." exact="ZIKV" post="was identified in Rhesus monkeys in Uganda and the"/>
   <result pre="are transmitting the virus to primates and humans9. Initially, the" exact="ZIKV" post="appearance was restricted to certain areas in Africa and"/>
   <result pre="other important flaviviruses as well. During the last ten years," exact="ZIKV" post="spread to Southeast Asia and the Polynesian Islands followed"/>
   <result pre="spread, the virus has undergone marked genetic evolution and presently" exact="ZIKV" post="strains have been classified as East African, West African"/>
   <result pre="DCs in humans have been shown to be permissive to" exact="ZIKV" post="infection, there is still some controversy on the impact"/>
   <result pre="immunity16–18. Macrophages, which are readily infected by many flaviviruses like" exact="Dengue" post="and West Nile viruses19,20, have been mostly neglected as"/>
   <result pre="which are readily infected by many flaviviruses like Dengue and" exact="West Nile" post="viruses19,20, have been mostly neglected as a potential target"/>
   <result pre="viruses19,20, have been mostly neglected as a potential target for" exact="ZIKV" post="infection. In the present study, we have characterized Zika"/>
   <result pre="for ZIKV infection. In the present study, we have characterized" exact="Zika" post="virus infection in primary human monocyte-derived DCs and macrophages."/>
   <result pre="we evaluated the susceptibility of human immune cells to a" exact="ZIKV" post="infection. Secondly, we compared the infection pattern of Asian"/>
   <result pre="the infection pattern of Asian lineage fetal brain and blood" exact="ZIKV" post="isolates and a historical African strain (initially a monkey"/>
   <result pre="both cell types. We observed that the recent Asian/American lineage" exact="Zika" post="viruses replicated well in DCs but poorly in macrophages,"/>
   <result pre="of innate antiviral gene expression and cytokine production. However, all" exact="ZIKV" post="strains analyzed induced innate immune responses in such a"/>
   <result pre="cell types. Results Infection of human DCs and macrophages by" exact="Zika" post="viruses of different evolutionary lineages In this study we"/>
   <result pre="lineages In this study we analysed the infection profiles of" exact="ZIKV" post="strains of African and Asian lineages in human innate"/>
   <result pre="in human innate immune cell models. A recent Asian lineage" exact="ZIKV" post="strain (infection contracted in Guatemala) isolated from fetal brains"/>
   <result pre="dendritic cells (DCs) and macrophages to fetal brain-isolated Asian lineage" exact="ZIKV" post="and historical African lineage ZIKV infection. (A) Phylogenetic analysis"/>
   <result pre="to fetal brain-isolated Asian lineage ZIKV and historical African lineage" exact="ZIKV" post="infection. (A) Phylogenetic analysis of complete coding regions of"/>
   <result pre="analysis of complete coding regions of the Asian and African" exact="ZIKV" post="strains used in this study. Maximum Likelihood tree based"/>
   <result pre="order to define the susceptibility of human immune cells to" exact="ZIKV" post="infection, we infected primary human monocyte-derived DCs and macrophages"/>
   <result pre="seen in immunofluorescence analysis (Supplementary Fig. S1). To further evaluate" exact="ZIKV" post="infection in DCs and macrophages we infected the cells"/>
   <result pre="cells in different donors (Fig. 1B,C). However, in African lineage" exact="ZIKV" post="#976 virus-infected DCs, only a few percentage of cells"/>
   <result pre="data indicates that DCs are more permissive to the Asian" exact="ZIKV" post="strains, whereas macrophages show low susceptibility to both Asian"/>
   <result pre="whereas macrophages show low susceptibility to both Asian and African" exact="ZIKV" post="strains. Replication of ZIKV in human DCs and macrophages"/>
   <result pre="susceptibility to both Asian and African ZIKV strains. Replication of" exact="ZIKV" post="in human DCs and macrophages As human DCs and"/>
   <result pre="and macrophages were found to be rather weakly permissive to" exact="ZIKV" post="infection even with an extremely high doses of viruses,"/>
   <result pre="48–72 h p.i. in macrophages (Fig. 2A,B). The Asian lineage GWUH" exact="Zika" post="virus replicated better in DCs compared to that in"/>
   <result pre="in DCs and macrophages (Fig. 2B). Altogether, by comparing the" exact="ZIKV" post="strains from African and Asian lineages, the data indicates"/>
   <result pre="from African and Asian lineages, the data indicates that different" exact="ZIKV" post="strains show clear differences in their replication and viral"/>
   <result pre="human DCs and macrophages infected with Asian and African lineage" exact="ZIKV" post="strains. The Asian lineage GWUH strain or the African"/>
   <result pre="The Asian lineage GWUH strain or the African lineage #976" exact="ZIKV" post="strain was used to separately infect human DCs or"/>
   <result pre="different times after infection as indicated in the figure. (A)" exact="ZIKV" post="RNA expression was quantitated by qRT-PCR using NS5 gene-specific"/>
   <result pre="positive control in immunoblotting. (C) For the measurement of infectious" exact="ZIKV" post="production into cell supernatants, cells were infected with low"/>
   <result pre="different blood donors. In order to evaluate the capability of" exact="ZIKV" post="strains to replicate and produce new progeny viruses, we"/>
   <result pre="progeny viruses, we challenged the cells with low doses of" exact="ZIKV" post="GWUH and #976 viruses (MOI 0.2, 1 or 5"/>
   <result pre="to 105/ml (Fig. 2C). In macrophages, instead, the productivity of" exact="ZIKV" post="infection was less efficient and secreted virus titers remained"/>
   <result pre="2C). Even though there were differences in the replication of" exact="ZIKV" post="in cells obtained from different blood donors, ZIKV was"/>
   <result pre="replication of ZIKV in cells obtained from different blood donors," exact="ZIKV" post="was able to replicate both in DCs and macrophages."/>
   <result pre="both in DCs and macrophages. However, clearly detectable increases in" exact="ZIKV" post="production was only seen in DCs (Fig. 2). Activation"/>
   <result pre="in ZIKV-infected human DCs and macrophages Since the Asian lineage" exact="ZIKV" post="GWUH appeared to grow well in DCs but inefficiently"/>
   <result pre="in DCs but inefficiently in macrophages, and the African lineage" exact="ZIKV" post="#976 showed weak replication in both cell types, we"/>
   <result pre="(Fig. 3). In macrophages, instead, the infection with the African" exact="ZIKV" post="#976 strain led to somewhat higher IFN-λ1, IFN-β and"/>
   <result pre="human DCs and macrophages infected with Asian and African lineage" exact="ZIKV" post="strains. Human monocyte-derived DCs or macrophages obtained from four"/>
   <result pre="GWUH strain (Asian lineage) or with an African lineage #976" exact="ZIKV" post="strain at MOI of 75 TCID50/cell. The cells were"/>
   <result pre="the secreted levels of IFNs were in good agreement with" exact="Zika" post="virus replication and virus-induced cytokine mRNA levels in different"/>
   <result pre="DCs and macrophages Since both the Asian and African lineage" exact="Zika" post="viruses induced cytokine gene expression in human DCs and"/>
   <result pre="level of phosphorylation of IRF3 and STAT2 in response to" exact="ZIKV" post="infection. In addition, the expression of IRF3, STAT2 and"/>
   <result pre="phospho-STAT2 (P-STAT2) and an enhanced expression of STAT2, MxA and" exact="ZIKV" post="NS5 proteins. In DCs the African #976 ZIKV strain"/>
   <result pre="MxA and ZIKV NS5 proteins. In DCs the African #976" exact="ZIKV" post="strain was also able to induce the phosphorylation of"/>
   <result pre="no P-IRF3 was detectable. The expression of STAT2, MxA and" exact="ZIKV" post="NS5 protein was enhanced starting at 24 h after infection"/>
   <result pre="DCs and (B) macrophages were infected with GWUH or #976" exact="ZIKV" post="strains at a MOI of 75 TCID50/cell and the"/>
   <result pre="were analyzed by immunoblotting using specific antibodies. The expression of" exact="ZIKV" post="NS5 protein was analyzed for visualizing the virus replication"/>
   <result pre="for visualizing the virus replication with ZIKV-infected DCs and macrophages." exact="ZIKV" post="infected (GWUH) Vero E6 cell lysate functioned as a"/>
   <result pre="some IFN production took place in macrophages in response to" exact="ZIKV" post="infection (Fig. 5B). It was of interest that some"/>
   <result pre="due to residual amounts of IFNs in Vero E6 cell-produced" exact="ZIKV" post="stocks, albeit Vero cells are considered to be IFN-deficient24."/>
   <result pre="Indeed, some IFN-λ1 (&amp;lt;100 pg/ml) was detectable by IFN-specific EIA in" exact="ZIKV" post="stocks. In most experiments the stocks were diluted to"/>
   <result pre="STAT2 phosphorylation did not take place (Fig. 5). Characterization of" exact="ZIKV" post="infection and activation of innate immunity induced by Asian"/>
   <result pre="ZIKV infection and activation of innate immunity induced by Asian" exact="ZIKV" post="strains of different origin Next we compared the ability"/>
   <result pre="Next we compared the ability of two recent Asian lineage" exact="ZIKV" post="isolates, the fetal brain isolate GWUH and HPF, a"/>
   <result pre="isolation of total cellular RNA and qRT-PCR analysis to quantitate" exact="ZIKV" post="RNA expression. Due to a considerable variability between the"/>
   <result pre="general view of the infection kinetics. In DCs, both Asian" exact="Zika" post="virus strains appeared to replicate with a similar efficacy"/>
   <result pre="DCs (Fig. 6A). The data clearly shows that, albeit both" exact="ZIKV" post="strains are able to infect both human DCs and"/>
   <result pre="virus replication is better in DCs. Figure 6 Expression of" exact="ZIKV" post="RNA and host innate immune genes in human DCs"/>
   <result pre="human DCs and macrophages infected with two recent Asian lineage" exact="ZIKV" post="strains. Differentiated DCs and macrophages from four independent blood"/>
   <result pre="and total cellular RNA was extracted and qRT-PCR analysis for" exact="ZIKV" post="RNA (using NS5 gene as a target) was carried"/>
   <result pre="individual experiments (altogether n = 8). Since the two analysed Asian lineage" exact="ZIKV" post="strains appeared to replicate equally well in DCs and"/>
   <result pre="undetectable levels with both Asian lineage viruses (data not shown)." exact="ZIKV" post="is highly sensitive to the antiviral actions of type"/>
   <result pre="Next, we addressed the question whether the recent Asian lineage" exact="Zika" post="viruses are sensitive to the antiviral effects of type"/>
   <result pre="with 10 or 100 IU/ml followed by infection with GWUH" exact="ZIKV" post="(MOI 2). At 24, 48 and 72 h after the"/>
   <result pre="infection cells were collected, total cellular RNA was isolated and" exact="ZIKV" post="RNA expression was analyzed by qRT-PCR. Pretreatment with as"/>
   <result pre="10 IU/ml of IFN-β led to almost complete inhibition of" exact="ZIKV" post="replication in DCs (Fig. 7A). In macrophages, ZIKV replication"/>
   <result pre="inhibition of ZIKV replication in DCs (Fig. 7A). In macrophages," exact="ZIKV" post="replication was also dramatically reduced by IFN-β pretreatment even"/>
   <result pre="line A54917,18,26, in our primary immune cell models the epidemic" exact="ZIKV" post="was highly sensitive to the antiviral actions of type"/>
   <result pre="to the antiviral actions of type I IFNs. Figure 7" exact="ZIKV" post="is highly sensitive to the antiviral activity of type"/>
   <result pre="or 100 IU/ml) for 16 h followed by infection with the" exact="ZIKV" post="GWUH strain (MOI 2). Cells were collected at different"/>
   <result pre="KO) mouse were infected with GWUH or HPF strains of" exact="ZIKV" post="at MOI of 2 and cells were harvested at"/>
   <result pre="were productively infected by the Asian lineage GWUH or HPF" exact="Zika" post="viruses and the expression of ZIKV RNA, as analyzed"/>
   <result pre="lineage GWUH or HPF Zika viruses and the expression of" exact="ZIKV" post="RNA, as analyzed by qRT-PCR, was very high in"/>
   <result pre="IFNs in restricting the infection in cell culture. Discussion The" exact="ZIKV" post="epidemic in the Americas and its association with congenital"/>
   <result pre="like microcephaly raised a global infection alert. The characterization of" exact="ZIKV" post="infection and the immune regulation induced by the infection"/>
   <result pre="present study, we have demonstrated that virus strains from different" exact="ZIKV" post="lineages show differential replication capacity and ability to induce"/>
   <result pre="observed a productive infection in DCs with a recent epidemic" exact="ZIKV" post="strain, while virus replication remained at a very low"/>
   <result pre="observed marked MxA expression in macrophages infected with the Asian" exact="Zika" post="virus strain. However, both cell types were as permissive"/>
   <result pre="primary human immune cells. The reports of human infections with" exact="ZIKV" post="remained sporadic until the outbreak in Yap Island in"/>
   <result pre="that humans must have served as the amplification host for" exact="ZIKV" post="during that epidemic28. The possibility that birds could transfer"/>
   <result pre="distances is still unclear29. Also, the neurotropic clinical picture of" exact="ZIKV" post="infection suggests that the increased pathogenicity may, at least"/>
   <result pre="show that this cell model is permissive to a recent" exact="ZIKV" post="strain (PRVABC59)32,33. Moreover, Khaibouillina and co-workers compared the infectivity"/>
   <result pre="with us, a higher susceptibility of macrophages to the African" exact="ZIKV" post="strain32. In DCs, Bowen and co-workers observed a faster"/>
   <result pre="and co-workers although they showed reduced IFN secretion suggesting that" exact="ZIKV" post="could block the translation of IFN mRNAs but yet"/>
   <result pre="antiviral response. Our data rather points to that direction since" exact="ZIKV" post="induced IFN gene expression at a much lower level"/>
   <result pre="be difficult. Collectively, the published and our data indicate that" exact="ZIKV" post="is able to induce IFN and IFN-induced antiviral gene"/>
   <result pre="expression in human immune cells, but the recent Asian-American lineage" exact="ZIKV" post="strains have evolved to show restricted replication in human"/>
   <result pre="show restricted replication in human macrophages. Given that the maternal" exact="ZIKV" post="infection can be transmitted vertically to the developing fetus4,5,"/>
   <result pre="studies have thus focused on identifying the target cells of" exact="ZIKV" post="infection in the placenta and the uterus. Several placental"/>
   <result pre="placental cell types have been shown to be permissive to" exact="ZIKV" post="infection, including placental fibroblast, human umbilical vein endothelial cells"/>
   <result pre="placental macrophages showed a more productive infection with recent epidemic" exact="ZIKV" post="strains compared with the placental trophoblasts35, which have been"/>
   <result pre="placental trophoblasts35, which have been postulated to transmit resistance to" exact="ZIKV" post="infection both in an autocrine and paracrine manner by"/>
   <result pre="in epithelial/endothelial-immune cell barrier against several human viral pathogens, including" exact="Dengue" post="virus37, influenza A virus38, as well as other viruses"/>
   <result pre="that human blood monocyte-derived macrophages can be infected with recent" exact="ZIKV" post="isolates, even though the level of virus replication and"/>
   <result pre="showed that placental macrophages were highly permissive to the epidemic" exact="ZIKV" post="strains which induced the production of IFNs35. In addition,"/>
   <result pre="co-workers shows that during pregnancy, the primary target cells for" exact="ZIKV" post="infection in in vitro whole blood cell infection are"/>
   <result pre="monocytes41. Furthermore, the same authors demonstrated that an Asian lineage" exact="ZIKV" post="infection promoted the differentiation of non-classical M2-type, IL-10-expressing immunosuppressive"/>
   <result pre="inhibiting the IFN pathway. However, the infection with an African" exact="ZIKV" post="strain led to monocyte differentiation to M1-type inflammatory responses"/>
   <result pre="but innate immunity was more weakly induced by the Asian" exact="ZIKV" post="strain (Fig. 3). These findings may provide insights into"/>
   <result pre="insights into immunological differences between early African and recent Asian-American" exact="ZIKV" post="strains which may be associated with increased frequency of"/>
   <result pre="infections. There is evidence that the primary target cells of" exact="ZIKV" post="infection, skin fibroblasts and DCs are highly permissive to"/>
   <result pre="the infection induces only weak immune responses16–18. This suggests that" exact="ZIKV" post="must have efficient ways to antagonize virus-induced IFN signaling."/>
   <result pre="from many groups have postulated different molecular mechanisms by which" exact="ZIKV" post="evades host’s IFN-mediated antiviral protection during the infection. The"/>
   <result pre="protection during the infection. The most convincing evidence is that" exact="ZIKV" post="NS5 is interfering with IFN signaling by inducing the"/>
   <result pre="proteasomal degradation of STAT2 in human cell lines42–44. In productive" exact="ZIKV" post="infection, STAT2 degradation has been shown to occur in"/>
   <result pre="increase in STAT2 levels together with other IFN-stimulated genes during" exact="ZIKV" post="infection17. However, they reported a significant inhibition of STAT1"/>
   <result pre="IFN-induced MxA expression in DCs, which was likely due to" exact="ZIKV" post="induced type I and type III IFNs at late"/>
   <result pre="was observed (Fig. 5A), suggesting that in primary human DCs" exact="ZIKV" post="infection is leading to down-regulation of STAT signaling. The"/>
   <result pre="STAT signaling. The role of STAT2 in the pathogenesis of" exact="ZIKV" post="has now been proven also with STAT2 knock-out mouse"/>
   <result pre="IRF3 and STAT2 degradation in macrophages at early times of" exact="ZIKV" post="infection. This degradation was evident for both African and"/>
   <result pre="the activation of phagocytosis of the virus and phagolysosome activation." exact="ZIKV" post="NS5 has been associated with proteasomal degradation of STAT2,"/>
   <result pre="and STAT2 in macrophages took place at early hours of" exact="ZIKV" post="infection, clearly before viral protein expression occurred (Fig. 5B)."/>
   <result pre="protein expression occurred (Fig. 5B). This suggests, that during the" exact="ZIKV" post="entry process, the virus is likely activating the host"/>
   <result pre="could provide insights into a completely new evasion strategy of" exact="ZIKV" post="where the early events of ZIKV entry trigger the"/>
   <result pre="new evasion strategy of ZIKV where the early events of" exact="ZIKV" post="entry trigger the degradation of innate signaling molecules. Other"/>
   <result pre="of inhibiting the signal transduction by non-structural proteins. For instance," exact="Dengue" post="and Tick-borne encephalitis viruses have been shown to use"/>
   <result pre="degradation of host signaling molecules during the early phases of" exact="ZIKV" post="infection in human macrophages. An early degradation of IRF3"/>
   <result pre="regulating pathogen recognition could lead to impaired IFN responses during" exact="ZIKV" post="infection. In addition of blocking IFN signaling via NS5-mediated"/>
   <result pre="suggesting another evasion strategy for ZIKV. With promoter-reporter assays some" exact="ZIKV" post="proteins, especially that of NS5 have been associated with"/>
   <result pre="TBK1 and IRF349. Thus, the exact molecular mechanisms by which" exact="ZIKV" post="is interfering with IFN induction and IFN signaling still"/>
   <result pre="needs further analysis in order to understand the pathogenicity of" exact="ZIKV" post="and identifying the targets for therapeutic interventions in severe"/>
   <result pre="ZIKV and identifying the targets for therapeutic interventions in severe" exact="ZIKV" post="infections. In summary, we show here that recent epidemic"/>
   <result pre="ZIKV infections. In summary, we show here that recent epidemic" exact="Zika" post="virus strains replicate very well in human DCs with"/>
   <result pre="innate immune responses. The infection rate of a historical African" exact="ZIKV" post="strain, instead, remains low in both human DCs and"/>
   <result pre="responses in these cells. In conclusion, our findings indicates that" exact="ZIKV" post="evolution has led to cell-type specific differences in the"/>
   <result pre="2mM L-glutamine, 20 mM HEPES and 10% FCS. Viruses and infections" exact="Zika" post="virus strain ZIKV-FB-GWUH-2016 (GenBank number KU870645) was isolated from"/>
   <result pre="and colleagues5, and it is a member of an Asian" exact="ZIKV" post="genotype. Another recent Asian lineage Zika virus strain ZIKV-H-PF-2013"/>
   <result pre="member of an Asian ZIKV genotype. Another recent Asian lineage" exact="Zika" post="virus strain ZIKV-H-PF-2013 (GenBank number KJ776791.2), originally a clinical"/>
   <result pre="from the European Virus Archive goes global (EVAg, Ref: 007V-EVAg1585)." exact="ZIKV" post="strains #976 was isolated in baby mouse brain in"/>
   <result pre="Vero E6 cells 3 times before preparing virus stocks. All" exact="Zika" post="virus strains were obtained as Vero E6 cultures and"/>
   <result pre="DCs and macrophages and immortalized MEFs were infected with indicated" exact="ZIKV" post="strains at different MOI values (based on TCID50 Vero"/>
   <result pre="IU/ml cencentrations to pretreat DCs or macrophages for 16 h before" exact="ZIKV" post="infection. Infective Zika viruses were handled strictly under Biosafety"/>
   <result pre="pretreat DCs or macrophages for 16 h before ZIKV infection. Infective" exact="Zika" post="viruses were handled strictly under Biosafety Level (BSL) 3"/>
   <result pre="Finland. End-point dilution assay For determining the viral titers from" exact="ZIKV" post="samples Vero E6 cells were cultured in 96-well plates."/>
   <result pre="the detection limit for the assay was 0.499. Antibodies against" exact="ZIKV" post="NS3 or NS5 protein Synthetic ZIKV NS3 or NS5"/>
   <result pre="was 0.499. Antibodies against ZIKV NS3 or NS5 protein Synthetic" exact="ZIKV" post="NS3 or NS5 genes were ordered from GenArt (Thermo"/>
   <result pre="genes were ordered from GenArt (Thermo Fisher Scientific), based on" exact="ZIKV" post="GWUH sequence. The coding sequence was cloned into a"/>
   <result pre="to produce GST-NS3 or GST-NS5 expressing baculoviruses. For producing recombinant" exact="ZIKV" post="proteins Sf9 cells were infected with GST-NS3 or GST-NS5"/>
   <result pre="or GST-NS5 expressing baculoviruses for 42 h. Cells were collected, and" exact="ZIKV" post="GST-NS3 or GST-NS5 were purified by glutathione Sepharose affinity"/>
   <result pre="previously described53. The rabbit or guinea pig polyclonal antibodies against" exact="ZIKV" post="NS3 or NS5 antigens were prepared by immunizing the"/>
   <result pre="were grown on glass coverslips for 24 h and infected with" exact="ZIKV" post="as indicated in the figure legends. After infection, the"/>
   <result pre="Universal PCR Mastermix and Gene Expression Assays (Applied Biosystems). The" exact="ZIKV" post="NS5 specific qRT-PCR primers used were modified from Faye"/>
   <result pre="IRF3 and MxA were as previously described21,22 and antibodies against" exact="ZIKV" post="NS5 were prepared as described above. The staining was"/>
   <result pre="Federated States of MicronesiaN. Engl. J. Med.20093602536254310.1056/NEJMoa080571519516034 2.CauchemezSet al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–15: a retrospective"/>
   <result pre="with MicrocephalyN. Engl. J. Med.201637495195810.1056/NEJMoa160065126862926 5.Driggers, R. W. et al." exact="Zika" post="Virus Infection with Prolonged Maternal Viremia and Fetal Brain"/>
   <result pre="and serological specificityTrans R Soc Trop Med Hyg19524650952010.1016/0035-9203(52)90042-412995440 9.MarchetteNJGarciaRRudnickAIsolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm. J. Trop."/>
   <result pre="pacific, 2013Emerg. Infect. Dis.2014201085108610.3201/eid2006.14013824856001 11.BogochIIet al.Anticipating the international spread of" exact="Zika" post="virus from BrazilLancet201638733533610.1016/S0140-6736(16)00080-526777915 12.CamposGSBandeiraACSardiSIZika Virus Outbreak, Bahia, BrazilEmerg. Infect."/>
   <result pre="12.CamposGSBandeiraACSardiSIZika Virus Outbreak, Bahia, BrazilEmerg. Infect. Dis.2015211885188610.3201/eid2110.15084726401719 13.LanciottiRSLambertAJHolodniyMSaavedraSSignor LdelCPhylogeny of" exact="Zika" post="Virus in Western Hemisphere, 2015Emerg. Infect. Dis.20162293393510.3201/eid2205.16006527088323 14.PaluckaKBanchereauJHow dendritic"/>
   <result pre="of human dendritic cells by African and Asian strains of" exact="Zika" post="virusScientific Reports2018811210.1038/s41598-018-23734-329311619 17.BowenJRet al.Zika Virus Antagonizes Type I Interferon"/>
   <result pre="during Infection of Human Dendritic CellsPLoS Pathog.201713e100616410.1371/journal.ppat.100616428152048 18.HamelRet al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJournal of virology2015898880889610.1128/JVI.00354-1526085147 19.ShenJet"/>
   <result pre="cellular activation responses to the flavivirus West NileImmunology1995842542647751002 20.JessieKFongMYDeviSLamSKWongKTLocalization of" exact="Dengue" post="Virus in Naturally Infected Human Tissues, by Immunohistochemistry and"/>
   <result pre="in human macrophagesVirology200027613814710.1006/viro.2000.054211022002 26.FrumenceEet al.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="IFN-β production and apoptosis inductionVirology201649321722610.1016/j.virol.2016.03.00627060565 27.LazearHMet al.A Mouse Model of" exact="Zika" post="Virus PathogenesisCell. Host Microbe20161972073010.1016/j.chom.2016.03.01027066744 28.VorouRZika virus, vectors, reservoirs, amplifying"/>
   <result pre="Medicine &amp;amp; Parasitology19837713113710.1080/00034983.1983.118116876309104 30.KuivanenSet al.Differences in the growth properties of" exact="Zika" post="virus foetal brain isolate and related epidemic strains in"/>
   <result pre="epidemic strains in vitroJ. Gen. Virol.2017981744174810.1099/jgv.0.00085728699857 31.HaddowADet al.Genetic characterization of" exact="Zika" post="virus strains: geographic expansion of the Asian lineagePLoS neglected"/>
   <result pre="D. P., Maharaj, P. N., Shi, P.-Y. &amp;amp; Verma, S." exact="Zika" post="Virus Infects Human Sertoli Cells and Modulates the Integrity"/>
   <result pre="III Interferons Produced by Human Placental Trophoblasts Confer Protection against" exact="Zika" post="Virus InfectionCell. Host Microbe20161970571210.1016/j.chom.2016.03.00827066743 37.Palma-OcampoHKet al.Interferon lambda inhibits dengue"/>
   <result pre="defense system that restricts enteric virus infectionsPLoS pathogens201511e100478210.1371/journal.ppat.100478225849543 41.FooSSet al.Asian" exact="Zika" post="virus strains target CD14(+) blood monocytes and induce M2-skewed"/>
   <result pre="44.Hertzog, J. et al. Infection with a Brazilian isolate of" exact="Zika" post="virus generates RIG-I stimulatory RNA and the viral NS5"/>
   <result pre="induction and signaling. Eur. J. Immunol (2018). 45.TripathiSet al.A novel" exact="Zika" post="virus mouse model reveals strain specific differences in virus"/>
   <result pre="system 03J. Virol. Methods2017242354510.1016/j.jviromet.2016.12.01428025125 54.FayeOet al.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught mosquitoesVirol. J.20131031110.1186/1743-422X-10-31124148652"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6827708\results\search\tropicalVirus\results.xml">
   <result pre=": Infectious Disease: Internal Medicine: Neurology Falling for a Diagnosis:" exact="West Nile" post="Myelitis without Encephalitis MuacevicAlexanderAdlerJohn R ChanVincent1MinalyanArtem1OttmanPatrick1RazaAhmad1TewaryAnubha1[1], Vincent Chan vincent.chan@jefferson.edu"/>
   <result pre="been implicated in poliomyelitis-like syndromes since the elimination of poliovirus." exact="West Nile" post="virus (WNV), since its westward migration in 1999, has"/>
   <result pre="a subsequent fall, without any symptoms of encephalitis, diagnosed with" exact="WNV" post="infection. west nile virus encephalitis viral fever west nile"/>
   <result pre="a considerable manner in the Western world in recent years." exact="West Nile" post="virus (WNV), belonging to the flavivirus genus, has recently"/>
   <result pre="including blood, CSF, and urine were negative for significant growth." exact="WNV" post="IgM serology returned positive during this period, with a"/>
   <result pre="positivity with IgG negativity. The patient was subsequently diagnosed with" exact="West Nile" post="myelitis based on clinical presentation, CSF, and serology. The"/>
   <result pre="caused by other viruses in the enterovirus genus, such as" exact="West Nile" post="virus (WNV), herpes zoster virus, or rabies virus [3-6]."/>
   <result pre="peripheral nerves and involvement of the central nervous system [7]." exact="WNV" post="belongs to the flavivirus genus and was first isolated"/>
   <result pre="breast milk [8]. Up to 80% of patients who contract" exact="WNV" post="can be asymptotic. A minority of patients develop West"/>
   <result pre="contract WNV can be asymptotic. A minority of patients develop" exact="West Nile" post="fever, which is accompanied by fever, fatigue, body aches,"/>
   <result pre="neuroinvasive diseases. This devastating complication can include encephalitis, meningitis, and/or" exact="West Nile" post="myelitis with symptoms consisting of high fever, headache, neck"/>
   <result pre="titers in CSF [11]. Up to 75% of cases of" exact="WNV" post="myelitis present with encephalitis, which was not present in"/>
   <result pre="in our patient [12]. Pathogenically, it presents similarly to poliomyelitis." exact="WNV" post="myelitis uniquely presents with asymmetric areflexic or hyporeflexic weakness"/>
   <result pre="response. These findings are consistent with anterior horn demyelination, and" exact="WNV" post="almost exclusively involves the anterior horn. Thus, these findings"/>
   <result pre="symptoms differs with GBS, occurring weeks after an acute infection." exact="West Nile" post="myelitis occurs more frequently during the acute infection. Fever"/>
   <result pre="the acute infection. Fever and leukocytosis are commonly present in" exact="West Nile" post="myelitis, while in GBS it is not. The distribution"/>
   <result pre="in GBS and asymmetrical paralysis and sometimes monoplegia evident in" exact="West Nile" post="myelitis. Bowel and bladder dysregulation are also commonly seen"/>
   <result pre="myelitis. Bowel and bladder dysregulation are also commonly seen in" exact="West Nile" post="myelitis, while in GBS it is usually not. As"/>
   <result pre="while in GBS it is usually not. As previously stated," exact="West Nile" post="myelitis often causes encephalopathy, which is not seen in"/>
   <result pre="encephalopathy, which is not seen in GBS. Electrodiagnostic studies in" exact="West Nile" post="myelitis show significantly decreased or absent motor function from"/>
   <result pre="the CSF can show both conditions having elevated protein, but" exact="West Nile" post="myelitis can have a pleocytosis while GBS does not"/>
   <result pre="supportive care [15]. The prognosis of neurological manifestations associated with" exact="WNV" post="infections depends primarily on the type and location of"/>
   <result pre="the resources aimed at improving motor recovery in patients with" exact="WNV" post="infection (physical therapy, occupation therapy) is crucial in providing"/>
   <result pre="this case demonstrates the need to have clinical suspicion for" exact="WNV" post="in patients presenting with fevers and acute flaccid paralysis,"/>
   <result pre="occur from other viral illnesses. We presented a case of" exact="West Nile" post="myelitis presenting with symptoms similar to poliomyelitis. This case"/>
   <result pre="demonstrates the need for doctors to have clinical suspicion for" exact="WNV" post="in patients presenting with fever and acute flaccid paralysis"/>
   <result pre="paralysisJ DermatolAkiyamaN25225727200010824489 7Paralytic rabies: a clinico-pathological studyBrainChopraJSBanerjeeAKMurthyJMPalSR78980210319807437890 8World Health Organization" exact="West Nile" post="virus102019World HealthOrganization2017https://www.who.int/news-room/fact-sheets/detail/west-nile-virus 9West Nile virusLancet NeurolKramerLDLiJShiPY1711816200717239804 10Neuromuscular manifestations of"/>
   <result pre="Nile virus102019World HealthOrganization2017https://www.who.int/news-room/fact-sheets/detail/west-nile-virus 9West Nile virusLancet NeurolKramerLDLiJShiPY1711816200717239804 10Neuromuscular manifestations of" exact="West Nile" post="virus infectionFront Neurol102019LeisAAStokicDS373201222461779 11West Nile virus myelitisSpinal CordOhryAKarpinHYoeliDLazariALermanY66266339200111781865 12West"/>
   <result pre="al.10211027112005 15Infections of the nervous systemAm J MedLevinSNLyonsJL2532131201828889928 16Prognosis after" exact="West Nile" post="virus InfectionAnn Intern MedLoebMHannaSNicolleLet al.232241149200818711153 17Neurologic complications of West"/>
   <result pre="West Nile virus InfectionAnn Intern MedLoebMHannaSNicolleLet al.232241149200818711153 17Neurologic complications of" exact="West Nile" post="virus102019LaraJehiCathyA2009http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/neurologic-complications-west-nile-virus/#top 18Prognosis of West Nile virus associated acute flaccid"/>
   <result pre="MedLoebMHannaSNicolleLet al.232241149200818711153 17Neurologic complications of West Nile virus102019LaraJehiCathyA2009http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/neurologic-complications-west-nile-virus/#top 18Prognosis of" exact="West Nile" post="virus associated acute flaccid paralysis: a case seriesJ Med"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832137\results\search\tropicalVirus\results.xml">
   <result pre="viruses, such as hepatitis C virus (HCV), dengue virus (DENV)," exact="Zika" post="virus (ZIKV), human immunodeficiency virus (HIV), and influenza virus"/>
   <result pre="of the Flaviviridae family of viruses that encompass dengue virus," exact="West Nile" post="virus, and Zika virus. HCV is an enveloped virus"/>
   <result pre="of viruses that encompass dengue virus, West Nile virus, and" exact="Zika" post="virus. HCV is an enveloped virus with a positive-stranded"/>
   <result pre="of the HCV replication platform. 3. Flavivirus Propagation and Sphingolipids" exact="Dengue" post="virus (DENV), West Nile virus (WNV), and Zika virus"/>
   <result pre="replication platform. 3. Flavivirus Propagation and Sphingolipids Dengue virus (DENV)," exact="West Nile" post="virus (WNV), and Zika virus (ZIKV) are archetype flaviviruses"/>
   <result pre="and Sphingolipids Dengue virus (DENV), West Nile virus (WNV), and" exact="Zika" post="virus (ZIKV) are archetype flaviviruses transmitted by mosquitoes, mainly"/>
   <result pre="aegypti and Aedes albopictus. According to the world health organization," exact="DENV" post="is responsible for 50–100 million infections each year with"/>
   <result pre="flu-like symptoms and major complications, including deadly dengue hemorrhagic fever." exact="WNV" post="causes flu-like symptoms, neuroinvasive disease, and death in many"/>
   <result pre="neuroinvasive disease, and death in many countries in the world." exact="WNV" post="was first introduced in the United States (US) in"/>
   <result pre="for many deaths in birds, humans and horses. By contrast," exact="ZIKV" post="only emerged as a global health concern since 2016,"/>
   <result pre="adults [27,43]. Like hepatitis C virus (HCV), DENV, WNV, and" exact="ZIKV" post="are enveloped viruses. Unlike HCV, the positive-stranded RNA genome"/>
   <result pre="specific antiviral treatments are currently available for DENV, WNV, or" exact="ZIKV" post="infection. 3.1. DENV Propagation and Sphingolipids There is evidence"/>
   <result pre="are currently available for DENV, WNV, or ZIKV infection. 3.1." exact="DENV" post="Propagation and Sphingolipids There is evidence that sphingolipids and"/>
   <result pre="also required for the replication of some flaviviruses. For example," exact="DENV" post="has been reported to upregulate the expression of sphingolipids"/>
   <result pre="study did not directly address the role of sphingolipids in" exact="DENV" post="replication. In a different study, Wang et al. [47]"/>
   <result pre="(GM95) to demonstrate that the glycosphingolipid GM3 is required for" exact="DENV" post="genome replication. The authors found higher levels of GM3"/>
   <result pre="in DENV-infected cells and relocalization of GM3 to sites where" exact="DENV" post="replicates its genome. Importantly, the authors found that inhibition"/>
   <result pre="DENV-infected mice [47]. While the exact role of GM3 in" exact="DENV" post="genome replication is currently unknown, these in vivo findings"/>
   <result pre="can serve as a foundation for new antiviral therapy. 3.2." exact="WNV" post="Propagation and Sphingolipids 3.2.1. Sphingolipids and WNV Entry and"/>
   <result pre="antiviral therapy. 3.2. WNV Propagation and Sphingolipids 3.2.1. Sphingolipids and" exact="WNV" post="Entry and Genome Replication The role of sphingomyelin in"/>
   <result pre="WNV Entry and Genome Replication The role of sphingomyelin in" exact="WNV" post="replication is well documented. A study by Martin-Acebes and"/>
   <result pre="documented. A study by Martin-Acebes and colleagues [48] showed that" exact="WNV" post="replicates at a much higher level in mice deficient"/>
   <result pre="their wild type controls. This suggested that sphingomyelin accumulation enhances" exact="WNV" post="infectivity. Consistent with these findings, adding sphingomyelin to infected"/>
   <result pre="these findings, adding sphingomyelin to infected fibroblast cells markedly increased" exact="WNV" post="infectivity. Further analysis showed that sphingomyelin colocalizes with WNV"/>
   <result pre="increased WNV infectivity. Further analysis showed that sphingomyelin colocalizes with" exact="WNV" post="dsRNA at cytoplasmic foci, implying that sphingomyelin plays a"/>
   <result pre="that sphingomyelin plays a role in the formation of the" exact="WNV" post="replication platform [48]. Interestingly, pharmacological inhibitors of sphingomyelin synthesis"/>
   <result pre="sphingomyelin synthesis (DS609 and SPK-601) markedly reduced the infectivity of" exact="WNV" post="released from infected cells, but had little impact on"/>
   <result pre="[48]. These findings imply that sphingomyelin is also required for" exact="WNV" post="attachment, internalization, and/or virus–endosome fusion. 3.2.2. Sphingolipids and WNV"/>
   <result pre="for WNV attachment, internalization, and/or virus–endosome fusion. 3.2.2. Sphingolipids and" exact="WNV" post="Particle Formation In an earlier report, Martin-Acebes and colleagues"/>
   <result pre="an earlier report, Martin-Acebes and colleagues [49] also showed that" exact="WNV" post="particles were enriched in sphingomyelin. Surprisingly, pharmacological inhibition of"/>
   <result pre="of neutral sphingomyelinase (converts sphingomyelin into ceramide and phosphorylcholine) reduced" exact="WNV" post="release from infected cells, implying perhaps that ceramide generated"/>
   <result pre="ceramide generated from sphingomyelin catabolism is critical for the infectious" exact="WNV" post="particle. Subsequent analysis showed that inhibition of neutral sphingomyelinase"/>
   <result pre="of neutral sphingomyelinase activity reduces the budding of the immature" exact="WNV" post="particles, a crucial step in infectious WNV particle formation"/>
   <result pre="of the immature WNV particles, a crucial step in infectious" exact="WNV" post="particle formation [49]. While this study appears to be"/>
   <result pre="be at odds with the putative role of sphingomyelin in" exact="WNV" post="entry, it also highlights the role of sphingomyelin in"/>
   <result pre="the role of sphingomyelin in two distinct steps of the" exact="WNV" post="replication cycle. 3.3. ZIKV Replication and Sphingolipids The role"/>
   <result pre="in two distinct steps of the WNV replication cycle. 3.3." exact="ZIKV" post="Replication and Sphingolipids The role of sphingolipids and glycosphingolipids"/>
   <result pre="Replication and Sphingolipids The role of sphingolipids and glycosphingolipids in" exact="ZIKV" post="replication is not well understood. This is crucial because"/>
   <result pre="ZIKV replication is not well understood. This is crucial because" exact="ZIKV" post="patients with Guillain–Barré Syndrome, have elevated levels of antibodies"/>
   <result pre="the need to define the role of glucosylceramide-derived glycosphingolipids in" exact="ZIKV" post="infectivity. Our group has evidence that ZIKV particles are"/>
   <result pre="glucosylceramide-derived glycosphingolipids in ZIKV infectivity. Our group has evidence that" exact="ZIKV" post="particles are enriched in sphingomyelin, ceramide, and glucosylecramide (unpublished"/>
   <result pre="glycosphingolipids leading to gangliosides biosynthesis (Figure 1) are required for" exact="ZIKV" post="particle assembly (unpublished data). Current efforts are focused on"/>
   <result pre="efforts are focused on understanding how sphingolipids and glycosphingolipids regulate" exact="ZIKV" post="infectivity. 4. Human Immunodeficiency Virus’s Propagation and Sphingolipids Human"/>
   <result pre="References References 1.NowakowskiT.J.PollenA.A.Di LulloE.Sandoval-EspinosaC.BershteynM.KriegsteinA.R.Expression Analysis Highlights AXL as a Candidate" exact="Zika" post="Virus Entry Receptor in Neural Stem CellsCell Stem Cell20161859159610.1016/j.stem.2016.03.01227038591"/>
   <result pre="Stem Cell20161859159610.1016/j.stem.2016.03.01227038591 2.RichardA.S.ShimB.-S.KwonY.-C.ZhangR.OtsukaY.SchmittK.BerriF.DiamondM.S.ChoeH.AXL-dependent infection of human fetal endothelial cells distinguishes" exact="Zika" post="virus from other pathogenic flavivirusesProc. Natl. Acad. Sci. USA20171142024202910.1073/pnas.162055811428167751"/>
   <result pre="USA20171142024202910.1073/pnas.162055811428167751 3.MeertensL.CarnecX.LecoinM.P.RamdasiR.Guivel-BenhassineF.LewE.LemkeG.SchwartzO.AmaraA.The TIM and TAM families of phosphatidylserine receptors mediate" exact="Dengue" post="virus entryCell Host Microbe20121254455710.1016/j.chom.2012.08.00923084921 4.AligoJ.JiaS.MannaD.KonanK.V Formation and function of"/>
   <result pre="Natl. Acad. Sci. USA1999969142914710.1073/pnas.96.16.914210430909 27.Cao-LormeauV.-M.BlakeA.MonsS.LastèreS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 28.HulkovaH.LedvinovaJ.KucharL.SmidF.HonzikovaJ.EllederM.Glycosphingolipid"/>
   <result pre="secretory apparatusJ. Virol.2003777843785510.1128/JVI.77.14.7843-7855.200312829824 43.PaploskiI.A.D.PratesA.P.P.B.CardosoC.W.KikutiM.SilvaM.M.O.WallerL.A.ReisM.G.KitronU.RibeiroG.S.Time lags between exanthematous illness attributed to" exact="Zika" post="virus, Guillain-Barré syndrome, and microcephaly, Salvador, BrazilEmerg. Infect. Dis.2016221438144410.3201/eid2208.16049627144515"/>
   <result pre="Cell20161966367110.1016/j.stem.2016.07.01927524440 46.YuanL.HuangX.-Y.LiuZ.-Y.ZhangF.ZhuX.-L.YuJ.-Y.JiX.XuY.-P.LiG.LiC.et al.A single mutation in the prM protein of" exact="Zika" post="virus contributes to fetal microcephalyScience201735893393610.1126/science.aam712028971967 47.WangK.WangJ.SunT.BianG.PanW.FengT.WangP.LiY.DaiJ.Glycosphingolipid GM3 is indispensable"/>
   <result pre="virus contributes to fetal microcephalyScience201735893393610.1126/science.aam712028971967 47.WangK.WangJ.SunT.BianG.PanW.FengT.WangP.LiY.DaiJ.Glycosphingolipid GM3 is indispensable for" exact="Dengue" post="virus genome replicationInt. J. Biol. Sci.20161287288310.7150/ijbs.1564127313500 48.Martín-AcebesM.A.Gabandé-RodríguezE.García-CabreroA.M.SánchezM.P.LedesmaM.D.SobrinoF.SaizJ.-C.Host sphingomyelin increases"/>
   <result pre="Dengue virus genome replicationInt. J. Biol. Sci.20161287288310.7150/ijbs.1564127313500 48.Martín-AcebesM.A.Gabandé-RodríguezE.García-CabreroA.M.SánchezM.P.LedesmaM.D.SobrinoF.SaizJ.-C.Host sphingomyelin increases" exact="West Nile" post="virus infection in vivoJ. Lipid Res.20165742243210.1194/jlr.M06421226764042 49.Martin-AcebesM.A.Merino-RamosT.BlazquezA.-B.CasasJ.Escribano-RomeroE.SobrinoF.SaizJ.-C.The composition of"/>
   <result pre="Nile virus infection in vivoJ. Lipid Res.20165742243210.1194/jlr.M06421226764042 49.Martin-AcebesM.A.Merino-RamosT.BlazquezA.-B.CasasJ.Escribano-RomeroE.SobrinoF.SaizJ.-C.The composition of" exact="West Nile" post="virus lipid envelope unveils a role of sphingolipid metabolism"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832525\results\search\tropicalVirus\results.xml">
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Yellow fever" post="virus (YFV) represents a re-emerging zoonotic pathogen, transmitted by"/>
   <result pre="mosquito vectors to humans from primate reservoirs. Sporadic outbreaks of" exact="YFV" post="occur in endemic tropical regions, causing a viral hemorrhagic"/>
   <result pre="a highly effective vaccine, no antiviral treatments currently exist. Therefore," exact="YFV" post="represents a neglected tropical disease and is chronically understudied,"/>
   <result pre="tropical disease and is chronically understudied, with many aspects of" exact="YFV" post="biology incompletely defined including host range, host–virus interactions and"/>
   <result pre="pathogenicity. In this article, we review the current state of" exact="YFV" post="research, focusing on the viral lifecycle, host responses to"/>
   <result pre="available sequence and structural data to assess global patterns of" exact="YFV" post="sequence diversity and identify potential drug targets. Finally, we"/>
   <result pre="immune response E protein structure re-emerging virus 1. General Introduction" exact="Yellow fever" post="was historically the first described viral hemorrhagic fever (VHF)"/>
   <result pre="subsequent eradication from Europe and North America [1,2,3,4]. However, today," exact="YFV" post="remains prevalent in tropical regions of Africa and South"/>
   <result pre="endemic areas, 500 million of whom reside in Africa [6]." exact="YFV" post="represents a zoonotic pathogen and complete eradication in tropical"/>
   <result pre="vaccination represents one of the core strategies employed to stop" exact="YFV" post="outbreaks or minimize their impact when they do occur"/>
   <result pre="tissue-tropism, pathogenicity and modes of transmission can differ greatly [10]." exact="YFV" post="is a member of the Flavivirus genus, which is"/>
   <result pre="pathogens which can cause acute infections, including dengue virus (DENV)," exact="West Nile" post="virus (WNV), Japanese encephalitis virus (JEV) and Zika virus"/>
   <result pre="(DENV), West Nile virus (WNV), Japanese encephalitis virus (JEV) and" exact="Zika" post="virus (ZIKV) (Figure 1). Transmission is mediated via mosquito"/>
   <result pre="JEV and ZIKV) or fatal hemorrhagic fever (YFV and DENV)." exact="YFV" post="continues to pose a very real threat to public"/>
   <result pre="vaccine production, which can easily be overwhelmed by a large" exact="YFV" post="outbreak, and the collapse of vector control programs [1,14,15],"/>
   <result pre="tissue culture and the availability of reverse genetic systems [19,20,21,22,23,24]," exact="YFV" post="remains a neglected tropical disease attracting relatively little research"/>
   <result pre="and recent commentaries have highlighted the need for intensification of" exact="YFV" post="research, as many facets of the virus life cycle"/>
   <result pre="host-ranges, identification of co-opted host factors which are essential for" exact="YFV" post="propagation in humans and insects, and identification of genetic"/>
   <result pre="humans. 2. Clinical Outcomes and Potential Therapeutic Options Infection with" exact="YFV" post="has a broad spectrum of clinical manifestations ranging from"/>
   <result pre="remain clinically silent [5]. In the majority of symptomatic cases," exact="YFV" post="infection is a self-limiting disease with abrupt onset of"/>
   <result pre="after an incubation period of 3–6 days. In this phase," exact="YFV" post="infection is difficult to diagnose, as symptoms are unspecific."/>
   <result pre="such as DENV, is believed to reduce the severity of" exact="YFV" post="infections [5,32]. Patients who survive the disease may suffer"/>
   <result pre="only current approach to control and prevent the spread of" exact="YFV" post="in endemic regions (see Section 6). Indeed, despite the"/>
   <result pre="Indeed, despite the long history of humankind being afflicted by" exact="YFV" post="and the large populations in tropical Africa and Central"/>
   <result pre="It also has described antiviral activity against the related flaviviruses," exact="ZIKV" post="[34] and DENV [35]. Computer modelling and in vitro"/>
   <result pre="described antiviral activity against the related flaviviruses, ZIKV [34] and" exact="DENV" post="[35]. Computer modelling and in vitro experiments in hepatoma"/>
   <result pre="experiments in hepatoma cell lines demonstrated sofosbuvir’s inhibitory effects on" exact="YFV" post="replication: in a mouse model, sofosbuvir was able to"/>
   <result pre="the case of pre-exposure treatment [36]. A varying efficacy against" exact="YFV" post="has also been demonstrated for other compounds targeting the"/>
   <result pre="apply a benzodiazepine compound (BDAA) in a hamster model of" exact="YFV" post="infection, where it protected 90% of animals from death"/>
   <result pre="interference (RNAi) technology, shRNAs (short hairpin RNAs) targeted at the" exact="YFV" post="E and NS1 regions were effective in inhibiting YFV"/>
   <result pre="the YFV E and NS1 regions were effective in inhibiting" exact="YFV" post="replication in cell lines as well as improving survival"/>
   <result pre="phase�?, but approaches targeting the host’s immune response in severe" exact="YFV" post="disease are lacking. When patients present with severe symptoms,"/>
   <result pre="animal studies and clinical trials. 3. The Replication Cycle of" exact="YFV" post="The replication cycle of YFV is defined by multiple"/>
   <result pre="3. The Replication Cycle of YFV The replication cycle of" exact="YFV" post="is defined by multiple distinct stages, which are shared"/>
   <result pre="processes differ between mosquitos and humans requires further investigation. 3.1." exact="YFV" post="Virion Composition and E Protein Functions The YFV virion"/>
   <result pre="investigation. 3.1. YFV Virion Composition and E Protein Functions The" exact="YFV" post="virion is spherical in shape, with a 40–60 nm"/>
   <result pre="highly basic core protein (C) which binds and encapsidates the" exact="YFV" post="RNA genome [47] and two envelope glycoproteins: prM/M (membrane)"/>
   <result pre="also represent ER retention signals [48]. The E protein of" exact="YFV" post="represents a class II fusion protein, which possesses structural"/>
   <result pre="no obvious amino acid conservation [49]. The E protein facilitates" exact="YFV" post="entry into permissive cells, mediating the interaction between the"/>
   <result pre="cell surface receptors, and also elicits host neutralizing antibody responses." exact="YFV" post="E consists of three domains: DI, DII and DIII"/>
   <result pre="2A, lower panel). DIII harbors epitopes essential for neutralization of" exact="YFV" post="[51,52]. However, antibody repertoire cloning from YFV patients also"/>
   <result pre="for neutralization of YFV [51,52]. However, antibody repertoire cloning from" exact="YFV" post="patients also identified key neutralizing epitope residues in domains"/>
   <result pre="antibody 5A identified in [53] was able to neutralize divergent" exact="YFV" post="strains (YFV-17D and Angola lineage) [54,56]. The mAb 5A"/>
   <result pre="is suggested that mAb 5A interferes at three stages during" exact="YFV" post="infection: (A) by inhibition of virus attachment due to"/>
   <result pre="lower panels). To date, only the structure of the immature" exact="YFV" post="particle has been resolved, with the architecture of mature"/>
   <result pre="cells and determining the global structure of the virion, the" exact="YFV" post="E is essential for infection. Thus, it represents an"/>
   <result pre="limits their widespread application in the resource constrained settings where" exact="YFV" post="epidemics often occur. 3.2. YFV Entry: Implicated Host Factors"/>
   <result pre="the resource constrained settings where YFV epidemics often occur. 3.2." exact="YFV" post="Entry: Implicated Host Factors Out of the three domains"/>
   <result pre="Implicated Host Factors Out of the three domains of the" exact="YFV" post="E protein, DIII is suspected to mediate interaction with"/>
   <result pre="the process. These include CD209 and the mannose receptor for" exact="DENV" post="entry [63,64] and G protein-coupled receptor kinase 6 (GRK6)"/>
   <result pre="entry [63,64] and G protein-coupled receptor kinase 6 (GRK6) for" exact="WNV" post="entry [65]. The related GRK2 was reported to both"/>
   <result pre="entry [65]. The related GRK2 was reported to both promote" exact="YFV" post="entry and enhance viral RNA synthesis, properties which were"/>
   <result pre="which were conserved across key members of the Flaviviridae, including" exact="DENV" post="and HCV [66]. The transmembrane immunoglobulin and mucin domain"/>
   <result pre="Mer) families of phosphatidylserine receptors have been shown to mediate" exact="DENV" post="infection, with TIM-1 and TIM-4 also enhancing infection rates"/>
   <result pre="infection, with TIM-1 and TIM-4 also enhancing infection rates for" exact="WNV" post="and YFV-17D to differing degrees, while herpes simplex virus-1"/>
   <result pre="represent general enhancers of flavivirus infection. Additionally, candidates implicated in" exact="YFV" post="host-cell attachment include heparin sulfate, a member of the"/>
   <result pre="(GAG) family, which also facilitates attachment for the related flaviviruses" exact="DENV" post="[68] and tick-borne encephalitis virus (TBEV) [69], as well"/>
   <result pre="effect of PI-88, a heparin sulfate mimetic, was demonstrated against" exact="DENV" post="and neurotropic flaviviruses [72]. Despite reports of multiple factors"/>
   <result pre="Despite reports of multiple factors which are potentially involved in" exact="YFV" post="entry, it is still unknown whether a ubiquitous cellular"/>
   <result pre="facilitating flavivirus infection of permissive cells [73]. Similarly to DENV," exact="YFV" post="is able to infect a range of cell-types from"/>
   <result pre="[74]. RNAi screening has revealed many potential host factors influencing" exact="WNV" post="or DENV infection of human or drosophila cell-lines [65,75]."/>
   <result pre="screening has revealed many potential host factors influencing WNV or" exact="DENV" post="infection of human or drosophila cell-lines [65,75]. Analogous to"/>
   <result pre="Divergent entry mechanisms have been observed for even closely related" exact="YFV" post="strains. The parental Asibi strain and the derived YFV-17D"/>
   <result pre="spread and attenuation [68,78]. In summary, mechanistic insights into the" exact="YFV" post="infection process, in addition to many host factors implicated"/>
   <result pre="infection process, in addition to many host factors implicated in" exact="YFV" post="entry, have been described. Nevertheless, identification of bona fide"/>
   <result pre="been described. Nevertheless, identification of bona fide receptor(s) integral for" exact="YFV" post="entry remains outstanding. The entry cascade of YFV is"/>
   <result pre="integral for YFV entry remains outstanding. The entry cascade of" exact="YFV" post="is comprised of multiple steps which could be targeted"/>
   <result pre="to ribosomes, are essential for efficient ribosomal translation of the" exact="YFV" post="polyprotein and have panflaviviral activity [82]. The YFV polyprotein"/>
   <result pre="of the YFV polyprotein and have panflaviviral activity [82]. The" exact="YFV" post="polyprotein is post-translationally modified by cellular glycosyltransferases, and the"/>
   <result pre="replication complex [85] which occurs on ER membranes [92]. Indeed," exact="DENV" post="NS3 and NS5 were identified on the virus-induced membrane"/>
   <result pre="a double-stranded complex with the genomic template [97]. Experiments with" exact="DENV" post="demonstrated that the phosphorylation of NS5 controls the interaction"/>
   <result pre="with NS3 [98]. Furthermore, mutation of the phosphorylation site on" exact="YFV" post="NS5 (S56) disrupted the capping process via inhibition of"/>
   <result pre="critical steps of the flavivirus replication cycle are described for" exact="DENV" post="or WNV, but confirmation with YFV is lacking. 4."/>
   <result pre="cycle are described for DENV or WNV, but confirmation with" exact="YFV" post="is lacking. 4. Host Responses to YFV Infection 4.1."/>
   <result pre="but confirmation with YFV is lacking. 4. Host Responses to" exact="YFV" post="Infection 4.1. Cytokine Induction by YFV Using paraffin-embedded liver"/>
   <result pre="4. Host Responses to YFV Infection 4.1. Cytokine Induction by" exact="YFV" post="Using paraffin-embedded liver tissue from patients who succumbed to"/>
   <result pre="Using paraffin-embedded liver tissue from patients who succumbed to fatal" exact="YFV" post="disease, it was demonstrated that CD4+ T cells represent"/>
   <result pre="pro- and anti-inflammatory cytokines is associated with the immunopathology of" exact="YFV" post="infection and responses to YFV-17D vaccination. 4.2. Cellular Responses"/>
   <result pre="infection and responses to YFV-17D vaccination. 4.2. Cellular Responses to" exact="YFV" post="Dendritic cells (DCs) are essential antigen-presenting cells, recognizing pathogens"/>
   <result pre="and cell populations of the innate and adaptive immune system." exact="YFV" post="also was shown to induce the production of IFN-γ"/>
   <result pre="more efficient at stimulating pDCs than mature virions [117]. However," exact="YFV" post="also possesses the ability to antagonize the IFN system."/>
   <result pre="YFV also possesses the ability to antagonize the IFN system." exact="YFV" post="NS5 interacts with STAT2 when STAT1 is phosphorylated during"/>
   <result pre="(MDM) were also shown to be susceptible to infection with" exact="YFV" post="wild-type Asibi and 17D vaccine strains, with differences in"/>
   <result pre="confirming differential patterns of immune induction between attenuated and wild-type" exact="YFV" post="[119]. Natural killer (NK) cells represent an essential component"/>
   <result pre="in YFV-17D infection but not for wild-type virus, indicating that" exact="YFV" post="vaccine attenuation results in increased sensitivity to IFN-γ [121]."/>
   <result pre="cells do not appear to be a major reservoir for" exact="YFV" post="replication [122]. After YFV-17D vaccination, NK expression of TLR3,"/>
   <result pre="I and III IFNs [124]. 4.3. Pattern Recognition Receptors and" exact="YFV" post="In addition to TLRs, the pattern recognition receptors (PRRs)"/>
   <result pre="important roles in restricting flavivirus infections ([127] as reported for" exact="DENV" post="[128], WNV [129] and JEV [130]), interacting with both"/>
   <result pre="in restricting flavivirus infections ([127] as reported for DENV [128]," exact="WNV" post="[129] and JEV [130]), interacting with both MAVS and"/>
   <result pre="genome modifications can prevent RIG-I recognition, with cap1 2′O-methylation of" exact="YFV" post="RNA constituting an RIG-I evasion mechanism [132]. Cyclic GMP-AMP"/>
   <result pre="including flaviviruses: cGAS knockout mice were more susceptible to lethal" exact="WNV" post="infection outcomes when compared to wild-type mice [134], and"/>
   <result pre="WNV infection outcomes when compared to wild-type mice [134], and" exact="DENV" post="is able to target cGAS for degradation via NS2B,"/>
   <result pre="target cGAS for degradation via NS2B, inhibiting IFN production [135,136]." exact="YFV" post="NS4B exhibits strong homology with the C-terminus of STING"/>
   <result pre="human STING can be targeted for cleavage by ZIKV, DENV," exact="WNV" post="and JEV proteases, it is not susceptible to cleavage"/>
   <result pre="alarmin HMGB1 [139]. While inflammasome activation has been reported for" exact="WNV" post="and DENV infection [126], the exact danger signals detected"/>
   <result pre="[139]. While inflammasome activation has been reported for WNV and" exact="DENV" post="infection [126], the exact danger signals detected and its"/>
   <result pre="[126], the exact danger signals detected and its significance in" exact="YFV" post="infection remains unclear. Together these studies implicate RLRs and"/>
   <result pre="implicate RLRs and the cGAS-STING axis as important modulators of" exact="YFV" post="infection, although further investigation is required. Additionally, whether inflammasome"/>
   <result pre="investigation is required. Additionally, whether inflammasome activation is mediated by" exact="YFV" post="replication warrants further study. 4.4. Anti-YFV Effectors The mammalian"/>
   <result pre="demonstrated to confer protection from YFV-mediated cell-death via inhibition of" exact="YFV" post="replication and possesses broad activity against diverse Flaviviridae members"/>
   <result pre="backgrounds [141]. This comprehensive study identified antiviral effectors which inhibited" exact="YFV" post="replication, including IRF1, TREX1, IFITM3, RTP4, IFI6 and HPSE:"/>
   <result pre="genes APOBEC3A, FAM46C, IDO1, LY6E, MCOLN2 and ADAR genes enhanced" exact="YFV" post="replication [141]. More recently, CRISPR/Cas9 knockout genetic screening confirmed"/>
   <result pre="and differential disease outcomes is currently unclear. 5. Tropism of" exact="YFV" post="In humans, after transcutaneous inoculation, YFV exhibits broad patterns"/>
   <result pre="unclear. 5. Tropism of YFV In humans, after transcutaneous inoculation," exact="YFV" post="exhibits broad patterns of tissue tropism and is disseminated"/>
   <result pre="liver, spleen, and less frequently, the brain tissue, can support" exact="YFV" post="replication [18]. The natural host range of YFV includes"/>
   <result pre="can support YFV replication [18]. The natural host range of" exact="YFV" post="includes humans, non-human primates and mosquitos. Additionally, wild animals"/>
   <result pre="for anti-YFV antibodies, and the elicitation of antibody responses against" exact="YFV" post="indicates a potentially productive infection within these species, indicating"/>
   <result pre="within these species, indicating that diverse mammalian species could represent" exact="YFV" post="potential reservoirs [143] (see Section 8.3). Mouse Models for"/>
   <result pre="YFV potential reservoirs [143] (see Section 8.3). Mouse Models for" exact="YFV" post="YFV research is currently limited as it remains challenging"/>
   <result pre="potential reservoirs [143] (see Section 8.3). Mouse Models for YFV" exact="YFV" post="research is currently limited as it remains challenging and"/>
   <result pre="challenging and expensive to establish workflows with non-human primates. While" exact="YFV" post="has a limited host species-tropism, artificial infection of laboratory"/>
   <result pre="in genetically modified or humanized mice have yielded insights into" exact="YFV" post="infection and dissemination in vivo. Single cell-tracking of YFV-17D"/>
   <result pre="cell-tracking of YFV-17D dissemination in different mouse models identified novel" exact="YFV" post="replication reservoirs in secondary lymphoid compartments, with hematopoietic STAT1"/>
   <result pre="[145,146], and these animals represent ideal tools for monitoring systemic" exact="YFV" post="infection in vivo as both compartments are permissive for"/>
   <result pre="both compartments are permissive for YFV. In addition to hepatotropism," exact="YFV" post="can also be neurotropic in rodents, primates and humans"/>
   <result pre="to antagonize IFN signaling and therefore enhance viral replication, the" exact="YFV" post="NS5 is unable to bind murine STAT2 and in"/>
   <result pre="is unable to bind murine STAT2 and in contrast to" exact="ZIKV" post="and DENV, is unable to engage human STAT2 in"/>
   <result pre="STAT2 in murine cells. Murine STAT2 was demonstrated to repress" exact="YFV" post="replication in murine cells, which was correlated with an"/>
   <result pre="ubiquitination [155]. Together, these mouse studies enhance our understanding of" exact="YFV" post="dissemination and host control in vivo. These findings are"/>
   <result pre="specific anti-YFV effectors that directly inhibit differential aspects of the" exact="YFV" post="lifecycle, rather than upstream master-regulators of the antiviral response."/>
   <result pre="the antiviral response. Screening approaches could identify such factors. 6." exact="YFV" post="Vaccine: Development and Limitations Immunization is one of the"/>
   <result pre="are eleven live attenuated vaccines (LAV) and among them, the" exact="YFV" post="vaccine is the oldest and the most potent. As"/>
   <result pre="the most potent. As there are no specific treatments for" exact="YFV" post="infection, vaccination represents the only current protection against the"/>
   <result pre="protection against the disease. 6.1. History and Development of the" exact="YFV" post="Vaccine In the 1920s, two parallel approaches were taken"/>
   <result pre="to develop a live attenuated vaccine against YFV. In 1927," exact="YFV" post="was isolated from a Ghanaian patient suffering from mild"/>
   <result pre="competence, while retaining its immunogenicity [8]. Concurrently, French researchers isolated" exact="YFV" post="from a patient in Dakar, followed by serial passage"/>
   <result pre="The 17D subculture is the seed strain for all modern-day" exact="YFV" post="vaccines. There are three sub-strains obtained from the original"/>
   <result pre="stick injury or inhalation of aerosolized viral droplets [161]. The" exact="YFV" post="vaccine is a freeze-dried live-attenuated virus delivered subcutaneously. It"/>
   <result pre="for other experimental vaccines including HIV-1, Lassa fever, malaria and" exact="DENV" post="[175,176,177,178,179,180]. After early successes in outbreak prevention and control"/>
   <result pre="routine child immunization programs in endemic countries, a reduction of" exact="YFV" post="cases was observed globally [181]. However, when Angola was"/>
   <result pre="urgent need for more than 28 million doses of the" exact="YFV" post="vaccine, exhausting the existing global vaccine supply [182,183,184]. Furthermore,"/>
   <result pre="in a context of depleted global stockpiles, fractional doses of" exact="YFV" post="vaccine were administered. Because promising data were available on"/>
   <result pre="risk of a large-scale epidemic in Asia remains daunting and" exact="YFV" post="is the only infectious disease where an international vaccination"/>
   <result pre="has been evidence of fake/forged certificates [198]. 6.5. Future Directions" exact="Yellow fever" post="is a re-emerging infectious disease, as vector control and"/>
   <result pre="there is a need to manage the potential risk of" exact="YFV" post="introduction to Asia. In the coming decade, vaccine manufacturers"/>
   <result pre="refining of this effective vaccine [183]. 7. Global Diversity of" exact="YFV" post="At the time of writing this review, n ="/>
   <result pre="At the time of writing this review, n = 1112" exact="YFV" post="sequences were deposited on the NCBI GenBank sequence database."/>
   <result pre="NCBI GenBank sequence database. To assess patterns of globally sampled" exact="YFV" post="diversity, we performed phylogenetic analyses of all available YFV"/>
   <result pre="sampled YFV diversity, we performed phylogenetic analyses of all available" exact="YFV" post="full-length ORF sequences (n = 178) (Figure 4a). Collapsed"/>
   <result pre="addition to 17D vaccine strains. Based on this analysis, global" exact="YFV" post="sequences can be divided into six well-supported lineages: West"/>
   <result pre="with South American lineages representing historical import of West African" exact="YFV" post="strains linked to European colonial expansions and the slave"/>
   <result pre="European colonial expansions and the slave trade [2,6,18,219]. While clinical" exact="YFV" post="isolates can be readily propagated in tissue culture, the"/>
   <result pre="Asibi strain, representing only a small fraction of the global" exact="YFV" post="diversity (Figure 4a). Consequently, the phenotypic correlates of YFV"/>
   <result pre="global YFV diversity (Figure 4a). Consequently, the phenotypic correlates of" exact="YFV" post="global sequence diversity are incompletely defined and future studies"/>
   <result pre="it is currently unknown whether infection with isolates from different" exact="YFV" post="lineages contributes to differential pathogenicity or mortality rates in"/>
   <result pre="humans. However, in spite of these deep-divergences apparent in the" exact="YFV" post="phylogeny, the 17D vaccine provides robust protection against strains"/>
   <result pre="17D vaccine provides robust protection against strains from all known" exact="YFV" post="lineages. YFV Genome and Polyprotein Conservation To visualize variability"/>
   <result pre="provides robust protection against strains from all known YFV lineages." exact="YFV" post="Genome and Polyprotein Conservation To visualize variability across YFV"/>
   <result pre="lineages. YFV Genome and Polyprotein Conservation To visualize variability across" exact="YFV" post="genomes and encoded polyproteins, similarity plots were generated from"/>
   <result pre="YFV genomes and encoded polyproteins, similarity plots were generated from" exact="YFV" post="nucleotide and amino acid alignments. Inspection of genetic and"/>
   <result pre="Inspection of genetic and amino acid variability in globally sampled" exact="YFV" post="isolates highlights conserved and variable regions in the genome"/>
   <result pre="in the genome and encoded polyprotein (Figure 4b). Of note," exact="YFV" post="nucleotide variability is much greater than amino acid variability,"/>
   <result pre="acid variability, indicating strong purifying selection shapes global patterns of" exact="YFV" post="evolution. This is likely a reflection of the selective"/>
   <result pre="of the selective constraints imposed by the viral transmission cycle:" exact="YFV" post="experiences sequential bottlenecks upon continued cycling through an insect"/>
   <result pre="host factor compatibility in both vertebrates and arthropods. Furthermore, the" exact="YFV" post="RdRp has a relatively high fidelity for an RNA"/>
   <result pre="analyses indicate that both the structural and non-structural proteins of" exact="YFV" post="exhibit extensive conserved regions which are therefore viable targets"/>
   <result pre="Consequently, the development or repurposing of direct-acting antiviral compounds targeting" exact="YFV" post="proteins should represent an achievable goal. Indeed, it was"/>
   <result pre="amino acid diversity on to the resolved helicase structures for" exact="YFV" post="[221] is presented in Figure 4c, highlighting the conserved"/>
   <result pre="inform rational development of antivirals targeting different components of the" exact="YFV" post="virion or replication machinery. Currently, structural data is only"/>
   <result pre="or replication machinery. Currently, structural data is only available for" exact="YFV" post="E, NS3 and NS5 proteins. The elucidation of structural"/>
   <result pre="NS5 proteins. The elucidation of structural information for the outstanding" exact="YFV" post="proteins will expand the number of potential viral targets"/>
   <result pre="targets for future structure-based antiviral drug design studies. 8. Monitoring" exact="YFV" post="Outbreaks, Disease-Course and Reservoir Species with NGS 8.1. Diagnostic"/>
   <result pre="surveillance in recent years [225]. In Africa and South America," exact="YFV" post="co-circulates with multiple endemic VHFs which can emerge in"/>
   <result pre="Flaviviridae, has been reported [226]. Indeed, using 454 sequencing (Roche)," exact="YFV" post="was identified as the causative agent of an outbreak"/>
   <result pre="[227], validating the diagnostic utility of NGS technologies for discriminating" exact="YFV" post="outbreaks from unrelated hemorrhagic fever viruses. 8.2. Outbreak Monitoring"/>
   <result pre="data in just a few hours [230]. The re-emergence of" exact="YFV" post="as a global health burden has been demonstrated by"/>
   <result pre="to provide insights into the molecular epidemiology of the 2016–2017" exact="YFV" post="outbreak in Brazil, generating data spatially correlating infections of"/>
   <result pre="African outbreaks. While future outbreaks are inevitable, rapid identification of" exact="YFV" post="as the causative agent and subsequent real-time tracking of"/>
   <result pre="patient DNA bio-banking to enable stratification of host-genetic correlates of" exact="YFV" post="infection outcomes, and correlation with host single nucleotide polymorphisms"/>
   <result pre="host genetics underlie the range of clinical symptoms observed in" exact="YFV" post="infection, which include subclinical, symptomatic, severe and fatal outcomes."/>
   <result pre="environmental conditions, including the presence of replication-competent Aedes vector species," exact="YFV" post="outbreaks in Asia remain conspicuously absent. However, import of"/>
   <result pre="YFV outbreaks in Asia remain conspicuously absent. However, import of" exact="YFV" post="from the Angolan outbreak to China was recorded for"/>
   <result pre="Using Illumina sequencing to follow virus evolution in 12 imported" exact="YFV" post="cases revealed the infecting strains were closely related to"/>
   <result pre="[233]. In agreement with these observations, the evolutionary rate of" exact="YFV" post="has been shown to be lower than that of"/>
   <result pre="YFV has been shown to be lower than that of" exact="DENV" post="[234] and the YFV RdRp possesses high fidelity [223]."/>
   <result pre="to be lower than that of DENV [234] and the" exact="YFV" post="RdRp possesses high fidelity [223]. In addition, sequential bottlenecks"/>
   <result pre="with an enhanced capacity for transmission, reducing variation. Constraints on" exact="YFV" post="evolution could also be mediated by the requirement for"/>
   <result pre="infection in human hosts. 8.3. Identification of Novel Animal Reservoirs" exact="YFV" post="represents a zoonotic pathogen: while many zoonotic viruses cause"/>
   <result pre="[235]. After long periods of absence, sporadic and often explosive" exact="YFV" post="outbreaks occur in endemic regions, initiated by vector-mediated spillover"/>
   <result pre="species can act as reservoirs for YFV. Vertical transmission of" exact="YFV" post="between mosquitos has been reported [236,237]. While transmission rates"/>
   <result pre="While transmission rates are low (~1%), this capacity could maintain" exact="YFV" post="reservoirs during dry periods which are not favorable for"/>
   <result pre="is often not sufficient to maintain stable sylvatic transmission, and" exact="YFV" post="reservoirs in non-primate species could maintain inter-epidemic YFV [4]."/>
   <result pre="transmission, and YFV reservoirs in non-primate species could maintain inter-epidemic" exact="YFV" post="[4]. Indeed, serum neutralizing antibodies for YFV were detected"/>
   <result pre="could maintain inter-epidemic YFV [4]. Indeed, serum neutralizing antibodies for" exact="YFV" post="were detected in ten forest mammal species from French"/>
   <result pre="well as multiple primate species [143]. Thus, the breadth of" exact="YFV" post="species-specificity remains to be determined. To further investigate this,"/>
   <result pre="this, extensive sampling and NGS screening of jungle species in" exact="YFV" post="endemic regions could be undertaken, potentially identifying novel animal"/>
   <result pre="be undertaken, potentially identifying novel animal reservoirs which silently maintain" exact="YFV" post="transmission between intermittent outbreaks. In summary, future YFV outbreaks"/>
   <result pre="silently maintain YFV transmission between intermittent outbreaks. In summary, future" exact="YFV" post="outbreaks can be rapidly identified and epidemics monitored at"/>
   <result pre="and the identification of novel animal reservoirs. 9. Modes of" exact="YFV" post="Transmission and Future Vector Control Strategies YFV is transmitted"/>
   <result pre="9. Modes of YFV Transmission and Future Vector Control Strategies" exact="YFV" post="is transmitted by mosquito vectors between primate hosts and"/>
   <result pre="3. The urban cycle—where invasive domesticated mosquitoes (Aedes aegypti) facilitate" exact="YFV" post="transmission from human-to-human in areas of high human and"/>
   <result pre="the epidemic [13]. Contrastingly, detailed analyses of the 2016–2017 Brazilian" exact="YFV" post="outbreak suggests the sylvatic cycle represents the dominant mode"/>
   <result pre="sylvatic cycle represents the dominant mode of transmission [16]. Urban" exact="YFV" post="outbreaks are associated with Ae. aegypti transmission, although the"/>
   <result pre="the Asian tiger mosquito, Aedes albopictus, is also competent for" exact="YFV" post="transmission [238]. Both species are invasive, are able to"/>
   <result pre="climate change [239], expanding the risk of human exposure to" exact="YFV" post="infection. The expansion of the 2016–2017 outbreak in Brazil"/>
   <result pre="in Brazil to an area not previously considered endemic for" exact="YFV" post="serves to underline this point [15,16]. However, during YFV"/>
   <result pre="for YFV serves to underline this point [15,16]. However, during" exact="YFV" post="outbreaks, while isolated cases can be imported from endemic"/>
   <result pre="from endemic to non-endemic regions [17], continued host-to-host transmission of" exact="YFV" post="observed in outbreaks is only possible in geographic regions"/>
   <result pre="been exploited in the past to control and even eradicate" exact="YFV" post="from specific regions. While YFV has never been controlled"/>
   <result pre="to control and even eradicate YFV from specific regions. While" exact="YFV" post="has never been controlled in Africa, vector control programs"/>
   <result pre="manage and reduce the likelihood of future arbovirus outbreaks, including" exact="YFV" post="[243]. Mosquito population suppression strategies which harness the power"/>
   <result pre="sexes were less susceptible to infection with the pathogenic flaviviruses" exact="DENV" post="and ZIKV [246]. Pupal irradiation boosted viable mosquito numbers"/>
   <result pre="less susceptible to infection with the pathogenic flaviviruses DENV and" exact="ZIKV" post="[246]. Pupal irradiation boosted viable mosquito numbers for use"/>
   <result pre="pave the way for analogous trials with Ae. aegypti in" exact="YFV" post="endemic regions. Arboviruses often replicate in mosquito mid-gut and"/>
   <result pre="another possible strategy for ablating vector-mediated transmission of YFV. Indeed," exact="DENV" post="dissemination and replication were restricted in transgenic Ae. aegypti"/>
   <result pre="factor during 17D attenuation. In the future, genetic modification of" exact="YFV" post="Aedes vector species using CRISPR/Cas9 [222] could preferentially target"/>
   <result pre="in the mosquito midgut or other tissues which are essential" exact="YFV" post="propagation and dissemination. The ability of researchers to identify"/>
   <result pre="[248]. Indeed, these data identified gene loci potentially associated with" exact="DENV" post="competence and insecticide resistance. In addition, quantification and comparison"/>
   <result pre="gene products, which could be further investigated to identify essential" exact="YFV" post="replication cofactors in the mosquito mid-gut via iterative screening"/>
   <result pre="resistant to traditional insecticides, will be key in reducing future" exact="YFV" post="outbreaks. The future of eliminating YFV from endemic regions"/>
   <result pre="key in reducing future YFV outbreaks. The future of eliminating" exact="YFV" post="from endemic regions may involve the suppression or replacement"/>
   <result pre="wild-type mosquitos with modified insects which are not competent for" exact="YFV" post="replication. Furthermore, sequencing efforts to expand the number of"/>
   <result pre="genomes from jungle-resident mosquito species should commence. 10. Concluding Remarks" exact="YFV" post="is the prototypic flavivirus—a zoonotic pathogen which is responsible"/>
   <result pre="increasing the potential for future outbreaks. Therefore, intensification of basic" exact="YFV" post="research is imperative to expand current knowledge of the"/>
   <result pre="of outbreaks and genetic modification of vector species to reduce" exact="YFV" post="permissiveness can all contribute to future efforts aimed at"/>
   <result pre="to future efforts aimed at reducing mortality rates associated with" exact="YFV" post="epidemics. Supplementary Materials The following are available online at"/>
   <result pre="https://www.mdpi.com/1999-4915/11/10/960/s1, Table S1: Summary of structural and functional properties of" exact="YFV" post="proteins. LINK Click here for additional data file. Author"/>
   <result pre="1998-2002Trans. R. Soc. Trop. Med. Hyg.200710116917510.1016/j.trstmh.2006.04.00116814821 32.OliveiraR.A.de Oliveira-FilhoE.F.FernandesI.V.A.BritoC.A.MarquesE.T.TenórioM.C.GilL.H.Previous dengue or" exact="Zika" post="virus exposure can drive to infection enhancement or neutralisation"/>
   <result pre="34.SacramentoC.Q.de MeloG.R.de FreitasC.S.RochaN.HoelzL.V.B.MirandaM.Fintelman-RodriguesN.MarttorelliA.FerreiraA.C.Barbosa-LimaG.et al.The clinically approved antiviral drug sofosbuvir inhibits" exact="Zika" post="virus replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine) as an"/>
   <result pre="replicationSci. Rep.201774092010.1038/srep4092028098253 35.XuH.-T.Colby-GerminarioS.P.HassounahS.A.FogartyC.OsmanN.PalanisamyN.HanY.OliveiraM.QuanY.WainbergM.A.Evaluation of Sofosbuvir (β-D-2’-deoxy-2’-α-fluoro-2’-β-C-methyluridine) as an inhibitor of" exact="Dengue" post="virus replicationSci. Rep.20177634510.1038/s41598-017-06612-228740124 36.De FreitasC.S.HigaL.M.SacramentoC.Q.FerreiraA.C.ReisP.A.DelvecchioR.MonteiroF.L.Barbosa-LimaG.James WestgarthH.VieiraY.R.et al.Yellow fever virus"/>
   <result pre="Med.200319782382910.1084/jem.2002184012682107 65.KrishnanM.N.NgA.SukumaranB.GilfoyF.D.UchilP.D.SultanaH.BrassA.L.AdametzR.TsuiM.QianF.et al.RNA interference screen for human genes associated with" exact="West Nile" post="virus infectionNature200845524224510.1038/nature0720718690214 66.Le SommerC.BarrowsN.J.BradrickS.S.PearsonJ.L.Garcia-BlancoM.A.G protein-coupled receptor kinase 2 promotes"/>
   <result pre="C-type lectin collaborates with a CD45 phosphatase homolog to facilitate" exact="West Nile" post="virus infection of mosquitoesCell201014271472510.1016/j.cell.2010.07.03820797779 78.Fernandez-GarciaM.D.MeertensL.ChazalM.HafirassouM.L.DejarnacO.ZamborliniA.DespresP.SauvonnetN.Arenzana-SeisdedosF.JouvenetN.et al.Vaccine and Wild-Type Strains"/>
   <result pre="protease-helicase as a target for antiviral drug developmentAntivir. Res.201511814815810.1016/j.antiviral.2015.03.01425842996 97.TanB.-H.FuJ.SugrueR.J.YapE.-H.ChanY.-C.TanY.H.Recombinant" exact="Dengue" post="Type 1 Virus NS5 Protein Expressed inEscherichia coliExhibits RNA-Dependent"/>
   <result pre="and NS4AVirology199824520321510.1006/viro.1998.91569636360 105.KaufusiP.H.KelleyJ.F.YanagiharaR.NerurkarV.R.Induction of endoplasmic reticulum-derived replication-competent membrane structures by" exact="West Nile" post="virus non-structural protein 4BPLoS ONE20149e8404010.1371/journal.pone.008404024465392 106.DesprèsP.GirardM.BouloyM.Characterization of yellow fever"/>
   <result pre="Med.200620341342410.1084/jem.2005172016461338 117.SinigagliaL.GraciasS.DécembreE.FritzM.BruniD.SmithN.HerbeuvalJ.-P.MartinA.DreuxM.TangyF.et al.Immature particles and capsid-free viral RNA produced by" exact="Yellow fever" post="virus-infected cells stimulate plasmacytoid dendritic cells to secrete interferonsSci."/>
   <result pre="Virol.2014884180419410.1128/JVI.03114-1324478443 129.FredericksenB.L.KellerB.C.FornekJ.KatzeM.G.GaleM.Establishment and maintenance of the innate antiviral response to" exact="West Nile" post="Virus involves both RIG-I and MDA5 signaling through IPS-1J."/>
   <result pre="new roles for cGAS in innate immunityNature201450569169510.1038/nature1286224284630 135.van GentM.GackM.U.Viral pathogenesis:" exact="Dengue" post="virus takes on cGASNat. Microbiol.201721705010.1038/nmicrobiol.2017.5028346454 136.AguirreS.LuthraP.Sanchez-AparicioM.T.MaestreA.M.PatelJ.LamotheF.FredericksA.C.TripathiS.ZhuT.Pintado-SilvaJ.et al.Dengue virus NS2B"/>
   <result pre="immunityNature200946178879210.1038/nature0847619776740 138.DingQ.GaskaJ.M.DouamF.WeiL.KimD.BalevM.HellerB.PlossA.Species-specific disruption of STING-dependent antiviral cellular defenses by the" exact="Zika" post="virus NS2B3 proteaseProc. Natl. Acad. Sci. USA2018115E6310E631810.1073/pnas.180340611529915078 139.LamkanfiM.DixitV.M.Modulation of"/>
   <result pre="vector for HIV-1 vaccine developmentVaccine2010285676568510.1016/j.vaccine.2010.06.05220600494 178.GuyB.GuirakhooF.BarbanV.HiggsS.MonathT.P.LangJ.Preclinical and clinical development of" exact="YFV" post="17D-based chimeric vaccines against dengue, West Nile and Japanese"/>
   <result pre="and clinical development of YFV 17D-based chimeric vaccines against dengue," exact="West Nile" post="and Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 179.StoyanovC.T.BoscardinS.B.DeroubaixS.Barba-SpaethG.FrancoD.NussenzweigR.S.NussenzweigM.RiceC.M.Immunogenicity and protective efficacy of"/>
   <result pre="ModelsAm. J. Trop. Med. Hyg.20189842043110.4269/ajtmh.16-029329231157 206.TripathiN.K.ShrivastavaA.Recent Developments in Recombinant Protein-Based" exact="Dengue" post="VaccinesFront. Immunol.20189191910.3389/fimmu.2018.0191930190720 207.KheraT.BehrendtP.BankwitzD.BrownR.J.P.TodtD.DoepkeM.KhanA.G.SchulzeK.LawJ.LoganM.et al.Functional and immunogenic characterization of diverse"/>
   <result pre="LamballerieX.Random codon re-encoding induces stable reduction of replicative fitness of" exact="Chikungunya" post="virus in primate and mosquito cellsPLoS Pathog.20139e100317210.1371/journal.ppat.100317223436995 218.de FabritusL.NougairedeA.AubryF.GouldE.A.de"/>
   <result pre="to the scale bar (units: substitutions per site). Figure 2" exact="YFV" post="E protein structures with 17D attenuating mutations and fusion"/>
   <result pre="with both top (left) and side (right) views presented. The" exact="YFV" post="E structures presented were previously described in [54] (PDB"/>
   <result pre="in UCSF Chimera [55]. Figure 3 Schematic representation of the" exact="YFV" post="genome and encoded polyprotein. The genome of YFV is"/>
   <result pre="of the YFV genome and encoded polyprotein. The genome of" exact="YFV" post="is a single-stranded positive-stranded RNA of approximately 11kb encoding"/>
   <result pre="proteins which are incorporated into the ER membrane. Figure 4" exact="YFV" post="genomic and amino acid diversity. (A) Phylogenetic analysis of"/>
   <result pre="YFV genomic and amino acid diversity. (A) Phylogenetic analysis of" exact="YFV" post="genomes. The presented tree was generated using PhyML [220]"/>
   <result pre="ensure maintenance of the polyprotein ORF. Collapsed clades in the" exact="YFV" post="phylogeny contain closely related isolates from the 2016–2017 Brazilian"/>
   <result pre="green filled circles in SAL I (n = 3) represent" exact="YFV" post="sequences isolated from non-human primates during the 2016–2017 Brazilian"/>
   <result pre="the main outbreak grouping (green triangle). The statistical robustness of" exact="YFV" post="lineages were calculated using the bootstrap approach in MEGA7"/>
   <result pre="bar (units: substitutions per site). (B) Conservation and variability in" exact="YFV" post="genomes. Amino acid and underlying nucleotide similarity plots for"/>
   <result pre="Amino acid and underlying nucleotide similarity plots for globally sampled" exact="YFV" post="genomes are presented. For the purpose of positional referencing,"/>
   <result pre="For the purpose of positional referencing, a cartoon of the" exact="YFV" post="reference strain polyprotein is provided directly above, with coordinates"/>
   <result pre="nucleotides in the alignment. (C) Conservation and variability in the" exact="YFV" post="RNA helicase. Amino acid conservation and variability estimated in"/>
   <result pre="conservation and variability estimated in (B) were mapped onto the" exact="YFV" post="NS3 RNA helicase structure. Relative conservation of amino acids"/>
   <result pre="while variable residues highlighted dark green through to orange. The" exact="YFV" post="helicase structure presented was described in [221] (PDB ID:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6832697\results\search\tropicalVirus\results.xml">
   <result pre="font-style : italic;} VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 6832697 doi: 10.3390/v11100886viruses-11-00886 : Review" exact="Zika" post="Virus Pathogenesis: From Early Case Reports to Epidemics PardyRyan"/>
   <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract For the first 60 years following its isolation," exact="Zika" post="virus (ZIKV) remained a relatively poorly described member of"/>
   <result pre="associated with neurological symptoms such as Guillain-Barré syndrome and congenital" exact="Zika" post="syndrome (CZS). A number of reports have improved our"/>
   <result pre="our understanding of rare complications that may be associated with" exact="ZIKV" post="infection in adults, the areas of the body to"/>
   <result pre="persistence in various tissues. Likewise, studies on the effect of" exact="ZIKV" post="infection during pregnancy have identified risk factors for CZS"/>
   <result pre="early childhood. Understanding these outcomes and the factors that drive" exact="ZIKV" post="pathogenesis are key to developing vaccination and therapeutic approaches"/>
   <result pre="therapeutic approaches to avoid these severe and potentially debilitating symptoms." exact="Zika" post="virus pathogenesis Guillain-Barré syndrome fetal microcephaly congenital Zika syndrome"/>
   <result pre="debilitating symptoms. Zika virus pathogenesis Guillain-Barré syndrome fetal microcephaly congenital" exact="Zika" post="syndrome 1. Introduction Zika virus (ZIKV) was first isolated"/>
   <result pre="pathogenesis Guillain-Barré syndrome fetal microcephaly congenital Zika syndrome 1. Introduction" exact="Zika" post="virus (ZIKV) was first isolated from a sentinel rhesus"/>
   <result pre="1947 in the Ziika forest (more commonly known as the" exact="Zika" post="forest) region of Uganda [1]. Although it was presumed"/>
   <result pre="handful of isolated case reports represented the breadth of the" exact="ZIKV" post="literature for the remainder of the 20th century [4,5]."/>
   <result pre="literature for the remainder of the 20th century [4,5]. However," exact="ZIKV" post="has since emerged as the cause of a series"/>
   <result pre="States of Micronesia, was estimated to have been infected with" exact="ZIKV" post="[6]. This was followed in 2013 by approximately 32,000"/>
   <result pre="was followed in 2013 by approximately 32,000 suspected cases of" exact="ZIKV" post="infection between October 2013 and April 2014 in French"/>
   <result pre="April 2014 in French Polynesia [7]. More recently, the 2015–2016" exact="ZIKV" post="epidemic began in Brazil before spreading rapidly throughout South"/>
   <result pre="spreading rapidly throughout South and Central America, with evidence of" exact="ZIKV" post="transmission in 84 countries worldwide [8]. In the Americas"/>
   <result pre="outbreaks have also highlighted the association of neurological symptoms with" exact="ZIKV" post="infection. In adults, the primary neurological condition associated with"/>
   <result pre="ZIKV infection. In adults, the primary neurological condition associated with" exact="ZIKV" post="infection is Guillain-Barré syndrome (GBS), an acute peripheral neuropathy"/>
   <result pre="acute peripheral neuropathy that causes ascending paralysis. The link between" exact="ZIKV" post="infection and GBS was first recognized during the French"/>
   <result pre="between 4–15% die from GBS [15]. Thus, the identification of" exact="ZIKV" post="as a possible trigger of GBS represents a dangerous"/>
   <result pre="new symptom for this typically innocuous virus. The impact of" exact="ZIKV" post="infection during pregnancy and on neonates is the most"/>
   <result pre="and on neonates is the most dramatic aspect of contemporary" exact="ZIKV" post="outbreaks. Fetal microcephaly, which is typically diagnosed based on"/>
   <result pre="average for gestational age and sex, was first associated with" exact="ZIKV" post="infection during the South and Central American outbreak [4,16]."/>
   <result pre="French Polynesian outbreak provided further evidence for an association between" exact="ZIKV" post="infection during pregnancy and fetal microcephaly [17]. Fetal microcephaly"/>
   <result pre="of several symptoms that are collectively referred to as congenital" exact="Zika" post="syndrome (CZS), which also includes thin cerebral cortices with"/>
   <result pre="well as its family. Together, GBS and CZS demonstrate how" exact="ZIKV" post="has emerged as a global health threat with the"/>
   <result pre="this review, we will describe typical and rare outcomes of" exact="ZIKV" post="infection in adults, including the areas of the body"/>
   <result pre="in adults, including the areas of the body in which" exact="ZIKV" post="has been detected, and the duration of virus detection."/>
   <result pre="of virus detection. We will also examine the effect of" exact="ZIKV" post="infection during pregnancy, risk factors for the development of"/>
   <result pre="for the development of CZS, and the impact of maternal" exact="ZIKV" post="exposure on early childhood development. Finally, we will discuss"/>
   <result pre="early childhood development. Finally, we will discuss pediatric cases of" exact="ZIKV" post="infection, and how the course of infection in children"/>
   <result pre="Improving our understanding of the severe symptoms that can follow" exact="ZIKV" post="infection, and the risk factors associated with them is"/>
   <result pre="the Yap Island outbreak, there were very few descriptions of" exact="ZIKV" post="infection duration and pathogenesis in humans. The first undisputed"/>
   <result pre="duration and pathogenesis in humans. The first undisputed account of" exact="ZIKV" post="infection in humans was described by a researcher working"/>
   <result pre="in humans was described by a researcher working in the" exact="Zika" post="forest in 1964 [3]. In this report of his"/>
   <result pre="[3]. Similar to this account, a researcher with a laboratory-acquired" exact="ZIKV" post="infection described rapid-onset disease with fever, sweating, retro-orbital pain,"/>
   <result pre="post-onset of symptoms (POS) [19]. Even 36 years later, after" exact="ZIKV" post="caused its first major outbreak on Yap Island, the"/>
   <result pre="These reports suggest that up until the French Polynesian outbreak," exact="ZIKV" post="caused only a mild, febrile illness with no neurological"/>
   <result pre="Yap Island outbreak. In addition to the classic symptoms of" exact="ZIKV" post="infection described above, the most common neurological symptom associated"/>
   <result pre="infection described above, the most common neurological symptom associated with" exact="ZIKV" post="infection in adults is GBS (Figure 1). This link"/>
   <result pre="non-febrile illness at the same hospital (control group 1), and" exact="ZIKV" post="patients with no neurological symptoms (control group 2) [10]."/>
   <result pre="mechanical ventilation was required for 12/42 patients [10]. Significantly more" exact="ZIKV" post="patients with GBS had IgM antibodies against ZIKV (93%)"/>
   <result pre="Significantly more ZIKV patients with GBS had IgM antibodies against" exact="ZIKV" post="(93%) than control group 1 patients, while ZIKV was"/>
   <result pre="antibodies against ZIKV (93%) than control group 1 patients, while" exact="ZIKV" post="was detected in 100% of control group 2 patients,"/>
   <result pre="in 100% of control group 2 patients, providing evidence for" exact="ZIKV" post="as a risk factor for GBS [10]. During the"/>
   <result pre="for GBS [10]. During the South and Central American outbreak," exact="ZIKV" post="was confirmed as a potential trigger for GBS [20],"/>
   <result pre="French Polynesian study, and almost all patients had evidence of" exact="ZIKV" post="infection based on either detection of ZIKV RNA or"/>
   <result pre="had evidence of ZIKV infection based on either detection of" exact="ZIKV" post="RNA or antibodies against ZIKV, in addition to a"/>
   <result pre="onset tended to be parainfectious, with no asymptomatic period between" exact="ZIKV" post="disease and GBS onset [9,13,14,23,24,25]. Additionally, while 25–33% of"/>
   <result pre="the end of the study [9,21,22,23,24]. Interestingly, GBS associated with" exact="ZIKV" post="infection was not restricted to a single subtype across"/>
   <result pre="as a rare but consistent and dangerous potential outcome of" exact="ZIKV" post="infection since the French Polynesian outbreak. In addition to"/>
   <result pre="series describing other rare outcomes that may be associated with" exact="ZIKV" post="infection. In one study from a hospital in Rio"/>
   <result pre="[21]. Other case studies have identified: meningoencephalitis and meningitis, with" exact="ZIKV" post="RNA in the cerebrospinal fluid (CSF; Figure 1) [23,26];"/>
   <result pre="in the cerebrospinal fluid (CSF; Figure 1) [23,26]; uveitis, with" exact="ZIKV" post="RNA in the aqueous humor [27]; and gastrointestinal symptoms"/>
   <result pre="in a small fraction of men who tested positive for" exact="ZIKV" post="RNA in their semen, however in a separate study,"/>
   <result pre="separate study, it was also observed that the presence of" exact="ZIKV" post="RNA correlated with lower semen volume and reduced sperm"/>
   <result pre="sperm count and motile sperm count [30,31]. Fatal cases of" exact="ZIKV" post="infection are exceedingly rare, with only 84 fatal ZIKV"/>
   <result pre="of ZIKV infection are exceedingly rare, with only 84 fatal" exact="ZIKV" post="cases reported during the entirety of the South and"/>
   <result pre="reported during the entirety of the South and Central American" exact="ZIKV" post="outbreak, out of over 800,000 reported cases [8,32]. Thus,"/>
   <result pre="reported cases [8,32]. Thus, in addition to causing the GBS," exact="ZIKV" post="appears to be capable of infecting and causing pathology"/>
   <result pre="numerous areas of the body (Figure 1). In recent outbreaks," exact="ZIKV" post="has been detected in a wide variety of bodily"/>
   <result pre="milk (Figure 1) [9,21,29,31,33,34,35]. Sexual transmission has been documented for" exact="ZIKV" post="[36,37], however there is currently no evidence to suggest"/>
   <result pre="saliva, or breastfeeding may occur. Several studies that have examined" exact="ZIKV" post="dissemination also analyzed clearance of the virus from bodily"/>
   <result pre="the virus from bodily fluids over time. In many cases," exact="ZIKV" post="is rapidly cleared, in line with the acute infection"/>
   <result pre="the acute infection most patients experience. However, prolonged presence of" exact="ZIKV" post="RNA has been documented in a number of cases"/>
   <result pre="a number of cases (Figure 1). In one study of" exact="ZIKV" post="patients in the United States (96% acquired ZIKV infection"/>
   <result pre="study of ZIKV patients in the United States (96% acquired" exact="ZIKV" post="infection in other countries), ZIKV RNA was detected as"/>
   <result pre="the United States (96% acquired ZIKV infection in other countries)," exact="ZIKV" post="RNA was detected as late as 13 days POS"/>
   <result pre="and colleagues found in their prospective cohort study of 252" exact="ZIKV" post="patients that the median time to clearance of viral"/>
   <result pre="even 90 days POS, 11% of male patients still had" exact="ZIKV" post="RNA in their semen [38]. Given the possibility of"/>
   <result pre="of sexual transmission, several other studies have understandably focused on" exact="ZIKV" post="RNA persistence in the female and male genital tracts."/>
   <result pre="Similar to the American study above, two case reports identified" exact="ZIKV" post="RNA in vaginal or cervical mucus swabs until 14"/>
   <result pre="until 14 and 11 days POS, respectively [34,39]. In men," exact="ZIKV" post="RNA has been detected in semen over 100 days"/>
   <result pre="as late as 240 days POS [30,31,40,41]. One study detected" exact="ZIKV" post="antigens in spermatozoa, which provides a potential mechanism for"/>
   <result pre="that are associated with a longer time to clearance of" exact="ZIKV" post="RNA from semen, include increased age, presence of conjunctivitis,"/>
   <result pre="ejaculation, as men who ejaculated four times per week cleared" exact="ZIKV" post="21 days earlier than those who ejaculated once per"/>
   <result pre="interpreted with a degree of caution, as the presence of" exact="ZIKV" post="RNA does not guarantee or necessarily indicate the presence"/>
   <result pre="virus. Indeed, Mead et al. were only able to culture" exact="ZIKV" post="from semen samples within the first few weeks POS,"/>
   <result pre="weeks POS, and only when greater than 107 copies of" exact="ZIKV" post="RNA were detected per milliliter of semen [30]. This"/>
   <result pre="the first 20 days [42,43,44,45,46,47]. Thus, although the detection of" exact="ZIKV" post="RNA in bodily fluids may overstate the possibility of"/>
   <result pre="Pathogenesis During Pregnancy, Infancy, and Childhood The shocking link between" exact="ZIKV" post="infection and pathogenesis during pregnancy first came to light"/>
   <result pre="fetal microcephaly and CZS has been a primary focus of" exact="ZIKV" post="research. ZIKV-specific IgM has been detected in the CSF"/>
   <result pre="other negative fetal outcomes are most closely linked with maternal" exact="ZIKV" post="infection early in pregnancy (first trimester), with one study"/>
   <result pre="significantly higher serum neutralizing activity and antibodies reactive to the" exact="ZIKV" post="envelope protein domain III, compared to control women [54]."/>
   <result pre="compared to control women [54]. Other birth defects linked to" exact="ZIKV" post="infection include patent foramen ovale (failure of a natural"/>
   <result pre="difficulty swallowing [16,50,51,52]. In some cases, fetal death following maternal" exact="ZIKV" post="infection has also been reported [33,53]. Thus, ZIKV infection,"/>
   <result pre="following maternal ZIKV infection has also been reported [33,53]. Thus," exact="ZIKV" post="infection, particularly early during pregnancy, can have devastating impacts"/>
   <result pre="and their families. In order to determine the impacts of" exact="ZIKV" post="infection during pregnancy on early life, one longitudinal study"/>
   <result pre="infants born to mothers who had a rash and positive" exact="ZIKV" post="RT-PCR in either serum or urine during pregnancy [52]."/>
   <result pre="that even infants born with no obvious brain abnormalities following" exact="ZIKV" post="exposure during pregnancy are also at risk for neurodevelopmental"/>
   <result pre="even post-natal CZS (Figure 1). Several studies have also characterized" exact="ZIKV" post="pathogenesis in pediatric cases of ZIKV infection. In one"/>
   <result pre="studies have also characterized ZIKV pathogenesis in pediatric cases of" exact="ZIKV" post="infection. In one case report, a seven-year-old boy in"/>
   <result pre="vomiting, headache, and tonic-clonic seizures, but no classic symptoms of" exact="ZIKV" post="infection [55]. Upon admission to the ICU, he developed"/>
   <result pre="of which resolved over several days, and which correlated with" exact="ZIKV" post="RNA and infectious ZIKV particles in his CSF [55]."/>
   <result pre="several days, and which correlated with ZIKV RNA and infectious" exact="ZIKV" post="particles in his CSF [55]. Similar CNS involvement was"/>
   <result pre="Similar CNS involvement was observed in a 15-year-old girl with" exact="ZIKV" post="RNA in her CSF, who presented with left side"/>
   <result pre="years [57]. Similar to what is typically described in adult" exact="ZIKV" post="infection, maculopapular rash and fever were present in the"/>
   <result pre="studies demonstrate that apart from rare cases with CNS involvement," exact="ZIKV" post="infection in children largely mirrors infection in adults. 4."/>
   <result pre="in adults. 4. Conclusions Following its initial isolation in 1947," exact="ZIKV" post="remained relatively unknown and innocuous until the Yap Island"/>
   <result pre="outbreak, this and the outbreaks that preceded it have defined" exact="ZIKV" post="as a pathogen with the clear capacity to cause"/>
   <result pre="[58,59,60]. Combined with the severe neurological symptoms associated with infection," exact="ZIKV" post="has clearly emerged as a major global health threat."/>
   <result pre="reports nor descriptions of the Yap Island outbreak indicated that" exact="ZIKV" post="caused more than acute febrile illness. However, recent outbreaks"/>
   <result pre="have also occurred in the context of the introduction of" exact="ZIKV" post="to novel host populations, which raises the possibility that"/>
   <result pre="or pathogenesis. Nonetheless, the neurological symptoms that remain associated with" exact="ZIKV" post="infection merit continued research efforts to understand risk factors"/>
   <result pre="therapeutic approaches that are best-suited to prevent and treat severe" exact="ZIKV" post="pathogenesis. Acknowledgments We gratefully thank Stephanie Condotta, Marilena Gentile,"/>
   <result pre="of MicronesiaN. Engl. J. Med.20093602536254310.1056/NEJMoa080571519516034 7.MalletH.P.VialA.L.MussoD.Bilan de l’épidémie à virus" exact="Zika" post="survenue en Polynésie française entre octobre 2013 et mars"/>
   <result pre="August 2019) 9.BrasilP.SequeiraP.C.FreitasA.D.ZogbiH.E.CalvetG.A.de SouzaR.V.SiqueiraA.M.de MendoncaM.C.NogueiraR.M.de FilippisA.M.et al.Guillain-Barre syndrome associated with" exact="Zika" post="virus infectionLancet2016387148210.1016/S0140-6736(16)30058-727115821 10.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barre Syndrome outbreak associated with Zika"/>
   <result pre="with Zika virus infectionLancet2016387148210.1016/S0140-6736(16)30058-727115821 10.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 11.Dos"/>
   <result pre="report, French Polynesia, December 2013Eurosurveillance2014192072010.2807/1560-7917.ES2014.19.9.2072024626205 13.ParraB.LizarazoJ.Jimenez-ArangoJ.A.Zea-VeraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.BeltranC.L.et al.Guillain-Barre Syndrome Associated with" exact="Zika" post="Virus Infection in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 14.Soto-HernandezJ.L.Ponce de"/>
   <result pre="14.Soto-HernandezJ.L.Ponce de Leon RosalesS.Vargas CanasE.S.CardenasG.Carrillo LozaK.Diaz-QuinonezJ.A.Lopez-MartinezI.Jimenez-CoronaM.E.Ruiz-MatusC.Kuri MoralesP.Guillain-Barre Syndrome Associated With" exact="Zika" post="Virus Infection: A Prospective Case Series From MexicoFront. Neurol.20191043510.3389/fneur.2019.0043531114537"/>
   <result pre="and/or SGA Zika-exposed InfantsClin Infect. Dis.2019ciz70410.1093/cid/ciz70431346616 17.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–2015: A retrospective"/>
   <result pre="retrospective studyLancet20163872125213210.1016/S0140-6736(16)00651-626993883 18.MooreC.A.StaplesJ.E.DobynsW.B.PessoaA.VenturaC.V.FonsecaE.B.RibeiroE.M.VenturaL.O.NetoN.N.ArenaJ.F.et al.Characterizing the Pattern of Anomalies in Congenital" exact="Zika" post="Syndrome for Pediatric CliniciansJAMA Pediatr.201717128829510.1001/jamapediatrics.2016.398227812690 19.FilipeA.R.MartinsC.M.RochaH.Laboratory infection with Zika"/>
   <result pre="Congenital Zika Syndrome for Pediatric CliniciansJAMA Pediatr.201717128829510.1001/jamapediatrics.2016.398227812690 19.FilipeA.R.MartinsC.M.RochaH.Laboratory infection with" exact="Zika" post="virus after vaccination against yellow feverArch. Gesamte Virusforsch.19734331531910.1007/BF015561474799154 20.KrauerF.RiesenM.ReveizL.OladapoO.T.Martinez-VegaR.PorgoT.V.HaefligerA.BroutetN.J.LowN.GroupW.H.O.Z.C.W.Zika"/>
   <result pre="ReviewPLoS Med.201714e100220310.1371/journal.pmed.100220328045901 21.Da SilvaI.R.F.FronteraJ.A.Bispo de FilippisA.M.NascimentoO.GroupR.-G.-Z.R.Neurologic Complications Associated With the" exact="Zika" post="Virus in Brazilian AdultsJAMA Neurol.2017741190119810.1001/jamaneurol.2017.170328806453 22.ZambranoL.I.Fuentes-BarahonaI.C.Soto-FernandezR.J.ZunigaC.da SilvaJ.C.Rodriguez-MoralesA.J.Guillain-Barre syndrome associated"/>
   <result pre="Virus in Brazilian AdultsJAMA Neurol.2017741190119810.1001/jamaneurol.2017.170328806453 22.ZambranoL.I.Fuentes-BarahonaI.C.Soto-FernandezR.J.ZunigaC.da SilvaJ.C.Rodriguez-MoralesA.J.Guillain-Barre syndrome associated with" exact="Zika" post="virus infection in Honduras, 2016–2017Int. J. Infect. Dis.20198413613710.1016/j.ijid.2019.05.00831096053 23.WrightJ.K.CastellaniL.LecceC.KhatibA.BontaM.BoggildA.K.Zika"/>
   <result pre="Associated with MeningoencephalitisN. Engl. J. Med.20163741595159610.1056/NEJMc160296426958738 27.FurtadoJ.M.EspositoD.L.KleinT.M.Teixeira-PintoT.da FonsecaB.A.Uveitis Associated with" exact="Zika" post="Virus InfectionN. Engl. J. Med.201637539439610.1056/NEJMc160361827332784 28.Sanchez-MontalvaA.PouD.SulleiroE.SalvadorF.BocanegraC.TrevinoB.RandoA.SerreN.PumarolaT.AlmiranteB.et al.Zika virus dynamics"/>
   <result pre="Int. Health2018239210010.1111/tmi.1301929194880 29.El SahlyH.M.GorchakovR.LaiL.NatrajanM.S.PatelS.M.AtmarR.L.KeitelW.A.HoftD.F.BarrettJ.BaileyJ.et al.Clinical, Virologic, and Immunologic Characteristics of" exact="Zika" post="Virus Infection in a Cohort of US Patients: Prolonged"/>
   <result pre="Symptomatic Infected MenN. Engl. J. Med.20183781377138510.1056/NEJMoa171103829641964 31.JoguetG.MansuyJ.M.MatusaliG.HamdiS.WalschaertsM.PaviliL.GuyomardS.PrisantN.LamarreP.Dejucq-RainsfordN.et al.Effect of acute" exact="Zika" post="virus infection on sperm and virus clearance in body"/>
   <result pre="in body fluids: A prospective observational studyLancet Infect. Dis.2017171200120810.1016/S1473-3099(17)30444-928838639 32.Rodriguez-MoralesA.J.Ramirez-VallejoE.Alvarado-ArnezL.E.Paniz-MondolfiA.ZambranoL.I.KoA.I.Fatal" exact="Zika" post="virus disease in adults: A critical reappraisal of an"/>
   <result pre="of Childbearing ageClin. Infect. Dis.20176410710910.1093/cid/ciw66927682065 35.BesnardM.LastereS.TeissierA.Cao-LormeauV.MussoD.Evidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Eurosurveillance2014192075110.2807/1560-7917.ES2014.19.13.2075124721538 36.FoyB.D.KobylinskiK.C.Chilson"/>
   <result pre="and February 2014Eurosurveillance2014192075110.2807/1560-7917.ES2014.19.13.2075124721538 36.FoyB.D.KobylinskiK.C.Chilson FoyJ.L.BlitvichB.J.Travassos da RosaA.HaddowA.D.LanciottiR.S.TeshR.B.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 37.DesclauxA.de LamballerieX.Leparc-GoffartI.Vilain-ParceA.CoatlevenF.FleuryH.MalvyD.Probable Sexually Transmitted"/>
   <result pre="Zika virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 37.DesclauxA.de LamballerieX.Leparc-GoffartI.Vilain-ParceA.CoatlevenF.FleuryH.MalvyD.Probable Sexually Transmitted" exact="Zika" post="Virus Infection in a Pregnant WomanN. Engl. J. Med.20183781458146010.1056/NEJMc171045329641959"/>
   <result pre="in a Pregnant WomanN. Engl. J. Med.20183781458146010.1056/NEJMc171045329641959 38.Paz-BaileyG.RosenbergE.S.DoyleK.Munoz-JordanJ.SantiagoG.A.KleinL.Perez-PadillaJ.MedinaF.A.WatermanS.H.GubernC.G.et al.Persistence of" exact="Zika" post="Virus in Body Fluids—Final ReportN. Engl. J. Med.20183791234124310.1056/NEJMoa161310828195756 39.MurrayK.O.GorchakovR.CarlsonA.R.BerryR.LaiL.NatrajanM.GarciaM.N.CorreaA.PatelS.M.AagaardK.et"/>
   <result pre="Body Fluids—Final ReportN. Engl. J. Med.20183791234124310.1056/NEJMoa161310828195756 39.MurrayK.O.GorchakovR.CarlsonA.R.BerryR.LaiL.NatrajanM.GarciaM.N.CorreaA.PatelS.M.AagaardK.et al.Prolonged Detection of" exact="Zika" post="Virus in Vaginal Secretions and Whole BloodEmerg. Infect. Dis.2017239910110.3201/eid2301.16139427748649"/>
   <result pre="Vaginal Secretions and Whole BloodEmerg. Infect. Dis.2017239910110.3201/eid2301.16139427748649 40.NicastriE.CastillettiC.LiuzziG.IannettaM.CapobianchiM.R.IppolitoG.Persistent detection of" exact="Zika" post="virus RNA in semen for six months after symptom"/>
   <result pre="al.Zika virus in semen and spermatozoaLancet Infect. Dis.2016161106110710.1016/S1473-3099(16)30336-X27676340 42.HillsS.L.RussellK.HennesseyM.WilliamsC.OsterA.M.FischerM.MeadP.Transmission of" exact="Zika" post="Virus Through Sexual Contact with Travelers to Areas of"/>
   <result pre="Morb. Mortal. Wkly. Rep.20166521521610.15585/mmwr.mm6508e226937739 43.D’OrtenzioE.MatheronS.YazdanpanahY.de LamballerieX.HubertB.PiorkowskiG.MaquartM.DescampsD.DamondF.Leparc-GoffartI.Evidence of Sexual Transmission of" exact="Zika" post="VirusN. Engl. J. Med.20163742195219810.1056/NEJMc160444927074370 44.FrankC.CadarD.SchlaphofA.NeddersenN.GuntherS.Schmidt-ChanasitJ.TappeD.Sexual transmission of Zika virus"/>
   <result pre="Transmission of Zika VirusN. Engl. J. Med.20163742195219810.1056/NEJMc160444927074370 44.FrankC.CadarD.SchlaphofA.NeddersenN.GuntherS.Schmidt-ChanasitJ.TappeD.Sexual transmission of" exact="Zika" post="virus in Germany, April 2016Eurosurveillance2016213025210.2807/1560-7917.ES.2016.21.23.3025227311329 45.VenturiG.ZammarchiL.FortunaC.RemoliM.E.BenedettiE.FiorentiniC.TrottaM.RizzoC.MantellaA.RezzaG.et al.An autochthonous case"/>
   <result pre="virus in Germany, April 2016Eurosurveillance2016213025210.2807/1560-7917.ES.2016.21.23.3025227311329 45.VenturiG.ZammarchiL.FortunaC.RemoliM.E.BenedettiE.FiorentiniC.TrottaM.RizzoC.MantellaA.RezzaG.et al.An autochthonous case of" exact="Zika" post="due to possible sexual transmission, Florence, Italy, 2014Eurosurveillance2016213014810.2807/1560-7917.ES.2016.21.8.3014826939607 46.PolenK.D.GilboaS.M.HillsS.OduyeboT.KohlK.S.BrooksJ.T.AdamskiA.SimeoneR.M.WalkerA.T.KissinD.M.et"/>
   <result pre="Guidance for Preconception Counseling and Prevention of Sexual Transmission of" exact="Zika" post="Virus for Men with Possible Zika Virus Exposure—United States,"/>
   <result pre="of Sexual Transmission of Zika Virus for Men with Possible" exact="Zika" post="Virus Exposure—United States, August 2018MMWR Morb. Mortal. Wkly. Rep.20186786887110.15585/mmwr.mm6731e230091965"/>
   <result pre="States, August 2018MMWR Morb. Mortal. Wkly. Rep.20186786887110.15585/mmwr.mm6731e230091965 47.HarrowerJ.KiedrzynskiT.BakerS.UptonA.RahnamaF.SherwoodJ.HuangQ.S.ToddA.PulfordD.Sexual Transmission of" exact="Zika" post="Virus and Persistence in Semen, New Zealand, 2016Emerg. Infect."/>
   <result pre="in the History of MedicineActa Med. Port.20152867968010.20344/amp.734126849748 49.CordeiroM.T.PenaL.J.BritoC.A.GilL.H.MarquesE.T.Positive IgM for" exact="Zika" post="virus in the cerebrospinal fluid of 30 neonates with"/>
   <result pre="microcephaly in BrazilLancet20163871811181210.1016/S0140-6736(16)30253-7 50.LimaG.P.RozenbaumD.PimentelC.FrotaA.C.C.VivacquaD.MachadoE.S.SztajnbokF.AbreuT.SoaresR.A.HoferC.B.Factors associated with the development of Congenital" exact="Zika" post="Syndrome: A case-control studyBMC Infect. Dis.20191927710.1186/s12879-019-3908-430902046 51.ViannaR.A.O.LoveroK.L.OliveiraS.A.FernandesA.R.SantosT.LimaL.CarvalhoF.R.QuintansM.D.S.BuenoA.C.TorbeyA.F.M.et al.Children Born"/>
   <result pre="Infect. Dis.20191927710.1186/s12879-019-3908-430902046 51.ViannaR.A.O.LoveroK.L.OliveiraS.A.FernandesA.R.SantosT.LimaL.CarvalhoF.R.QuintansM.D.S.BuenoA.C.TorbeyA.F.M.et al.Children Born to Mothers with Rash During" exact="Zika" post="Virus Epidemic in Brazil: First 18 Months of LifeJ."/>
   <result pre="Rio de JaneiroN. Engl. J. Med.20163752321233410.1056/NEJMoa160241226943629 54.RobbianiD.F.OlsenP.C.CostaF.WangQ.OliveiraT.Y.NeryN.Jr.AromolaranA.do RosarioM.S.SacramentoG.A.CruzJ.S.et al.Risk of" exact="Zika" post="microcephaly correlates with features of maternal antibodiesJ. Exp. Med.201910.1084/jem.2019106131413072"/>
   <result pre="Souza AndradeA.CandianiT.M.S.CrispimA.P.C.GaspariniM.C.S.CastroF.S.de SousaA.Z.A.ViegasE.C.C.et al.Central and peripheral nervous system involvement in" exact="Zika" post="virus infection in a childJ. Neurovirol.201910.1007/s13365-019-00770-x31222674 56.MecharlesS.HerrmannC.PoullainP.TranT.H.DeschampsN.MathonG.LandaisA.BreurecS.LannuzelA.Acute myelitis due"/>
   <result pre="virus infection in a childJ. Neurovirol.201910.1007/s13365-019-00770-x31222674 56.MecharlesS.HerrmannC.PoullainP.TranT.H.DeschampsN.MathonG.LandaisA.BreurecS.LannuzelA.Acute myelitis due to" exact="Zika" post="virus infectionLancet2016387148110.1016/S0140-6736(16)00644-926946926 57.LindseyN.P.PorseC.C.PottsE.HyunJ.SandhuK.SchiffmanE.CervantesK.B.WhiteJ.L.MasonK.OwensK.et al.Postnatally acquired Zika virus disease among"/>
   <result pre="56.MecharlesS.HerrmannC.PoullainP.TranT.H.DeschampsN.MathonG.LandaisA.BreurecS.LannuzelA.Acute myelitis due to Zika virus infectionLancet2016387148110.1016/S0140-6736(16)00644-926946926 57.LindseyN.P.PorseC.C.PottsE.HyunJ.SandhuK.SchiffmanE.CervantesK.B.WhiteJ.L.MasonK.OwensK.et al.Postnatally acquired" exact="Zika" post="virus disease among children, United States, 2016–2017Clin. Infect. Dis.2019ciz19510.1093/cid/ciz19530855072"/>
   <result pre="disease among children, United States, 2016–2017Clin. Infect. Dis.2019ciz19510.1093/cid/ciz19530855072 58.collab: Singapore" exact="Zika" post="Study, G.Outbreak of Zika virus infection in Singapore: An"/>
   <result pre="States, 2016–2017Clin. Infect. Dis.2019ciz19510.1093/cid/ciz19530855072 58.collab: Singapore Zika Study, G.Outbreak of" exact="Zika" post="virus infection in Singapore: An epidemiological, entomological, virological, and"/>
   <result pre="Genet. Evol.20196919920210.1016/j.meegid.2019.01.02630703541 60.GrubaughN.D.SarafS.GangavarapuK.WattsA.TanA.L.OidtmanR.J.LadnerJ.T.OliveiraG.MattesonN.L.KraemerM.U.G.et al.Travel Surveillance and Genomics Uncover a Hidden" exact="Zika" post="Outbreak during the Waning EpidemicCell20191781057107110.1016/j.cell.2019.07.01831442400 Figure 1 Novel aspects"/>
   <result pre="during the Waning EpidemicCell20191781057107110.1016/j.cell.2019.07.01831442400 Figure 1 Novel aspects of contemporary" exact="Zika" post="virus (ZIKV) outbreaks. Recent ZIKV outbreaks have highlighted the"/>
   <result pre="1 Novel aspects of contemporary Zika virus (ZIKV) outbreaks. Recent" exact="ZIKV" post="outbreaks have highlighted the novel epidemic capacity of the"/>
   <result pre="have highlighted the novel epidemic capacity of the virus. Furthermore," exact="ZIKV" post="has been shown to disseminate to many sites throughout"/>
   <result pre="shown to disseminate to many sites throughout the body and" exact="ZIKV" post="RNA has been persistently detected long after infection in"/>
   <result pre="infection in semen and in the vaginal tract. Most strikingly," exact="ZIKV" post="has been associated with Guillain-Barré syndrome and congenital Zika"/>
   <result pre="strikingly, ZIKV has been associated with Guillain-Barré syndrome and congenital" exact="Zika" post="syndrome (CZS), with impacts on neurodevelopment occurring even in"/>
   <result pre="occurs early during pregnancy. Abbreviations: CSF, cerebrospinal fluid; CZS, congenital" exact="Zika" post="syndrome; ZIKV, Zika virus."/>
   <result pre="pregnancy. Abbreviations: CSF, cerebrospinal fluid; CZS, congenital Zika syndrome; ZIKV," exact="Zika" post="virus."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834095\results\search\tropicalVirus\results.xml">
   <result pre="Neurology: Internal Medicine: Infectious Disease Amyotrophic Lateral Sclerosis-like Syndrome after" exact="Chikungunya" post="MuacevicAlexanderAdlerJohn R AndradeFelipe César1VergettiVinicius1CozzaGabriella2FalcaoMaria Clara1AzevedoGustavo3[1], [2], [3], Felipe César"/>
   <result pre="to present a case that occurred after the epidemic of" exact="Zika" post="and CHK in Pernambuco, Brazil in 2016 with characteristics"/>
   <result pre="lower limbs after seven months of suspected arboviral disease during" exact="Zika" post="and CHK epidemics in Pernambuco, Brazil, evolving with gradual"/>
   <result pre="IgG for CHK was elevated in the CSF. Serology for" exact="Zika" post="virus was negative. She presented signs of arthritis in"/>
   <result pre="refers to an ALS-like syndrome after an infection by the" exact="Chikungunya" post="virus (CHIKV). CHIKV is an arbovirus belonging to the"/>
   <result pre="ALS-like syndrome after an infection by the Chikungunya virus (CHIKV)." exact="CHIKV" post="is an arbovirus belonging to the family Togaviridae, genus"/>
   <result pre="reportsIndian J Crit Care MedMahtoSKGuptaPKSin ghAMeenaRC30630822201829743772 11Chikungunya: epidemiologyF1000ResPetersenLRPowersAM052016 12Arrival of" exact="Chikungunya" post="virus in the new world: prospects for spread and"/>
   <result pre="healthPLoS Negl Trop DisWeaverSC292182014 13Emergence and potential for spread of" exact="Chikungunya" post="virus in BrazilBMC MedNunesMRTFariaNRde VasconcelosJMet al.102132015https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0348-x25976325"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6834551\results\search\tropicalVirus\results.xml">
   <result pre="Original Research Vaccine-Induced Skewing of T Cell Responses Protects Against" exact="Chikungunya" post="Virus Disease BroeckelRebecca M.1†HaeseNicole1AndoTakeshi1DmitrievIgor2KreklywichCraig N.1PowersJohn1DentonMichael1SmithPatricia1MorrisonThomas E.3HeiseMark45DeFilippisVictor1MessaoudiIlhem6CurielDavid T.2StreblowDaniel N.17*†[], 1Vaccine"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="Chikungunya" post="virus (CHIKV) infections can cause severe and debilitating joint"/>
   <result pre="joint and muscular pain that can be long lasting. Current" exact="CHIKV" post="vaccines under development rely on the generation of neutralizing"/>
   <result pre="for protection; however, the role of T cells in controlling" exact="CHIKV" post="infection and disease is still unclear. Using an overlapping"/>
   <result pre="T cell responses to higher levels than normally observed following" exact="CHIKV" post="infection, but the vaccine vectors did not elicit neutralizing"/>
   <result pre="had significantly reduced infectious viral load when challenged by intramuscular" exact="CHIKV" post="injection. Depletion of both CD4+ and CD8+ T cells"/>
   <result pre="cells in vaccinated mice rendered them fully susceptible to intramuscular" exact="CHIKV" post="challenge. Depletion of CD8+ T cells alone reduced vaccine"/>
   <result pre="data demonstrated a protective role for CD8+ T cells in" exact="CHIKV" post="infection. However, CHKVf5-vaccinated mice that were challenged by footpad"/>
   <result pre="vectors expressing only CHIKV-specific CD8+ T cell epitopes followed by" exact="CHIKV" post="challenge in the footpad prevented footpad swelling and reduced"/>
   <result pre="associated with disease, indicating that CHIKV-specific CD8+ T cells prevent" exact="CHIKV" post="disease. These results also indicate that a T cell-biased"/>
   <result pre="that a T cell-biased prophylactic vaccination approach is effective against" exact="CHIKV" post="challenge and reduces CHIKV-induced disease in mice. Chikungunya virus"/>
   <result pre="effective against CHIKV challenge and reduces CHIKV-induced disease in mice." exact="Chikungunya" post="virus (CHIKV) vaccine T cell pathogenesis cytokine Funding Foundation"/>
   <result pre="Institutes of Health10.13039/100000009 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) is a mosquito-transmitted virus that causes fever,"/>
   <result pre="reporting limited mobility, depression, and decreased quality of life (4)." exact="CHIKV" post="can rapidly spread and cause disease in millions of"/>
   <result pre="could be involved in viral clearance of persistent joint-localized CHIKV." exact="CHIKV" post="vaccine candidates under development elicit both humoral and cellular"/>
   <result pre="candidates under development elicit both humoral and cellular responses to" exact="CHIKV" post="antigens. CHIKV vaccines currently being pursued in clinical trials"/>
   <result pre="development elicit both humoral and cellular responses to CHIKV antigens." exact="CHIKV" post="vaccines currently being pursued in clinical trials cover a"/>
   <result pre="the direct contribution of vaccine-induced T cells in protection against" exact="CHIKV" post="is rarely characterized. Two preclinical vaccines, the live-attenuated CHIKV/IRES"/>
   <result pre="cells (17–20). Both vaccines elicited humoral and cellular responses against" exact="CHIKV" post="antigens. However, in the context of vaccine-induced neutralizing antibodies,"/>
   <result pre="or CD8+ T cells did not protect A129 mice from" exact="CHIKV" post="(18). However, a modified vaccinia virus ankara (MVA) vaccine"/>
   <result pre="for protection since CD4+ T cell depletion increased susceptibility to" exact="CHIKV" post="challenge (20). While low levels of E2 neutralizing antibodies"/>
   <result pre="been implicated as a major contributor to joint inflammation during" exact="CHIKV" post="infection of mice. Footpad injection of C57BL/6 mice with"/>
   <result pre="CHIKV infection of mice. Footpad injection of C57BL/6 mice with" exact="CHIKV" post="results in edema, arthritis, and tenosynovitis in the ankle"/>
   <result pre="footpad swelling and joint vascular leakage compared to controls after" exact="CHIKV" post="infection, while viral load in the blood remained the"/>
   <result pre="controls (23). Furthermore, therapeutic administration of mice with CTLA4-Ig after" exact="CHIKV" post="infection inhibited T cell recruitment to the ankle and"/>
   <result pre="unclear. Some evidence suggest T cells promote viral clearance during" exact="CHIKV" post="infection. Mice lacking B and T cells (Rag1−/− or"/>
   <result pre="transfer of neutralizing antibodies into Rag1−/− mice fails to clear" exact="CHIKV" post="in tissues of persistently infected animals (9). In addition,"/>
   <result pre="lacking mature B cells (μMT mice) vaccinated with an inactivated" exact="CHIKV" post="vaccine have decreased levels of virus in the serum"/>
   <result pre="of virus in the serum compared to control-vaccinated mice after" exact="CHIKV" post="challenge, although the vaccinated mice also had increased footpad"/>
   <result pre="suggestive of a role of cellular immunity in protection against" exact="CHIKV" post="infection. Antiviral CD8+ T cells have been shown to"/>
   <result pre="the role for antiviral CD4+ and CD8+ T cells during" exact="CHIKV" post="infection. We profiled T cell epitopes recognized in CHIKV"/>
   <result pre="during CHIKV infection. We profiled T cell epitopes recognized in" exact="CHIKV" post="mice using a complete CHIKV (22) overlapping peptide library."/>
   <result pre="T cell epitopes recognized in CHIKV mice using a complete" exact="CHIKV" post="(22) overlapping peptide library. Based upon the results from"/>
   <result pre="Based upon the results from this screen, we generated a" exact="CHIKV" post="fusion gene called CHIKVf5 that encodes several peptides that"/>
   <result pre="study describes a protective role for CD8+ T cells in" exact="CHIKV" post="infection and disease. Materials and Methods Cells Vero cells,"/>
   <result pre="CO2 in DMEM supplemented with 10% FBS and PSG. Viruses" exact="CHIKV" post="SL15649 and CHIKV 181/25 was generated from the infectious"/>
   <result pre="supplemented with 10% FBS and PSG. Viruses CHIKV SL15649 and" exact="CHIKV" post="181/25 was generated from the infectious clones. Briefly, the"/>
   <result pre="RNA was transfected into Vero cells using Lipofectamine 2000 (ThermoFisher)." exact="CHIKV" post="virus stocks were passaged once C6/36 cells for 72"/>
   <result pre="resuspended in PBS and aliquots were stored at −80°C. For" exact="CHIKV" post="limiting dilution plaque assays, 10-fold serial dilutions of virus"/>
   <result pre="thigh (108 PFU, i.m.). Mice were challenged with 103 PFU" exact="CHIKV" post="in a 20 μl volume in the footpad (f.p.),"/>
   <result pre="5% FBS and PSG. Roughly 100 plaque forming units of" exact="CHIKV" post="181/25 were added to serum dilutions, and the complexes"/>
   <result pre="and graphed using GraphPad Prism v6 software. Results Identification of" exact="CHIKV" post="T Cell Epitopes in C57BL/6 Mice Few dominant CHIKV"/>
   <result pre="of CHIKV T Cell Epitopes in C57BL/6 Mice Few dominant" exact="CHIKV" post="T cell epitopes have been experimentally described in C57BL/6"/>
   <result pre="mice (23, 36). To identify T cell epitopes recognized during" exact="CHIKV" post="infection of C57BL/6 mice, we screened T cell responses"/>
   <result pre="we screened T cell responses by IFNγ ELISpot using a" exact="CHIKV" post="18mer peptide library with 10 amino acid overlap. For"/>
   <result pre="splenocytes were isolated and pooled from three mice infected with" exact="CHIKV" post="for 7 or 14 days (Figure 1A) and cultured"/>
   <result pre="wells were scanned and spots were enumerated. We identified several" exact="CHIKV" post="peptides that elicited an IFNγ response that mapped to"/>
   <result pre="responses in C57BL/6 mice at 7 and 14 days post" exact="CHIKV" post="infection. Mice were infected with 1,000 PFU CHIKV SL15649"/>
   <result pre="days post CHIKV infection. Mice were infected with 1,000 PFU" exact="CHIKV" post="SL15649 in the footpad. At 7 or 14 dpi,"/>
   <result pre="14 dpi, mouse splenocytes were isolated and incubated with individual" exact="CHIKV" post="18-mer peptides overlapping by 10 amino acids and 1e5"/>
   <result pre="from three mice were pooled and incubated with each individual" exact="CHIKV" post="18-mer in the CHIKV peptidome. Peptide numbers for reactive"/>
   <result pre="pooled and incubated with each individual CHIKV 18-mer in the" exact="CHIKV" post="peptidome. Peptide numbers for reactive samples are indicated. (B)"/>
   <result pre="immunoreactive peptides in C57BL/6 mice. 18-mer peptide sequence Peptide #" exact="CHIKV" post="protein MSDRKYHCVCPMRSAEDP 10 nsP1 VYAVHAPTSLYHQAIKGV 20 nsP1 HLKGKLSFTCRCDTVVSC 34"/>
   <result pre="E1 KDHIVNYPASHTTLGVQD 458 E1 Splenocytes from C57BL/6 mice infected with" exact="CHIKV" post="were stimulated with CHIKV-specific 18-mer overlapping peptides, and IFNγ"/>
   <result pre="bold lettering. Generation of MCMV and AdV-Vectored Vaccines Directed Against" exact="CHIKV" post="A fusion polypeptide (CHKVf5) was constructed containing two peptides"/>
   <result pre="fusion gene. (A) Shown is the genomic position of the" exact="CHIKV" post="peptides contained in CHIKVf5. (B) The CHIKVf5 fusion gene"/>
   <result pre="3 CHKVf5 vaccines did not protect mice against a footpad" exact="CHIKV" post="challenge. (A) Mice were administered MCMV-CHKVf5, MCMV WT, or"/>
   <result pre="IFNγ ELISpot assays were performed by stimulating the splenocytes with" exact="CHIKV" post="peptides incorporated in the CHKVf5 fusion gene. (C) IFNγ"/>
   <result pre="from mice vaccinated with the indicated vaccine and challenged with" exact="CHIKV" post="SL15649 in the footpad (&quot;#�? indicates too numerous to"/>
   <result pre="by qRT-PCR. The remaining animals were challenged with 1,000 PFU" exact="CHIKV" post="SL15649 s.c. in the right footpad, and four mice"/>
   <result pre="all vaccine groups (Figure 3C). While control mice challenged with" exact="CHIKV" post="developed IFNγ responses to CHIKV peptides, CHKf5-vaccined mice had"/>
   <result pre="While control mice challenged with CHIKV developed IFNγ responses to" exact="CHIKV" post="peptides, CHKf5-vaccined mice had a higher frequency of responding"/>
   <result pre="CHKf5-vaccined mice had a higher frequency of responding cells. After" exact="CHIKV" post="challenge, footpad swelling was monitored from 3 to 16"/>
   <result pre="that T cells do not reduce viral load in the" exact="CHIKV" post="footpad infection model (22, 23). CHKVf5 Vaccines Induced Protective"/>
   <result pre="Protective Responses in Mice Challenged Intramuscularly In general, s.c. footpad" exact="CHIKV" post="infection quickly replicates to high titers in the ankle,"/>
   <result pre="contralateral calf muscle. Figure 4 C57BL/6 mice were infected with" exact="CHIKV" post="by three different routes, and their footpad swelling and"/>
   <result pre="distributions are compared. C57BL/6 mice were infected with 1,000 PFU" exact="CHIKV" post="SL15649 intramuscularly in the right calf (i.m. R calf),"/>
   <result pre="higher levels of IFNγ expressing T cells in response to" exact="CHIKV" post="peptide stimulation compared to the MCMV vaccine platform, T"/>
   <result pre="to CHIKV, but their splenocytes produce IFNγ in response to" exact="CHIKV" post="peptide stimulation. (A) Mice were vaccinated with the indicated"/>
   <result pre="(A) Mice were vaccinated with the indicated vaccine, challenged with" exact="CHIKV" post="i.m., and harvested at 5 dpi. (B) Prior to"/>
   <result pre="CHIKV i.m., and harvested at 5 dpi. (B) Prior to" exact="CHIKV" post="challenge, IFNγ ELISpot assays were performed on vaccinated mice"/>
   <result pre="assay positive controls included convalescent mouse sera from a previously" exact="CHIKV" post="infected mouse (shown in purple) as well as a"/>
   <result pre="T cell depleting antibodies had significantly reduced levels of infectious" exact="CHIKV" post="present in the calf muscle relative to animals that"/>
   <result pre="However, depletion of CD8+ T cells increased levels of infectious" exact="CHIKV" post="present in the calf, which was enhanced in mice"/>
   <result pre="while CD8+ T cells are required for vaccine-mediated protection against" exact="CHIKV" post="i.m. challenge, CD4+ and CD8+ T cells cooperate to"/>
   <result pre="prior to challenge. Mice were infected i.m. with 10,000 PFU" exact="CHIKV" post="SL15649, and (B) ankle and calf tissue viral loads"/>
   <result pre="(D) Splenocytes from vaccinated mice were collected and stimulated with" exact="CHIKV" post="peptides on ELISpot plates. The results of the ELISpot"/>
   <result pre="all groups (Figure 6B). Data in Figure 6C demonstrate that" exact="CHIKV" post="neutralizing antibodies were not present in the vaccinated mice"/>
   <result pre="antibodies were not present in the vaccinated mice prior to" exact="CHIKV" post="challenge. In addition, splenocytes from the various groups were"/>
   <result pre="the muscle tissue. CD8-Specific AdV 260 and AdV 451 Reduce" exact="CHIKV" post="Disease Since CD8+ T cells were essential for the"/>
   <result pre="the CHKVf5 vaccine, we generated adenoviruses individually expressing the CD8-specific" exact="CHIKV" post="peptides 260 and 451. CHIKV-specific T cell responses in"/>
   <result pre="An additional cohort of these vaccinated mice were challenged with" exact="CHIKV" post="i.m. AdV 260 vaccination alone resulted in significantly reduced"/>
   <result pre="with adenovirus-delivered peptides 260 and 451 are protective against i.m." exact="CHIKV" post="challenge. Figure 7 AdV-260 and AdV-451 vaccination elicits T"/>
   <result pre="AdV-451 vaccination elicits T cells responses and protects mice from" exact="CHIKV" post="in ipsilateral calf. (A) Mice were vaccinated with AdV-260"/>
   <result pre="or PBS (i.m.). Mice were infected i.m. with 10,000 PFU" exact="CHIKV" post="SL15649. (B) Prior to CHIKV challenge, IFNγ ELISpot assays"/>
   <result pre="infected i.m. with 10,000 PFU CHIKV SL15649. (B) Prior to" exact="CHIKV" post="challenge, IFNγ ELISpot assays were performed on a subset"/>
   <result pre="protection for the AdV-260 and AdV-451 vaccines using the f.p." exact="CHIKV" post="challenge model as outlined in Figure 8A. Footpad swelling"/>
   <result pre="AdV (Figure 8B), despite having no statistically significant effect on" exact="CHIKV" post="viral RNA loads in the ipsilateral ankles at 8"/>
   <result pre="with AdV-260, AdV-451, or AdV-Control (i.m.) followed by 1,000 PFU" exact="CHIKV" post="challenge in the right footpad. (B) Footpad swelling was"/>
   <result pre="footpad. (B) Footpad swelling was measured for 13 days after" exact="CHIKV" post="footpad challenge. Statistics were performed using Dunnett's multiple comparison"/>
   <result pre="both AdV-260 and AdV-451. Mice were challenged with 1,000 PFU" exact="CHIKV" post="in the footpad. (F) Survival of Ifnar−/− mice vaccinated"/>
   <result pre="with AdV-260 and AdV-451 could improve survival in a lethal" exact="CHIKV" post="mouse model. Mice lacking the type I IFN receptor"/>
   <result pre="the type I IFN receptor (Ifnar1−/−) are extremely susceptible to" exact="CHIKV" post="and succumb to virus infection 3-4 dpi (40), and"/>
   <result pre="cell vaccine could protect immunocompetent mice from footpad swelling after" exact="CHIKV" post="f.p. challenge, and the vaccine provided significant survival advantage"/>
   <result pre="was unknown what role T cells play in protection against" exact="CHIKV" post="infection and disease. In the current study, we mapped"/>
   <result pre="the current study, we mapped the T cell responses to" exact="CHIKV" post="in C57BL/6 mice using an overlapping CHIKV peptide library"/>
   <result pre="cell responses to CHIKV in C57BL/6 mice using an overlapping" exact="CHIKV" post="peptide library in order to identify potential CHIKV targets"/>
   <result pre="an overlapping CHIKV peptide library in order to identify potential" exact="CHIKV" post="targets for development of a T cell vaccine. During"/>
   <result pre="either CD4+ or CD8+ T cells failed to fully restore" exact="CHIKV" post="tissue load to control levels. However, depletion of CD8+"/>
   <result pre="is required for full efficacy but these cells specifically enhance" exact="CHIKV" post="inflammatory joint disease. Second, the CHKVf5 vaccine does not"/>
   <result pre="disease. Second, the CHKVf5 vaccine does not contain any known" exact="CHIKV" post="neutralizing domains. As such, we did not detect neutralizing"/>
   <result pre="domains. As such, we did not detect neutralizing antibodies against" exact="CHIKV" post="in any of the vaccinated mice, and the generation"/>
   <result pre="the vaccinated mice, and the generation of antibody responses against" exact="CHIKV" post="following challenge developed with normal kinetics and amplitude when"/>
   <result pre="vaccine constructs elicit robust T cell responses that protected against" exact="CHIKV" post="in muscle tissues. Finally, we showed that vaccination with"/>
   <result pre="footpad challenge, but it reduced footpad swelling and inflammation following" exact="CHIKV" post="challenge. In addition, the CD8+ T cell vaccine provided"/>
   <result pre="enhanced survival for Ifnar1−/− mice. T cell responses directed against" exact="CHIKV" post="have been reported in humans during both the acute"/>
   <result pre="cells (41). Following the acute phase, patients who recovered from" exact="CHIKV" post="and patients with chronic CHIKV-induced arthritis both had roughly"/>
   <result pre="(42). There is also evidence that T cells can enter" exact="CHIKV" post="infected joint tissues in humans. In a synovial biopsy"/>
   <result pre="infiltrate, but oddly, CD8+ T cells were rarely found (1)." exact="CHIKV" post="RNA and antigen have been detected in joint synovial"/>
   <result pre="Though it is not known whether T cells protect against" exact="CHIKV" post="in humans, our data would suggest that the presence"/>
   <result pre="We showed that vaccinated animals had a significant reduction of" exact="CHIKV" post="titers in the calf muscle. The tissue-specific protection is"/>
   <result pre="directed against different epitopes when compared to those observed following" exact="CHIKV" post="infection. For example, splenocytes from CHIKV infected mice had"/>
   <result pre="to those observed following CHIKV infection. For example, splenocytes from" exact="CHIKV" post="infected mice had high frequencies of IFNγ responses to"/>
   <result pre="in induction of a diverse T cell memory response to" exact="CHIKV" post="epitopes resulting in a more protective phenotype. Neutralizing antibodies"/>
   <result pre="for CHIKV, and it would be essential for a prophylactic" exact="CHIKV" post="vaccine to induce neutralizing antibody responses to protect from"/>
   <result pre="CHIKV vaccine to induce neutralizing antibody responses to protect from" exact="CHIKV" post="acquisition. The data presented here show that a CD8-directed"/>
   <result pre="skew the responses toward additional epitopes for increased protection against" exact="CHIKV" post="acquisition. This approach could be effective for eliminating CHIKV-induced"/>
   <result pre="will examine the effects of therapeutic T cell vaccines against" exact="CHIKV" post="persistence and disease. Data Availability Statement This manuscript contains"/>
   <result pre="1.HoarauJJJaffar BandjeeMCKrejbich TrototPDasTLi-Pat-YuenGDassaBet al.. Persistent chronic inflammation and infection by" exact="Chikungunya" post="arthritogenic alphavirus in spite of a robust host immune"/>
   <result pre="10.4049/jimmunol.090025520404278 2.GérardinPFianuAMalvyDMussardCBoussaïdKRollotOet al.. Perceived morbidity and community burden after a" exact="Chikungunya" post="outbreak: the TELECHIK survey, a population-based cohort study. BMC"/>
   <result pre="population-based cohort study. BMC Med. (2011) 9:5. 10.1186/1741-7015-9-521235760 3.SchilteCStaikowskyFStaikovskyFCoudercTMadecYCarpentierFet al.." exact="Chikungunya" post="virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS"/>
   <result pre="Res. (2015) 120:32–9. 10.1016/j.antiviral.2015.04.01625979669 8.CoudercTKhandoudiNGrandadamMVisseCGangneuxNBagotSet al.. Prophylaxis and therapy for" exact="Chikungunya" post="virus infection. J Infect Dis. (2009) 200:516–23. 10.1086/60038119572805 9.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet"/>
   <result pre="200:516–23. 10.1086/60038119572805 9.HawmanDWStoermerKAMontgomerySAPalPOkoLDiamondMSet al.. Chronic joint disease caused by persistent" exact="Chikungunya" post="virus infection is controlled by the adaptive immune response."/>
   <result pre="dose-escalation trial. Lancet. (2014) 384:2046–52. 10.1016/S0140-6736(14)61185-525132507 13.HallengärdDKakoulidouMLullaAKümmererBMJohanssonDXMutsoMet al.. Novel attenuated" exact="Chikungunya" post="vaccine candidates elicit protective immunity in C57BL/6 mice. J"/>
   <result pre="and active-controlled phase 2 trial. Lancet. (2019) 392:2718–27. 10.1016/S0140-6736(18)32488-730409443 16.RezzaGWeaverSC." exact="Chikungunya" post="as a paradigm for emerging viral diseases: evaluating disease"/>
   <result pre="of adaptive immunity to CHIKV/IRES a novel candidate vaccine against" exact="Chikungunya" post="in the A129 mouse model. Vaccine. (2013) 31:3353–60. 10.1016/j.vaccine.2013.05.05923727003"/>
   <result pre="the A129 mouse model. Vaccine. (2013) 31:3353–60. 10.1016/j.vaccine.2013.05.05923727003 19.RoyCJAdamsAPWangEPlanteKGorchakovRSeymourRLet al.." exact="Chikungunya" post="vaccine candidate is highly attenuated and protects nonhuman primates"/>
   <result pre="Infect Dis. (2014) 209:1891–9. 10.1093/infdis/jiu01424403555 20.Weger-LucarelliJChuHAliotaMTPartidosCDOsorioJE. A novel MVA vectored" exact="Chikungunya" post="virus vaccine elicits protective immunity in mice. PLoS Negl"/>
   <result pre="22.TeoTHLumFMClaserCLullaVLullaAMeritsAet al.. A pathogenic role for CD4+ T cells during" exact="Chikungunya" post="virus infection in mice. J Immunol. (2013) 190:259–69. 10.4049/jimmunol.120217723209328"/>
   <result pre="10.1038/ncomms1352027901019 36.MuthumaniKLankaramanKMLaddyDJSundaramSGChungCWSakoEet al.. Immunogenicity of novel consensus-based DNA vaccines against" exact="Chikungunya" post="virus. Vaccine. (2008) 26:5128–34. 10.1016/j.vaccine.2008.03.06018471943 37.PratheekBMSuryawanshiARChattopadhyayS. In silico analysis"/>
   <result pre="10.1016/j.vaccine.2008.03.06018471943 37.PratheekBMSuryawanshiARChattopadhyayS. In silico analysis of MHC-I restricted epitopes of" exact="Chikungunya" post="virus proteins: implication in understanding anti-CHIKV CD8(+) T cell"/>
   <result pre="T cell response and advancement of epitope based immunotherapy for" exact="CHIKV" post="infection. Infect Genet Evol. (2015) 31:118–26. 10.1016/j.meegid.2015.01.01725643869 38.KarrerUWagnerMSierroSOxeniusAHengelHDumreseTet al.."/>
   <result pre="PLoS Pathog. (2008) 4:e29. 10.1371/journal.ppat.004002918282093 41.WauquierNBecquartPNkogheDPadillaCNdjoyi-MbiguinoALeroyEM. The acute phase of" exact="Chikungunya" post="virus infection in humans is associated with strong innate"/>
   <result pre="of the T cell responses against E2, nsP1 and capsid" exact="CHIKV" post="proteins in recovered and chronic patients after the epidemics"/>
   <result pre="10.1371/journal.pone.008469524376836 43.OzdenSHuerreMRiviereJPCoffeyLLAfonsoPVMoulyVet al.. Human muscle satellite cells as targets of" exact="Chikungunya" post="virus infection. PLoS ONE. (2007) 2:e527. 10.1371/journal.pone.000052717565380 44.TatsisNFitzgeraldJCReyes-SandovalAHarris-McCoyKCHensleySEZhouDet al.."/>
   <result pre="in murine cytomegalovirus infection. J Immunol. (2013) 190:3410–6. 10.4049/jimmunol.120315123455500 Abbreviations" exact="CHIKV" post="Chikungunya virus RRV Ross River virus SINV Sindbis virus"/>
   <result pre="murine cytomegalovirus infection. J Immunol. (2013) 190:3410–6. 10.4049/jimmunol.120315123455500 Abbreviations CHIKV" exact="Chikungunya" post="virus RRV Ross River virus SINV Sindbis virus VEEV"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6838024\results\search\tropicalVirus\results.xml">
   <result pre="have reported the binding of HNRNPA2B1 to Influenza virus and" exact="Dengue" post="virus RNA and explained its role in regulation of"/>
   <result pre="et al., 2014). HNRNPK binds to the core protein of" exact="Dengue" post="virus, whereas in Sindbis virus infection, it binds to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6839921\results\search\tropicalVirus\results.xml">
   <result pre="arginine substitutions at distinct residues within the E2 glycoproteins of" exact="CHIKV" post="and ONNV (E2 K200R) as well as RRV (E2"/>
   <result pre="unprecedented scale, leading to global outbreaks of diseases such as" exact="Zika" post="or chikungunya fever. The severity of these diseases and"/>
   <result pre="several decades, multiple arboviruses, including dengue (DENV), chikungunya (CHIKV), and" exact="Zika" post="(ZIKV) viruses, have re-emerged to cause widespread epidemics affecting"/>
   <result pre="can result in death (Bhatt et al., 2013). Since 2004," exact="CHIKV" post="has infected millions of people and expanded into Europe,"/>
   <result pre="stiffness, and tenosynovitis, can endure for months to years after" exact="CHIKV" post="infection (Borgherini et al., 2008; Couturier et al., 2012;"/>
   <result pre="Rodriguez-Morales et al., 2016; Schilte et al., 2013). As chronic" exact="CHIKV" post="disease is debilitating, large epidemics have severe economic impact"/>
   <result pre="al., 2015; Soumahoro et al., 2011; Vijayakumar et al., 2013)." exact="ZIKV" post="caused outbreaks on Yap Island (Duffy et al., 2009)"/>
   <result pre="being introduced to the Americas (Metsky et al., 2017). Here," exact="ZIKV" post="caused nearly one million confirmed and suspected cases and"/>
   <result pre="(K) to arginine (R) mutations in the E2 glycoproteins of" exact="CHIKV" post="and o’nyong ‘nyong virus (ONNV) (E2 K200R), as well"/>
   <result pre="rapid viral dissemination. Moreover, substitution of the lysine residues at" exact="CHIKV" post="E2 200 or RRV E2 251 with a variety"/>
   <result pre="fraction of the blood (Figure 1—figure supplement 1), demonstrating that" exact="CHIKV" post="particles had been removed from the circulation. These findings"/>
   <result pre="(CLL). At 42 hr post-treatment, mice were inoculated i.v. with" exact="CHIKV" post="(A), ONNV (B) or RRV (C), and viral genomes"/>
   <result pre="Raw data for Figure 1A-C. LINK Liver Kupffer cells clear" exact="CHIKV" post="from the circulation The spleen and liver contain phagocytic"/>
   <result pre="was evaluated in mice that underwent sham or splenectomy surgeries." exact="CHIKV" post="was efficiently cleared from the circulation of splenectomized mice"/>
   <result pre="not required for clearance of circulating CHIKV. Moreover, CLL-pretreatment blocked" exact="CHIKV" post="clearance in splenectomized mice (Figure 2B), suggesting that the"/>
   <result pre="remaining phagocytic cells in the liver are sufficient to clear" exact="CHIKV" post="from the circulation. Consistent with this, CHIKV RNA accumulated"/>
   <result pre="sufficient to clear CHIKV from the circulation. Consistent with this," exact="CHIKV" post="RNA accumulated in the liver of control PLL-treated mice,"/>
   <result pre="the high amounts of virus present in contaminating blood. Moreover," exact="CHIKV" post="RNA is readily detectable by in situ hybridization in"/>
   <result pre="particles from the circulation. Figure 2. Liver Kupffer cells clear" exact="CHIKV" post="from the circulation. (A) WT C57BL/6 mice that underwent"/>
   <result pre="underwent a sham or splenectomy surgery were inoculated i.v. with" exact="CHIKV" post="and viral genomes in the inoculum and serum at"/>
   <result pre="CLL. At 42 hr post-treatment, mice were inoculated i.v. with" exact="CHIKV" post="and viral genomes in the inoculum (input) and serum"/>
   <result pre="C57BL/6 mice were treated as in (B) and inoculated with" exact="CHIKV" post="at 42 hr post-treatment. Livers were collected at 45"/>
   <result pre="two experiments. Figure 2—figure supplement 1 shows representative images of" exact="CHIKV" post="RNA Scope in situ hybridization and F4/80 IHC for"/>
   <result pre="and Jenne, 2018; van Lookeren Campagne et al., 2007). However," exact="CHIKV" post="and RRV particles were efficiently cleared from the circulation"/>
   <result pre="with CLL, poly(I) pretreatment potently inhibited the clearance of circulating" exact="CHIKV" post="and RRV particles (Figure 3C). Similar results were observed"/>
   <result pre="1998). To investigate the relative contributions of SR-A1 and MARCO," exact="CHIKV" post="clearance was evaluated in SR-A1-/- and MARCO-/- mice. CHIKV"/>
   <result pre="MARCO, CHIKV clearance was evaluated in SR-A1-/- and MARCO-/- mice." exact="CHIKV" post="particles were efficiently cleared from the circulation of SR-A1-/-"/>
   <result pre="pre-treatment of SR-A1-/- mice with poly(I) (Figure 3E), indicating that" exact="CHIKV" post="clearance was still occurring through a SR-dependent mechanism. In"/>
   <result pre="clearance was still occurring through a SR-dependent mechanism. In contrast," exact="CHIKV" post="particles remained readily detectable in the serum of MARCO-/-"/>
   <result pre="3F). Moreover, whereas pretreatment with CLL blocked clearance of circulating" exact="CHIKV" post="particles in WT mice, this treatment had no effect"/>
   <result pre="mice, this treatment had no effect on the level of" exact="CHIKV" post="in the circulation of MARCO-/- mice (Figure 3G). Furthermore,"/>
   <result pre="CHIKV in the circulation of MARCO-/- mice (Figure 3G). Furthermore," exact="CHIKV" post="RNA was detectable by in situ hybridization in the"/>
   <result pre="these findings demonstrate that MARCO is essential for clearance of" exact="CHIKV" post="particles from the circulation. Figure 3. The scavenger receptor"/>
   <result pre="3. The scavenger receptor MARCO is required for clearance of" exact="CHIKV" post="and RRV. (A) WT or C3-/- C57BL/6 mice were"/>
   <result pre="3—source data 1. Raw data for Figure 3A-G, I. LINK" exact="CHIKV" post="E2 K200R evades phagocytic cell-mediated clearance We next investigated"/>
   <result pre="clearance of alphaviral particles from the circulation. In prior studies," exact="DENV" post="and West Nile virus (WNV) clearance from the circulation"/>
   <result pre="alphaviral particles from the circulation. In prior studies, DENV and" exact="West Nile" post="virus (WNV) clearance from the circulation of mice was"/>
   <result pre="N-linked glycans on viral envelope glycoproteins (Fuchs et al., 2010)." exact="CHIKV" post="E2 is predicted to be glycosylated at N345, N263"/>
   <result pre="or in combination, had no effect on the clearance of" exact="CHIKV" post="particles from the circulation (Figure 4—figure supplement 1), demonstrating"/>
   <result pre="the circulation (Figure 4—figure supplement 1), demonstrating that clearance of" exact="CHIKV" post="particles does not rely on glycosylation at these sites."/>
   <result pre="at these sites. Previously, we identified a mutation in the" exact="CHIKV" post="E2 glycoprotein (E2 K200R) in virus persistently circulating in"/>
   <result pre="in Rag1-/- mice (Hawman et al., 2017). This mutation enhanced" exact="CHIKV" post="dissemination in mice following subcutaneous inoculation and caused more"/>
   <result pre="role for phagocytic cells and MARCO in the clearance of" exact="CHIKV" post="particles from the circulation, we hypothesized that the E2"/>
   <result pre="unlike WT CHIKV, which is efficiently cleared from the circulation," exact="CHIKV" post="E2 K200R particles remained stably detectable in the serum"/>
   <result pre="were derived, as differential clearance of WT and E2 K200R" exact="CHIKV" post="particles was maintained when virions were derived from human"/>
   <result pre="not due to differential stability of WT and E2 K200R" exact="CHIKV" post="particles (Figure 4—figure supplement 2A). Moreover, the levels of"/>
   <result pre="(Figure 4—figure supplement 2A). Moreover, the levels of E2 K200R" exact="CHIKV" post="particles in control PLL-treated mice were indistinguishable from WT"/>
   <result pre="control PLL-treated mice were indistinguishable from WT and E2 K200R" exact="CHIKV" post="particles in the circulation of mice pre-treated with CLL"/>
   <result pre="circulation of mice pre-treated with CLL (Figure 4C), demonstrating that" exact="CHIKV" post="E2 K200R allows for evasion of phagocytic cell-mediated clearance."/>
   <result pre="and BALB/cJ mouse strains (Figure 4—figure supplement 2B). Figure 4." exact="CHIKV" post="E2 K200R evades phagocytic cell-mediated clearance. (A) WT C57BL/6"/>
   <result pre="cell-mediated clearance. (A) WT C57BL/6 mice were inoculated i.v. with" exact="CHIKV" post="or CHIKV E2 K200R, and viral genomes in the"/>
   <result pre="(A) WT C57BL/6 mice were inoculated i.v. with CHIKV or" exact="CHIKV" post="E2 K200R, and viral genomes in the inoculum and"/>
   <result pre="****p&amp;lt;0.0001. (B) WT C57BL/6 mice were inoculated with human fibroblast-derived" exact="CHIKV" post="or CHIKV E2 K200R, and viral genomes in the"/>
   <result pre="WT C57BL/6 mice were inoculated with human fibroblast-derived CHIKV or" exact="CHIKV" post="E2 K200R, and viral genomes in the inoculum and"/>
   <result pre="or clodronate liposomes 42 hr prior to i.v. inoculation with" exact="CHIKV" post="or CHIKV E2 K200R. Viral genomes in the inoculum"/>
   <result pre="liposomes 42 hr prior to i.v. inoculation with CHIKV or" exact="CHIKV" post="E2 K200R. Viral genomes in the inoculum and serum"/>
   <result pre="shows that mutation of E2 glycosylation sites does not influence" exact="CHIKV" post="clearance from the circulation. Figure 4—figure supplement 2 shows"/>
   <result pre="the E2 K200R mutation does not alter the thermostability of" exact="CHIKV" post="particles in serum (A), and that the E2 K200R"/>
   <result pre="in serum (A), and that the E2 K200R mutation allows" exact="CHIKV" post="particles to evade clearance from the circulation in multiple"/>
   <result pre="effects of the E2 K200R mutation were unique to the" exact="CHIKV" post="strain tested (AF15561; Asian genotype) or functioned within broader"/>
   <result pre="we introduced an E2 K200R mutation into the genome of" exact="CHIKV" post="strains representative of all phylogenetic lineages: Asian-American (strain 99659;"/>
   <result pre="SG650 strain of ONNV (Lanciotti et al., 1998). Similar to" exact="CHIKV" post="AF15561, all WT strains of CHIKV and ONNV were"/>
   <result pre="al., 1998). Similar to CHIKV AF15561, all WT strains of" exact="CHIKV" post="and ONNV were cleared from the circulation at 45"/>
   <result pre="mutation broadly facilitates evasion of phagocytic-cell mediated clearance in multiple" exact="CHIKV" post="strains, as well as the related ONNV. An E2"/>
   <result pre="or MARCO-/- C57BL/6 mice were inoculated as in (A) with" exact="CHIKV" post="or CHIKV E2 K200R. At 24 hpi, infectious virus"/>
   <result pre="C57BL/6 mice were inoculated as in (A) with CHIKV or" exact="CHIKV" post="E2 K200R. At 24 hpi, infectious virus in the"/>
   <result pre="inoculation of virus, we inoculated MARCO-/- mice subcutaneously with WT" exact="CHIKV" post="and evaluated viral burdens at 1 d post-inoculation. Similar"/>
   <result pre="1 d post-inoculation. Similar to infection of WT mice with" exact="CHIKV" post="E2 K200R, infection of MARCO-/- mice with WT CHIKV"/>
   <result pre="with CHIKV E2 K200R, infection of MARCO-/- mice with WT" exact="CHIKV" post="resulted in an elevated viremia and more rapid viral"/>
   <result pre="5B). Collectively, these findings indicate that MARCO-dependent clearance of circulating" exact="CHIKV" post="particles controls viremia and impedes viral dissemination. CHIKV E2"/>
   <result pre="of circulating CHIKV particles controls viremia and impedes viral dissemination." exact="CHIKV" post="E2 K200R does not impact vector competence or viral"/>
   <result pre="mosquitoes. Following blood-feeding inoculation of mosquitoes, similar levels of WT" exact="CHIKV" post="and E2 K200R were detected in the bodies, legs"/>
   <result pre="in vitro and in vivo competition experiments with a WT" exact="CHIKV" post="strain genetically marked with an ApaI restriction site (CHIKV-ApaI)."/>
   <result pre="with an ApaI restriction site (CHIKV-ApaI). Control 1:1 competitions of" exact="CHIKV" post="and CHIKV-ApaI in C6/36 cells (Figure 6B) and microinjected"/>
   <result pre="fitness. Similar results were observed following direct 1:1 competition of" exact="CHIKV" post="and CHIKV E2 K200R, (Figure 6B, C and D),"/>
   <result pre="results were observed following direct 1:1 competition of CHIKV and" exact="CHIKV" post="E2 K200R, (Figure 6B, C and D), suggesting that"/>
   <result pre="findings suggest that while the E2 K200R mutation dramatically influences" exact="CHIKV" post="dissemination in the vertebrate host, it is neutral in"/>
   <result pre="host, it is neutral in the mosquito vector. Figure 6." exact="CHIKV" post="E2 K200R has no impact on vector competence or"/>
   <result pre="fed a blood meal containing 1.1 × 106 PFU/mL of" exact="CHIKV" post="or CHIKV E2 K200R, and the head, legs, and"/>
   <result pre="blood meal containing 1.1 × 106 PFU/mL of CHIKV or" exact="CHIKV" post="E2 K200R, and the head, legs, and saliva were"/>
   <result pre="an MOI of 1 PFU/cell with a 1:1 mixture of" exact="CHIKV" post="marked with an ApaI restriction site (CHIKV-ApaI) and WT"/>
   <result pre="CHIKV marked with an ApaI restriction site (CHIKV-ApaI) and WT" exact="CHIKV" post="or CHIKV E2 K200R, and 1/10th of the supernatant"/>
   <result pre="with an ApaI restriction site (CHIKV-ApaI) and WT CHIKV or" exact="CHIKV" post="E2 K200R, and 1/10th of the supernatant was serially"/>
   <result pre="of 1:1 mixtures of CHIKV-ApaI and CHIKV, or CHIKV-ApaI and" exact="CHIKV" post="E2 K200R. Bodies (C) and saliva (D) were collected"/>
   <result pre="E2 K251 The critical lysine at position E2 200 of" exact="CHIKV" post="and ONNV is not conserved within RRV strains, which"/>
   <result pre="± SD. N = 6, two experiments. Kruskal-Wallis; **p&amp;lt;0.01. (C)" exact="CHIKV" post="trimeric spike (PDB 3J2W), with E2 K200 highlighted in"/>
   <result pre="residues at E2 200 or E2 251 are essential for" exact="CHIKV" post="and RRV clearance, respectively The impact of lysine to"/>
   <result pre="cells, we introduced a variety of amino acid substitutions at" exact="CHIKV" post="E2 200. The amino acid panel was designed to"/>
   <result pre="8A). Remarkably, all substitutions tested prevented efficient clearance of circulating" exact="CHIKV" post="particles following i.v. inoculation (Figure 8B). Moreover, a subset"/>
   <result pre="that mediates clearance in RRV (E2 K251) is conserved in" exact="CHIKV" post="(E2 K252). To investigate if this lysine residue also"/>
   <result pre="K252). To investigate if this lysine residue also contributes to" exact="CHIKV" post="clearance, we introduced an E2 K252R mutation. However, we"/>
   <result pre="we introduced an E2 K252R mutation. However, we found that" exact="CHIKV" post="E2 K252R remained susceptible to clearance by phagocytic cells"/>
   <result pre="lysine at this position in E2 is not required for" exact="CHIKV" post="clearance. Collectively, these findings demonstrate that specific lysine residues"/>
   <result pre="residues at E2 200 or E2 251 are essential for" exact="CHIKV" post="and RRV clearance, respectively. (A) Properties of the amino"/>
   <result pre="WT C57BL/6 mice were inoculated i.v. with a panel of" exact="CHIKV" post="mutants with different amino acid substitutions at position E2"/>
   <result pre="K; ****p&amp;lt;0.0001. (D) WT C57BL/6 mice were inoculated i.v. with" exact="CHIKV" post="or CHIKV E2 K252R, and viral genomes in inoculum"/>
   <result pre="(D) WT C57BL/6 mice were inoculated i.v. with CHIKV or" exact="CHIKV" post="E2 K252R, and viral genomes in inoculum and in"/>
   <result pre="the spleen is not necessary for the clearance of circulating" exact="CHIKV" post="particles, it remains possible that MZM contribute to the"/>
   <result pre="in vivo. Beyond GAGs, previous work demonstrated that opsonization of" exact="DENV" post="particles by mannose binding lectin (MBL), which can neutralize"/>
   <result pre="2010). However, we found that the innate clearance of circulating" exact="CHIKV" post="and RRV was maintained in mice lacking C3 and"/>
   <result pre="et al., 2013). We found that the clearance of circulating" exact="CHIKV" post="and RRV particles was inhibited by pre-treatment of mice"/>
   <result pre="critical roles for MARCO in the efficient clearance of circulating" exact="CHIKV" post="particles and for limiting viral dissemination and the magnitude"/>
   <result pre="of viremia, suggesting that MARCO may limit disease severity following" exact="CHIKV" post="infection. Beyond identification of the cell type and specific"/>
   <result pre="clearance of viral particles by phagocytic cells. N-linked glycosylation of" exact="DENV" post="and WNV glycoproteins was previously found to influence clearance"/>
   <result pre="viral particles by phagocytic cells. N-linked glycosylation of DENV and" exact="WNV" post="glycoproteins was previously found to influence clearance of these"/>
   <result pre="2010). However, we found that mutation of the predicted surface-exposed" exact="CHIKV" post="E2 glycosylation sites had no impact on the clearance"/>
   <result pre="E2 glycosylation sites had no impact on the clearance of" exact="CHIKV" post="particles from the circulation, suggesting that clearance occurs independent"/>
   <result pre="features that mediated clearance of circulating alphavirus particles, we identified" exact="CHIKV" post="and RRV strains that evade phagocytic cell-mediated clearance. CHIKV"/>
   <result pre="identified CHIKV and RRV strains that evade phagocytic cell-mediated clearance." exact="CHIKV" post="E2 K200R was isolated from the serum of a"/>
   <result pre="of a Rag1-/- mouse chronically infected with an Asian genotype" exact="CHIKV" post="strain (Hawman et al., 2017), suggesting that this mutation"/>
   <result pre="from the circulation. Introduction of an E2 K200R mutation into" exact="CHIKV" post="strains representative of the Asian-American, ECSA, and West African"/>
   <result pre="CHIKV strains representative of the Asian-American, ECSA, and West African" exact="CHIKV" post="clades also facilitated escape of viral particles from phagocytic"/>
   <result pre="To more thoroughly evaluate biochemical features of the residue at" exact="CHIKV" post="E2 200 or RRV E2 251 that promote particle"/>
   <result pre="clearance or particle escape from clearance, we generated panels of" exact="CHIKV" post="and RRV strains encoding amino acids at positions E2"/>
   <result pre="with the exception of lysine, all amino acid substitutions at" exact="CHIKV" post="E2 200 or RRV E2 251 allowed for evasion"/>
   <result pre="the circulation. These findings suggest that a lysine residue at" exact="CHIKV" post="E2 200 or RRV E2 251 is essential for"/>
   <result pre="variety of distinct genetic backgrounds to facilitate escape of circulating" exact="CHIKV" post="and ONNV particles from MARCO-dependent clearance; (2) a lysine"/>
   <result pre="mutating this lysine has no impact on clearance of circulating" exact="CHIKV" post="particles; (4) lysine is frequently post-translationally modified, and can"/>
   <result pre="amino acid at E2 200 or 251, lysine residues at" exact="CHIKV" post="E2 200, ONNV E2 200, and RRV E2 251"/>
   <result pre="the ViPR database (Pickett et al., 2012) revealed that 1,333/1,335" exact="CHIKV" post="sequences encode a lysine at position E2 200 (2/1,335"/>
   <result pre="fitness advantage in the mosquito vector. However, we found that" exact="CHIKV" post="E2 K200R replication and dissemination was indistinguishable from that"/>
   <result pre="K200R replication and dissemination was indistinguishable from that of WT" exact="CHIKV" post="in Ae. aegypti mosquitoes, and no selective disadvantage of"/>
   <result pre="direct competition experiments, suggesting that the conservation of lysine at" exact="CHIKV" post="E2 200 is not due to constraints in the"/>
   <result pre="cells has important implications for the course of infection. The" exact="CHIKV" post="E2 K200R strain that escapes MARCO-dependent clearance generates a"/>
   <result pre="et al., 2017). Analogously, infection of MARCO-/- mice with WT" exact="CHIKV" post="also resulted in enhanced viremia and more rapid viral"/>
   <result pre="in a higher magnitude and duration of viremia following subcutaneous" exact="CHIKV" post="infection of mice (Gardner et al., 2010). Similarly, clodronate"/>
   <result pre="al., 2010). Similarly, clodronate liposome depletion of phagocytic cells enhanced" exact="WNV" post="viremia and disease severity in mice (Bryan et al.,"/>
   <result pre="also greatly influences transmission cycles. While some arboviruses, such as" exact="WNV" post="and Japanese Encephalitis virus, are unable to generate a"/>
   <result pre="the transmission cycle (Weaver, 2018), others like CHIKV, DENV, and" exact="Zika" post="virus are readily amplified through human-mosquito-human cycles (Weaver, 2018)."/>
   <result pre="were incubated at 30°C. Cells tested negative for mycoplasma. Viruses" exact="CHIKV" post="strains used include Asian strain AF15561 (Ashbrook et al.,"/>
   <result pre="2011), and WA strain 37997 (Vanlandingham et al., 2005b). All" exact="CHIKV" post="stocks were derived from infectious cDNA clones by electroporating"/>
   <result pre="fibroblasts. Unless otherwise noted, AF15561 was used as the representative" exact="CHIKV" post="strain. RRV strains used include SN11 (Liu et al.,"/>
   <result pre="on BHK-21 cells or by RT-qPCR. The cDNA clone of" exact="CHIKV" post="99659 was a gift from Mark Heise (University of"/>
   <result pre="Mark Heise (University of North Carolina), the cDNA clones of" exact="CHIKV" post="37997 and ONNV SG650 were gifts from Stephen Higgs"/>
   <result pre="in TRIzol using the PureLink RNA mini kit (Life Technologies)." exact="CHIKV" post="cDNA was generated using random primers (Invitrogen) with SuperScript"/>
   <result pre="random primers (Invitrogen) with SuperScript IV reverse transcriptase (Life Technologies)." exact="CHIKV" post="genome copies were quantified by RT-qPCR using a CHIKV"/>
   <result pre="Technologies). CHIKV genome copies were quantified by RT-qPCR using a" exact="CHIKV" post="specific forward primer (5′-TTTGCGTGCCACTCTGG-3′) and reverse primer (5′-CGGGTCACCACAAAGTACAA-3′) with"/>
   <result pre="prior to i.v. inoculation with 2.5 × 109 genomes of" exact="CHIKV" post="AF15561 diluted in 100 μl of diluent. At 45"/>
   <result pre="cycle. Mosquitoes were provided an infectious blood meal containing either" exact="CHIKV" post="AF15561 WT or CHIKV AF15561 E2 K200R. Defibrinated calf"/>
   <result pre="an infectious blood meal containing either CHIKV AF15561 WT or" exact="CHIKV" post="AF15561 E2 K200R. Defibrinated calf blood was mixed 1:1"/>
   <result pre="viral competition assays, we generated a genetically marked clone of" exact="CHIKV" post="AF15561 using sight- directed mutagenesis (Forward Primer: 5′-ctaaactaaaggggcccaaagcagcagcgctgt-3′; Reverse"/>
   <result pre="an MOI of 1 PFU/cell with a 1:1 ratio of" exact="CHIKV" post="AF15561-ApaI and CHIKV AF15561 or CHIKV AF15561-ApaI and CHIKV"/>
   <result pre="1 PFU/cell with a 1:1 ratio of CHIKV AF15561-ApaI and" exact="CHIKV" post="AF15561 or CHIKV AF15561-ApaI and CHIKV AF15561 E2 K200R."/>
   <result pre="a 1:1 ratio of CHIKV AF15561-ApaI and CHIKV AF15561 or" exact="CHIKV" post="AF15561-ApaI and CHIKV AF15561 E2 K200R. Following a 1"/>
   <result pre="of CHIKV AF15561-ApaI and CHIKV AF15561 or CHIKV AF15561-ApaI and" exact="CHIKV" post="AF15561 E2 K200R. Following a 1 hr adsorption, virus"/>
   <result pre="the supernatant, and cDNA was generated as described above for" exact="CHIKV" post="quantification. For in vivo competition experiments, Aedes aegypti mosquitoes"/>
   <result pre="microinjected intrathoracically with 138 PFU of a 1:1 mixture of" exact="CHIKV" post="AF15561-ApaI and CHIKV AF15561 or CHIKV AF15561-ApaI and CHIKV"/>
   <result pre="138 PFU of a 1:1 mixture of CHIKV AF15561-ApaI and" exact="CHIKV" post="AF15561 or CHIKV AF15561-ApaI and CHIKV AF15561 E2 K200R."/>
   <result pre="a 1:1 mixture of CHIKV AF15561-ApaI and CHIKV AF15561 or" exact="CHIKV" post="AF15561-ApaI and CHIKV AF15561 E2 K200R. At seven dpi,"/>
   <result pre="of CHIKV AF15561-ApaI and CHIKV AF15561 or CHIKV AF15561-ApaI and" exact="CHIKV" post="AF15561 E2 K200R. At seven dpi, mosquito bodies and"/>
   <result pre="the manufacturer’s instructions. cDNA was generated as described above for" exact="CHIKV" post="quantification. Relative amounts of each virus in samples were"/>
   <result pre="using control PCR products amplified from cDNA plasmid clones of" exact="CHIKV" post="AF15561 WT or CHIKV AF15561-ApaI. Digested products were run"/>
   <result pre="amplified from cDNA plasmid clones of CHIKV AF15561 WT or" exact="CHIKV" post="AF15561-ApaI. Digested products were run on a 1% TAE"/>
   <result pre="inhaled particlesThe Journal of Experimental Medicine20026727210.1084/jem.2004073115263032 AshbrookAWBurrackKSSilvaLAMontgomerySAHeiseMTMorrisonTEDermodyTS2014Residue 82 of the" exact="Chikungunya" post="virus E2 attachment protein modulates viral dissemination and arthritis"/>
   <result pre="function during Blood-Borne infectionsFrontiers in Immunology660660910.3389/fimmu.2015.0048026648935 BorgheriniGPoubeauPJossaumeAGouixACotteLMichaultAArvin-BerodCPaganinF2008Persistent arthralgia associated with" exact="Chikungunya" post="virus: a study of 88 adult patients on reunion"/>
   <result pre="bottleneck as major evolutionary forcesPLOS Pathogens9e100359110.1371/journal.ppat.100359124009512 ChowAHerZOngEKChenJMDimatatacFKwekDJBarkhamTYangHRéniaLLeoYSNgLF2011Persistent arthralgia induced by" exact="Chikungunya" post="virus infection is associated with interleukin-6 and granulocyte macrophage"/>
   <result pre="for severe diseasePLOS Pathogens4e2910.1371/journal.ppat.004002918282093 CouturierEGuilleminFMuraMLeonLVirionJ-MLetortM-JDe ValkHSimonFVaillantV2012Impaired quality of life after" exact="Chikungunya" post="virus infection: a 2-year follow-up studyRheumatology511315132210.1093/rheumatology/kes01522427407 DaughertyMDMalikHS2012Rules of engagement:"/>
   <result pre="viruses promotes neurovirulencePNAS108160261603110.1073/pnas.111061710821896745 GérardinPFianuAMalvyDMussardCBoussaïdKRollotOMichaultAGaüzereBABréartGFavierF2011Perceived morbidity and community burden after a" exact="Chikungunya" post="outbreak: the TELECHIK survey, a population-based cohort studyBMC Medicine9510.1186/1741-7015-9-521235760"/>
   <result pre="in the E2 glycoprotein and the 3′ Untranslated Region Enhance" exact="Chikungunya" post="Virus Virulence in MiceJournal of Virology913210.1128/JVI.00816-17 HeilMLAlbeeAStraussJHKuhnRJ2001An amino acid"/>
   <result pre="the liverNature Immunology14996100610.1038/ni.269124048121 JonesJELongKMWhitmoreACSandersWThurlowLRBrownJAMorrisonCRVincentHPeckKMBrowningCMoormanNLimJKHeiseMT2017Disruption of the opal stop Codon attenuates" exact="Chikungunya" post="Virus-Induced arthritis and pathologymBio811610.1128/mBio.01456-17 JupilleHJOkoLStoermerKAHeiseMTMahalingamSGunnBMMorrisonTE2011Mutations in nsP1 and PE2"/>
   <result pre="virus E1 and E2 glycoproteins in insect cellsVirology Journal835310.1186/1743-422X-8-35321762510 MoroMLGagliottiCSilviGAngeliniRSambriVRezzaGMassimilianiEMattiviAGrilliEFinarelliACSpataroNPierroAMSeylerTMaciniPcollab:" exact="Chikungunya" post="Study Group2010Chikungunya virus in North-Eastern Italy: a seroprevalence surveyThe"/>
   <result pre="mouse model of chikungunya Virus–Induced Musculoskeletal Inflammatory DiseaseAJPA178324010.1016/j.ajpath.2010.11.018 MorrisonTE2014Reemergence of" exact="Chikungunya" post="virusJournal of Virology88116441164710.1128/JVI.01432-1425078691 MukhopadhyaySGordonS2004The role of scavenger receptors in"/>
   <result pre="choriomeningitis virus infectionEuropean Journal of Immunology272626263310.1002/eji.18302710239368619 SilvaLAKhomandiakSAshbrookAWWellerRHeiseMTMorrisonTEDermodyTS2014A single-amino-acid polymorphism in" exact="Chikungunya" post="virus E2 glycoprotein influences glycosaminoglycan utilizationJournal of Virology882385239710.1128/JVI.03116-1324371059 SmitJMWaartsBLKimataKKlimstraWBBittmanRWilschutJ2002Adaptation"/>
   <result pre="viruses with liposomes containing lipid-conjugated heparinJournal of Virology76101281013710.1128/JVI.76.20.10128-10137.200212239287 SoumahoroMKBoellePYGaüzereBAAtsouKPelatCLambertBLa RucheGGastellu-EtchegorryMRenaultPSarazinMYazdanpanahYFlahaultAMalvyDHanslikT2011The" exact="Chikungunya" post="epidemic on la réunion island in 2005-2006: a cost-of-illness"/>
   <result pre="and applicationsJournal of Immunological Methods174839310.1016/0022-1759(94)90012-48083541 VanlandinghamDLHongCKlinglerKTsetsarkinKMcElroyKLPowersAMLehaneMJHiggsS2005aDifferential infectivities of o'nyong-nyong and" exact="Chikungunya" post="virus isolates in anopheles gambiae and aedes aegypti mosquitoesThe"/>
   <result pre="aedes aegypti in MexicoPLOS Neglected Tropical Diseases9e000426310.1371/journal.pntd.000426326658798 VijayakumarKGeorgeBAnishTSRajasiRSTeenaMJSujinaCM2013Economic impact of" exact="Chikungunya" post="epidemic: out-of-pocket health expenditures during the 2007 outbreak in"/>
   <result pre="of Tropical Medicine and Public Health44546123682438 VolkSMChenRTsetsarkinKAAdamsAPGarciaTISallAANasarFSchuhAJHolmesECHiggsSMaharajPDBraultACWeaverSC2010Genome-scale phylogenetic analyses of" exact="Chikungunya" post="virus reveal independent emergences of recent epidemics and various"/>
   <result pre="and clinical presentation in nicaraguan patients infected with zika virus," exact="Chikungunya" post="virus, and dengue virusClinical Infectious Diseases631584159010.1093/cid/ciw58927578819 WeaverSC2018Prediction and prevention"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6841724\results\search\tropicalVirus\results.xml">
   <result pre="naringenin impairs the in vitro infection of human cells by" exact="Zika" post="virus http://orcid.org/0000-0002-3567-7471CataneoAllan Henrique Depieri1KuczeraDiogo1http://orcid.org/0000-0002-3542-1353KoishiAndrea Cristine1ZanlucaCamila1http://orcid.org/0000-0002-1866-0563SilveiraGuilherme Ferreira1http://orcid.org/0000-0001-8015-7152ArrudaThais Bonato de1SuzukawaAndréia Akemi1http://orcid.org/0000-0002-0915-8205BortotLeandro"/>
   <result pre="view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract The" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus that belongs to"/>
   <result pre="an arthropod-borne virus that belongs to the Flaviviridae family. The" exact="ZIKV" post="infection is usually asymptomatic or is associated with mild"/>
   <result pre="vaccine nor an antiviral treatment has become available to control" exact="ZIKV" post="replication. Among the natural compounds recognized for their medical"/>
   <result pre="Here, we demonstrate that the citrus flavanone naringenin (NAR) prevented" exact="ZIKV" post="infection in human A549 cells in a concentration-dependent and"/>
   <result pre="NAR and the protease domain of the NS2B-NS3 protein of" exact="ZIKV" post="which could explain the anti-ZIKV activity of NAR. Finally,"/>
   <result pre="developing anti-ZIKV treatments. Subject terms Antivirals Viral infection Introduction The" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus from the Flavivirus"/>
   <result pre="that was first isolated from a rhesus monkey from the" exact="Zika" post="forest of Uganda in 19471. The ZIKV is transmitted"/>
   <result pre="monkey from the Zika forest of Uganda in 19471. The" exact="ZIKV" post="is transmitted primarily by Aedes spp. mosquitoes2. However, transmission"/>
   <result pre="from mother to fetus has also been described3–5. Infection by" exact="ZIKV" post="progresses as a self-limiting disease like observed in dengue"/>
   <result pre="conjunctivitis, myalgia, headache, edema, orbital pain and vomiting6,7. However, during" exact="Zika" post="epidemics in French Polynesia (2013) and Brazil (2015), greater"/>
   <result pre="syndrome (microcephaly) were observed7–9. Strong evidence suggests a link between" exact="ZIKV" post="infection and microcephaly once the viral genome has been"/>
   <result pre="an antiviral drug is available to prevent or treat the" exact="ZIKV" post="infection. Despite recent advances in drug discovery against ZIKV,"/>
   <result pre="fever14–18. Additionally, it was demonstrated that several flavonoids could inhibit" exact="Zika" post="virus infection in vitro and in vivo19–25. The antiviral"/>
   <result pre="similarities between these flaviviruses prompted us to test NAR against" exact="ZIKV" post="infection in vitro. Here, NAR was shown to present"/>
   <result pre="experiments, each one in technical triplicate. In vitro inhibition of" exact="Zika" post="virus infection by NAR is concentration-dependent Based on the"/>
   <result pre="the anti-ZIKV activity of NAR. A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261) and treated with different concentrations of"/>
   <result pre="concentration-dependent (Fig. 2A–C). Surprisingly, IFN-α 2A-treated cells presented more viable" exact="ZIKV" post="particles in the cell culture supernatant than NAR-treated cells"/>
   <result pre="of NAR is concentration-dependent. The A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261; MOI 0.1) for 90 minutes and treated"/>
   <result pre="one-way ANOVA followed by Tukey´s Multiple Comparison Test (*p &amp;lt; 0.05 vs" exact="ZIKV" post="infected and untreated cells and # p &amp;lt; 0.05 vs mock-infected"/>
   <result pre="(Fig. 3A,B). Additionally, RT-qPCR (Fig. 3C) demonstrated that NAR impairs" exact="ZIKV" post="replication. Furthermore, results from two different assays indicate the"/>
   <result pre="Fig. 3). Figure 3 NAR impairs the A549 infection by" exact="Zika" post="virus. A549 cells were infected with ZIKV (ZV BR"/>
   <result pre="A549 infection by Zika virus. A549 cells were infected with" exact="ZIKV" post="(ZV BR 2015/15261; MOI 0.1) and treated with NAR"/>
   <result pre="secondary antibody. (B) The average number of infected-A549 cells. (C)" exact="ZIKV" post="RNA detection in A549 cells by RT-qPCR assay. The"/>
   <result pre="ZIKV RNA detection in A549 cells by RT-qPCR assay. The" exact="ZIKV" post="NS2B RNA was quantified in infected cells compared to"/>
   <result pre="phylogenetic analyses it was demonstrated the existence of two main" exact="Zika" post="virus lineages, the African- and Asian- lineages34. To confirm"/>
   <result pre="Moreover, it was shown that the African- and Asian-lineage of" exact="ZIKV" post="present differences in virulence/pathogenicity in vitro and in vivo37."/>
   <result pre="anti-ZIKV activity of NAR against ZV BR 2015/15261, four additional" exact="ZIKV" post="strains were tested, three from Asian-lineage (ZV BR 2016/16288,"/>
   <result pre="tested, three from Asian-lineage (ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243) and one from African-lineage (ZIKV MR766). Using FACS"/>
   <result pre="NAR impairs the A549-infection with both Asian- and African-lineages of" exact="ZIKV" post="(Fig. 4). However, despite NAR was effective to reduce"/>
   <result pre="despite NAR was effective to reduce the infection with both" exact="ZIKV" post="lineages, a higher effect was observed for Asian-lineage (~4"/>
   <result pre="(Supplementary Fig. 5). Figure 4 NAR impairs the infection of" exact="Zika" post="virus from Asian- and African-lineage in A549 cells. A549"/>
   <result pre="cells. A549 cells were infected with four additional strains of" exact="ZIKV" post="(ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243, ZIKV"/>
   <result pre="additional strains of ZIKV (ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243, ZIKV MR766; MOI 0.1), three from Asian- and"/>
   <result pre="of ZIKV (ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243," exact="ZIKV" post="MR766; MOI 0.1), three from Asian- and one from"/>
   <result pre="were infected with the ZV BR 2016/16288, ZV BR 2015/15098," exact="ZIKV" post="PE243 and ZIKV MR766 strains. The frequency of A549"/>
   <result pre="the ZV BR 2016/16288, ZV BR 2015/15098, ZIKV PE243 and" exact="ZIKV" post="MR766 strains. The frequency of A549 cells infected (4G2+)"/>
   <result pre="with the ZV BR 2016/16288 (B), ZV BR 2015/15098 (D)," exact="ZIKV" post="PE243 (F) and ZIKV MR766 (H) strains. Determination of"/>
   <result pre="2016/16288 (B), ZV BR 2015/15098 (D), ZIKV PE243 (F) and" exact="ZIKV" post="MR766 (H) strains. Determination of viable ZIKV in the"/>
   <result pre="PE243 (F) and ZIKV MR766 (H) strains. Determination of viable" exact="ZIKV" post="in the cell culture supernatant of A549 cells infected"/>
   <result pre="infected with ZV BR 2016/16288 (C), ZV BR 2015/15098 (E)," exact="ZIKV" post="PE243 (G) and ZIKV MR766 (I) strains using the"/>
   <result pre="2016/16288 (C), ZV BR 2015/15098 (E), ZIKV PE243 (G) and" exact="ZIKV" post="MR766 (I) strains using the foci-forming immunodetection assay (FFUC6/36/mL)."/>
   <result pre="one-way ANOVA followed by Tukey´s Multiple Comparison Test (*p &amp;lt; 0.05 vs" exact="ZIKV" post="infected and untreated A549 cells). Time of NAR addition"/>
   <result pre="of NAR addition experiments To determine which step of the" exact="ZIKV" post="life cycle NAR exerts its effects, a time of"/>
   <result pre="only after inoculum removal (after infection) seems to impact the" exact="ZIKV" post="infected-A549 cells (Fig. 5B–E). Also, a slightly anti-ZIKV effect"/>
   <result pre="cells. The A549 cells were infected with 0.1 MOI of" exact="ZIKV" post="(ZV BR 2015/15261 strain) and cells were treated with"/>
   <result pre="(2) treated with NAR (125 μM) for 90 minutes prior to" exact="ZIKV" post="infection; (3) treated with NAR during ZIKV infection; (4)"/>
   <result pre="90 minutes prior to ZIKV infection; (3) treated with NAR during" exact="ZIKV" post="infection; (4) treated with NAR during and after ZIKV"/>
   <result pre="during ZIKV infection; (4) treated with NAR during and after" exact="ZIKV" post="infection; (5) treated with NAR after ZIKV infection; or"/>
   <result pre="during and after ZIKV infection; (5) treated with NAR after" exact="ZIKV" post="infection; or (6) treated with IFN-α 2A (200 UI/ml)"/>
   <result pre="infection; or (6) treated with IFN-α 2A (200 UI/ml) after" exact="ZIKV" post="infection as a control of treatment. (B) Representative density"/>
   <result pre="to indicate the potential mechanism of action of flavonoids against" exact="Zika" post="virus24,39. Once the experimental data indicated that NAR could"/>
   <result pre="For validation, two flavonoids known as non-competitive inhibitors of the" exact="ZIKV" post="protease were chosen, namely myricetin, because of its high"/>
   <result pre="calculations show that NAR is able to interact with the" exact="ZIKV" post="protease in a similar way as myricetin and apigenin"/>
   <result pre="we speculate that NAR is able to bind to the" exact="ZIKV" post="protease and inhibit it via a non-competitive mechanism in"/>
   <result pre="(A172) and human embryonic stem cell line (NKX2-5eGFP/whESC). Thus, using" exact="ZIKV" post="strains from Asian- and African-lineage and two different techniques"/>
   <result pre="shown. For antiviral activity of NAR, hmdDCs were infected with" exact="ZIKV" post="(ZV BR 2015/15261 at MOI 10) and treated with"/>
   <result pre="cells in the immune response and its highly susceptibility to" exact="ZIKV" post="infection we decide to test the antiviral activity of"/>
   <result pre="impair the infection of hmdDCs, a key target cell for" exact="ZIKV" post="infection and for the immune system function41,44. Discussion The"/>
   <result pre="ZIKV infection and for the immune system function41,44. Discussion The" exact="Zika" post="virus epidemic in Brazil (2015) was associated with new"/>
   <result pre="flavonoids are able to interact with the NS2B-NS3 protease of" exact="ZIKV" post="through chemical structures, and they play important roles in"/>
   <result pre="different techniques showed that NAR was able to impair the" exact="ZIKV" post="infection in A549 cells. Additionally, we observed that NAR"/>
   <result pre="cells, despite having lower impact on the secretion of viable" exact="ZIKV" post="particles. The same phenotype was observed for A172 and"/>
   <result pre="of type I IFN is needed to reduce 1–2 log of" exact="ZIKV" post="RNA in Vero cell culture supernatant. Finally, this effect"/>
   <result pre="culture supernatant. Finally, this effect seems to be specific for" exact="ZIKV" post="infection, once IFN-α 2A was able to reduce the"/>
   <result pre="context, we tested the antiviral activity of NAR against distinct" exact="ZIKV" post="recent clinical isolates from Asian-lineage obtained from patients in"/>
   <result pre="a higher reduction of infection was observed for Asian-lineages of" exact="ZIKV" post="when compared to the African-lineage. Intrinsic differences in the"/>
   <result pre="in the pathogenicity and virulence of African- and Asian-lineage of" exact="ZIKV" post="were already demonstrated37,60. While those differences could account for"/>
   <result pre="human cell (hmdDCs) NAR seems to be able to impair" exact="ZIKV" post="infection. It was demonstrated that the absorption and metabolism"/>
   <result pre="differential cell-line responses observed62. To determine the stage of the" exact="ZIKV" post="life cycle that is affected by NAR, a time-of-drug-addition"/>
   <result pre="and virus assembly, as already shown for the dengue and" exact="Chikungunya" post="viruses18,63. In addition, the antiviral effect of NAR was"/>
   <result pre="would represent an additional advantage of using NAR for treating" exact="ZIKV" post="infected patients31,32,65,66. The inhibition of viral RNA metabolism occurs"/>
   <result pre="presents anti-ZIKV activity. In vitro NAR was effective against distinct" exact="ZIKV" post="lineages (Asian and African) and seems to act during"/>
   <result pre="results demonstrated that NAR could be a suitable candidate for" exact="ZIKV" post="therapy. Finally, further studies should be undertaken to improve"/>
   <result pre="to establish whether it is effective in vivo. Methods Cells," exact="Zika" post="virus and naringenin Aedes albopictus C6/36 (ATCC: CLR-1660) mosquito"/>
   <result pre="were from Thermo Fisher Scientific (Grand Island, New York, USA)." exact="Zika" post="viruses were isolated from serum of infected patients in"/>
   <result pre="Brazilian National Ethics Committee of Human Experimentation. Additionally, the laboratory-adapted" exact="ZIKV" post="strains ZIKV PE24359 and ZIKV MR7661 were tested. Viral"/>
   <result pre="Ethics Committee of Human Experimentation. Additionally, the laboratory-adapted ZIKV strains" exact="ZIKV" post="PE24359 and ZIKV MR7661 were tested. Viral stocks were"/>
   <result pre="Human Experimentation. Additionally, the laboratory-adapted ZIKV strains ZIKV PE24359 and" exact="ZIKV" post="MR7661 were tested. Viral stocks were grown in C6/36,"/>
   <result pre="were incubated for 18 hours. The cells were then infected with" exact="ZIKV" post="at a multiplicity of infection (MOI) of 0.1 for"/>
   <result pre="Mini Kit, Qiagen, Hilden, Germany) was used to quantify the" exact="ZIKV" post="NS2B genes using a RT-qPCR69. In brief, 5 µg of"/>
   <result pre="In brief, 5 µg of RNA was used to amplify the" exact="ZIKV" post="NS2B gene using specific primers (10 pmol) and a"/>
   <result pre="the RT-PCR assays. Target gene Primer name Sequence (5′–3′) Cycling" exact="Zika" post="virus NS2B gene70 Zika4481 CTGTGGCATGAACCCAATAG 50 °C-30 min 95 °C-15 min"/>
   <result pre="40 cycles 95 °C-15 s 60 °C-30 s 72 °C-1 min 18SR CCCGTCGGCATGTATTAGCT" exact="Zika" post="virus envelope (E) gene72 ZIKVENVF GCTGGDGCRGACACHGGRACT 95 °C-2 min 35"/>
   <result pre="for A549 cells using three different ZIKV-strains (ZV BR 2015/15261;" exact="ZIKV" post="PE243 and ZIKV MR766). The anti-ZIKV activity of NAR"/>
   <result pre="using three different ZIKV-strains (ZV BR 2015/15261; ZIKV PE243 and" exact="ZIKV" post="MR766). The anti-ZIKV activity of NAR in hmdDCs was"/>
   <result pre="assay was performed as described18. In brief, 2 × 106 FFUC6/36 of" exact="ZIKV" post="(ZV BR 2015/15261) was incubated with NAR (125 μM)"/>
   <result pre="μg/mL) (USB-Affymetrix; Santa Clara, CA, USA) at 37 °C for 1 hour." exact="Zika" post="virus RNA samples that were treated with RNase or"/>
   <result pre="untreated were used as controls. After incubation, the amplification of" exact="ZIKV" post="envelope gene was performed based on a one-step RT-PCR"/>
   <result pre="conditions are available in Table 1. Additionally, 2 × 106 FFUC6/36 of" exact="ZIKV" post="was incubated with NAR (125 μM) for 1 h at"/>
   <result pre="(125 μM) for 1 h at 37 °C and residual infectivity of" exact="ZIKV" post="was assessed by foci-forming immunodetection assay in C6/36 as"/>
   <result pre="(2) treated with NAR (125 μM) for 1.5 h prior to" exact="ZIKV" post="infection; (3) treated with NAR during ZIKV infection; (4)"/>
   <result pre="1.5 h prior to ZIKV infection; (3) treated with NAR during" exact="ZIKV" post="infection; (4) treated with NAR during and after ZIKV"/>
   <result pre="during ZIKV infection; (4) treated with NAR during and after" exact="ZIKV" post="infection; (5) treated with NAR after ZIKV infection; or"/>
   <result pre="during and after ZIKV infection; (5) treated with NAR after" exact="ZIKV" post="infection; or (6) treated with IFN-α 2A (200 UI/ml)"/>
   <result pre="infection; or (6) treated with IFN-α 2A (200 UI/ml) after" exact="ZIKV" post="infection as a control of treatment (Fig. 5A). After"/>
   <result pre="for each different treatment. Furthermore, the cells were infected with" exact="ZIKV" post="MOI 0.1 and treated with NAR (125 μM) at"/>
   <result pre="treated with NAR (125 μM) at different time points after" exact="ZIKV" post="infection, namely as 0, 1, 2, 4, 6, and"/>
   <result pre="was the crystallographic structure of the NS2B-NS3 protease from the" exact="ZIKV" post="in a complex with the peptide PDB ID 5GPI76."/>
   <result pre="Hyg.19524650952010.1016/0035-9203(52)90042-412995440 2.LiMWongPSNgLCTanCHOral susceptibility of Singapore Aedes (Stegomya) aegypti (Linnaeus) to" exact="Zika" post="virusPloS. Negl. Trop. Dis.201268e179210.1371/journal.pntd.000179222953014 3.MussoDet al.Potential for Zika virus"/>
   <result pre="(Linnaeus) to Zika virusPloS. Negl. Trop. Dis.201268e179210.1371/journal.pntd.000179222953014 3.MussoDet al.Potential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
   <result pre="2013 to February 2014Euro. Surveill.201419142076110.2807/1560-7917.ES2014.19.14.2076124739982 4.MussoDet al.Potential Sexual Transmission of" exact="Zika" post="VirusEmerg. Infect. Dis.20152123596110.3201/eid2102.14136325625872 5.NoronhaLZanlucaCAzevedoMLVLuzKGDuarte dos SantosCNZika virus damages the"/>
   <result pre="case report, French PolynesiaEuro. Surveill.20141991310.2807/1560-7917.ES2014.19.9.20720 9.CalvetGet al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="alterações no crescimento e desenvolvimento relacionadas à infecção pelo vírus" exact="Zika" post="e outras etiologias infecciosas, até a Semana Epidemiológica 15"/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 17 de 2018 http://portalarquivos2.saude.gov.br/images/pdf/2018/junho/11/2018-022.pdf (2018)."/>
   <result pre="de 2018 http://portalarquivos2.saude.gov.br/images/pdf/2018/junho/11/2018-022.pdf (2018). 12.SaizJCMartín-AcebesMAThe Race To Find Antivirals for" exact="Zika" post="VirusAntimicrob. Agents Chemother.2017616e004111710.1128/AAC.00411-1728348160 13.HavsteenBFlavonoids, a class of natural products"/>
   <result pre="in human cellsSci. Rep.201774186410.1038/srep4186428157234 19.CarneiroBMBatistaMNBragaACSNogueiraMLRahalPThe green tea molecule EGCG inhibits" exact="Zika" post="virus entryVirol.201649621521810.1016/j.virol.2016.06.012 20.WongGet al.Antivrial activity of quercetin-3-b-O-D-glucosidase against Zika"/>
   <result pre="inhibits Zika virus entryVirol.201649621521810.1016/j.virol.2016.06.012 20.WongGet al.Antivrial activity of quercetin-3-b-O-D-glucosidase against" exact="Zika" post="virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts Dengue and"/>
   <result pre="quercetin-3-b-O-D-glucosidase against Zika virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts" exact="Dengue" post="and Zika Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet"/>
   <result pre="Zika virus infectionVirol. Sin.201732654554710.1007/s12250-017-4057-928884445 21.SzeAet al.Sophoraflavenone G Restricts Dengue and" exact="Zika" post="Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins"/>
   <result pre="Virus Infection via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins Inhibit" exact="Dengue" post="and Zika Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin"/>
   <result pre="via RNA Polymerase InterferenceViruses2017910E28710.3390/v910028728972551 22.SuroengritAet al.Halogenated Chrysins Inhibit Dengue and" exact="Zika" post="Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin Precludes Initiation"/>
   <result pre="Virus InfectivitySci. Rep.2017711369610.1038/s41598-017-14121-529057920 23.GaudryAet al.The Flavonoid Isoquercetin Precludes Initiation of" exact="Zika" post="Virus Infection in Human CellsInt. J. Mol. Sci.2018194E109310.3390/ijms1904109329621184 24.OoATeohBTSamSSBakarSAZandiKBaicalein"/>
   <result pre="in Human CellsInt. J. Mol. Sci.2018194E109310.3390/ijms1904109329621184 24.OoATeohBTSamSSBakarSAZandiKBaicalein and baicalin as" exact="Zika" post="virus inhibitorsArch. Virol.2019164258559310.1007/s00705-018-4083-430392049 25.LeeJLLoeMWCLeeRCHChuJJHAntiviral activity of pinocembrin against Zika"/>
   <result pre="as Zika virus inhibitorsArch. Virol.2019164258559310.1007/s00705-018-4083-430392049 25.LeeJLLoeMWCLeeRCHChuJJHAntiviral activity of pinocembrin against" exact="Zika" post="virus replicationAntiviral Res.2019167132410.1016/j.antiviral.2019.04.00330959074 26.de SousaLRFet al.Flavonoids as noncompetitive inhibitors"/>
   <result pre="virus replicationAntiviral Res.2019167132410.1016/j.antiviral.2019.04.00330959074 26.de SousaLRFet al.Flavonoids as noncompetitive inhibitors of" exact="Dengue" post="virus NS2B-NS3 protease: Inhibition kinetics and docking studiesBioorganic Med."/>
   <result pre="Inhibition kinetics and docking studiesBioorganic Med. Chem.20152346647010.1016/j.bmc.2014.12.015 27.RoyALimLSrivastavaSLuYSongJSolution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
   <result pre="Signaling PathwayPloS One2016114e015301510.1371/journal.pone.015301527045367 33.FrumenceEet al.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="to IFN-b production and apoptosis inductionVirology201649321722610.1016/j.virol.2016.03.00627060565 34.HaddowADet al.Genetic Characterization of" exact="Zika" post="Virus Strains: Geographic Expansion of the Asian LineagePLoS Negl."/>
   <result pre="LineagePLoS Negl. Trop. Dis.201262e147710.1371/journal.pntd.000147722389730 35.LanciottiRSet al.Genetic and Serologic Properties of" exact="Zika" post="Virus Associated with an Epidemic, Yap State, Micronesia, 2007Emerg."/>
   <result pre="State, Micronesia, 2007Emerg. Infect. Dis.20081481232123910.3201/eid1408.08028718680646 36.BinghamAMConeMMockVComparison of Test Results for" exact="Zika" post="Virus RNA in Urine, Serum, and Saliva Specimens from"/>
   <result pre="in Urine, Serum, and Saliva Specimens from Persons with Travel-Associated" exact="Zika" post="Virus Disease – Florida, 2016MMWR Morb Mortal Wkly Rep.20166518475810.15585/mmwr.mm6518e227171533"/>
   <result pre="Rep.20166518475810.15585/mmwr.mm6518e227171533 37.SimoninYRielDVde PerrePVRockxBSalinasSDifferential virulence between Asian and African lineages of" exact="Zika" post="virusPLoS Negl. Trop. Dis.2017119e000582110.1371/journal.pntd.000582128934211 38.DaelemansDPauwelsRDe ClercqEPannecouqueCA time-of-drug addition approach"/>
   <result pre="requirements and prediction of inhibitory activity of natural flavonoids against" exact="Zika" post="virus through molecular docking and Monte Carlos based QSAR"/>
   <result pre="Virus Associated with MicrocephalyN. Engl. J. Med.2016374951810.1056/NEJMoa160065126862926 41.HamelRet al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015891788809610.1128/JVI.00354-1526085147 42.SunXet al.Transcriptional"/>
   <result pre="Human Skin CellsJ. Virol.2015891788809610.1128/JVI.00354-1526085147 42.SunXet al.Transcriptional Changes during Naturally Acquired" exact="Zika" post="Virus Infection Render Dendritic Highly Conductive to Viral ReplicationCell"/>
   <result pre="of human dendritic cells by African and Asian strains of" exact="Zika" post="virusSci. Rep.201881544010.1038/s41598-018-23734-329615676 44.Reis e SouzaCActivation of dendritic cells: translating"/>
   <result pre="Opin. Immunol.200416121510.1016/j.coi.2003.11.00714734106 45.WahidBAliARafiqueSIdreesMCurrent status of therapeutic and vaccine approaches against" exact="Zika" post="virusEur. J. Intern. Med.201744121810.1016/j.ejim.2017.08.00128797534 46.Pires de MelloCPet al.Zika virus"/>
   <result pre="48.ZandiKTeohBSamSWongPMustafaMRIn vitro antiviral activity of Fisetin, Rutin and Naringenin against" exact="Dengue" post="virus type-2J. Med. Plants Res.2011555345539 49.ZhangTet al.Anti-Japanese-encephalitis-viral effects of"/>
   <result pre="al.A sensitive virus yield assay for evaluation of Antiviral against" exact="Zika" post="VirusJ. Virol. Meth.2016238132010.1016/j.jviromet.2016.09.015 57.SchneiderWHChevillotteMDRiceCMInterferon-Stimulated Genes: A Complex Web of"/>
   <result pre="DefensesAnn. Rev. Immunol.20143251354510.1146/annurev-immunol-032713-12023124555472 58.ZanlucaCet al.First report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem. Inst. Oswaldo Cruz2015110456957210.1590/0074-0276015019226061233 59.DonaldCLet al.Full Genome"/>
   <result pre="59.DonaldCLet al.Full Genome Sequence and sfRNA Interferon Antagonist Activity of" exact="Zika" post="Virus from Recife, BrazilPLoS Negl Trop Dis.2016510e000504810.1371/journal.pntd.0005048 60.SheridanMAet al.African"/>
   <result pre="BrazilPLoS Negl Trop Dis.2016510e000504810.1371/journal.pntd.0005048 60.SheridanMAet al.African and Asian strains of" exact="Zika" post="virus differ in their ability to infect and lyse"/>
   <result pre="al.Inhibitors of alphavirus entry and replication identified with a stable" exact="Chikungunya" post="replicon cell line and virus-based assaysPLoS One2011612e2892310.1371/journal.pone.002892322205980 64.Valério De"/>
   <result pre="2(-Delta Delta C(T)) methodMethods20012540240810.1006/meth.2001.126211846609 71.StrottmannDMet al.Genetic and biological characterization of" exact="Zika" post="virus isolates from different Brazilian regionsMem. Inst. Osw. Cruz2019114e19015010.1590/0074-02760190150"/>
   <result pre="regionsMem. Inst. Osw. Cruz2019114e19015010.1590/0074-02760190150 72.FayeOet al.One-step RT-PCR for detection of" exact="Zika" post="virusJ. Clin. Virol.20084319610110.1016/j.jcv.2008.05.00518674965 73.TrottOOlsonAAutoDock Vina: improving the speed and"/>
   <result pre="Mol. Model.20131913210.1007/s00894-012-1667-x23187683 76.ZhangZet al.Crystal structure of unlinked NS2B-NS3 protease from" exact="Zika" post="virusScience.201635463191597160010.1126/science.aai930927940580 77.Van Der SpoelDet al.GROMACS: Fast, flexible, and freeJ."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6849232\results\search\tropicalVirus\results.xml">
   <result pre="Patient sample/ SiHa cell – Induce poor prognosis [49, 50]" exact="ZIKV" post="METTL3/14 Down Vero cell – Increase viral titer [51]"/>
   <result pre="– Decrease viral titer YTHDF2 Up Vero cell – Suppress" exact="ZIKV" post="replication SV40 METTL3 Down BCS40 cell – Reduce SV40"/>
   <result pre="CC. So far, no study has described the relationship between" exact="HPV" post="and m6A methylation, and future studies should address this"/>
   <result pre="and m6A methylation, and future studies should address this gap." exact="Zika" post="virus related diseases Zika virus (ZIKV), which causes Zika"/>
   <result pre="future studies should address this gap. Zika virus related diseases" exact="Zika" post="virus (ZIKV), which causes Zika virus disease (ZVD)-a type"/>
   <result pre="gap. Zika virus related diseases Zika virus (ZIKV), which causes" exact="Zika" post="virus disease (ZVD)-a type of acute infectious disease, was"/>
   <result pre="serum of apyrexial rhesus monkey caged in the canopy of" exact="Zika" post="Forest [71]. In 2007, a large outbreak of ZIKV"/>
   <result pre="of Zika Forest [71]. In 2007, a large outbreak of" exact="ZIKV" post="occurred in Yap Island of the Western Pacific [72],"/>
   <result pre="of m6A modification in ZIKV. Lichinchi et al. confirmed that" exact="ZIKV" post="viral RNA was methylated and twelve discrete m6A peaks"/>
   <result pre="and twelve discrete m6A peaks spanning the full length of" exact="ZIKV" post="RNA were identified, most of which were present in"/>
   <result pre="region encoding NS5 and the 3’UTR [51]. Like other virus," exact="ZIKV" post="viral-RNA is also modified at adenosines by writers and"/>
   <result pre="modified at adenosines by writers and erasers; and perturbation of" exact="ZIKV" post="m6A affects the replication efficiency and viral titer of"/>
   <result pre="writers (METTL3 or METTL14) significantly increased the viral-production, viral titer," exact="ZIKV" post="RNA levels in cell supernatants and the expression of"/>
   <result pre="ZIKV RNA levels in cell supernatants and the expression of" exact="ZIKV" post="envelope protein, whereas silencing of erasers (ALKBH5 or FTO)"/>
   <result pre="was also reported that readers (YTHDF proteins) that bind to" exact="ZIKV" post="RNA may regulate the replication of ZIKV. Compared to"/>
   <result pre="to YTHDF1 and YTHDF3, YTHDF2 has the greatest effect on" exact="ZIKV" post="replication, RNA expression and stability of viral RNA. Generally,"/>
   <result pre="Carcinoma HCV Hepatitis C virus HIV-1 Human immunodeficiency virus I" exact="HPV" post="Human papillomavirus IAV Influenza A virus IGF2BPs the insulin-like"/>
   <result pre="RNA VSV vesicular stomatitis virus WTAP Wilms’ tumor 1-associating protein" exact="ZIKV" post="Zika virus ZVD Zika virus disease Publisher’s Note Springer"/>
   <result pre="VSV vesicular stomatitis virus WTAP Wilms’ tumor 1-associating protein ZIKV" exact="Zika" post="virus ZVD Zika virus disease Publisher’s Note Springer Nature"/>
   <result pre="virus WTAP Wilms’ tumor 1-associating protein ZIKV Zika virus ZVD" exact="Zika" post="virus disease Publisher’s Note Springer Nature remains neutral with"/>
   <result pre="demethylationMol Carcinog20185759059710.1002/mc.2278229315835 51.LichinchiGZhaoBSWuYLuZQinYHeCRanaTMDynamics of human and viral RNA methylation during" exact="Zika" post="virus infectionCell Host Microbe20162066667310.1016/j.chom.2016.10.00227773536 52.TsaiKCourtneyDGCullenBRAddition of m6A to SV40"/>
   <result pre="Valour F, Baudouin L, Mallet H, Musso D, Ghawche F." exact="Zika" post="virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia,"/>
   <result pre="Polynesia, December 2013. Euro Surveill. 2014;19. 74.Schuler-FacciniLRibeiroEMFeitosaIMHorovitzDDCavalcantiDPPessoaADoriquiMJNeriJINetoJMWanderleyHYet al.Possible association between" exact="Zika" post="virus infection and microcephaly - Brazil, 2015MMWR Morb Mortal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6853075\results\search\tropicalVirus\results.xml">
   <result pre="Científica pmcid: 685307500605 doi: 10.1590/1414-431X20198339 : Research Article Identification of" exact="Zika" post="virus in immature phases of Aedes aegypti and Aedes"/>
   <result pre="objective of this article was to identify the presence of" exact="Zika" post="(ZIKV), dengue (DENV), and Chikungunya (CHIKV) viruses in immature"/>
   <result pre="to identify the presence of Zika (ZIKV), dengue (DENV), and" exact="Chikungunya" post="(CHIKV) viruses in immature stages of Aedes aegypti and"/>
   <result pre="This reduction was accompanied by a decrease in suspected human" exact="ZIKV" post="cases from March to June 2015. The RT-qPCR performed"/>
   <result pre="albopictus) were positive for ZIKV, and none were positive for" exact="DENV" post="or CHIKV. Our findings demonstrated that ZIKV was present"/>
   <result pre="were positive for DENV or CHIKV. Our findings demonstrated that" exact="ZIKV" post="was present in immature stages of insect vectors in"/>
   <result pre="region at least five months prior to the peak of" exact="ZIKV" post="associated cases. Xenomonitoring of immature phases of the vectors"/>
   <result pre="phases of the vectors may prove useful for predicting outbreaks." exact="Zika" post="virus Aedes aegypti Aedes albopictus Arbovirus Georeferencing Xenomonitoring fig-count:"/>
   <result pre="has been considered endemic for this arbovirus (2). In 2014," exact="Chikungunya" post="(CHIKV) and Zika (ZIKV) viruses, two exotic arboviruses, were"/>
   <result pre="endemic for this arbovirus (2). In 2014, Chikungunya (CHIKV) and" exact="Zika" post="(ZIKV) viruses, two exotic arboviruses, were introduced in Brazil"/>
   <result pre="rapid dispersion in different states (3). The increasing outbreaks of" exact="ZIKV" post="due to vector dispersion and lack of effective control"/>
   <result pre="public health concern (4). The most alarming clinical manifestations of" exact="ZIKV" post="were cases associated with Guillain-Barré syndrome in adults (5)"/>
   <result pre="associated with Guillain-Barré syndrome in adults (5) and the congenital" exact="ZIKV" post="syndrome (6). Furthermore, reports of outbreaks of CHIKV emphasize"/>
   <result pre="the congenital ZIKV syndrome (6). Furthermore, reports of outbreaks of" exact="CHIKV" post="emphasize the magnitude of its epidemics that accounted for"/>
   <result pre="2018 in the Southeast of Brazil (7). Adverse outcomes of" exact="CHIKV" post="include neurological disease in the acute phase, and longstanding"/>
   <result pre="attempt to eradicate dengue, the Brazilian government created the National" exact="Dengue" post="Control Program (PNCD). This program promoted initiatives aimed at"/>
   <result pre="study was to identify the presence of ZIKV, DENV, and" exact="CHIKV" post="in the immature stages of Ae. aegypti and Ae."/>
   <result pre="and/or non-purulent conjunctivitis were included in the study as suspected" exact="ZIKV" post="cases. All illegible or incomplete medical records were excluded"/>
   <result pre="those suggested by the Ministry of Health to classify suspected" exact="ZIKV" post="cases (14). Any other related description in the medical"/>
   <result pre="of the National Guidelines for the Prevention and Control of" exact="Dengue" post="Epidemics (10)) was carried out during the months of"/>
   <result pre="detect the presence of nucleic acid of ZIKV, DENV, and" exact="CHIKV" post="in each pool containing viral RNA extracted. For this,"/>
   <result pre="with primers and probes specifically designed for DENV, ZIKV, and" exact="CHIKV" post="(19-20) (Supplementary Table S1). Cycle threshold values below 38.5"/>
   <result pre="of the QGIS software (version 3.2.0; ). The number of" exact="ZIKV" post="cases per 100,000 inhabitants was calculated from the total"/>
   <result pre="per 100,000 inhabitants was calculated from the total number of" exact="ZIKV" post="cases in the census tract, divided by the total"/>
   <result pre="777 (38.6%) were classified as ZIKV. Although the symptoms of" exact="ZIKV" post="among other arboviruses are very similar, the analyses showed"/>
   <result pre="that in the years 2015 and 2016, among 146 suspected" exact="ZIKV" post="cases, two symptoms were the most frequent: rash occurred"/>
   <result pre="or 38.6% of Ae. albopictus). Our data demonstrated that suspected" exact="ZIKV" post="cases were concentrated in the urbanized area of Xerem."/>
   <result pre="noteworthy that in 2015 there were already suspected cases of" exact="ZIKV" post="in this region, and the number of cases reached"/>
   <result pre="outbreak was characterized (Figure 1.). Figure 1 Spatial distribution of" exact="Zika" post="virus (ZIKV) suspected cases in March and June 2015"/>
   <result pre="169 mm (Figure 2). Figure 2. Relationship of number of" exact="Zika" post="virus (ZIKV) suspected cases with rainfall and temperature data"/>
   <result pre="rainfall index was high (Figure 2), and there were 777" exact="ZIKV" post="suspected cases, a considerable number. A strong positive correlation"/>
   <result pre="(28%) as Ae. aegypti. The RT-qPCR for DENV, ZIKV, and" exact="CHIKV" post="was performed in all pools and, of the 18"/>
   <result pre="positive for ZIKV, suggesting the occurrence of transovarian transmission of" exact="ZIKV" post="of 11.6% (2/173) for Ae. aegypti and 2.3% (1/442)"/>
   <result pre="and December/2015: 36.00 (larvae Ae. albopictus); 37.84 (larvae Ae. aegypti)." exact="CHIKV" post="and DENV were not identified in any of the"/>
   <result pre="36.00 (larvae Ae. albopictus); 37.84 (larvae Ae. aegypti). CHIKV and" exact="DENV" post="were not identified in any of the pools evaluated."/>
   <result pre="the pools evaluated. Table 1. Identification of dengue virus (DENV)," exact="Zika" post="virus (ZIKV), and Chikungunya virus (CHIKV) in the immature"/>
   <result pre="1. Identification of dengue virus (DENV), Zika virus (ZIKV), and" exact="Chikungunya" post="virus (CHIKV) in the immature stages of Aedes aegypti"/>
   <result pre="by RT-qPCR. Month/year Ae. aegypti Ae. albopictus RT-qPCR Pools Pools" exact="DENV" post="ZIKV CHIKV Larvae Pupae Larvae Pupae Jun/15 0 0"/>
   <result pre="RT-qPCR. Month/year Ae. aegypti Ae. albopictus RT-qPCR Pools Pools DENV" exact="ZIKV" post="CHIKV Larvae Pupae Larvae Pupae Jun/15 0 0 80"/>
   <result pre="Month/year Ae. aegypti Ae. albopictus RT-qPCR Pools Pools DENV ZIKV" exact="CHIKV" post="Larvae Pupae Larvae Pupae Jun/15 0 0 80 0"/>
   <result pre="neg neg neg Discussion Our results showed the identification of" exact="ZIKV" post="in immature phases of the vectors Ae. aegypti and"/>
   <result pre="and Ae. albopictus mosquitoes from Thailand were capable of transmitting" exact="CHIKV" post="vertically in the laboratory; Ae. albopictus was more susceptible"/>
   <result pre="Ae. aegypti and Ae. albopictus mosquitoes were able to transmit" exact="CHIKV" post="vertically to F5 and F6 progenies, respectively (24). However,"/>
   <result pre="However, in the present study, none of our pools yielded" exact="CHIKV" post="or DENV, which may be related to the small"/>
   <result pre="tested associated to the fact that in 2015 and 2016" exact="CHIKV" post="and DENV were not epidemic in this area in"/>
   <result pre="to the fact that in 2015 and 2016 CHIKV and" exact="DENV" post="were not epidemic in this area in Brazil (25)."/>
   <result pre="adult Ae. aegypti females, the MIR was 11.6 (24/2065) for" exact="DENV" post="but no vertical transmission of DENV could be detected"/>
   <result pre="was 11.6 (24/2065) for DENV but no vertical transmission of" exact="DENV" post="could be detected in 1552 male Ae. aegypti collected"/>
   <result pre="Ae. albopictus, may be related to the persistent survival of" exact="ZIKV" post="during interepidemic periods, which has already been demonstrated by"/>
   <result pre="albopictus may play an important role in the maintenance of" exact="ZIKV" post="throughout the year, as it was found persistently in"/>
   <result pre="an area not distant from ours showed the presence of" exact="ZIKV" post="in nature, in the adult insect (mosquitoes). A total"/>
   <result pre="transmission, as only female mosquitoes are blood-sucking. These results reinforced" exact="ZIKV" post="circulation in this region during this period, indicating the"/>
   <result pre="difference between their study and ours is that we identified" exact="ZIKV" post="in the immature forms of both Aedes species, showing"/>
   <result pre="showing that Ae. albopictus may also be a vector for" exact="ZIKV" post="in Brazil (32). Aedes albopictus has been found naturally"/>
   <result pre="low efficiency (34). In another study, designed to test whether" exact="ZIKV" post="could be vertically transmitted, female Ae. aegypti and Ae."/>
   <result pre="with ZIKV, and their F1 adult progeny were tested for" exact="ZIKV" post="infection. Six of 69 Ae. aegypti pools, comprised of"/>
   <result pre="pools, comprised of a total of 1738 F1 adults, yielded" exact="ZIKV" post="upon culture, giving a minimum filial infection rate of"/>
   <result pre="none of 803 F1 Ae. albopictus adults (32 pools) yielded" exact="ZIKV" post="(35). It is important to note that injecting mosquitoes"/>
   <result pre="by Ciota et al. (36), adult insects fed orally with" exact="ZIKV" post="in the laboratory had their progeny tested; of 104"/>
   <result pre="their progeny tested; of 104 Ae. aegypti pools, 6 were" exact="ZIKV" post="positive, indicating a filial infection rate (FIR) of 11.9,"/>
   <result pre="aegypti, as obtained in other studies (27,39). Due to the" exact="ZIKV" post="outbreak in Brazil, several cases of the congenital syndrome,"/>
   <result pre="fluid of the affected patients (6). The threat posed by" exact="ZIKV" post="has great implications not only on immediate public health"/>
   <result pre="resources, due to the persistent long-term sequelae of the congenital" exact="ZIKV" post="syndrome (40). Reliable and sensitive surveillance of these arboviruses,"/>
   <result pre="order to effectively manage future outbreaks. Our findings demonstrated that" exact="ZIKV" post="was present in immature stages of vector insects in"/>
   <result pre="region at least five months prior to the peak of" exact="ZIKV" post="associated cases in March 2016. Data from molecular xenomonitoring"/>
   <result pre="3CardosoCWPaploskiIAKikutiMRodriguesMSSilvaMMCamposGSet al.Outbreak of exanthematous illness associated with Zika, Chikungunya, and" exact="Dengue" post="Viruses, Salvador, BrazilEmerging Infect Dis2015212274227610.3201/eid2112.15116726584464 4collab: PAHO/WHO (Pan American"/>
   <result pre="challengesPLoS Negl Trop Dis201610e000453010.1371/journal.pntd.000453026934531 6CalvetGAguiarRSMeloASOSampaioSAde FilippisIFabriAet al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
   <result pre="da Saúde,201384p: Il 11CostaCFDos PassosRALimaJBPRoqueRAde Souza SampaioVCampolinaTBet al.Transovarial transmission of" exact="DENV" post="in Aedes aegypti in the Amazon basin: a local"/>
   <result pre="a serem adotados para a vigilância da Febre do vírus" exact="Zika" post="no Brasilhttp://portalsaude.saude.gov.br/images/pdf/2016/marco/07/Nota-informativa-zika.pdfaccessed Nov 202017 15collab: Consoli, RAGB; Lourenco de"/>
   <result pre="India, 2006Emerg Infect Dis20071376476710.3201/eid1305.07001517553261 20LanciottiRSKosoyOLLavenJJVelezJOLambertAJJohnsonAJet al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007Emerg"/>
   <result pre="in ColombiaMed Vet Entomol19981228428810.1046/j.1365-2915.1998.00117.x9737600 29GrunnillMBootsMJHow Important is Vertical Transmission of" exact="Dengue" post="Viruses by Mosquitoes (Diptera: Culicidae)?J Med Entomol20165311910.1093/jme/tjv16826545718 30LiCXGuoXXDengYQXingDSunAJLiuQMet al.Vector"/>
   <result pre="competence and transovarial transmission of two Aedes aegypti strains to" exact="Zika" post="virusEmerg Microbes Infect20176e2310.1038/emi.2017.828442754 31Pereira Dos SantosTRoizDSantos AbreuFVLuzSLBSantaluciaMJiolleDet al.Potential of"/>
   <result pre="32Ferreira-de-BritoARibeiroIPMirandaRMFernandesRSCamposSSSilvaKABet al.First detection of natural infection of Aedes aegypti with" exact="Zika" post="virus in Brazil and throughout South AmericaMem Inst Oswaldo"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="virusPLoS Negl Trop Dis201610e000454310.1371/journal.pntd.000454326938868 35ThangamaniSHuangJHartCEGuzmanHTeshRBVertical transmission of Zika virus"/>
   <result pre="Americas to Zika virusPLoS Negl Trop Dis201610e000454310.1371/journal.pntd.000454326938868 35ThangamaniSHuangJHartCEGuzmanHTeshRBVertical transmission of" exact="Zika" post="virus in Aedes aegypti mosquitoesAm J Trop Med Hyg2016951169117310.4269/ajtmh.16-044827573623"/>
   <result pre="Aedes aegypti mosquitoesAm J Trop Med Hyg2016951169117310.4269/ajtmh.16-044827573623 36CiotaATBialosukniaSMEhrbarDJKramerLDVertical transmission of" exact="Zika" post="virus by Aedes aegypti and Ae. albopictusmosquitoes.Emerg Infect Dis20172388088210.3201/eid2305.16204128277199"/>
   <result pre="al.Development of real time PCR for detection and quantitation of" exact="Dengue" post="VirusesVirol J200961010.1186/1743-422X-6-1019166574 38MiagostovichMPSantosFBAraújoESMDiasJSchatzmayrHGNogueiraRMDiagnosis of dengue by using reverse transcriptase-polimerase"/>
   <result pre="chain reactionInfect Genet Evol2005517718410.1016/j.meegid.2004.09.00415639750 40BogochIIBradyOJKraemerMUGGermanMCreatoreMIKulkarniMAet al.Anticipating the international spread of" exact="Zika" post="virus from BrazilLancet201638733533610.1016/S0140-6736(16)00080-526777915"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6854512\results\search\tropicalVirus\results.xml">
   <result pre="(NS1, NS3, and NS4B) (62) and is crucially involved in" exact="DENV" post="RNA replication independent of its canonical roles in N-linked"/>
   <result pre="result shows characteristics that differ from those of flavivirus, since" exact="DENV" post="NS1 and NS4B were shown to be fully glycosylated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6855448\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Evolutionary Biology"/>
   <result pre="medium, provided the original author and source are credited.pone.0224676.pdf Abstract" exact="Dengue" post="fever is a major worldwide public health problem that,"/>
   <result pre="Province almost every year since the first epidemic in 1978." exact="DENV" post="infections persisted in Guangzhou in consecutive years since 2000,"/>
   <result pre="dengue prevention strategies. In this study, a total of 34" exact="DENV" post="strains, including 29 DENV-1 strains and 5 DENV-2 strains,"/>
   <result pre="phylogenetic analysis. The results from the phylogenetic analysis showed that" exact="DENV" post="in Guangzhou was mainly imported from Southeast Asian countries."/>
   <result pre="are within the paper and its Supporting Information files. Introduction" exact="Dengue" post="fever, also known as &quot;break-bone fever&quot;, is an acute"/>
   <result pre="disease caused by dengue virus (DENV) [1]. Patients infected with" exact="DENV" post="can have flu-like symptoms, including a high fever, headache,"/>
   <result pre="hemorrhagic fever (DHF) or dengue shock syndrome (DSS) [2, 3]." exact="Dengue" post="is principally spread by Aedes aegypti and Aedes albopictus"/>
   <result pre="one of the most dangerous vector-borne viral diseases worldwide [4]." exact="Dengue" post="outbreaks have a devastating effect on public health and"/>
   <result pre="vector management as the primary means to control and prevent" exact="DENV" post="transmission, it should be noted that improper use of"/>
   <result pre="family Flaviviridae, is an enveloped, single-stranded, positive-sense RNA virus. The" exact="DENV" post="genome is approximately 11,000 nucleotides in length and encodes"/>
   <result pre="open reading frame (ORF). Specifically, the 5' end of the" exact="DENV" post="genome encodes the C/prM/E proteins, while the 3' end"/>
   <result pre="3' end encodes the seven NS protein[8]. There are five" exact="DENV" post="serotypes, which are referred to as DENV-1, DENV-2, DENV-3,"/>
   <result pre="of Guangdong Province, dengue incidence, regardless of the number of" exact="DENV" post="infections, has been reported every year since 2000 [14]."/>
   <result pre="experienced its worst dengue outbreak on record, during which different" exact="DENV" post="serotypes were detected in the DENV-infected patients [12, 15]."/>
   <result pre="cumulative number of infections between 1990 and 2013 [14, 16]." exact="DENV" post="infections are simply classified as imported and autochthonous cases"/>
   <result pre="imported and autochthonous cases according to patients' recent travel records." exact="Dengue" post="epidemics refer to continued widespread outbreaks of dengue fever"/>
   <result pre="to continued widespread outbreaks of dengue fever in areas where" exact="DENV" post="affects a large population and is transmitted between people"/>
   <result pre="aegypti and Aedes albopictus. To date, there are no other" exact="DENV" post="foci in mainland China, except for the reported natural"/>
   <result pre="local dengue transmission in Guangzhou [10]. In the present study," exact="DENV" post="strains were isolated from blood samples drawn from DENV-infected"/>
   <result pre="Guangzhou during 2018. We described the epidemiological characteristics of isolated" exact="DENV" post="based on phylogenetic reconstruction and analysis using a dataset"/>
   <result pre="on phylogenetic reconstruction and analysis using a dataset comprised of" exact="DENV" post="sequences downloaded from the GenBank database and those obtained"/>
   <result pre="in this study. 2. Virus isolation, RNA extraction and serotyping" exact="Dengue" post="virus was isolated from 55 positive blood samples. To"/>
   <result pre="for 90 min and then at 70°C for 10 min." exact="DENV" post="serotyping was carried out by multiplex RT-PCR [22]. 3."/>
   <result pre="for nucleotide BLAST on the NCBI web server, and 100" exact="DENV" post="sequences were downloaded from each BLAST run. On this"/>
   <result pre="assessment The substitution saturation level of each dataset of the" exact="DENV" post="E gene was assessed with DAMBE. The results of"/>
   <result pre="genetic distances of different clusters. Species 1 Species 2 Distance" exact="DENV" post="1-Genotype I others-1 sample2 0.0205329387 others-1 sample1 0.0189086126 sample2"/>
   <result pre="I others-1 sample2 0.0205329387 others-1 sample1 0.0189086126 sample2 sample1 0.0202604556" exact="DENV" post="1-Genotype V others-2 sample3 0.0067526479 DENV 2-Cosmopolitan others-3 sample4"/>
   <result pre="0.0189086126 sample2 sample1 0.0202604556 DENV 1-Genotype V others-2 sample3 0.0067526479" exact="DENV" post="2-Cosmopolitan others-3 sample4 0.0336621574 sample4 sample5 0.0670677460 sample5 others-3"/>
   <result pre="Guangzhou during 2018, and an analysis was performed on the" exact="DENV" post="strains isolated from these blood samples. Through gel electrophoresis"/>
   <result pre="exposed to a relatively high risk of the disease, as" exact="DENV" post="may enter the city along with imported goods and"/>
   <result pre="city along with imported goods and migrant workers. In addition," exact="DENV" post="continuously flows into China because Thailand, Malaysia, Singapore, and"/>
   <result pre="prevention and control. For instance, suspected and confirmed cases of" exact="DENV" post="infection should be isolated and treated properly to reduce"/>
   <result pre="in dengue prevention and control. To reduce the risk of" exact="DENV" post="infection, public health authorities should provide the necessary materials"/>
   <result pre="patient isolates. Regarding the sources of spread or propagation, some" exact="DENV" post="strains were imported from endemic countries and regions and"/>
   <result pre="was found in this study to prove vertical transmission of" exact="DENV" post="in Guangzhou, previous phylogenetic analyses indicated possible local transmission"/>
   <result pre="the city. Since Aedes albopictus is the main medium for" exact="DENV" post="transmission, the localization of DENV largely depends on the"/>
   <result pre="is the main medium for DENV transmission, the localization of" exact="DENV" post="largely depends on the formation of localized and virus-carrying"/>
   <result pre="formation of localized and virus-carrying eggs and the survival of" exact="DENV" post="in the eggs and offspring mosquitoes through winter[34]. A"/>
   <result pre="and offspring mosquitoes through winter[34]. A previous study demonstrated that" exact="DENV" post="can survive in eggs and spread to offspring mosquitoes."/>
   <result pre="in eggs and spread to offspring mosquitoes. Transovarial transmission of" exact="DENV" post="is strongly temperature-related as it determines whether the eggs"/>
   <result pre="As an example, Yunnan Province has reported the localization of" exact="DENV" post="as it has a subtropical monsoon climate and provides"/>
   <result pre="prevent further transmission. We should pay closer attention to localized" exact="DENV" post="in Guangzhou and strictly implement relevant dengue prevention and"/>
   <result pre="the results of this study implied that vertical transmission of" exact="DENV" post="might exist in Guangzhou, there is no solid evidence"/>
   <result pre="and prevention departments of Southeast Asian countries to observe how" exact="DENV" post="is prevalent in these countries, thereby identifying sources of"/>
   <result pre="prevalent in these countries, thereby identifying sources of propagation for" exact="DENV" post="in China and exploring the epidemiological characteristics of dengue"/>
   <result pre="falling short, leading to an increased risk of dengue and" exact="Zika" post="fever in the countries along the Belt and Road."/>
   <result pre="and control, as well as intensified measures against dengue and" exact="Zika" post="fever. It is necessary to establish joint prevention and"/>
   <result pre="4GuoC, ZhouZ, WenZ, LiuY, ZengC, XiaoD, et al.Global Epidemiology of" exact="Dengue" post="Outbreaks in 1990–2015: A Systematic Review and Meta-Analysis. Front"/>
   <result pre="WangM, HuangD, LiJ, HuangS, et al.Differences in the Transmission of" exact="Dengue" post="Fever by Different Serotypes of Dengue Virus. Vector Borne"/>
   <result pre="in the Transmission of Dengue Fever by Different Serotypes of" exact="Dengue" post="Virus. Vector Borne Zoonotic Dis. 201910.1089/vbz.2019.2477 .31503521 10LiG, PanP,"/>
   <result pre="HongWX, ZhaoLZ, et al.Epidemiological and Virological Characterizations of the 2014" exact="Dengue" post="Outbreak in Guangzhou, China. PLoS One. 2016;11(6):e0156548 Epub 2016/06/04."/>
   <result pre="SunGQ, YakobL, ZhuHP, JinZ, ZhangWY. The Driving Force for 2014" exact="Dengue" post="Outbreak in Guangdong, China. PLoS One. 2016;11(11):e0166211 Epub 2016/11/20."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6856673\results\search\tropicalVirus\results.xml">
   <result pre="Proc AMIA Symp. (2001) 9:711–5. 10.1197/jamia.M1224 14.FaverjonCVialFAnderssonMGLecollinetSLeblondA. Early detection of" exact="West Nile" post="virus in France: quantitative assessment of syndromic surveillance system"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6857389\results\search\tropicalVirus\results.xml">
   <result pre="6857389JFMPC-8-3125 doi: 10.4103/jfmpc.jfmpc_716_19 : Review Article A notorious vector-borne disease:" exact="Dengue" post="fever, its evolution as public health threat PathakVineet K.1MohanM1[1],"/>
   <result pre="the new creations are licensed under the identical terms. Abstract" exact="Dengue" post="fever, the most notorious of vector borne diseases is"/>
   <result pre="is available in India. Aedes dengue epidemiology surveillance urbanization Background" exact="Dengue" post="virus (DENV) is a positive-stranded encapsulated RNA virus of"/>
   <result pre="Aedes albopictus.[2] Aedes Aegypti also transmits Chikungunya, yellow fever, and" exact="Zika" post="infections.[1] Dengue also referred to as &quot;water poison,�? &quot;cramp-like"/>
   <result pre="Aedes Aegypti also transmits Chikungunya, yellow fever, and Zika infections.[1]" exact="Dengue" post="also referred to as &quot;water poison,�? &quot;cramp-like seizure,�? or"/>
   <result pre="importance Government of India has named 16th May 2019 &quot;National" exact="Dengue" post="day.�? The theme was &quot;Fight the bite: Prevent Dengue�?"/>
   <result pre="of prevention and role of primary healthcare providers.[6] Epidemiology of" exact="Dengue" post="Virus The epidemiology of dengue significantly changed in south-east"/>
   <result pre="some patients with multiple serotypes of DEN.[18] Concurrent infection by" exact="Chikungunya" post="and DEN-2 was reported from Vellore and Delhi.[1920] Transmission"/>
   <result pre="known as dengue shock syndrome. Infection with one serotype of" exact="DENV" post="confers short-lived immunity against heterologous serotypes and with waning"/>
   <result pre="5KutsunaSKatoYMoiMLKotakiAOtaMShinoharaKet al.Autochthonous dengue fever, Tokyo, Japan, 2014Emerg Infect Dis2015215172025695200 6National" exact="Dengue" post="Day 2019 | National Health Portal of India [Internet]cited"/>
   <result pre="from: https://linkinghub.elsevier.com/retrieve/pii/S1201971219300153 35RajapakseSRodrigoCRajapakseTreatment of dengue feverInfect Drug Resist201251031222870039 36WHO |" exact="Dengue" post="guidelines for diagnosis, treatment, prevention and control: New edition"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6858332\results\search\tropicalVirus\results.xml">
   <result pre="evaluating the importance of intra-city human mobility in dengue spread." exact="Dengue" post="fever is a mosquito-borne viral infection, transmitted by female"/>
   <result pre="with a different type increases the risk of severe complications." exact="Dengue" post="continues to be a global threat, with about half"/>
   <result pre="half a million hospitalizations and up to 25 thousands deaths." exact="Dengue" post="is prevalent in tropical and sub-tropical climates worldwide, mostly"/>
   <result pre="development for vaccines, with a first-generation vaccine becoming available recently22." exact="Dengue" post="affects Singapore in particular and two major outbreaks were"/>
   <result pre="and 2014 (Fig. 1(a)). Figure 1 Temperature Dependency of the" exact="Dengue" post="cases and Schematic representation of the Human-Vectors interactions in"/>
   <result pre="materials. Epidemiological data Information about the weekly number of reported" exact="Dengue" post="cases in Singapore was collected from the official Singapore’s"/>
   <result pre="and 2014 in Fig. 1(a). For the spatial analysis of" exact="Dengue" post="outbreaks, we use a dataset that is a collection"/>
   <result pre="threatNature Reviews Microbiology20108S7S1610.1038/nrmicro246021079655 22.Rothman, A. L. &amp;amp; Ennis, F. A." exact="Dengue" post="vaccine: The need, the challenges, and progress. Journal of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6862117\results\search\tropicalVirus\results.xml">
   <result pre="responses of representative flaviviruses associated with diverse neurological diseases, i.e.," exact="Zika" post="virus (ZIKV), West Nile virus (WNV), and dengue virus"/>
   <result pre="flaviviruses associated with diverse neurological diseases, i.e., Zika virus (ZIKV)," exact="West Nile" post="virus (WNV), and dengue virus (DENV). In addition, we"/>
   <result pre="dengue virus (DENV). In addition, we exploited hiPSCs to model" exact="ZIKV" post="infection in the embryo and during neurogenesis. The results"/>
   <result pre="neurogenesis. The results of this study confirmed the tropism of" exact="ZIKV" post="for NSCs, but showed that WNV replicated in these"/>
   <result pre="confirmed the tropism of ZIKV for NSCs, but showed that" exact="WNV" post="replicated in these cells with much higher efficiency than"/>
   <result pre="WNV replicated in these cells with much higher efficiency than" exact="ZIKV" post="and DENV, inducing massive cell death. Although with lower"/>
   <result pre="are responsible for the peculiarities of disease phenotype in humans." exact="Zika" post="virus West Nile virus dengue virus flavivirus neural stem"/>
   <result pre="for the peculiarities of disease phenotype in humans. Zika virus" exact="West Nile" post="virus dengue virus flavivirus neural stem cell neuron induced"/>
   <result pre="severe hemorrhagic fever or neuroinvasive disease. Neurotropic flaviviruses, such as" exact="West Nile" post="virus (WNV), Japanese encephalitis virus (JEV), and tick-borne encephalitis"/>
   <result pre="a minority of cases, mostly immunocompromised and elderly individuals [1]." exact="Zika" post="virus (ZIKV) has recently drawn attention due to the"/>
   <result pre="in Pacific Ocean countries and the Americas. Like other flaviviruses," exact="ZIKV" post="generally causes asymptomatic infections or a mild febrile illness"/>
   <result pre="causes fetal microcephaly and other developmental anomalies, defined as congenital" exact="Zika" post="virus syndrome [3]. Guillain–Barré syndrome and meningoencephalitis are rare"/>
   <result pre="syndrome [3]. Guillain–Barré syndrome and meningoencephalitis are rare complications of" exact="ZIKV" post="infection in adult individuals. ZIKV is transmitted between humans"/>
   <result pre="meningoencephalitis are rare complications of ZIKV infection in adult individuals." exact="ZIKV" post="is transmitted between humans through the bite of infected"/>
   <result pre="mosquitoes, with humans serving as amplifying hosts. Unique among flaviviruses," exact="ZIKV" post="can persist in immune-privileged sites like the testis and"/>
   <result pre="organoids have been extensively used to investigate the mechanisms of" exact="ZIKV" post="and other flavivirus infection and pathogenesis and have been"/>
   <result pre="studies were crucial to provide evidence of the tropism of" exact="ZIKV" post="for human cortical neural progenitor cells and to demonstrate"/>
   <result pre="for human cortical neural progenitor cells and to demonstrate that" exact="ZIKV" post="infection impairs cell differentiation and induces apoptosis [14,15], supporting"/>
   <result pre="differentiation and induces apoptosis [14,15], supporting the causative role of" exact="ZIKV" post="in fetal microcephaly. Human iPSC-derived brain organoids, which are"/>
   <result pre="structures mimicking endogenous human brain development and organization, showed that" exact="ZIKV" post="preferentially infects radial glia cells as compared to intermediate"/>
   <result pre="TLR3-mediated innate immune response was one of the mechanisms involved" exact="ZIKV" post="deleterious effects on neurogenesis [17]. In addition, the ability"/>
   <result pre="tropism for neural stem cells was a distinguishing feature of" exact="ZIKV" post="[23], but no extensive comparative analyses have been performed"/>
   <result pre="infectivity, tropism, and replication kinetics of ZIKV, in comparison with" exact="WNV" post="and DENV in hiPSCs, hiPSCs-derived neural stem cells (NSCs)"/>
   <result pre="and replication kinetics of ZIKV, in comparison with WNV and" exact="DENV" post="in hiPSCs, hiPSCs-derived neural stem cells (NSCs) and undifferentiated"/>
   <result pre="innate antiviral responses. In addition, we exploited hiPSCs to model" exact="ZIKV" post="infection in the embryo and during stem cell differentiation"/>
   <result pre="lineage. The results of this study confirmed the tropism of" exact="ZIKV" post="for NSCs, but showed that WNV replicated in these"/>
   <result pre="confirmed the tropism of ZIKV for NSCs, but showed that" exact="WNV" post="replicated in these cells with much higher efficiency, inducing"/>
   <result pre="cells differentiated towards the neural lineage. Among flaviviruses, we chose" exact="WNV" post="as representative of neurotropic viruses, DENV as representative of"/>
   <result pre="Among flaviviruses, we chose WNV as representative of neurotropic viruses," exact="DENV" post="as representative of viruses associated with hemorrhagic fever, which"/>
   <result pre="neurons (Figure 3 and Figure 4). In both cell types," exact="WNV" post="infection was more efficient than ZIKV and DENV-2 infection."/>
   <result pre="In both cell types, WNV infection was more efficient than" exact="ZIKV" post="and DENV-2 infection. In particular, 30% ± 7%, 80%"/>
   <result pre="Comparison of replication kinetics of the different flaviviruses showed that" exact="WNV" post="had the highest efficiency, as shown by a more"/>
   <result pre="Cytopatic Effects and Cell Death by Apoptosis in Infected Cells" exact="ZIKV" post="exerted a cytopathic effect (CPE) not only in NSCs,"/>
   <result pre="no significant decrease in cell viability occurred following infection with" exact="ZIKV" post="and DENV-2 (Figure 6a). A significant 3-fold and 6-fold"/>
   <result pre="by qRT-PCR on hiPSCs, NSCs, and neurons after infection with" exact="ZIKV" post="(MOI 1), WNV (MOI 0.01), and DENV-2 (MOI 1)"/>
   <result pre="hiPSCs, NSCs, and neurons after infection with ZIKV (MOI 1)," exact="WNV" post="(MOI 0.01), and DENV-2 (MOI 1) at 48 and"/>
   <result pre="effector IFIT2, a critical mediator involved in antiviral immunity. 2.4." exact="ZIKV" post="Infection and Replication during Neurogenesis In order to model"/>
   <result pre="ZIKV Infection and Replication during Neurogenesis In order to model" exact="ZIKV" post="infection during neurogenesis, hiPSCs and NSCs were infected with"/>
   <result pre="ZIKV infection during neurogenesis, hiPSCs and NSCs were infected with" exact="ZIKV" post="at MOI 0.1 and 1, followed by triggering the"/>
   <result pre="assay. In hiPSCs infected prior to their differentiation into NSCs," exact="ZIKV" post="replicated efficiently and induced massive cell death. At 7"/>
   <result pre="neural induction was almost completed, most cells were positive for" exact="ZIKV" post="E protein. Cells also expressed PAX6, a marker of"/>
   <result pre="PAX6, a marker of the early ectoderm, thus indicating that" exact="ZIKV" post="infection did not impair the differentiation process (Figure 8)."/>
   <result pre="infection did not impair the differentiation process (Figure 8). Likewise," exact="ZIKV" post="replicated efficiently in NSCs infected prior to their differentiation"/>
   <result pre="prior to their differentiation into neurons. A progressive increase of" exact="ZIKV" post="titer was measured in cell supernatant, followed by a"/>
   <result pre="decline due to massive cell death. Also in this case," exact="ZIKV" post="infection did not block the neural differentiation process, as"/>
   <result pre="the neuron-specific protein β-Tubulin in infected cells (Figure 9). 2.5." exact="ZIKV" post="Infection during Embryogenesis Modeling of ZIKV infection during embryogenesis"/>
   <result pre="cells (Figure 9). 2.5. ZIKV Infection during Embryogenesis Modeling of" exact="ZIKV" post="infection during embryogenesis was performed by infection of hiPSCs"/>
   <result pre="infection during embryogenesis was performed by infection of hiPSCs with" exact="ZIKV" post="MOI 1 during their differentiation into embryoid bodies (EBs),"/>
   <result pre="live cells (Figure 10a). As shown in the Figure 10b," exact="ZIKV" post="infection of hiPSCs and subsequent random differentiation into EBs"/>
   <result pre="detachment. 3. Discussion In the epidemiological context of the recent" exact="ZIKV" post="epidemics in Asia and the Americas, the continuous expansion"/>
   <result pre="epidemics in Asia and the Americas, the continuous expansion of" exact="WNV" post="in Europe, and the dramatic increase of dengue epidemics,"/>
   <result pre="neurons and brain organoids have been extensively used to investigate" exact="ZIKV" post="neural tropism and pathogenesis in comparison with other flaviviruses"/>
   <result pre="agreement with the accumulating evidences reporting infection of NSCs by" exact="ZIKV" post="[14,15,16,17], this study confirmed the permissiveness of hiPSCs-derived NSCs"/>
   <result pre="this study confirmed the permissiveness of hiPSCs-derived NSCs to productive" exact="ZIKV" post="infection. Immature neurons and hiPSCs also supported ZIKV replication,"/>
   <result pre="to productive ZIKV infection. Immature neurons and hiPSCs also supported" exact="ZIKV" post="replication, although at lower efficiency. These data are in"/>
   <result pre="other studies that demonstrated permissiveness of developing immature neurons to" exact="ZIKV" post="infection as well as relative resistance of mature neurons"/>
   <result pre="of mature neurons in adult human brains [25]. DENV-2 and" exact="WNV" post="also infected NSCs, hiPSCs, and neurons. DENV-2 infected hNSCs"/>
   <result pre="than ZIKV, in agreement with previous reports [17]. At variance," exact="WNV" post="infected and replicated in all cell types with significantly"/>
   <result pre="replicated in all cell types with significantly higher efficiency than" exact="ZIKV" post="and DENV-2. Notably, WNV was able to infect hiPSCs"/>
   <result pre="types with significantly higher efficiency than ZIKV and DENV-2. Notably," exact="WNV" post="was able to infect hiPSCs and immature neurons, although"/>
   <result pre="report resistance of undifferentiated embryonic stem cells and hiPSCs to" exact="WNV" post="infection [26] and increase of permissiveness to viral infection"/>
   <result pre="neuronal subtypes in the cerebral cortex confer differential susceptibility to" exact="WNV" post="infection and other neurotropic viruses [28]. Both ZIKV and"/>
   <result pre="susceptibility to WNV infection and other neurotropic viruses [28]. Both" exact="ZIKV" post="and WNV exerted CPEs in hiPSCs, NSCs and neurons,"/>
   <result pre="WNV infection and other neurotropic viruses [28]. Both ZIKV and" exact="WNV" post="exerted CPEs in hiPSCs, NSCs and neurons, leading to"/>
   <result pre="confirming results in literature [17]. Cell viability assays demonstrated that" exact="WNV" post="induced massive cell death with complete cell loss at"/>
   <result pre="while only 10% reduction of NSC viability was observed after" exact="ZIKV" post="infection. These findings suggest that ZIKV replication is slower"/>
   <result pre="viability was observed after ZIKV infection. These findings suggest that" exact="ZIKV" post="replication is slower and the virus can persist for"/>
   <result pre="cells. Regarding the investigation of the innate antiviral response during" exact="ZIKV" post="infection, studies based on different cell types and viral"/>
   <result pre="strains led to different observations. In primary human skin fibroblasts," exact="ZIKV" post="Asian lineage induced the upregulation of three important PRRs"/>
   <result pre="(CCL5) [30]. In the human lung epithelial cell line A549," exact="ZIKV" post="(H/PF/2013) stimulated the production of type-I IFN, ISGs and"/>
   <result pre="cytokines, in particular IL-1β [31]. In human fetal neural progenitors," exact="ZIKV" post="Asian lineage induced partial CPE and did not stimulate"/>
   <result pre="TLR3 was upregulated in cerebral organoids and human neurospheres after" exact="ZIKV" post="MR766 infection, and TLR3 activation was associated with cell"/>
   <result pre="cell apoptosis, organoid shrinkage, and dysregulation of neurogenesis induced by" exact="ZIKV" post="infection. In this study, we investigated expression of a"/>
   <result pre="antiviral genes were observed in cells infected by WNV, while" exact="ZIKV" post="and DENV infections had milder effects on host innate"/>
   <result pre="were observed in cells infected by WNV, while ZIKV and" exact="DENV" post="infections had milder effects on host innate antiviral response."/>
   <result pre="and IFIT2 has been suggested to have antiviral activity against" exact="WNV" post="[34]. However, WNV uses the 2′ O-methylation of the"/>
   <result pre="been suggested to have antiviral activity against WNV [34]. However," exact="WNV" post="uses the 2′ O-methylation of the 5′ guanosine cap"/>
   <result pre="with our observations of a stronger upregulation of IFIT2 following" exact="WNV" post="infection than ZIKV and DENV-2 infection. Also, IFIT2 triggers"/>
   <result pre="of a stronger upregulation of IFIT2 following WNV infection than" exact="ZIKV" post="and DENV-2 infection. Also, IFIT2 triggers a mitochondrial pathway"/>
   <result pre="studies to elucidate the molecular mechanisms. Recent reports demonstrated that" exact="ZIKV" post="directly infects NSCs of the fetus and impairs growth"/>
   <result pre="NSCs of the fetus and impairs growth in mice [39]." exact="ZIKV" post="has a negative impact on neurogenesis either by abrogating"/>
   <result pre="by disrupting neural cell organization [17]. To further investigate if" exact="ZIKV" post="could impair the formation of neural precursors and neurons,"/>
   <result pre="critical for brain development, was analyzed. Our experiments showed that" exact="ZIKV" post="infected and replicated in hiPSCs during their differentiation into"/>
   <result pre="Likewise, in NSCs infected prior to their differentiation into neurons," exact="ZIKV" post="did not block neuronal development, as confirmed by the"/>
   <result pre="of the neuron marker β-tubulin during neurogenesis. In these cells," exact="ZIKV" post="induced massive cell death that increased with time, leading"/>
   <result pre="3D structures, we used EBs to investigate the effect of" exact="ZIKV" post="infection during embryogenesis. Cells forming EBs exhibit heterogeneous patterns"/>
   <result pre="differentiation and morphogenesis yielding micro-tissues similar to native tissue structures." exact="ZIKV" post="infected EBs leading to a reduction in their volume"/>
   <result pre="attach to the substrate and died. These data suggest that" exact="ZIKV" post="induces cell death and abrogates cell differentiation and EBs"/>
   <result pre="which can explain the impairment of embryo development observed after" exact="ZIKV" post="infection in vivo. In conclusion, this study highlighted similarities"/>
   <result pre="this study highlighted similarities and differences in ZIKV, WNV, and" exact="DENV" post="mechanisms of infection of pluripotent stem cells and neural"/>
   <result pre="(PECAM, CDH5, GATA2, FLK1), and endoderm (AFP, GATA4). To model" exact="ZIKV" post="infection during embryogenesis, ZIKV infection was performed during EB"/>
   <result pre="and endoderm (AFP, GATA4). To model ZIKV infection during embryogenesis," exact="ZIKV" post="infection was performed during EB formation. Specifically, hiPSCs were"/>
   <result pre="and Infections The following viral strains were used in experiments:" exact="ZIKV" post="strain H/PF/2013 (GenBank KJ776791), Asian lineage, clinical isolate from"/>
   <result pre="(GenBank KJ776791), Asian lineage, clinical isolate from French Polynesia, 2013;" exact="WNV" post="strain AUT/2008 (GenBank KF179640), lineage 2, goshwak isolate from"/>
   <result pre="AUT/2008 (GenBank KF179640), lineage 2, goshwak isolate from Austria, 2008;" exact="DENV" post="serotype 2 strain, clinical isolate. Viruses were grown on"/>
   <result pre="using quantitative qRT-PCR with primers and TaqMan-probe sets specific for" exact="ZIKV" post="NS5, WNV NS5, and DENV NS5, plaque count assay,"/>
   <result pre="qRT-PCR with primers and TaqMan-probe sets specific for ZIKV NS5," exact="WNV" post="NS5, and DENV NS5, plaque count assay, and TCID50"/>
   <result pre="and TaqMan-probe sets specific for ZIKV NS5, WNV NS5, and" exact="DENV" post="NS5, plaque count assay, and TCID50 assay. 4.6. Analysis"/>
   <result pre="From pathogenesis to disease controlFEMS Microbiol. Lett.2016363fnw20210.1093/femsle/fnw20227549304 3.PiersonT.C.DiamondM.S.The emergence of" exact="Zika" post="virus and its new clinical syndromesNature201856057358110.1038/s41586-018-0446-y30158602 4.BarzonL.PercivalleE.PacentiM.RovidaF.ZavattoniM.del BravoP.CattelanA.M.PalùG.BaldantiF.Virus and"/>
   <result pre="syndromesNature201856057358110.1038/s41586-018-0446-y30158602 4.BarzonL.PercivalleE.PacentiM.RovidaF.ZavattoniM.del BravoP.CattelanA.M.PalùG.BaldantiF.Virus and antibody dynamics in travelers with acute" exact="Zika" post="virus infectionClin. Infect. Dis.2018661173118010.1093/cid/cix96729300893 5.KurscheidtF.A.MesquitaC.S.S.DamkeG.M.Z.F.DamkeE.CarvalhoA.R.B.A.SuehiroT.T.TeixeiraJ.J.V.da SilvaV.R.S.SouzaR.P.ConsolaroM.E.L.Persistence and clinical relevance"/>
   <result pre="virus infectionClin. Infect. Dis.2018661173118010.1093/cid/cix96729300893 5.KurscheidtF.A.MesquitaC.S.S.DamkeG.M.Z.F.DamkeE.CarvalhoA.R.B.A.SuehiroT.T.TeixeiraJ.J.V.da SilvaV.R.S.SouzaR.P.ConsolaroM.E.L.Persistence and clinical relevance of" exact="Zika" post="virus in the male genital tractNat. Rev. Urol.20191621123010.1038/s41585-019-0149-730696994 6.Carod-ArtalF.J.WichmannO.FarrarJ.GascónJ.Neurological"/>
   <result pre="infection and immunityNat. Rev. Microbiol.20131111512810.1038/nrmicro295023321534 9.FerreiraR.O.GarcezP.P.Dissecting the toxic effects of" exact="Zika" post="virus proteins on neural progenitor cellsNeuron201910198999110.1016/j.neuron.2019.03.00930897362 10.NazeraiL.Pravsgaard ChristensenJ.Randrup ThomsenA.A"/>
   <result pre="proteins on neural progenitor cellsNeuron201910198999110.1016/j.neuron.2019.03.00930897362 10.NazeraiL.Pravsgaard ChristensenJ.Randrup ThomsenA.A ‘furry-tale’ of" exact="Zika" post="virus infection: What have we learned from animal models?Viruses2019112910.3390/v11010029"/>
   <result pre="from animal models?Viruses2019112910.3390/v11010029 11.Alves Dos SantosE.FinkK.Animal models for dengue and" exact="Zika" post="vaccine developmentAdv. Exp. Med. Biol.2018106221523910.1007/978-981-10-8727-1_1629845536 12.TrevisanM.SinigagliaA.DesoleG.BertoA.PacentiM.PalùG.BarzonL.Modeling viral infectious diseases"/>
   <result pre="therapies using human induced pluripotent stem cell-derived systemsViruses.201573835385610.3390/v707280026184286 13.MingG.L.TangH.SongH.Advances in" exact="Zika" post="virus research: Stem cell models, challenges, and opportunitiesCell Stem"/>
   <result pre="growthCell Stem Cell20161858759010.1016/j.stem.2016.02.01626952870 15.QianX.NguyenH.N.SongM.M.HadionoC.OgdenS.C.HammackC.YaoB.HamerskyG.R.JacobF.ZhongC.et al.Brain-region-specific organoids using mini-bioreactors for modeling" exact="ZIKV" post="exposureCell20161651238125410.1016/j.cell.2016.04.03227118425 16.GarcezP.P.LoiolaE.C.Madeiro da CostaR.HigaL.M.TrindadeP.DelvecchioR.NascimentoJ.M.BrindeiroR.TanuriA.RehenS.K.Zika virus impairs growth in human"/>
   <result pre="receptor TLR3Cell Stem Cell20161925826510.1016/j.stem.2016.04.01427162029 18.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
   <result pre="cell death via a drug repurposing screenNat. Med.2016221101110710.1038/nm.418427571349 19.GabrielE.RamaniA.KarowU.GottardoM.NatarajanK.GooiL.M.Goranci-BuzhalaG.KrutO.PetersF.NikolicM.et al.Recent" exact="Zika" post="virus isolates induce premature differentiation of neural progenitors in"/>
   <result pre="al.High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit" exact="Zika" post="virus infection in fetal-like organoids and adult brainCell Stem"/>
   <result pre="adult brainCell Stem Cell201721274283.e510.1016/j.stem.2017.06.01728736217 21.MesciP.MaciaA.LaRockC.N.TejwaniL.FernandesI.R.SuarezN.A.de A. ZanottoP.M.Beltrão-BragaP.C.B.NizetV.MuotriA.R.Modeling neuro-immune interactions during" exact="Zika" post="virus infectionHum. Mol. Genet.201827415210.1093/hmg/ddx38229048558 22.LiY.MuffatJ.Omer JavedA.KeysH.R.LungjangwaT.BoschI.KhanM.VirgilioM.C.GehrkeL.SabatiniD.M.et al.Genome-wide CRISPR screen"/>
   <result pre="virus infectionHum. Mol. Genet.201827415210.1093/hmg/ddx38229048558 22.LiY.MuffatJ.Omer JavedA.KeysH.R.LungjangwaT.BoschI.KhanM.VirgilioM.C.GehrkeL.SabatiniD.M.et al.Genome-wide CRISPR screen for" exact="Zika" post="virus resistance in human neural cellsProc. Natl. Acad. Sci."/>
   <result pre="cell-derived glial cells and neural progenitors display divergent responses to" exact="Zika" post="and dengue infectionsProc. Natl. Acad. Sci. USA20181157117712210.1073/pnas.171926611529915057 24.WuX.Dao ThiV.L.HuangY.BillerbeckE.SahaD.HoffmannH.H.WangY.SilvaL.A.V.SarbanesS.SunT.et"/>
   <result pre="viral resistance of stem cellsCell2018172423438.e2510.1016/j.cell.2017.11.01829249360 25.HughesB.W.AddankiK.C.SriskandaA.N.McLeanE.BagasraO.Infectivity of immature neurons to" exact="Zika" post="Virus: A link to congenital Zika syndromeEBioMedicine201610657010.1016/j.ebiom.2016.06.02627364784 26.ShrestaB.GottliebD.DiamondM.S.Infection and"/>
   <result pre="of immature neurons to Zika Virus: A link to congenital" exact="Zika" post="syndromeEBioMedicine201610657010.1016/j.ebiom.2016.06.02627364784 26.ShrestaB.GottliebD.DiamondM.S.Infection and injury of neurons by West Nile"/>
   <result pre="to congenital Zika syndromeEBioMedicine201610657010.1016/j.ebiom.2016.06.02627364784 26.ShrestaB.GottliebD.DiamondM.S.Infection and injury of neurons by" exact="West Nile" post="encephalitis virusJ. Virol.200373132031321310.1128/JVI.77.24.13203-13213.2003 27.LucasM.MashimoT.FrenkielM.P.Simon-ChazottesD.MontagutelliX.CeccaldiP.E.GuénetJ.L.DesprèsP.Infection of mouse neurons by West"/>
   <result pre="West Nile encephalitis virusJ. Virol.200373132031321310.1128/JVI.77.24.13203-13213.2003 27.LucasM.MashimoT.FrenkielM.P.Simon-ChazottesD.MontagutelliX.CeccaldiP.E.GuénetJ.L.DesprèsP.Infection of mouse neurons by" exact="West Nile" post="is modulated by the interferon-inducible 2′-5′ oligoadenylate synthetase 1b"/>
   <result pre="death of human neural progenitor cellsSci. Rep.201663977510.1038/srep3977528008958 30.HamelR.DejarnacO.WichitS.EkchariyawatP.NeyretA.LuplertlopN.Perera-LecoinM.SurasombatpattanaP.TalignaniL.ThomasF.et al.Biology of" exact="Zika" post="virus infection in human skin cellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 31.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The South"/>
   <result pre="human skin cellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 31.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="A549 cells leading to IFN-β production and apoptosis inductionVirology201649321722610.1016/j.virol.2016.03.00627060565 32.HannersN.W.EitsonJ.L.UsuiN.RichardsonR.B.WexlerE.M.KonopkaG.SchogginsJ.W.Western" exact="Zika" post="virus in human fetal neural progenitors persists long term"/>
   <result pre="in viral pathogenesisJ. Virol.2015892462246810.1128/JVI.02744-1425428874 34.ChoH.ShresthaB.SenG.C.DiamondM.S.A role for Ifit2 in restricting" exact="West Nile" post="virus infection in the brainJ. Virol.2013878363837110.1128/JVI.01097-1323740986 35.DaffisS.SzretterK.J.SchriewerJ.LiJ.YounS.ErrettJ.LinT.Y.SchnellerS.ZustR.DongH.et al.2′-O methylation"/>
   <result pre="response in human embryonic stem cellsCell Cycle201093552356410.4161/cc.9.17.1279220814227 39.WuK.Y.ZuoG.L.LiX.F.YeQ.DengY.Q.HuangX.Y.CaoW.C.QinC.F.LuoZ.G.Vertical transmission of" exact="Zika" post="virus targeting the radial glial cells affects cortex development"/>
   <result pre="embryonic developmentCell200813266168010.1016/j.cell.2008.02.00818295582 41.RichardA.S.ShimB.S.KwonY.C.ZhangR.OtsukaY.SchmittK.BerriF.DiamondM.S.ChoeH.AXL-dependent infection of human fetal endothelial cells distinguishes" exact="Zika" post="virus from other pathogenic flavivirusesProc. Natl. Acad. Sci. USA20171142024202910.1073/pnas.162055811428167751"/>
   <result pre="immunityCell Host Microbe201926493503.e610.1016/j.chom.2019.09.01231600501 45.Esser-NobisK.AarrebergL.D.RobyJ.A.FairgrieveM.R.GreenR.GaleM.Jr.Comparative Analysis of African and Asian lineage-derived" exact="Zika" post="virus strains reveals differences in activation of and sensitivity"/>
   <result pre="20×. Figure 2 Confocal microscopy images of NSCs infected with" exact="ZIKV" post="(A), WNV (B) and DENV-2 (C), MOI 1, 72"/>
   <result pre="2 Confocal microscopy images of NSCs infected with ZIKV (A)," exact="WNV" post="(B) and DENV-2 (C), MOI 1, 72 hpi. Flavivirus"/>
   <result pre="(red). Merged images, 60× magnification, zoomed two times. Figure 3" exact="WNV" post="and ZIKV infection of hiPSCs. Immunofluorescence staining of flavivirus"/>
   <result pre="images, 60× magnification, zoomed two times. Figure 3 WNV and" exact="ZIKV" post="infection of hiPSCs. Immunofluorescence staining of flavivirus envelope E"/>
   <result pre="the pluripotency marker OCT4 was performed at 72 hpi with" exact="ZIKV" post="and WNV, MOI 1. Nuclei were stained with DAPI;"/>
   <result pre="1. Nuclei were stained with DAPI; magnification 20×. Figure 4" exact="WNV" post="and ZIKV infection of neurons. Immunofluorescence staining of flavivirus"/>
   <result pre="were stained with DAPI; magnification 20×. Figure 4 WNV and" exact="ZIKV" post="infection of neurons. Immunofluorescence staining of flavivirus E protein"/>
   <result pre="neuron marker β-tubulin (red) in neurons at 72 hpi with" exact="WNV" post="and ZIKV at MOI 1. Nuclei were stained with"/>
   <result pre="β-tubulin (red) in neurons at 72 hpi with WNV and" exact="ZIKV" post="at MOI 1. Nuclei were stained with DAPI; magnification"/>
   <result pre="stained with DAPI; magnification 20×. Figure 5 WNV, ZIKV, and" exact="DENV" post="replication kinetics of hiPSCs, NSCs, and neurons. Cell were"/>
   <result pre="cell death (a) and apoptosis (b) in WNV, ZIKV, and" exact="DENV" post="infected neural stem cells. (a) Cell viability was measured"/>
   <result pre="flavivirus infection (b). hiPSCs, NSCs, and neurons were infected with" exact="ZIKV" post="(MOI 1), DENV-2 (MOI 1), and WNV (MOI 0.01)"/>
   <result pre="were infected with ZIKV (MOI 1), DENV-2 (MOI 1), and" exact="WNV" post="(MOI 0.01) and harvested at 96 hpi. Data are"/>
   <result pre="* p &amp;lt; 0.05, Student’s t-test. Figure 8 Analysis of" exact="ZIKV" post="infection in differentiating hiPSCs. (a) Cytopathic effect of ZIKV"/>
   <result pre="of ZIKV infection in differentiating hiPSCs. (a) Cytopathic effect of" exact="ZIKV" post="in differentiating hiPSCs (MOI 1) at 2, 4, and"/>
   <result pre="7 dpi; nuclei were stained with DAPI; 20× magnification. (c)" exact="ZIKV" post="load in culture supernatants measured by TCID50 assay from"/>
   <result pre="* p &amp;lt; 0.05, Student’s t-test. Figure 9 Analysis of" exact="ZIKV" post="infection in differentiating NSCs. (a) CPE of ZIKV-infected differentiating"/>
   <result pre="20 dpi. Nuclei were stained with DAPI. 20× magnification. (c)" exact="ZIKV" post="RNA load measured by qRT-PCR in cell culture supernatants."/>
   <result pre="RNA load measured by qRT-PCR in cell culture supernatants. (d)" exact="ZIKV" post="load measured by TCID50 assay in cell culture supernatants."/>
   <result pre="* p &amp;lt; 0.05, Student’s t-test. Figure 10 Analysis of" exact="ZIKV" post="infection in hiPSCs differentiating into embryoid bodies (EBs). (a)"/>
   <result pre="differentiating into embryoid bodies (EBs). (a) hiPSCs were infected with" exact="ZIKV" post="at MOI 1 and, after 2 days, cells were"/>
   <result pre="of the poor quantity and quality of purified RNA. (c)" exact="ZIKV" post="RNA load measured by qRT-PCR and (d) infectious ZIKV"/>
   <result pre="(c) ZIKV RNA load measured by qRT-PCR and (d) infectious" exact="ZIKV" post="titer determined by TCID50 assay in the supernatant of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863562\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Epidemiology: Infectious"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and Life Sciences : Population Biology"/>
   <result pre="Colombian municipalities with chikungunya outbreaks during 2014-2016 Eco-environmental variables and" exact="Chikungunya" post="basic reproduction number (R0) http://orcid.org/0000-0002-4856-3166Peña-GarcíaVíctor HugoConceptualizationData curationFormal analysisInvestigationMethodologyVisualizationWriting –"/>
   <result pre="medium, provided the original author and source are credited.pntd.0007878.pdf Abstract" exact="Chikungunya" post="virus (CHIKV) emerged in Colombia in 2014 into a"/>
   <result pre="(R0) in 85 municipalities, which accounted for 65.6% of reported" exact="CHIKV" post="cases in Colombia, was estimated. Estimates of R0 ranged"/>
   <result pre="advantageous for the virus in terms of transmission. Author summary" exact="Chikungunya" post="virus emerged in Colombia in 2014 into a presumed"/>
   <result pre="created in ArcGIS 10.4.1 from publicly available dataset described. Introduction" exact="Chikungunya" post="(CHIKV) is an arbovirus that causes a febrile illness,"/>
   <result pre="illness, and belongs to the family Togaviridae and genus Alphavirus." exact="CHIKV" post="is transmitted by vectors belonging to genus Aedes, primarily"/>
   <result pre="to genus Aedes, primarily Ae. aegypti and Ae. albopictus [1]." exact="CHIKV" post="had been limited to Asia and Africa until 2007"/>
   <result pre="2013, where it quickly caused over 1 million cases [2]." exact="CHIKV" post="emerged in Colombia in 2014, where the population was"/>
   <result pre="the population was generally naïve. The subsequent Colombian epidemic of" exact="CHIKV" post="accounts for approximately 49.15% of cases in Latin America"/>
   <result pre="important to acknowledge that while the intrinsic incubation period for" exact="CHIKV" post="has been estimated to be approximately 3 days, there"/>
   <result pre="level incidence data in Colombia. Accordingly, we estimated R0 of" exact="CHIKV" post="from the Colombian National Institute of Health (INS) and"/>
   <result pre="eco-environmental variables to determine if and how they influence the" exact="CHIKV" post="spread and incidence in an outbreak scenario. Further, given"/>
   <result pre="epidemiological week), which allows for some range in estimation of" exact="CHIKV" post="serial interval that could be related to variability in"/>
   <result pre="by the national system of epidemiological surveillance (SIVIGILA). Data for" exact="CHIKV" post="cases was taken for the years 2014 to 2016."/>
   <result pre="of R0 from those datasets. Results Estimation of R0 from" exact="CHIKV" post="incidence data From 846 municipalities that reported chikungunya cases"/>
   <result pre="range of cases reported over the two years of peak" exact="CHIKV" post="incidence in Colombia was 151 (city of Soledad) to"/>
   <result pre="by INS, (B) R0 estimated for 85 municipalities with epidemic" exact="CHIKV" post="in Colombia and their geographical locations, (C) Behavior in"/>
   <result pre="9% with R0&amp;gt;4. When we visualized the estimated R0 versus" exact="CHIKV" post="incidence in each municipality, we found the relationship to"/>
   <result pre="3 (see below). Fig 2 Relationship of R0 and cumulative" exact="CHIKV" post="incidence of 85 municipalities during their respective outbreaks between"/>
   <result pre="that in municipalities that account for over 64% of the" exact="CHIKV" post="cases in Colombia, the R0 ranged from 1.11 to"/>
   <result pre="result is highly focal transmission, which has been reported for" exact="CHIKV" post="[42]. Of interest was the negative correlation of R0"/>
   <result pre="interest was the negative correlation of R0 grouping with urbanicity," exact="CHIKV" post="case counts, and outbreak time-to-peak. That is, those municipalities"/>
   <result pre="explosive outbreak with a fast increase of the number of" exact="CHIKV" post="cases but a shorter time-to-peak. These higher R0 municipalities"/>
   <result pre="outbreak peak is given. In summary, this work suggests that" exact="CHIKV" post="outbreaks are affected by high maximum temperatures and smaller"/>
   <result pre="areas where control is implemented–such as in Brazil during the" exact="Zika" post="epidemic, or Miami during local transmission there–a faster &quot;out-of-the-gate�?"/>
   <result pre="Click here for additional data file. S2 Fig Frequency of" exact="CHIKV" post="R0 values across 85 Colombian municipalities during epidemic peak"/>
   <result pre=".25979669 3Oviedo-PastranaM, MéndezN, MattarS, ArrietaG, GomezcaceresL. Lessons learned of emerging" exact="Chikungunya" post="virus in two populations of social vulnerability of the"/>
   <result pre="Epub 2014/03/17. 10.4269/ajtmh.13-0403 .24639305 12ChanM, JohanssonMA. The incubation periods of" exact="Dengue" post="viruses. PLoS One. 2012;7(11):e5097210.1371/journal.pone.005097223226436 13AltoBW, WigginsK, EastmondB, OrtizS, ZirbelK,"/>
   <result pre="13AltoBW, WigginsK, EastmondB, OrtizS, ZirbelK, LounibosLP. Diurnal Temperature Range and" exact="Chikungunya" post="Virus Infection in Invasive Mosquito Vectors. J Med Entomol."/>
   <result pre=".30077856 16TeslaB, DemakovskyLR, MordecaiEA, RyanSJ, BondsMH, NgonghalaCN, et al.Temperature drives" exact="Zika" post="virus transmission: evidence from empirical and mathematical models. Proc"/>
   <result pre="17HeitmannA, JansenS, LuhkenR, LeggewieM, BaduscheM, PluskotaB, et al.Experimental transmission of" exact="Zika" post="virus by mosquitoes from central Europe. Euro Surveill. 2017;22(2)."/>
   <result pre="ArmijosMV, LambrechtsL, ScottTW. Fluctuations at a Low Mean Temperature Accelerate" exact="Dengue" post="Virus Transmission by Aedes aegypti. PLoS Negl Trop Dis."/>
   <result pre="GuJ, et al.Temperature Increase Enhances Aedes albopictus Competence to Transmit" exact="Dengue" post="Virus. Front Microbiol. 2017;8:233710.3389/fmicb.2017.02337 .29250045 20WhiteLF, PaganoM. A likelihood-based"/>
   <result pre="Khayeka-WandabwaC, TigoiC, et al.Vector competence of Aedes aegypti in transmitting" exact="Chikungunya" post="virus: effects and implications of extrinsic incubation temperature on"/>
   <result pre="AbiodunGJ, HalaiUA, et al.Behavioral, climatic, and environmental risk factors for" exact="Zika" post="and Chikungunya virus infections in Rio de Janeiro, Brazil,"/>
   <result pre="et al.Behavioral, climatic, and environmental risk factors for Zika and" exact="Chikungunya" post="virus infections in Rio de Janeiro, Brazil, 2015–16. PLoS"/>
   <result pre=".23438766 36HuangYJ, HsuWW, HiggsS, VanlandinghamDL. Temperature Tolerance and Inactivation of" exact="Chikungunya" post="Virus. Vector Borne Zoonotic Dis. 2015;15(11):674–7. 10.1089/vbz.2015.1795 .26565772 37ParkSL,"/>
   <result pre="SalasIY, MarinK, TrujilloAI, OsorioJE, Arboleda-SanchezSO, et al.Risk Factors Associated with" exact="Dengue" post="Transmission and Spatial Distribution of High Seroprevalence in Schoolchildren"/>
   <result pre="AleraMT, Rodriguez-BarraquerI, ThaisomboonsukB, SrikiatkhachornA, et al.Reconstruction of 60 Years of" exact="Chikungunya" post="Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission."/>
   <result pre=".26150665 44HeukelbachJ, AlencarCH, KelvinAA, de OliveiraWK, Pamplona de Goes CavalcantiL." exact="Zika" post="virus outbreak in Brazil. J Infect Dev Ctries. 2016;10(2):116–20."/>
   <result pre="Epub 2016/03/02. 10.3855/jidc.8217 .26927450 45PhilipC, NovickCG, NovickLF. Local Transmission of" exact="Zika" post="Virus in Miami-Dade County: The Florida Department of Health"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6863851\results\search\tropicalVirus\results.xml">
   <result pre="of weather seasonality and sexual transmission on the spread of" exact="Zika" post="fever http://orcid.org/0000-0003-1827-7932DénesAttiladenesa@math.u-szeged.hu1http://orcid.org/0000-0003-0258-2019IbrahimMahmoud A.12OluochLillian1TekeliMiklós1TekeliTamás1[1], 0000 0001 1016 9625grid.9008.1Bolyai Institute, University"/>
   <result pre="We establish a compartmental model to study the transmission of" exact="Zika" post="virus disease including spread through sexual contacts and the"/>
   <result pre="Sensitivity analysis shows that, although the most important factors in" exact="Zika" post="transmission are the birth rate of mosquitoes and the"/>
   <result pre="through sexual contacts also highly contributes to the transmission of" exact="Zika" post="virus: our study suggests that the practice of safe"/>
   <result pre="possibly contracted the disease, can significantly reduce the number of" exact="Zika" post="cases. Subject terms Infectious diseases Viral infection Funding János"/>
   <result pre="Development and Innovation Fund of Hungary, grant No. FK124016. Introduction" exact="Zika" post="virus Zika virus (ZIKV) is a virus belonging to"/>
   <result pre="Innovation Fund of Hungary, grant No. FK124016. Introduction Zika virus" exact="Zika" post="virus (ZIKV) is a virus belonging to the family"/>
   <result pre="and subtropical regions and spreading in temperate areas as well." exact="ZIKV" post="is related to other arboviruses like chikungunya and dengue."/>
   <result pre="be passed on through other means. Unlike the above-listed diseases," exact="Zika" post="can be transmitted through sexual contacts, mostly from men"/>
   <result pre="women2. The disease can be passed from a person with" exact="Zika" post="before the start of the symptoms, while having symptoms,"/>
   <result pre="may also be passed by asymptomatic carriers3. Studies suggest that" exact="ZIKV" post="can remain in semen longer (possibly even six months)"/>
   <result pre="around the time of birth. This may lead to Congenital" exact="Zika" post="Syndrome the symptoms of which include microcephaly and a"/>
   <result pre="transfusion and breastfeeding5,6. Figure 1 shows the possible methods of" exact="Zika" post="transmission. Figure 1 Biology of Zika Virus (ZIKV). The"/>
   <result pre="the possible methods of Zika transmission. Figure 1 Biology of" exact="Zika" post="Virus (ZIKV). The figure shows modes of transmission and"/>
   <result pre="transmission and illustrates the critical pathological manifestation (microcephaly) associated with" exact="Zika" post="infection. The infection, known as Zika fever or Zika"/>
   <result pre="manifestation (microcephaly) associated with Zika infection. The infection, known as" exact="Zika" post="fever or Zika virus disease, shares clinical signs and"/>
   <result pre="with Zika infection. The infection, known as Zika fever or" exact="Zika" post="virus disease, shares clinical signs and symptoms with dengue"/>
   <result pre="properly resulting in a head smaller than its normal size." exact="ZIKV" post="poses a serious threat to public health internationally due"/>
   <result pre="First identified in 1947 in a rhesus monkey in the" exact="Zika" post="forest in Uganda10, the virus was recovered in 1948"/>
   <result pre="in 1948 from the mosquito Aedes africanus, caught in the" exact="Zika" post="forest11. The first human cases were reported in Uganda"/>
   <result pre="the Cook Islands, New Caledonia. In 2008, a scientist contracted" exact="Zika" post="fever in Senegal and after returning to the US,"/>
   <result pre="of 2015, and several other countries from the region confirmed" exact="Zika" post="cases at the end of 2015 and early 2016"/>
   <result pre="end of 2015 and early 2016 (for the incidence of" exact="Zika" post="fever in Central and South American countries affected by"/>
   <result pre="the epidemic 2015–2017, see Fig. 2). The rapid spread of" exact="Zika" post="in Brazil can be attributed to the completely susceptible"/>
   <result pre="in the number of microcephaly cases among newborns. In November," exact="Zika" post="virus genome was detected in the blood and tissues"/>
   <result pre="with microcephaly in Brazil. In January 2016, intrauterine transmission of" exact="Zika" post="virus was detected for the first time in two"/>
   <result pre="from other countries of South America. Figure 2 Incidence of" exact="Zika" post="fever in Central and South American countries affected by"/>
   <result pre="countries affected by the epidemic 2015–201716. The course of the" exact="Zika" post="epidemic was different in various countries of South America."/>
   <result pre="major peaks in two successive years16. Although the number of" exact="Zika" post="cases has declined since the virus was first introduced"/>
   <result pre="virus was first introduced in the Americas, in February 2018," exact="Zika" post="fever was included in WHO’s Blueprint list of priority"/>
   <result pre="the distribution of carrying mosquitoes implying a possible introduction of" exact="Zika" post="into so far unaffected regions, Zika virus will most"/>
   <result pre="a possible introduction of Zika into so far unaffected regions," exact="Zika" post="virus will most probably continue to be an important"/>
   <result pre="be an important menace in the future. Mathematical models for" exact="Zika" post="transmission Various mathematical models have been established to study"/>
   <result pre="established to study the transmission dynamics of the spread of" exact="Zika" post="virus. Gao et al.19 introduced a compartmental model of"/>
   <result pre="Zika virus. Gao et al.19 introduced a compartmental model of" exact="Zika" post="spread considering vector-borne and sexual transmission proposing an SEIR-type"/>
   <result pre="of the outbreaks. Suparit et al.21 studied the spread of" exact="Zika" post="fever in Bahia, Brazil considering two vector control strategies:"/>
   <result pre="model also includes the influences of seasonal change on the" exact="ZIKV" post="transmission dynamics via time-varying mosquito biting rate, however, it"/>
   <result pre="al.24, Marini et al.25 studied models for the spread of" exact="Zika" post="to new areas. Further models for Zika transmission are"/>
   <result pre="the spread of Zika to new areas. Further models for" exact="Zika" post="transmission are studied e.g. in26–33. The majority of models"/>
   <result pre="In the present work, we establish a compartmental model for" exact="Zika" post="transmission, considering the important features of the disease included"/>
   <result pre="model with time-dependent parameters As described in the Introduction, the" exact="Zika" post="epidemic had different outcome in the countries of South"/>
   <result pre="This motivated us to establish a new compartmental model for" exact="Zika" post="virus transmission which also considers the periodicity of weather."/>
   <result pre="applicable for evaluation of the role of sexual transmission of" exact="Zika" post="as well. As the number of sexual transmissions from"/>
   <result pre="S f ) are those who can be infected by" exact="Zika" post="virus. After contracting the disease, one moves to the"/>
   <result pre="work are described in Table 1. Figure 3 Dynamics of" exact="Zika" post="virus spread considering two sexes and involving vectorial and"/>
   <result pre="in which country there was only one peak of the" exact="Zika" post="epidemic, as well as to data from Costa Rica16,41."/>
   <result pre="able to reproduce both typical types of scenarios of the" exact="Zika" post="epidemic. Depending on the parameter values characteristic of the"/>
   <result pre="model is able to reproduce both typical outcomes of the" exact="Zika" post="epidemic, showing that the periodic change of weather, resulting"/>
   <result pre="sexual protection are both important factors in the spread of" exact="Zika" post="fever and that vector control might be insufficient to"/>
   <result pre="through an analysis of the exponential rise in clinically identified" exact="ZIKV" post="cases gave an estimate of \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts}"/>
   <result pre="sexual transmission As the main concern about the spread of" exact="Zika" post="virus disease is mother-to-child transmission resulting in brain malformations,"/>
   <result pre="several studies and news articles reported a higher number of" exact="Zika" post="virus infections in women compared to cases in men45–47."/>
   <result pre="studies, our simulation shows similar or somewhat smaller surplus of" exact="Zika" post="cases in women, though, the high number given in"/>
   <result pre="fact that women (and especially pregnant women) suspected to have" exact="Zika" post="are more likely to visit their doctors because of"/>
   <result pre="unknown in mosquito-borne diseases, significantly contributed to the number of" exact="Zika" post="cases. More precisely, based on our model, we estimate"/>
   <result pre="and (b) Suriname. Sensitivity analysis As currently no vaccine against" exact="Zika" post="is available, the most important control measures to decrease"/>
   <result pre="the most important control measures to decrease the transmission of" exact="Zika" post="include decreasing mosquito bites in areas affected by the"/>
   <result pre="parameters. The results suggest that the most important factors in" exact="Zika" post="transmission are the birth rate of mosquitoes and the"/>
   <result pre="sexual contacts has a smaller effect on the number of" exact="Zika" post="cases, it is shown to be an important factor"/>
   <result pre="shown to be an important factor in the transmission of" exact="Zika" post="virus. Considering this and the results presented in the"/>
   <result pre="possibly contracted the disease, can significantly reduce the number of" exact="Zika" post="cases. However, the most important ways to reduce transmission"/>
   <result pre="are negatively correlated with the number of infections. Discussion The" exact="Zika" post="fever outbreak in South America, started in 2015, has"/>
   <result pre="have established a compartmental model to study the transmission of" exact="Zika" post="virus disease including spread through sexual contacts, asymptomatic carriers"/>
   <result pre="our knowledge, our model is the first compartmental model for" exact="Zika" post="fever transmission which, besides considering both mosquito-borne and sexual"/>
   <result pre="of weather. We fitted the model to the number of" exact="Zika" post="cases in two countries where the Zika epidemic had"/>
   <result pre="the number of Zika cases in two countries where the" exact="Zika" post="epidemic had a different outcome: Suriname, where there was"/>
   <result pre="their pregnancy. Our results suggests that a 39–65% surplus in" exact="Zika" post="cases in women in comparison with men, which can"/>
   <result pre="be attributed to the fact that women suspected to have" exact="Zika" post="are more likely to visit their doctors. Further, we"/>
   <result pre="sexual transmission could be responsible for about 32–54% of the" exact="Zika" post="infections. Our findings are in accordance with similar earlier"/>
   <result pre="have possibly been infected can significantly reduce the number of" exact="Zika" post="cases. Both the basic reproduction number of the time-periodic"/>
   <result pre="statements about the possibility of reduction of the number of" exact="Zika" post="cases by decreasing the probability of sexual transmission. Supplementary"/>
   <result pre="1.PetersenLRJamiesonDJPowersAMHoneinMAZika virusN. Engl. J. Med.201637529429527355409 2.MagalhaesTFoyBDMarquesETAEbelGDWeger-LucarelliJMosquito-borne and sexual transmission of" exact="Zika" post="virus: recent developments and future directionsVirus Research20182541910.1016/j.virusres.2017.07.01128705681 3.Centers for"/>
   <result pre="guidance for healthcare providers for prevention of sexual transmission of" exact="Zika" post="virus, https://www.cdc.gov/zika/hc-providers/clinical-guidance/sexualtransmission.html (accessed 27 June 2019). 4.MeadPSet al.Zika virus"/>
   <result pre="menN. Engl. J. Med.20183781377138510.1056/NEJMoa171103829641964 5.BlohmGMet al.Evidence for mother-to-child transmission of" exact="Zika" post="virus through breast milkClin. Infect. Dis.2018661120112110.1093/cid/cix96829300859 6.GregoryCJet al.Modes of"/>
   <result pre="through breast milkClin. Infect. Dis.2018661120112110.1093/cid/cix96829300859 6.GregoryCJet al.Modes of transmission of" exact="Zika" post="virusJ. Infect. Dis.2017216S875S88310.1093/infdis/jix39629267909 7.World Health Organization, Zika virus, microcephaly"/>
   <result pre="of transmission of Zika virusJ. Infect. Dis.2017216S875S88310.1093/infdis/jix39629267909 7.World Health Organization," exact="Zika" post="virus, microcephaly and Guillain–Barré syndrome. Situation report. 7 April"/>
   <result pre="November 2018). 8.CarlsonCJDoughertyERGetzWAn ecological assessment of the pandemic threat of" exact="Zika" post="VirusPLOS Negl. Trop. Dis.201610.8e000496810.1371/journal.pntd.000496827564232 9.SongBHet al.Zika virus: history, epidemiology,"/>
   <result pre="residing in East AfricaJ. Immunol.19526922323414946416 13.FoyBDet al.Probable non-vector-borne transmission of" exact="Zika" post="Virus, Colorado, USAEmerg. Infect. Dis.20111788088210.3201/eid1705.10193921529401 14.CaminadeCet al.Global risk model"/>
   <result pre="Infect. Dis.20111788088210.3201/eid1705.10193921529401 14.CaminadeCet al.Global risk model for vector-borne transmission of" exact="Zika" post="virus reveals the role of El Niño 2015Proc. Natl."/>
   <result pre="American Health Organization, Countries and territories with autochthonous transmission of" exact="Zika" post="virus in the Americas reported in 2015–2017, https://www.paho.org/hq/index.php?option=com_content&amp;amp;view=article&amp;amp;id=11603:countries-and-territories-with-autochthonous-transmission-of-zika-virus-in-the-americas-reported-in-2015-2017&amp;amp;Itemid=41696&amp;amp;lang=en. 17.World"/>
   <result pre="of blueprint priority diseases, https://www.who.int/blueprint/priority-diseases/en/ (February 2018). 18.TeslaBet al.Temperature drives" exact="Zika" post="virus transmission: evidence from empirical and mathematical modelsProc. R."/>
   <result pre="mathematical modelsProc. R. Soc. B20182852018079510.1098/rspb.2018.079530111605 19.GaoDet al.Prevention and control of" exact="Zika" post="as a mosquito-borne and sexually transmitted disease: a mathematical"/>
   <result pre="modeling analysisSci. Rep.201662807010.1038/srep2807027312324 20.Baca-CarrascoDVelasco-HernándezJXSex, mosquitoes and epidemics: an evaluation of" exact="Zika" post="disease dynamicsBull. Math. Biol.2016782228224210.1007/s11538-016-0219-427743310 21.SuparitPWiratsudakulAModchangCA mathematical model for Zika"/>
   <result pre="of Zika disease dynamicsBull. Math. Biol.2016782228224210.1007/s11538-016-0219-427743310 21.SuparitPWiratsudakulAModchangCA mathematical model for" exact="Zika" post="virus transmission dynamics with a time-dependent mosquito biting rateTheor."/>
   <result pre="modelsPLoS Negl. Trop. Dis.201711e000556810.1371/journal.pntd.000556828448507 23.GuzzettaGet al.Assessing the potential risk of" exact="Zika" post="virus epidemics in temperate areas with established Aedes albopictus"/>
   <result pre="al.Assessing seasonal risks for the introduction and mosquito-borne spread of" exact="Zika" post="virus in EuropeEBioMedicine2016925025610.1016/j.ebiom.2016.06.00927344225 25.MariniGet al.First outbreak of Zika virus"/>
   <result pre="spread of Zika virus in EuropeEBioMedicine2016925025610.1016/j.ebiom.2016.06.00927344225 25.MariniGet al.First outbreak of" exact="Zika" post="virus in the continental United States: a modelling analysisEuro"/>
   <result pre="Surveill.2017223710.2807/1560-7917.ES.2017.22.37.30612 26.NahKet al.Estimating risks of importation and local transmission of" exact="Zika" post="virus infectionPeerJ20164e190410.7717/peerj.190427069825 27.AgustoFBBewickSFaganWFMathematical model of Zika virus with vertical"/>
   <result pre="and local transmission of Zika virus infectionPeerJ20164e190410.7717/peerj.190427069825 27.AgustoFBBewickSFaganWFMathematical model of" exact="Zika" post="virus with vertical transmissionInfect. Dis. Model.2017224426729928740 28.OkuneyeKOVelasco-HernándezJXGumelABThe &quot;unholy�? chikungunya–dengue–Zika"/>
   <result pre="Syst.20172554558510.1142/S0218339017400046 29.PadmanabhanPSeshaiyerPCastillo-ChavezCMathematical modeling, analysis and simulation of the spread of" exact="Zika" post="with influence of sexual transmission and preventive measuresLett. Biomath.2017414816610.1080/23737867.2017.1319746"/>
   <result pre="local transmission of vector-borne diseases in Florida: the case of" exact="Zika" post="outbreak in 2016J. Theor. Biol.201845534235610.1016/j.jtbi.2018.07.02630053386 31.Saad-RoyCMMaJvan den DriesschePThe effect"/>
   <result pre="Theor. Biol.201845534235610.1016/j.jtbi.2018.07.02630053386 31.Saad-RoyCMMaJvan den DriesschePThe effect of sexual transmission on" exact="Zika" post="virus dynamicsJ. Math. Biol.2018771917194110.1007/s00285-018-1230-129696377 32.SasmalSKGhoshIHuppertAChattopadhyayJModeling the spread of Zika"/>
   <result pre="on Zika virus dynamicsJ. Math. Biol.2018771917194110.1007/s00285-018-1230-129696377 32.SasmalSKGhoshIHuppertAChattopadhyayJModeling the spread of" exact="Zika" post="virus in a stage-structured population: effect of sexual transmissionBull."/>
   <result pre="of sexual transmissionBull. Math. Biol.2018803038306710.1007/s11538-018-0510-730229426 33.Cruz-PachecoGEstevaLPio FerreiraCA mathematical analysis of" exact="Zika" post="virus epidemic in Rio de Janeiro as a vector-borne"/>
   <result pre="for Disease Control and Prevention, First female-to-male sexual transmission of" exact="Zika" post="virus infection reported in New York City, http://www.cdc.gov/media/releases/2016/s0715-zika-female-to-male.html (Accessed"/>
   <result pre="http://www.cdc.gov/media/releases/2016/s0715-zika-female-to-male.html (Accessed on December 2016). 35.DavidsonASlavinskiSKomotoKRakemanJWeissDSuspected female-to-male sexual transmission of" exact="Zika" post="virus – New York City, 2016MMWR Morb. Mortal. Wkly"/>
   <result pre="transmitidas por vectores (23. Nov. 2018). 42.Saad-RoyCMvan den DriesschePMaJEstimation of" exact="Zika" post="virus prevalence by appearance of microcephalyBMC Infect Dis.201616.175410.1186/s12879-016-2076-z27955630 43.TowersSet"/>
   <result pre="Dis.201616.175410.1186/s12879-016-2076-z27955630 43.TowersSet al.Estimate of the reproduction number of the 2015" exact="Zika" post="virus outbreak in Barranquilla, Colombia, and estimation of the"/>
   <result pre="the reproductive number, total outbreak size, and reporting rates for" exact="Zika" post="epidemics in South and Central AmericaEpidemics201721637910.1016/j.epidem.2017.06.00528803069 45.LozierMet al.Incidence of"/>
   <result pre="Zika epidemics in South and Central AmericaEpidemics201721637910.1016/j.epidem.2017.06.00528803069 45.LozierMet al.Incidence of" exact="Zika" post="virus disease by age and sex – Puerto Rico,"/>
   <result pre="20, 2016MMWR Morb. Mortal. Wkly. Rep.2016651219122310.15585/mmwr.mm6544a427832051 46.CoelhoFCet al.Higher incidence of" exact="Zika" post="in adult women than adult men in Rio de"/>
   <result pre="men to womenInt. J. Infect. Dis.20165112813210.1016/j.ijid.2016.08.02327664930 47. 1.106 casos de" exact="Zika" post="se registran en Ecuador; 73 infectadas son embarazadas, El"/>
   <result pre="https://www.eluniverso.com/noticias/2016/07/14/nota/5689806/1106-casos-zika-se-registran-pais-73-infectadas-son-embarazadas (14 July, 2016). 48.AlthausCLLowNHow relevant is sexual transmission of" exact="Zika" post="virus?PLOS Med.20161310e100215710.1371/journal.pmed.100215727780196 49.World Health Organization, WHO Global Health Observatory"/>
   <result pre="a human volunteerTrans. R. Soc. Trop. Med. Hyg.19565044244810.1016/0035-9203(56)90090-613380987 54.GourinatA-CO’ConnorOCalvezEGoarantCDupont-RouzeyrolMDetection of" exact="Zika" post="virus in urineEmerg. Infect. Dis201521848610.3201/eid2101.140894 55.MussoDet al.Potential sexual transmission"/>
   <result pre="virus in urineEmerg. Infect. Dis201521848610.3201/eid2101.140894 55.MussoDet al.Potential sexual transmission of" exact="Zika" post="virusEmerg. Infect. Dis.20152135936110.3201/eid2110.151125 56.BoormanJPPorterfieldJSA simple technique for infection of"/>
   <result pre="simple technique for infection of mosquitoes with viruses; transmission of" exact="Zika" post="virusTrans. R. Soc. Trop. Med. Hyg.19565023824210.1016/0035-9203(56)90029-3"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6868920\results\search\tropicalVirus\results.xml">
   <result pre="viruses are especially important in tropical and subtropical regions; where," exact="ZIKV" post="and CHIKV are involved in epidemics worldwide, while the"/>
   <result pre="especially important in tropical and subtropical regions; where, ZIKV and" exact="CHIKV" post="are involved in epidemics worldwide, while the DENV remains"/>
   <result pre="ZIKV and CHIKV are involved in epidemics worldwide, while the" exact="DENV" post="remains as the biggest problem in public health. Factors,"/>
   <result pre="a summary about their treatment with natural extracts from plants." exact="Dengue" post="virus Zika virus Chikungunya virus viral replication viruses biology"/>
   <result pre="about their treatment with natural extracts from plants. Dengue virus" exact="Zika" post="virus Chikungunya virus viral replication viruses biology natural extracts"/>
   <result pre="treatment with natural extracts from plants. Dengue virus Zika virus" exact="Chikungunya" post="virus viral replication viruses biology natural extracts Introduction Arbovirus"/>
   <result pre="zika, which is then followed by Malaria, Chagas, Leishmaniasis and" exact="Yellow fever" post="(PAHO-CHA-IR, 2016[57]). It is important, from the public health"/>
   <result pre="in 1927 in Ghana. The estimated number of cases of" exact="YFV" post="in Africa and Latin America are about 120,000 per"/>
   <result pre="which raised interest in relation to the potential impact of" exact="YFV" post="into non-endemic countries, where usually people do not get"/>
   <result pre="patients with severe dengue (Bhatt et al., 2013[10]; PAHO-CHA-IR, 2016[57])." exact="Dengue" post="fever may be caused by four different serotypes: DENV1,"/>
   <result pre="and efficacy (Malisheni et al., 2017[46]; Prompetchara et al., 2019[62])." exact="ZIKV" post="is a public health problem since it caused a"/>
   <result pre="in the proliferation and apoptosis processes of glial cells. Although" exact="ZIKV" post="presents a mature structure similar to other known flaviviral"/>
   <result pre="differs from other flaviviruses. Additionally, the genomic divergences among the" exact="ZIKV" post="strains/isolates can in turn be associated with the differential"/>
   <result pre="important arbovirus family found in Latin America is Togaviridae. The" exact="CHIKV" post="belongs to this family, and the Alphavirus genus. Currently"/>
   <result pre="of them were named based in their geographic distribution. The" exact="CHIKV" post="has a close relation with more alphaviruses such as:"/>
   <result pre="causative agents of arthritis (Vu et al., 2017[91]). Since 1950," exact="CHIKV" post="was found and characterized only in East Africa; only"/>
   <result pre="East Africa; only in the late 1990s and early 2000s," exact="CHIKV" post="remerged on a global scale (Ganesan et al., 2017[25]),"/>
   <result pre="viral production, pH sensitivity and neuroinvasiveness in most flaviviruses. Interestingly," exact="ZIKV" post="has a single glycosylation site (N154) in the EDI"/>
   <result pre="et al., 2017[102]). The structure of the Domain III of" exact="YFV" post="differs from the structure of other mosquito-transmitted flaviviruses, specifically"/>
   <result pre="In the case of evasion of the immune response by" exact="DENV" post="the following are involved: NS2A, NS2B3, NS4A, NS4B and"/>
   <result pre="replication, and virulence. Thus, deletion of NS1 glycosylation sites of" exact="DENV" post="and YFV, significantly reduce their viral replication. NS1 can"/>
   <result pre="structure of NS1 is similar among YFV, ZIKV, DENV, and" exact="WNV" post="(Wang et al., 2017[94]). NS1 of ZIKV has a"/>
   <result pre="ZIKV, DENV, and WNV (Wang et al., 2017[94]). NS1 of" exact="ZIKV" post="has a diversity of electrostatic surface features in the"/>
   <result pre="Spontaneous mutation resulting in a single amino acid substitution in" exact="ZIKV" post="NS1 protein increased its infectivity in Aedes aegypti mosquitoes,"/>
   <result pre="It has been reported that the expression of the WNV," exact="YFV" post="or DENV-2 NS1 protein, does not alter the TLR3"/>
   <result pre="plays an important role in the viral replication process. Furthermore," exact="YFV" post="and DENV are associated with hemorrhagic fever, this may"/>
   <result pre="important role in the viral replication process. Furthermore, YFV and" exact="DENV" post="are associated with hemorrhagic fever, this may be due"/>
   <result pre="and platelets producing cell damage (Chen et al., 2018[18]). Besides," exact="ZIKV" post="NS1, from Asian lineage strains, can be involved in"/>
   <result pre="However, an alternative protein, the NS1', has been reported in" exact="ZIKV" post="(specifically Asian lineage) and other neuroinvasive Flavivirus. This suggests"/>
   <result pre="et al., 2008[39]). Additionally, it has been reported that in" exact="DENV" post="there are two different sets of NS2A molecules, which"/>
   <result pre="shows approximately 65 % sequence identity between DENV, ZIKV, and" exact="YFV" post="(Brand et al., 2017[13]), therefore is interesting for the"/>
   <result pre="protease activity, for example, it has been described that in" exact="DENV" post="is responsible for the cleavage between NS2A/2B, NS2B3, NS3/4A"/>
   <result pre="between NS2A/2B, NS2B3, NS3/4A and NS4B/5 (Chen et al., 2017[19])." exact="DENV" post="NS4 protein is cleaved by the NS3 host signal"/>
   <result pre="as well as modulating the function of NS3 helicase. In" exact="YFV" post="and WNV, NS4B and STAT1 show cytoplasmic localization, and"/>
   <result pre="Even though the NS4B protein is highly conserved among the" exact="DENV" post="serotypes, mutations in the NS4B of YFV can modulate"/>
   <result pre="conserved among the DENV serotypes, mutations in the NS4B of" exact="YFV" post="can modulate its neuro-invasion capacity, as well as its"/>
   <result pre="as well as its neuro-virulence (Zmurko et al., 2015[103]). During" exact="Zika" post="infection, NS4A and B are involved in the induction"/>
   <result pre="Flavivirus, with a homology of about 68 % between DENV," exact="ZIKV" post="and YFV (Potisopon et al., 2014[61]; Brand et al.,"/>
   <result pre="a homology of about 68 % between DENV, ZIKV and" exact="YFV" post="(Potisopon et al., 2014[61]; Brand et al., 2017[13]). NS5"/>
   <result pre="RNA splicing within the host cell (Murray et al., 2008[50])." exact="DENV" post="infected cells show localization of NS5 protein mainly in"/>
   <result pre="cleavage products (E3 and 6K). The 5' end of the" exact="CHIKV" post="genome also shows a 7-methylguanosine cap (Figure 1(Fig. 1))"/>
   <result pre="putative ion channel that may enhance particle release. E1 in" exact="CHIKV" post="is a 436 aa type II fusion protein, through"/>
   <result pre="2017[83]), however mutation of a nucleolar localization sequence in the" exact="CHIKV" post="N-terminal region of capsid protein, is involved in viral"/>
   <result pre="present four non-structural proteins (nsP), which are well characterized in" exact="CHIKV" post="(Pietilä et al., 2017[59]; Silva and Dermody, 2017[75]): nsP1"/>
   <result pre="al., 1991[8]); this is detected during the early phases of" exact="CHIKV" post="replication. When nsP123 concentration is enough to support an"/>
   <result pre="although, the viral replication is not affected. A vaccine for" exact="DENV" post="has been recently implemented to be used in people"/>
   <result pre="Therefore, there is no vaccine available for the treatment of" exact="DENV" post="(Lim et al., 2013[42]). In the middle of this"/>
   <result pre="and characterization of a modified Ankara virus-based vaccine, and expressing" exact="CHIKV" post="E3 and E2 proteins, the authors demonstrated that the"/>
   <result pre="demonstrated that the vaccine protected different type of mice against" exact="CHIKV" post="infection (Weger-Lucarelli et al., 2014[96]). Prow and colleagues, described"/>
   <result pre="curcumin, a common food additive, was considered capable of reducing" exact="ZIKV" post="infectivity by preventing the virus binding to cells, without"/>
   <result pre="Also, it has been reported that commercially available quercetine inhibits" exact="ZIKV" post="protease with an IC50 of 26.0 ± 0.1 μM"/>
   <result pre="with possibilities to inhibit their replication. In the case of" exact="ZIKV" post="these proteins are well known as possible targets: NS2B-NS3"/>
   <result pre="NS3, NS5 and the capsid protein. In the case of" exact="CHIKV" post="one of the most suitable targets is the cysteine"/>
   <result pre="involved over 1350 extracts of plants as inhibitors of the" exact="DENV" post="polymerase using the domain RdRp of DENV-2 NS5, 49"/>
   <result pre="natural products and 233 clinical approved drugs) as inhibitors of" exact="CHIKV" post="infection, using a stable replication cell line. Their results"/>
   <result pre="apigenin, chrysin, naringenin and silybin, were the most actives against" exact="CHIKV" post="(Pohjala et al., 2011[60]). The Harringtonine, a natural product"/>
   <result pre="is no specific treatment for infection caused by DENV, ZIKV," exact="CHIKV" post="and other human-related infections caused by arbovirus. The development"/>
   <result pre="of a vaccine is still ongoing, but that directed against" exact="DENV" post="has not shown safety results. Despite the enormous difficulties"/>
   <result pre="possible therapeutic targets of action were stated. Highlighting that for" exact="DENV" post="and ZIKV the NS2B.NS3 protease coincides as a potential"/>
   <result pre="targets of action were stated. Highlighting that for DENV and" exact="ZIKV" post="the NS2B.NS3 protease coincides as a potential target, further"/>
   <result pre="of action the NS5RdRp protein. Nevertheless, in the case of" exact="CHIKV" post="still is not clear a possible action target, however,"/>
   <result pre="the genus FlavivirusVirus Res2015206108–1925683510 16CarneiroBMBatistaMNBragaACSNogueiraMLRahalPThe green tea molecule EGCG inhibits" exact="Zika" post="virus entryVirology2016496215–827344138 17CecchettoJFernandesFCBLopesRBuenoPRThe capacitive sensing of NS1 Flavivirus biomarkerBiosens"/>
   <result pre="mediated by flaviviridae non-structural proteinsViruses2017910E29128991176 20Colón-GonzálezFJPeresCASteiner São BernardoCHunterPRLakeIRAfter the epidemic:" exact="Zika" post="virus projections for Latin America and the Caribbean. Ekpo"/>
   <result pre="2015-January 2016Am J Transplant2016161031–4 29HigueraARamírezJDMolecular epidemiology of dengue, yellow fever," exact="Zika" post="and Chikungunya arboviruses: An updateActa Trop201919099–11130444971 30HubálekZRudolfINowotnyNArboviruses pathogenic for"/>
   <result pre="J Transplant2016161031–4 29HigueraARamírezJDMolecular epidemiology of dengue, yellow fever, Zika and" exact="Chikungunya" post="arboviruses: An updateActa Trop201919099–11130444971 30HubálekZRudolfINowotnyNArboviruses pathogenic for domestic and"/>
   <result pre="enzyme activity is a potential target for the inhibition of" exact="Chikungunya" post="virus replication and virus induced apoptosis in cultured mammalian"/>
   <result pre="of in vitro prophylactic and therapeutic efficacy of chloroquine against" exact="Chikungunya" post="virus in vero cellsJ Med Virol201082817–2420336760 36KiatTSPippenRYusofRIbrahimHKhalidNRahmanNAInhibitory activity of"/>
   <result pre="Res20035923–6114696326 44LitvocMNNovaesCTGLopesMIBFLitvocMNNovaesCTGLopesMIBFYellow feverRev Assoc Med Bras201864106–1329641667 45LiuYLiuJDuSShanCNieKZhangRet al.Evolutionary enhancement of" exact="Zika" post="virus infectivity in Aedes aegypti mosquitoesNature2017545482–628514450 46MalisheniMKhaiboullinaSFRizvanovAATakahNMurewanhemaGBatesMClinical efficacy, safety,"/>
   <result pre="against death and enhances virus replicationJ Biol Chem201128622147–5921511946 49MounceBCCesaroTCarrauLValletTVignuzziMCurcumin inhibits" exact="Zika" post="and chikungunya virus infection by inhibiting cell bindingAntiviral Res2017142148–5728343845"/>
   <result pre="al.Inhibitors of alphavirus entry and replication identified with a stable" exact="Chikungunya" post="replicon cell line and virus-based assaysPLoS One2011612e2892322205980 61PotisoponSPrietSColletADecrolyECanardBSeliskoBThe methyltransferase"/>
   <result pre="al.A vaccinia-based single vector construct multi-pathogen vaccine protects against both" exact="Zika" post="and chikungunya virusesNat Commun201891123029581442 64Puerta-GuardoHGlasnerDRHarrisEDengue virus NS1 disrupts the"/>
   <result pre="bioactives reveals nanchangmycin as a broad spectrum antiviral active against" exact="Zika" post="virusCell Rep201718804–1528099856 68Rodenhuis-ZybertIAWilschutJSmitJMDengue virus life cycle: viral and host"/>
   <result pre="host factors modulating infectivityCell Mol Life Sci2010672773–8620372965 69RoyALimLSrivastavaSLuYSongJSolution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
   <result pre="natural products from edible plantsPLoS One2017127e018063228700665 70SchuffeneckerIItemanIMichaultAMurriSFrangeulLVaneyM-Cet al.Genome microevolution of" exact="Chikungunya" post="viruses causing the Indian ocean outbreakPLoS Med20063e26316700631 71SharmaRKesariPKumarPTomarSStructure-function insights"/>
   <result pre="Small molecules targeting capsid hydrophobic pocketVirology2018515223–3429306785 72ShiYGaoGFStructural biology of the" exact="Zika" post="virusTrends Biochem Sci201742443–5628318966 73ShinGYostSAMillerMTElrodEJGrakouiAMarcotrigianoJStructural and functional insights into alphavirus"/>
   <result pre="prospective intervention strategiesJ Clin Invest2017127737–4928248203 76SilvaLAKhomandiakSAshbrookAWWellerRHeiseMTMorrisonTEet al.A single-amino-acid polymorphism in" exact="Chikungunya" post="virus E2 glycoprotein influences glycosaminoglycan utilizationJ Virol2014882385–9724371059 77SimonFJavelleEOliverMLeparc-GoffartIMarimoutouCChikungunya virus"/>
   <result pre="of electrostatic surfaces among flavivirusesNat Struct Mol Biol201623456–827088990 81SuwanmaneeSLuplertlopNDengue and" exact="Zika" post="viruses: lessons learned from the similarities between these Aedes"/>
   <result pre="between these Aedes mosquito-vectored arbovirusesJ Microbiol20175581–928120186 82TambonisTContessotoVGBittarCCalmonMFNogueiraMLRahalPet al.Asian lineage of" exact="Zika" post="virus RNA pseudoknot may induce ribosomal frameshift and produce"/>
   <result pre="neuroinvasive protein ZIKV-NS1’bioRxiv2017105809 83TaylorALiuXZaidAGohLYHHobson-PetersJHallRAet al.Mutation of the N-terminal region of" exact="Chikungunya" post="virus capsid protein: Implications for vaccine designMBio20178e01970e0191628223458 84TeoCSHChuJJHCellular vimentin"/>
   <result pre="protein nsP4 possesses terminal adenylyltransferase activityJ Virol2006809962–917005674 87TorresJROrdunaTAPiña-PozasMVázquez-VegaDSartiEEpidemiological characteristics of" exact="Dengue" post="disease in Latin America and in the Caribbean: A"/>
   <result pre="Microbes Infect20176e1328325921 93WangDChenCLiuSZhouHYangKZhaoQet al.A mutation identified in neonatal microcephaly destabilizes" exact="Zika" post="virus NS1 assembly in vitroSci Rep201774258028198446 94WangHHanMQiJHilgenfeldRLuoTShiYet al.Crystal structure"/>
   <result pre="95WeaverSCReisenWKPresent and future arboviral threatsAntiviral Res201085328–4519857523 96Weger-LucarelliJChuHAliotaMTPartidosCDOsorioJEA novel MVA vectored" exact="Chikungunya" post="virus vaccine elicits protective immunity in micePLoS Negl Trop"/>
   <result pre="assembly sitesCell Host Microbe20095365–7519380115 98XiaHLuoHShanCMuruatoAENunesBTDMedeirosDBAet al.An evolutionary NS1 mutation enhances" exact="Zika" post="virus evasion of host interferon inductionNat Commun2018941429379028 99XieXZouJPuttikhuntCYuanZShiP-YTwo distinct"/>
   <result pre="Commun2018941429379028 99XieXZouJPuttikhuntCYuanZShiP-YTwo distinct sets of NS2A molecules are responsible for" exact="Dengue" post="virus RNA synthesis and virion assemblyJ Virol2015891298–31325392211 100YapMLKloseTUrakamiAHasanSSAkahataWRossmannMGStructural studies"/>
   <result pre="virus RNA synthesis and virion assemblyJ Virol2015891298–31325392211 100YapMLKloseTUrakamiAHasanSSAkahataWRossmannMGStructural studies of" exact="Chikungunya" post="virus maturationProc Natl Acad Sci U S A201711413703–729203665 101YapSNguyen-KhuongTRuddPMAlonsoSDengue"/>
   <result pre="cleavage products (E3 and 6K). Figure 2 Life cycle of" exact="DENV" post="in infected cells. The viral particles are released in"/>
   <result pre="and can infect more cells. Figure 3 Life cycle of" exact="CHIKV" post="in infected cells. The majority of the cells that"/>
   <result pre="cells. The majority of the cells that get infected by" exact="CHIKV" post="express glycosaminoglycans that apparently act as a virus-cell binding"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6872174\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="which can last for months or even years [6,7]. Recent" exact="CHIKV" post="epidemics have been associated with an increased number of"/>
   <result pre="is associated with a higher likelihood of being seropositive for" exact="CHIKV" post="[19,20], Sindbis virus (SINV) [21], and dengue virus (DENV)"/>
   <result pre="a risk factor for greater disease severity following infection with" exact="CHIKV" post="[23] and DENV [22]. Undernourishment, in contrast, has been"/>
   <result pre="for greater disease severity following infection with CHIKV [23] and" exact="DENV" post="[22]. Undernourishment, in contrast, has been associated with protection"/>
   <result pre="Undernourishment, in contrast, has been associated with protection from severe" exact="DENV" post="disease [24,25]. However, these data are not conclusive as"/>
   <result pre="conclusive as other studies have found either no association with" exact="DENV" post="disease severity [26,27] or an increased risk of severe"/>
   <result pre="to have both an increased or decreased risk for severe" exact="DENV" post="disease [28]. While the epidemiological data are quite clear"/>
   <result pre="an SP6 promoter in the same plasmid backbone of the" exact="CHIKV" post="clone described above. The MAYV infectious clone used in"/>
   <result pre="the hind left-footpad as previously described [34]. For experiments involving" exact="CHIKV" post="and MAYV, 104 PFU of virus in 50 μl"/>
   <result pre="alphavirus, namely CHIKV. Obese mice lost significantly more weight following" exact="CHIKV" post="challenge compared to lean mice (Fig 2C, two-way ANOVA,"/>
   <result pre="observe differences in histopathology between any of the groups following" exact="CHIKV" post="infection (S4 Fig). Furthermore, we did not observe differences"/>
   <result pre="viral RNA levels in the blood of mice infected with" exact="CHIKV" post="except for day 3 post-infection where obese mice had"/>
   <result pre="has been associated with increased disease severity upon infection with" exact="CHIKV" post="in humans [17,23,48]. In contrast, no information exists regarding"/>
   <result pre="alphaviruses, focusing on MAYV but including other important human pathogens," exact="CHIKV" post="and RRV. We fed mice different diets leading to"/>
   <result pre="index (BMI) and more severe disease sequelae in humans following" exact="CHIKV" post="infection [23]. In these studies, undernutrition did not result"/>
   <result pre="severe morbidity in acute arthritis models of infection with either" exact="CHIKV" post="or MAYV. Our use of only one type of"/>
   <result pre="associated with both protection [24,25] or increased susceptibility to [22]" exact="DENV" post="disease. We next showed that obesity alters viral replication."/>
   <result pre="next showed that obesity alters viral replication. For MAYV and" exact="CHIKV" post="infection, we observed increased early viral replication in the"/>
   <result pre="environments. Arthritogenic alphaviruses are known to cause chronic inflammation, and" exact="CHIKV" post="RNA and protein have been found in an infected"/>
   <result pre="infected human up to 18-months post initial infection [47]. Furthermore," exact="CHIKV" post="has been found in the infected joints of mice"/>
   <result pre="would not have been possible. References References 1collab: Outbreak news." exact="Chikungunya" post="and dengue, south-west Indian Ocean. Wkly Epidemiol Rec. 2006;81:"/>
   <result pre="Rec. 2006;81: 106–108. 2YactayoS, StaplesJE, MillotV, CibrelusL, Ramon-PardoP. Epidemiology of" exact="Chikungunya" post="in the Americas. J Infect Dis. 2016;214: S441–S445. 10.1093/infdis/jiw39027920170"/>
   <result pre="1–5. 9FreitasARR, CavalcantiL, Von ZubenAP, DonalisioMR. Excess Mortality Related to" exact="Chikungunya" post="Epidemics in the Context of Co-circulation of Other Arboviruses"/>
   <result pre="HenningssonR, ChenR, MatheusS, EnfissiA, et al.Whole-Genome Sequencing Analysis from the" exact="Chikungunya" post="Virus Caribbean Outbreak Reveals Novel Evolutionary Genomic Elements. PLoS"/>
   <result pre="Rescue and Characterization of Recombinant Virus from a New World" exact="Zika" post="Virus Infectious Clone. J Vis Exp. 2017; 10.3791/5585728654045 34Weger-LucarelliJ,"/>
   <result pre="I interferon signaling in CD8+ T cell maturation during acute" exact="West Nile" post="virus infection. PLoS Pathog. 2011;7: e100240710.1371/journal.ppat.100240722144897 36KarkeniE, MorinSO, Bou"/>
   <result pre="RNA extraction step for the detection and quantification of African" exact="Chikungunya" post="viruses. J Virol Methods. 2005;124: 65–71. 10.1016/j.jviromet.2004.11.00215664052 38WilmA, AwPPK,"/>
   <result pre="DasT, Li-Pat-YuenG, DassaB, et al.Persistent chronic inflammation and infection by" exact="Chikungunya" post="arthritogenic alphavirus in spite of a robust host immune"/>
   <result pre="e100289710.1371/journal.ppat.100289723028310 69Weger-LucarelliJ, GarciaSM, RückertC, ByasA, O’ConnorSL, AliotaMT, et al.Using barcoded" exact="Zika" post="virus to assess virus population structure in vitro and"/>
   <result pre="PalP, OkoL, DiamondMS, et al.Chronic joint disease caused by persistent" exact="Chikungunya" post="virus infection is controlled by the adaptive immune response."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6877935\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.1155/2019/3085827 : Research Article Epidemiological and Clinical Features of" exact="Dengue" post="Infection in Adults in the 2017 Outbreak in Vietnam"/>
   <result pre="the mosquito vector and circulation of all four types of" exact="Dengue" post="virus, dengue could rapidly spread across the country [6–9]."/>
   <result pre="spread across the country [6–9]. Therefore, the Viet Nam's National" exact="Dengue" post="Control Program was established in 1999, and Vietnam has"/>
   <result pre="low frequency (Table 2). 3.3. Laboratory Findings in Patients with" exact="Dengue" post="Fever From day 4 of fever, hematocrit began to"/>
   <result pre="Large dengue outbreaks were reported elsewhere globally in 2016 [3]." exact="Dengue" post="fever has been recognized as a health problem in"/>
   <result pre="Highlands, and 19/25 (76%) of the provinces, cities in Northern." exact="Dengue" post="fever has occurred in the midlands and northern mountains,"/>
   <result pre="or underlying disease in dengue in adults. 4.2.1. Outcome of" exact="Dengue" post="Fever There is a note in comparison with the"/>
   <result pre="more information for dengue fever situation in Vietnam. 5. Conclusion" exact="Dengue" post="fever is becoming more serious medical issue in Vietnam."/>
   <result pre="Office for South-East AsiaComprehensive Guidelines for Prevention and Control of" exact="Dengue" post="and Dengue Haemorrhagic Fever (Revised and Expanded Edition)2011New Delhi,"/>
   <result pre="South-East AsiaComprehensive Guidelines for Prevention and Control of Dengue and" exact="Dengue" post="Haemorrhagic Fever (Revised and Expanded Edition)2011New Delhi, IndiaWorld Health"/>
   <result pre="Regional Office for South-East Asia 3collab: World Health OrganizationFact Sheet" exact="Dengue" post="and Severe Dengue2017Geneva, SwitzerlandWorld Health Organizationhttps://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue 4CucunawangsihLugitoN. P. H.Trends"/>
   <result pre="D.PhuongH. L.Thanh NgaT. T.et al.Clinical, epidemiological and virological features of" exact="Dengue" post="virus infections in Vietnamese patients presenting to primary care"/>
   <result pre="evolution, history and emergence as a global PublicHealth problemDengue and" exact="Dengue" post="Hemorrhagic Fever20142ndCroydon, UKCPI Group Ltd.129 13ÅströmC.RocklövJ.HalesS.BéguinA.LouisV.SauerbornR.Potential distribution of dengue"/>
   <result pre="classification NHTD HTD Total n (%) n (%) n (%)" exact="Dengue" post="fever 1108 (63.8) 567 (47.9) 1675 (57.3) Warning signs"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881000\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Earth Sciences : Atmospheric Science : Meteorology:"/>
   <result pre="provided the original author and source are credited.pone.0224353.pdf Abstract Background" exact="Dengue" post="fever is the most widespread infectious disease of humans"/>
   <result pre="compared predicted and observed incidence estimated using the validation data." exact="Dengue" post="incidence predictions for 2010–2012 were also used to generate"/>
   <result pre="visiting the International Livestock Research Institute’s data portal: data.ilri.org/portal/dataset/surveillance_climate_sensitive_diseases. Introduction" exact="Dengue" post="fever (dengue) is a major infectious disease of humans"/>
   <result pre="the family Flaviviridae and genus Flavivirus. There are 4 antigenetically-related" exact="DENV" post="(DENV 1–4) each capable of causing the disease [1]."/>
   <result pre="DENV (DENV 1–4) each capable of causing the disease [1]." exact="DENV" post="infections cause various symptoms ranging from asymptomatic or uncomplicated"/>
   <result pre="to more severe illnesses especially following secondary infections with heterotypic" exact="DENV" post="[2]. A haemorrhagic form of the disease has also"/>
   <result pre="the virus [4]. Humans are the primary vertebrate host of" exact="DENV" post="but in Africa and Asia, an enzootic transmission cycle"/>
   <result pre="bodies, mixed agriculture, open land and neglected grasslands [7], determine" exact="DENV" post="persistence, while factors which influence vectorial competence of DENV"/>
   <result pre="determine DENV persistence, while factors which influence vectorial competence of" exact="DENV" post="vectors (such as emergence rate, gonotrophic cycle, survival rate,"/>
   <result pre="have important effects on the incidence of the disease [8]." exact="Dengue" post="incidence has also increased in endemic countries over time"/>
   <result pre="hierarchical Bayesian model to analyse surveillance data from the National" exact="Dengue" post="Control Programme (NDCP) in Vietnam. Bayesian models were preferred"/>
   <result pre="which favours many infectious agents and vectors such as mosquitoes." exact="Dengue" post="virus has been isolated from various mosquito species in"/>
   <result pre="[25]. Ae. aegypti and Ae. albopictus are classical vectors of" exact="DENV" post="but for the first time, Lien et al. [25]"/>
   <result pre="environmental data used are given in S1 Fig. Descriptive analyses" exact="Dengue" post="incidence, seasonal and interannual trends Crude dengue incidence was"/>
   <result pre="used to validate the forecasting model developed in this study." exact="Dengue" post="incidence had a strong seasonal pattern which often peaked"/>
   <result pre="variables including LC and altitude are shown in Fig 4." exact="Dengue" post="incidence declined with an increase in altitude, area under"/>
   <result pre="enhancement (ADE) of infection due to the introduction of new" exact="DENV" post="into a sub-population or an area with cross-reactive antibodies"/>
   <result pre="paper. More work is needed though to identify how new" exact="DENV" post="are introduced to new areas or sub-populations of exposed"/>
   <result pre="including malaria [59], schistosomiasis [60], Rift Valley fever [61], and" exact="West Nile" post="fever [62]. However, Ae. aegypti, the main vector of"/>
   <result pre="as those for), (ii) investigation of the distribution of the" exact="DENV" post="serotypes in relation to population immunity, (iii) capacity building"/>
   <result pre="2009; x, 147. WHO/HTM/NTD/DEN/2009.1 2ChaudhuryS, GromowskiGD, RipollDR, KhavrutskiiIV., DesaiV, WallqvistA." exact="Dengue" post="virus antibody database: Systematically linking serotype-specificity with epitope mapping"/>
   <result pre="9WartelTA, PrayitnoA, HadinegoroSRS, CapedingMR, ThisyakornU, TranNH, et al.Three Decades of" exact="Dengue" post="Surveillance in Five Highly Endemic South East Asian Countries."/>
   <result pre="Asia Pacific J Public Heal. 2017;29: 7–16. 10.1177/101053951667570128198645 10ChenB, LiuQ." exact="Dengue" post="fever in China. Lancet. 2015;385: 1621–2. 10.1016/S0140-6736(15)60793-0 11LeeHS, Nguyen-VietH,"/>
   <result pre="HashizumeM, TranDN, YamamotoT. Regional Differences in the Growing Incidence of" exact="Dengue" post="Fever in Vietnam Explained by Weather Variability. Trop Med"/>
   <result pre="BabinSM, Ramac-ThomasLC, GuvenE, ElbertY, et al.Prediction of High Incidence of" exact="Dengue" post="in the Philippines. PLoS Negl Trop Dis. 2014;810.1371/journal.pntd.000277124722434 20ThaiKTD,"/>
   <result pre="Elsevier; 2011;37: 371–381. 10.1016/j.cageo.2010.01.008 44CarbajoAE, SchweigmannN, CurtoSI, de GarinA, BejaranR." exact="Dengue" post="transmission risk maps of Argentina. Trop Med Int Heal."/>
   <result pre="Zoraida I, Manuel A, Gloria M, Velasco-salas ZI, et al." exact="Dengue" post="Hyperendemic City of Venezuela Spatial Analysis of Dengue Seroprevalence"/>
   <result pre="et al. Dengue Hyperendemic City of Venezuela Spatial Analysis of" exact="Dengue" post="Seroprevalence and Modeling of Transmission Risk Factors in a"/>
   <result pre="Dengue Seroprevalence and Modeling of Transmission Risk Factors in a" exact="Dengue" post="Hyperendemic City of Venezuela. 2017; 47XuL, StigeLC, ChanK-S, ZhouJ,"/>
   <result pre="2016;114: 20161855810.1073/pnas.161855811427940911 48ThuHM, LowryK, MyintTT, ShweTN, HanAM, KhinKK, et al.Myanmar" exact="Dengue" post="Outbreak Associated with Displacement of Serotypes 2, 3, and"/>
   <result pre="Associated with Displacement of Serotypes 2, 3, and 4 by" exact="Dengue" post="1. Emerg Infect Dis. 2004;10: 593–597. 10.3201/eid1004.03021615200847 49HaySI, MyersMF,"/>
   <result pre="JoshiHD, O’HaraRB, AhrensB, KuchU. Risk Factors for the Presence of" exact="Chikungunya" post="and Dengue Vectors (Aedes aegypti and Aedes albopictus), Their"/>
   <result pre="AhrensB, KuchU. Risk Factors for the Presence of Chikungunya and" exact="Dengue" post="Vectors (Aedes aegypti and Aedes albopictus), Their Altitudinal Distribution"/>
   <result pre="10.1111/tbed.1267428710814 62NyamwayaD, Wang’onduV, AmimoJ, MichukiG, OgugoM, OntiriE, et al.Detection of" exact="West Nile" post="virus in wild birds in Tana River and Garissa"/>
   <result pre="Implications. MoresCN, editor. PLoS One. 2012;7: e3091910.1371/journal.pone.003091922363516 64World Health Organization(WHO)." exact="Dengue" post="and severe dengue: key facts [Internet]. 2019 [cited 1"/>
   <result pre="65Fullerton LM, Dickin SK, Schuster-wallace CJ. Mapping Global Vulnerability to" exact="Dengue" post="using the Water Associated Disease Index. United Nations University."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881067\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="medium, provided the original author and source are credited.pntd.0007889.pdf Abstract" exact="Dengue" post="fever is endemic in Malaysia, contributing to significant economic"/>
   <result pre="for decades. The study investigated the presence and distribution of" exact="DENV" post="in urban localities in the Klang Valley, Peninsular Malaysia."/>
   <result pre="sentinel monkeys in Peninsular Malaysia in the 1970s. All four" exact="DENV" post="serotypes were co-circulating throughout the study period. The detection"/>
   <result pre="of sylvatic virus into the human transmission cycle. Author summary" exact="Dengue" post="is a mosquito-borne disease that has re-emerged as a"/>
   <result pre="data are within the manuscript and its Supporting Information files." exact="Dengue" post="virus CprM gene sequences have been deposited in GenBank"/>
   <result pre="and Sequence ID can be found in S3 Table. Introduction" exact="Dengue" post="is a mosquito-borne viral infection that has re-emerged as"/>
   <result pre="to a historic high of 120,836 cases in 2015 [4]." exact="Dengue" post="virus (DENV) is transmitted to humans primarily by infected"/>
   <result pre="are also the main vectors of chikungunya (CHIKV) [5] and" exact="Zika" post="virus (ZIKV) [6]. DENV is a Flavivirus with four"/>
   <result pre="vectors of chikungunya (CHIKV) [5] and Zika virus (ZIKV) [6]." exact="DENV" post="is a Flavivirus with four antigenically distinct serotypes, namely"/>
   <result pre="DENV is a Flavivirus with four antigenically distinct serotypes, namely" exact="DENV" post="serotype 1 to serotype 4 (DENV-1 to DENV-4) [7]."/>
   <result pre="involving domestic and peridomestic Aedes mosquitoes [8]. Sylvatic strains of" exact="DENV" post="serotypes 1, 2 and 4 have been isolated from"/>
   <result pre="distinct from other circulating DENV-2 strains [12]. Compared to sylvatic" exact="DENV" post="strains detected in Africa, phylogenetic studies have noted the"/>
   <result pre="have noted the presence of a wider diversity of sylvatic" exact="DENV" post="strains in Malaysia, suggesting that a DENV ancestor most"/>
   <result pre="diversity of sylvatic DENV strains in Malaysia, suggesting that a" exact="DENV" post="ancestor most likely originated in the Asian region and"/>
   <result pre="the Asian region and subsequently diverged into at least four" exact="DENV" post="serotypes that are currently circulating [13]. In 2008, a"/>
   <result pre="vectors [15]. These findings indicate that in this region, sylvatic" exact="DENV" post="is being maintained in a zoonotic cycle, as it"/>
   <result pre="in Malaysia [18]. These reports suggest that sylvatic strains of" exact="DENV" post="are capable of causing clinical disease in humans and,"/>
   <result pre="host. There exist considerable genetic differences between human and sylvatic" exact="DENV" post="strains. However, studies by Vasilakis and colleagues comparing human"/>
   <result pre="a lack of information on the presence and distribution of" exact="DENV" post="strains in Aedes mosquitoes in Malaysia. In this study"/>
   <result pre="study we aimed to investigate the presence and distribution of" exact="DENV" post="in urban localities in the Klang Valley, Peninsular Malaysia."/>
   <result pre="Valley, Peninsular Malaysia. We report the presence of all four" exact="DENV" post="serotypes, including a sylvatic strain of DENV-4, in field"/>
   <result pre="BJ-I Residential area (individual house) 3° 3'58.13&quot;N, 101°41'59.31&quot;E Detection of" exact="DENV" post="in larvae and adult mosquitoes cDNA synthesis was performed"/>
   <result pre="second round of PCR amplification was carried out using the" exact="DENV" post="consensus primers Dcon [25], D1 and D2 [26]. To"/>
   <result pre="primers Dcon [25], D1 and D2 [26]. To determine the" exact="DENV" post="serotype present, the amplified DNA sequence was subjected to"/>
   <result pre="amplification are detailed in S1 Table. Positive controls for each" exact="DENV" post="serotype (DENV-1-DENV-4) as detailed in S2 Table and a"/>
   <result pre="genotype and genetic relationship of each strain. Reference sequences of" exact="DENV" post="genotypes from different years and geographical regions were included"/>
   <result pre="= 364) collected from the same bimonthly intervals were screened." exact="DENV" post="serotype detection Overall, DENV was detected in 30 (2.2%)"/>
   <result pre="the same bimonthly intervals were screened. DENV serotype detection Overall," exact="DENV" post="was detected in 30 (2.2%) samples out of the"/>
   <result pre="only one (1.9%) out of 52 samples was positive for" exact="DENV" post="(Tables 4 and 5). All four DENV serotypes were"/>
   <result pre="was positive for DENV (Tables 4 and 5). All four" exact="DENV" post="serotypes were detected during the study period, where the"/>
   <result pre="accession numbers (MH377083-115) are shown in S3 Table. 10.1371/journal.pntd.0007889.t002Table 2" exact="DENV" post="detected in Aedes larvae collected in Selangor from June"/>
   <result pre="0 2 (DENV-3) 0 0 0 0 2 10.1371/journal.pntd.0007889.t003Table 3" exact="DENV" post="detected in Aedes larvae collected in Kuala Lumpur from"/>
   <result pre="1 (DENV-4) 0 0 0 0 0 2 10.1371/journal.pntd.0007889.t004Table 4" exact="DENV" post="detected in adult Aedes mosquitoes collected in Selangor from"/>
   <result pre="positive 0 0 0 0 0 0 0 10.1371/journal.pntd.0007889.t005Table 5" exact="DENV" post="detected in adult Aedes mosquitoes collected in Kuala Lumpur"/>
   <result pre="analysis Phylogenetic trees of the CprM gene sequences for each" exact="DENV" post="serotype and reference sequences for the respective genotypes are"/>
   <result pre="Malaysia. Based on this analysis, we can confirm that the" exact="DENV" post="strain sequenced from an Ae. albopictus larva collected from"/>
   <result pre="Malaysia [9]. Discussion This study reports the detection of four" exact="DENV" post="serotypes amongst field collected Ae. aegypti and Ae. albopictus"/>
   <result pre="Aedes larvae. Co-infections of Aedes larvae with multiple serotypes of" exact="DENV" post="have previously been reported in Brazil [34] and may"/>
   <result pre="the multiple feeding behaviour of Ae. aegypti. However, as the" exact="DENV" post="co-infections were detected in larvae it is unclear if"/>
   <result pre="three decades and is one of the most widely distributed" exact="DENV" post="genotypes globally [37]. All DENV-3-RNA-positive samples in the current"/>
   <result pre="of the virus. DENV-4 has not been associated with major" exact="DENV" post="epidemics in Malaysia since the 1960s [41] and appears"/>
   <result pre="circulate amongst rural villages and is capable of transmitting sylvatic" exact="DENV" post="to resident human populations. In the study by Diallo"/>
   <result pre="susceptibility to infection [43]. Evidence of the ability of sylvatic" exact="DENV" post="to emerge from an enzootic cycle to infect humans,"/>
   <result pre="would make it the most likely vector for transmission of" exact="DENV" post="to both primate and non-primate hosts which may act"/>
   <result pre="additional data file. S2 Table List of positive controls for" exact="DENV" post="serotypes 1 to 4. (DOC) LINK Click here for"/>
   <result pre="for additional data file. S3 Table List of sequences of" exact="DENV" post="serotypes 1 to 4 detected in Aedes mosquitoes from"/>
   <result pre="prevention and control 2012–2020Geneva: collab: World Health Organization. 4MudinRN (2015)" exact="Dengue" post="Incidence and the Prevention and Control Program in Malaysia."/>
   <result pre="10.1016/S0140-6736(11)60281-X22100854 6ThangamaniS, HuangJ, HartCE, GuzmanH, TeshRB (2016) Vertical Transmission of" exact="Zika" post="Virus in Aedes aegypti Mosquitoes. Am J Trop Med"/>
   <result pre="public health. Nat Rev Microbiol9: 532–541. 10.1038/nrmicro259521666708 9RudnickA, LimT (1986)" exact="Dengue" post="virus ecology in Malaysia. Inst Med Res Malays Bull23:"/>
   <result pre="Malays Bull23: 51–152. 10RudnickA (1965) Studies of the Ecology of" exact="Dengue" post="in Malaysia: A Preliminary Report. J Med Entomol2: 203–208."/>
   <result pre="523–540. 10.1016/j.meegid.2009.02.00319460319 14CardosaJ, OoiMH, TioPH, PereraD, HolmesEC, et al. (2009)" exact="Dengue" post="virus serotype 2 from a sylvatic lineage isolated from"/>
   <result pre="VázquezA, SavjiN, et al. (2011) First Report of Sylvatic DENV-2-Associated" exact="Dengue" post="Hemorrhagic Fever in West Africa. PLoS Negl Trop Dis5:"/>
   <result pre="keys for the identification of mosquitoes (Diptera: Culicidae) associated with" exact="Dengue" post="Virus Transmission. DTIC Document. 23collab: CDC (2016) Surveillance and"/>
   <result pre="Control and Prevention. 24JohariNA, TohSY, VoonK, LimPKC (2019) Detection of" exact="Zika" post="Virus RNA in Aedes aegypti and Aedes albopictus larvae"/>
   <result pre="14210.1186/s12879-015-0908-x25885572 32AquinoVH, AmarillaAA, AlfonsoHL, BatistaWC, FigueiredoLTM (2009) New Genotype of" exact="Dengue" post="Type 3 Virus Circulating in Brazil and Colombia Showed"/>
   <result pre="et al. (2017) Complete Genome Sequence of a Highly Divergent" exact="Dengue" post="Virus Type 2 Strain, Imported into Australia from Sabah,"/>
   <result pre="e00546–00517. 10.1128/genomeA.00546-1728729258 46LiuW, PickeringP, DuchêneS, HolmesEC, AaskovJG (2016) Highly Divergent" exact="Dengue" post="Virus Type 2 in Traveler Returning from Borneo to"/>
   <result pre="409–412. 10.1016/j.trstmh.2003.12.00315138077 49Aguilar-SetiénA, Romero-AlmarazML, Sánchez-HernándezC, FigueroaR, Juárez-PalmaLP, et al. (2008)" exact="Dengue" post="virus in Mexican bats. Epidemiol infect136: 1678–1683. 10.1017/S095026880800046018325131"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881073\results\search\tropicalVirus\results.xml">
   <result pre="[31], Japanese encephalitis virus [32], Murray Valley encephalitis virus [32]," exact="West Nile" post="virus [33], yellow fever virus [34] and tick-borne encephalitis"/>
   <result pre="viruses, including Sindbis virus [36], Venezuelan equine encephalitis virus [59]," exact="West Nile" post="virus [33], yellow fever virus [34] and Japanese encephalitis"/>
   <result pre="determinants for attenuation of glycosaminoglycan-binding variants of Japanese encephalitis and" exact="West Nile" post="viruses. J Virol. 2004;78(15):8271–80. Epub 2004/07/16. 10.1128/JVI.78.15.8271-8280.2004 .15254199 34LeeE,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6881638\results\search\tropicalVirus\results.xml">
   <result pre="virulence of JEV. However, recent reports suggest that prM of" exact="Zika" post="virus is involved in its pathogenicity in mice (Yuan"/>
   <result pre="miceJ. Virol.8920156328633725855730 KatoF.TajimaS.NakayamaE.KawaiY.TaniguchiS.ShibasakiK.TairaM.MaekiT.LimC.K.TakasakiT.SaijoM.Characterization of large and small-plaque variants in the" exact="Zika" post="virus clinical isolate ZIKV/Hu/S36/Chiba/2016Sci. Rep.720171616029170504 KimH.ChaG.W.JeongY.E.LeeW.G.ChangK.S.RohJ.Y.YangS.C.ParkM.Y.ParkC.ShinE.H.Detection of Japanese encephalitis"/>
   <result pre="brain membrane receptor preparation escape variantsVirology241199830369454714 NybakkenG.E.NelsonC.A.ChenB.R.DiamondM.S.FremontD.H.Crystal structure of the" exact="West Nile" post="virus envelope glycoproteinJ. Virol.802006114671147416987985 PiersonT.C.DiamondM.S.FlavivirusesKnipeD.M.H.P. M.Fields Virology6 ed.2013Lippincott Williams"/>
   <result pre="genotype of Japanese encephalitis virus throughout AsiaJ. Virol.8820144522453224501419 ShiratoK.MiyoshiH.KariwaH.TakashimaI.Detection of" exact="West Nile" post="virus and Japanese encephalitis virus using real-time PCR with"/>
   <result pre="their stabilitiesVaccine2820103635364120226891 YuanL.HuangX.Y.LiuZ.Y.ZhangF.ZhuX.L.YuJ.Y.JiX.XuY.P.LiG.LiC.WangH.J.DengY.Q.WuM.ChengM.L.YeQ.XieD.Y.LiX.F.WangX.ShiW.HuB.ShiP.Y.XuZ.QinC.F.A single mutation in the prM protein of" exact="Zika" post="virus contributes to fetal microcephalyScience358201793393628971967 ZhaoZ.DateT.LiY.KatoT.MiyamotoM.YasuiK.WakitaT.Characterization of the E-138"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6882728\results\search\tropicalVirus\results.xml">
   <result pre="of Bangladesh (BDvetNET)Bangladesh pmcid: 6882728 doi: 10.5455/javar.2019.f385 : Mini Review" exact="Zika" post="virus: A possible emerging threat for Bangladesh! HossainMd. Golzar12NazirK."/>
   <result pre="any medium, provided the original work is properly cited. Abstract" exact="Zika" post="virus, a member of Flaviviridae is the etiology of"/>
   <result pre="Zika virus, a member of Flaviviridae is the etiology of" exact="Zika" post="or Zika fever or Zika virus (ZIKV) disease characterized"/>
   <result pre="a member of Flaviviridae is the etiology of Zika or" exact="Zika" post="fever or Zika virus (ZIKV) disease characterized by mild"/>
   <result pre="Flaviviridae is the etiology of Zika or Zika fever or" exact="Zika" post="virus (ZIKV) disease characterized by mild symptoms similar to"/>
   <result pre="characterized by mild symptoms similar to very mild form of" exact="Dengue" post="or Chikungunya. The virus transmits through Aedes mosquitoes, particularly"/>
   <result pre="mosquitoes, particularly by Aedes aegypti. The most dangerous effect of" exact="ZIKV" post="infection is the ability of the virus to cause"/>
   <result pre="syndrome might be associated with adults and children due to" exact="ZIKV" post="infections. Zika has emerged as a serious global public"/>
   <result pre="be associated with adults and children due to ZIKV infections." exact="Zika" post="has emerged as a serious global public health problem"/>
   <result pre="treatment so far. Bangladesh is at a high risk of" exact="ZIKV" post="infection and we consider ZIKV as a possible emerging"/>
   <result pre="at a high risk of ZIKV infection and we consider" exact="ZIKV" post="as a possible emerging threat for Bangladesh. This short"/>
   <result pre="threat for Bangladesh. This short review summarizes the insights of" exact="ZIKV" post="infection, present status of the disease in Bangladesh and"/>
   <result pre="and strategies to be taken for effective controlling of the" exact="ZIKV" post="infection in Bangladesh before getting any havoc. Zika virus"/>
   <result pre="of the ZIKV infection in Bangladesh before getting any havoc." exact="Zika" post="virus Bangladesh Aedes mosquitoes Zika diagnosis Zika prevention Introduction"/>
   <result pre="Bangladesh before getting any havoc. Zika virus Bangladesh Aedes mosquitoes" exact="Zika" post="diagnosis Zika prevention Introduction Zika virus (ZIKV) infection is"/>
   <result pre="getting any havoc. Zika virus Bangladesh Aedes mosquitoes Zika diagnosis" exact="Zika" post="prevention Introduction Zika virus (ZIKV) infection is one of"/>
   <result pre="Zika virus Bangladesh Aedes mosquitoes Zika diagnosis Zika prevention Introduction" exact="Zika" post="virus (ZIKV) infection is one of the important infectious"/>
   <result pre="one of the important infectious diseases of human caused by" exact="ZIKV" post="belonging to the genus Flavivirus under the family Flaviviridae,"/>
   <result pre="including dengue and chikungunya viruses [1,2]. It is synonymous to" exact="Zika" post="fever or Zika or Zika virus disease. Most of"/>
   <result pre="chikungunya viruses [1,2]. It is synonymous to Zika fever or" exact="Zika" post="or Zika virus disease. Most of the ZIKV infections"/>
   <result pre="[1,2]. It is synonymous to Zika fever or Zika or" exact="Zika" post="virus disease. Most of the ZIKV infections are asymptomatic"/>
   <result pre="fever or Zika or Zika virus disease. Most of the" exact="ZIKV" post="infections are asymptomatic and, if symptoms appear, are similar"/>
   <result pre="infections are asymptomatic and, if symptoms appear, are similar to" exact="Dengue" post="and Chikungunya [3]. However, ZIKV might be fatal for"/>
   <result pre="asymptomatic and, if symptoms appear, are similar to Dengue and" exact="Chikungunya" post="[3]. However, ZIKV might be fatal for the fetus"/>
   <result pre="symptoms appear, are similar to Dengue and Chikungunya [3]. However," exact="ZIKV" post="might be fatal for the fetus and many neurological"/>
   <result pre="So far, there is no preventive vaccines and medicines against" exact="ZIKV" post="infection [7]. Like other flaviviruses, ZIKV is an enveloped"/>
   <result pre="vaccines and medicines against ZIKV infection [7]. Like other flaviviruses," exact="ZIKV" post="is an enveloped virus containing a single stranded 10-kb"/>
   <result pre="positive sense RNA genome with icosahedral capsid [8,9]. During biting," exact="ZIKV" post="present in the saliva of mosquitoes infects the epidermal"/>
   <result pre="a rhesus macaque monkey (Macaca mulatta) in 1947 from the" exact="Zika" post="forest of Uganda, it has been confirmed in 1952"/>
   <result pre="1952 by a serological survey in the same country that" exact="ZIKV" post="can infect human [11,12]. However, now a day, ZIKV"/>
   <result pre="that ZIKV can infect human [11,12]. However, now a day," exact="ZIKV" post="infections have been reported around the world including Asian"/>
   <result pre="data from different countries are limited, but new information regarding" exact="ZIKV" post="transmission patterns, incidence, and prevalence has been gathering time"/>
   <result pre="time by recent studies [19]. The first major outbreak of" exact="ZIKV" post="infection was reported at Micronesia in 2007 where about"/>
   <result pre="large outbreak in French during 2013–2014 [20]. Severe outbreak of" exact="ZIKV" post="infection occurred in Brazil in 2015 with increase cases"/>
   <result pre="Brazil in 2015 with increase cases of microcephaly [21]. The" exact="ZIKV" post="cases have been sporadically reported in many countries in"/>
   <result pre="reported that 87 countries of the world had evidence of" exact="ZIKV" post="infection until July 2019 [19]. Because of such increasing"/>
   <result pre="until July 2019 [19]. Because of such increasing incidence of" exact="ZIKV" post="infection throughout the world, severe pathological manifestations and lack"/>
   <result pre="world, severe pathological manifestations and lack of vaccine and treatment," exact="Zika" post="became a serious public health emergency of international concern"/>
   <result pre="serious public health emergency of international concern [23]. Presence of" exact="ZIKV" post="infection in Bangladesh has been reported in 2013 and"/>
   <result pre="However, there is no evidence of the current outbreak of" exact="ZIKV" post="in Bangladesh that might be due to very limited"/>
   <result pre="new cases. According to recent reports, Bangladesh is endemic for" exact="Dengue" post="which is also transmitted by Aedes mosquitoes as well"/>
   <result pre="which is also transmitted by Aedes mosquitoes as well [26,27]." exact="ZIKV" post="might follow the path of spreading Dengue and Chikungunya"/>
   <result pre="as well [26,27]. ZIKV might follow the path of spreading" exact="Dengue" post="and Chikungunya throughout the world [28,29]. Therefore, it is"/>
   <result pre="[26,27]. ZIKV might follow the path of spreading Dengue and" exact="Chikungunya" post="throughout the world [28,29]. Therefore, it is crucial to"/>
   <result pre="throughout the world [28,29]. Therefore, it is crucial to investigate" exact="Zika" post="throughout the country with proper diagnosis so that effective"/>
   <result pre="endemic occurs. In this short review, we have discussed the" exact="Zika" post="outbreaks in the context of Bangladesh and neighboring countries"/>
   <result pre="context of Bangladesh and neighboring countries and future perspective of" exact="ZIKV" post="surveillance, diagnosis, prevention measures, and research need to be"/>
   <result pre="to be taken in Bangladesh. Figure 1. Outbreak (Risk) of" exact="Zika" post="infection in different Asian countries (https://wwwnc.cdc.gov/travel/page/zika-travel-information). Red arrow indicates"/>
   <result pre="(https://wwwnc.cdc.gov/travel/page/zika-travel-information). Red arrow indicates the location of Bangladesh (23.6850°N, 90.3563°E)." exact="Zika" post="Virus Transmission and Pathogenesis ZIKV primarily transmits and spreads"/>
   <result pre="location of Bangladesh (23.6850°N, 90.3563°E). Zika Virus Transmission and Pathogenesis" exact="ZIKV" post="primarily transmits and spreads by the biting of infected"/>
   <result pre="infected pregnant women to her babies (Fig. 2) [5,31–35]. Though" exact="ZIKV" post="infections might be asymptomatic, the infected patients may have"/>
   <result pre="fatigue, and maculopapular rashes which are similar to that of" exact="Dengue" post="and Chikungunya, but may cure within a week [3]."/>
   <result pre="Guillain-Barre syndrome [36,37]. Miscarriage and stillbirth may found if the" exact="ZIKV" post="infection happens during pregnancy [5,38,39]. The most dangerous effects"/>
   <result pre="of the corpus callosum, calcifications, and cortical malformations [40,41]. However," exact="ZIKV" post="infected patient may also show local hyperemia and petechiae"/>
   <result pre="petechiae on the hard palate [42,43]. Figure 2. Transmission of" exact="Zika" post="virus. (1) Infected mosquito (particularly female A. aegypti) may"/>
   <result pre="(particularly female A. aegypti) may bite a healthy human. The" exact="Zika" post="infected human may act as a source of infection"/>
   <result pre="(2) Infected pregnant woman may act as a source for" exact="Zika" post="virus transmission to her fetus. (3) Human to human"/>
   <result pre="interaction between male and female. (4) Blood transfusion may cause" exact="Zika" post="virus transmission from one human to another. Zoonosis Monkey"/>
   <result pre="to another. Zoonosis Monkey and apes could be infected with" exact="ZIKV" post="with mild signs of illness. Few monkeys were diagnosed"/>
   <result pre="mild signs of illness. Few monkeys were diagnosed positive with" exact="ZIKV" post="in Brazil with high number of human cases [44,45]."/>
   <result pre="water buffaloes, goat, duck, and bat could be infected with" exact="ZIKV" post="without clinical symptoms and having no evidence of transmission"/>
   <result pre="human [46]. Though no microcephaly has been reported in the" exact="Zika" post="endemic areas, further research is needed for better learning"/>
   <result pre="endemic areas, further research is needed for better learning the" exact="ZIKV" post="and microcephaly in animal pregnancy as suggested by the"/>
   <result pre="Prevention (CDC) and others scientists [47]. Diagnosis Clinical symptoms of" exact="ZIKV" post="infections are very similar with Dengue and Chikungunya with"/>
   <result pre="Diagnosis Clinical symptoms of ZIKV infections are very similar with" exact="Dengue" post="and Chikungunya with few distinguished features [48]. In ZIKV,"/>
   <result pre="symptoms of ZIKV infections are very similar with Dengue and" exact="Chikungunya" post="with few distinguished features [48]. In ZIKV, there is"/>
   <result pre="there is low grade fever, while fever is high in" exact="Dengue" post="and Chikungunya infection. On the other hand, edema of"/>
   <result pre="low grade fever, while fever is high in Dengue and" exact="Chikungunya" post="infection. On the other hand, edema of limb is"/>
   <result pre="limb is very common in ZIKV, which is absent in" exact="Dengue" post="and Chikungunya. In addition, unlike Dengue and Chikungunya, arthralgia"/>
   <result pre="which is absent in Dengue and Chikungunya. In addition, unlike" exact="Dengue" post="and Chikungunya, arthralgia is very less common in ZIKV."/>
   <result pre="be tested according to CDC guideline [49]. Confirmatory diagnosis of" exact="ZIKV" post="is based on reverse transcription PCR (RT-PCR) and enzyme-linked"/>
   <result pre="immunosorbent assay (ELISA), and laboratory tests are useful to distinguish" exact="Zika" post="from other flaviviruses. ELISA and immunofluorescence assay of serum"/>
   <result pre="days onward of clinical symptoms appeared are useful to detect" exact="ZIKV" post="specific IgM. It is recommended to test the serum"/>
   <result pre="test (NAAT) can be used to detect the viral RNA." exact="ZIKV" post="RNA can be detected in serum up to day-10"/>
   <result pre="samples would be the alternative way for NAAT [34]. However," exact="ZIKV" post="diagnosis from the serum samples of a patient having"/>
   <result pre="the tests. WHO recommended an algorithm for differential diagnosis of" exact="ZIKV" post="with Dengue and Chikungunya (Fig. 3). Recently, several rapid"/>
   <result pre="WHO recommended an algorithm for differential diagnosis of ZIKV with" exact="Dengue" post="and Chikungunya (Fig. 3). Recently, several rapid diagnostic kits"/>
   <result pre="an algorithm for differential diagnosis of ZIKV with Dengue and" exact="Chikungunya" post="(Fig. 3). Recently, several rapid diagnostic kits such as"/>
   <result pre="Chikungunya (Fig. 3). Recently, several rapid diagnostic kits such as" exact="Zika" post="NS1 Rapid Test (Biopanda Reagents, The United Kingdom), Zika"/>
   <result pre="as Zika NS1 Rapid Test (Biopanda Reagents, The United Kingdom)," exact="Zika" post="Rapid Test (Maternova, USA), and Artron’s One Step Zika"/>
   <result pre="Kingdom), Zika Rapid Test (Maternova, USA), and Artron’s One Step" exact="Zika" post="Virus Test Kit (Bio-Connect Diagnostics, The Netherlands) specific for"/>
   <result pre="Zika Virus Test Kit (Bio-Connect Diagnostics, The Netherlands) specific for" exact="ZIKV" post="have been developed which can be used for primary"/>
   <result pre="in the field level [54]. Figure 3. Algorithm for detecting" exact="ZIKV" post="from the suspected case of infection due to arbovirus."/>
   <result pre="of infection due to arbovirus. The algorithm is re-prepared from" exact="ZIKV" post="Surveillance in the Americas: Laboratory detection and diagnosis by"/>
   <result pre="Health Organization; https://www.paho.org/hq/dmdocuments/2016/2015-cha-algorithm-detecting-zikv.pdf). Prevention Currently, there is no vaccine against" exact="ZIKV" post="in the market; however, some vaccines are under the"/>
   <result pre="developmental stage including a trial in animal model [55–57]. As" exact="ZIKV" post="is primarily transmitted through Aedes mosquitoes bite, mosquitoes control"/>
   <result pre="mosquitoes control can be the prime strategies to control the" exact="ZIKV" post="infection [58]. The standard Aedes mosquitoes’ control strategies have"/>
   <result pre="suggested to avoid unnecessary travel to the areas of ongoing" exact="ZIKV" post="transmission. The unprotected sexual contact with the person having"/>
   <result pre="unprotected sexual contact with the person having the risk of" exact="ZIKV" post="infection should be avoided. Zika Virus Infection in Neighbor"/>
   <result pre="person having the risk of ZIKV infection should be avoided." exact="Zika" post="Virus Infection in Neighbor Countries of Bangladesh Although the"/>
   <result pre="Infection in Neighbor Countries of Bangladesh Although the origin of" exact="ZIKV" post="is in Uganda, currently it has been reported from"/>
   <result pre="According to WHO, till December 2018, around 159 cases of" exact="ZIKV" post="infections have been identified in India, the neighboring country"/>
   <result pre="formed in India to monitor preparedness and response measure for" exact="ZIKV" post="infections [60]. A recent study conducted on 462 samples"/>
   <result pre="recent study conducted on 462 samples collected from patients showing" exact="Dengue" post="symptoms and asymptomatic patients during the year from 2004"/>
   <result pre="during the year from 2004 to 2017 in Myanmar; however," exact="ZIKV" post="infection has been confirmed in 4.9% of patients showing"/>
   <result pre="infection has been confirmed in 4.9% of patients showing the" exact="Dengue" post="symptoms and 8.6% in asymptomatic persons at Mandalay and"/>
   <result pre="The most recent assessment showed long term and wide spread" exact="ZIKV" post="infection is circulating since 2006 in Thailand [62]. A"/>
   <result pre="among 76 Thai provinces, and 368 cases were confirmed as" exact="ZIKV" post="infection at 29 provinces which were reported [62]. ZIKV"/>
   <result pre="as ZIKV infection at 29 provinces which were reported [62]." exact="ZIKV" post="clinical surveillance and Flavivirus laboratory performed a comprehensive and"/>
   <result pre="only 8 out of 4,043 suspected samples were positive for" exact="ZIKV" post="but two pregnant women confirmed with the infection [63]."/>
   <result pre="women confirmed with the infection [63]. There is evidence of" exact="ZIKV" post="infections in Nepal and co-infection with Dengue virus in"/>
   <result pre="is evidence of ZIKV infections in Nepal and co-infection with" exact="Dengue" post="virus in Singapore as well [64–66]. Most importantly, 10"/>
   <result pre="importantly, 10 Bangladeshi people living in Singapore were affected by" exact="ZIKV" post="as reported by Singapore Ministry of Health at August"/>
   <result pre="Ministry of Health at August 2016 [67]. Risk Analysis of" exact="Zika" post="in Bangladesh The ZIKV infections was first reported in"/>
   <result pre="August 2016 [67]. Risk Analysis of Zika in Bangladesh The" exact="ZIKV" post="infections was first reported in Bangladesh at 2013 by"/>
   <result pre="reported in Bangladesh at 2013 by a seroprevalence study and" exact="ZIKV" post="neutralizing antibodies were detected onward from 2013 [25]. In"/>
   <result pre="antibodies were detected onward from 2013 [25]. In 2014, another" exact="ZIKV" post="infection was reported in Chittagong district of Bangladesh, and"/>
   <result pre="within last 2 weeks of symptoms appeared. However, this Bangladeshi" exact="ZIKV" post="was closely related with Brazilian and South American strains"/>
   <result pre="we know, until that there is no other report of" exact="ZIKV" post="infectious in Bangladesh, Does it mean really there is"/>
   <result pre="infectious in Bangladesh, Does it mean really there is no" exact="ZIKV" post="infection in Bangladesh? ZIKV has been circulating among almost"/>
   <result pre="it mean really there is no ZIKV infection in Bangladesh?" exact="ZIKV" post="has been circulating among almost all the neighboring countries"/>
   <result pre="Bangladeshi people living in Singapore have been also affected by" exact="ZIKV" post="[67]. Peoples are also frequently visiting these neighboring countries,"/>
   <result pre="frequently visiting these neighboring countries, enabling easy entry of the" exact="ZIKV" post="to Bangladesh. Moreover, many Burmese (Rohingya) recently entered Bangladesh"/>
   <result pre="recently entered Bangladesh could also be the potential source for" exact="ZIKV" post="in Bangladesh as local transmission reported by the travelers"/>
   <result pre="rapid urbanization which might be also a risk factor for" exact="ZIKV" post="[69–71]. Very recently, the endemic Chikungunya virus infection occurred"/>
   <result pre="a risk factor for ZIKV [69–71]. Very recently, the endemic" exact="Chikungunya" post="virus infection occurred throughout the countries followed by massive"/>
   <result pre="Chikungunya virus infection occurred throughout the countries followed by massive" exact="Dengue" post="infection. Currently, there is no effective surveillance on ZIKV"/>
   <result pre="massive Dengue infection. Currently, there is no effective surveillance on" exact="ZIKV" post="infections in Bangladesh. Either Zika is circulating and remained"/>
   <result pre="is no effective surveillance on ZIKV infections in Bangladesh. Either" exact="Zika" post="is circulating and remained to be undiagnosed or it"/>
   <result pre="might be next endemic infection in Bangladesh next to the" exact="Chikungunya" post="and Dengue virus infections [24,67]. How can we Handle"/>
   <result pre="next endemic infection in Bangladesh next to the Chikungunya and" exact="Dengue" post="virus infections [24,67]. How can we Handle Zika Virus"/>
   <result pre="Chikungunya and Dengue virus infections [24,67]. How can we Handle" exact="Zika" post="Virus Infection in Bangladesh? Establishment of national ZIKV surveillance"/>
   <result pre="we Handle Zika Virus Infection in Bangladesh? Establishment of national" exact="ZIKV" post="surveillance system and laboratory facilities Government should take immediate"/>
   <result pre="border region. To keep the surveillance in action, a high-power" exact="ZIKV" post="surveillance and monitoring unit should be formed with relevant"/>
   <result pre="immigration area such as in airport, land, and seaport. The" exact="ZIKV" post="specific symptoms showed by overseas visitors and having history"/>
   <result pre="showed by overseas visitors and having history of travel in" exact="Zika" post="endemic region should be tested by rapid Zika diagnosis"/>
   <result pre="travel in Zika endemic region should be tested by rapid" exact="Zika" post="diagnosis kit followed by taking necessary action for further"/>
   <result pre="Disease Control and Research could play a vital role in" exact="Zika" post="surveillance. Engagement of international organizations such as Food and"/>
   <result pre="and other supports. Establishment of national Arbovirus reference laboratory for" exact="ZIKV" post="and other related virus also need to be established"/>
   <result pre="and One Health approach should be conducted to find whether" exact="Zika" post="infection is silently circulating in human or domestic animals"/>
   <result pre="or domestic animals or non-human primates. Intensive studies of the" exact="ZIKV" post="and the possible changes in their genomes/pathogenicity must be"/>
   <result pre="Figure 4. Possible actions need to be adopted to prevent/control" exact="Zika" post="from Bangladesh. Public awareness The word &quot;Zika�? and way"/>
   <result pre="their self-protection before, during, and after the travel to a" exact="Zika" post="risk area. The traveler especially pregnant women must also"/>
   <result pre="must also be careful during their overseas visit to the" exact="Zika" post="endemic regions. The CDC released toolkit for Zika awareness"/>
   <result pre="to the Zika endemic regions. The CDC released toolkit for" exact="Zika" post="awareness and prevention which includes, CDC-approved messaging, info cards,"/>
   <result pre="to campaign message and materials to the mass people regarding" exact="Zika" post="awareness and prevention information. Through these social platforms, we"/>
   <result pre="to prevent themselves from mosquito bite to protect infections like" exact="ZIKV" post="(Fig. 4). Mosquitoes control Zika virus is a mosquito-borne"/>
   <result pre="bite to protect infections like ZIKV (Fig. 4). Mosquitoes control" exact="Zika" post="virus is a mosquito-borne virus. Control of mosquitoes is"/>
   <result pre="important step to control the disease. Since Zika, Dengue, and" exact="Chikungunya" post="are transmitted by same vector, i.e., Aedes spp., the"/>
   <result pre="This is very alarming, as evident from recent outbreak of" exact="Dengue" post="in Bangladesh, where in many instances, insecticides used in"/>
   <result pre="other hand, around 25 mosquitoes species might be carrier of" exact="ZIKV" post="[75]. Therefore, it is necessary to reconfirm the vector"/>
   <result pre="is necessary to reconfirm the vector biology and transmission of" exact="ZIKV" post="considering the geographical perspective of Bangladesh. However, more funding"/>
   <result pre="insecticides for mosquitoes control (Fig. 4). Conclusions and Recommendations Though" exact="ZIKV" post="infection might be asymptomatic or shows mild clinical symptoms,"/>
   <result pre="neurological disorders due to ZILV infection. On the other hand," exact="ZIKV" post="infection has been reported in almost all the neighboring"/>
   <result pre="Bangladesh. Bangladesh is at high risk for emerging threat for" exact="ZIKV" post="infection and currently, there is no active surveillance system"/>
   <result pre="this short review for the prevention and control of the" exact="ZIKV" post="infection in Bangladesh, particularly by establishing national ZIKV surveillance,"/>
   <result pre="of the ZIKV infection in Bangladesh, particularly by establishing national" exact="ZIKV" post="surveillance, increase public awareness and mosquito control. Acknowledgments Nothing"/>
   <result pre="its possible molecular mechanismIntervirology20165931528https://doi.org/10.1159/00045295028081529 [6]do RosarioMSde JesusPAVasilakisNFariasDSNovaesMARodriguesSGet al.Guillain-Barre syndrome after" exact="Zika" post="virus infection in BrazilAm J Trop Med Hyg2016955115760https://doi.org/10.4269/ajtmh.16-030627645785 [7]ShehuNYShweDOnyedibeKIPamVCAbokIIsaSEet"/>
   <result pre="Maturation, and ReceptorsJ Infect Dis2017216suppl 10S93544https://doi.org/10.1093/infdis/jix51529267925 [9]ShiYGaoGFStructural biology of the" exact="Zika" post="virusTrends Biochem Sci201742644356https://doi.org/10.1016/j.tibs.2017.02.00928318966 [10]PiersonTCDiamondMSDegrees of maturity: the complex structure"/>
   <result pre="physical propertiesTrans R Soc Trop Med Hyg195246552134https://doi.org/10.1016/0035-9203(52)90043-612995441 [12]MlackerSShafaGAldahanASShahVVSamarkandySNouriKOrigin of the" exact="Zika" post="virus revealed: a historical journey across the worldInt J"/>
   <result pre="worldInt J Dermatol20165512136972https://doi.org/10.1111/ijd.1339927650823 [13]HeryLBoullisADelannayCVega-RúaATransmission potential of African, Asian and American" exact="Zika" post="virus strains by Aedes aegypti and Culex quinquefasciatus from"/>
   <result pre="from Guadeloupe (French West Indies)Emerg microbes infect201981699706https://doi.org/10.1080/22221751.2019.161584931109248 [14]LiuZ-YShiW-FQinC-FThe evolution of" exact="Zika" post="virus from Asia to the AmericasNat Rev Microbiol20191731319https://doi.org/10.1038/s41579-018-0134-930617340 [15]DuongVDussartPBuchyPZika"/>
   <result pre="trends in Southeast AsiaAsian Pac J Trop Med20171032119https://doi.org/10.1016/j.apjtm.2017.03.00228442104 [18]MussoDCao-LormeauVMIs the" exact="Zika" post="threat over?Clin Microbiol Infect20182465667https://doi.org/10.1016/j.cmi.2018.03.00729549059 [19]collab: WHOZika epidemiology update2019Available via"/>
   <result pre="emerging global health threatFront Cell Infect Microbiol20177486https://doi.org/10.3389/fcimb.2017.0048629276699 [21]BaudDGublerDJSchaubBLanteriMCMussoDAn update on" exact="Zika" post="virus infectionLancet2017390101072099109https://doi.org/10.1016/S0140-6736(17)31450-228647173 [22]PlourdeARBlochEMA literature review of Zika virusEmerg Infect"/>
   <result pre="[21]BaudDGublerDJSchaubBLanteriMCMussoDAn update on Zika virus infectionLancet2017390101072099109https://doi.org/10.1016/S0140-6736(17)31450-228647173 [22]PlourdeARBlochEMA literature review of" exact="Zika" post="virusEmerg Infect Dis2016227118592https://doi.org/10.3201/eid2207.15199027070380 [23]JiangDHaoMDingFFuJLiMMapping the transmission risk of Zika"/>
   <result pre="of Zika virusEmerg Infect Dis2016227118592https://doi.org/10.3201/eid2207.15199027070380 [23]JiangDHaoMDingFFuJLiMMapping the transmission risk of" exact="Zika" post="virus using machine learning modelsActa Trop20181853919https://doi.org/10.1016/j.actatropica.2018.06.02129932934 [24]MuraduzzamanAKMSultanaSShirinTKhatunSIslamMRahmanMIntroduction of Zika"/>
   <result pre="of Zika virus using machine learning modelsActa Trop20181853919https://doi.org/10.1016/j.actatropica.2018.06.02129932934 [24]MuraduzzamanAKMSultanaSShirinTKhatunSIslamMRahmanMIntroduction of" exact="Zika" post="virus in Bangladesh: an impending public health threatAsian Pac"/>
   <result pre="chikungunya?Lancet201538699902434https://doi.org/10.1016/S0140-6736(15)61273-926194519 [30]GuoXXLiCXDengYQXingDLiuQMWuQet al.Culex pipiens quinquefasciatus: a potential vector to transmit" exact="Zika" post="virusEmerg Microbes Infect201659e102https://doi.org/10.1038/emi.2016.10227599470 [31]BesnardMLastereSTeissierACao-LormeauVMussoDEvidence of perinatal transmission of Zika"/>
   <result pre="transmit Zika virusEmerg Microbes Infect201659e102https://doi.org/10.1038/emi.2016.10227599470 [31]BesnardMLastereSTeissierACao-LormeauVMussoDEvidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014Euro Surveill20141913https://doi.org/10.2807/1560-7917.ES2014.19.13.20751"/>
   <result pre="2014Euro Surveill20141913https://doi.org/10.2807/1560-7917.ES2014.19.13.20751 [32]FoyBDKobylinskiKCChilson FoyJLBlitvichBJTravassos da RosaAHaddowADet al.Probable non-vector-borne transmission of" exact="Zika" post="virus, Colorado, USAEmerg Infect Dis20111758802https://doi.org/10.3201/eid1705.10193921529401 [33]MussoDRocheCNhanTXRobinETeissierACao-LormeauVMDetection of Zika virus"/>
   <result pre="transmission of Zika virus, Colorado, USAEmerg Infect Dis20111758802https://doi.org/10.3201/eid1705.10193921529401 [33]MussoDRocheCNhanTXRobinETeissierACao-LormeauVMDetection of" exact="Zika" post="virus in salivaJ Clin Virol201568535https://doi.org/10.1016/j.jcv.2015.04.02126071336 [34]GourinatA-CO’ConnorOCalvezEGoarantCDupont-RouzeyrolMDetection of Zika virus"/>
   <result pre="[33]MussoDRocheCNhanTXRobinETeissierACao-LormeauVMDetection of Zika virus in salivaJ Clin Virol201568535https://doi.org/10.1016/j.jcv.2015.04.02126071336 [34]GourinatA-CO’ConnorOCalvezEGoarantCDupont-RouzeyrolMDetection of" exact="Zika" post="virus in urineEmerg Infect Dis2015211846https://doi.org/10.3201/eid2101.14089425530324 [35]PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN Engl J"/>
   <result pre="in urineEmerg Infect Dis2015211846https://doi.org/10.3201/eid2101.14089425530324 [35]PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN Engl J Med201637416155263https://doi.org/10.1056/NEJMra160211327028561 [36]SwaminathanSSchlabergRLewisJHansonKECouturierMRFatal" exact="Zika" post="virus infection with secondary nonsexual transmissionN Engl J Med20163751919079https://doi.org/10.1056/NEJMc161061327681699"/>
   <result pre="Med20163751919079https://doi.org/10.1056/NEJMc161061327681699 [37]KarimiOGoorhuisASchinkelJCodringtonJVredenSGSVermaatJSet al.Thrombocytopenia and subcutaneous bleedings in a patient with" exact="Zika" post="virus infectionLancet20163871002293940https://doi.org/10.1016/S0140-6736(16)00502-X26906627 [38]DudleyDMVan RompayKKCoffeyLLArdeshirAKeeslerRIBliss-MoreauEet al.Miscarriage and stillbirth following maternal"/>
   <result pre="Zika virus infectionLancet20163871002293940https://doi.org/10.1016/S0140-6736(16)00502-X26906627 [38]DudleyDMVan RompayKKCoffeyLLArdeshirAKeeslerRIBliss-MoreauEet al.Miscarriage and stillbirth following maternal" exact="Zika" post="virus infection in nonhuman primatesNat Med201824811047https://doi.org/10.1038/s41591-018-0088-529967348 [39]PeregrineJGurungSLindgrenMCHusainSZavyMTMyersDAet al.Zika virus"/>
   <result pre="al.Clinical features and neuroimaging (CT and MRI) findings in presumed" exact="Zika" post="virus related congenital infection and microcephaly: retrospective case series"/>
   <result pre="studyBMJ2016353i1901https://doi.org/10.1136/bmj.i190127075009 [41]HussainAAliFLatiweshOBHussainSA comprehensive review of the manifestations and pathogenesis of" exact="Zika" post="virus in neonates and adultsCureus2018109e3290https://doi.org/10.7759/cureus.329030443460 [42]SiqueiraWLZuanazziDKhurshidZKhanRSOliveriraTMJorgePKet al.Oral clinical manifestations"/>
   <result pre="and adultsCureus2018109e3290https://doi.org/10.7759/cureus.329030443460 [42]SiqueiraWLZuanazziDKhurshidZKhanRSOliveriraTMJorgePKet al.Oral clinical manifestations of patients infected with" exact="Zika" post="virusOral Health20161212 [43]BrasilPCalvetGAde SouzaRVSiqueiraAMExanthema associated with Zika virus infectionLancet"/>
   <result pre="patients infected with Zika virusOral Health20161212 [43]BrasilPCalvetGAde SouzaRVSiqueiraAMExanthema associated with" exact="Zika" post="virus infectionLancet Infect Dis2016167866https://doi.org/10.1016/S1473-3099(16)30117-727352763 [44]AidMAbbinkPLaroccaRABoydMNityanandamRNanayakkaraOet al.Zika virus persistence in"/>
   <result pre="nervous system and lymph nodes of rhesus monkeysCell2017169461020https://doi.org/10.1016/j.cell.2017.04.00828457610 [45]SlavovSNOtaguiriKKKashimaSCovasDTOverview of" exact="Zika" post="virus (ZIKV) infection in regards to the Brazilian epidemicBraz"/>
   <result pre="Wkly Rep2017662978193https://doi.org/10.15585/mmwr.mm6629e128749921 [50]SinghRKDhamaKKarthikKTiwariRKhandiaRMunjalAet al.Advances in diagnosis, surveillance, and monitoring of" exact="Zika" post="virus: an updateFront Microbiol201882677https://doi.org/10.3389/fmicb.2017.0267729403448 [51]KhurshidZZafarMKhanEMaliMLatifMHuman saliva can be a"/>
   <result pre="updateFront Microbiol201882677https://doi.org/10.3389/fmicb.2017.0267729403448 [51]KhurshidZZafarMKhanEMaliMLatifMHuman saliva can be a diagnostic tool for" exact="Zika" post="virus detectionJ Infect Public Health20191256014https://doi.org/10.1016/j.jiph.2019.05.00431129010 [52]ZuanazziDArtsEJJorgePKMulyarYGibsonRXiaoYet al.Postnatal identification of"/>
   <result pre="Zika virus detectionJ Infect Public Health20191256014https://doi.org/10.1016/j.jiph.2019.05.00431129010 [52]ZuanazziDArtsEJJorgePKMulyarYGibsonRXiaoYet al.Postnatal identification of" exact="Zika" post="virus peptides from salivaJ Dent Res20179610107884https://doi.org/10.1177/002203451772332528825520 [53]ShanCXieXBarrettADTGarcia-BlancoMATeshRBVasconcelosPFdCet al.Zika Virus:"/>
   <result pre="a rapid diagnostic test kit to detect IgG/IgM antibody against" exact="Zika" post="Virus using monoclonal antibodies to the envelope and non-structural"/>
   <result pre="virusKorean J Parasitol20185616170https://doi.org/10.3347/kjp.2018.56.1.6129529852 [55]AbbinkPStephensonKEBarouchDHZika virus vaccinesNat Rev Microbiol20181610594600https://doi.org/10.1038/s41579-018-0039-729921914 [56]KhusroAAartiCBarbabosa-PilegoASanchez-AparicioPOutbreak of" exact="Zika" post="virus pathogenesis and quest of its vaccine development: where"/>
   <result pre="Pathog201811628995https://doi.org/10.1016/j.micpath.2018.02.00129407238 [57]HraberPBradfuteSClarkeEYeCPitardBAmphiphilic block copolymer delivery of a DNA vaccine against" exact="Zika" post="virusVaccine2018364669117https://doi.org/10.1016/j.vaccine.2018.10.02230337177 [58]DiazJHPreparing the United States for Zika virus: pre-emptive"/>
   <result pre="DNA vaccine against Zika virusVaccine2018364669117https://doi.org/10.1016/j.vaccine.2018.10.02230337177 [58]DiazJHPreparing the United States for" exact="Zika" post="virus: pre-emptive vector control and personal protectionWilderness Environ Med20162744507https://doi.org/10.1016/j.wem.2016.07.00628340908"/>
   <result pre="virus: pre-emptive vector control and personal protectionWilderness Environ Med20162744507https://doi.org/10.1016/j.wem.2016.07.00628340908 [59]WattsAGHuberCBogochIIBradyOJKraemerMUGKhanKPotential" exact="Zika" post="virus spread within and beyond IndiaJ Travel Med2019261https://doi.org/10.1093/jtm/tay132 [60]YadavPDMalhotraBSapkalGNyayanitDADeshpandeGGuptaNet"/>
   <result pre="virus endemic to AsiaInfect Genet Evol201969199202https://doi.org/10.1016/j.meegid.2019.01.02630703541 [61]Ngwe TunMMKyawAKHmoneSWInoueSBueranoCCSoeAMet al.Detection of" exact="Zika" post="virus infection in MyanmarAm J Trop Med Hyg201898386871https://doi.org/10.4269/ajtmh.17-070829363460 [62]RuchusatsawatKWongjaroenPPosanacharoenARodriguez-BarraquerISangkitpornSCummingsDATet"/>
   <result pre="in MyanmarAm J Trop Med Hyg201898386871https://doi.org/10.4269/ajtmh.17-070829363460 [62]RuchusatsawatKWongjaroenPPosanacharoenARodriguez-BarraquerISangkitpornSCummingsDATet al.Long-term circulation of" exact="Zika" post="virus in Thailand: an observational studyLancet Infect Dis201919443946https://doi.org/10.1016/S1473-3099(18)30718-730826189 [63]WoonYLLimMFTg"/>
   <result pre="Nepal Health Res Counc2016https://doi.org/10.33314/jnhrc.v0i0.686 [65]ChiaPYYewHSHoHChowASadaranganiSPChanMet al.Clinical features of patients with" exact="Zika" post="and dengue virus co-infection in SingaporeJ Infect20177466115https://doi.org/10.1016/j.jinf.2017.03.00728344113 [66]HoZJMHapuarachchiHCBarkhamTChowANgLCLeeJMVet al.Outbreak"/>
   <result pre="and dengue virus co-infection in SingaporeJ Infect20177466115https://doi.org/10.1016/j.jinf.2017.03.00728344113 [66]HoZJMHapuarachchiHCBarkhamTChowANgLCLeeJMVet al.Outbreak of" exact="Zika" post="virus infection in Singapore: an epidemiological, entomological, virological, and"/>
   <result pre="pandemicsMethods Mol Biol20181604331https://doi.org/10.1007/978-1-4939-6981-4_128986822 [72]Alpuche-LazcanoSPMcCulloghCRDel CorpoORanceEScarboroughRJMoulandAJet al.Higher Cytopathic Effects of a" exact="Zika" post="Virus Brazilian Isolate from Bahia Compared to a Canadian-Imported"/>
   <result pre="Thai StrainViruses2018102https://doi.org/10.3390/v10020053 [73]PetterssonJHBohlinJDupont-RouzeyrolMBrynildsrudOBAlfsnesKCao-LormeauVMet al.Re-visiting the evolution, dispersal and epidemiology of" exact="Zika" post="virus in AsiaEmerg Microbes Infect20187179https://doi.org/10.1038/s41426-018-0082-529739925 [74]RossiSLEbelGDShanCShiP-YVasilakisNDid Zika virus mutate"/>
   <result pre="and epidemiology of Zika virus in AsiaEmerg Microbes Infect20187179https://doi.org/10.1038/s41426-018-0082-529739925 [74]RossiSLEbelGDShanCShiP-YVasilakisNDid" exact="Zika" post="virus mutate to cause severe outbreaks?Trends Microbiol2018261087785https://doi.org/10.1016/j.tim.2018.05.00729903417 [75]GregoryCJOduyeboTBraultACBrooksJTChungK-WHillsSet al.Modes"/>
   <result pre="to cause severe outbreaks?Trends Microbiol2018261087785https://doi.org/10.1016/j.tim.2018.05.00729903417 [75]GregoryCJOduyeboTBraultACBrooksJTChungK-WHillsSet al.Modes of transmission of" exact="Zika" post="virusJ Infect Dis2017216suppl 10S87583https://doi.org/10.1093/infdis/jix39629267909"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6882796\results\search\tropicalVirus\results.xml">
   <result pre="visit http://creativecommons.org/licenses/by/4.0/. Abstract Arboviral diseases such as chikungunya, dengue, and" exact="Zika" post="viruses have been threatening the European countries since the"/>
   <result pre="vector Aedes albopictus. In 2017, more than three hundred of" exact="CHIKV" post="autochthonous cases were reported in Italy, highlighting the urgent"/>
   <result pre="Southern European Ae. albopictus were susceptible to CHIKV, DENV-1 and" exact="ZIKV" post="with the highest vector competence for CHIKV. Based on"/>
   <result pre="competence data and vector distribution, a prediction risk map for" exact="CHIKV" post="was generated stressing the fear of CHIKV and to"/>
   <result pre="risk map for CHIKV was generated stressing the fear of" exact="CHIKV" post="and to a lesser extent, of other arboviruses for"/>
   <result pre="Europe, calling us for new public health strategies. Subject terms" exact="Dengue" post="virus Virus-host interactions Viral transmission Alphaviruses Viral vectors Funding"/>
   <result pre="several arboviral diseases such as chikungunya (CHIKV), dengue (DENV) and" exact="Zika" post="(ZIKV) have received global attention as major public health"/>
   <result pre="and dengue fever in Croatia8,9, France10–14, and Italy15. The 2017" exact="CHIKV" post="outbreak in Italy was attributed to few incident cases"/>
   <result pre="presence of Ae. albopictus in Italy favors the occurrence of" exact="CHIKV" post="epidemics16. Mosquitoes are able to transmit arboviruses by acquiring"/>
   <result pre="Montenegro, and Switzerland, and experimentally infected them with three arboviruses," exact="CHIKV" post="(Alphavirus, Togaviridae), and DENV and ZIKV (Flavivirus, Flaviviridae). Based"/>
   <result pre="experimentally infected them with three arboviruses, CHIKV (Alphavirus, Togaviridae), and" exact="DENV" post="and ZIKV (Flavivirus, Flaviviridae). Based on data obtained, we"/>
   <result pre="them with three arboviruses, CHIKV (Alphavirus, Togaviridae), and DENV and" exact="ZIKV" post="(Flavivirus, Flaviviridae). Based on data obtained, we elaborated a"/>
   <result pre="data obtained, we elaborated a vector competence data-driven prediction for" exact="CHIKV" post="transmission using computational modeling to assist in evaluating the"/>
   <result pre="to chikungunya and to a lesser extent, to dengue, and" exact="Zika" post="viruses To analyze the vector competence of European mosquito"/>
   <result pre="and saliva at 7 and 14 days post-infection (dpi) for" exact="CHIKV" post="and 7, 14, and 21 dpi for DENV-1 and"/>
   <result pre="CHIKV and 7, 14, and 21 dpi for DENV-1 and" exact="ZIKV" post="(Table 2). Table 1 Details on Aedes albopictus populations"/>
   <result pre="virus for each combination population, virus and day post-infection. Virus" exact="CHIKV" post="DENV ZIKV Population 7 dpi 14 dpi 7 dpi"/>
   <result pre="for each combination population, virus and day post-infection. Virus CHIKV" exact="DENV" post="ZIKV Population 7 dpi 14 dpi 7 dpi 14"/>
   <result pre="each combination population, virus and day post-infection. Virus CHIKV DENV" exact="ZIKV" post="Population 7 dpi 14 dpi 7 dpi 14 dpi"/>
   <result pre="24/1/0/0 24/1/0/0 24/0/0/0 dpi, days post-infection. Among the three viruses," exact="CHIKV" post="(Fig. 1a–c) provided the highest indexes of vector competence"/>
   <result pre="competence (infection, dissemination and transmission) than DENV-1 (Fig. 1d–f) and" exact="ZIKV" post="(Fig. 1g–i). For CHIKV, while populations could show different"/>
   <result pre="transmission efficiencies of each Southern European Ae. albopictus population for" exact="CHIKV" post="(a–c), DENV-1 (d–f), and ZIKV (g–i). Mosquitoes challenged an"/>
   <result pre="European Ae. albopictus population for CHIKV (a–c), DENV-1 (d–f), and" exact="ZIKV" post="(g–i). Mosquitoes challenged an infectious blood meal were analyzed"/>
   <result pre="For ZIKV, infection, dissemination and transmission were lower than for" exact="CHIKV" post="and DENV-1. IRs were (Fig. 1g): &amp;lt;16% at 7"/>
   <result pre="from Canton (Table 1) has a higher efficiency to transmit" exact="CHIKV" post="compared to DENV-1 and ZIKV like the European populations"/>
   <result pre="a higher efficiency to transmit CHIKV compared to DENV-1 and" exact="ZIKV" post="like the European populations tested (Fig. 1). Estimated CHIKV"/>
   <result pre="and ZIKV like the European populations tested (Fig. 1). Estimated" exact="CHIKV" post="dissemination threshold among Southern European Ae. albopictus populations Vector"/>
   <result pre="(Fig. S1). According to the dissemination model, the ability for" exact="CHIKV" post="dissemination differed among the Southern European Ae. albopictus tested,"/>
   <result pre="the Southern European Ae. albopictus tested, whereas the ability for" exact="CHIKV" post="transmission was relatively consistent across populations (Fig. 2). The"/>
   <result pre="in mosquitoes from Southern European populations (Table 4). Figure 2" exact="CHIKV" post="dissemination (a) and transmission (b) models according to viral"/>
   <result pre="The grey envelopes present 95% confidence intervals. Table 3 Estimated" exact="CHIKV" post="titers in bodies corresponding to a 50% and 75%"/>
   <result pre="2,332 1,212–4,168 31,188 19,587–46,880 CI, Confidence Interval. Table 4 Estimated" exact="CHIKV" post="titers in heads corresponding to a 50% and 75%"/>
   <result pre="Interval. Several Southern European countries are at high risk of" exact="CHIKV" post="transmission The interpolated risk of transmission from a mosquito"/>
   <result pre="Italy, notably higher than the median risk (12%). Regions where" exact="CHIKV" post="outbreaks have already been observed in the past are"/>
   <result pre="25% and Guardavalle: 18%). Figure 3 Probabilities of Ae. albopictus-mediated" exact="CHIKV" post="transmission in Southern Europe. The colors correspond to probabilities:"/>
   <result pre="sampling locations while red labeled dots highlight places where a" exact="CHIKV" post="outbreak has been reported in a recent past. This"/>
   <result pre="in European countries. Ae. albopictus populations were highly competent to" exact="CHIKV" post="and to a lesser extent, to DENV-1 and ZIKV."/>
   <result pre="with vector distribution, can provide an accurate risk map for" exact="CHIKV" post="transmission, which matched with the occurrence of human local"/>
   <result pre="2007, this mosquito has been responsible in Europe for local" exact="CHIKV" post="cases11,13,23,29–31 and DENV cases8,10 stressing that the species is"/>
   <result pre="has been responsible in Europe for local CHIKV cases11,13,23,29–31 and" exact="DENV" post="cases8,10 stressing that the species is a competent vector"/>
   <result pre="Ae. albopictus from Southeast France was highly efficient to transmit" exact="CHIKV" post="with virus detected in mosquito saliva from day 3"/>
   <result pre="3 post-infection35, as was also Ae. albopictus from Italy36. Interestingly," exact="CHIKV" post="strains belonged exclusively to the ECSA genotype11,13,23,29,31. Nine years"/>
   <result pre="to the ECSA genotype11,13,23,29,31. Nine years after the emergence of" exact="CHIKV" post="in the Indian Ocean region, CHIKV was detected in"/>
   <result pre="after the emergence of CHIKV in the Indian Ocean region," exact="CHIKV" post="was detected in October 2013 in Saint-Martin Island in"/>
   <result pre="expectations, belonged to the Asian genotype38. Despite several hundreds of" exact="CHIKV" post="cases imported to continental Europe from the Americas, no"/>
   <result pre="Europe from the Americas, no autochthonous transmission of the Asian" exact="CHIKV" post="was reported. A previous study showed that low temperatures"/>
   <result pre="x E) interactions40. To a lesser extent, local cases of" exact="DENV" post="were also reported in Europe; in 2010, autochthonous transmission"/>
   <result pre="dengue caused ~1 million cases in Athens, Greece, in 1927–192844." exact="Zika" post="has caused an outbreak impressive by its magnitude and"/>
   <result pre="this new health threat46. With the increasing number of imported" exact="ZIKV" post="cases reported in Europe, local transmission of ZIKV was"/>
   <result pre="of imported ZIKV cases reported in Europe, local transmission of" exact="ZIKV" post="was expected. The first European Zika autochthonous cases were"/>
   <result pre="Europe, local transmission of ZIKV was expected. The first European" exact="Zika" post="autochthonous cases were reported in Hyères, France47, although the"/>
   <result pre="albopictus, in Southern Europe has increased the risk of mosquito-mediated" exact="Zika" post="transmission. However, using experimental infections, it has been demonstrated"/>
   <result pre="demonstrated that Ae. albopictus in Europe were poorly susceptible to" exact="ZIKV" post="infection (Asian genotype) requiring at least 14 days to"/>
   <result pre="in mosquito saliva after an infectious blood meal48–51. Compared to" exact="CHIKV" post="and DENV-1 mentioned above, ZIKV is the less-transmitted virus"/>
   <result pre="infectious blood meal48–51. Compared to CHIKV and DENV-1 mentioned above," exact="ZIKV" post="is the less-transmitted virus by Ae. albopictus indicating that"/>
   <result pre="Ae. albopictus indicating that the risk of autochthonous transmission of" exact="ZIKV" post="in Europe is still minimal52. Based on the vector"/>
   <result pre="European Ae. albopictus showed the highest susceptibilities to CHIKV. Therefore" exact="CHIKV" post="dissemination and transmission of each population were analyzed by"/>
   <result pre="competence depending on pairings vector and pathogen genotypes33. In 2017," exact="CHIKV" post="autochthonous outbreaks have caused hundreds of infections in Italy16,"/>
   <result pre="risk prediction map. We elaborated an Ae. albopictus-driven prediction of" exact="CHIKV" post="transmission risk. Based on previously predicted probability of occurrence"/>
   <result pre="albopictus4, an European Ae. albopictus vector competence data-driven map of" exact="CHIKV" post="transmission risk was generated. Although the predicted Ae. albopictus"/>
   <result pre="high except in Faliro region (Greece), the predicted risk of" exact="CHIKV" post="transmission in European regions was significant: several regions share"/>
   <result pre="several regions share the same, and even higher risk of" exact="CHIKV" post="transmission than in Anzio, Guardavalle, and Rome regions, where"/>
   <result pre="transmission than in Anzio, Guardavalle, and Rome regions, where autochthonous" exact="CHIKV" post="cases were reported in 201716. Of note is that"/>
   <result pre="computed probabilities represent higher boundaries of the risk to transmit" exact="CHIKV" post="to the human population. The use of data from"/>
   <result pre="associated diseases. As a newly emerging arboviral disease in Europe," exact="CHIKV" post="has become a new threat to European public health."/>
   <result pre="vector competence of European Ae. albopictus for CHIKV, DENV, and" exact="ZIKV" post="were analyzed. This study provides complete information on viral"/>
   <result pre="differences in vector competence among populations highlighting the risk of" exact="CHIKV" post="outbreaks in Europe associated with Ae. albopictus. Adding data"/>
   <result pre="mosquito distribution holds particular promise for addressing epidemiological risks of" exact="CHIKV" post="transmission at local, national and European scales. Materials and"/>
   <result pre="at 28 °C until analysis. Viral strains and Infectious blood meal" exact="CHIKV" post="(CHIKV 06.21; accession number AM258992) isolated in 2005 from"/>
   <result pre="obtained in 2010 from an autochthonous case in Nice, France35." exact="ZIKV" post="(ZIKV PE243; accession number KX197192) isolated from a patient"/>
   <result pre="after several passages of the isolate onto C6/36 cells for" exact="CHIKV" post="and DENV, and Vero cells for ZIKV. Seven-day-old female"/>
   <result pre="Virus titers of blood meals were at 107 ffu/mL for" exact="CHIKV" post="and DENV, and 107 pfu/ml for ZIKV. Engorged mosquitoes"/>
   <result pre="tip to 45 µL of L-15 medium (Invitrogen, CA, USA) for" exact="CHIKV" post="and DENV samples, and Dulbecco’s Modified Eagle (DMEM) medium"/>
   <result pre="45 µL of L-15 medium (Invitrogen, CA, USA) for CHIKV and" exact="DENV" post="samples, and Dulbecco’s Modified Eagle (DMEM) medium (ThermoFisher, MA,"/>
   <result pre="and Dulbecco’s Modified Eagle (DMEM) medium (ThermoFisher, MA, USA) for" exact="ZIKV" post="samples. After salivation, mosquito head and body were collected"/>
   <result pre="= European communicable disease bulletin201116pii: 19805 9.Schmidt-Chanasit, J. et al." exact="Dengue" post="virus infection in a traveller returning from Croatia to"/>
   <result pre="transmissibles = European communicable disease bulletin2013182066110.2807/1560-7917.ES2013.18.50.2066124342514 13.Delisle, E. et al." exact="Chikungunya" post="outbreak in Montpellier, France, September to October 2014. Euro"/>
   <result pre="fever in the province of Ravenna, ItalyEuro Surveill200712E070906070901 16.Rezza, G." exact="Chikungunya" post="is back in Italy: 2007–2017. J Travel Med25, 10.1093/jtm/tay004"/>
   <result pre="2007–2017. J Travel Med25, 10.1093/jtm/tay004 (2018). 17.ChanMJohanssonMAThe incubation periods of" exact="Dengue" post="virusesPLoS One20127e5097210.1371/journal.pone.005097223226436 18.Vega-RuaAZouacheKGirodRFaillouxABLourenco-de-OliveiraRHigh level of vector competence of Aedes"/>
   <result pre="American countries as a crucial factor in the spread of" exact="Chikungunya" post="virusJ Virol2014886294630610.1128/JVI.00370-1424672026 19.MussoDGublerDJZika VirusClin Microbiol Rev20162948752410.1128/CMR.00072-1527029595 20.FranzAWKantorAMPassarelliALClemRJTissue Barriers to"/>
   <result pre="potentialProceedings of the Royal Society B: Biological Sciences201428117922014107810.1098/rspb.2014.1078 41.Rezza, G." exact="Dengue" post="and other Aedes-borne viruses: a threat to Europe? Euro"/>
   <result pre="(2016). 42.LiuZet al.Temperature Increase Enhances Aedes albopictus Competence to Transmit" exact="Dengue" post="VirusFront Microbiol20178233710.3389/fmicb.2017.0233729250045 43.AltoBWet al.Susceptibility of Florida Aedes aegypti and"/>
   <result pre="epidemics: A challenge for the global virology communityAntiviral Res2018156808410.1016/j.antiviral.2018.06.00929906475 47.ECDC." exact="Zika" post="virus disease in Var department, France – 16 October"/>
   <result pre="al. Experimental studies of susceptibility of Italian Aedes albopictus to" exact="Zika" post="virus. Euro Surveill21, 10.2807/1560-7917.ES.2016.21.18.30223 (2016). 50.GonzalezMAet al.Limited risk of"/>
   <result pre="Zika virus. Euro Surveill21, 10.2807/1560-7917.ES.2016.21.18.30223 (2016). 50.GonzalezMAet al.Limited risk of" exact="Zika" post="virus transmission by five Aedes albopictus populations from SpainParasit"/>
   <result pre="from SpainParasit Vectors20191215010.1186/s13071-019-3359-130922370 51.Heitmann, A. et al. Experimental transmission of" exact="Zika" post="virus by mosquitoes from central Europe. Euro Surveill22, 10.2807/1560-7917.ES.2017.22.2.30437"/>
   <result pre="(2017). 52.Guzzetta, G. et al. Assessing the potential risk of" exact="Zika" post="virus epidemics in temperate areas with established Aedes albopictus"/>
   <result pre="56.DonaldCLet al.Full Genome Sequence and sfRNA Interferon Antagonist Activity of" exact="Zika" post="Virus from Recife, BrazilPLoS Negl Trop Dis201610e000504810.1371/journal.pntd.000504827706161 57.CarratFValleronAJEpidemiologic mapping"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6883514\results\search\tropicalVirus\results.xml">
   <result pre="meningitis in adults was rather associated with herpes simplex and" exact="West Nile" post="virus, whereas children were more likely to be tested"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6884470\results\search\tropicalVirus\results.xml">
   <result pre="in Brazil, surpassed only by dengue. Now due the recent" exact="Chikungunya" post="and Zika viruses epidemics, OROV fever is considered the"/>
   <result pre="surpassed only by dengue. Now due the recent Chikungunya and" exact="Zika" post="viruses epidemics, OROV fever is considered the 4th most"/>
   <result pre="reside in an endemic area to several Flaviviruses such as" exact="Dengue" post="virus, Yellow fevervirus and Zika virus, and potentially also"/>
   <result pre="to several Flaviviruses such as Dengue virus, Yellow fevervirus and" exact="Zika" post="virus, and potentially also to different Orthobunyaviruses such as"/>
   <result pre="11.KleinRSet al.Neuronal CXCL10 directs CD8+ T-cell recruitment and control of" exact="West Nile" post="virus encephalitisJ Virol.20057911457116610.1128/JVI.79.17.11457-11466.200516103196 12.de-Oliveira-PintoLMet al.Profile of circulating levels of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6884810\results\search\tropicalVirus\results.xml">
   <result pre="and Vaccines2055-0936BioMed CentralLondon pmcid: 688481099 doi: 10.1186/s40794-019-0099-3 : Case Report" exact="Dengue" post="fever and chikungunya virus infections: identification in travelers in"/>
   <result pre="with arbovirus-compatible illness and include differential diagnoses when appropriate. Keywords" exact="Dengue" post="Chikungunya International traveler Introduction Febrile illnesses in travelers have"/>
   <result pre="arbovirus-compatible illness and include differential diagnoses when appropriate. Keywords Dengue" exact="Chikungunya" post="International traveler Introduction Febrile illnesses in travelers have been"/>
   <result pre="land-use, spread by viremic travelers and vector range expansion [3]." exact="Dengue" post="virus (DENV), genus flavivirus, family Flaviviridae, and chikungunya virus"/>
   <result pre="bite from the Aedes (Ae.) aegypti and Ae. albopictus mosquito." exact="Dengue" post="fever (DF) and chikungunya are typically characterized by fever,"/>
   <result pre="observed in areas which previously had circulation of a single" exact="DENV" post="serotype [5]. Cohort studies of travelers have found high"/>
   <result pre="and therefore not reported [6]. Because the incubation period of" exact="DENV" post="is 4 to 7 days (range 3 to 14) [7],"/>
   <result pre="than 14 days post-travel will unlikely be travel-associated dengue virus infection." exact="Chikungunya" post="is normally associated with acute diffuse polyarthralgia with recovery"/>
   <result pre="extent, Mayaro and Ross River viruses [8]. A number of" exact="CHIKV" post="outbreaks have been reported in Africa, the Middle East,"/>
   <result pre="in the United States, and more recently in Europe [9]." exact="CHIKV" post="outbreaks can involve large numbers of human cases and"/>
   <result pre="southern India, Ae. albopictus has been co-implicated [10]. In Africa," exact="CHIKV" post="is maintained in an enzootic cycle involving nonhuman primates,"/>
   <result pre="transmission [11]. Several studies in Uganda, have reported presence of" exact="DENV" post="and CHIKV competent transmission vectors [12–14]. Dengue and chikungunya"/>
   <result pre="Several studies in Uganda, have reported presence of DENV and" exact="CHIKV" post="competent transmission vectors [12–14]. Dengue and chikungunya while endemic"/>
   <result pre="reported presence of DENV and CHIKV competent transmission vectors [12–14]." exact="Dengue" post="and chikungunya while endemic in Uganda, are increasingly being"/>
   <result pre="typically 2–4 days. Herein, we report two serologically confirmed infections of" exact="DENV" post="in patients traveling from Ethiopia and, one CHIKV positive"/>
   <result pre="infections of DENV in patients traveling from Ethiopia and, one" exact="CHIKV" post="positive infection confirmed by virus culture and RT-PCR in"/>
   <result pre="3000 (Stratagene, La Jolla, CA). Total nucleic acid from the" exact="CHIKV" post="CPE positive cell culture sample was sequenced using the"/>
   <result pre="samples collected in 2017 were tested for yellow virus (YFV)," exact="West Nile" post="virus (WNV), DENV1–4, CHIKV and Zika virus (ZIKV) antibodies"/>
   <result pre="tested for yellow virus (YFV), West Nile virus (WNV), DENV1–4," exact="CHIKV" post="and Zika virus (ZIKV) antibodies by IgM capture ELISA"/>
   <result pre="yellow virus (YFV), West Nile virus (WNV), DENV1–4, CHIKV and" exact="Zika" post="virus (ZIKV) antibodies by IgM capture ELISA [16]. Only"/>
   <result pre="Positive Negative Negative RT-PCR  Group-specific Alphavirus positive Negative Negative  Virus-specific" exact="CHIKV" post="positive NDa NDa aND Not Done The boldface in"/>
   <result pre="cell culture supernatant of the CPE-positive culture sample identified a" exact="CHIKV" post="genome that genetically clustered within a CHIKV clade containing"/>
   <result pre="sample identified a CHIKV genome that genetically clustered within a" exact="CHIKV" post="clade containing predominantly Asian CHIKV strains (Fig. 1). The"/>
   <result pre="that genetically clustered within a CHIKV clade containing predominantly Asian" exact="CHIKV" post="strains (Fig. 1). The CHIKV strain most related to"/>
   <result pre="CHIKV clade containing predominantly Asian CHIKV strains (Fig. 1). The" exact="CHIKV" post="strain most related to the virus isolated from ARB01183/Uganda"/>
   <result pre="2017 (MF77773566, Fig. 1 insert). Fig. 1 Phylogenetic tree of" exact="CHIKV" post="culture isolate ARB01183/Uganda showing the African and Asian genotypes,"/>
   <result pre="extracted from the culture supernatant confirmed a diagnosis of acute" exact="CHIKV" post="infection. No convalescent sample was collected from the patient"/>
   <result pre="a positive PCR result is considered definitive of infection. Three" exact="CHIKV" post="genotypes are known; Asia, East/Central/South Africa (ECSA) and West"/>
   <result pre="ARB01227UVRI and ARB01228UVRI also had cross neutralizing antibody responses to" exact="ZIKV" post="and DENV-2 by PRNT. However, both exhibited DENV-2 neutralization"/>
   <result pre="[22]. This is illustrated by the recent global spread of" exact="CHIKV" post="and ZIKV to previously non-endemic countries [23]. Case report"/>
   <result pre="is illustrated by the recent global spread of CHIKV and" exact="ZIKV" post="to previously non-endemic countries [23]. Case report 1 had"/>
   <result pre="1 had the potential to introduce an Asian strain of" exact="CHIKV" post="to a region that recently reported the spread of"/>
   <result pre="and sustainable funding from both local and international partners. Abbreviations" exact="CHIKV" post="Chikungunya virus CPE Cytopathic effect DENV Dengue virus DF"/>
   <result pre="sustainable funding from both local and international partners. Abbreviations CHIKV" exact="Chikungunya" post="virus CPE Cytopathic effect DENV Dengue virus DF Dengue"/>
   <result pre="and international partners. Abbreviations CHIKV Chikungunya virus CPE Cytopathic effect" exact="DENV" post="Dengue virus DF Dengue fever ELISA Enzyme linked immunosorbent"/>
   <result pre="international partners. Abbreviations CHIKV Chikungunya virus CPE Cytopathic effect DENV" exact="Dengue" post="virus DF Dengue fever ELISA Enzyme linked immunosorbent assay"/>
   <result pre="CHIKV Chikungunya virus CPE Cytopathic effect DENV Dengue virus DF" exact="Dengue" post="fever ELISA Enzyme linked immunosorbent assay IgM Immunoglobulin M"/>
   <result pre="RT-PCR Reverse-transcriptase polymerase chain reaction UVRI Uganda Virus Research Institute" exact="WNV" post="West Nile virus YFV Yellow fever virus ZIKV Zika"/>
   <result pre="Reverse-transcriptase polymerase chain reaction UVRI Uganda Virus Research Institute WNV" exact="West Nile" post="virus YFV Yellow fever virus ZIKV Zika virus Publisher’s"/>
   <result pre="reaction UVRI Uganda Virus Research Institute WNV West Nile virus" exact="YFV" post="Yellow fever virus ZIKV Zika virus Publisher’s Note Springer"/>
   <result pre="UVRI Uganda Virus Research Institute WNV West Nile virus YFV" exact="Yellow fever" post="virus ZIKV Zika virus Publisher’s Note Springer Nature remains"/>
   <result pre="Research Institute WNV West Nile virus YFV Yellow fever virus" exact="ZIKV" post="Zika virus Publisher’s Note Springer Nature remains neutral with"/>
   <result pre="Institute WNV West Nile virus YFV Yellow fever virus ZIKV" exact="Zika" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
   <result pre="of chikungunya in metropolitan France: update to June 20062006 9.StaplesEBreimanRFAnnMPowers," exact="Chikungunya" post="Fever: An Epidemiological Review of a Re-Emerging Infectious Disease2009"/>
   <result pre="Lancet Infectious Diseases20066846346410.1016/S1473-3099(06)70531-X16870524 11.RaoTRPaulSDSinghKRExperimental studies on the mechanical transmission of" exact="Chikungunya" post="virus by Aedes aegyptiMosq News196828406408 12.Mayanja M, Mutebi JP,"/>
   <result pre="Ataliba I, Mossel EC, Crabtree MB, Lutwama JJ. Confirmation of" exact="Zika" post="virus infection through hospital-based sentinel surveillance of acute febrile"/>
   <result pre="J.VelezJason O.LambertAmy J.JohnsonAlison J.StanfieldStephanie M.DuffyMark R.Genetic and Serologic Properties of" exact="Zika" post="Virus Associated with an Epidemic, Yap State, Micronesia, 2007Emerging"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6886976\results\search\tropicalVirus\results.xml">
   <result pre="re-emergence of infectious diseases.1 Recent outbreaks of Ebola, SARS and" exact="Zika" post="have triggered international health emergencies, often exacerbated by the"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6890994\results\search\tropicalVirus\results.xml">
   <result pre="Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed" exact="Zika" post="Virus Clearance SIV Infection of Macaques Delays Zika Virus"/>
   <result pre="in Delayed Zika Virus Clearance SIV Infection of Macaques Delays" exact="Zika" post="Virus Clearance Vinton et al. VintonCarol L.aMagazinerSamuel J.bDowdKimberly A.cRobertsonShelly"/>
   <result pre="to coinfections in human immunodeficiency virus (HIV)-infected individuals are multifaceted." exact="ZIKV" post="and other flaviviruses are sensitive to neutralizing antibodies, whose"/>
   <result pre="adaptive immune responses which become perturbed in HIV-infected individuals influence" exact="ZIKV" post="infection. Abstract ABSTRACT Flaviviruses are controlled by adaptive immune"/>
   <result pre="flavivirus clearance and pathogenesis is unclear. Here, we studied how" exact="Zika" post="virus (ZIKV) infection is modulated in SIV-infected nonhuman primates."/>
   <result pre="(ZIKV) infection is modulated in SIV-infected nonhuman primates. We measured" exact="ZIKV" post="replication, cellular ZIKV RNA levels, and immune responses in"/>
   <result pre="modulated in SIV-infected nonhuman primates. We measured ZIKV replication, cellular" exact="ZIKV" post="RNA levels, and immune responses in non-SIV-infected and SIV-infected"/>
   <result pre="Coinfected animals had a 1- to 2-day delay in peak" exact="ZIKV" post="viremia, which was 30% of that in non-SIV-infected animals."/>
   <result pre="viremia, which was 30% of that in non-SIV-infected animals. However," exact="ZIKV" post="viremia was significantly prolonged in SIV-positive (SIV+) RMs. ISG"/>
   <result pre="in SIV-positive (SIV+) RMs. ISG levels at the time of" exact="ZIKV" post="infection were predictive for lower ZIKV viremia in the"/>
   <result pre="at the time of ZIKV infection were predictive for lower" exact="ZIKV" post="viremia in the SIV+ RMs, while prolonged ZIKV viremia"/>
   <result pre="for lower ZIKV viremia in the SIV+ RMs, while prolonged" exact="ZIKV" post="viremia was associated with muted and delayed adaptive responses"/>
   <result pre="muted and delayed adaptive responses in SIV+ RMs. KEYWORDS SIV" exact="ZIKV" post="innate immunity type I interferon Funding HHS | NIH"/>
   <result pre="table-count: equation-count: ref-count: page-count: word-count: INTRODUCTION The high prevalence of" exact="Zika" post="virus (ZIKV) in northeast Brazil and its spread in"/>
   <result pre="infection and microcephaly in fetuses of ZIKV-infected mothers (3–5). Since" exact="ZIKV" post="and other flaviviruses are transmitted by arthropods, flavivirus epidemics"/>
   <result pre="areas with a high incidence of HIV infection (6, 7)." exact="ZIKV" post="and other flaviviruses are sensitive to type I interferons"/>
   <result pre="other flaviviruses are sensitive to type I interferons (IFNs). Indeed," exact="ZIKV" post="replicates poorly in immunocompetent mice (8–10), in part due"/>
   <result pre="mice (8–10), in part due to an inability of the" exact="ZIKV" post="nonstructural 5 (NS5) protein to degrade mouse STAT2 (11–13)."/>
   <result pre="of over 300 IFN-stimulated genes (ISGs) (13). Mouse models of" exact="ZIKV" post="infection, therefore, generally require type I IFN signaling to"/>
   <result pre="immune responses are also clearly important for the clearance of" exact="ZIKV" post="and other flaviviruses (19–21). Human immunodeficiency virus (HIV) infection"/>
   <result pre="I IFN production which occurs in HIV infection might limit" exact="ZIKV" post="replication. Both ZIKV and SIV have individually been isolated"/>
   <result pre="which occurs in HIV infection might limit ZIKV replication. Both" exact="ZIKV" post="and SIV have individually been isolated from wild nonhuman"/>
   <result pre="disease progression (42–45). To explore how HIV infection might impact" exact="ZIKV" post="antiviral responses and disease progression, we followed ZIKV viremia,"/>
   <result pre="might impact ZIKV antiviral responses and disease progression, we followed" exact="ZIKV" post="viremia, ZIKV RNA levels within cells targeted by ZIKV"/>
   <result pre="ZIKV antiviral responses and disease progression, we followed ZIKV viremia," exact="ZIKV" post="RNA levels within cells targeted by ZIKV in vivo,"/>
   <result pre="followed ZIKV viremia, ZIKV RNA levels within cells targeted by" exact="ZIKV" post="in vivo, and innate and adaptive immune responses in"/>
   <result pre="SIV-infected RMs that were infected with ZIKV. We found that" exact="ZIKV" post="viremia peaked later and was prolonged in SIV-coinfected RMs."/>
   <result pre="These data provide insight into how preexisting lentiviral infection modulates" exact="ZIKV" post="viremia in a relevant NHP model for both infections."/>
   <result pre="SIV infection might influence viremia and the host response to" exact="ZIKV" post="infection, we infected 7 Asian RMs with 3,000 50%"/>
   <result pre="thereafter, we subcutaneously infected these animals with 104 PFU of" exact="ZIKV" post="isolate Nicaragua/2016 (SIV/ZIKV animals) (Table 1). For a control,"/>
   <result pre="a control, we also infected 12 rhesus macaques (RMs) with" exact="ZIKV" post="only (Table 1). The time point 3 weeks post-SIV"/>
   <result pre="nodes at numerous time points both pre- and post-SIV and/or" exact="ZIKV" post="infection (Fig. 1A) to study viremia and innate and"/>
   <result pre="a significant loss of memory CD4+ T cells prior to" exact="ZIKV" post="challenge (Fig. 1B) (P = 0.0156), consistent with these animals being"/>
   <result pre="(P = 0.0156), consistent with these animals being progressively SIV infected, but" exact="ZIKV" post="infection did not exacerbate the loss of CD4+ T"/>
   <result pre="12 SIV/ZIKV 2,300,000 A01+ B08– B17– RH37073 Female 10.2 12" exact="ZIKV" post="NA A01+ B08– B17+ RH788 Male 16.5 13 ZIKV"/>
   <result pre="12 ZIKV NA A01+ B08– B17+ RH788 Male 16.5 13" exact="ZIKV" post="NA A01– B08– B17– RHDF86 Male 13.2 6 ZIKV"/>
   <result pre="13 ZIKV NA A01– B08– B17– RHDF86 Male 13.2 6" exact="ZIKV" post="NA A01– B08– B17– RHDBC4 Male 14.9 13 ZIKV"/>
   <result pre="6 ZIKV NA A01– B08– B17– RHDBC4 Male 14.9 13" exact="ZIKV" post="NA A01– B08– B17– RHA0P003 Male 13.3 18 ZIKV"/>
   <result pre="13 ZIKV NA A01– B08– B17– RHA0P003 Male 13.3 18" exact="ZIKV" post="NA ND RH734 Male 12.0 16 ZIKV NA A01–"/>
   <result pre="Male 13.3 18 ZIKV NA ND RH734 Male 12.0 16" exact="ZIKV" post="NA A01– B08– B17– RHZJ31 Male 7.2 7 ZIKV"/>
   <result pre="16 ZIKV NA A01– B08– B17– RHZJ31 Male 7.2 7" exact="ZIKV" post="NA ND RHZG41 Female 5.6 10 ZIKV NA A01–"/>
   <result pre="Male 7.2 7 ZIKV NA ND RHZG41 Female 5.6 10" exact="ZIKV" post="NA A01– B08– B17– RHDF0B Male 8.6 4 ZIKV"/>
   <result pre="10 ZIKV NA A01– B08– B17– RHDF0B Male 8.6 4" exact="ZIKV" post="NA ND RHDF2H Male 4.7 4 ZIKV NA ND"/>
   <result pre="Male 8.6 4 ZIKV NA ND RHDF2H Male 4.7 4" exact="ZIKV" post="NA ND RHDFWF Male 4.9 4 ZIKV NA ND"/>
   <result pre="Male 4.7 4 ZIKV NA ND RHDFWF Male 4.9 4" exact="ZIKV" post="NA ND RHDFWL Male 4.7 5 ZIKV NA ND"/>
   <result pre="Male 4.9 4 ZIKV NA ND RHDFWL Male 4.7 5" exact="ZIKV" post="NA ND aNA, not applicable; ND, not determined. bThe"/>
   <result pre="SIV RNA per milliliter of plasma at day 0 of" exact="ZIKV" post="infection. FIG 1 Effect of SIV coinfection on ZIKV"/>
   <result pre="of ZIKV infection. FIG 1 Effect of SIV coinfection on" exact="ZIKV" post="viremia and cellular infection in peripheral lymph nodes. (A)"/>
   <result pre="(A) Study design depicting longitudinal time points for SIV infection," exact="ZIKV" post="infection, and PBMC and peripheral LN sampling. (B) Memory"/>
   <result pre="peripheral LN sampling. (B) Memory CD4+ T cell counts for" exact="ZIKV" post="(blue squares; n = 6) and SIV/ZIKV animals (red circles; n = 7)."/>
   <result pre="(red circles; n = 7). Each line represents an individual animal. (C)" exact="ZIKV" post="mean viral titer in plasma (ZIKV, n = 12; SIV/ZIKV, n = 7)."/>
   <result pre="from day 2 (d2) to day 7. (D and E)" exact="ZIKV" post="RNA per 1,000 sorted cells in peripheral LN T"/>
   <result pre="and 27 days post-ZIKV infection (E) in SIV/ZIKV-coinfected animals (red) and" exact="ZIKV" post="animals (blue). (F) Representative lymph node immunohistochemistry images at"/>
   <result pre="lymph node immunohistochemistry images at day 27 post-ZIKV infection of" exact="ZIKV" post="vRNA (RNAscope; red), CD20 (B cell follicle; green), CD68"/>
   <result pre="green), CD68 (white), and DAPI (blue). (G) Percentages of the" exact="ZIKV" post="probe signal that are found within the B cell"/>
   <result pre="post-ZIKV infection. (H) Quantification of the LN area positive for" exact="ZIKV" post="vRNA probe per total LN area quantified at day"/>
   <result pre="within the same group represent Wilcoxon matched-pair results. Peak plasma" exact="ZIKV" post="viremia is delayed in SIV-infected RMs. We next measured"/>
   <result pre="viremia is delayed in SIV-infected RMs. We next measured plasma" exact="ZIKV" post="viremia between animals that were and were not SIV"/>
   <result pre="Consistently with the results of previous reports, in non-SIV-infected RMs," exact="ZIKV" post="RNA was detectable in plasma by 2 days postinfection (dpi),"/>
   <result pre="undetectable levels by 7 dpi (47–53). In contrast, the dynamics of" exact="ZIKV" post="viremia were delayed in SIV-infected animals (Fig. 1C; see"/>
   <result pre="were delayed in SIV-infected animals (Fig. 1C; see also the" exact="ZIKV" post="viremia in individual animals discussed in Fig. S1 in"/>
   <result pre="animals discussed in Fig. S1 in the supplemental material). Peak" exact="ZIKV" post="RNA in SIV-infected animals occurred at approximately 4 days postinfection"/>
   <result pre="in non-SIV-infected animals. Furthermore, the SIV-infected RMs had significantly lower" exact="ZIKV" post="plasma RNA at both day 2 (Fig. 1C) ("/>
   <result pre="post-ZIKV infection. Likely as a consequence of this delayed peak," exact="ZIKV" post="RNA levels were higher in SIV+ animals than in"/>
   <result pre="SIV+ animals than in SIV-negative animals at day 7 after" exact="ZIKV" post="infection, a time when ZIKV had been cleared from"/>
   <result pre="animals at day 7 after ZIKV infection, a time when" exact="ZIKV" post="had been cleared from most non-SIV-infected RMs (Fig. 1C)"/>
   <result pre="while solid lines represent the mean viral titer for the" exact="ZIKV" post="cohort (blue; n = 12) and the SIV/ZIKV cohort (red; n = 7)."/>
   <result pre="may apply. Peripheral lymph node macrophages are a source of" exact="ZIKV" post="replication. To understand ZIKV tropism in our coinfection model,"/>
   <result pre="node macrophages are a source of ZIKV replication. To understand" exact="ZIKV" post="tropism in our coinfection model, we used flow cytometry"/>
   <result pre="cytometric sorting strategy is shown in Fig. S2) and measured" exact="ZIKV" post="RNA by quantitative reverse transcription-PCR (qRT-PCR). We found ZIKV"/>
   <result pre="measured ZIKV RNA by quantitative reverse transcription-PCR (qRT-PCR). We found" exact="ZIKV" post="RNA in lymph node-resident macrophages and, to a lesser"/>
   <result pre="a lesser extent, in B cells, with higher levels of" exact="ZIKV" post="RNA in macrophages isolated from non-SIV-infected animals at day"/>
   <result pre="than in SIV-infected animals ( P = 0.021). Interestingly, we also found" exact="ZIKV" post="RNA in macrophages isolated from LNs of animals at"/>
   <result pre="at day 27 post-ZIKV infection, a time point when plasma" exact="ZIKV" post="RNA was undetectable in plasma (Fig. 1E). This is"/>
   <result pre="This is consistent with previous reports of the persistence of" exact="ZIKV" post="in the lymph nodes of RMs, with virus being"/>
   <result pre="infection status by RT-PCR. A representative staining profile from the" exact="ZIKV" post="cohort is shown. Live, singlet leukocytes were sorted into"/>
   <result pre="States. Foreign copyrights may apply. Fluorescence in situ hybridization for" exact="ZIKV" post="RNA in lymph node sections verified that ZIKV RNA"/>
   <result pre="hybridization for ZIKV RNA in lymph node sections verified that" exact="ZIKV" post="RNA could be detected both within B cell follicles"/>
   <result pre="B cell follicles and in the paracortex (Fig. 1F, where" exact="ZIKV" post="RNA is indicated with red arrows), with the majority"/>
   <result pre="is indicated with red arrows), with the majority of the" exact="ZIKV" post="RNA at days 5 and day 27 post-ZIKV infection"/>
   <result pre="follicle (Fig. 1G). To understand how lymph node levels of" exact="ZIKV" post="RNA compared between SIV+ and non-SIV-infected animals, we performed"/>
   <result pre="image analysis (Fig. 1G and H). Consistently with our plasma" exact="ZIKV" post="RNA analysis, we observed modestly higher levels of ZIKV"/>
   <result pre="plasma ZIKV RNA analysis, we observed modestly higher levels of" exact="ZIKV" post="RNA within lymph nodes of non-SIV-infected animals at day"/>
   <result pre="SIV+ animals (P = 0.056) (Fig. 1H) but significantly higher levels of" exact="ZIKV" post="RNA in lymph nodes of SIV+ animals at day"/>
   <result pre="(Fig. 1H). These data are consistent with delayed clearance of" exact="ZIKV" post="in SIV+ animals and further demonstrate that the LN"/>
   <result pre="and further demonstrate that the LN serves as a prolonged" exact="ZIKV" post="reservoir in RMs. SIV coinfection reduces immune responses to"/>
   <result pre="analysis, we next measured innate and adaptive immunological responses during" exact="ZIKV" post="infection of the animals in our cohort (the flow"/>
   <result pre="found that RMs mounted robust proliferative responses to SIV and" exact="ZIKV" post="infections in several cellular populations as measured by Ki67"/>
   <result pre="mounted NK cell proliferative responses to both SIV infection and" exact="ZIKV" post="infection (Fig. 2A). However, the NK cell proliferative response"/>
   <result pre="infection (Fig. 2A). However, the NK cell proliferative response during" exact="ZIKV" post="replication among the SIV+ animals was restricted compared to"/>
   <result pre="the Ki67+ memory CD8+ T cell population (P = 0.0368 in the" exact="ZIKV" post="cohort and P = 0.0009 in the SIV/ZIKV cohort). We did"/>
   <result pre="SIV/ZIKV cohort). We did not observe any proliferative response to" exact="ZIKV" post="among B cells (Fig. 2D). SIV infection was also"/>
   <result pre="(Fig. 2). Proliferative responses of T and B cells to" exact="ZIKV" post="infection among SIV+ animals were, thus, less clear given"/>
   <result pre="memory (mem) B cells (D) longitudinally pre- and post-ZIKV infection." exact="ZIKV" post="cohort mean percentages are illustrated by blue squares (n = 6),"/>
   <result pre="Error bars represent standard deviations for each time point. (E)" exact="Zika" post="virus-neutralizing antibody titers (EC50 values) post-ZIKV infection in ZIKV"/>
   <result pre="(E) Zika virus-neutralizing antibody titers (EC50 values) post-ZIKV infection in" exact="ZIKV" post="RMs (blue squares; n = 5) and SIV/ZIKV RMs (red circles;"/>
   <result pre="the analysis of PBMCs. A representative staining profile from the" exact="ZIKV" post="cohort is shown. Live, singlet lymphocytes were phenotypically characterized"/>
   <result pre="longitudinal plasma samples (Fig. 2E). In non-SIV-infected animals, NAbs to" exact="ZIKV" post="became detectable by day 7 post-ZIKV infection and then"/>
   <result pre="56 (Fig. 2E). In SIV/ZIKV-coinfected RMs, the NAb response to" exact="ZIKV" post="was slightly delayed and peaked at a lower titer"/>
   <result pre="SIV-infected RMs have reduced innate and adaptive immune responses to" exact="ZIKV" post="infection. ZIKV has no significant effect on CD4 T"/>
   <result pre="have reduced innate and adaptive immune responses to ZIKV infection." exact="ZIKV" post="has no significant effect on CD4 T cell functionality"/>
   <result pre="the maintenance and development of Th1 cells (57). Given that" exact="ZIKV" post="is also an RNA virus which induces Th1 cells"/>
   <result pre="which induces Th1 cells (58), we sought to explore whether" exact="ZIKV" post="coinfection further exacerbates immune dysfunction. Thus, we assessed whether"/>
   <result pre="CD40L, IL-22, IL-2, and TNF-α) of Th17 cells (Fig. 3B)." exact="ZIKV" post="infection did not influence the functional capacity of memory"/>
   <result pre="IL-2, and TNF-α (B) in SIV/ZIKV (top pie charts)- and" exact="ZIKV" post="(bottom pie charts)-infected RMs prior to and after infection"/>
   <result pre="are listed as not significant (NS). Interferon signaling predicts peak" exact="ZIKV" post="plasma viremia. The observed delays in both ZIKV viremia"/>
   <result pre="predicts peak ZIKV plasma viremia. The observed delays in both" exact="ZIKV" post="viremia and immunological responses in coinfected RMs suggested that"/>
   <result pre="that SIV viremia might, itself, either directly or indirectly limit" exact="ZIKV" post="replication. However, when we compared SIV plasma viral loads"/>
   <result pre="we compared SIV plasma viral loads at day 0 of" exact="ZIKV" post="infection with ZIKV plasma viral loads at day 3"/>
   <result pre="plasma viral loads at day 0 of ZIKV infection with" exact="ZIKV" post="plasma viral loads at day 3 post-ZIKV infection (peak"/>
   <result pre="ZIKV plasma viral loads at day 3 post-ZIKV infection (peak" exact="ZIKV" post="viremia in non-SIV-infected animals) we found no clear evidence"/>
   <result pre="evidence that SIV viremia correlates with the extent of subsequent" exact="ZIKV" post="replication (Fig. 4A) (r = –0.1081, P = 0.8190). Considering that"/>
   <result pre="whether there was an association of ISGs with levels of" exact="ZIKV" post="viremia in our SIV/ZIKV animals. To measure systemic levels"/>
   <result pre="levels of IP-10/CXCL10 in our animals longitudinally after SIV and" exact="ZIKV" post="infections (Fig. 4B). This IFN-induced protein has been shown"/>
   <result pre="individuals and strongly associated with exanthema (63). In non-SIV-infected animals," exact="ZIKV" post="infection led to increased plasma levels of IP-10 that"/>
   <result pre="elicited by SIV infection might predict lower levels of peak" exact="ZIKV" post="viremia and compared the plasma levels of IP-10 prior"/>
   <result pre="viremia and compared the plasma levels of IP-10 prior to" exact="ZIKV" post="infection with the levels of ZIKV viremia at day"/>
   <result pre="of IP-10 prior to ZIKV infection with the levels of" exact="ZIKV" post="viremia at day 3 (Fig. 4C). Higher levels of"/>
   <result pre="day 3 (Fig. 4C). Higher levels of IP-10 prior to" exact="ZIKV" post="infection, produced in response to SIV infection, were predictive"/>
   <result pre="response to SIV infection, were predictive of lower levels of" exact="ZIKV" post="viremia. Moreover, the prolonged ZIKV viremia observed in SIV/ZIKV-coinfected"/>
   <result pre="predictive of lower levels of ZIKV viremia. Moreover, the prolonged" exact="ZIKV" post="viremia observed in SIV/ZIKV-coinfected RMs at day 7 post-ZIKV"/>
   <result pre="infection was associated with plasma levels of IP-10 prior to" exact="ZIKV" post="infection (Fig. 4D). Thus, the IFN-stimulated response mounted against"/>
   <result pre="SIV correlated with a delayed peak and prolonged clearance of" exact="ZIKV" post="viremia. FIG 4 IFN-stimulated IP-10 gene levels are predictive"/>
   <result pre="FIG 4 IFN-stimulated IP-10 gene levels are predictive of peak" exact="ZIKV" post="plasma viremia. (A) Association between ZIKV plasma viremia (log10"/>
   <result pre="are predictive of peak ZIKV plasma viremia. (A) Association between" exact="ZIKV" post="plasma viremia (log10 GE/ml) at day 3 and SIV"/>
   <result pre="day 3 and SIV plasma viremia at day 0 of" exact="ZIKV" post="infection (7 RMs in the SIV/ZIKV cohort). VL, viral"/>
   <result pre="levels with standard deviation error bars are represented for the" exact="ZIKV" post="cohort (n = 6) in blue squares and for the SIV/ZIKV"/>
   <result pre="IP-10 plasma levels (picograms per milliliter) at day 0 of" exact="ZIKV" post="infection and ZIKV plasma viremia (log10 GE/ml) at day"/>
   <result pre="(picograms per milliliter) at day 0 of ZIKV infection and" exact="ZIKV" post="plasma viremia (log10 GE/ml) at day 3 (C) and"/>
   <result pre="SIV/ZIKV RM data points are shown as red circles, and" exact="ZIKV" post="RM data points are shown as blue squares. Spearman"/>
   <result pre="associations in panels A, C, and D. Transcriptional analysis of" exact="ZIKV" post="and SIV immune responses. Since we observed associations between"/>
   <result pre="we observed associations between increased IP-10 levels and lower peak" exact="ZIKV" post="viremia at day 3 post-Zika infection in our coinfected"/>
   <result pre="to explore global transcriptional responses that coincide with SIV and" exact="ZIKV" post="infection. Gene expression was measured from mRNAs extracted from"/>
   <result pre="Principal-component analysis revealed that transcript profiles of PBMCs from the" exact="ZIKV" post="RMs were distinct from those of the SIV/ZIKV RMs"/>
   <result pre="within the gene expression data was related to SIV or" exact="ZIKV" post="infection, most of which was attributable to SIV infection."/>
   <result pre="infection, most of which was attributable to SIV infection. While" exact="ZIKV" post="coinfection did not dramatically alter the transcriptional profile of"/>
   <result pre="dramatically alter the transcriptional profile of PBMCs from SIV-infected animals," exact="ZIKV" post="did alter the transcriptional profile of circulating leukocytes (Fig."/>
   <result pre="which were induced by SIV infection were also induced by" exact="ZIKV" post="infection, albeit to lower levels. Indeed, when we compared"/>
   <result pre="Indeed, when we compared non-SIV-infected and SIV-infected RMs prior to" exact="ZIKV" post="infection (ZIKV day 0), 163 genes were significantly differentially"/>
   <result pre="FIG 5 Transcriptional gene profiling of expression changes in acute" exact="ZIKV" post="infection. Immunology panel gene expression profiling in the ZIKV"/>
   <result pre="acute ZIKV infection. Immunology panel gene expression profiling in the" exact="ZIKV" post="RM cohort (n = 4) at day 0 (filled blue circles)"/>
   <result pre="RM. (B) Heatmap of 163 differentially expressed genes (P &amp;gt; 0.05) in" exact="ZIKV" post="and SIV/ZIKV RM cohorts (n = 4 and n = 5, respectively) at"/>
   <result pre="in plasma at day 0. (E to G) Associations between" exact="ZIKV" post="plasma viremia (log10 number of GE per milliliter) at"/>
   <result pre="(I). (D to I) Blue squares represent data from the" exact="ZIKV" post="cohort, and red circles represent data from the SIV/ZIKV"/>
   <result pre="analysis. 10.1128/mBio.02790-19.4FIG S4Transcriptional gene profiling of expression changes in acute" exact="ZIKV" post="infection. Immunology panel gene expression profiling in the ZIKV"/>
   <result pre="acute ZIKV infection. Immunology panel gene expression profiling in the" exact="ZIKV" post="RM cohort (n = 4) at day 0 (filled blue circles)"/>
   <result pre="may apply. 10.1128/mBio.02790-19.5TABLE S1Transcriptional gene expression differences between SIV/ZIKV and" exact="ZIKV" post="cohorts at day 0. Download Table S1, PDF file,"/>
   <result pre="I IFN response to SIV (Fig. 5C and Fig. S4B," exact="ZIKV" post="monoinfection). We compared levels of mRNA for IP-10/CXCL10 in"/>
   <result pre="association between levels of IP-10 mRNA at day 0 and" exact="ZIKV" post="viremia at day 3 (Fig. 5E), as we did"/>
   <result pre="message levels of interferon-stimulated IFIT3 as a predictor of subsequent" exact="ZIKV" post="peak viremia (Fig. 5F). To further understand the robustness"/>
   <result pre="these findings, we also examined and found a relationship between" exact="ZIKV" post="viremia and levels of IRF7, a central ISG (Fig."/>
   <result pre="the SIV-induced type I IFN response may lead to diminished" exact="ZIKV" post="viremia during coinfection. DISCUSSION NHPs are often used as"/>
   <result pre="limited. Here, we studied how preexisting SIV infection influences subsequent" exact="ZIKV" post="infection. We find that the type I IFN responses"/>
   <result pre="I IFN responses elicited in SIV-infected RMs correlates with reduced" exact="ZIKV" post="replication, that these coinfected animals mount inferior humoral responses"/>
   <result pre="humoral responses to ZIKV, and that these animals have delayed" exact="ZIKV" post="clearance. A recent study, using a small cohort of"/>
   <result pre="simian-human immunodeficiency virus (SHIV)- and SIV-infected RMs also found that" exact="ZIKV" post="viremia was uncharacteristically low during coinfection; however, the authors"/>
   <result pre="that SHIV/SIV infections did not dramatically influence the course of" exact="ZIKV" post="infection (64). This small study of only 4 Asian"/>
   <result pre="antiretroviral therapy (71). That we also find higher levels of" exact="ZIKV" post="RNA in the lymph node follicles than in the"/>
   <result pre="the paracortex (irrespective of coinfection) (Fig. 1G) coupled with delayed" exact="ZIKV" post="clearance (Fig. 1C) in SIV-coinfected animals suggests that replication-competent"/>
   <result pre="ZIKV clearance (Fig. 1C) in SIV-coinfected animals suggests that replication-competent" exact="ZIKV" post="may persist in lymphoid follicles and suggests that similar"/>
   <result pre="However, it is unclear which particular types of cells become" exact="ZIKV" post="RNA+ in lymphoid follicles or whether FDCs can become"/>
   <result pre="to a robust production of ISGs (37–41). While infection with" exact="ZIKV" post="was sufficient to induce expression of ISGs, the response"/>
   <result pre="generated in acute SIV infection far exceeded that induced by" exact="ZIKV" post="(Fig. 4B). The differences in ISG induction may be"/>
   <result pre="distinct differences between the duration of viremia and magnitude of" exact="ZIKV" post="infection, which is typically cleared from plasma within 7 days,"/>
   <result pre="demonstrate that the level of IP-10/CXCL10 at the time of" exact="ZIKV" post="infection predicts subsequent ZIKV replication (Fig. 4C and D),"/>
   <result pre="of IP-10/CXCL10 at the time of ZIKV infection predicts subsequent" exact="ZIKV" post="replication (Fig. 4C and D), the SIV-generated IFN response"/>
   <result pre="D), the SIV-generated IFN response was insufficient to completely prevent" exact="ZIKV" post="replication. Moreover, recent work suggests that particular ISGs may"/>
   <result pre="bind to flavivirus receptors (72–74), which may explain the delayed" exact="ZIKV" post="viremia that we observed in SIV+ animals. Paradoxically, this"/>
   <result pre="delayed antibody responses, in turn, may lead to moderately prolonged" exact="ZIKV" post="viremia in SIV+ animals. Interestingly, levels of IP-10 have"/>
   <result pre="to differentiate between patients with and without neurological complications after" exact="ZIKV" post="infection in Brazil and between infants with and without"/>
   <result pre="consistent with the idea that IFN signaling is associated with" exact="ZIKV" post="pathogenesis (78). Tfh cells are an important reservoir for"/>
   <result pre="SIV in our coinfection model may compromise the generation of" exact="ZIKV" post="antibodies. A combination of Tfh loss and ISG-mediated hypoantigenemia"/>
   <result pre="flaviviral coinfection is unclear, these data coupled with the prolonged" exact="ZIKV" post="viremia demonstrate that SIV infection shapes the resultant anti-ZIKV"/>
   <result pre="similarly compromised or biased during hyperacute infection. Delayed clearance of" exact="ZIKV" post="in SIV-infected RMs coupled with the higher levels of"/>
   <result pre="of virus within the lymphoid follicle might result in prolonged" exact="ZIKV" post="transmission risks. This may be related to antibody complex"/>
   <result pre="nucleotides1338 to 1317 of the SIVmac239gag gene (80). To assess" exact="ZIKV" post="RNA levels in the plasma of our study RMs,"/>
   <result pre="PCR using a TaqMan probe (Integrated DNA Technologies) targeting the" exact="ZIKV" post="E protein. ZIKV RNA levels were measured in all"/>
   <result pre="TaqMan probe (Integrated DNA Technologies) targeting the ZIKV E protein." exact="ZIKV" post="RNA levels were measured in all animals to at"/>
   <result pre="assays). Reporter virus particles (RVPs) incorporating the structural proteins of" exact="ZIKV" post="(strain H/PF/2013) (81), dengue virus 2 (DENV2; strain 16681)"/>
   <result pre="H/PF/2013) (81), dengue virus 2 (DENV2; strain 16681) (82), or" exact="West Nile" post="virus (WNV) lineage I (strain NY99) (83) were produced"/>
   <result pre="protein (GFP)-expressing replicon derived from a lineage II strain of" exact="WNV" post="as previously described (81–84). To determine virus titer, 2-fold"/>
   <result pre="antibody excess at informative points. Neutralization assays. For neutralization studies," exact="ZIKV" post="RVPs were mixed with serial dilutions of heat-inactivated macaque"/>
   <result pre="plasma per well), which was designated the limit of detection." exact="ZIKV" post="infection assessment in LN cells. Lymph node cells from"/>
   <result pre="B cell, and macrophage populations (Fig. S2) for assessment of" exact="ZIKV" post="viral RNA via qRT-PCR. RNA was extracted from sorted"/>
   <result pre="(Qiagen) with on-column DNase I treatment per the manufacturer’s instructions." exact="ZIKV" post="positive-strand RNA was measured by qRT-PCR using the primers"/>
   <result pre="slightly modified probe to more closely correspond to the Nicaragua" exact="ZIKV" post="sequence (86). The following primer and probe sequences were"/>
   <result pre="instrument (ThermoFisher). A standard curve was generated using in vitro-transcribed" exact="ZIKV" post="RNA using an Ambion MEGAscript kit (ThermoFisher) and a"/>
   <result pre="MEGAscript kit (ThermoFisher) and a pCRII-TOPO plasmid containing French Polynesia" exact="ZIKV" post="bases 700 to 1500 (kindly provided by Thomas C."/>
   <result pre="curve was used to extrapolate the number of copies of" exact="ZIKV" post="RNA per 1,000 cells. Samples were considered positive if"/>
   <result pre="were biopsied 5 or 27 days post-ZIKV infection in both the" exact="ZIKV" post="and SIV/ZIKV cohorts. LNs were then fixed overnight in"/>
   <result pre="reagent kit (Advanced Cell Diagnostics) according to the manufacturer’s suggestions." exact="ZIKV" post="RNA was detected using the V-ZIKA-pp RNAscope probe, and"/>
   <result pre="Prism v7.0 software (GraphPad). Mann-Whitney U tests were used when" exact="Zika" post="mean titers and infection cell frequencies were compared between"/>
   <result pre="using the Mann-Whitney U test (Fig. 2). AUC analysis for" exact="Zika" post="mean titers was carried out similarly, except that it"/>
   <result pre="the curve defined by day 2 to day 7 of" exact="ZIKV" post="infection (Fig. 1C). Comparisons of ZIKV 50% effective concentrations"/>
   <result pre="to day 7 of ZIKV infection (Fig. 1C). Comparisons of" exact="ZIKV" post="50% effective concentrations (EC50s) were analyzed via 2-way analysis"/>
   <result pre="(ANOVA) of log-transformed data (Fig. 2E). Responses to SIV and" exact="ZIKV" post="were determined by repeated-measures one-way ANOVA analysis (Fig. 2A"/>
   <result pre="then subsequently challenged subcutaneously on day 21 post-SIV infection with" exact="Zika" post="virus isolate Nicaragua/2016 (UCB 7420) at 104 PFU (SIV/ZIKV"/>
   <result pre="104 PFU (SIV/ZIKV cohort); 12 RMs were infected with the" exact="Zika" post="virus isolate Nicaragua/2016 alone (ZIKV cohort) (Table 1). This"/>
   <result pre="Zika virus isolate Nicaragua/2016 alone (ZIKV cohort) (Table 1). This" exact="ZIKV" post="challenge virus was chosen due to its relatively high"/>
   <result pre="sampling time points were chosen to focus extensively on early" exact="ZIKV" post="infection prior to clearance from plasma circulation, as well"/>
   <result pre="exception of RHA0P003, free of the presence of antibodies for" exact="West Nile" post="virus, dengue virus, and ZIKV prior to study infection."/>
   <result pre="presence of antibodies for West Nile virus, dengue virus, and" exact="ZIKV" post="prior to study infection. Neutralizing antibody titers from RHA0P003"/>
   <result pre="analysis in Fig. 2E due to clear evidence of prior" exact="WNV" post="infection detected in a prospective antibody-dependent enhancement WNV reporter"/>
   <result pre="of prior WNV infection detected in a prospective antibody-dependent enhancement" exact="WNV" post="reporter virus particle assay. The NAb titers from this"/>
   <result pre="Simian immunodeficiency virus infection of rhesus macaques results in delayed" exact="Zika" post="virus clearance. mBio 10:e02790-19. https://doi.org/10.1128/mBio.02790-19. ACKNOWLEDGMENTS We thank Heather"/>
   <result pre="RojasDP, MerlerS, MistryD, PolettiP, RossiL, BrayM, HalloranME, LonginiIMJr, VespignaniA2017Spread of" exact="Zika" post="virus in the Americas. Proc Natl Acad Sci U"/>
   <result pre="A114:E4334–E4343. doi:10.1073/pnas.1620161114.28442561 3.BarbiL, CoelhoAVC, AlencarLCA, CrovellaS2018Prevalence of Guillain-Barre syndrome among" exact="Zika" post="virus infected cases: a systematic review and meta-analysis. Braz"/>
   <result pre="de Souza KuchenbeckerR, SchmidtMI2017Infection-related microcephaly after the 2015 and 2016" exact="Zika" post="virus outbreaks in Brazil: a surveillance-based analysis. Lancet390:861–870. doi:10.1016/S0140-6736(17)31368-5.28647172"/>
   <result pre="a surveillance-based analysis. Lancet390:861–870. doi:10.1016/S0140-6736(17)31368-5.28647172 5.NascimentoOJM, da SilvaI2017Guillain-Barre syndrome and" exact="Zika" post="virus outbreaks. Curr Opin Neurol30:500–507. doi:10.1097/WCO.0000000000000471.28617719 6.SamyAM, ThomasSM, WahedAA,"/>
   <result pre="6.SamyAM, ThomasSM, WahedAA, CohoonKP, PetersonAT2016Mapping the global geographic potential of" exact="Zika" post="virus spread. Mem Inst Oswaldo Cruz111:559–560. doi:10.1590/0074-02760160149.27653360 7. 2017"/>
   <result pre="De La BarreraRA, JarmanRG, EckelsKH, MichaelNL, ThomasSJ, BarouchDH2016Vaccine protection against" exact="Zika" post="virus from Brazil. Nature536:474–478. doi:10.1038/nature18952.27355570 9.LazearHM, GoveroJ, SmithAM, PlattDJ,"/>
   <result pre="9.LazearHM, GoveroJ, SmithAM, PlattDJ, FernandezE, MinerJJ, DiamondMS2016A mouse model of" exact="Zika" post="virus pathogenesis. Cell Host Microbe19:720–730. doi:10.1016/j.chom.2016.03.010.27066744 10.RossiSL, TeshRB, AzarSR,"/>
   <result pre="PaesslerS, VasilakisN, WeaverSC2016Characterization of a novel murine model to study" exact="Zika" post="virus. Am J Trop Med Hyg94:1362–1369. doi:10.4269/ajtmh.16-0111.27022155 11.GrantA, PoniaSS,"/>
   <result pre="Viruses10:E712. doi:10.3390/v10120712.30558110 14.Alves Dos SantosE, FinkK2018Animal models for dengue and" exact="Zika" post="vaccine development. Adv Exp Med Biol1062:215–239. doi:10.1007/978-981-10-8727-1_16.29845536 15.GormanMJ, CaineEA,"/>
   <result pre="EbelGD, BaricRS, BestSM, ArtyomovMN, Garcia-SastreA, DiamondMS2018An immunocompetent mouse model of" exact="Zika" post="virus infection. Cell Host Microbe23:672–685.e6. doi:10.1016/j.chom.2018.04.003.29746837 16.BrassAL, HuangIC, BenitaY,"/>
   <result pre="IFITM proteins mediate cellular resistance to influenza A H1N1 virus," exact="West Nile" post="virus, and dengue virus. Cell139:1243–1254. doi:10.1016/j.cell.2009.12.017.20064371 17.JohnSP, ChinCR, PerreiraJM,"/>
   <result pre="doi:10.1128/JVI.00481-13.23658454 18.SavidisG, PerreiraJM, PortmannJM, MeranerP, GuoZ, GreenS, BrassAL2016The IFITMs inhibit" exact="Zika" post="virus replication. Cell Rep15:2323–2330. doi:10.1016/j.celrep.2016.05.074.27268505 19.AbbinkP, StephensonKE, BarouchDH2018Zika virus"/>
   <result pre="and therapy. Curr HIV/AIDS Rep12:41–53. doi:10.1007/s11904-014-0244-6.25662992 42.BradleyMP, NagamineCM2017Animal models of" exact="Zika" post="virus. Comp Med67:242–252.28662753 43.DudleyDM, AliotaMT, MohrEL, WeilerAM, Lehrer-BreyG, WeisgrauKL,"/>
   <result pre="CapuanoS, GolosTG, OsorioJE, FriedrichTC, O'ConnorDH2016A rhesus macaque model of Asian-lineage" exact="Zika" post="virus infection. Nat Commun7:12204. doi:10.1038/ncomms12204.27352279 44.EstesJD, WongSW, BrenchleyJM2018Nonhuman primate"/>
   <result pre="GaoGF, CaoWC, ShiPY, QinCF2016Characterization of a 2016 clinical isolate of" exact="Zika" post="virus in non-human primates. EBioMedicine12:170–177. doi:10.1016/j.ebiom.2016.09.022.27693104 51.O'ConnorMA, Tisoncik-GoJ, LewisTB,"/>
   <result pre="EdlefsenPT, SmedleyJ, KlattNR, GaleM, FullerDH2018Early cellular innate immune responses drive" exact="Zika" post="viral persistence and tissue tropism in pigtail macaques. Nat"/>
   <result pre="dynamics in rhesus macaques infected with a Brazilian strain of" exact="Zika" post="virus. J Immunol199:1003–1011. doi:10.4049/jimmunol.1700256.28667164 54.BrenchleyJM, PaiardiniM, KnoxKS, AsherAI, CervasiB,"/>
   <result pre="EckelsKH, ThomasSJ, MichaelNL, BarouchDH2017Durability and correlates of vaccine protection against" exact="Zika" post="virus in rhesus monkeys. Sci Transl Med9:eaao4163. doi:10.1126/scitranslmed.aao4163.29237759 59.AndersonJF,"/>
   <result pre="Med9:eaao4163. doi:10.1126/scitranslmed.aao4163.29237759 59.AndersonJF, RahalJJ2002Efficacy of interferon alpha-2b and ribavirin against" exact="West Nile" post="virus in vitro. Emerg Infect Dis8:107–108. doi:10.3201/eid0801.010252.11749765 60.CranceJM, ScaramozzinoN,"/>
   <result pre="Antiviral Res58:73–79. doi:10.1016/s0166-3542(02)00185-7.12719009 61.DiamondMS, RobertsTG, EdgilD, LuB, ErnstJ, HarrisE2000Modulation of" exact="Dengue" post="virus infection in human cells by alpha, beta, and"/>
   <result pre="activity of Sofosbuvir and type-I interferons (alpha and beta) against" exact="Zika" post="virus. J Med Virol90:8–12. doi:10.1002/jmv.24932.28851097 63.BarrosJBS, da SilvaPAN, KogaRCR,"/>
   <result pre="SilvaPAN, KogaRCR, Gonzalez-DiasP, Carmo FilhoJR, NagibPRA, CoelhoV, NakayaHI, FonsecaSG, PfrimerI2018Acute" exact="Zika" post="virus infection in an endemic area shows modest proinflammatory"/>
   <result pre="73.KimSY, ZhaoJ, LiuX, FraserK, LinL, ZhangX, ZhangF, DordickJS, LinhardtRJ2017Interaction of" exact="Zika" post="virus envelope protein with glycosaminoglycans. Biochemistry56:1151–1162. doi:10.1021/acs.biochem.6b01056.28151637 74.ChenY, MaguireT,"/>
   <result pre="KongWP, MascolaJR, PiersonTC, GrahamBS2016Rapid development of a DNA vaccine for" exact="Zika" post="virus. Science354:237–240. doi:10.1126/science.aai9137.27708058 76.GaudinskiMR, HouserKV, MorabitoKM, HuZ, YamshchikovG, RothwellRS,"/>
   <result pre="VRC 320 study teams. 2018Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
   <result pre="with neurological complications and congenital central nervous system abnormalities from" exact="Zika" post="virus-infected patients in Brazil. J Infect Dis216:172–181. doi:10.1093/infdis/jix261.28838147 79.OrtizAM,"/>
   <result pre="PlattDJ, MascolaJR, GrahamBS, MulliganMJ, DiamondMS, LedgerwoodJE, PiersonTC2016Broadly neutralizing activity of" exact="Zika" post="virus-immune sera identifies a single viral serotype. Cell Rep16:1485–1491."/>
   <result pre="DomsRW2006A rapid and quantitative assay for measuring antibody-mediated neutralization of" exact="West Nile" post="virus infection. Virology346:53–65. doi:10.1016/j.virol.2005.10.030.16325883 84.MukherjeeS, PiersonTC, DowdKA2014Pseudo-infectious reporter virus"/>
   <result pre="LavenJJ, VelezJO, LambertAJ, JohnsonAJ, StanfieldSM, DuffyMR2008Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap State, Micronesia, 2007."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892364\results\search\tropicalVirus\results.xml">
   <result pre="Space Station [20]. MinION helped the surveillance and sequencing of" exact="Zika" post="virus in the 2016 Brazil outbreak [21]. During the"/>
   <result pre="‘tiling amplification’ was used to amplify the whole genome of" exact="Zika" post="virus. This technique also was employed in the Ebola"/>
   <result pre="sequencing with MinION has been used in many clinical studies." exact="Chikungunya" post="virus (CHIKV), EBOV, and hepatitis C virus can be"/>
   <result pre="viral genomes [38]. In a similar experiment, a coinfection of" exact="DENV" post="and CHIKV was found from one clinical specimen [39]."/>
   <result pre="[38]. In a similar experiment, a coinfection of DENV and" exact="CHIKV" post="was found from one clinical specimen [39]. Pathogens causing"/>
   <result pre="the international space stationSci Rep2017711210.1038/s41598-017-18364-028127051 21.FariaNRet al.Mobile real-time surveillance of" exact="Zika" post="virus in BrazilGenome Med201682510.1186/s13073-016-0356-226739746 22.QuickJet al.Real-time, portable genome sequencing"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6892822\results\search\tropicalVirus\results.xml">
   <result pre="IFITM proteins mediate cellular resistance to influenza A H1N1 virus," exact="West Nile" post="virus, and dengue virusCell20091391243125410.1016/j.cell.2009.12.01720064371 19.WatanabeTet al.Influenza virus–host interactome screen"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893414\results\search\tropicalVirus\results.xml">
   <result pre="VirusesVirusesvirusesViruses1999-4915MDPI pmcid: 6893414 doi: 10.3390/v11111064viruses-11-01064 : Article Erythromycin Estolate Inhibits" exact="Zika" post="Virus Infection by Blocking Viral Entry as a Viral"/>
   <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Recently," exact="Zika" post="virus (ZIKV) has attracted much attention in consideration of"/>
   <result pre="prophylactic vaccines or therapeutic drugs approved for clinical treatments of" exact="ZIKV" post="infection. To determine the potential anti-ZIKV inhibitors, we screened"/>
   <result pre="one of the macrolide antibiotics, was found to effectively inhibit" exact="ZIKV" post="infection in different cell types and significantly protect A129"/>
   <result pre="and mortality. Through further investigation, Ery-Est was verified to inhibit" exact="ZIKV" post="entry by disrupting the integrity of the viral membrane"/>
   <result pre="of the viral membrane which resulted in the loss of" exact="ZIKV" post="infectivity. Furthermore, Ery-Est also showed inhibitory activity against dengue"/>
   <result pre="Thus, Ery-Est may be a promising drug for patients with" exact="ZIKV" post="infection, particularly pregnant women. erythromycin estolate ZIKV viral entry"/>
   <result pre="for patients with ZIKV infection, particularly pregnant women. erythromycin estolate" exact="ZIKV" post="viral entry inhibitor inactivator 1. Introduction Zika virus (ZIKV),"/>
   <result pre="women. erythromycin estolate ZIKV viral entry inhibitor inactivator 1. Introduction" exact="Zika" post="virus (ZIKV), a mosquito-borne enveloped RNA virus, is a"/>
   <result pre="viruses, such as dengue virus (DENV), yellow fever virus (YFV)," exact="West Nile" post="virus, and Japanese encephalitis virus, which have resulted in"/>
   <result pre="resulted in epidemics and threatened public health around the world." exact="ZIKV" post="was initially isolated from a sentinel rhesus monkey in"/>
   <result pre="ZIKV was initially isolated from a sentinel rhesus monkey in" exact="Zika" post="forest, Uganda in 1947 [1,2], and had been perceived"/>
   <result pre="conjunctivitis. However, since 2007, the threat to public health from" exact="ZIKV" post="has steadily increased due to outbreaks in varying places,"/>
   <result pre="such as Yap Island, French Polynesia, and Micronesia [3,4]. Thus," exact="ZIKV" post="has been recognized as an emerging arbovirus and received"/>
   <result pre="arbovirus and received attention globally. More recently, unexpected outbreaks of" exact="ZIKV" post="infection have occurred in Brazil and rapidly spread from"/>
   <result pre="millions of residents [5]. Meanwhile, the neurological disorders caused by" exact="ZIKV" post="have been declared a global public health emergency by"/>
   <result pre="public health emergency by the World Health Organization (WHO) [6]." exact="ZIKV" post="was found to be associated with Guillain–Barré syndrome in"/>
   <result pre="abnormality, and reproductive system injury, have been discovered in recent" exact="ZIKV" post="outbreaks [7,8,9,10]. Microcephaly, the most worrying abnormality caused by"/>
   <result pre="life of affected children [11]. As the increasing cases of" exact="ZIKV" post="sexual transmission and multiple harmful outcomes to fetuses have"/>
   <result pre="conceive are now regarded as at especially high risk for" exact="ZIKV" post="infection, and thus the need for effective treatments has"/>
   <result pre="With the increasing recognition of the epidemiology and pathogenicity of" exact="ZIKV" post="infection, it is urgent to develop potent therapies. Currently,"/>
   <result pre="there are no vaccines or therapeutic drugs approved to treat" exact="ZIKV" post="infection, although great progress has been achieved. Many potent"/>
   <result pre="patients. Many already-approved drugs have been discovered to significantly inhibit" exact="ZIKV" post="infection, but few can be safely used by pregnant"/>
   <result pre="the safety profile for pregnant women in the development of" exact="ZIKV" post="inhibitors must be considered a priority. To determine the"/>
   <result pre="be considered a priority. To determine the ready-to-use inhibitors for" exact="ZIKV" post="infection, we screened a drug library consisting of FDA-approved"/>
   <result pre="be safely used by pregnant women, was found to inhibit" exact="ZIKV" post="infection efficiently. Ery-Est, one of the macrolide antibiotics, is"/>
   <result pre="and ivermectin and azithromycin (Azi) were identified to effectively inhibit" exact="ZIKV" post="infection [17,18,19,20,21,22,23]. To the best of our knowledge, this"/>
   <result pre="containing 10% FBS at 28 °C with 5% CO2. Three" exact="ZIKV" post="strains, SZ01 (GenBank: KU866423), FLR (GenBank: KU820897.5), and MR766"/>
   <result pre="monkey in Uganda in 1947 [1], were obtained from ATCC." exact="YFV" post="strain 17D was obtained from Beijing Tiantan Biological products,"/>
   <result pre="Tiantan Biological products, Ltd. and prepared as previously described [26]." exact="DENV" post="II strain New Guinea C was kindly provided by"/>
   <result pre="by Zhigang Song at Shanghai Public Health Clinical Center. The" exact="ZIKV" post="strains SZ01 (passage 6–8), MR766 (passage 4–6) and FLR"/>
   <result pre="SZ01 (passage 6–8), MR766 (passage 4–6) and FLR (passage 4–6)," exact="DENV" post="II strain New Guinea C (passage 5–7), and YFV"/>
   <result pre="4–6), DENV II strain New Guinea C (passage 5–7), and" exact="YFV" post="strain 17D (passage 5–7) were used in the experiments."/>
   <result pre="17D (passage 5–7) were used in the experiments. Besides the" exact="ZIKV" post="strain SZ01 prepared in Vero cells (V-ZIKV), all flaviviruses"/>
   <result pre="for Antiviral Activity For the drug screen, equal volume of" exact="ZIKV" post="strain SZ01 (100 PFU/mL) and compounds diluted in serum-free"/>
   <result pre="h. BHK21 cells (2 × 104) were infected with compounds-treated" exact="ZIKV" post="at 37 °C for 12 h, followed by replacing"/>
   <result pre="to the instruction manual. To evaluate the antiviral efficacy against" exact="ZIKV" post="(SZ01, FLR, and MR766) and DENV II New Guinea"/>
   <result pre="the antiviral efficacy against ZIKV (SZ01, FLR, and MR766) and" exact="DENV" post="II New Guinea C and YFV 17D, Ery-Est and"/>
   <result pre="FLR, and MR766) and DENV II New Guinea C and" exact="YFV" post="17D, Ery-Est and Ery were serially diluted in serum-free"/>
   <result pre="NC, USA). To test the inhibitory activity of Ery-Est against" exact="ZIKV" post="in neuronal cells, U-251 MG cells were used. Briefly,"/>
   <result pre="normalized to untreated infected cells. The inhibition of Ery-Est against" exact="ZIKV" post="in multiple rounds of infection was performed as previously"/>
   <result pre="× 105) were infected by 2 × 103 PFU of" exact="ZIKV" post="treated with Ery-Est (20 µM), Ery (20 µM), and"/>
   <result pre="supernatant was collected at different timepoints after infection, and the" exact="ZIKV" post="titers of collected supernatants were respectively detected by the"/>
   <result pre="was respectively collected at 48 h post infection, and the" exact="ZIKV" post="titers of collected supernatants were detected by the plaque"/>
   <result pre="Staining Assay To confirm the inhibitory activity of Ery-Est on" exact="ZIKV" post="infection, BHK21 and Vero cells were seeded onto coverslips"/>
   <result pre="24 h. The mixture of 2 × 103 PFU of" exact="ZIKV" post="and the equal volume of serially diluted Ery-Est (20,"/>
   <result pre="visualization. For the entry experiment, BHK21 cells were infected with" exact="ZIKV" post="in the presence of Ery-Est at 37 °C for"/>
   <result pre="and drugs. For the attachment assay, cells were infected with" exact="ZIKV" post="in the presence of Ery-Est at 4 °C for"/>
   <result pre="For the fusion assay, BHK21 cells were firstly infected with" exact="ZIKV" post="at 4 °C for 1 h to allow viral"/>
   <result pre="In the post-entry assay, after BHK21 cells were infected with" exact="ZIKV" post="at 37 °C for 1 h to allow viral"/>
   <result pre="and RT-qPCR To detect the genomic RNA released from the" exact="ZIKV" post="particles, the RNase digestion assay and RT-qPCR were developed"/>
   <result pre="previously described [27,35]. Briefly, Ery-Est and Ery were incubated with" exact="ZIKV" post="(1 × 103 PFU) at 37 °C for 2"/>
   <result pre="°C for 2 h. Then, the released RNA from treated" exact="ZIKV" post="was digested by micrococcal nuclease (New England BioLabs, Ipswich,"/>
   <result pre="as follows: F1 (5′-TGGAGGCTGAGATGGATGG-3′)/R1 (5′-GAACGCTGCGGTACACAAGGA-3′). 2.10. Sucrose Density Gradient Assay" exact="ZIKV" post="(1 × 106 PFU) with 100 µM Ery-Est, Ery,"/>
   <result pre="37 °C for 2 h. Then, the treated or untreated" exact="ZIKV" post="was gently loaded onto the top of the sucrose"/>
   <result pre="assigned into six groups and three groups were infected with" exact="ZIKV" post="strain SZ01 intraperitoneally (i.p.) at a dose of 1"/>
   <result pre="of 1 × 105 PFU/ mouse. At 1 h post" exact="ZIKV" post="challenge, infected mice were i.p. administrated with Ery-Est and"/>
   <result pre="tremors; and 5, moribund or death. Mice administrated with heat-inactivated" exact="ZIKV" post="(iZIKV) or only administrated with Ery-Est and Ery at"/>
   <result pre="four groups (n = 5). One group infected with heat-inactivated" exact="ZIKV" post="(iZIKV) was used as mock controls, and other three"/>
   <result pre="mock controls, and other three groups were i.p. infected with" exact="ZIKV" post="strain SZ01 at a dose of 2 × 105"/>
   <result pre="refers to the sample size. 3. Results 3.1. Ery-Est Inhibited" exact="ZIKV" post="Infection in Different Cell Types To determine the inhibitory"/>
   <result pre="Ery-Est and Ery of serially diluted concentrations were incubated with" exact="ZIKV" post="strain SZ01 at 37 °C for 1 h, and"/>
   <result pre="to BHK21 cells, which were reported to be susceptible to" exact="ZIKV" post="and develop obvious cytopathic effects (CPE) after infection [38],"/>
   <result pre="crystal violet dyeing. As shown in Figure 1B, numbers of" exact="ZIKV" post="plaques were reduced more as the concentration of Ery-Est"/>
   <result pre="the assay were generally unchanged. This suggests that Ery-Est inhibits" exact="ZIKV" post="infection in a dose-dependent manner. The 50% inhibitory concentration"/>
   <result pre="manner. The 50% inhibitory concentration (IC50) value of Ery-Est against" exact="ZIKV" post="was 3.22 ± 0.28 µM in the plaque assay"/>
   <result pre="(Figure 1C). To test the inhibitory activity of Ery-Est against" exact="ZIKV" post="in neuronal cells whose damage caused by ZIKV was"/>
   <result pre="Ery-Est against ZIKV in neuronal cells whose damage caused by" exact="ZIKV" post="was especially serious, which would reduce fetal brain growth,"/>
   <result pre="reduce fetal brain growth, U-251 MG cells were infected by" exact="ZIKV" post="with serially diluted Ery-Est and Ery treatments. It was"/>
   <result pre="with the data from the plaque assay. The expression of" exact="ZIKV" post="E protein was almost completely blocked by Ery-Est at"/>
   <result pre="in BHK21 and Vero cells (Figure 1E). Furthermore, CPE of" exact="ZIKV" post="in BHK21 and Vero cells would make cells progress"/>
   <result pre="viabilities, thus, could be detected by CCK8, which could evaluate" exact="ZIKV" post="infection indirectly. As a result, Ery-Est was testified to"/>
   <result pre="infection indirectly. As a result, Ery-Est was testified to inhibit" exact="ZIKV" post="strain SZ01 infection with IC50 values of 3.55 ±"/>
   <result pre="S1A,B). Taken together, these data indicate that Ery-Est notably inhibits" exact="ZIKV" post="infection in different cell types, including neuronal cells. In"/>
   <result pre="of Ery-Est against viral growth, Ery-Est was tested to inhibit" exact="ZIKV" post="infection in a multistep growth curve. It was demonstrated"/>
   <result pre="multistep growth curve. It was demonstrated that Ery-Est greatly decreased" exact="ZIKV" post="titers (supplementary Figure S2A) in multiple rounds of infection,"/>
   <result pre="that Ery-Est has a strong and lasting inhibitory effect on" exact="ZIKV" post="infection. Besides, it was also shown that Ery-Est could"/>
   <result pre="was also shown that Ery-Est could exhibit inhibitory activity against" exact="ZIKV" post="infection even with relatively higher viral doses (Figure S2B),"/>
   <result pre="against relatively higher dose infection of ZIKV. 3.2. Ery-Est Inhibited" exact="ZIKV" post="Strains FLR and MR766, DENV II, and YFV 17D"/>
   <result pre="of ZIKV. 3.2. Ery-Est Inhibited ZIKV Strains FLR and MR766," exact="DENV" post="II, and YFV 17D Infections As Ery-Est was demonstrated"/>
   <result pre="Ery-Est Inhibited ZIKV Strains FLR and MR766, DENV II, and" exact="YFV" post="17D Infections As Ery-Est was demonstrated to potently inhibit"/>
   <result pre="YFV 17D Infections As Ery-Est was demonstrated to potently inhibit" exact="ZIKV" post="strain SZ01, we then evaluated its inhibitory activity against"/>
   <result pre="strain SZ01, we then evaluated its inhibitory activity against other" exact="ZIKV" post="strains through plaque assay. As shown in Figure 2A,B,"/>
   <result pre="shown in Figure 2A,B, Ery-Est significantly inhibited the infections of" exact="ZIKV" post="strains FLR and MR766 with IC50 values of 7.65"/>
   <result pre="and 7.15 ± 0.96 µM respectively. Similar to strain SZ01," exact="ZIKV" post="strains MR766 and FLR were approximately half inhibited by"/>
   <result pre="inhibited by micromole Ery-Est, suggesting that Ery-Est could broadly inhibit" exact="ZIKV" post="strains that were isolated from rhesus monkeys or patients"/>
   <result pre="Ery-Est was able to inhibit other mosquito-borne flaviviruses, such as" exact="DENV" post="and YFV. It was demonstrated that Ery-Est potently inhibited"/>
   <result pre="YFV. It was demonstrated that Ery-Est potently inhibited infections of" exact="DENV" post="II and YFV 17D with IC50 values of about"/>
   <result pre="demonstrated that Ery-Est potently inhibited infections of DENV II and" exact="YFV" post="17D with IC50 values of about 1.22 ± 0.63"/>
   <result pre="2E,F). To rule out the possibility that Ery-Est only inhibits" exact="ZIKV" post="prepared in mosquito cells, we further tested whether Ery-Est"/>
   <result pre="further tested whether Ery-Est could effectively inhibit the infection of" exact="ZIKV" post="(V-ZIKV) produced in one kind of mammalian cells, Vero"/>
   <result pre="0.11 µM, which was similar to the inhibitory activity against" exact="ZIKV" post="propagated in mosquito cells. Meanwhile, both Ery-Est and Ery"/>
   <result pre="inhibit flavivirus infections with a broad spectrum. 3.3. Ery-Est Inhibited" exact="ZIKV" post="Infection in the Early Stage To determine which step"/>
   <result pre="time-of-addition experiment with different time points for Ery-Est addition post" exact="ZIKV" post="infection. At 12 h post infection, the supernatant was"/>
   <result pre="virus infection from 8 h post infection. Generally, Ery-Est inhibited" exact="ZIKV" post="infection mainly in the early 2 h stage post"/>
   <result pre="early 2 h stage post infection, indicating that Ery-Est inhibits" exact="ZIKV" post="infection in the early stage. Next, to confirm the"/>
   <result pre="exhibited obvious inhibitory effects on viral entry, but barely inhibited" exact="ZIKV" post="infection in the viral post-entry stage. The result was"/>
   <result pre="of different macrolide antibiotics may vary widely. 3.4. Ery-Est Inactivated" exact="ZIKV" post="Virons The above study of the inhibitory mechanism of"/>
   <result pre="the inhibitory mechanism of Ery-Est demonstrates that it mainly obstructs" exact="ZIKV" post="attachment, implying that Ery-Est may bind to viral particles"/>
   <result pre="its infectivity. We, thus, further investigated whether Ery-Est could inactivate" exact="ZIKV" post="directly. PEG-8000 was used to separate the treated ZIKV"/>
   <result pre="inactivate ZIKV directly. PEG-8000 was used to separate the treated" exact="ZIKV" post="virions from the free Ery-Est after the incubation of"/>
   <result pre="ZIKV virions from the free Ery-Est after the incubation of" exact="ZIKV" post="and Ery-Est or Ery as previously described [34]. The"/>
   <result pre="or Ery as previously described [34]. The infectivity of treated" exact="ZIKV" post="was then detected by plaque assay. Results showed that"/>
   <result pre="plaque assay. Results showed that Ery-Est decreased the infectivity of" exact="ZIKV" post="in a dose-dependent manner with 50% effective concentration of"/>
   <result pre="± 0.85 µM, while Ery showed no inactivated activity against" exact="ZIKV" post="(Figure 3C). Additionally, other mosquito-borne flaviviruses of DENV II"/>
   <result pre="activity against ZIKV (Figure 3C). Additionally, other mosquito-borne flaviviruses of" exact="DENV" post="II and YFV 17D were also used to verify"/>
   <result pre="(Figure 3C). Additionally, other mosquito-borne flaviviruses of DENV II and" exact="YFV" post="17D were also used to verify the inactivated effect"/>
   <result pre="of Ery-Est. As shown in Figure 3D,E, Ery-Est potently inactivated" exact="DENV" post="II and YFV 17D with 50% effective concentrations of"/>
   <result pre="shown in Figure 3D,E, Ery-Est potently inactivated DENV II and" exact="YFV" post="17D with 50% effective concentrations of 2.56 ± 0.11"/>
   <result pre="through directly inactivating viral particles. It was reported that some" exact="ZIKV" post="inhibitors, such as Z2 and human breast milk, could"/>
   <result pre="milk, could inactivate virus particles by destructing the integrity of" exact="ZIKV" post="[27,39]. Using similar approaches, we investigated whether Ery-Est inactivated"/>
   <result pre="ZIKV [27,39]. Using similar approaches, we investigated whether Ery-Est inactivated" exact="ZIKV" post="by inducing the release of genomic RNA from virions."/>
   <result pre="the RNase digestion assay, we found genomic RNA from untreated" exact="ZIKV" post="(0 µM Ery-Est) or treated by Ery were protected"/>
   <result pre="Ery were protected from RNase digestion, but the RNA of" exact="ZIKV" post="treated by Ery-Est was digested in a dose-dependence manner"/>
   <result pre="may cause the release of genomic RNA to inactivate the" exact="ZIKV" post="virions. Next, to further confirm this potential inactivated mechanism,"/>
   <result pre="ZIKV virions. Next, to further confirm this potential inactivated mechanism," exact="ZIKV" post="with media alone or respectively treated with Ery-Est and"/>
   <result pre="Western blot was used to measure the E protein of" exact="ZIKV" post="in each fraction of the above four treated groups,"/>
   <result pre="genomic RNA detection. Through the percent analysis of each fraction," exact="ZIKV" post="E protein and genomic RNA of Ery, DMSO, and"/>
   <result pre="ZIKV E protein and genomic RNA of Ery, DMSO, and" exact="ZIKV" post="(media alone) groups were consistently distributed in the fourth"/>
   <result pre="of viral integrity. These results indicate that Ery-Est may inhibit" exact="ZIKV" post="infection by destructing the viral integrity, resulting in the"/>
   <result pre="of genomic RNA. 3.5. Ery-Est Protected A129 Mice from Lethal" exact="ZIKV" post="Challenge As the results in vitro demonstrated that Ery-Est"/>
   <result pre="established transgenic (type I interferon receptor-deficient) A129 mouse model for" exact="ZIKV" post="lethal challenge [40]. Ery-Est and Ery were tested at"/>
   <result pre="an inhibitory role in the early stage, possibly by inactivating" exact="ZIKV" post="virions newly produced from the body and suppressing them"/>
   <result pre="more target cells. 3.6. Ery-Est Protected Against Vertical Transmission of" exact="ZIKV" post="in Pregnant C57BL/6 Mice To determine whether Ery-Est could"/>
   <result pre="by iZIKV (mock infected controls) or 2 × 105 PFU" exact="ZIKV" post="as described previously [27], followed by treatments of Ery-Est"/>
   <result pre="or vehicle treatments (Figure 5A). Meanwhile, the viral load of" exact="ZIKV" post="in placentas and fetal heads from pregnant mice with"/>
   <result pre="treatment. These results suggest that Ery-Est may directly inactivate some" exact="ZIKV" post="virions before they have penetrated to the placenta and"/>
   <result pre="placentas and fetuses, as well as blocking vertical transmission of" exact="ZIKV" post="in pregnant mice. 4. Discussion In consideration of worldwide"/>
   <result pre="mice. 4. Discussion In consideration of worldwide attention to recent" exact="ZIKV" post="outbreaks, many efforts have been made to explore potential"/>
   <result pre="against ZIKV. In our study, Ery-Est was demonstrated to inhibit" exact="ZIKV" post="infection in a dose-dependent manner in plaque assay (Figure"/>
   <result pre="could still suppress viral growth and exhibit inhibitory activity against" exact="ZIKV" post="infection even with relatively higher viral dose (Figure S2A,B),"/>
   <result pre="azithromycin and ivermectin, have been previously found to effectively inhibit" exact="ZIKV" post="infection. Moreover, azithromycin was reported to not only inhibit"/>
   <result pre="ZIKV infection. Moreover, azithromycin was reported to not only inhibit" exact="ZIKV" post="in vitro, but also to prevent ZIKV-induced lethality in"/>
   <result pre="research about why macrolide antibiotics exhibit different inhibitory mechanisms against" exact="ZIKV" post="is needed. As the effective macrolides with diverse characteristics"/>
   <result pre="baby with microcephaly [48,49,50,51]. Meanwhile, as the sexual transmission of" exact="ZIKV" post="was constantly reported [52,53], Ery-Est also showed great potential"/>
   <result pre="effects, which would not only block the sexual transmission of" exact="ZIKV" post="but would be conducive to the healthy vaginal environment."/>
   <result pre="thus, increases clinical options of the treatment and prevention for" exact="ZIKV" post="infection. Moreover, Ery-Est was demonstrated to protect against vertical"/>
   <result pre="Moreover, Ery-Est was demonstrated to protect against vertical transmission of" exact="ZIKV" post="in pregnant mice, indicating it may have a good"/>
   <result pre="women. In our study, besides the inhibitory activity against different" exact="ZIKV" post="strains, Ery-Est was also demonstrated to potently inhibit other"/>
   <result pre="was also demonstrated to potently inhibit other mosquito-borne flaviviruses, including" exact="DENV" post="and YFV. This presents an opportunity for clinical applications"/>
   <result pre="for clinical applications to patients, who may suffer co-infections by" exact="ZIKV" post="and DENV, in epidemic areas where the viral vector,"/>
   <result pre="Aedes aegypti, is prevalent. Moreover, it was reported that preexisting" exact="DENV" post="antibodies may aggravate the ZIKV infection through an antibody-dependent"/>
   <result pre="it was reported that preexisting DENV antibodies may aggravate the" exact="ZIKV" post="infection through an antibody-dependent enhancement (ADE) effect [54,55], the"/>
   <result pre="micromolecular inhibitors that target viral binding, endocytosis, and replication against" exact="ZIKV" post="have been discovered, but their suppressing activities are only"/>
   <result pre="inactivator like Z2 that is a synthetic peptide derived from" exact="ZIKV" post="envelope proteins, makes it possible to effectively inhibit ZIKV"/>
   <result pre="from ZIKV envelope proteins, makes it possible to effectively inhibit" exact="ZIKV" post="before viral entry and is, therefore, beneficial to treat"/>
   <result pre="of Ery-Est and other inhibitors with different inhibitory stages against" exact="ZIKV" post="may have synergistic effects of improving protection. In conclusion,"/>
   <result pre="be further repurposed as a novel antiviral drug to treat" exact="ZIKV" post="infection in populations with high risk, particularly pregnant women."/>
   <result pre="available online at https://www.mdpi.com/1999-4915/11/11/1064/s1, Figure S1: Inhibition of Ery-Est against" exact="ZIKV" post="in BHK21 and Vero cells through CCK8 assay. Figure"/>
   <result pre="cells through CCK8 assay. Figure S2: Inhibition of Ery-Est against" exact="ZIKV" post="in multiple rounds of infection; Inhibitory activity of Ery-Est"/>
   <result pre="dose infection of ZIKV. Figure S3: Inhibition of Ery-Est against" exact="ZIKV" post="(V-ZIKV) prepared in Vero cells. LINK Click here for"/>
   <result pre="NigeriaTrans. R Soc. Trop. Med. Hyg.19544813914510.1016/0035-9203(54)90006-113157159 3.MussoD.NillesE.J.Cao-LormeauV.M.Rapid spread of emerging" exact="Zika" post="virus in the Pacific areaClin. Microbiol. Infect.201420O595O59610.1111/1469-0691.1270724909208 4.JouannicJ.M.FriszerS.Leparc-GoffartI.GarelC.Eyrolle-GuignotD.Zika virus"/>
   <result pre="a global public health emergency, declares WHOBMJ2016352i65710.1136/bmj.i65726839247 7.TsetsarkinK.A.MaximovaO.A.LiuG.KenneyH.TeterinaN.BloomM.E.GrabowskiJ.M.MleraL.NagataB.M.MooreI.et al.Routes of" exact="Zika" post="virus dissemination in the testis and epididymis of immunodeficient"/>
   <result pre="MoraesC.G.PettitoM.YepezJ.B.SakuntabhaiA.Simon-LoriereE.ZaidiM.B.ProtM.RuffieC.KimS.S.AllikmetsR.et al.Corrigendum: Optic neuropathy and congenital glaucoma associated with probable" exact="Zika" post="virus infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections:"/>
   <result pre="Zika virus infection in Venezuelan patientsJMM Case Rep.20185e00516110.1099/jmmcr.0.00516130323937 9.MalkkiH.CNS infections:" exact="Zika" post="virus infection could trigger Guillain-Barre syndromeNat. Rev. Neurol.20161218710.1038/nrneurol.2016.3026988905 10.CarteauxG.MaquartM.BedetA.ContouD.BrugieresP.FouratiS.Cleret"/>
   <result pre="officials reportBMJ2016352i72010.1136/bmj.i72026848011 13.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 14.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking"/>
   <result pre="Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 14.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects"/>
   <result pre="Infection in Different Cell ModelsViruses2016832210.3390/v8120322 15.LiC.DengY.Q.WangS.MaF.AliyariR.HuangX.Y.ZhangN.N.WatanabeM.DongH.L.LiuP.et al.25-Hydroxycholesterol Protects Host against" exact="Zika" post="Virus Infection and Its Associated Microcephaly in a Mouse"/>
   <result pre="Bioactives Reveals Nanchangmycin as a Broad Spectrum Antiviral Active against" exact="Zika" post="VirusCell Rep.20171880481510.1016/j.celrep.2016.12.06828099856 17.ArabiY.M.DeebA.M.Al-HameedF.MandourahY.AlmekhlafiG.A.SindiA.A.Al-OmariA.ShalhoubS.MadyA.AlraddadiB.et al.Macrolides in critically ill patients with"/>
   <result pre="Aedes aegyptiPLoS Negl. Trop. Dis.20191310.1371/journal.pntd.0007681 20.BosseboeufE.AubryM.NhanT.PinaJ.J.RolainJ.M.RaoultD.MussoD.Azithromycin Inhibits the Replication of" exact="Zika" post="VirusJ. Antivir. Antiretrovir.20181061110.4172/1948-5964.1000173 21.IannettaM.IppolitoG.NicastriE.Azithromycin Shows Anti-Zika Virus Activity in"/>
   <result pre="Proc. Natl. Acad. Sci. USA2016113144081441310.1073/pnas.161802911327911847 23.WuY.H.TsengC.K.LinC.K.WeiC.K.LeeJ.C.YoungK.C.ICR suckling mouse model of" exact="Zika" post="virus infection for disease modeling and drug validationPLoS Negl."/>
   <result pre="24.DengY.Q.ZhaoH.LiX.F.ZhangN.N.LiuZ.Y.JiangT.GuD.Y.ShiL.HeJ.A.QinC.F.et al.Isolation, identification and genomic characterization of the Asian lineage" exact="Zika" post="virus imported to ChinaSci. China Life Sci.20165942843010.1007/s11427-016-5043-426993654 25.LahonA.AryaR.P.KneubehlA.R.VogtM.B.Dailey GarnesN.J.Rico-HesseR.Characterization"/>
   <result pre="imported to ChinaSci. China Life Sci.20165942843010.1007/s11427-016-5043-426993654 25.LahonA.AryaR.P.KneubehlA.R.VogtM.B.Dailey GarnesN.J.Rico-HesseR.Characterization of a" exact="Zika" post="Virus Isolate from ColombiaPLoS Negl. Trop. Dis.201610e000501910.1371/journal.pntd.000501927654889 26.DengY.Q.DaiJ.X.JiG.H.JiangT.WangH.J.YangH.O.TanW.L.LiuR.YuM.QinC.F.et al.A"/>
   <result pre="of E proteinPLoS ONE20116e1605910.1371/journal.pone.001605921264311 27.YuY.DengY.Q.ZouP.WangQ.DaiY.YuF.DuL.QinC.F.JiangS.LuL.et al.A peptide-based viral inactivator inhibits" exact="Zika" post="virus infection in pregnant mice and fetusesNat. Commun.201781567210.1038/ncomms1567228742068 28.XieJ.LiuJ.H.LiuH.LiaoX.Z.ChenY.LinM.G.GuY.Y.LiuT.L.WangD.M.GeH.et"/>
   <result pre="cell line in a synergistic wayBMC Cancer20161689910.1186/s12885-016-2921-x27863471 29.EspanoE.NamJ.H.SongE.J.Lipophilic statins inhibit" exact="Zika" post="virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits Zika"/>
   <result pre="inhibit Zika virus production in Vero cellsSci. Rep.201991146110.1038/s41598-019-47956-131391514 30.MounceB.C.CesaroT.CarrauL.ValletT.VignuzziM.Curcumin inhibits" exact="Zika" post="and chikungunya virus infection by inhibiting cell bindingAntivir. Res.201714214815710.1016/j.antiviral.2017.03.01428343845"/>
   <result pre="genome induced by a peptide inhibitorPLoS ONE20127e5099510.1371/journal.pone.005099523226444 36.AliotaM.T.CaineE.A.WalkerE.C.LarkinK.E.CamachoE.OsorioJ.E.Characterization of Lethal" exact="Zika" post="Virus Infection in AG129 MicePLoS Negl. Trop. Dis.201610e000468210.1371/journal.pntd.000468227093158 37.LiS.ArmstrongN.ZhaoH.HouW.LiuJ.ChenC.ZhongC.LiuC.ZhuH.XiaN.et"/>
   <result pre="Nervous SystemViruses2018104910.3390/v10010049 38.ChanJ.F.YipC.C.TsangJ.O.TeeK.M.CaiJ.P.ChikK.K.ZhuZ.JinD.Y.ChanK.H.YuenK.Y.et al.Differential cell line susceptibility to the emerging" exact="Zika" post="virus: Implications for disease pathogenesis, non-vector-borne human transmission and"/>
   <result pre="Anti-ZIKV Activity in Human Breast MilkViruses20191159110.3390/v11070591 40.DaiL.SongJ.LuX.DengY.Q.MusyokiA.M.ChengH.ShiY.QinC.F.QiJ.GaoG.F.et al.Structures of the" exact="Zika" post="Virus Envelope Protein and Its Complex with a Flavivirus"/>
   <result pre="a Flavivirus Broadly Protective AntibodyCell Host Microbe20161969670410.1016/j.chom.2016.04.01327158114 41.ParkJ.G.Avila-PerezG.MadereF.HilimireT.A.NogalesA.AlmazanF.Martinez-SobridoL.Potent Inhibition of" exact="Zika" post="Virus Replication by Aurintricarboxylic AcidFront. Microbiol.20191071810.3389/fmicb.2019.0071831031722 42.RazaS.AbbasG.AzamS.S.Screening pipeline for"/>
   <result pre="Aurintricarboxylic AcidFront. Microbiol.20191071810.3389/fmicb.2019.0071831031722 42.RazaS.AbbasG.AzamS.S.Screening pipeline for Flavivirus based Inhibitors for" exact="Zika" post="Virus NS1IEEE/ACM Trans. Comput. Biol. Bioinform.201910.1109/TCBB.2019.2911081 43.GorshkovK.ShiryaevS.A.FertelS.LinY.W.HuangC.T.PintoA.FarhyC.StronginA.Y.ZhengW.TerskikhA.V.Zika Virus: Origins,"/>
   <result pre="Pregnant Women and InfantsAdv. Neonatal Care20181835035910.1097/ANC.000000000000055730239403 50.MotaV.M.R.CavalcantiL.P.G.DelfinoA.D.S.LopesT.PessoaA.L.S.RibeiroE.M.Abortion in Cases of" exact="Zika" post="Virus Congenital InfectionRev. Bras. Ginecol. Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor"/>
   <result pre="Obstet.20184041742410.1055/s-0038-164821929959761 51.CuiL.ZouP.ChenE.YaoH.ZhengH.WangQ.ZhuJ.N.JiangS.LuL.ZhangJ.Visual and Motor Deficits in Grown-up Mice with Congenital" exact="Zika" post="Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of Zika"/>
   <result pre="Congenital Zika Virus InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of" exact="Zika" post="virusPathogens201876610.3390/pathogens7030066 53.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent Zika Virus Sexual Transmission and Prolonged Viral"/>
   <result pre="InfectionEBioMedicine20172019320110.1016/j.ebiom.2017.04.02928583742 52.SakkasH.BozidisP.GiannakopoulosX.SofikitisN.PapadopoulouC.An update on sexual transmission of Zika virusPathogens201876610.3390/pathogens7030066 53.DuggalN.K.RitterJ.M.PestoriusS.E.ZakiS.R.DavisB.S.ChangG.J.BowenR.A.BraultA.C.Frequent" exact="Zika" post="Virus Sexual Transmission and Prolonged Viral RNA Shedding in"/>
   <result pre="Immunodeficient Mouse ModelCell Rep.2017181751176010.1016/j.celrep.2017.01.05628199846 54.GunawardanaS.A.ShawR.H.Cross-reactive dengue virus-derived monoclonal antibodies to" exact="Zika" post="virus envelope protein: Panacea or Pandora’s box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531"/>
   <result pre="or Pandora’s box?BMC Infect. Dis.20181864110.1186/s12879-018-3572-030526531 55.LiM.ZhaoL.ZhangC.WangX.HongW.SunJ.LiuR.WangJ.ZhangF.JinX.et al.Dengue immune sera enhance" exact="Zika" post="virus infection in human peripheral blood monocytes through Fc"/>
   <result pre="of dengue virusCurr. Opin. Virol.2019361810.1016/j.coviro.2019.02.00230844538 58.SapparapuG.FernandezE.KoseN.BinC.FoxJ.M.BombardiR.G.FremontD.H.DoranzB.J.DiamondM.S.CroweJ.E.et al.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature201654044344710.1038/nature2056427819683 Figure 1"/>
   <result pre="erythromycin estolate (Ery-Est) and Ery and their inhibitory activity against" exact="Zika" post="virus (ZIKV) in different cell types. (A) The molecular"/>
   <result pre="Ery. (B) BHK21 cells (2 × 106) were infected by" exact="ZIKV" post="strain SZ01 that were treated with serial concentrations of"/>
   <result pre="(D) U-251 MG cells (2 × 105) were infected by" exact="ZIKV" post="treated with different concentrations of Ery-Est and Ery. The"/>
   <result pre="BHK21 and Vero cells (2 × 105) were infected with" exact="ZIKV" post="strain SZ01 and treated by Ery-Est and Ery, then"/>
   <result pre="strain SZ01 and treated by Ery-Est and Ery, then the" exact="ZIKV" post="infection was evaluated by immunofluorescence staining after 4 days."/>
   <result pre="ZIKV infection was evaluated by immunofluorescence staining after 4 days." exact="ZIKV" post="E protein were stained by mAb 4G2 (green); nuclei"/>
   <result pre="its cytotoxicity. BHK21 cells (2 × 106) were infected by" exact="ZIKV" post="strains (A) FLR, (B) MR766, (C) DENV II, and"/>
   <result pre="were infected by ZIKV strains (A) FLR, (B) MR766, (C)" exact="DENV" post="II, and (D) YFV 17D with the treatment of"/>
   <result pre="strains (A) FLR, (B) MR766, (C) DENV II, and (D)" exact="YFV" post="17D with the treatment of serial concentrations of Ery-Est"/>
   <result pre="0.001; **** p &amp;lt; 0.0001. Figure 3 Early stages of" exact="ZIKV" post="infection were inhibited by Ery-Est. (A) BHK21 cells (2"/>
   <result pre="Ery-Est. (A) BHK21 cells (2 × 106) were infected with" exact="ZIKV" post="SZ01 and Ery-Est was added at different time points"/>
   <result pre="viral lifecycle. In the entry experiment, cells were infected with" exact="ZIKV" post="SZ01 in the presence of Ery-Est, Azi, Ery, or"/>
   <result pre="four experiments were evaluated by plaque assay. (C) ZIKV, (D)" exact="DENV" post="II, and (E) YFV 17D were respectively treated by"/>
   <result pre="by plaque assay. (C) ZIKV, (D) DENV II, and (E)" exact="YFV" post="17D were respectively treated by Ery-Est at 37 °C"/>
   <result pre="measured for their infectivity. Degradation of released genomic RNA of" exact="ZIKV" post="treated by (F) Ery-Est or (G) Ery in an"/>
   <result pre="protein was detected. The separation of E protein and of" exact="ZIKV" post="treated by Ery-Est, Ery, 1% DMSO, and Triton X-100"/>
   <result pre="p &amp;lt; 0.0001. Figure 4 Protective activity of Ery-Est against" exact="ZIKV" post="infection in lethal mouse models. Three groups of A129"/>
   <result pre="50 mg/kg respectively (n = 8). Mice administrated with heat-inactivated" exact="ZIKV" post="(iZIKV) or only administrated with Ery-Est and Ery were"/>
   <result pre="Figure 5 Protective activity of Ery-Est against vertical transmission of" exact="ZIKV" post="in pregnant C57BL/6 mice. C57BL/6 pregnant mice were infected"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893437\results\search\tropicalVirus\results.xml">
   <result pre="next-generation SOMAscan version 1.3, which measures &amp;gt;1300 proteins, to measure" exact="Zika" post="virus-induced proteomic alterations in Vero cells [23] and in"/>
   <result pre="SSM-002, Rev. 4SOMAScanVenice, Italy2017 23.GloverK.K.M.GaoA.CoombsK.M.Vero cell proteomic changes induced by" exact="Zika" post="virus infectionProteomics201919e180030910.1002/pmic.20180030930578658 24.XieH.WanX.F.YeZ.P.PlantE.P.ZhaoY.Q.XuY.F.LiX.FinchC.ZhaoN.KawanoT.et al.H3N2 mismatch of 2014–2015 Northern hemisphere"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893470\results\search\tropicalVirus\results.xml">
   <result pre="model viral distributions, although most research has focused on the" exact="West Nile" post="virus. Direct temperature effects are frequently observed, as are"/>
   <result pre="genotype and temperature have been completed with dengue, chikungunya and" exact="Zika" post="viruses [52,53,54,55,56,57,58,59]. A recent study by Tesla et al."/>
   <result pre="[52,53,54,55,56,57,58,59]. A recent study by Tesla et al. which studied" exact="Zika" post="virus competence at a temperature range from 16.0–38.0 °C"/>
   <result pre="Murray valley encephalitis virus (MVEV) in Cx. annulirostris [61] or" exact="West Nile" post="virus (WNV) in Cx. tarsalis [62]. These relationships could"/>
   <result pre="decrease populations of Cx. restuans, involved in early-season amplification of" exact="WNV" post="[115]. Vector distribution can also lead to non-intuitive patterns"/>
   <result pre="models [3], and Susceptible-Infectious-Recovered (SIR) and Susceptible-Exposed-Infectious-Recovered (SEIR) models [3,124,151,161,162,163,164,165,166,167]." exact="West Nile" post="virus is by far the most studied enzootic arbovirus"/>
   <result pre="studied enzootic arbovirus (Table 3). Models have been reviewed for" exact="WNV" post="[15,149,163,168], Japanese encephalitis virus (JEV) [15,16,20], RVFV [14,15], RRV"/>
   <result pre="typically associated with an increase in arboviral activity. For example," exact="WNV" post="infection rates north of 30° N, have been associated"/>
   <result pre="tropics, where there is concern that the Kunjin strain of" exact="WNV" post="will shift further south in Australia [205,206]. Low temperatures"/>
   <result pre="many arboviruses. Low temperatures are generally thought to be limiting" exact="WNV" post="expansion northward [25,32,143,207,208,209,210,211]. Further, high temperatures have been observed"/>
   <result pre="observed to aid in the establishment of arboviruses. For example," exact="WNV" post="often invaded new locations following heatwaves [44], but once"/>
   <result pre="[27,212]. Indeed, simulations found that temperature was more important in" exact="WNV" post="establishment than mosquito population composition (i.e., biotype ratio of"/>
   <result pre="temperatures (18 °C), mosquito-to-host ratio has a greater influence on" exact="WNV" post="establishment [32]. Similarly, amplification of SLEV was estimated to"/>
   <result pre="range. For instance, high temperatures have been predicted to limit" exact="WNV" post="in subtropical regions [117]. WEEV risk has been predicted"/>
   <result pre="to 27 °C [219]. Data on Cx. quinquefasciatus suggests that" exact="WNV" post="will decline in some portions of its Southern range"/>
   <result pre="with a strong association between drought and drier conditions and" exact="WNV" post="[150,180,227,228,229,230,231] and SLEV [174,201,232,233]. Increased snow depth was predictive"/>
   <result pre="change, due to increasing temperatures. Migratory birds with antibodies to" exact="WNV" post="already arrive in northern Europe (Sweden) [236], demonstrating that"/>
   <result pre="that dispersal is not limiting arboviral activity in these locations." exact="WNV" post="is expected to increase in Europe, even in locations"/>
   <result pre="drought expected under climate change has the potential to triple" exact="WNV" post="cases over a 30-year time frame in locations where"/>
   <result pre="contrast, increased rainfall has been predicted to lead to decreased" exact="WNV" post="in some regions despite temperature increases [208]. Increasing temperatures"/>
   <result pre="in the model [169]. 5.3. Case Study: Season-Specific Effects in" exact="West Nile" post="Virus in Temperate Regions The role of temperature across"/>
   <result pre="5.3.1. Winter Temperatures Warmer winter temperatures have been associated with" exact="WNV" post="across the continental US [155,179], Russia [186,187] and in"/>
   <result pre="to halt viral replication (e.g., 14.3 °C or below for" exact="WNV" post="in Cx. tarsalis [44]), although infections in mosquitoes persist"/>
   <result pre="Spring Temperatures Warm and dry springs have been associated with" exact="WNV" post="[154], especially maximum temperatures, which are likely associated with"/>
   <result pre="amplification [149]. Temperature in May and June were linked to" exact="WNV" post="in Russia [186]. Early-season temperatures were predictive of human"/>
   <result pre="5.3.3. Summer Temperatures Above average summer temperatures likely contributed to" exact="WNV" post="epidemics in 2002–2004 [44] and hot dry summers were"/>
   <result pre="and hot dry summers were also identified as associated with" exact="WNV" post="foci in Connecticut, while warm wet summers were associated"/>
   <result pre="warm wet summers were associated with more distributed cases of" exact="WNV" post="[242]. Minimum summer temperature was found to predict human"/>
   <result pre="Increased temperatures at a two-week lag interval were associated with" exact="WNV" post="in Suffolk County, NY [152] and Nassau County, NY"/>
   <result pre="NY [153]. August and September temperatures were associated with increased" exact="WNV" post="incidence in Russia [186]. Increased summer temperatures were associated"/>
   <result pre="incidence in Russia [186]. Increased summer temperatures were associated with" exact="West Nile" post="fever in Europe [184,189]. In Romania, temperatures twenty days"/>
   <result pre="In Romania, temperatures twenty days earlier were found to increase" exact="WNV" post="infection rates [227]. High temperature anomalies in July were"/>
   <result pre="rates [227]. High temperature anomalies in July were linked to" exact="WNV" post="outbreaks in Europe [184,243]. In contrast, in West Texas,"/>
   <result pre="cool summer following a wet spring was associated with increased" exact="WNV" post="cases [244]. In locations with high summer temperatures (i.e.,"/>
   <result pre="locations with high summer temperatures (i.e., deserts), habitat suitability for" exact="WNV" post="may be low during the summer [245]. In South"/>
   <result pre="In South Africa, an increase in minimum summer temperature decreased" exact="WNV" post="infection rates [173]. Similarly, summer temperatures have also been"/>
   <result pre="temperatures in the fall have the potential to end the" exact="West Nile" post="virus season. However, late season temperatures associated with the"/>
   <result pre="However, late season temperatures associated with the end of the" exact="WNV" post="season have generally not been retained in final models"/>
   <result pre="season have generally not been retained in final models of" exact="WNV" post="risk [e.g., 149]. One explanation for this is that"/>
   <result pre="but not in governing dynamics within that range. For example," exact="WNV" post="frequently increased with increasing temperature, even in locations where"/>
   <result pre="non-linear temperature relationships are important [57], have been observed for" exact="WNV" post="[183], and can be accounted for in analyses of"/>
   <result pre="reemerging mosquito-borne viral disease in EuropeEmerg. Infect. Dis.1999564365010.3201/eid0505.99050510511520 25.ReisenW.K.Ecology of" exact="West Nile" post="virus in North AmericaViruses201352079210510.3390/v509207924008376 26.ChanceyC.GrinevA.VolkovaE.RiosM.The global ecology and epidemiology"/>
   <result pre="virus in North AmericaViruses201352079210510.3390/v509207924008376 26.ChanceyC.GrinevA.VolkovaE.RiosM.The global ecology and epidemiology of" exact="West Nile" post="virusBioMed. Res. Int.2015201510.1155/2015/376230 27.PazS.Climate change impacts on West Nile"/>
   <result pre="of West Nile virusBioMed. Res. Int.2015201510.1155/2015/376230 27.PazS.Climate change impacts on" exact="West Nile" post="virus transmission in a global contextPhil. Trans. R. Soc."/>
   <result pre="incubation rate is not accelerated in recent California strains of" exact="West Nile" post="virus in Culex tarsalis (Diptera: Culicidae)J. Med. Entomol.2015521083108910.1093/jme/tjv08226336222 32.VogelsC.B.F.HarteminkN.KoenraadtC.J.M.Modelling"/>
   <result pre="Nile virus in Culex tarsalis (Diptera: Culicidae)J. Med. Entomol.2015521083108910.1093/jme/tjv08226336222 32.VogelsC.B.F.HarteminkN.KoenraadtC.J.M.Modelling" exact="West Nile" post="virus transmission risk in Europe: effect of temperature and"/>
   <result pre="competence of northern European Culex pipiens biotypes and hybrids for" exact="West Nile" post="virus is differentially affected by temperatureParasit Vectors2016939310.1186/s13071-016-1677-027388451 34.TurellM.J.RossiC.A.BaileyC.L.Effect of"/>
   <result pre="Trop. Med. Hyg.19934967267610.4269/ajtmh.1993.49.6728279634 37.KilpatrickA.M.MeolaM.A.MoudyR.M.KramerL.D.Temperature, viral genetics, and the transmission of" exact="West Nile" post="virus by Culex pipiens mosquitoesPLoS Pathog.20084e100009210.1371/journal.ppat.100009218584026 38.AndersonS.L.RichardsS.L.TabachnickW.J.SmarttC.T.Effects of West"/>
   <result pre="West Nile virus by Culex pipiens mosquitoesPLoS Pathog.20084e100009210.1371/journal.ppat.100009218584026 38.AndersonS.L.RichardsS.L.TabachnickW.J.SmarttC.T.Effects of" exact="West Nile" post="virus dose and extrinsic incubation temperature on temporal progression"/>
   <result pre="vector competence of Culex pipiens quinquefasciatus Say (Diptera: Culicidae) for" exact="West Nile" post="virusVector Borne Zoonotic Dis.2007762963610.1089/vbz.2007.010118021028 40.HurlbutH.S.The effect of environmental temperature"/>
   <result pre="on the vector competence of Culex univittatus (Diptera: Culicidae) for" exact="West Nile" post="virusJ. Med. Entomol.19933044945610.1093/jmedent/30.2.4498459423 42.TakahashiM.The effects of environmental and physiological"/>
   <result pre="on the ability of Culex pipiens (Diptera: Culicidae) to transmit" exact="West Nile" post="virusJ. Med. Entomol.20023922122510.1603/0022-2585-39.1.22111931261 44.ReisenW.K.FangY.MartinezV.M.Effects of Temperature on the Transmission"/>
   <result pre="virusJ. Med. Entomol.20023922122510.1603/0022-2585-39.1.22111931261 44.ReisenW.K.FangY.MartinezV.M.Effects of Temperature on the Transmission of" exact="West Nile" post="Virus by Culex tarsalis (Diptera: Culicidae)J. Med. Entomol.20064330931710.1093/jmedent/43.2.30916619616 45.KayB.JenningsC.Enhancement"/>
   <result pre="Hyg.195562295305 48.DanforthM.E.ReisenW.K.BarkerC.M.The impact of cycling temperature on the transmission of" exact="West Nile" post="virusJ. Med. Entomol.20165368168610.1093/jme/tjw01327026160 49.BrubakerJ.F.TurellM.J.Effect of environmental temperature on the"/>
   <result pre="Entomol.19983591892110.1093/jmedent/35.6.9189835680 50.CiotaA.T.StyerL.M.MeolaM.A.KramerL.D.The costs of infection and resistance as determinants of" exact="West Nile" post="virus susceptibility in Culex mosquitoesBMC Ecol.2011112310.1186/1472-6785-11-2321975028 51.KramerL.D.HardyJ.L.PresserS.B.HoukE.J.Dissemination barriers for"/>
   <result pre="Aedes aegypti in ArgentinaAm. J. Trop. Med. Hyg.20189941742410.4269/ajtmh.18-009729869610 54.TeslaB.DemakovskyL.R.MordecaiE.A.RyanS.J.BondsM.H.NgonghalaC.N.BrindleyM.A.MurdockC.C.Temperature drives" exact="Zika" post="virus transmission: evidence from empirical and mathematical modelsProc. Biol."/>
   <result pre="and the susceptibility of Aedes albopictus Skuse (Diptera: Culicidae) to" exact="Chikungunya" post="virusVector Borne Zoonotic Dis.20101024124710.1089/vbz.2009.003519725768 61.KayB.H.FanningI.D.MottramP.Rearing temperature influences flavivirus vector"/>
   <result pre="Entomol.1989341542210.1111/j.1365-2915.1989.tb00249.x2562419 62.DodsonB.L.KramerL.D.RasgonJ.L.Effects of larval rearing temperature on immature development and" exact="West Nile" post="virus vector competence of Culex tarsalisParasit Vectors2012519910.1186/1756-3305-5-19922967798 63.MuturiE.J.AltoB.W.Larval environmental"/>
   <result pre="Trop. Dis.20137e223910.1371/journal.pntd.000223923738025 72.SpanoudisC.G.AndreadisS.S.TsaknisN.K.PetrouA.P.GkekaC.D.Savopoulou–SoultaniM.Effect of Temperature on Biological Parameters of the" exact="West Nile" post="Virus Vector Culex pipiens form ‘molestus’ (Diptera: Culicidae) in"/>
   <result pre="adult longevity of Culex pipiens f. pipiens, vector of the" exact="West Nile" post="VirusParasitol. Res.20141134315431910.1007/s00436-014-4152-x25284257 83.AltoB.W.RichardsS.L.AndersonS.L.LordC.C.Survival of West Nile virus-challenged Southern house"/>
   <result pre="pipiens, vector of the West Nile VirusParasitol. Res.20141134315431910.1007/s00436-014-4152-x25284257 83.AltoB.W.RichardsS.L.AndersonS.L.LordC.C.Survival of" exact="West Nile" post="virus-challenged Southern house mosquitoes, Culex pipiens quinquefasciatus, in relation"/>
   <result pre="(Diptera: Culicidae)J. Med. Entomo.20003770170610.1603/0022-2585-37.5.70111004781 96.CiotaA.T.EhrbarD.J.MatacchieroA.C.Van SlykeG.A.KramerL.D.The evolution of virulence of" exact="West Nile" post="virus in a mosquito vector: implications for arbovirus adaptation"/>
   <result pre="valley, southeast AustraliaMed. Vet. Entomol.19961037538410.1111/j.1365-2915.1996.tb00760.x8994141 115.ChuangT.-W.KnepperR.G.StanuszekW.W.WalkerE.D.WilsonM.L.Temporal and Spatial Patterns of" exact="West Nile" post="Virus Transmission in Saginaw County, Michigan, 2003–2006J. Med. Entomol.2011481047105610.1603/ME1013821936324"/>
   <result pre="human healthInt. J. Parasitol.19982895596910.1016/S0020-7519(98)00053-89673874 117.MorinC.W.ComrieA.C.Regional and seasonal response of a" exact="West Nile" post="virus vector to climate changeProc. Natl. Acad. Sci. USA2013110156201562510.1073/pnas.130713511024019459"/>
   <result pre="on Culex pipiens population abundance and on the probability of" exact="West Nile" post="Fever outbreaks (Israeli case study: 2001–2005)EcoHealth20085404810.1007/s10393-007-0150-018648796 119.YooE.-H.Exploring space-time models"/>
   <result pre="Fever outbreaks (Israeli case study: 2001–2005)EcoHealth20085404810.1007/s10393-007-0150-018648796 119.YooE.-H.Exploring space-time models for" exact="West Nile" post="virus mosquito abundance dataAppl. Geogr.20134520321010.1016/j.apgeog.2013.09.007 120.YooE.-H.ChenD.DiaoC.RussellC.The Effects of Weather"/>
   <result pre="dataAppl. Geogr.20134520321010.1016/j.apgeog.2013.09.007 120.YooE.-H.ChenD.DiaoC.RussellC.The Effects of Weather and Environmental Factors on" exact="West Nile" post="Virus Mosquito Abundance in Greater Toronto AreaEarth Interact.20162012210.1175/EI-D-15-0003.130026656 121.RosaR.MariniG.BolzoniL.NetelerM.MetzM.DelucchiL.ChadwickE.A.BalboL.MoscaA.GiacobiniM.et"/>
   <result pre="Abundance in Greater Toronto AreaEarth Interact.20162012210.1175/EI-D-15-0003.130026656 121.RosaR.MariniG.BolzoniL.NetelerM.MetzM.DelucchiL.ChadwickE.A.BalboL.MoscaA.GiacobiniM.et al.Early warning of" exact="West Nile" post="virus mosquito vector: climate and land use models successfully"/>
   <result pre="Fever in Barkedji, SenegalPLoS ONE20149e11404710.1371/journal.pone.011404725437856 128.ConleyA.K.FullerD.O.HaddadN.HassanA.N.GadA.M.BeierJ.C.Modeling the distribution of the" exact="West Nile" post="and Rift Valley Fever vector Culex pipiens in arid"/>
   <result pre="assessment of Aedes aegypti and Culex quinquefasciatus: a scenario of" exact="Zika" post="virus exposureEpidemiol. Infect.2019147e5210.1017/S095026881800310230474578 133.KamalM.KenawyM.A.RadyM.H.KhaledA.S.SamyA.M.Mapping the global potential distributions of"/>
   <result pre="and determination of the zones susceptible to the development of" exact="Zika" post="virusActa Trop.2017168809028111132 136.MessinaJ.P.KraemerM.U.G.BradyO.J.PigottD.M.ShearerF.M.WeissD.J.GoldingN.RuktanoncharC.W.GethingP.W.CohnE.et al.Mapping global environmental suitability for Zika"/>
   <result pre="of Zika virusActa Trop.2017168809028111132 136.MessinaJ.P.KraemerM.U.G.BradyO.J.PigottD.M.ShearerF.M.WeissD.J.GoldingN.RuktanoncharC.W.GethingP.W.CohnE.et al.Mapping global environmental suitability for" exact="Zika" post="viruseLife20165e1527210.7554/eLife.1527227090089 137.CampbellL.P.LutherC.Moo-LlanesD.RamseyJ.M.Danis-LozanoR.PetersonA.T.Climate change influences on global distributions of dengue"/>
   <result pre="global potential distribution of the mosquito Culex quinquefasciatus, vector of" exact="West Nile" post="virus and lymphatic filariasisPLoS ONE201611e016386310.1371/journal.pone.016386327695107 142.FarajollahiA.FonsecaD.M.KramerL.D.KilpatrickA.M.&quot;Bird biting�? mosquitoes and"/>
   <result pre="on Newfoundland’s Avalon PeninsulaJ. Med. Entomol.2016531364136910.1093/jme/tjw10527592550 146.MorinC.W.ComrieA.C.Modeled response of the" exact="West Nile" post="virus vector Culex quinquefasciatus to changing climate using the"/>
   <result pre="ONE201510e014048610.1371/journal.pone.014048626466364 148.YoungS.G.TullisJ.A.CothrenJ.A remote sensing and GIS-assisted landscape epidemiology approach to" exact="West Nile" post="virusAppl. Geogr.20134524124910.1016/j.apgeog.2013.09.022 149.KeyelA.C.Elison TimmO.BackensonP.B.PrussingC.QuinonesS.McDonoughK.A.VuilleM.ConnJ.E.ArmstrongP.M.AndreadisT.G.et al.Seasonal temperatures and hydrological conditions"/>
   <result pre="TimmO.BackensonP.B.PrussingC.QuinonesS.McDonoughK.A.VuilleM.ConnJ.E.ArmstrongP.M.AndreadisT.G.et al.Seasonal temperatures and hydrological conditions improve the prediction of" exact="West Nile" post="virus infection rates in Culex mosquitoes and human case"/>
   <result pre="and ConnecticutPLoS ONE201914e021785410.1371/journal.pone.021785431158250 150.RuizM.O.ChavesL.F.HamerG.L.SunT.BrownW.M.WalkerE.D.HaramisL.GoldbergT.L.KitronU.D.Local impact of temperature and precipitation on" exact="West Nile" post="virus infection in Culex species mosquitoes in northeast Illinois,"/>
   <result pre="northeast Illinois, USAParasit Vectors201031910.1186/1756-3305-3-1920302617 151.DeFeliceN.B.SchneiderZ.D.LittleE.BarkerC.CaillouetK.A.CampbellS.R.DamianD.IrwinP.JonesH.M.P.TownsendJ.et al.Use of temperature to improve" exact="West Nile" post="virus forecastsPLoS Comput. Biol.201814e100640710.1371/journal.pcbi.100604729522514 152.MyerM.H.CampbellS.R.JohnstonJ.M.Spatiotemporal modeling of ecological and"/>
   <result pre="Comput. Biol.201814e100640710.1371/journal.pcbi.100604729522514 152.MyerM.H.CampbellS.R.JohnstonJ.M.Spatiotemporal modeling of ecological and sociological predictors of" exact="West Nile" post="virus in Suffolk County, NY, mosquitoesEcosphere20178e0185410.1002/ecs2.185430147987 153.MyerM.H.JohnstonJ.M.Spatiotemporal Bayesian modeling"/>
   <result pre="virus in Suffolk County, NY, mosquitoesEcosphere20178e0185410.1002/ecs2.185430147987 153.MyerM.H.JohnstonJ.M.Spatiotemporal Bayesian modeling of" exact="West Nile" post="virus: Identifying risk of infection in mosquitoes with local-scale"/>
   <result pre="154.LittleE.CampbellS.R.ShamanJ.Development and validation of a climate-based ensemble prediction model for" exact="West Nile" post="Virus infection rates in Culex mosquitoes, Suffolk County, New"/>
   <result pre="YorkParasit Vectors2016944310.1186/s13071-016-1720-127507279 155.ManoreC.A.DavisJ.K.ChristoffersonR.C.WessonD.M.HymanJ.M.MoresC.N.Towards an early warning system for forecasting human" exact="West Nile" post="virus incidencePLoS Curr.2014610.1371/currents.outbreaks.f0b3978230599a56830ce30cb9ce0500 156.DavisJ.K.VincentG.P.HildrethM.B.KightlingerL.CarlsonC.WimberlyM.C.Improving the prediction of arbovirus outbreaks:"/>
   <result pre="prediction of arbovirus outbreaks: A comparison of climate-driven models for" exact="West Nile" post="virus in an endemic region of the United StatesActa"/>
   <result pre="Rep.201774018610.1038/srep4018628071683 158.SoverowJ.E.WelleniusG.A.FismanD.N.MittlemanM.A.Infectious disease in a warming world: how weather influenced" exact="West Nile" post="virus in the United States (2001–2005)Environ. Health Perspect.2009117104910.1289/ehp.080048719654911 159.TrawinskiP.MackayD.Meteorologically"/>
   <result pre="United States (2001–2005)Environ. Health Perspect.2009117104910.1289/ehp.080048719654911 159.TrawinskiP.MackayD.Meteorologically conditioned time-series predictions of" exact="West Nile" post="virus vector mosquitoesVector Borne Zoonotic Dis.2008850552210.1089/vbz.2007.020218279008 160.PohK.C.ChavesL.F.Reyna-NavaM.RobertsC.M.FredregillC.BuenoR.Jr.DebbounM.HamerG.L.The influence of"/>
   <result pre="weather and weather variability on mosquito abundance and infection with" exact="West Nile" post="virus in Harris County, Texas, USASci. Total Environ.201967526027210.1016/j.scitotenv.2019.04.10931030133 161.HartleyD.M.BarkerC.M.Le"/>
   <result pre="Environ.201967526027210.1016/j.scitotenv.2019.04.10931030133 161.HartleyD.M.BarkerC.M.Le MenachA.NiuT.GaffH.D.ReisenW.K.Effects of Temperature on Emergence and Seasonality of" exact="West Nile" post="Virus in CaliforniaAm. J. Trop. Med. Hyg.20128688489410.4269/ajtmh.2012.11-034222556092 162.KioutsioukisI.StilianakisN.I.Assessment of"/>
   <result pre="163.LaperriereV.BruggerK.RubelF.Simulation of the seasonal cycles of bird, equine and human" exact="West Nile" post="virus casesPrev. Vet. Med.2011989911010.1016/j.prevetmed.2010.10.01321093946 164.Lo IaconoG.CunninghamA.A.BettB.GraceD.ReddingD.W.WoodJ.L.N.Environmental limits of Rift"/>
   <result pre="virus transmissioneLife20187e3776210.7554/eLife.3776230152328 168.BarkerC.M.Models and Surveillance Systems to Detect and Predict" exact="West Nile" post="Virus OutbreaksJ. Med. Entomol.2019561508151510.1093/jme/tjz15031549727 169.NaishS.MengersenK.HuW.TongS.Forecasting the Future Risk of"/>
   <result pre="factors explaining a peculiar disease patternEpidemiol. Infect.200212933534510.1017/S095026880200740912403109 173.UejioC.K.KempA.ComrieA.C.Climatic Controls on" exact="West Nile" post="Virus and Sindbis Virus Transmission and Outbreaks in South"/>
   <result pre="virus infectionParasit Vectors20171050110.1186/s13071-017-2482-029047412 179.HahnM.B.MonaghanA.J.HaydenM.H.EisenR.J.DeloreyM.J.LindseyN.P.NasciR.S.FischerM.Meteorological conditions associated with increased incidence of" exact="West Nile" post="virus disease in the United States, 2004–2012Am. J. Trop."/>
   <result pre="and hydrological influences on the spatial and temporal prevalence of" exact="West Nile" post="virus in Culex mosquitoes, Suffolk County, New YorkJ. Med."/>
   <result pre="New YorkJ. Med. Entomol.20114886787510.1603/ME1026921845947 181.LiuA.LeeV.GalushaD.SladeM.D.Diuk-WasserM.AndreadisT.ScotchM.RabinowitzP.M.Risk factors for human infection with" exact="West Nile" post="Virus in Connecticut: A multi-year analysisInt. J. Health Geogr.200986710.1186/1476-072X-8-6719943935"/>
   <result pre="Role of Hydrogeography and Climate in the Landscape Epidemiology of" exact="West Nile" post="Virus in New York State from 2000 to 2010PLoS"/>
   <result pre="vector-host contact (VHC) ratios and ecological niche modeling of the" exact="West Nile" post="virus mosquito vector, Culex quinquefasciatus, in the City of"/>
   <result pre="LA, USAInt. J. Environ. Res. Public Health20171489210.3390/ijerph1408089228786934 184.TranA.SudreB.PazS.RossiM.DesbrosseA.ChevalierV.SemenzaJ.C.Environmental predictors of" exact="West Nile" post="fever risk in EuropeInt. J. Health Geogr.2014132610.1186/1476-072X-13-2624986363 185.PazS.The West"/>
   <result pre="West Nile fever risk in EuropeInt. J. Health Geogr.2014132610.1186/1476-072X-13-2624986363 185.PazS.The" exact="West Nile" post="Virus outbreak in Israel (2000) from a new perspective:"/>
   <result pre="of climate changeInt. J. Environ. Health Res.20061611310.1080/0960312050039240016507476 186.PlatonovA.E.TolpinV.A.GridnevaK.A.TitkovA.V.PlatonovaO.V.KolyasnikovaN.M.BusaniL.RezzaG.The Incidence of" exact="West Nile" post="Disease in Russia in Relation to Climatic and Environmental"/>
   <result pre="and Environmental FactorsInt. J. Environ. Res. Public Health2014111211123210.3390/ijerph11020121124464233 187.PlatonovA.E.FedorovaM.V.KaranL.S.ShopenskayaT.A.PlatonovaO.V.ZhuravlevV.I.Epidemiology of" exact="West Nile" post="infection in Volgograd, Russia, in relation to climate change"/>
   <result pre="Culicidae) bionomicsParasitol. Res.2008103455310.1007/s00436-008-1050-0 188.BakonyiT.FerencziE.ErdelyiK.KutasiO.CsoergoT.SeidelB.WeissenboeckH.BruggerK.BanE.NowotnyN.Explosive spread of a neuroinvasive lineage 2" exact="West Nile" post="virus in Central Europe, 2008/2009Vet. Microbiol.2013165617010.1016/j.vetmic.2013.03.00523570864 189.MarcantonioM.RizzoliA.MetzM.RosaR.MariniG.ChadwickE.NetelerM.Identifying the Environmental"/>
   <result pre="in Central Europe, 2008/2009Vet. Microbiol.2013165617010.1016/j.vetmic.2013.03.00523570864 189.MarcantonioM.RizzoliA.MetzM.RosaR.MariniG.ChadwickE.NetelerM.Identifying the Environmental Conditions Favouring" exact="West Nile" post="Virus Outbreaks in EuropePLoS ONE201510e012115810.1371/journal.pone.012115825803814 190.DavisJ.K.VincentG.HildrethM.B.KightlingerL.CarlsonC.WimberlyM.C.Integrating Environmental monitoring and"/>
   <result pre="mosquito surveillance to predict vector-borne disease: prospective forecasts of a" exact="West Nile" post="virus outbreakPLoS Curr.2017910.1371/currents.outbreaks.90e80717c4e67e1a830f17feeaaf85de 191.GibbsS.WimberlyM.MaddenM.MasourJ.YabsleyM.StallknechtD.Factors affecting the geographic distribution of"/>
   <result pre="Nile virus outbreakPLoS Curr.2017910.1371/currents.outbreaks.90e80717c4e67e1a830f17feeaaf85de 191.GibbsS.WimberlyM.MaddenM.MasourJ.YabsleyM.StallknechtD.Factors affecting the geographic distribution of" exact="West Nile" post="virus in Georgia, USA: 2002–2004Vector Borne Zoonotic Dis.20066738210.1089/vbz.2006.6.7316584329 192.ChenC.-C.EppT.JenkinsE.WaldnerC.CurryP.S.SoosC.Modeling"/>
   <result pre="192.ChenC.-C.EppT.JenkinsE.WaldnerC.CurryP.S.SoosC.Modeling Monthly Variation of Culex tarsalis (Diptera: Culicidae) Abundance and" exact="West Nile" post="Virus Infection Rate in the Canadian PrairiesInt. J. Environ."/>
   <result pre="J. Environ. Res. Public Health2013103033305110.3390/ijerph1007303323880728 193.EppT.Y.WaldnerC.L.BerkeO.Predicting Geographical Human Risk of" exact="West Nile" post="Virus—Saskatchewan, 2003 and 2007Can. J. Public Health200910034434810.1007/BF0340526619994734 194.BaiY.XuZ.ZhangJ.MaoD.LuoC.HeY.LiangG.LuB.BisesiM.S.SunQ.et al.Regional"/>
   <result pre="Australian mosquito species in the transmission of endemic and exotic" exact="West Nile" post="virus strainsInt. J. Environ. Res. Public Health2013103735375210.3390/ijerph1008373523965926 207.HooverK.C.BarkerC.M.West Nile"/>
   <result pre="vulnerabilityWiley Interdiscip. Rev. Clim. Chang.2016728330010.1002/wcc.382 208.HarriganR.J.ThomassenH.A.BuermannW.SmithT.B.A continental risk assessment of" exact="West Nile" post="virus under climate changeGlob. Chang. Biol.2014202417242510.1111/gcb.1253424574161 209.SemenzaJ.C.TranA.EspinosaL.SudreB.DomanovicD.PazS.Climate change projections"/>
   <result pre="virus under climate changeGlob. Chang. Biol.2014202417242510.1111/gcb.1253424574161 209.SemenzaJ.C.TranA.EspinosaL.SudreB.DomanovicD.PazS.Climate change projections of" exact="West Nile" post="virus infections in Europe: implications for blood safety practicesEnviron."/>
   <result pre="and Warrants Increased SurveillancePLoS Negl. Trop. Dis.20159e000395610.1371/journal.pntd.000395626225555 211.ChenC.C.JenkinsE.EppT.WaldnerC.CurryP.S.SoosC.Climate change and" exact="West Nile" post="virus in a highly endemic region of North AmericaInt."/>
   <result pre="North AmericaInt. J. Environ. Res. Public Health2013103052307110.3390/ijerph1007305223880729 212.PazS.SemenzaJ.C.Environmental drivers of" exact="West Nile" post="fever epidemiology in Europe and Western Asia—A reviewInt. J."/>
   <result pre="and Environmental Variables in NepalPLoS ONE20116e2219210.1371/journal.pone.002219221811573 227.CotarA.I.FalcutaE.PrioteasaL.F.DinuS.CeianuC.S.PazS.Transmission Dynamics of the" exact="West Nile" post="Virus in Mosquito Vector Populations under the Influence of"/>
   <result pre="the Danube Delta, RomaniaEcoHealth20161379680710.1007/s10393-016-1176-y27709311 228.ShamanJ.DayJ.F.StieglitzM.Drought-induced amplification and epidemic transmission of" exact="West Nile" post="virus in southern FloridaJ. Med. Entomol.20054213414110.1093/jmedent/42.2.13415799522 229.PaullS.H.HortonD.E.AshfaqM.RastogiD.KramerL.D.DiffenbaughN.S.KilpatrickA.M.Drought and immunity"/>
   <result pre="FloridaJ. Med. Entomol.20054213414110.1093/jmedent/42.2.13415799522 229.PaullS.H.HortonD.E.AshfaqM.RastogiD.KramerL.D.DiffenbaughN.S.KilpatrickA.M.Drought and immunity determine the intensity of" exact="West Nile" post="virus epidemics and climate change impactsProc. R. Soc. B20172842016207810.1098/rspb.2016.2078"/>
   <result pre="impactsProc. R. Soc. B20172842016207810.1098/rspb.2016.2078 230.JohnsonB.J.SukhdeoM.V.K.Drought-Induced Amplification of Local and Regional" exact="West Nile" post="Virus Infection Rates in New JerseyJ. Med. Entomol.20135019520410.1603/ME1203523427670 231.DayJ.F.ShamanJ.Using"/>
   <result pre="widespread epidemic in south Florida, USAJ. Med. Entomol.19993661462410.1093/jmedent/36.5.61410534957 236.JourdainE.OlsenB.LundkvistA.HubálekZ.ŠikutováS.WaldenströmJ.KarlssonM.WahlströmM.JozanM.FalkK.I.Surveillance for" exact="West Nile" post="virus in wild birds from northern EuropeVector Borne Zoonotic"/>
   <result pre="diapausing female Culex tarsalis (Diptera: Culicidae)J. Med. Entomol.20023922623310.1603/0022-2585-39.1.22611931262 240.Montecino-LatorreD.BarkerC.M.Overwintering of" exact="West Nile" post="virus in a bird community with a communal crow"/>
   <result pre="bird community with a communal crow roostSci. Rep.20188608810.1038/s41598-018-24133-429666401 241.ReisenW.K.WheelerS.S.Overwintering of" exact="West Nile" post="Virus in the United StatesJ. Med. Entomol.2019561498150710.1093/jme/tjz07031549726 242.AndreadisT.G.AndersonJ.F.VossbrinckC.R.MainA.J.Epidemiology of"/>
   <result pre="Nile Virus in the United StatesJ. Med. Entomol.2019561498150710.1093/jme/tjz07031549726 242.AndreadisT.G.AndersonJ.F.VossbrinckC.R.MainA.J.Epidemiology of" exact="West Nile" post="virus in Connecticut: a five-year analysis of mosquito data"/>
   <result pre="Zoonotic Dis.2004436037810.1089/vbz.2004.4.36015682518 243.PazS.MalkinsonD.GreenM.S.TsioniG.PapaA.DanisK.SirbuA.CeianuC.KatalinK.FerencziE.et al.Permissive Summer Temperatures of the 2010 European" exact="West Nile" post="Fever UpsurgePLoS ONE20138e5639810.1371/journal.pone.005639823431374 244.UkawubaI.ShamanJ.Association of spring-summer hydrology and meteorology"/>
   <result pre="UpsurgePLoS ONE20138e5639810.1371/journal.pone.005639823431374 244.UkawubaI.ShamanJ.Association of spring-summer hydrology and meteorology with human" exact="West Nile" post="virus infection in West Texas, USA, 2002–2016Parasit Vectors20181122410.1186/s13071-018-2781-029618375 245.ConteA.CandeloroL.IppolitiC.MonacoF.De"/>
   <result pre="245.ConteA.CandeloroL.IppolitiC.MonacoF.De MassisF.BrunoR.Di SabatinoD.Luisa DanzettaM.BenjellounA.BelkadiB.et al.Spatio-Temporal Identification of Areas Suitable for" exact="West Nile" post="Disease in the Mediterranean Basin and Central EuropePLoS ONE201510e014602410.1371/journal.pone.014602426717483"/>
   <result pre="(SLEV) [22,23] mosquito (Culex) bird NA, C/SA febrile illness, encephalitis" exact="West Nile" post="virus (WNV) [15,24,25,26,27] mosquito (Culex) bird NA, C/SA, AF,"/>
   <result pre="at 32 °C. Reisen et al., 2006 WNV, SLEV, WEEV" exact="WNV" post="NY99, WNV SA, SLEV BFS1750, WEEV BFS1703 Cx. tarsalis,"/>
   <result pre="°C. Reisen et al., 2006 WNV, SLEV, WEEV WNV NY99," exact="WNV" post="SA, SLEV BFS1750, WEEV BFS1703 Cx. tarsalis, Cx. univitattus"/>
   <result pre="species-specific differences in magnitude of effect. Cornel et al., 1993" exact="WNV" post="H442 Cx. univittatus Johannesburg, South Africa F1-F8 14, 18,"/>
   <result pre="26 °C (similar at 30 °C). Dohm et al., 2002" exact="WNV" post="NY99 Cx. pipiens Westchester, NY F3-F4 18, 20, 26,"/>
   <result pre="and transmission rates over 20 °C. Richards et al., 2007" exact="WNV" post="WN-FL03p2-3 Cx. quinque-fasciatus Gainesville, FL (colonized) 25, 28, 30"/>
   <result pre="lower at intermediated temperature (28 °C). Kilpatrick et al., 2008" exact="WNV" post="NY99-3356 WN02-1956 Cx. pipiens PA (colonized) 15, 18, 22,"/>
   <result pre="magnitude of increase is virus strain-dependent. Anderson et al., 2010" exact="WNV" post="FL03p2-3 Cx. quinque-fasciatus Gainesville, FL (colonized) 25, 28 Increased"/>
   <result pre="at high and low virus dose. Danforth et al., 2015" exact="WNV" post="NY99/COAV03, KERN11 Cx. tarsalis Kern Co, CA (colonized) 22,"/>
   <result pre="No effect of viral strain found. Vogels et al., 2016" exact="WNV" post="Lin. 2, Greece 2010 Cx. Pipiens Cx. Molestus hybrids"/>
   <result pre="to 28 °C in Cx. molestus. Danforth et al., 2016" exact="WNV" post="KERN11 Cx. tarsalis Kern Co, CA (colonized) 14.2, 21.5,"/>
   <result pre="Results statistically similar to constant temperatures. Vogels et al., 2017" exact="WNV" post="Lin. 2, Greece 2010 Cx. pipiens Netherlands, Italy, F4-F6"/>
   <result pre="291 9 3 1 SLEV 3 687 49 7 5" exact="WNV" post="11310 526 5 53 1 Virus abbreviations defined in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893508\results\search\tropicalVirus\results.xml">
   <result pre="culicoides midges [1]. 2. Epidemiology Various virulent arboviruses, such as" exact="West Nile" post="virus, Rift Valley fever virus, Chikungunya virus, Zika virus,"/>
   <result pre="arboviruses, such as West Nile virus, Rift Valley fever virus," exact="Chikungunya" post="virus, Zika virus, and Bluetongue virus (BTV), have emerged"/>
   <result pre="as West Nile virus, Rift Valley fever virus, Chikungunya virus," exact="Zika" post="virus, and Bluetongue virus (BTV), have emerged and caused"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893686\results\search\tropicalVirus\results.xml">
   <result pre="the growing number of imported cases of dengue, chikungunya or" exact="Zika" post="viruses into continental Europe and to the expansion of"/>
   <result pre="Ireland, The Netherlands, Luxembourg and Switzerland) for dengue, chikungunya, Zika," exact="West Nile" post="and Usutu viruses. Methods: A bibliographical search with research"/>
   <result pre="needed to assess that risk. Aedes Culex Anopheles Culiseta transmission" exact="West Nile" post="Usutu dengue Zika chikungunya 1. Introduction Emerging or re-emerging"/>
   <result pre="risk. Aedes Culex Anopheles Culiseta transmission West Nile Usutu dengue" exact="Zika" post="chikungunya 1. Introduction Emerging or re-emerging disease outbreaks caused"/>
   <result pre="range. Over the last two decades, arboviruses such as dengue," exact="Zika" post="or chikungunya achieved incursions in European countries [1,2,3], causing"/>
   <result pre="work, we investigated the vector competence for dengue virus (DENV)," exact="Zika" post="virus (ZIKV), chikungunya virus (CHIKV), West Nile virus (WNV)"/>
   <result pre="for dengue virus (DENV), Zika virus (ZIKV), chikungunya virus (CHIKV)," exact="West Nile" post="virus (WNV) and Usutu virus (USUV) according to the"/>
   <result pre="Brief Summary of the Reviewed Arboviruses Is Presented Below 3.1." exact="Chikungunya" post="Virus Chikungunya virus (genus Alphavirus, family Togaviridae) was reported"/>
   <result pre="of the Reviewed Arboviruses Is Presented Below 3.1. Chikungunya Virus" exact="Chikungunya" post="virus (genus Alphavirus, family Togaviridae) was reported for the"/>
   <result pre="Ocean, making Ae. albopictus more efficient for the transmission of" exact="CHIKV" post="[68]. In Europe, the autochthonous transmission of CHIKV was"/>
   <result pre="transmission of CHIKV [68]. In Europe, the autochthonous transmission of" exact="CHIKV" post="was first reported in Italy in 2007 [69]. In"/>
   <result pre="In our area of interest, the first autochthonous cases of" exact="CHIKV" post="occurred in 2010 in Southern France [70]. According to"/>
   <result pre="cases (Switzerland excluded) in 2012–2016 [71]. An autochthonous circulation of" exact="CHIKV" post="was observed in France 2014 and 2017 [4,70,72]. An"/>
   <result pre="in France 2014 and 2017 [4,70,72]. An autochthonous outbreak of" exact="CHIKV" post="also occurred in Italy in 2017 [73]. French Ae."/>
   <result pre="French Ae. albopictus and German Ae. japonicus are competent for" exact="CHIKV" post="[11,45]. Aedes detritus from the UK was found inefficient"/>
   <result pre="Aedes detritus from the UK was found inefficient to transmit" exact="CHIKV" post="[12]. Aedes vexans from Northern Italy showed a low"/>
   <result pre="showed a low disseminated infection rate and its role in" exact="CHIKV" post="transmission should not be neglected [13]. In Europe, the"/>
   <result pre="neglected [13]. In Europe, the declaration of imported cases of" exact="CHIKV" post="shows three temporal peaks, namely February, April, and August"/>
   <result pre="with the peaks of imported cases promoting autochthonous transmission. 3.2." exact="Dengue" post="Virus Dengue virus (genus Flavivirus, family Flaviviridae) includes four"/>
   <result pre="peaks of imported cases promoting autochthonous transmission. 3.2. Dengue Virus" exact="Dengue" post="virus (genus Flavivirus, family Flaviviridae) includes four serotypes (DENV-1"/>
   <result pre="Aedes aegypti and Ae. albopictus are the main vectors of" exact="DENV" post="acting in urban cycles. According to the latest ECDC"/>
   <result pre="detritus (United Kingdom) were tested for their competence toward a" exact="DENV" post="Serotype 2 isolated in Bangkok (Thailand); only Ae. japonicus"/>
   <result pre="are only active during the second and third peaks. 3.3." exact="Zika" post="Virus Zika virus (genus Flavivirus, family Flaviviridae), was first"/>
   <result pre="active during the second and third peaks. 3.3. Zika Virus" exact="Zika" post="virus (genus Flavivirus, family Flaviviridae), was first isolated in"/>
   <result pre="virus (genus Flavivirus, family Flaviviridae), was first isolated in the" exact="Zika" post="forest of Uganda in 1947 [79]. Since the Yap"/>
   <result pre="in 1947 [79]. Since the Yap island epidemic in 2007," exact="ZIKV" post="has circulated on all continents except Europe [80]. There"/>
   <result pre="pipiens s.l. and Cx. pipiens molestus are not competent for" exact="ZIKV" post="[8]. According to the ECDC 2016 annual epidemiological report"/>
   <result pre="[8]. According to the ECDC 2016 annual epidemiological report [75]," exact="ZIKV" post="case reports are steadily increasing from January to reach"/>
   <result pre="October (Figure 2). European Ae. albopictus is competent to transmit" exact="ZIKV" post="[8] and Ae. japonicus is poorly competent [37]. 3.4."/>
   <result pre="bird species affected by USUV [94]. An exhaustive review about" exact="WNV" post="and USUV has been published [93]. Cx. pipiens s.l."/>
   <result pre="Europe has been demonstrated to be competent for USUV. 3.5." exact="West Nile" post="Virus West Nile virus (genus Flavivirus, family Flaviviridae) was"/>
   <result pre="demonstrated to be competent for USUV. 3.5. West Nile Virus" exact="West Nile" post="virus (genus Flavivirus, family Flaviviridae) was first recorded in"/>
   <result pre="virus (genus Flavivirus, family Flaviviridae) was first recorded in the" exact="West Nile" post="district of Uganda in 1937 [96]. In natural conditions,"/>
   <result pre="horses and humans) are considered dead-end hosts [97]. In Europe," exact="WNV" post="is mainly transmitted by Culex mosquitoes. The first documented"/>
   <result pre="mainly transmitted by Culex mosquitoes. The first documented introduction of" exact="WNV" post="in metropolitan France dates from 1962, in Camargue [98]."/>
   <result pre="1964 was Culex modestus [99]. During the following 40 years," exact="WNV" post="did not cause any human cases in France, and"/>
   <result pre="and equine populations during the 1970s [98]. The resurgence of" exact="WNV" post="in France occurred in 2000 with 76 laboratory confirmed"/>
   <result pre="exceptionally high [103]. European mosquitoes display a variable susceptibility to" exact="WNV" post="infection and transmission. Culex spp. from France, The Netherlands,"/>
   <result pre="from France, The Netherlands, Switzerland and Germany are competent for" exact="WNV" post="lineages 1 and 2. Culex pipiens biotype pipiens, Culex"/>
   <result pre="area (France, The Netherlands, Switzerland and Germany) are competent for" exact="WNV" post="lineage 1 and 2 [41,51,53,55,56,104]. Culex pipiens s.l. from"/>
   <result pre="2 [41,51,53,55,56,104]. Culex pipiens s.l. from Switzerland is susceptible to" exact="WNV" post="infection but is not competent for WNV lineage 1"/>
   <result pre="is susceptible to WNV infection but is not competent for" exact="WNV" post="lineage 1 FIN Italy [55]. The competence of Ae."/>
   <result pre="The competence of Ae. detritus (United Kingdom) was demonstrated for" exact="WNV" post="lineage 1 strain NY99 [12]. The vector competence of"/>
   <result pre="[41]. Ae. japonicus (Germany) could not be infected nor transmit" exact="WNV" post="lineage 1 strain NY99 [38]. 4. Discussion North-Western Europe"/>
   <result pre="or re-emerging arboviruses. The epidemiology of arboviruses such as DENV," exact="ZIKV" post="or CHIKV is very different in Europe as compared"/>
   <result pre="arboviruses. The epidemiology of arboviruses such as DENV, ZIKV or" exact="CHIKV" post="is very different in Europe as compared to tropical"/>
   <result pre="human case. The number of imported human cases of CHIKV," exact="DENV" post="and ZIKV peaks in January, March–April, and September–October [71,74,75],"/>
   <result pre="The number of imported human cases of CHIKV, DENV and" exact="ZIKV" post="peaks in January, March–April, and September–October [71,74,75], corresponding to"/>
   <result pre="no consequences regarding a local transmission. During the March–April peak," exact="DENV" post="and CHIKV can be transmitted by Ae. japonicus [23],"/>
   <result pre="regarding a local transmission. During the March–April peak, DENV and" exact="CHIKV" post="can be transmitted by Ae. japonicus [23], and ZIKV"/>
   <result pre="and CHIKV can be transmitted by Ae. japonicus [23], and" exact="ZIKV" post="by Ae. vexans if European mosquitoes appear to be"/>
   <result pre="albopictus. The competence of native populations has been characterized for" exact="CHIKV" post="and ZIKV [8,45,46]. Outbreaks have already occurred in southern"/>
   <result pre="competence of native populations has been characterized for CHIKV and" exact="ZIKV" post="[8,45,46]. Outbreaks have already occurred in southern European countries"/>
   <result pre="[5]. Established vectors Ae. albopictus are also competent for transmitting" exact="ZIKV" post="in Italy and Spain [106,107]. To date, Ae. albopictus"/>
   <result pre="native Ae. albopictus and Ae. japonicus can transmit CHIKV, DENV," exact="ZIKV" post="[11,37,45,46]. This work highlights that invasive species represent the"/>
   <result pre="most probable candidates for the circulation of CHIKV, DENV, and" exact="ZIKV" post="in our area of interest. To date, three species"/>
   <result pre="leading to consider its potential role as a vector for" exact="WNV" post="[36]. While the vector competence of Ae. albopictus for"/>
   <result pre="however, was tested competent for WNV, and Ae. geniculatus for" exact="CHIKV" post="and WNV [35,36]. For USUV and WNV, the entanglement"/>
   <result pre="tested competent for WNV, and Ae. geniculatus for CHIKV and" exact="WNV" post="[35,36]. For USUV and WNV, the entanglement of mosquito"/>
   <result pre="enzootic cycle. Recent years have shown a sharp increase in" exact="WNV" post="cases [103]. Although serological and molecular screening is regularly"/>
   <result pre="[39,87,115], the screening of mosquito populations is less systematic. Also," exact="WNV" post="antibodies are more prevalent in migratory birds, while USUV"/>
   <result pre="birds [115]. USUV was more commonly found in mosquitoes than" exact="WNV" post="[115]. Epizootics of WNV are episodic [98]; after the"/>
   <result pre="more commonly found in mosquitoes than WNV [115]. Epizootics of" exact="WNV" post="are episodic [98]; after the first emergence of WNV"/>
   <result pre="of WNV are episodic [98]; after the first emergence of" exact="WNV" post="in France in 1962 [98], the virus was only"/>
   <result pre="Ae. vexans, Ae. japonicus and other Aedes species for ZIKV," exact="CHIKV" post="and DENV; An. plumbeus, Ae. geniculatus, Cs. annulata, and"/>
   <result pre="declare no conflict of interest. References References 1.VasquezV.HaddadE.PerignonA.JaureguiberryS.BrichlerS.Leparc-GoffartI.CaumesE.Dengue, chikungunya, and" exact="Zika" post="virus infections imported to Paris between 2009 and 2016:"/>
   <result pre="of Guadeloupe and MartiniqueInt. J. Infect. Dis.201872343910.1016/j.ijid.2018.05.00729782922 2.WongN.AhmedA.AhmedO.ElsanousiF.VeaterJ.OsborneJ.AaronsE.TangJ.W.A series of" exact="Zika" post="virus cases imported into the UK 2016: Comparative epidemiological"/>
   <result pre="clinical featuresJ. Infect.20177461661810.1016/j.jinf.2017.03.00428344115 3.WiwanitkitS.WiwanitkitV.Estimated number of local transmission cases of" exact="Zika" post="virus infection imported from Brazil to FranceAsian Pac. J."/>
   <result pre="7.VazeilleM.JeanninC.MartinE.SchaffnerF.FaillouxA.B.Chikungunya: A risk for Mediterranean countries?Acta Trop.200810520020210.1016/j.actatropica.2007.09.00918005927 8.HeitmannA.JansenS.LühkenR.LeggewieM.BaduscheM.PluskotaB.BeckerN.VapalahtiO.Schmidt-ChanasitJ.TannichE.Experimental transmission of" exact="Zika" post="virus by mosquitoes from central EuropeEurosurveillance2017224610.2807/1560-7917.ES.2017.22.2.30437 9.CiocchettaS.ProwN.A.DarbroJ.M.FrentiuF.D.SavinoS.MontarsiF.CapelliG.AaskovJ.G.DevineG.J.The new European"/>
   <result pre="10.VeronesiE.PaslaruA.SilaghiC.ToblerK.GlavinicU.TorgersonP.MathisA.Experimental evaluation of infection, dissemination, and transmission rates for two" exact="West Nile" post="virus strains in European Aedes japonicus under a fluctuating"/>
   <result pre="UK mosquito Ochlerotatus detritus (Aedes detritus) for dengue, chikungunya and" exact="West Nile" post="virusesParasit. Vectors2016945210.1186/s13071-016-1739-327527700 13.TalbalaghiA.MoutaillerS.VazeilleM.FaillouxA.B.Are Aedes albopictus or other mosquito species"/>
   <result pre="Del Vecchio 1939-a new mosquito species for GermanyParasitol. Res.20161152671267710.1007/s00436-016-5014-527003404 26.TimmermannU.BeckerN.Mosquito-borne" exact="West Nile" post="virus (WNV) surveillance in the Upper Rhine Valley, GermanyJ."/>
   <result pre="in the Upper Rhine Valley, GermanyJ. Vector Ecol.20103514014310.1111/j.1948-7134.2010.00069.x20618659 27.AndreadisT.G.AndersonJ.F.VossbrinckC.R.MainA.J.Epidemiology of" exact="West Nile" post="virus in Connecticut: A five-year analysis of mosquito data"/>
   <result pre="(Diptera: Culicidae) surveillance for arboviruses in an area endemic for" exact="West Nile" post="(lineage Rabensburg) and Tahyna viruses in central EuropeJ. Med."/>
   <result pre="29.GendernalikA.Weger-LucarelliJ.Garcia LunaS.M.FauverJ.R.RuckertC.MurrietaR.A.BergrenN.SamarasD.NguyenC.KadingR.C.et al.American Aedes vexans mosquitoes are competent vectors of" exact="Zika" post="virusAm. J. Trop. Med. Hyg.2017961338134010.4269/ajtmh.16-096328719283 30.DibernardoA.TurellM.J.LindsayL.R.LoomerC.IranpourM.Vector competence of some"/>
   <result pre="Hyg.2017961338134010.4269/ajtmh.16-096328719283 30.DibernardoA.TurellM.J.LindsayL.R.LoomerC.IranpourM.Vector competence of some mosquito species from Canada for" exact="Zika" post="virusJ. Am. Mosq. Control Assoc.20173327628110.2987/17-6664.129369018 31.TurellM.J.O’GuinnM.L.DohmD.J.JonesJ.W.Vector competence of North"/>
   <result pre="Control Assoc.20173327628110.2987/17-6664.129369018 31.TurellM.J.O’GuinnM.L.DohmD.J.JonesJ.W.Vector competence of North American mosquitoes (Diptera-Culicidae) for" exact="West Nile" post="virusJ. Med. Entomol.20013813013410.1603/0022-2585-38.2.13011296813 32.TakkenW.KnolsB.G.J.Emerging Pests and Vector-Borne Diseases in"/>
   <result pre="2003–2006Am. J. Trop. Med. Hyg.20159237739310.4269/ajtmh.14-029125487728 34.collab: CDCMosquito Species in Which" exact="West Nile" post="Virus Has Been Detected, United-States, 1999–2016Available online: https://www.cdc.gov/westnile/resources/pdfs/MosquitoSpecies1999–2016.pdf(accessed on"/>
   <result pre="can transmit chikungunya virusEmerg. Microbes Infect.2019896297210.1080/22221751.2019.163448931259662 36.VermeilC.LavillaureixJ.ReebE.Survival and transmission of" exact="West Nile" post="virus by various arthropodsBull. Soc. Pathol. Exot.196053300306 37.JansenS.HeitmannA.LühkenR.JöstH.HelmsM.VapalahtiO.Schmidt-ChanasitJ.TannichE.Experimental transmission"/>
   <result pre="virus by various arthropodsBull. Soc. Pathol. Exot.196053300306 37.JansenS.HeitmannA.LühkenR.JöstH.HelmsM.VapalahtiO.Schmidt-ChanasitJ.TannichE.Experimental transmission of" exact="Zika" post="virus by Aedes japonicus japonicus from southwestern GermanyEmerg. Microbes"/>
   <result pre="for Japan encephalitis virus but are refractory to infection with" exact="West Nile" post="virusParasitol. Res.20141133195319910.1007/s00436-014-3983-924948103 39.PietschC.TrawinskiH.LubbertC.LiebertU.G.Short communication: West nile fever imported from"/>
   <result pre="41.BalenghienT.VazeilleM.GrandadamM.SchaffnerF.ZellerH.ReiterP.SabatierP.FouqueF.BicoutD.J.Vector competence of some French Culex and Aedes mosquitoes for" exact="West Nile" post="virusVector Borne Zoonotic Dis.2008858959510.1089/vbz.2007.026618447623 42.ManciniG.MontarsiF.CalzolariM.CapelliG.DottoriM.RavagnanS.LelliD.ChiariM.SantilliA.QuagliaM.et al.Mosquito species involved in"/>
   <result pre="Zoonotic Dis.2008858959510.1089/vbz.2007.026618447623 42.ManciniG.MontarsiF.CalzolariM.CapelliG.DottoriM.RavagnanS.LelliD.ChiariM.SantilliA.QuagliaM.et al.Mosquito species involved in the circulation of" exact="West Nile" post="and Usutu viruses in ItalyVet. Ital.2017539711028675249 43.GoddardL.B.RothA.E.ReisenW.K.ScottT.W.Vector competence of"/>
   <result pre="viruses in ItalyVet. Ital.2017539711028675249 43.GoddardL.B.RothA.E.ReisenW.K.ScottT.W.Vector competence of California mosquitoes for" exact="West Nile" post="virusEmerg. Infect. Dis.200281385139110.3201/eid0812.02053612498652 44.PaupyC.OllomoB.KamgangB.MoutaillerS.RoussetD.DemanouM.HerveJ.P.LeroyE.SimardF.Comparative role of Aedes albopictus and"/>
   <result pre="(=Aedes albopictus) populations as vectors for lineage 1 and 2" exact="West Nile" post="virus in EuropeMed. Vet. Entomol.20163016617310.1111/mve.1216426890285 49.SchaffnerF.KarchS.Première observation d’Aedes albopictus"/>
   <result pre="Sci.200032337337510.1016/S0764-4469(00)00143-8 50.BalenghienT.VazeilleM.ReiterP.SchaffnerF.ZellerH.BicoutD.J.Evidence of laboratory vector competence of Culex modestus for" exact="West Nile" post="virusJ. Am. Mosq. Control Assoc.20072323323610.2987/8756-971X(2007)23[233:EOLVCO]2.0.CO;217847861 51.FrosJ.J.MiesenP.VogelsC.B.GaibaniP.SambriV.MartinaB.E.KoenraadtC.J.van RijR.P.VlakJ.M.TakkenW.et al.Comparative Usutu"/>
   <result pre="virusJ. Am. Mosq. Control Assoc.20072323323610.2987/8756-971X(2007)23[233:EOLVCO]2.0.CO;217847861 51.FrosJ.J.MiesenP.VogelsC.B.GaibaniP.SambriV.MartinaB.E.KoenraadtC.J.van RijR.P.VlakJ.M.TakkenW.et al.Comparative Usutu and" exact="West Nile" post="virus transmission potential by local Culex pipiens mosquitoes in"/>
   <result pre="of northern and southern European Culex pipiens pipiens mosquitoes for" exact="West Nile" post="virus across a gradient of temperaturesMed. Vet. Entomol.20173135836410.1111/mve.1225128752627 55.WagnerS.MathisA.SchonenbergerA.C.BeckerS.Schmidt-ChanasitJ.SilaghiC.VeronesiE.Vector"/>
   <result pre="Aedes japonicus japonicus and Culex pipiens from Switzerland for two" exact="West Nile" post="virus strainsMed. Vet. Entomol.20183212112410.1111/mve.1227329082585 56.LeggewieM.BaduscheM.RudolfM.JansenS.BörstlerJ.KrumkampR.HuberK.KrügerA.Schmidt-ChanasitJ.TannichE.et al.Culex pipiens and Culex"/>
   <result pre="and Culex torrentium populations from central Europe are susceptible to" exact="West Nile" post="virus infectionOne Health (Amst. Neth.)20162889410.1016/j.onehlt.2016.04.00128616480 57.EidenM.GilP.ZieglerU.RakotoarivonyI.MarieA.FrancesB.L’AmbertG.SimoninY.FoulongneV.GroschupM.H.et al.Emergence of two"/>
   <result pre="novel African Usutu virus, Central EuropeEmerg. Infect. Dis.2015211647165010.3201/eid2109.14202626291923 61.VauxA.G.GibsonG.Hernandez-TrianaL.M.ChekeR.A.McCrackenF.JeffriesC.L.HortonD.L.SpringateS.JohnsonN.FooksA.R.et al.Enhanced" exact="West Nile" post="virus surveillance in the North Kent marshes, UKParasit. Vectors201589110.1186/s13071-015-0705-925884920"/>
   <result pre="marshes, UKParasit. Vectors201589110.1186/s13071-015-0705-925884920 62.AmraouiF.Atyame-NtenC.Vega-RuaA.Lourenco-de-OliveiraR.VazeilleM.FaillouxA.B.Culex mosquitoes are experimentally unable to transmit" exact="Zika" post="virusEurosurveillance2016212510.2807/1560-7917.ES.2016.21.35.3033326889644 63.CampJ.V.BakonyiT.SolteszZ.ZechmeisterT.NowotnyN.Uranotaenia unguiculata Edwards, 1913 are attracted to sound,"/>
   <result pre="are infected with multiple virusesParasit. Vectors20181145610.1186/s13071-018-3030-230081963 64.KemenesiG.DallosB.OldalM.KutasA.FoldesF.NemethV.ReiterP.BakonyiT.BanyaiK.JakabF.Putative novel lineage of" exact="West Nile" post="virus in Uranotaenia unguiculata mosquito, HungaryVirus Dis.20142550050310.1007/s13337-014-0234-8 65.PachlerK.LeblK.BererD.RudolfI.HubalekZ.NowotnyN.Putative new"/>
   <result pre="Nile virus in Uranotaenia unguiculata mosquito, HungaryVirus Dis.20142550050310.1007/s13337-014-0234-8 65.PachlerK.LeblK.BererD.RudolfI.HubalekZ.NowotnyN.Putative new" exact="West Nile" post="virus lineage in Uranotaenia unguiculata mosquitoes, Austria, 2013Emerg. Infect."/>
   <result pre="Infect. Dis.20111791091310.3201/eid1705.10187321529410 71.collab: European Center for Disease Prevention and Control2016" exact="Chikungunya" post="Virus DiseaseEuropean Center for Disease Prevention and ControlStockholm, Sweden2018"/>
   <result pre="Soc. Trop. Med. Hyg.19524650952010.1016/0035-9203(52)90042-412995440 80.BoyerS.CalvezE.Chouin-CarneiroT.DialloD.FaillouxA.B.An overview of mosquito vectors of" exact="Zika" post="virusMicrobes Infect.20182064666010.1016/j.micinf.2018.01.00629481868 81.FayeO.FreireC.C.IamarinoA.FayeO.de OliveiraJ.V.DialloM.ZanottoP.M.SallA.A.Molecular evolution of Zika virus during"/>
   <result pre="mosquito vectors of Zika virusMicrobes Infect.20182064666010.1016/j.micinf.2018.01.00629481868 81.FayeO.FreireC.C.IamarinoA.FayeO.de OliveiraJ.V.DialloM.ZanottoP.M.SallA.A.Molecular evolution of" exact="Zika" post="virus during its emergence in the 20(th) centuryPLoS Negl."/>
   <result pre="lineages of Usutu virus, western Europe, 2016Eurosurveillance201722111710.2807/1560-7917.ES.2017.22.4.30452 85.BuckleyA.DawsonA.MossS.R.HinsleyS.A.BellamyP.E.GouldE.A.Serological evidence of" exact="West Nile" post="virus, Usutu virus and Sindbis virus infection of birds"/>
   <result pre="woodpecker (Dendrocopos major) in north-west EuropeVet. J.201419919119310.1016/j.tvjl.2013.10.01724268481 87.LimS.M.GeervlietM.VerhagenJ.H.MuskensG.MajoorF.A.OsterhausA.MartinaB.E.E.Serologic evidence of" exact="West Nile" post="virus and Usutu virus infections in Eurasian coots in"/>
   <result pre="to 2013 and monitoring of wild birds for Usutu and" exact="West Nile" post="virusesVector Borne Zoonotic Dis.20151548148810.1089/vbz.2014.174626273809 89.BuchebnerN.ZenkerW.WenkerC.SteinmetzH.W.SosE.LussyH.NowotnyN.Low Usutu virus seroprevalence in"/>
   <result pre="zoological gardens in central EuropeBMC Vet. Res.2013915310.1186/1746-6148-9-15323919825 90.VittecoqM.LecollinetS.JourdainE.ThomasF.BlanchonT.ArnalA.LowenskiS.Gauthier-ClercM.Recent circulation of" exact="West Nile" post="virus and potentially other closely related flaviviruses in southern"/>
   <result pre="Usutu virus neuroinvasive infection, Italy, august-september 2009Eurosurveillance2009141517 93.NikolayB.A review of" exact="West Nile" post="and Usutu virus co-circulation in Europe: How much do"/>
   <result pre="and human-seeking behavior and seasonal abundance of mosquitoes in a" exact="West Nile" post="virus focus of southern FranceJ. Med. Entomol.20064393694610.1093/jmedent/43.5.93617017231 100.Van Den"/>
   <result pre="FranceJ. Med. Entomol.20064393694610.1093/jmedent/43.5.93617017231 100.Van Den BosscheD.CnopsL.MeersmanK.DomingoC.van GompelA.van EsbroeckM.Chikungunya virus and" exact="West Nile" post="virus infections imported into Belgium, 2007–2012Epidemiol. Infect.20151432227223610.1017/S095026881400068524690286 101.BahuonC.Marcillaud-PitelC.BournezL.LeblondA.BeckC.HarsJ.Leparc-GoffartI.L’AmbertG.PatyM.C.CavalerieL.et al.West"/>
   <result pre="103.collab: European Center for Disease Prevention and ControlWeekly Updates: 2018" exact="West Nile" post="Fever Transmission SeasonAvailable online: https://www.ecdc.europa.eu/en/news-events/epidemiological-update-west-nile-virus-transmission-season-europe-2018(accessed on 1 February 2019)"/>
   <result pre="on 1 February 2019) 104.VogelsC.B.GoertzG.P.PijlmanG.P.KoenraadtC.J.Vector competence of European mosquitoes for" exact="West Nile" post="virusEmerg. Microbes Infect.20176e9610.1038/emi.2017.8229116220 105.DialloM.ThonnonJ.Traore-LamizanaM.FontenilleD.Vectors of chikungunya virus in Senegal:"/>
   <result pre="LucaM.SeveriniF.TomaL.BoccoliniD.RomiR.RemoliM.E.SabbatucciM.RizzoC.VenturiG.RezzaG.et al.Experimental studies of susceptibility of Italian Aedes albopictus to" exact="Zika" post="virusEurosurveillance2016216910.2807/1560-7917.ES.2016.21.18.3022326876980 107.Gutierrez-LopezR.BialosukniaS.M.CiotaA.T.MontalvoT.Martinez-de la PuenteJ.GangosoL.FiguerolaJ.KramerL.D.Vector competence of Aedes caspius and"/>
   <result pre="PuenteJ.GangosoL.FiguerolaJ.KramerL.D.Vector competence of Aedes caspius and Ae. albopictus mosquitoes for" exact="Zika" post="virus, SpainEmerg. Infect. Dis.20192534634810.3201/eid2502.17112330666939 108.collab: European Center for Disease"/>
   <result pre="ClercqE.M.HendrickxG.SchaffnerF.et al.Human-induced expanded distribution of Anopheles plumbeus, experimental vector of" exact="West Nile" post="virus and a potential vector of human malaria in"/>
   <result pre="potential vector of human malaria in BelgiumJ. Med. Entomol.20114892492810.1603/ME1023521845955 113.RabelP.O.PlanitzerC.B.FarcetM.R.OrlingerK.K.IlkR.BarrettP.N.KreilT.R.Increasing" exact="West Nile" post="virus antibody titres in central European plasma donors from"/>
   <result pre="114.LinkeS.MuehlenM.NiedrigM.EllerbrokH.KaiserA.FiedlerW.SonnenbergK.AlpersK.StarkK.PauliG.Assessing the exposure of German and Austrian bird ringers to" exact="West Nile" post="virus (Flavivirus) and evaluating their potential risk of infectionJ."/>
   <result pre="2000: The return after 35 yearsEmerg. Infect. Dis.2001769269610.3201/eid0704.01741711585534 117.Del GiudiceP.SchuffeneckerI.VandenbosF.CounillonE.ZelletH.Human" exact="West Nile" post="virus, FranceEmerg. Infect. Dis.2004101885188610.3201/eid1010.03102115515250 118.BuckleyA.DawsonA.GouldE.A.Detection of seroconversion to West"/>
   <result pre="West Nile virus, FranceEmerg. Infect. Dis.2004101885188610.3201/eid1010.03102115515250 118.BuckleyA.DawsonA.GouldE.A.Detection of seroconversion to" exact="West Nile" post="virus, Usutu virus and Sindbis virus in UK sentinel"/>
   <result pre="Figure 2 Number of imported cases of chikungunya, dengue and" exact="Zika" post="viruses in Europe in 2016 (adapted from [71,74,75]). viruses-11-01059-t001_Table"/>
   <result pre="no capture of chikungunya virus (CHIKV), dengue virus (DENV) and" exact="Zika" post="virus (ZIKV) has been reported in our area of"/>
   <result pre="field data part of the table. Laboratory Experiment Field Data" exact="Dengue" post="Chikungunya Zika Usutu West Nile Usutu West Nile Aedes"/>
   <result pre="data part of the table. Laboratory Experiment Field Data Dengue" exact="Chikungunya" post="Zika Usutu West Nile Usutu West Nile Aedes cinereus"/>
   <result pre="part of the table. Laboratory Experiment Field Data Dengue Chikungunya" exact="Zika" post="Usutu West Nile Usutu West Nile Aedes cinereus *,"/>
   <result pre="the table. Laboratory Experiment Field Data Dengue Chikungunya Zika Usutu" exact="West Nile" post="Usutu West Nile Aedes cinereus *, Aedes geminus *"/>
   <result pre="Experiment Field Data Dengue Chikungunya Zika Usutu West Nile Usutu" exact="West Nile" post="Aedes cinereus *, Aedes geminus * - - -"/>
   <result pre="Post Infection Reference Aedes vexans France Côte d’Azur 107 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 NA - 12–14 [7] Aedes"/>
   <result pre="- 12–14 [7] Aedes japonicus japonicus Switzerland Zürich 107 ffu/mL" exact="CHIKV" post="06.21 La Réunion 2005 + + 14 [11] Aedes"/>
   <result pre="+ 14 [11] Aedes japonicus japonicus Switzerland Zürich 107 ffu/mL" exact="DENV" post="Serotype 2, Bangkok Thailand + + 14 [11] Aedes"/>
   <result pre="+ 14 [11] Aedes japonicus japonicus Switzerland Zürich 106 TCID50/mL" exact="West Nile" post="virus (WNV) lineage 1 FIN Italy + + 14"/>
   <result pre="[10] Aedes japonicus japonicus Germany Stuttgart 2 × 107 PFU/mL" exact="WNV" post="lineage 1 strain NY99 - - 14 [38] Aedes"/>
   <result pre="- 14 [38] Aedes japonicus japonicus Switzerland Zürich 106 TCID50/mL" exact="WNV" post="lineage 1 strain NY99 + + 14 [10] Aedes"/>
   <result pre="+ 14 [37] Aedes caspius France Côte d’Azur 107 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 NA + 12–14 [7] Aedes"/>
   <result pre="NA + 12–14 [7] Aedes caspius France Camargue 1010,3 PFU/mL" exact="WNV" post="PaAn001 AY268135 + - 14 [41] Aedes detritus France"/>
   <result pre="- 14 [41] Aedes detritus France Côte d’Azur 107 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 NA + 12–14 [7] Aedes"/>
   <result pre="12–14 [7] Aedes detritus United Kingdom Little Neston 107 PFU/mL" exact="CHIKV" post="NC/ 2011-568 - - 17 [12] Aedes detritus United"/>
   <result pre="17 [12] Aedes detritus United Kingdom Little Neston 107 PFU/mL" exact="DENV" post="Serotype 2, Bangkok Thailand - - 17 [12] Aedes"/>
   <result pre="Aedes detritus United Kingdom Little Neston 2 × 106 PFU/mL" exact="WNV" post="NY-99 + + 17 [12] Aedes albopictus France Bar-sur-Loup"/>
   <result pre="+ + 17 [12] Aedes albopictus France Bar-sur-Loup 106,5 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 + + 3,5,7 [45] Aedes"/>
   <result pre="+ 3,5,7 [45] Aedes albopictus France Côte d’Azur 107 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 NA + 12–14 [7] Aedes"/>
   <result pre="NA + 12–14 [7] Aedes albopictus France Bar-sur-Loup 106,5 PFU/mL" exact="CHIKV" post="20235 2013 + + 3,5,7 [45] Aedes albopictus France"/>
   <result pre="+ + 3,5,7 [45] Aedes albopictus France Nice 107 TCID50/mL" exact="ZIKV" post="strain (NC-2014-5132) + + 14 [46] Aedes albopictus Germany"/>
   <result pre="+ + 21 [8] Culex modestus France Camargue 1010,3 PFU/mL" exact="WNV" post="PaAn001 AY268132 + + 14 [50] Culex modestus France"/>
   <result pre="+ + 14 [50] Culex modestus France Camargue 1010,3 PFU/mL" exact="WNV" post="PaAn001 AY268134 + + 14 [41] Culex pipiens hybrid"/>
   <result pre="pipiens hybrid form Netherlands - 5.2 × 107 TCID50 /mL" exact="WNV" post="lineage 2 strain Greece 2010 + + 14 [54]"/>
   <result pre="molestus Germany Heidelberg, Wendland, and Langenhelsten 1–1.6 × 107 PFU/mL" exact="WNV" post="lineage 1 strain NY99 + + 14 [56] Culex"/>
   <result pre="Culex pipiens molestus Netherlands Amsterdam 5.2 × 107 TCID50 /mL" exact="WNV" post="lineage 2 strain Greece 2010 + + 14 [54]"/>
   <result pre="[52] Culex pipiens pipiens Germany Hamburg 1–1.6 × 107 PFU/mL" exact="WNV" post="lineage 1 strain NY99 + + 14 [56] Culex"/>
   <result pre="Culex pipiens pipiens Netherlands Best 5.2 × 107 TCID50 /mL" exact="WNV" post="lineage 2 strain Greece 2010 + + 14 [54]"/>
   <result pre="- [8] Culex pipiens s.l. France Côte d’Azur 107 PFU/mL" exact="CHIKV" post="06.21 La Réunion 2005 NA - 12–14 [7] Culex"/>
   <result pre="[51] Culex pipiens s.l. Switzerland Zürich 102.6 to 104.2 PFU/mL" exact="WNV" post="lineage 1 FIN Italy + - 14 [55] Culex"/>
   <result pre="[55] Culex pipiens s.l. Switzerland Zürich 102.6 to 104.2 PFU/mL" exact="WNV" post="lineage 1 strain NY99 + + 14 [55] Culex"/>
   <result pre="[55] Culex pipiens s.l. Netherlands Brummen 1.4 × 108 TCID50/ml" exact="WNV" post="lineage 2 strain Greece 2010 + + 14 [53]"/>
   <result pre="[53] Culex pipiens s.l. Netherlands Brummen 4 × 107 TCID50/mL" exact="WNV" post="lineage 2 strain Greece 2010 + + 14 [51]"/>
   <result pre="+ 14 [51] Culex pipiens s.l. France Camargue 1010,3 PFU/mL" exact="WNV" post="PaAn001 AY268133 + + 14 [41] Culex torrentium Germany"/>
   <result pre="14 [41] Culex torrentium Germany Hamburg 1–1,6 × 107 PFU/mL" exact="WNV" post="lineage 1 strain NY99 + + 14 [56] Culex"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893747\results\search\tropicalVirus\results.xml">
   <result pre="In addition, apoptosis is regulated by some microRNAs response to" exact="West Nile" post="virus [26] and respiratory syncytial virus [27]. More specifically,"/>
   <result pre="in the pathogenesis and replication of many viruses such as" exact="Zika" post="virus [43], Ebola virus [44,45], and porcine reproductive and"/>
   <result pre="responseJ. Viral. Hepat.20142112112810.1111/jvh.1213124383925 26.SmithJ.L.GreyF.E.UhrlaubJ.L.Nikolich-ZugichJ.HirschA.J.Induction of the cellular microRNA, Hs_154, by" exact="West Nile" post="virus contributes to virus-mediated apoptosis through repression of antiapoptotic"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893791\results\search\tropicalVirus\results.xml">
   <result pre="Physiol. Pathophysiol. Pharmacol.2017910111128694921 198.QianX.NguyenH.N.SongM.M.HadionoC.OgdenS.C.HammackC.YaoB.HamerskyG.R.JacobF.ZhongC.et al.Brain-Region-Specific Organoids Using Mini-Bioreactors for Modeling" exact="ZIKV" post="ExposureCell20161651238125410.1016/j.cell.2016.04.03227118425 199.SabellaC.Measles: Not Just a Childhood RashCleve. Clin. J."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6893968\results\search\tropicalVirus\results.xml">
   <result pre="of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of" exact="Chikungunya" post="Virus (CHIKV) PuranikNinad V.†§∥RaniRuchi‡∥SinghVedita Anand‡TomarShailly*‡PuntambekarHemalata M.†§SrivastavaPratibha*†§[†], Agharkar Research InstituteIndia[‡],"/>
   <result pre="to nearly 95 and 93% concentration, respectively, in cells with" exact="CHIKV" post="infection. Further, the CHIKV-inhibitory capacity of these compounds was"/>
   <result pre="against prime antiviral entrants, leading to remedial management to preclude" exact="CHIKV" post="infection. Introduction The cases of chikungunya viral fever are"/>
   <result pre="going through joint ache as a result of chikungunya infection." exact="Chikungunya" post="virus (CHIKV) spreads by mosquito vectors Aedes aegypti and"/>
   <result pre="are primates and humans. In humans, the symptoms associated with" exact="CHIKV" post="are nausea, fever, joint pain, vomiting, rashes, and persistent"/>
   <result pre="by positive polymerase chain reaction (PCR) results.3,4 In Togaviridae family," exact="CHIKV" post="comes under the genus Alphavirus. Alphaviruses are configured as"/>
   <result pre="Encapsidated by 240 copies of CP, the RNA genome of" exact="CHIKV" post="makes the nucleocapsid core.13,14 The grown-up alphavirus virion (70"/>
   <result pre="E1 and E2 (surface glycoproteins) heterodimers build up every spike.15" exact="CHIKV" post="bears a genome of almost ∼11.7 kb, polyadenylated at"/>
   <result pre="and the activity of nsP3 mono(ADP-ribosyl)hydrolase is somewhere decisive for" exact="CHIKV" post="replication and virulence in mice. At the N-terminus, nsP3"/>
   <result pre="in the market for the cure of CHIKV-infected patients. Some" exact="CHIKV" post="vaccine approaches have been analyzed, together with inefficient, live"/>
   <result pre="in vitro screening of chloroquine, ribavirin, and arbidol to curb" exact="CHIKV" post="progress have failed to produce noteworthy therapeutic aids in"/>
   <result pre="356 natural product molecules and clinically recommended medicines to counteract" exact="CHIKV" post="replicon, and an accompanying test with the surrogate infection"/>
   <result pre="(SFV),25 during analyses of 3040 small compounds as inhibitors of" exact="CHIKV" post="nsP2, was also tested by the phenotypic assay protocol.26"/>
   <result pre="protocol.26 Still, the problem for the prevention and treatment of" exact="CHIKV" post="fever is recalcitrant. Therefore, it is necessary to work"/>
   <result pre="with the macrodomain of nsP3 and their antiviral potential against" exact="CHIKV" post="are reported. Based on the outcomes of antiviral screening"/>
   <result pre="were conducted to determine the inhibitory potential of compounds on" exact="CHIKV" post="replication, and quantitative real-time polymerase chain reaction (qRT-PCR) was"/>
   <result pre="assay (IFA) was carried out to investigate the reduction in" exact="CHIKV" post="antigen upon treatment with the screened compounds. Results and"/>
   <result pre="molecular understanding of the particular binding of ADP-ribose to the" exact="CHIKV" post="nsP3 macrodomain revealed that nsP3 amino acids Asp 10,"/>
   <result pre="contacts with the amino acid residues of nsP3 in the" exact="CHIKV" post="nsP3–ADP-ribose complex (Figure 2a,b). Figure 2 Molecular docking of"/>
   <result pre="Residues of 3GPO with 5a–f Table 2 Interaction Analysis of" exact="CHIKV" post="nsP3 with ADP-Ribose and Halogenated Dihydrorugosaflavonoids s. no. ADP-ribose"/>
   <result pre="with a dotted line; (c and d) dose-dependent inhibition of" exact="CHIKV" post="shown by 5c and 5d, respectively. 5c and 5d"/>
   <result pre="5c and 5d both exhibit a statistically significant reduction in" exact="CHIKV" post="titer at micromolar concentrations. In the analysis, statistical significance"/>
   <result pre="70 μM concentration. Plaque Reduction Assay The reduction in the" exact="CHIKV" post="infectivity in the presence of 5c and 5d compounds"/>
   <result pre="compounds for CHIKV. Figure 4 Demonstration of antiviral activity against" exact="CHIKV" post="in treated Vero cells. Dihydrorugosaflavonoid-treated Vero cells (pretreated cells)"/>
   <result pre="Vero cells. Dihydrorugosaflavonoid-treated Vero cells (pretreated cells) were infected with" exact="CHIKV" post="at an MOI of 1 for 90 min. Followed"/>
   <result pre="validating the antiviral effect of 5c and 5d by quantifying" exact="CHIKV" post="RNA levels in the infected cells. The reduction in"/>
   <result pre="treated with 5c and 5d compounds at 24 hpi. The" exact="CHIKV" post="RNA levels upon treatment with 70 and 50 μM"/>
   <result pre="5d, with 70 and 50 μM, the RNA levels of" exact="CHIKV" post="were reduced to ∼ 93 and 91%, respectively (Figure"/>
   <result pre="respectively (Figure 5). Figure 5 (a, b) Relative quantification of" exact="CHIKV" post="mRNA of Vero cells treated with 5c and 5d"/>
   <result pre="PCR. Compounds were added to the cells 12 h before" exact="CHIKV" post="infection and were present in the post-infection medium. Viral"/>
   <result pre="antigen in this study for virus detection by IFA. Here," exact="CHIKV" post="at an MOI of 1 was propagated in Vero"/>
   <result pre="6 clearly shows that both 5c and 5d compounds inhibited" exact="CHIKV" post="at 70 and 50 μM concentrations. Figure 6 Evaluation"/>
   <result pre="all over the world to identify the lead molecules restricting" exact="CHIKV" post="infection or replication. In this piece of work, molecular"/>
   <result pre="reduction assay displayed that compounds 5c and 5d potentially inhibit" exact="CHIKV" post="infection. Further, qRT-PCR assay results clearly show the potential"/>
   <result pre="in infected cells. Furthermore, the antiviral activity of dihydrorugosaflavonoids toward" exact="CHIKV" post="is also well delivered by IFA. Conclusions Flavonoid compounds"/>
   <result pre="to the same class and display their potential to inhibit" exact="CHIKV" post="replication. In conclusion, it could be explicated that halogenated"/>
   <result pre="in a 5% CO2 incubator. Using the virus adsorption technique," exact="CHIKV" post="(accession number, KY057363.1; strain, 119067)50 stocks were prepared in"/>
   <result pre="At MOI of 1, the cell monolayer was infected with" exact="CHIKV" post="with gentle shaking after every 15 min for 90"/>
   <result pre="plate to isolate RNA for qRT-PCR. Furthermore, the CPE of" exact="CHIKV" post="on the Vero cell line appeared in ∼48 h"/>
   <result pre="hpi, the cell supernatant was harvested, and the 10-fold serial-diluted" exact="CHIKV" post="supernatant was added to the Vero cells and incubated"/>
   <result pre="4. Table 4 Sequence of Oligonucleotides Used as Primers in" exact="CHIKV" post="Virus in Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) primers"/>
   <result pre="control to screen possible contamination. RNA extracted from the untreated" exact="CHIKV" post="supernatant was used as a positive control. Experiments were"/>
   <result pre="concentrations of 5c and 5d compounds prior to and after" exact="CHIKV" post="infection. At 36 hpi, cells were washed three times"/>
   <result pre="Virol.2014, 88, 11644–11647. 10.1128/JVI.01432-14.25078691 National Vector Borne Disease Control Programme." exact="Chikungunya" post="Fever. http://nvbdcp.gov.in/chikun-status.html (accessed April 2018). ChoiH. K.; LeeS.; ZhangY."/>
   <result pre="DuquerroyS.; VonrheinC.; Girard-BlancC.; CrubletE.; ThompsonA.; BricogneG.; ReyF. A.Glycoprotein organization of" exact="Chikungunya" post="virus particles revealed by X-ray crystallography. Nature2010, 468, 709–712."/>
   <result pre="KistemakereH. A.; FilippovD. V.; GriffinD. E.; LeungA. K.ADP-ribosylhydrolase activity of" exact="Chikungunya" post="virus macrodomain is critical for virus replication and virulence."/>
   <result pre="KamY. W.; OngE. K.; ReniaL.; TongJ. C.; NgL. F.Immuno-biology of" exact="Chikungunya" post="and implications for disease intervention. Microbes. Infect.2009, 11, 1186–1196."/>
   <result pre="10.1086/514240.9498442 BriolantS.; GarinD.; ScaramozzinoN.; JouanA.; CranceJ. M.In vitro inhibition of" exact="Chikungunya" post="and Semliki Forest viruses replication by antiviral compounds: synergistic"/>
   <result pre="PastorinoB.; BarontiC.; NougairedeA.; BonnetE.In vitro antiviral activity of arbidol against" exact="Chikungunya" post="virus and characteristics of a selected resistant mutant. Antiviral"/>
   <result pre="mutant. Antiviral Res.2011, 90, 99–107. 10.1016/j.antiviral.2011.03.182.21440006 RavichandranR.; ManianM.Ribavirin therapy for" exact="Chikungunya" post="arthritis. J. Infect. Dev. Ctries.2008, 2, 140–142. 10.3855/T2.2.140.19738340 PohjalaL.;"/>
   <result pre="MeritsA.Inhibitors of alphavirus entry and replication identified with a stable" exact="Chikungunya" post="replicon cell line and virus-based assays. PLoS One2011, 6,"/>
   <result pre="e2892310.1371/journal.pone.0028923.22205980 Lucas-HouraniM.; LupanA.; DespresP.; ThoretS.; PamlardO.A phenotypic assay to identify" exact="Chikungunya" post="virus inhibitors targeting the nonstructural protein nsP2. J. Biomol."/>
   <result pre="SchwartzO.; HansenM. A. E.; Freitas-JuniorL. H.Identification of Novel Compounds Inhibiting" exact="Chikungunya" post="Virus-Induced Cell Death by High Throughput Screening of a"/>
   <result pre="RossettiG.; LüscherB.; VerheugdP.The conserved macrodomains of the non-structural proteins of" exact="Chikungunya" post="virus and other pathogenic positive strand RNA viruses function"/>
   <result pre="HiggsS.; VanlandinghamD.; BakarS. A.; ZandiK.Antiviral activity of selected flavonoids against" exact="Chikungunya" post="virus. Antiviral Res.2016, 133, 50–61. 10.1016/j.antiviral.2016.07.009.27460167 FrosJ. J.; DomeradzkaN."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6894787\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Dengue" post="Fever : Medicine and Health Sciences : Pulmonology: Respiratory"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Engineering and Technology : Civil Engineering :"/>
   <result pre="inbound passengers: Infrared thermometer–based active surveillance at an international airport" exact="Dengue" post="fever screening at airport http://orcid.org/0000-0001-7528-0199SuChia-pingConceptualizationData curationFormal analysisMethodologyWriting – original"/>
   <result pre="provided the original author and source are credited.pone.0225840.pdf Abstract Background" exact="Dengue" post="fever is endemic in tropical and subtropical areas, especially"/>
   <result pre="number is 886-2-2395-9825 EXT3070. The email address is r04841010@cdc.gov.tw. Introduction" exact="Dengue" post="fever is one of the leading arthropod-borne viral infections,"/>
   <result pre="for dengue among all inbound passengers at an international airport." exact="Dengue" post="has been reported as the most common cause of"/>
   <result pre="volumes of international travelers [27]. An additional international concern is" exact="Zika" post="virus, an emerging mosquito-borne disease with serious perinatal and"/>
   <result pre="several regions of the world since 2015. Taiwan quickly adopted" exact="Zika" post="surveillance at international airports and has detected several imported"/>
   <result pre="Zika surveillance at international airports and has detected several imported" exact="Zika" post="cases through this system [28]. When emerging/re-emerging diseases become"/>
   <result pre="travelers, 2007–2011. Ann Intern Med. 2013;158(6): 456–468. 10.7326/0003-4819-158-6-201303190-0000523552375 6SchaffnerF, MathisA." exact="Dengue" post="and dengue vectors in the WHO European region: past,"/>
   <result pre="for the future. Lancet Infect Dis. 2014;14(12):1271–80. 10.1016/S1473-3099(14)70834-525172160 7TomaselloD, SchlagenhaufP." exact="Chikungunya" post="and dengue autochthonous cases in Europe, 2007–2012. Travel Med"/>
   <result pre="Geneva 2009. 35WichmannO, MuehlbergerN, JelinekT. Dengue—the underestimated risk in travellers." exact="Dengue" post="Bull. 2003;27:126–37. 36Centers for Disease Control and Prevention. Chapter"/>
   <result pre="N Engl J Med. 2017;376(6):54810.1056/NEJMra150843528177860 39MasyeniS, YohanB, SomiaIKA, MyintKSA, SasmonoRT." exact="Dengue" post="infection in international travellers visiting Bali, Indonesia. J Travel"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6895170\results\search\tropicalVirus\results.xml">
   <result pre="different viruses: (A) HIV, (B) Avian influenza, (C) Hepatitis (D)" exact="Dengue" post="and (E) Human influenza. The networks are generated using"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6897401\results\search\tropicalVirus\results.xml">
   <result pre="CerqueiraE. M., LimaM. M., PybusO. G., AlcantaraL. C. J.Epidemiology of" exact="Chikungunya" post="Virus in Bahia, Brazil, 2014–2015. PLoS Currents Outbreaks. 2016;110.1371/currents.outbreaks.c97507e3e48efb946401755d468c28b227330849"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6902501\results\search\tropicalVirus\results.xml">
   <result pre="is related to the viruses causing dengue, yellow fever, and" exact="West Nile" post="fevers [1]. The first case of JE was documented"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904267\results\search\tropicalVirus\results.xml">
   <result pre="neutralization ability of a human monoclonal antibody against serotype 1" exact="Dengue" post="virus. Front. Microbiol.9:1214. 10.3389/fmicb.2018.0121429928270 Makulska-NowakE. (1993). Muromonab CD3–the first"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6904818\results\search\tropicalVirus\results.xml">
   <result pre="6904818S1525-0016(19)30458-7 doi: 10.1016/j.ymthe.2019.10.004 : Commentary Repurposing an HIV Drug for" exact="Zika" post="Virus Therapy XieXuping1ShiPei-Yongpeshi@utmb.edu1∗[1], ∗Corresponding author: Pei-Yong Shi, Department of"/>
   <result pre="American Society of Gene and Cell Therapy, 2019 Main Text" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus that can cause"/>
   <result pre="a US Food and Drug Administration (FDA)-approved HIV drug, inhibits" exact="ZIKV" post="RNA-dependent RNA polymerase (RdRp), leading to potent anti-ZIKV activity"/>
   <result pre="repurposing clinically approved drugs for possible prevention and treatment of" exact="ZIKV" post="infection and its associated disease. Although emerging infectious diseases"/>
   <result pre="syndrome (SARS), middle east respiratory syndrome (MERS), Ebola, Nipah, chikungunya," exact="West Nile," post="yellow fever, and ZIKV. Given the unpredictable nature of"/>
   <result pre="blocking the viral RdRp (Figure 1). Figure 1 Rilpivirine Inhibits" exact="ZIKV" post="by Blocking Viral RdRp (A) Proposed rilpivirine binding site"/>
   <result pre="by Blocking Viral RdRp (A) Proposed rilpivirine binding site on" exact="ZIKV" post="RdRp. ZIKV NS5 (PDB: 5TMH)15 contains an N-terminal methyltransferase"/>
   <result pre="Viral RdRp (A) Proposed rilpivirine binding site on ZIKV RdRp." exact="ZIKV" post="NS5 (PDB: 5TMH)15 contains an N-terminal methyltransferase domain (blue)"/>
   <result pre="al.2 found that human primary astrocytes are more susceptible to" exact="ZIKV" post="infection than several other human cell types, including fetal"/>
   <result pre="including fetal microglia, fetal neuron, and neural progenitor cells. Using" exact="ZIKV" post="infection of astrocytes as a screening assay, they identified"/>
   <result pre="astrocytes as a screening assay, they identified rilpivirine as a" exact="ZIKV" post="inhibitor from eight FDA-approved HIV nucleoside and non-nucleoside reverse"/>
   <result pre="reverse transcriptase drugs. Rilpivirine is a non-nucleoside inhibitor and suppressed" exact="ZIKV" post="RNA replication by ∼70% at 5 μM concentration. The"/>
   <result pre="The higher susceptibility of astrocytes than other cell types to" exact="ZIKV" post="infection is intriguing because previous studies suggested that ZIKV"/>
   <result pre="to ZIKV infection is intriguing because previous studies suggested that" exact="ZIKV" post="preferentially infected human neural progenitor cells.6, 7, 8 Since"/>
   <result pre="ZIKV preferentially infected human neural progenitor cells.6, 7, 8 Since" exact="ZIKV" post="was proposed as a potential oncolytic virotherapy for glioblastoma,7,"/>
   <result pre="also inhibits closely related flaviviruses, such as dengue, yellow fever," exact="West Nile," post="and Japanese encephalitis viruses. Nevertheless, the authors have established"/>
   <result pre="the authors have established the antiviral activity of rilpivirine against" exact="ZIKV" post="in cell culture. Second, Sariyer et al.2 provided five"/>
   <result pre="provided five lines of evidence to support that rilpivirine targets" exact="ZIKV" post="RdRp (Figure 1A). (1) Computational docking suggests that rilpivirine"/>
   <result pre="design of analogs with improved potency. (2) The selection of" exact="ZIKV" post="variants resistant to rilpivirine will identify mutations that are"/>
   <result pre="al.2 demonstrated the in vivo efficacy of rilpivirine in a" exact="ZIKV" post="interferon α/β receptor (IFNAR)−/− mouse (type I interferon receptor"/>
   <result pre="cells, and neurons, but not neural progenitor cells. In addition," exact="ZIKV" post="infection caused significant inflammation and abundant apoptotic/necrotic cell damage."/>
   <result pre="good example of repurposing clinical drugs for potential treatment of" exact="ZIKV" post="infection. For any repurposed drug to work, the compound"/>
   <result pre="trials for the new indication.11 As rilpivirine inhibits HIV-1 and" exact="ZIKV" post="with EC50 in the single-digit nanomolar and micromolar range,"/>
   <result pre="single-digit nanomolar and micromolar range, respectively,2, 12 its potency against" exact="ZIKV" post="needs to be improved to ensure clinical efficacy in"/>
   <result pre="lead optimization could be tested against ZIKV. Because HIV-1 and" exact="ZIKV" post="may have different structure-and-activity (SAR) relationships, compounds with better"/>
   <result pre="have different structure-and-activity (SAR) relationships, compounds with better potency for" exact="ZIKV" post="may be identified from the rilpivirine analogs. Meanwhile, efforts"/>
   <result pre="A report from the Global Virus NetworkAntiviral Res.144201722324628595824 2SariyerI.K.GordonJ.BurdoT.H.WolleboH.GiantiE.DonadoniM.BellizziA.CicaleseS.LoomisR.RobinsonJ.A.Suppression of" exact="Zika" post="virus infection in the brain by the antiretroviral drug"/>
   <result pre="Infect. Dis.2201617017227623030 4BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MuñozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.A Screen of FDA-Approved Drugs for Inhibitors of" exact="Zika" post="Virus InfectionCell Host Microbe20201625927027476412 5XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of"/>
   <result pre="Zika Virus InfectionCell Host Microbe20201625927027476412 5XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
   <result pre="Exp. Med.21420172843285728874392 8ChenQ.WuJ.YeQ.MaF.ZhuQ.WuY.ShanC.XieX.LiD.ZhanX.Treatment of Human Glioblastoma with a Live Attenuated" exact="Zika" post="Virus Vaccine CandidateMBio92018e01683-1830228241 9FerreiraA.C.Zaverucha-do-ValleC.ReisP.A.Barbosa-LimaG.VieiraY.R.MattosM.SilvaP.P.SacramentoC.de Castro Faria NetoH.C.CampanatiL.Sofosbuvir protects Zika"/>
   <result pre="Attenuated Zika Virus Vaccine CandidateMBio92018e01683-1830228241 9FerreiraA.C.Zaverucha-do-ValleC.ReisP.A.Barbosa-LimaG.VieiraY.R.MattosM.SilvaP.P.SacramentoC.de Castro Faria NetoH.C.CampanatiL.Sofosbuvir protects" exact="Zika" post="virus-infected mice from mortality, preventing short- and long-term sequelaeSci."/>
   <result pre="sequelaeSci. Rep.72017940928842610 10DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.N.XieX.P.ShiP.Y.QinC.F.Adenosine Analog NITD008 Is a Potent Inhibitor of" exact="Zika" post="VirusOpen Forum Infect. Dis.32016ofw17527747251 11ZouJ.ShiP.Y.Strategies for Zika drug discoveryCurr."/>
   <result pre="Potent Inhibitor of Zika VirusOpen Forum Infect. Dis.32016ofw17527747251 11ZouJ.ShiP.Y.Strategies for" exact="Zika" post="drug discoveryCurr. Opin. Virol.352019192630852345 12AzijnH.TirryI.VingerhoetsJ.de BéthuneM.P.KrausG.BovenK.JochmansD.Van CraenenbroeckE.PicchioG.RimskyL.T.TMC278, a next-generation"/>
   <result pre="and NNRTI-resistant HIV-1Antimicrob. Agents Chemother.54201071872719933797 13NobleC.G.LimS.P.AroraR.YokokawaF.NilarS.SehC.C.WrightS.K.BensonT.E.SmithP.W.ShiP.Y.A Conserved Pocket in the" exact="Dengue" post="Virus Polymerase Identified through Fragment-based ScreeningJ. Biol. Chem.29120168541854826872970 14RichnerJ.M.JaggerB.W.ShanC.FontesC.R.DowdK.A.CaoB.HimansuS.CaineE.A.NunesB.T.D.MedeirosD.B.A.Vaccine"/>
   <result pre="Identified through Fragment-based ScreeningJ. Biol. Chem.29120168541854826872970 14RichnerJ.M.JaggerB.W.ShanC.FontesC.R.DowdK.A.CaoB.HimansuS.CaineE.A.NunesB.T.D.MedeirosD.B.A.Vaccine mediated protection against" exact="Zika" post="virus induced congenital diseaseCell1702017273283.e1228708997 15DuanW.SongH.WangH.ChaiY.SuC.QiJ.ShiY.GaoG.F.The crystal structure of Zika"/>
   <result pre="against Zika virus induced congenital diseaseCell1702017273283.e1228708997 15DuanW.SongH.WangH.ChaiY.SuC.QiJ.ShiY.GaoG.F.The crystal structure of" exact="Zika" post="virus NS5 reveals conserved drug targetsEMBO J.36201791993328254839"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6905541\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus Re-introduction of dengue virus serotype 2 in the"/>
   <result pre="has been facing large arbovirus epidemics year by year [5]." exact="Dengue" post="virus (DENV) is an arbovirus that belongs to the"/>
   <result pre="mosquitoes from genera Aedes. Four genetically related but antigenically distinct" exact="DENV" post="serotypes have been described: DENV-1, DENV-2, DENV-3, and DENV-4."/>
   <result pre="have been described: DENV-1, DENV-2, DENV-3, and DENV-4. Besides Brazil," exact="DENV" post="is widely distributed across tropical and subtropical areas of"/>
   <result pre="since late 2014, different arboviruses such as chikungunya virus (CHIKV)," exact="Zika" post="virus (ZIKV), and yellow fever virus (YFV), joined alternating"/>
   <result pre="the statal health department claimed to intensify surveillance, even though" exact="DENV" post="detection during 2017 was low, and the focus was"/>
   <result pre="lineage IV could be consistent with the fact that other" exact="DENV" post="serotypes and arboviruses like ZIKV and CHIKV have been"/>
   <result pre="with the fact that other DENV serotypes and arboviruses like" exact="ZIKV" post="and CHIKV have been responsible for the main epidemics"/>
   <result pre="fact that other DENV serotypes and arboviruses like ZIKV and" exact="CHIKV" post="have been responsible for the main epidemics of these"/>
   <result pre="last years in the American continent [37–39]. Furthermore, the four" exact="DENV" post="serotypes are circulating in the Americas, and have been"/>
   <result pre="may be difficult to trace the exact history of each" exact="DENV" post="serotype in the whole Latin America, it is visible"/>
   <result pre="[41]. This means that in a certain way, Latin American" exact="DENV" post="history is capturing the Brazilian one. In this regard,"/>
   <result pre="Cruz. 1990, 85: 25310.1590/s0074-027619900002000222087163 9NogueiraRM, MiagostovichMP, LampeE, SouzaRW, ZagneSM, SchatzmayrHG." exact="Dengue" post="epidemic in the stage of Rio de Janeiro, Brazil,"/>
   <result pre="em Saúde.–Brasília: Ministério da Saúde; 2011 p. 157–72. 14CONASS. 2011." exact="Dengue" post="situação atual, desafios e estratégias para enfrentamento [Dengue: presente"/>
   <result pre="de Morais BronzoniRV, BoschI, NogueiraML. Circulation of different lineages of" exact="Dengue" post="virus 2, genotype American/Asian in Brazil: dynamics and molecular"/>
   <result pre="Janeiro, Brazil. J Med Virol. 2016;88(7):1130–6. 10.1002/jmv.2446427061403 17NogueiraRMR &amp;amp; EppinghausALF." exact="Dengue" post="virus type 4 arrives in the state of Rio"/>
   <result pre="análise da situação de saúde e da epidemia pelo vírus" exact="Zika" post="e por outras doenças transmitidas pelo Aedes aegypti. Pages"/>
   <result pre="de Janeiro. Boletim epidemiológico arboviroses N° 001/2017. Cenário epidemiológico: Dengue," exact="Chikungunya" post="e Zika no Estado RJ. http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=7eeHrPVyjGk%3d 22Secretaria de estado"/>
   <result pre="Boletim epidemiológico arboviroses N° 001/2017. Cenário epidemiológico: Dengue, Chikungunya e" exact="Zika" post="no Estado RJ. http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=7eeHrPVyjGk%3d 22Secretaria de estado de saúde"/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 5 de 2018. http://portalarquivos2.saude.gov.br/images/pdf/2018/fevereiro/20/2018-007.pdf 25Secretaria"/>
   <result pre="de dengue, febre de chikungunya e doença aguda pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52 de 2018. http://portalarquivos2.saude.gov.br/images/pdf/2019/janeiro/28/2019-002.pdf 26Secretaria"/>
   <result pre="de Janeiro. Boletim epidemiológico arboviroses. N° 002/2019. Cenário epidemiológico: Dengue," exact="Chikungunya" post="e Zika no Estado RJ. 1° semestre de 2019."/>
   <result pre="Boletim epidemiológico arboviroses. N° 002/2019. Cenário epidemiológico: Dengue, Chikungunya e" exact="Zika" post="no Estado RJ. 1° semestre de 2019. http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=F%2bJ77ZiVqng%3d 35Secretaria"/>
   <result pre="a junho 2008. http://bvsms.saude.gov.br/bvs/publicacoes/informe_epidemiologico_dengue_janeiro_junho_2008.pdf 36PAHO, Pan-American Health Organization. Actualización Epidemiológica" exact="Dengue" post="2019. https://www.paho.org/hq/index.php?option=com_docman&amp;amp;view=download&amp;amp;category_slug=2019-3&amp;amp;alias=47784-22-de-febrero-de-2019-dengue-actualizacion-epidemiologica&amp;amp;Itemid=270&amp;amp;lang=en 37Brathwaite DickO, San MartínJL, MontoyaRH, del DiegoJ,"/>
   <result pre="http://www.paho.org/data/index.php/es/temas/indicadores-dengue/dengue-regional/506-dengue-reg-ano-es.html?start=1 42TeixeiraMG, SiqueiraJBJr, FerreiraGLC, BricksL, JointG (2013) Epidemiological Trends of" exact="Dengue" post="Disease in Brazil (2000–2010): A Systematic Literature Search and"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6906739\results\search\tropicalVirus\results.xml">
   <result pre="IFITM proteins mediate cellular resistance to influenza A H1N1 virus," exact="West Nile" post="virus, and dengue virus. Cell139:1243–1254. doi:10.1016/j.cell.2009.12.017.20064371 9.HaoL, SakuraiA, WatanabeT,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6908683\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.1038/s41467-019-13589-1 : Article Maternal vaccination and protective immunity against" exact="Zika" post="virus vertical transmission http://orcid.org/0000-0002-3953-3782ShanChao12XieXuping1LuoHuanle3MuruatoAntonio E.3LiuYang1WakamiyaMaki1LaJun-Ho4ChungJin Mo4WeaverScott C.35678910WangTian3711ShiPei-Yongpeshi@utmb.edu156781112[1], 0000 0001"/>
   <result pre="this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract An important goal of the" exact="Zika" post="virus (ZIKV) vaccine is to prevent a congenital syndrome"/>
   <result pre="of pregnant women, but studies directly evaluating maternal vaccination for" exact="ZIKV" post="are lacking. Here we report maternal vaccination using a"/>
   <result pre="are lacking. Here we report maternal vaccination using a live-attenuated" exact="ZIKV" post="vaccine (3ʹUTR-∆10-LAV) in a pregnant mouse model. Maternal immunization"/>
   <result pre="or offspring behavior. One maternal immunization fully protects dams against" exact="ZIKV" post="infection and in utero transmission. Although neutralizing antibody alone"/>
   <result pre="dams transfer maternal antibodies to pups, which protect neonates against" exact="ZIKV" post="infection. Notably, pregnancy weakens maternal T cell response to"/>
   <result pre="individuals, 3ʹUTR-∆10-LAV may also be considered for maternal vaccination. A" exact="Zika" post="virus vaccine should protect the fetus during pregnancy. Here,"/>
   <result pre="should protect the fetus during pregnancy. Here, using a live-attenuated" exact="Zika" post="vaccine, the authors show that a higher neutralizing antibody"/>
   <result pre="(Center for Information Technology, National Institutes of Health) U19AI142759ShiPei-Yong Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus that has recently"/>
   <result pre="emerged and caused major epidemics1. The most devastating disease of" exact="ZIKV" post="infection is congenital Zika syndrome, including microcephaly, congenital malformations,"/>
   <result pre="epidemics1. The most devastating disease of ZIKV infection is congenital" exact="Zika" post="syndrome, including microcephaly, congenital malformations, and demise fetuses from"/>
   <result pre="malformations, and demise fetuses from infected pregnant women2,3. In adults," exact="ZIKV" post="infection is associated with Guillain-Barré syndrome (GBS), an autoimmune"/>
   <result pre="One out of seven infants born to mothers with laboratory-confirmed" exact="ZIKV" post="infection during pregnancy has birth defects, most likely due"/>
   <result pre="explosive epidemics led the World Health Organization (WHO) to declare" exact="ZIKV" post="as a Public Health Emergency of International Concern in"/>
   <result pre="Emergency of International Concern in February 2016. Since then, various" exact="ZIKV" post="vaccine platforms have been developed, with the goal to"/>
   <result pre="entered clinical phase I/II trials8–10. We previously developed a live-attenuated" exact="ZIKV" post="vaccine with a 10-nucleotide deletion in the 3ʹUTR of"/>
   <result pre="viral genome (3ʹUTR-∆10-LAV). A single-dose immunization of 3ʹUTR-∆10-LAV protected against" exact="ZIKV" post="infection and in utero transmission in mice and non-human"/>
   <result pre="the above promising progress, a number of important questions about" exact="ZIKV" post="vaccine research remain to be addressed. Could maternal vaccination"/>
   <result pre="and in utero transmission? Does pregnancy affect immune responses to" exact="ZIKV" post="vaccination? Does maternal immunity derived from vaccination during pregnancy"/>
   <result pre="and non-pregnant individuals require different levels of immunity to prevent" exact="ZIKV" post="infections? Is neutralizing antibody alone sufficient to prevent in"/>
   <result pre="critical to guide the clinical development and regulatory approval of" exact="ZIKV" post="vaccines. In this study, we have addressed the above"/>
   <result pre="and fetuses. A single-dose maternal immunization fully protects dams against" exact="ZIKV" post="infection and in utero transmission. Neutralizing antibody alone is"/>
   <result pre="Furthermore, maternal neutralizing antibodies are transferred to offspring to prevent" exact="ZIKV" post="infection. Results Rapid immunity and long-lasting neutralizing antibodies We"/>
   <result pre="pregnant mice were subcutaneously infected with 105 FFU wild-type (WT)" exact="ZIKV" post="or 3ʹUTR-∆10-LAV. At E18.5, the animals were sacrificed and"/>
   <result pre="twelve-week-old pregnant mice were subcutaneously infected with 105 FFU WT" exact="ZIKV" post="(n = 5) and 3′UTR-Δ10-LAV (Δ10; n = 5) at E0.5. Maternal and"/>
   <result pre="of fetuses collected at E18.5 from placebo, Δ10, and WT" exact="ZIKV" post="groups. Scale bar, 5 mm. Viral loads quantified by plaque"/>
   <result pre="spleen (50%), brain (100%), and placenta (100%) from the WT" exact="ZIKV" post="group; in contrast, no infectious virus was found in"/>
   <result pre="(defined by no increase of neutralizing antibody titers after WT" exact="ZIKV" post="challenge) in A129 mice12. Thus, the dose of 105"/>
   <result pre="(Fig. 2b). After subcutaneously challenged with 106 PFU Puerto Rico" exact="ZIKV" post="strain (PRVABC59) at E10.5, the PBS placebo group developed"/>
   <result pre="with the neutralizing antibody titers detected at E10.5 (Fig. 2b)," exact="ZIKV" post="challenge did not increase the maternal neutralizing titers at"/>
   <result pre="for NT50 measurement and subcutaneously challenged with 106 PFU of" exact="ZIKV" post="PRVABC59. Viremia was quantified by at E12.5. Maternal and"/>
   <result pre="well as fetal weight loss (Supplementary Fig. 7c-h). Challenge with" exact="ZIKV" post="PRVABC59 did not significantly boost maternal neutralizing antibody titers"/>
   <result pre="characterize the effect of maternal vaccination on offspring protection against" exact="ZIKV" post="infection. We performed three experiments to address this question"/>
   <result pre="first experiment examined the protection of maternally transferred immunity against" exact="ZIKV" post="infection in pups. Dams subcutaneously immunized with 103 FFU"/>
   <result pre="naïve pups succumbed to challenges as low as 1 PFU" exact="ZIKV" post="(Supplementary Fig. 8). The results demonstrate that maternal antibodies"/>
   <result pre="to pups through placenta and milk) can protect neonates against" exact="ZIKV" post="infection. Fig. 3 Protection of offspring born to dams"/>
   <result pre="2 pups were subcutaneously challenged at one-day-old with 100 PFU" exact="ZIKV" post="PRVABC59 and monitored for survival for 21 days. Group"/>
   <result pre="day 70, these mice were subcutaneously challenged with 106 FFU" exact="ZIKV" post="PRVABC59 and measured for viremia on day 72. b"/>
   <result pre="n = 9). d Survival of pups after challenge with 100 FFU" exact="ZIKV" post="PRVABC59 (Group 2, n = 11 or 12). e Decay kinetics"/>
   <result pre="Fig. 2). After challenging the 70-day-old pups with 106 PFU" exact="ZIKV" post="PRVABC59, 32% of the animals were protected against viremia"/>
   <result pre="that a minimal NT50 of 1/120 is required to prevent" exact="ZIKV" post="infection accompanied by viremia (Fig. 3g). The third experiment"/>
   <result pre="bled for NT50 measurement and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. The pregnant offspring were quantified for viremia at"/>
   <result pre="minimal NT50 titers are required to protect different organs against" exact="ZIKV" post="infection during pregnancy: 1/200, 1/290, 1/290, and 1/430 for"/>
   <result pre="measured for NT50 levels and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. The animals were assayed for viremia at E12.5"/>
   <result pre="The pregnant mice were then subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59 at E10.5 and measured for viremia at E12.5."/>
   <result pre="mice require distinct levels of neutralizing antibodies to prevent apparent" exact="ZIKV" post="infection. Ten- to twelve-week-old non-pregnant mice were passively transferred"/>
   <result pre="for measuring NT50 titers and subcutaneously challenged with 106 PFU" exact="ZIKV" post="PRVABC59. Viremia was assayed on day 2 (peak viremia"/>
   <result pre="neutralizing antibodies, T cells play an important role in preventing" exact="ZIKV" post="infection and disease19–21. Thus, we examined T cell response"/>
   <result pre="for T cell analysis by culturing splenocytes, stimulating them with" exact="ZIKV" post="or a viral envelope peptide19, and analysis by an"/>
   <result pre="of CD8+ T cell subsets. Splenocytes were stimulated by a" exact="ZIKV" post="E peptide. Cytokines IL-2 (e) and IFN-γ (f) in"/>
   <result pre="Data file. Discussion The feasibility of a safe and efficacious" exact="ZIKV" post="vaccine is supported by the availability of clinically licensed"/>
   <result pre="and dengue). Compared with the licensed flavivirus vaccines, a successful" exact="ZIKV" post="vaccine has to overcome the unique challenge of protecting"/>
   <result pre="it is essential to determine the correlations of protection against" exact="ZIKV" post="infection in non-pregnant individuals as well as against in"/>
   <result pre="in utero transmission in pregnant women. Given the decline of" exact="ZIKV" post="human cases, identifying these parameters has become even more"/>
   <result pre="that neutralizing antibody alone is sufficient to protect against apparent" exact="ZIKV" post="infection as well as in utero transmission in mice."/>
   <result pre="in utero transmission (NT50 ≥ 1/460) than that required to prevent apparent" exact="ZIKV" post="infection in non-pregnant mice (NT50 ≥ 1/130). The requirement of NT50 ≥ 1/460"/>
   <result pre="(Fig. 4). The requirement of NT50 ≥ 1/130 for prevention of apparent" exact="ZIKV" post="infection in non-pregnant mice is in agreement with previous"/>
   <result pre="development of humoral immunity. Besides prevention of in utero transmission," exact="ZIKV" post="vaccine development also has to overcome the challenge of"/>
   <result pre="Recent studies reported that passively transferred DENV-specific antibodies or previous" exact="DENV" post="infection could increase ZIKV pathogenesis in pregnant mice through"/>
   <result pre="passively transferred DENV-specific antibodies or previous DENV infection could increase" exact="ZIKV" post="pathogenesis in pregnant mice through increasing damage to the"/>
   <result pre="are needed to further determine if pre-immunity derived from natural" exact="DENV" post="or other flavivirus infection enhances ZIKV infection and congenital"/>
   <result pre="pre-immunity derived from natural DENV or other flavivirus infection enhances" exact="ZIKV" post="infection and congenital syndromes39. Vaccination with 3ʹUTR-∆10-LAV may mitigate"/>
   <result pre="detected by the current assays. Infection of placenta with WT" exact="ZIKV" post="was recently shown to mediate pregnancy complications42,43, suggesting that"/>
   <result pre="transmission, transferred maternal antibodies to pups, and protected neonates against" exact="ZIKV" post="infection. However, the protection of offspring declined as the"/>
   <result pre="it should be emphasized that an ideal vaccination strategy for" exact="ZIKV" post="is to immunize children before they reach child-bearing age."/>
   <result pre="maternal vaccination and protective immunity for vertical transmission in a" exact="ZIKV" post="pregnant mouse model. Compared with LAVs, other vaccine platforms"/>
   <result pre="mouse model. Compared with LAVs, other vaccine platforms (particularly inactivated" exact="ZIKV" post="vaccine or DNA subunit vaccine) may be more appropriate"/>
   <result pre="pregnant women because of their non-infective nature. Although both inactivated" exact="ZIKV" post="vaccine or DNA subunit vaccine require multiple doses, the"/>
   <result pre="vaccine platforms in parallel to provide complementary options for preventing" exact="ZIKV" post="infection and disease. Finally, caution should be taken when"/>
   <result pre="made to minimize animal suffering. Viruses, antibodies, and cells The" exact="ZIKV" post="Cambodian strain FSS13025 (GenBank number KU955593.1, referred as WT"/>
   <result pre="in text) was produced from an infectious cDNA clone47. The" exact="ZIKV" post="3’UTR-∆10-LAV strain was generated from the FSS13025 infectious cDNA"/>
   <result pre="strain was generated from the FSS13025 infectious cDNA clone12. The" exact="Zika" post="Puerto Rico strain PRVABC59 (GenBank number KU501215) used for"/>
   <result pre="used to measure the neutralizing antibody titer using an mCherry" exact="ZIKV" post="reporter virus11. Supplementary Fig. 11 depicts the construction of"/>
   <result pre="penicillin/streptomycin and then incubated with an equal volume of mCherry" exact="ZIKV" post="reporter virus at 37 °C for 1 h. Antibody-virus complexes were"/>
   <result pre="stage (E0.5). The mice were infected with 105 FFU WT" exact="ZIKV" post="or 3ʹUTR-∆10-LAV by subcutaneous route at E0.5 or E10.5."/>
   <result pre="for 30 min prior to measuring neutralizing antibodies by the mCherry" exact="ZIKV" post="reporter virus as described above. A129 mouse pregnancy efficacy"/>
   <result pre="retro orbital sinus (R.O.), and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. At E12.5, mice were anesthetized"/>
   <result pre="test. All antibody neutralization titers were determined using an mCherry" exact="ZIKV" post="as described above. Behavioral assays Ten- to twelve-week-old A129"/>
   <result pre="and the force evoking such withdrawal was recorded. Virulence of" exact="ZIKV" post="in one-day-old A129 pups To determine the lethal dose"/>
   <result pre="in one-day-old A129 pups To determine the lethal dose of" exact="ZIKV" post="PRVABC59 on one-day-old A129 pups, pups were injected with"/>
   <result pre="pups, pups were injected with 1, 10, or 100 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route and monitored for morbidity and"/>
   <result pre="morbidity and mortality. To test the maternal antibody protection against" exact="ZIKV" post="infection, one-day-old pups from 3’UTR-∆10-LAV- or PBS-immunized mice were"/>
   <result pre="3’UTR-∆10-LAV- or PBS-immunized mice were inoculated subcutaneously with 100 PFU" exact="ZIKV" post="PRVABC59. The infected pups were monitored for morbidity and"/>
   <result pre="the mice were bled and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. On day 2 post-challenge, the"/>
   <result pre="the mice were bled and immediately challenged with 106 PFU" exact="ZIKV" post="PRVABC59 via subcutaneous route. The mice were bled for"/>
   <result pre="above. Neutralization antibodies in fetal blood were measured using mCherry" exact="ZIKV" post="reporter virus infection assay as described above. Intracellular cytokine"/>
   <result pre="analyses. Approximately 2.5 × 106 splenocytes were stimulated with 105 FFU live" exact="ZIKV" post="(strain FSS13025) for 24 h or 10 mg/mL E peptide (amino"/>
   <result pre="for 24 h or 10 mg/mL E peptide (amino acids 294–302 from" exact="ZIKV" post="polyprotein) for 5 h. Live ZIKV was used as a"/>
   <result pre="peptide (amino acids 294–302 from ZIKV polyprotein) for 5 h. Live" exact="ZIKV" post="was used as a stimulant to measure CD4+ T"/>
   <result pre="were plated in 96-well plates and stimulated with 1.2 × 104 FFU" exact="ZIKV" post="FSS13025 or 10 mg/mL E peptide19 for 3 days. Culture"/>
   <result pre="of Emerging Virus and Arboviruses (WRCEVA) from UTMB for providing" exact="ZIKV" post="PRVABC59 strain and ZIKV-specific hyper-immune ascitic fluid. P.-Y.S. lab"/>
   <result pre="causalityN. Engl. J. Med.201610.1056/NEJMsr160433828029926 4.Cao-LormeauVMet al.Guillain-Barre Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 5.Oehler,"/>
   <result pre="in French Polynesia: a case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 5.Oehler, E. et al." exact="Zika" post="virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia,"/>
   <result pre="Zika-associated birth defects and neurodevelopmental abnormalities possibly associated with congenital" exact="Zika" post="virus infection—U.S. territories and freely associated states, 2018Mmwr. Morb."/>
   <result pre="challengesCell. Host. Microbe201824121710.1016/j.chom.2018.05.02130008291 8.GaudinskiMRet al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="double-blind, placebo-controlled clinical trialsLancet201839156357110.1016/S0140-6736(17)33106-929217375 11.ShanCet al.A single-dose live-attenuated vaccine prevents" exact="Zika" post="virus pregnancy transmission and testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 12.ShanCet al.A"/>
   <result pre="virus pregnancy transmission and testis damageNat. Commun.2017867610.1038/s41467-017-00737-828939807 12.ShanCet al.A live-attenuated" exact="Zika" post="virus vaccine candidate induces sterilizing immunity in mouse modelsNat."/>
   <result pre="et al. Treatment of human glioblastoma with a live attenuated" exact="Zika" post="virus vaccine candidate. MBio9, 10.1128/mBio.01683-18 (2018). 14.ZouJet al.A single-dose"/>
   <result pre="vaccine candidate. MBio9, 10.1128/mBio.01683-18 (2018). 14.ZouJet al.A single-dose plasmid-launched live-attenuated" exact="Zika" post="vaccine induces protective immunityEBioMedicine2018369210210.1016/j.ebiom.2018.08.05630201444 15.ChenJet al.Outcomes of congenital Zika"/>
   <result pre="live-attenuated Zika vaccine induces protective immunityEBioMedicine2018369210210.1016/j.ebiom.2018.08.05630201444 15.ChenJet al.Outcomes of congenital" exact="Zika" post="disease depend on timing of infection and maternal-fetal interferon"/>
   <result pre="interferon actionCell Rep.2017211588159910.1016/j.celrep.2017.10.05929117563 16.DengYQet al.Intranasal infection and contact transmission of" exact="Zika" post="virus in guinea pigsNat. Commun.20178164810.1038/s41467-017-01923-429162827 17.FoudaGGMartinezDRSwamyGKPermarSRThe Impact of IgG"/>
   <result pre="and role of the CD8(+) T cell response during primary" exact="Zika" post="virus infection in miceCell. Host. Microbe201721354610.1016/j.chom.2016.12.01028081442 20.GrifoniAet al.Prior Dengue"/>
   <result pre="primary Zika virus infection in miceCell. Host. Microbe201721354610.1016/j.chom.2016.12.01028081442 20.GrifoniAet al.Prior" exact="Dengue" post="virus exposure shapes T cell immunity to Zika virus"/>
   <result pre="20.GrifoniAet al.Prior Dengue virus exposure shapes T cell immunity to" exact="Zika" post="virus in humansJ. Virol.201710.1128/JVI.01469-1728978707 21.WenJet al.Identification of Zika virus"/>
   <result pre="immunity to Zika virus in humansJ. Virol.201710.1128/JVI.01469-1728978707 21.WenJet al.Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 23.LaroccaRAet al.Vaccine protection against Zika virus from"/>
   <result pre="and licensure of Zika vaccine candidatesVaccine20193786386810.1016/j.vaccine.2018.12.04030639461 23.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 24.AbbinkPet al.Therapeutic and protective efficacy of"/>
   <result pre="24.AbbinkPet al.Therapeutic and protective efficacy of a dengue antibody against" exact="Zika" post="infection in rhesus monkeysNat. Med.20182472172310.1038/s41591-018-0056-029867228 25.AbbinkPet al.Protective efficacy of"/>
   <result pre="monkeysNat. Med.20182472172310.1038/s41591-018-0056-029867228 25.AbbinkPet al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 26.EspinosaDet al.Passive transfer of"/>
   <result pre="monkeysScience20163531129113210.1126/science.aah615727492477 26.EspinosaDet al.Passive transfer of immune sera induced by a" exact="Zika" post="virus-like particle vaccine protects AG129 mice against lethal Zika"/>
   <result pre="a Zika virus-like particle vaccine protects AG129 mice against lethal" exact="Zika" post="virus challengeEBioMedicine201827617010.1016/j.ebiom.2017.12.01029269041 27.JamiesonDJTheilerRNRasmussenSAEmerging infections and pregnancyEmerg. Infect. Dis.2006121638164310.3201/eid1211.06015217283611 28.PazosMSperlingRSMoranTMKrausTAThe"/>
   <result pre="future of early infant protectionHum. Vaccines Immunotherapeutics2015112549255510.1080/21645515.2015.1070984 30.BardinaSVet al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunityScience201735617518010.1126/science.aal436528360135 31.DejnirattisaiWet al.Dengue virus"/>
   <result pre="pre-existing immunity to dengue virusNat. Commun.201781567410.1038/ncomms1567428643775 33.GeorgeJet al.Prior exposure to" exact="Zika" post="virus significantly enhances peak Dengue-2 Viremia in Rhesus MacaquesSci."/>
   <result pre="Viremia in Rhesus MacaquesSci. Rep.201771049810.1038/s41598-017-10901-128874759 34.BrownJAet al.Dengue virus immunity increases" exact="Zika" post="virus-induced damage during pregnancyImmunity201910.1016/j.immuni.2019.01.00531732166 35.RathoreAPSSaronWAALimTJahanNSt JohnALMaternal immunity and antibodies"/>
   <result pre="JohnALMaternal immunity and antibodies to dengue virus promote infection and" exact="Zika" post="virus-induced microcephaly in fetusesSci. Adv.20195eaav320810.1126/sciadv.aav320830820456 36.CamargosVNet al.In-depth characterization of"/>
   <result pre="virus-induced microcephaly in fetusesSci. Adv.20195eaav320810.1126/sciadv.aav320830820456 36.CamargosVNet al.In-depth characterization of congenital" exact="Zika" post="syndrome in immunocompetent mice: antibody-dependent enhancement and an antiviral"/>
   <result pre="antiviral peptide therapyEBioMedicine20194451652910.1016/j.ebiom.2019.05.01431130472 37.Rodriguez-BarraquerIet al.Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic regionScience201936360761010.1126/science.aav661830733412 38.TerzianACBet al.Viral"/>
   <result pre="cytokine response profile does not support antibody-dependent enhancement in dengue-primed" exact="Zika" post="virus-infected patientsClin. Infect. Dis.2017651260126510.1093/cid/cix55829017246 39.RibeiroGSet al.Does immunity after Zika"/>
   <result pre="dengue-primed Zika virus-infected patientsClin. Infect. Dis.2017651260126510.1093/cid/cix55829017246 39.RibeiroGSet al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengueLancet Glob. Health20186e140e14110.1016/S2214-109X(17)30496-529389533 40.HalsteadSBAchieving safe,"/>
   <result pre="cross-protect against dengueLancet Glob. Health20186e140e14110.1016/S2214-109X(17)30496-529389533 40.HalsteadSBAchieving safe, effective, and durable" exact="Zika" post="virus vaccines: lessons from dengueLancet Infect. Dis.201717e378e38210.1016/S1473-3099(17)30362-628711586 41.HalsteadScott B.Which"/>
   <result pre="Zika virus vaccines: lessons from dengueLancet Infect. Dis.201717e378e38210.1016/S1473-3099(17)30362-628711586 41.HalsteadScott B.Which" exact="Dengue" post="Vaccine Approach Is the Most Promising, and Should We"/>
   <result pre="K.FikrigErolKongYongHorvathTamas L.WeatherbeeScottKlimanHarvey J.CoyneCarolyn B.IwasakiAkikoType I interferons instigate fetal demise after" exact="Zika" post="virus infectionScience Immunology2018319eaao168010.1126/sciimmunol.aao168029305462 44.collab: WHO.Vaccines and vaccination against yellow"/>
   <result pre="2012Mmwr-Morbidity Mortal. Wkly. Rep.201362131135 47.ShanCet al.An infectious cDNA clone of" exact="Zika" post="Virus to study viral virulence, mosquito transmission, and antiviral"/>
   <result pre="48.YangYet al.A cDNA clone-launched platform for high-yield production of inactivated" exact="Zika" post="vaccineEBioMedicine20171714515610.1016/j.ebiom.2017.02.00328196656 49.XieXet al.A single-dose live-attenuated Zika virus vaccine with"/>
   <result pre="high-yield production of inactivated Zika vaccineEBioMedicine20171714515610.1016/j.ebiom.2017.02.00328196656 49.XieXet al.A single-dose live-attenuated" exact="Zika" post="virus vaccine with controlled infection rounds that protects against"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6908948\results\search\tropicalVirus\results.xml">
   <result pre="intercontinental spread of hitherto obscure diseases such as chikungunya and" exact="Zika" post="have highlighted the significant threat to global health security"/>
   <result pre="et al., 1990). The flaviviruses Murray Valley encephalitis (MVEV) and" exact="West Nile" post="virus (Kunjin strain, KUNV) cause encephalitis, while dengue viruses"/>
   <result pre="bacterial, parasitic or viral agent – including RRV, BFV, and" exact="DENV" post="– were excluded. Determination of Background Infection Rates With"/>
   <result pre="have influenced the results obtained. There are both locally acquired" exact="DENV" post="infections and large numbers of Australian tourists returning with"/>
   <result pre="DENV infections and large numbers of Australian tourists returning with" exact="DENV" post="infection acquired overseas. However, few, if any, of the"/>
   <result pre="rate of transmission of the common arboviruses RRV, BFV, and" exact="DENV" post="is highest, the annual value might be less than"/>
   <result pre="of Hawkes (1964), who also described enhancement of infection by" exact="West Nile" post="virus (Hawkes, 1964). However, antibody-mediated enhancement of infection with"/>
   <result pre="antibody-mediated enhancement of infection with KUNV, an Australian strain of" exact="West Nile" post="virus, by human antisera has not been reported previously."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912272\results\search\tropicalVirus\results.xml">
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is an emerging human mosquito-transmitted pathogen of"/>
   <result pre="complications such as congenital defects and neurological disorders in adults." exact="ZIKV" post="infection is associated with induction of cell death. However,"/>
   <result pre="production. In this present study, we investigated the capacity of" exact="ZIKV" post="to delay host cell apoptosis. We provide evidence that"/>
   <result pre="ZIKV to delay host cell apoptosis. We provide evidence that" exact="ZIKV" post="has the ability to interfere with apoptosis whether it"/>
   <result pre="role for anti-apoptotic Bcl-2 family protein in the ability of" exact="ZIKV" post="to control apoptotic pathways, avoiding premature cell death and"/>
   <result pre="cell death and thereby promoting virus replication in the host-cell." exact="Zika" post="virus apoptosis viral replication Bcl-2 protein family 1. Introduction"/>
   <result pre="Zika virus apoptosis viral replication Bcl-2 protein family 1. Introduction" exact="Zika" post="virus (ZIKV), which is a flavivirus belonging to the"/>
   <result pre="which is a flavivirus belonging to the Flaviviridae family, like" exact="Dengue" post="virus (DENV), yellow fever virus (YFV) or West Nile"/>
   <result pre="family, like Dengue virus (DENV), yellow fever virus (YFV) or" exact="West Nile" post="virus (WNV), has become a major medical problem worldwide."/>
   <result pre="a major medical problem worldwide. The human disease known as" exact="Zika" post="fever is characterized by mild flu-like symptoms including fever,"/>
   <result pre="Polynesia outbreak in 2013 and in Brazil in 2015 [2,3]." exact="ZIKV" post="is an arbovirus, mainly transmitted to humans through the"/>
   <result pre="species [4]. Due to an increasingly global distribution of Aedes," exact="ZIKV" post="emergence is a threat in many areas that are"/>
   <result pre="are no longer necessarily located in intertropical areas [5]. The" exact="ZIKV" post="particle is composed of a single strand RNA molecule"/>
   <result pre="those that recently affected Brazil and the Americas [7]. Once" exact="ZIKV" post="has entered the human body, it targets many types"/>
   <result pre="virions by exocytosis. As with many other viruses, interactions between" exact="ZIKV" post="and its host trigger a variety of host responses"/>
   <result pre="and thus optimizes its spread [12]. Typically, alphaviruses such as" exact="CHIKV" post="(but also Sindbis virus, Ross River virus and Semliki"/>
   <result pre="was shown to induce a caspase-9-dependent apoptosis [15]. Whereas the" exact="WNV" post="capsid protein was shown to suppress the activation of"/>
   <result pre="late-onset apoptosis 48 h after infection of A549 cells with" exact="ZIKV" post="isolate PF13 [17]. In some other cell types (human"/>
   <result pre="contribute to persistent infection [18]. In the particular case of" exact="Zika" post="pathology, homeostasis disorder; involving a lack of apoptosis control,"/>
   <result pre="we examined the time course of cellular death associated with" exact="ZIKV" post="infection. We confirm that, in A549 cells infected with"/>
   <result pre="death. As this protection was also obtained in cells expressing" exact="ZIKV" post="&quot;replicons�?, we deduced that viral replication was efficient at"/>
   <result pre="that, with a subversion mechanism that remains to be elucidated," exact="ZIKV" post="is able to maintain an anti-apoptotic status in infected"/>
   <result pre="The clinical isolate PF-25013-18 (PF13) and the molecular clones of" exact="ZIKV" post="(BR15MC and MR766MC) have been previously described [20,21]. Vero"/>
   <result pre="and 100 μg.mL−1 zeocin (InvivoGen, Toulouse, France). To detect the" exact="ZIKV" post="envelope E protein (ZIKV-E), we used the mouse anti-pan"/>
   <result pre="h post-infection (hpi) or 2 h before infection (hbi) for" exact="ZIKV" post="infected cells. For the replicons, cells were treated 24"/>
   <result pre="Omega Microplate Reader (BMG LABTECH, Orthenberg, Germany). 2.9. Generation of" exact="ZIKV" post="Replicon by the ISA Method The production of HEK"/>
   <result pre="ISA Method The production of HEK 293T expressing a stable" exact="ZIKV" post="RNA replicon with GFP as a reporter protein, named"/>
   <result pre="ZIKV-GFP in the study, was based on the sequence of" exact="ZIKV" post="strain MR766 Uganda 47-NIID (Genbank access # LC002520) and"/>
   <result pre="1 µg.mL−1. The production of A549 cells transiently expressing a" exact="ZIKV" post="RNA replicon was based on the ISA method and"/>
   <result pre="p &amp;lt; 0.0001, ns = not significant. 3. Results 3.1." exact="ZIKV" post="Does Not Trigger Apoptosis Until the Release of Most"/>
   <result pre="previously demonstrated that a South Pacific epidemic clinical isolate of" exact="ZIKV" post="(PF13-25013-18) was able to infect A549 epithelial cells. These"/>
   <result pre="In order to characterize the cellular death profile that accompanies" exact="ZIKV" post="infection more precisely, we conducted a study of the"/>
   <result pre="viro-induced apoptosis, together with a regulatory mechanism implemented by the" exact="ZIKV" post="to delay apoptosis. To rule out that delayed apoptosis"/>
   <result pre="by other arboviruses like alphaviruses (Figure S2 and [12]). 3.2." exact="ZIKV" post="Infected Cells Display Resistance to Apoptosis Inducers Apoptosis can"/>
   <result pre="of apoptosis in infected cells led us to postulate that" exact="ZIKV" post="may modulate the apoptotic response of the cell, delaying"/>
   <result pre="through transient inhibition. To test this hypothesis, we investigated whether" exact="ZIKV" post="could counteract the effect of death inducers added during"/>
   <result pre="2 h post infection (Figure 3 and Figure 4). 3.2.1." exact="ZIKV" post="Provides Protection Against Death Receptor Mediated Cell Death To"/>
   <result pre="was observed when TNFα/CHX was added 2 h prior to" exact="ZIKV" post="infection. Conversely, if TNFα/CHX was added 2 h post"/>
   <result pre="by around 75% after treatment with TNFα/CHX (Figure 3C). 3.2.2." exact="ZIKV" post="Provides Protection Against Intrinsically Induced Cell Death Intrinsically induced"/>
   <result pre="of etoposide treatment was significantly reduced in the case where" exact="ZIKV" post="was added 2 h post-infection (Figure 4A). In addition,"/>
   <result pre="(Figure 4A). In addition, both BR15, the molecular clone of" exact="ZIKV" post="(Figure 4A) and a clinical isolate of the epidemic"/>
   <result pre="by MTT assay and caspase 3/7 activity again suggested that" exact="ZIKV" post="infection represses apoptosis, regardless of cell type and death"/>
   <result pre="death inducers (Figure 5A,B). In order to ensure that the" exact="ZIKV" post="mediated repression of apoptosis was conserved between ZIKV strains,"/>
   <result pre="that the ZIKV mediated repression of apoptosis was conserved between" exact="ZIKV" post="strains, we looked at the effect of apoptosis induction"/>
   <result pre="MR766-NIID isolated in Uganda in 1947 (MR766MC; Supplemental Figure S4)." exact="ZIKV" post="infection resulted in reduced apoptosis for all tested strains."/>
   <result pre="establish the death rate and degree of protection confirm that" exact="ZIKV" post="interferes with the achievement of apoptosis in response to"/>
   <result pre="response to a death signal. 3.3. Apoptosis is Repressed Through" exact="ZIKV" post="Replication Our data suggest that protection against an exogenous"/>
   <result pre="we exploited the &quot;replicon�? systems. 3.3.1. Cells Stably Expressing a" exact="ZIKV" post="Replicon are Protected from Intrinsically and Extrinsically Mediated Apoptosis"/>
   <result pre="both epidemic Asian (BR15MC) and historical African (MR766MC) strains of" exact="ZIKV" post="were found to be able to control apoptosis, we"/>
   <result pre="(Figure 6B) and released LDH activity (Figure 6C) demonstrated that" exact="ZIKV" post="replicon resulted in a significant reduction in the indicators"/>
   <result pre="replication of a viral RNA associated with the expression of" exact="ZIKV" post="NS proteins makes cells resistant to several extrinsic and"/>
   <result pre="and intrinsic apoptotic inducers. 3.3.2. A549 Cells Transiently Expressing a" exact="ZIKV" post="Replicon are Protected from Different Intrinsically Induced Apoptosis To"/>
   <result pre="the ISA method to obtain A549 cells transiently expressing a" exact="ZIKV" post="replicon with the non-structural sequences from BeH819015 (REP BR15)."/>
   <result pre="in an experiment conducted with A549 cells transiently expressing a" exact="ZIKV" post="replicon from the MR766 strain of ZIKV (Figure S5)."/>
   <result pre="transiently expressing a ZIKV replicon from the MR766 strain of" exact="ZIKV" post="(Figure S5). All together these results suggest that replication"/>
   <result pre="S5). All together these results suggest that replication of the" exact="ZIKV" post="was capable of inhibiting apoptosis. 3.4. ZIKV Promotes an"/>
   <result pre="replication of the ZIKV was capable of inhibiting apoptosis. 3.4." exact="ZIKV" post="Promotes an Anti-Apoptotic Prevailing Status in Infected Cells Through"/>
   <result pre="long delay in the onset of viral apoptosis induced by" exact="ZIKV" post="infection, particularly in the case of Asian viral strains"/>
   <result pre="in which anti-apoptotic activity prevails. The protective effect acquired with" exact="ZIKV" post="could be at the level of convergence of the"/>
   <result pre="anti-apoptotic activity of Bcl-2 family proteins. When Bcl-2/Bcl-XL is inhibited," exact="ZIKV" post="no longer allows a quantitative reduction of apoptosis. As"/>
   <result pre="assays, we could therefore assume that the mechanism implemented by" exact="ZIKV" post="did not involve a &quot;de novo�? synthesis of proteins."/>
   <result pre="proteins. Based on these remarks, we formulated the hypothesis that" exact="ZIKV" post="might allow stabilization of the Bcl-2 protein over time."/>
   <result pre="a western blot assay to measure Bcl-2 protein level upon" exact="ZIKV" post="infection. Upon ZIKV infection, we observed an increase of"/>
   <result pre="assay to measure Bcl-2 protein level upon ZIKV infection. Upon" exact="ZIKV" post="infection, we observed an increase of Bcl-2 at the"/>
   <result pre="Bcl-2 could support the anti-apoptotic capacity of ZIKV. 4. Discussion" exact="ZIKV" post="has attracted tremendous attention in the field of medically"/>
   <result pre="the global outcomes of the infection. Many studies support that" exact="ZIKV" post="infection induces apoptosis in vivo as well as in"/>
   <result pre="in vitro [31,32,33] However, several of them also assert that" exact="ZIKV" post="induced cell death could be delayed [17,18]. We therefore"/>
   <result pre="define whether this capacity was specific to the strain of" exact="ZIKV" post="responsible for the current epidemic and whether ZIKV was"/>
   <result pre="strain of ZIKV responsible for the current epidemic and whether" exact="ZIKV" post="was able to interfere with the induction of apoptosis."/>
   <result pre="French Polynesian 2013 outbreak (PF13), our work has highlighted that" exact="ZIKV" post="strains from the actual epidemic Asian lineage are particularly"/>
   <result pre="compared to the molecular clone of the historical strain of" exact="ZIKV" post="MR766 from the African lineage [21]. Infection with MR766MC"/>
   <result pre="titer. This observation suggests a manipulation of apoptosis orchestrated by" exact="ZIKV" post="in order to give it enough time to complete"/>
   <result pre="been described for other flaviviruses such as DENV, JEV and" exact="WNV" post="as they can delay apoptosis through activation of the"/>
   <result pre="work mainly shows that in the early stages of infection," exact="ZIKV" post="infection provides a solid protection against an exogenous induced"/>
   <result pre="in apoptosis entry. Cell death inhibition ability acquired with the" exact="ZIKV" post="replicons would imply that the single presence of a"/>
   <result pre="However, studies have also shown that some NS may help" exact="ZIKV" post="to evade antiviral immunity and cell death. NS2B in"/>
   <result pre="be discovered which factor associated with the replication process of" exact="ZIKV" post="viral RNA is involved in the protection mechanism. What"/>
   <result pre="protein as ABT-737 abrogates the protection acquired against apoptosis by" exact="ZIKV" post="infection (Figure 8). The anti-apoptotic capacity of the pro-survival"/>
   <result pre="of Bcl-xL for cells survival, in deficient Bcl-2 cells during" exact="ZIKV" post="infection [41], but here we could not exclude a"/>
   <result pre="on the fact that Bcl-2 family protein was involved in" exact="ZIKV" post="infection with a Bcl-2 protein level quantitatively maintained (Figure"/>
   <result pre="level quantitatively maintained (Figure 8), we formulated the hypothesis that" exact="ZIKV" post="might allow a stabilization of the Bcl-2 protein over"/>
   <result pre="S2. Alphavirus RRV induces early and massive apoptosis compared to" exact="Zika" post="virus. Figure S3. ZIKV-PF13 does not cause significant activation"/>
   <result pre="ReviewAm. J. Public Health201610660661226959260 2.Cao-LormeauV.-M.BlakeA.MonsS.LastèreS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 3.LoverA.A.Zika"/>
   <result pre="microcephalyLancet Infect. Dis.2016161331133210.1016/S1473-3099(16)30462-527998594 4.McKenzieB.A.WilsonA.E.ZohdyS.Aedes albopictus is a competent vector of" exact="Zika" post="virus: A meta-analysisPLoS ONE201910.1371/journal.pone.0216794 5.KraemerM.U.SinkaM.E.DudaK.A.MylneA.Q.ShearerF.M.BarkerC.M.MooreC.G.CarvalhoR.G.CoelhoG.E.Van BortelW.et al.The global distribution"/>
   <result pre="arbovirus vectors Aedes aegypti and Ae. albopictuseLife201510.7554/eLife.0834726126267 6.HaddowA.D.SchuhA.J.YasudaC.Y.KasperM.R.HeangV.HuyR.GuzmanH.TeshR.B.WeaverS.C.Genetic Characterization of" exact="Zika" post="Virus Strains: Geographic Expansion of the Asian LineagePLoS Negl."/>
   <result pre="replication and assembly in flavivirusesCurr. Opin. Virol.2014913414210.1016/j.coviro.2014.09.02025462445 9.HamelR.DejarnacO.WichitS.EkchariyawatP.NeyretA.LuplertlopN.Perera-LecoinM.SurasombatpattanaP.TalignaniL.ThomasF.et al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 10.MehrbodP.AndeS.R.AlizadehJ.RahimizadehS.ShariatiA.MalekH.HashemiM.GloverK.K.M.SherA.A.CoombsK.M.et al.The"/>
   <result pre="protein is regulated by protein kinase C-mediated phosphorylationMicrobes Infect.20101261562510.1016/j.micinf.2010.04.00520417716 16.UrbanowskiM.D.HobmanT.C.The" exact="West Nile" post="Virus Capsid Protein Blocks Apoptosis through a Phosphatidylinositol 3-Kinase-Dependent"/>
   <result pre="Phosphatidylinositol 3-Kinase-Dependent MechanismJ. Virol.20138787288110.1128/JVI.02030-1223115297 17.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="and apoptosis inductionVirology201649321722610.1016/j.virol.2016.03.00627060565 18.LimontaD.JovelJ.KumarA.AiroA.M.HouS.SaitoL.BrantonW.Ka-Shu WongG.MasonA.PowerC.et al.Human Fetal Astrocytes Infected with" exact="Zika" post="Virus Exhibit Delayed Apoptosis and Resistance to Interferon: Implications"/>
   <result pre="of 13 Infants Born During October 2015-January 2016 With Congenital" exact="Zika" post="Virus Infection Without Microcephaly at Birth-BrazilMMWR Morb. Mortal. Wkly."/>
   <result pre="Rep.2016651343134810.15585/mmwr.mm6547e227906905 20.GadeaG.BosS.Krejbich-TrototP.ClainE.ViranaickenW.El-KalamouniC.MavinguiP.DesprèsP.A robust method for the rapid generation of recombinant" exact="Zika" post="virus expressing the GFP reporter geneVirology201649715716210.1016/j.virol.2016.07.01527471954 21.BosS.ViranaickenW.TurpinJ.El-KalamouniC.RocheM.Krejbich-TrototP.DesprèsP.GadeaG.The structural proteins"/>
   <result pre="geneVirology201649715716210.1016/j.virol.2016.07.01527471954 21.BosS.ViranaickenW.TurpinJ.El-KalamouniC.RocheM.Krejbich-TrototP.DesprèsP.GadeaG.The structural proteins of epidemic and historical strains of" exact="Zika" post="virus differ in their ability to initiate viral infection"/>
   <result pre="25.El KalamouniC.FrumenceE.BosS.TurpinJ.NativelB.HarrabiW.WilkinsonD.A.MeilhacO.GadeaG.DesprèsP.et al.Subversion of the Heme Oxygenase-1 Antiviral Activity by" exact="Zika" post="VirusViruses20181110.3390/v11010002 26.KantariC.WalczakH.Caspase-8 and bid: Caught in the act between"/>
   <result pre="the co-operation of multiple nonstructural proteins in vitroCell Discov.201710.1038/celldisc.2017.6 37.BarnardT.R.RajahM.M.SaganS.M.Contemporary" exact="Zika" post="Virus Isolates Induce More dsRNA and Produce More Negative-Strand"/>
   <result pre="More Negative-Strand Intermediate in Human Astrocytoma CellsViruses201810.3390/v10120728 38.GöertzG.P.AbboS.R.FrosJ.J.PijlmanG.P.Functional RNA during" exact="Zika" post="virus infectionVirus Res.2018254415310.1016/j.virusres.2017.08.01528864425 39.KimH.Rafiuddin-ShahM.TuH.-C.JeffersJ.R.ZambettiG.P.HsiehJ.J.-D.ChengE.H.-Y.Hierarchical regulation of mitochondrion-dependent apoptosis by"/>
   <result pre="for cell survivalPLOS Pathog.201810.1371/journal.ppat.100729930261081 Figure 1 Cell death during a" exact="Zika" post="virus (ZIKV) infection of A549 cells. A549 cells were"/>
   <result pre="were immunostained for active mitochondrial BAX, cytochrome c (Cyt c)," exact="ZIKV" post="E and cleaved caspase 3 (CASP 3), 48 hpi."/>
   <result pre="(white square). Arrows indicate (a): an infected cell (stained for" exact="ZIKV" post="E) and (b): an infected and apoptotic cell (stained"/>
   <result pre="E) and (b): an infected and apoptotic cell (stained for" exact="ZIKV" post="E and with mitochondrial localization of BAX or Cytosolic"/>
   <result pre="cleaved CASP3. (B) Percentage of A549 infected cells co-immunolabeled for" exact="ZIKV" post="E and for active mitochondrial BAX, among the ZIKV"/>
   <result pre="for ZIKV E and for active mitochondrial BAX, among the" exact="ZIKV" post="E positive cells were determined at 24, 48 and"/>
   <result pre="72 hpi. (C) Percentage of A549 infected cells co-immunolabeled for" exact="ZIKV" post="E and for cytosolic Cyt c, among the ZIKV"/>
   <result pre="for ZIKV E and for cytosolic Cyt c, among the" exact="ZIKV" post="E positive cells were determined at 24, 48 and"/>
   <result pre="infected cells immunostained with anti-cleaved CASP 3 antibody among the" exact="ZIKV" post="E positive cells were followed at 24, 48 and"/>
   <result pre="**** p &amp;lt; 0.0001, ns = not significant). Figure 4" exact="ZIKV" post="provides a protection against intrinsically induced cell death by"/>
   <result pre="**** p &amp;lt; 0.0001, ns = not significant). Figure 5" exact="ZIKV" post="provides a protection against intrinsically induced cell death by"/>
   <result pre="**** p &amp;lt; 0.0001, ns = not significant). Figure 6" exact="ZIKV" post="replicon-expressing cells are protected from apoptosis. HEK-293 cells stably"/>
   <result pre="cells are protected from apoptosis. HEK-293 cells stably expressing a" exact="ZIKV" post="replicon (Rep ZIKV-GFP) are protected from intrinsically and extrinsically"/>
   <result pre="= not significant). Figure 7 A549 cells transiently expressing a" exact="ZIKV" post="replicon are protected against cell death by apoptosis. A549"/>
   <result pre="against cell death by apoptosis. A549 cells were transfected with" exact="ZIKV" post="amplicons (Z genomic overlapping fragments) for production of REP"/>
   <result pre="the protection mediated by ZIKV. A549 cells were infected with" exact="ZIKV" post="at MOI of 1. TNFα and CHX were added"/>
   <result pre="was followed after treatment (B). A549 cells were infected with" exact="ZIKV" post="at MOI of 1 and level of Bcl-2 was"/>
   <result pre="not significant). Figure 9 Model depicting the protective action of" exact="ZIKV" post="infection against apoptosis. Intrinsic or extrinsic activation of cell"/>
   <result pre="the complex formation by sequestering BAX via their BH3 domain." exact="ZIKV" post="replication interferes with BAX relocalization at the mitochondria. ABT-737,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6912530\results\search\tropicalVirus\results.xml">
   <result pre="6912530 doi: 10.3390/cells8111444cells-08-01444 : Article The Envelope Residues E152/156/158 of" exact="Zika" post="Virus Influence the Early Stages of Virus Infection in"/>
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Emerging infections of mosquito-borne" exact="Zika" post="virus (ZIKV) pose an increasing threat to human health,"/>
   <result pre="structural proteins capsid (C), pre-membrane (prM), and envelop (E) of" exact="ZIKV" post="epidemic strains with the initiation of viral infection in"/>
   <result pre="C-prM region contributes to permissiveness of human host cells to" exact="ZIKV" post="infection and ZIKV-induced cytopathic effects, whereas the E protein"/>
   <result pre="and early infection. In the present study, we further characterize" exact="ZIKV" post="E proteins by investigating the roles of residues isoleucine"/>
   <result pre="site (E-154), in permissiveness of human host cells to epidemic" exact="ZIKV" post="infection. For comparison purpose, we generated mutant molecular clones"/>
   <result pre="important contribution of E-152/156/158 residues to the early steps of" exact="ZIKV" post="infection in human cells. flavivirus Zika virus envelope protein"/>
   <result pre="the early steps of ZIKV infection in human cells. flavivirus" exact="Zika" post="virus envelope protein glycosylation fusion loop viral fusion cell"/>
   <result pre="glycosylation fusion loop viral fusion cell entry 1. Introduction Mosquito-borne" exact="Zika" post="(ZIKV), dengue (DENV), Yellow fever (YFV) and Japanese encephalitis"/>
   <result pre="fusion cell entry 1. Introduction Mosquito-borne Zika (ZIKV), dengue (DENV)," exact="Yellow fever" post="(YFV) and Japanese encephalitis (JEV) viruses belonging to flavivirus"/>
   <result pre="RNA viruses of significant public health concern worldwide [1,2,3,4]. Recent" exact="ZIKV" post="global outbreaks, with Brazil at the epicentre, highlighted how"/>
   <result pre="turn into a severe threat for human health. While human" exact="ZIKV" post="infections remained only sporadic and with a limited impact"/>
   <result pre="a limited impact for decades [5,6,7,8], recent outbreaks revealed that" exact="ZIKV" post="caused clusters of severe congenital and neurological abnormalities in"/>
   <result pre="enhancement/cross-reactivity of reactive antibodies [18,19,20,21]. Recently, our studies on chimeric" exact="ZIKV" post="clones between an epidemic Brazilian strain of ZIKV BeH819015"/>
   <result pre="on chimeric ZIKV clones between an epidemic Brazilian strain of" exact="ZIKV" post="BeH819015 (hereafter called BR15) and a historical African strain"/>
   <result pre="important role of two structural proteins prM/M, and E in" exact="ZIKV" post="ability to infect human cells [16,22,23,24]. We further showed"/>
   <result pre="C-prM region plays a role in triggering cell death by" exact="ZIKV" post="and E protein is associated with viral attachment to"/>
   <result pre="position E-56 and E-154. The first site is lacking in" exact="ZIKV" post="E protein and contribution of the second site in"/>
   <result pre="ZIKV E protein and contribution of the second site in" exact="ZIKV" post="viral cycle, including in the mosquito vector, has been"/>
   <result pre="E protein was shown to be an important determinant of" exact="ZIKV" post="virulence in a mouse model of viral encephalitis [22,26]."/>
   <result pre="a mouse model of viral encephalitis [22,26]. In invertebrate vectors," exact="ZIKV" post="bearing an unglycosylated E protein was attenuated in its"/>
   <result pre="could remain unglycosylated as it has been observed in some" exact="ZIKV" post="strains. To date, the exact mechanism by which the"/>
   <result pre="the N-glycosylation motif region of the E protein contributes to" exact="ZIKV" post="infectivity still remains elusive. In the present study, we"/>
   <result pre="the present study, we further characterised structural protein contribution in" exact="ZIKV" post="infectivity by focusing on the ZIKV E protein. Our"/>
   <result pre="structural protein contribution in ZIKV infectivity by focusing on the" exact="ZIKV" post="E protein. Our goal was to determine whether three"/>
   <result pre="from Sigma-Aldrich (Saint-Louis, MO, USA). Rat antibody specifically raised against" exact="ZIKV" post="E protein Domain III was developed in-house and used"/>
   <result pre="purchased from Vector Laboratories (Burlingame, CA, USA). 2.2. Design of" exact="ZIKV" post="Molecular Clones ZIKV molecular clones (MR766, GenBank accession number"/>
   <result pre="Laboratories (Burlingame, CA, USA). 2.2. Design of ZIKV Molecular Clones" exact="ZIKV" post="molecular clones (MR766, GenBank accession number LC002520, and BR15,"/>
   <result pre="viral sequence of MR766 in which E-152/156/158 residues of BR15" exact="ZIKV" post="strain were introduced and viral sequence of BR15 in"/>
   <result pre="which E-152/156/158 residues were replaced with its counterpart from MR766" exact="ZIKV" post="strain. 2.4. Plaque-Forming Assay Viral titres were determined by"/>
   <result pre="units (PFU) per mL (PFU·mL−1). 2.5. Quantification of Viral Stocks" exact="Zika" post="virus samples were analysed by titration on Vero cells"/>
   <result pre="(Qiagen, Hilden, Germany). PCR standard curve used for quantification of" exact="ZIKV" post="copy numbers was obtained with a pUC57/ZIKV-E amplicon plasmid"/>
   <result pre="961 to 1301 of genomic RNA (MR766). The pair of" exact="ZIKV" post="E primers was used to equally amplify pUC57/ZIKV-E amplicon"/>
   <result pre="cDNA encompassing nucleotides 1046 to 1213 from genomic RNA of" exact="ZIKV" post="molecular clones used in this study. 2.6. Immunoblot Assay"/>
   <result pre="control. Primers used in this study are listed in [31]." exact="ZIKV" post="E primers were designed to match both MR766-NIID and"/>
   <result pre="2% FBS. Pre-chilled cells were incubated at 4 °C with" exact="ZIKV" post="at MOI of 1 in 1.5 mL of cold"/>
   <result pre="RT-qPCR analysis on viral RNA was performed using primers for" exact="ZIKV" post="E gene as described above. 2.10. Fusion Assay Cells"/>
   <result pre="10% FBS. Pre-chilled cells were incubated at 4 °C with" exact="ZIKV" post="at MOI of 1 in 1 mL of cold"/>
   <result pre="cells. 2.13. TMD2-M/E Expression To express recombinant E proteins from" exact="ZIKV" post="in mammalian cells, TMD2-prM (TransMembrane Domain II) and E"/>
   <result pre="La Jolla, CA, USA). 3. Results 3.1. Characterization of Mutant" exact="ZIKV" post="Molecular Clones To determine the contribution of E-152/156/158 residues"/>
   <result pre="Molecular Clones To determine the contribution of E-152/156/158 residues in" exact="ZIKV" post="E protein functions, we generated two mutant molecular clones:"/>
   <result pre="confirmed that the introduced mutations affected the electrophoretic mobility of" exact="ZIKV" post="E proteins, suggesting that E-152/156/158 residues from BR15 E"/>
   <result pre="virion infectivity. 3.3. Alteration of Residues E-152 to E-158 of" exact="ZIKV" post="E Protein Does Not Affect Virus Binding to Host"/>
   <result pre="Virus Progeny Production We previously showed that historical and epidemic" exact="ZIKV" post="strains display differences in their abilities to bind host"/>
   <result pre="data suggest that alteration of residues E-152 to E-158 of" exact="ZIKV" post="E protein does not affect virus bindings to A549-Dual™"/>
   <result pre="cells. Instead, these results suggest that E-152/156/158 residues might influence" exact="ZIKV" post="progeny production. Indeed, the progeny production of MR766E-MUT was"/>
   <result pre="we showed previously that this pathway is not activated upon" exact="ZIKV" post="infection [23]. These results indicate that differences in the"/>
   <result pre="our previous observations suggesting a link between host-cell responses and" exact="ZIKV" post="nonstructural proteins [23]. 3.5. E-152/156/158 Residues from BR15 Facilitate"/>
   <result pre="inhibition of pH-dependent steps. Recently, chloroquine was shown to inhibit" exact="Zika" post="virus infection in different cellular models [36,37]. As BR15"/>
   <result pre="differences observed between BR15 and mutant BR15 TMD2-prM/E suggested that" exact="ZIKV" post="E proteins bear different conformations that only depend on"/>
   <result pre="bearing E-152/156/158 residues from MR766. Preliminary in silico modelling of" exact="ZIKV" post="E proteins suggest that changes in the glycosylation motif"/>
   <result pre="residues in the EDI domain support conformational changes on the" exact="ZIKV" post="E protein, which could be detected in the fusion"/>
   <result pre="of structural proteins in determining infectivity of human cells to" exact="ZIKV" post="infection has been previously reported [23]. Zika viruses of"/>
   <result pre="human cells to ZIKV infection has been previously reported [23]." exact="Zika" post="viruses of historical or epidemic strains display differences in"/>
   <result pre="susceptibility to infection. To further characterise biological properties of contemporary" exact="ZIKV" post="strains, which have been associated with recent epidemics and"/>
   <result pre="E proteins [38]. Our data demonstrate that E-152/156/158 residues of" exact="ZIKV" post="E protein do not influence virus binding, which suggests"/>
   <result pre="by E-152/156/158 residues. We conclude that this initial step of" exact="ZIKV" post="entry into cells does not depend on E-152/156/158 residues"/>
   <result pre="Sevvana and colleagues proposed that, given the close proximity of" exact="ZIKV" post="glycan and fusion loops, any interaction of the glycan"/>
   <result pre="study based on antibody neutralizing activities demonstrated that residues surrounding" exact="ZIKV" post="E protein glycan regulate virus antigenicity [44]. In a"/>
   <result pre="access of the fusion loop. The role of N-glycosylation on" exact="ZIKV" post="E protein has also been investigated using pseudoviral particles,"/>
   <result pre="we demonstrated with recombinant proteins that E-152/156/158 residues of epidemic" exact="ZIKV" post="E protein also facilitate production of more soluble proteins."/>
   <result pre="[49]. All these observations suggest that E-152/156/158 residues of epidemic" exact="ZIKV" post="E protein could also be an advantage during virion"/>
   <result pre="Altogether, our data indicate that the envelope residues E152/156/158 of" exact="Zika" post="virus influence early stages of virus infection in human"/>
   <result pre="cells. This study highlights the importance of E-152/156/158 residues in" exact="ZIKV" post="biology and specifically in their roles in supporting viral"/>
   <result pre="findings could potentially help to design innovative strategies for future" exact="ZIKV" post="infection control. Acknowledgments We gratefully acknowledge Pascale Krejbich-Trotot and"/>
   <result pre="https://www.mdpi.com/2073-4409/8/11/1444/s1, Figure S1: Tunicamycin treatment of Vero cells infected with" exact="ZIKV" post="mutant molecular clones, Figure S2: structures of ZIKV E"/>
   <result pre="infected with ZIKV mutant molecular clones, Figure S2: structures of" exact="ZIKV" post="E wild-type and mutant proteins. LINK Click here for"/>
   <result pre="no conflict of interest. References References 1.LeeI.BosS.LiG.WangS.GadeaG.DesprèsP.ZhaoR.Y.Probing Molecular Insights into" exact="Zika" post="Virus–Host InteractionsViruses20181023310.3390/v1005023329724036 2.BosS.GadeaG.DespresP.Dengue: A growing threat requiring vaccine development"/>
   <result pre="Soc. Pathol. Exot. Filiales19787113114033772 9.Cao-LormeauV.-M.BlakeA.MonsS.LastèreS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 10.CugolaF.R.FernandesI.R.RussoF.B.FreitasB.C.DiasJ.L.M.GuimarãesK.P.BenazzatoC.AlmeidaN.PignatariG.C.RomeroS.et"/>
   <result pre="infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 10.CugolaF.R.FernandesI.R.RussoF.B.FreitasB.C.DiasJ.L.M.GuimarãesK.P.BenazzatoC.AlmeidaN.PignatariG.C.RomeroS.et al.The Brazilian" exact="Zika" post="virus strain causes birth defects in experimental modelsNature201653426727110.1038/nature1829627279226 11.MerfeldE.Ben-AviL.KennonM.CervenyK.L.Potential"/>
   <result pre="microcephalyWiley Interdiscip. Rev. Dev. Biol.2017e27310.1002/wdev.27328383800 12.ParraB.LizarazoJ.Jiménez-ArangoJ.A.Zea-VeraA.F.González-ManriqueG.VargasJ.AngaritaJ.A.ZuñigaG.Lopez-GonzalezR.BeltranC.L.et al.Guillain-Barré Syndrome Associated with" exact="Zika" post="Virus Infection in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 13.SmitJ.MoeskerB.Rodenhuis-ZybertI.WilschutJ.Flavivirus Cell"/>
   <result pre="y AlmeidaM.E.Garcia-CorderoJ.CamposF.D.Namorado-TonixK.PerezF.Serological tests reveal significant cross-reactive human antibody responses to" exact="Zika" post="and Dengue viruses in the Mexican populationActa Trop.201920110520110.1016/j.actatropica.2019.10520131562846 20.Montecillo-AguadoM.R.Montes-GómezA.E.García-CorderoJ.Corzo-GómezJ.Vivanco-CidH.Mellado-SánchezG.Muñoz-MedinaJ.E.Gutiérrez-CastañedaB.Santos-ArgumedoL.González-BonillaC.et"/>
   <result pre="tests reveal significant cross-reactive human antibody responses to Zika and" exact="Dengue" post="viruses in the Mexican populationActa Trop.201920110520110.1016/j.actatropica.2019.10520131562846 20.Montecillo-AguadoM.R.Montes-GómezA.E.García-CorderoJ.Corzo-GómezJ.Vivanco-CidH.Mellado-SánchezG.Muñoz-MedinaJ.E.Gutiérrez-CastañedaB.Santos-ArgumedoL.González-BonillaC.et al.Cross-Reaction, Enhancement,"/>
   <result pre="Mexican populationActa Trop.201920110520110.1016/j.actatropica.2019.10520131562846 20.Montecillo-AguadoM.R.Montes-GómezA.E.García-CorderoJ.Corzo-GómezJ.Vivanco-CidH.Mellado-SánchezG.Muñoz-MedinaJ.E.Gutiérrez-CastañedaB.Santos-ArgumedoL.González-BonillaC.et al.Cross-Reaction, Enhancement, and Neutralization Activity of" exact="Dengue" post="Virus Antibodies against Zika Virus: A Study in the"/>
   <result pre="al.Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against" exact="Zika" post="Virus: A Study in the Mexican PopulationJ. Immunol. Res.20192019723934710.1155/2019/723934731565661"/>
   <result pre="in the Mexican PopulationJ. Immunol. Res.20192019723934710.1155/2019/723934731565661 21.DaiL.SongJ.LuX.DengY.-Q.MusyokiA.M.ChengH.ZhangY.YuanY.SongH.HaywoodJ.et al.Structures of the" exact="Zika" post="Virus Envelope Protein and Its Complex with a Flavivirus"/>
   <result pre="Virol.201791e01348-1710.1128/JVI.01348-1728931684 23.BosS.ViranaickenW.TurpinJ.El-KalamouniC.RocheM.Krejbich-TrototP.DesprèsP.GadeaG.The structural proteins of epidemic and historical strains of" exact="Zika" post="virus differ in their ability to initiate viral infection"/>
   <result pre="cellsVirology201851626527310.1016/j.virol.2017.12.00329395111 24.LiG.BosS.TsetsarkinK.A.PletnevA.G.DesprèsP.GadeaG.ZhaoR.Y.The Roles of prM-E Proteins in Historical and Epidemic" exact="Zika" post="Virus-mediated Infection and NeurocytotoxicityViruses20191115710.3390/v11020157 25.GongD.ZhangT.-H.ZhaoD.DuY.ChapaT.J.ShiY.WangL.ContrerasD.ZengG.ShiP.-Y.et al.High-Throughput Fitness Profiling of"/>
   <result pre="Zika Virus-mediated Infection and NeurocytotoxicityViruses20191115710.3390/v11020157 25.GongD.ZhangT.-H.ZhaoD.DuY.ChapaT.J.ShiY.WangL.ContrerasD.ZengG.ShiP.-Y.et al.High-Throughput Fitness Profiling of" exact="Zika" post="Virus E Protein Reveals Different Roles for Glycosylation during"/>
   <result pre="Infection of Mammalian and Mosquito CellsiScience201819711110.1016/j.isci.2018.02.00530227960 26.CarbaughD.L.BaricR.S.LazearH.M.Envelope Protein Glycosylation Mediates" exact="Zika" post="Virus PathogenesisJ. Virol.201993e00113-1910.1128/JVI.00113-1930944176 27.Fontes-GarfiasC.R.ShanC.LuoH.MuruatoA.E.MedeirosD.B.A.MaysE.XieX.ZouJ.RoundyC.M.WakamiyaM.et al.Functional Analysis of Glycosylation of"/>
   <result pre="Zika Virus PathogenesisJ. Virol.201993e00113-1910.1128/JVI.00113-1930944176 27.Fontes-GarfiasC.R.ShanC.LuoH.MuruatoA.E.MedeirosD.B.A.MaysE.XieX.ZouJ.RoundyC.M.WakamiyaM.et al.Functional Analysis of Glycosylation of" exact="Zika" post="Virus Envelope ProteinCell Rep.2017211180119010.1016/j.celrep.2017.10.01629091758 28.ViranaickenW.NativelB.Krejbich-TrototP.HarrabiW.BosS.El KalamouniC.RocheM.GadeaG.DesprèsP.ClearColi BL21(DE3)-based expression of"/>
   <result pre="Zika Virus Envelope ProteinCell Rep.2017211180119010.1016/j.celrep.2017.10.01629091758 28.ViranaickenW.NativelB.Krejbich-TrototP.HarrabiW.BosS.El KalamouniC.RocheM.GadeaG.DesprèsP.ClearColi BL21(DE3)-based expression of" exact="Zika" post="virus antigens illustrates a rapid method of antibody production"/>
   <result pre="pathogensBiochimie201714217918210.1016/j.biochi.2017.09.01128942054 29.GadeaG.BosS.Krejbich-TrototP.ClainE.ViranaickenW.El-KalamouniC.MavinguiP.DesprèsP.A robust method for the rapid generation of recombinant" exact="Zika" post="virus expressing the GFP reporter geneVirology201649715716210.1016/j.virol.2016.07.01527471954 30.AubryF.NougairedeA.de FabritusL.QueratG.GouldE.A.de LamballerieX.Single-stranded"/>
   <result pre="subgenomic ampliconsJ. Gen. Virol.2014952462246710.1099/vir.0.068023-025053561 31.FrumenceE.RocheM.Krejbich-TrototP.El-KalamouniC.NativelB.RondeauP.MisséD.GadeaG.ViranaickenW.DesprèsP.The South Pacific epidemic strain of" exact="Zika" post="virus replicates efficiently in human epithelial A549 cells leading"/>
   <result pre="keratinocytesJ. Cell Sci.20111243568358010.1242/jcs.08405322045735 36.DelvecchioR.HigaL.PezzutoP.ValadãoA.GarcezP.MonteiroF.LoiolaE.DiasA.SilvaF.AliotaM.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v8120322 37.ZhangS.YiC.LiC.ZhangF.PengJ.WangQ.LiuX.YeX.LiP.WuM.et al.Chloroquine inhibits"/>
   <result pre="viral replication and effectively prevents maternal to fetal transmission of" exact="Zika" post="virusAntivir. Res.201916910454710.1016/j.antiviral.2019.10454731251958 38.ChenY.MaguireT.HilemanR.E.FrommJ.R.EskoJ.D.LinhardtR.J.MarksR.M.Dengue virus infectivity depends on envelope protein"/>
   <result pre="Rev.20153915517010.1093/femsre/fuu00425725010 40.PiersonT.C.KielianM.Flaviviruses: Braking the enteringCurr. Opin. Virol.2013331210.1016/j.coviro.2012.12.00123352692 41.LeeE.WeirR.C.DalgarnoL.Changes in the" exact="Dengue" post="Virus Major Envelope Protein on Passaging and Their Localization"/>
   <result pre="tick cellsJ. Gen. Virol.2013942249225810.1099/vir.0.055269-023824303 43.SevvanaM.LongF.MillerA.S.KloseT.BudaG.SunL.KuhnR.J.RossmannM.G.Refinement and Analysis of the Mature" exact="Zika" post="Virus Cryo-EM Structure at 3.1 Å ResolutionStructure20182611691177.e310.1016/j.str.2018.05.00629958768 44.GooL.DeMasoC.R.PelcR.S.LedgerwoodJ.E.GrahamB.S.KuhnR.J.PiersonT.C.The Zika"/>
   <result pre="Mature Zika Virus Cryo-EM Structure at 3.1 Å ResolutionStructure20182611691177.e310.1016/j.str.2018.05.00629958768 44.GooL.DeMasoC.R.PelcR.S.LedgerwoodJ.E.GrahamB.S.KuhnR.J.PiersonT.C.The" exact="Zika" post="virus envelope protein glycan loop regulates virion antigenicityVirology201851519120210.1016/j.virol.2017.12.03229304471 45.FrumenceE.ViranaickenW.GadeaG.DesprèsP.A"/>
   <result pre="Reporter MR766-Based Flow Cytometry Neutralization Test for Rapid Detection of" exact="Zika" post="Virus-Neutralizing Antibodies in Serum SpecimensVaccines201976610.3390/vaccines703006631315283 46.FrumenceE.ViranaickenW.BosS.Alvarez-MartinezM.-T.RocheM.ArnaudD.J.GadeaG.DesprèsP.A Chimeric Zika Virus"/>
   <result pre="Detection of Zika Virus-Neutralizing Antibodies in Serum SpecimensVaccines201976610.3390/vaccines703006631315283 46.FrumenceE.ViranaickenW.BosS.Alvarez-MartinezM.-T.RocheM.ArnaudD.J.GadeaG.DesprèsP.A Chimeric" exact="Zika" post="Virus between Viral Strains MR766 and BeH819015 Highlights a"/>
   <result pre="Loop in Antibody-mediated Virus NeutralizationVaccines201975510.3390/vaccines7020055 47.MossentaM.MarcheseS.PoggianellaM.Slon CamposJ.L.BurroneO.R.Role of N-glycosylation on" exact="Zika" post="virus E protein secretion, viral assembly and infectivityBiochem. Biophys."/>
   <result pre="Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive EpitopesJ. Virol.200478139751398610.1128/JVI.78.24.13975-13986.200415564505 Figure 1" exact="ZIKV" post="mutant molecular clones. In (a), schematic representation of mutant"/>
   <result pre="A549-Dual™ cells. Pre-chilled cells were incubated at 4 °C with" exact="ZIKV" post="at MOI of 1. After 1-h incubation, cells were"/>
   <result pre="0.1 Figure 5 Conformational changes induced by residues E-152/156/158 of" exact="ZIKV" post="E protein. In (a) and (b), HEK-293T cells were"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6913635\results\search\tropicalVirus\results.xml">
   <result pre="Culex mosquitoes in Europe: the alphavirus Sindbis and the flaviviruses" exact="West Nile" post="virus and Usutu virus. Cases of Sindbis fever occur"/>
   <result pre="awareness. KEYWORDS Culex torrentium Culex pipiens pan-flavi PCR infection rate" exact="West Nile" post="virus Usutu virus ref-count: page-count: Introduction In Europe, there"/>
   <result pre="human pathogenic viruses transmitted from birds, by mosquitoes, to humans:" exact="West Nile" post="virus (WNV), Usutu virus (USUV) (Flaviviridae) and Sindbis virus"/>
   <result pre="and importance of Flaviviruses is increasing in Europe, with both" exact="WNV" post="and USUV detected from mosquitoes and birds as far"/>
   <result pre="far north as Germany [1–3], and with human and equid" exact="WNV" post="cases as far north as the Czech Republic and"/>
   <result pre="[11]. Results The modified pan-flavi RTqPCR could detect 103 PFU/mL" exact="WNV" post="and the cut off was set at cycle threshold"/>
   <result pre="SINV were detected. During the years studied, 2006–2008, transmission of" exact="WNV" post="was still mainly reported from the Mediterranean and Eastern"/>
   <result pre="Austria and Hungary [18]. Since then, the reports of both" exact="WNV" post="and USUV have increased, indicating a spread of the"/>
   <result pre="of the viruses. However, seroconversion of sentinel chickens to both" exact="WNV" post="and USUV was detected on the British Isles already"/>
   <result pre="the authors. References References [1]MichelF, SiegM, FischerD, et alEvidence for" exact="West Nile" post="virus and Usutu virus infections in Wild and resident"/>
   <result pre="Virol J. 2013;10:58.23410000 [17]Di SabatinoD, BrunoR, SauroF, et alEpidemiology of" exact="West Nile" post="disease in Europe and in the Mediterranean Basin from"/>
   <result pre="virus. Microbes Infect. 2017;19(7):382–387.28602915 [19]BuckleyA, DawsonA, GouldEADetection of seroconversion to" exact="West Nile" post="virus, Usutu virus and Sindbis virus in UK sentinel"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6914775\results\search\tropicalVirus\results.xml">
   <result pre="Adjusted Time-varying Reproductive Numbers: Understanding the Geographical Expansion of Urban" exact="Dengue" post="Outbreaks NgTa-Chou1WenTzai-Hungwenthung@ntu.edu.tw2[1], 0000 0004 0546 0241grid.19188.39Graduate Institute of Epidemiology"/>
   <result pre="generated by R package ggplot2, and sf (version 3.6.1, https://cran.r-project.org)." exact="Dengue" post="data Dengue fever is listed as a notifiable infectious"/>
   <result pre="R package ggplot2, and sf (version 3.6.1, https://cran.r-project.org). Dengue data" exact="Dengue" post="fever is listed as a notifiable infectious disease in"/>
   <result pre="potential of other acute contagious diseases, such as influenza and" exact="Zika" post="virus infection, with observed generation interval and the context"/>
   <result pre="29.Center for Diseases Control, M. o. H. a. W., Taiwan." exact="Dengue" post="daily Confirmed cases since 1998, https://data.cdc.gov.tw/dataset/dengue-daily-determined-cases-1998 (2019). 30.ChampredonDDushoffJEarnDJEquivalence of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6915707\results\search\tropicalVirus\results.xml">
   <result pre="Group UKLondon pmcid: 691570713628 doi: 10.1038/s41467-019-13628-x : Article Impacts of" exact="Zika" post="emergence in Latin America on endemic dengue transmission BorcheringRebecca"/>
   <result pre="of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract In 2015 and 2016," exact="Zika" post="virus (ZIKV) swept through dengue virus (DENV) endemic areas"/>
   <result pre="incidence from Brazil and Colombia before, during, and after the" exact="Zika" post="epidemic. We find evidence that dengue incidence was atypically"/>
   <result pre="low in 2017 in both countries. We investigate whether subnational" exact="Zika" post="incidence is associated with changes in dengue incidence and"/>
   <result pre="mixed results. Using simulations with multiple assumptions of interactions between" exact="DENV" post="and ZIKV, we find cross-protection suppresses incidence of dengue"/>
   <result pre="and ZIKV, we find cross-protection suppresses incidence of dengue following" exact="Zika" post="outbreaks and low periods of dengue incidence are followed"/>
   <result pre="incidence are followed by resurgence. Our simulations suggest correlations in" exact="DENV" post="and ZIKV reproduction numbers could complicate associations between ZIKV"/>
   <result pre="followed by resurgence. Our simulations suggest correlations in DENV and" exact="ZIKV" post="reproduction numbers could complicate associations between ZIKV incidence and"/>
   <result pre="in DENV and ZIKV reproduction numbers could complicate associations between" exact="ZIKV" post="incidence and post-ZIKV DENV incidence and that periods of"/>
   <result pre="reproduction numbers could complicate associations between ZIKV incidence and post-ZIKV" exact="DENV" post="incidence and that periods of low dengue incidence are"/>
   <result pre="dengue incidence are followed by large increases in dengue incidence." exact="Dengue" post="and Zika virus are related flaviviruses, and introduction of"/>
   <result pre="are followed by large increases in dengue incidence. Dengue and" exact="Zika" post="virus are related flaviviruses, and introduction of Zika in"/>
   <result pre="Dengue and Zika virus are related flaviviruses, and introduction of" exact="Zika" post="in the Americas may have impacted dengue epidemiology. Here,"/>
   <result pre="and simulations incorporating immune-mediated interactions predict reductions in dengue following" exact="Zika" post="outbreaks with subsequent rebounds. Subject terms Computational biology and"/>
   <result pre="subsequent rebounds. Subject terms Computational biology and bioinformatics Ecological epidemiology" exact="Dengue" post="virus Infectious diseases Funding https://doi.org/10.13039/100000030U.S. Department of Health &amp;amp;"/>
   <result pre="Institutes of Health (NIH) R01AI102939LesslerJustin Introduction In 2015 and 2016," exact="Zika" post="virus (ZIKV) swept through many Latin American countries1 where"/>
   <result pre="epidemic, many locations appeared to experience abnormally low dengue incidence." exact="DENV" post="and ZIKV share a vector2,3 and are both flaviviruses."/>
   <result pre="locations appeared to experience abnormally low dengue incidence. DENV and" exact="ZIKV" post="share a vector2,3 and are both flaviviruses. Evidence suggests"/>
   <result pre="affect reported dengue cases. Conditions (climate16, vector abundance) that favor" exact="Zika" post="may be similar to those favoring dengue. Epidemics of"/>
   <result pre="the potential to disrupt the ecology of other circulating pathogens." exact="ZIKV" post="was identified in the Americas in Brazil in late"/>
   <result pre="Americas in Brazil in late 201517, though phylogeographic analyses suggest" exact="ZIKV" post="may have arrived as early as mid-201318, entering northeast"/>
   <result pre="63% (Salvador, Brazil22). These are comparable to seroprevalence in previous" exact="ZIKV" post="outbreaks; 73% in Yap Island, Micronesia23, 49% in French"/>
   <result pre="in Yap Island, Micronesia23, 49% in French Polynesia24. Associations between" exact="ZIKV" post="infection and severe disease outcomes such as microcephaly and"/>
   <result pre="March 20161, prompting intensified surveillance and control efforts. Since 2016," exact="Zika" post="incidence in Brazil has dropped precipitously, from over 200,000"/>
   <result pre="susceptible to infection. Multiple human and animal studies show that" exact="ZIKV" post="induces potently neutralizing antibody responses26,27, suggesting enduring ZIKV-specific immunity28."/>
   <result pre="potently neutralizing antibody responses26,27, suggesting enduring ZIKV-specific immunity28. The primary" exact="ZIKV" post="vectors, Aedes aegypti and Aedes albopictus2,3,29, also transmit chikungunya"/>
   <result pre="also transmit chikungunya virus (CHIKV) and DENV. In contrast to" exact="CHIKV" post="(an alphavirus), DENV and ZIKV are genetically similar flaviviruses8."/>
   <result pre="virus (CHIKV) and DENV. In contrast to CHIKV (an alphavirus)," exact="DENV" post="and ZIKV are genetically similar flaviviruses8. DENV exists as"/>
   <result pre="and DENV. In contrast to CHIKV (an alphavirus), DENV and" exact="ZIKV" post="are genetically similar flaviviruses8. DENV exists as four antigenically"/>
   <result pre="CHIKV (an alphavirus), DENV and ZIKV are genetically similar flaviviruses8." exact="DENV" post="exists as four antigenically distinct serotypes (DENV1-4). When an"/>
   <result pre="It has been speculated that, due to the similarity between" exact="DENV" post="and ZIKV, immunity to one of these viruses may"/>
   <result pre="periods, we do not find a negative association between cumulative" exact="Zika" post="incidence and biweekly dengue incidence in either country. To"/>
   <result pre="insight into how immunological interactions would impact the relationship between" exact="ZIKV" post="and DENV incidence in this period, we use a"/>
   <result pre="how immunological interactions would impact the relationship between ZIKV and" exact="DENV" post="incidence in this period, we use a stochastic compartmental"/>
   <result pre="period, we use a stochastic compartmental model of the four" exact="DENV" post="serotypes and ZIKV under multiple assumptions. In almost all"/>
   <result pre="a stochastic compartmental model of the four DENV serotypes and" exact="ZIKV" post="under multiple assumptions. In almost all simulations incorporating strong"/>
   <result pre="ZIKV under multiple assumptions. In almost all simulations incorporating strong" exact="ZIKV" post="cross-protection against subsequent DENV infection, ZIKV epidemics are followed"/>
   <result pre="In almost all simulations incorporating strong ZIKV cross-protection against subsequent" exact="DENV" post="infection, ZIKV epidemics are followed by a trough in"/>
   <result pre="all simulations incorporating strong ZIKV cross-protection against subsequent DENV infection," exact="ZIKV" post="epidemics are followed by a trough in dengue incidence,"/>
   <result pre="dengue incidence, followed by a larger than average peak in" exact="DENV" post="incidence. Correlated hazards of DENV and ZIKV transmission may"/>
   <result pre="larger than average peak in DENV incidence. Correlated hazards of" exact="DENV" post="and ZIKV transmission may complicate the relationship between ZIKV"/>
   <result pre="average peak in DENV incidence. Correlated hazards of DENV and" exact="ZIKV" post="transmission may complicate the relationship between ZIKV incidence and"/>
   <result pre="of DENV and ZIKV transmission may complicate the relationship between" exact="ZIKV" post="incidence and resulting dengue incidence. Our simulations consistently show"/>
   <result pre="from expected dengue incidence At the population level, the large" exact="ZIKV" post="epidemic could plausibly have led to either increases or"/>
   <result pre="dengue incidence in Brazil and Colombia (per 100,000). Note that" exact="Zika" post="incidence was not systematically reported prior to 2016 in"/>
   <result pre="Brazil (a) or late 2015 in Colombia (c) and that" exact="Chikungunya" post="was not systematically reported prior to 2015 and late"/>
   <result pre="For a baseline, we also fit models incorporating chikungunya incidence." exact="CHIKV" post="shares climate and vector determinants as DENV and ZIKV"/>
   <result pre="incorporating chikungunya incidence. CHIKV shares climate and vector determinants as" exact="DENV" post="and ZIKV but is of a different viral family"/>
   <result pre="incidence. CHIKV shares climate and vector determinants as DENV and" exact="ZIKV" post="but is of a different viral family and thus"/>
   <result pre="yellow. Shared effect coefficients for Brazil (a) and Colombia (c)." exact="Zika" post="and chikungunya coefficients are estimated from autoregressive dengue models."/>
   <result pre="year model and indirectly as effects on transmission for the" exact="Zika" post="and chikungunya models. Shared year multipliers for expected dengue"/>
   <result pre="gray. We found a positive association between the previous biweek’s" exact="Zika" post="incidence and dengue transmission potential in Brazil (mean coefficient:"/>
   <result pre="CrI: 0.05–0.26, Fig. 3a). Putting this coefficient in context, 1000" exact="Zika" post="cases observed in the previous biweek translates to a"/>
   <result pre="CrI: 1.40–6.15). We also found a positive association between cumulative" exact="Zika" post="incidence on dengue transmission potential in Brazil (mean coefficient:"/>
   <result pre="95% CrI: 0.003, 0.08). No significant associations were found between" exact="Zika" post="incidence and dengue transmission potential in Colombia. In Brazil,"/>
   <result pre="potential in Colombia. In Brazil, states with positive effects of" exact="Zika" post="on dengue transmission potential often observed positive effects of"/>
   <result pre="of chikungunya on dengue (Supplementary Fig. 7). Totals of suspected" exact="Zika" post="and suspected chikungunya cases at state- and department-level were"/>
   <result pre="Simulations incorporating immune-mediated interactions We tested whether immune-mediated interactions between" exact="DENV" post="and ZIKV could produce the dengue dynamics observed in"/>
   <result pre="immune-mediated interactions We tested whether immune-mediated interactions between DENV and" exact="ZIKV" post="could produce the dengue dynamics observed in Brazil and"/>
   <result pre="observed in Brazil and Colombia by simulating the arrival of" exact="Zika" post="in a dengue endemic population (Fig. 4 and Supplementary"/>
   <result pre="(see &quot;Methods�? for further details). We performed simulations in which" exact="ZIKV" post="was introduced to a population in which DENV was"/>
   <result pre="in which ZIKV was introduced to a population in which" exact="DENV" post="was in a stable state as well as simulations"/>
   <result pre="the sequential introduction of dengue over the decades preceding the" exact="ZIKV" post="introduction reflecting the observed detection of DENV serotypes37 (see"/>
   <result pre="decades preceding the ZIKV introduction reflecting the observed detection of" exact="DENV" post="serotypes37 (see Supplementary Fig. 12 for sample simulations from"/>
   <result pre="12 for sample simulations from both settings). In simulations where" exact="ZIKV" post="infection temporarily reduces an individual’s risk of DENV infection"/>
   <result pre="simulations where ZIKV infection temporarily reduces an individual’s risk of" exact="DENV" post="infection by 80%, Zika epidemics are followed by a"/>
   <result pre="temporarily reduces an individual’s risk of DENV infection by 80%," exact="Zika" post="epidemics are followed by a trough in dengue incidence"/>
   <result pre="Supplementary Table 1). Even in the absence of enhancement between" exact="DENV" post="and ZIKV, multiple simulations showed increases in dengue after"/>
   <result pre="assumed one-year duration of cross-protection. In all scenarios, suppression of" exact="DENV" post="transmission resulted in subsequent increases in DENV prevalence, suggesting"/>
   <result pre="scenarios, suppression of DENV transmission resulted in subsequent increases in" exact="DENV" post="prevalence, suggesting that the low period of incidence observed"/>
   <result pre="in DENV. Fig. 4 Simulation results incorporating immune-mediated interactions between" exact="DENV" post="and ZIKV. Mean and 95% inter-quantile range from stochastic"/>
   <result pre="ZIKV-introduction. 100 simulations per scenario (see &quot;Methods�? for further details)." exact="ZIKV" post="introduced after a 100 year burn-in period for four"/>
   <result pre="ZIKV introduced after a 100 year burn-in period for four" exact="DENV" post="serotypes (see Supplementary Fig. 11 for results when ZIKV"/>
   <result pre="four DENV serotypes (see Supplementary Fig. 11 for results when" exact="ZIKV" post="is introduced 40 years after DENV). DENV and ZIKV"/>
   <result pre="for results when ZIKV is introduced 40 years after DENV)." exact="DENV" post="and ZIKV reproduction numbers are assumed to be 4"/>
   <result pre="when ZIKV is introduced 40 years after DENV). DENV and" exact="ZIKV" post="reproduction numbers are assumed to be 4 and 2,"/>
   <result pre="which we use to define the start and end of" exact="DENV" post="prevalence troughs (see Methods and Supplementary Table 1). a–d"/>
   <result pre="a–d Individuals with previous dengue exposure experience 20% of the" exact="DENV" post="force of infection (FOI) that a fully susceptible person"/>
   <result pre="that a fully susceptible person would. e–h Individuals with previous" exact="ZIKV" post="exposure experience 80% of the FOI that a fully"/>
   <result pre="FOI that a fully susceptible person would. i–l Individuals with" exact="ZIKV" post="exposure experience 20% of the DENV FOI (same amount"/>
   <result pre="would. i–l Individuals with ZIKV exposure experience 20% of the" exact="DENV" post="FOI (same amount of cross-protection between dengue and Zika"/>
   <result pre="the DENV FOI (same amount of cross-protection between dengue and" exact="Zika" post="than between dengue serotypes). We also tested the impact"/>
   <result pre="dengue serotypes). We also tested the impact of correlation in" exact="ZIKV" post="and DENV transmission intensity on observed associations between cumulative"/>
   <result pre="We also tested the impact of correlation in ZIKV and" exact="DENV" post="transmission intensity on observed associations between cumulative ZIKV and"/>
   <result pre="ZIKV and DENV transmission intensity on observed associations between cumulative" exact="ZIKV" post="and DENV incidence (see Supplementary Fig. 10). We consistently"/>
   <result pre="DENV transmission intensity on observed associations between cumulative ZIKV and" exact="DENV" post="incidence (see Supplementary Fig. 10). We consistently observed a"/>
   <result pre="Supplementary Fig. 10). We consistently observed a reduced impact of" exact="ZIKV" post="on dengue in simulations where DENV transmissibility was assumed"/>
   <result pre="a reduced impact of ZIKV on dengue in simulations where" exact="DENV" post="transmissibility was assumed to be higher. When the transmissibility"/>
   <result pre="transmissibility was assumed to be higher. When the transmissibility of" exact="ZIKV" post="and DENV were assumed to be equal, reductions in"/>
   <result pre="assumed to be higher. When the transmissibility of ZIKV and" exact="DENV" post="were assumed to be equal, reductions in DENV due"/>
   <result pre="ZIKV and DENV were assumed to be equal, reductions in" exact="DENV" post="due to cross protection were not larger in simulations"/>
   <result pre="to cross protection were not larger in simulations with higher" exact="ZIKV" post="attack rates as the impact of ZIKV was offset"/>
   <result pre="simulations with higher ZIKV attack rates as the impact of" exact="ZIKV" post="was offset by increased DENV transmissibility. These results are"/>
   <result pre="rates as the impact of ZIKV was offset by increased" exact="DENV" post="transmissibility. These results are consistent with an unclear or"/>
   <result pre="results are consistent with an unclear or variable relationship between" exact="DENV" post="reductions and cumulative ZIKV incidence as we have observed"/>
   <result pre="an unclear or variable relationship between DENV reductions and cumulative" exact="ZIKV" post="incidence as we have observed in the data. Discussion"/>
   <result pre="reduction in dengue incidence in Brazil and Colombia. Utilizing available" exact="Zika" post="case data, we were unable to establish a direct"/>
   <result pre="to establish a direct link between this reduction and the" exact="Zika" post="epidemic. It is important to note that there are"/>
   <result pre="particularly when novel pathogens are involved. In the case of" exact="ZIKV" post="invasion in the Americas, many cases that occurred early"/>
   <result pre="since it took time to first identify the presence of" exact="ZIKV" post="and then to establish reporting protocols. The unavailability of"/>
   <result pre="ZIKV and then to establish reporting protocols. The unavailability of" exact="Zika" post="case count data during the height of the ZIKV"/>
   <result pre="of Zika case count data during the height of the" exact="ZIKV" post="epidemic in northeast Brazil, one of the most severely"/>
   <result pre="contributed to our inability to identify a relationship between cumulative" exact="Zika" post="cases and observed dengue incidence. In both Brazil and"/>
   <result pre="both confirmed and unconfirmed cases) in all of our analyses." exact="Zika" post="and chikungunya case counts were first reported in the"/>
   <result pre="most comparable to the preceding historical data. Analogous updated probable" exact="Zika" post="and chikungunya case counts were first reported in 2017"/>
   <result pre="they were reported separately. We extracted additional data for probable" exact="Zika" post="and chikungunya cases from the weekly Epidemiological Bulletins36 for"/>
   <result pre="Colombia’s Directorate of Surveillance and Risk Analysis in Public Health," exact="Zika" post="has been in the country since 2015 Epiweek 40"/>
   <result pre="1 bulletin. In the updated Colombia dataset, the first documented" exact="Zika" post="cases were in 2015 Epiweek 25. Case counts in"/>
   <result pre="years (2015, 2016, 2017) or a multiplicative effect of either" exact="Zika" post="or chikungunya case counts (previous biweek or total count"/>
   <result pre="offset for year-specific subnational population size (Ni,t). Xi,t represents either:" exact="Zika" post="or chikungunya incidence (either at biweek t or the"/>
   <result pre="overlap zero. Stochastic compartmental model We developed a four serotype" exact="DENV" post="model that also allowed for ZIKV infection in both"/>
   <result pre="developed a four serotype DENV model that also allowed for" exact="ZIKV" post="infection in both mosquito and human populations. There are"/>
   <result pre="infected with ZIKV. The human compartments are based on both" exact="DENV" post="and ZIKV status. With respect to DENV infection status,"/>
   <result pre="ZIKV. The human compartments are based on both DENV and" exact="ZIKV" post="status. With respect to DENV infection status, individuals in"/>
   <result pre="based on both DENV and ZIKV status. With respect to" exact="DENV" post="infection status, individuals in the human population are either"/>
   <result pre="cross-protected, or recovered. We keep track of primary and secondary" exact="DENV" post="infections and assume that after two heterotypic DENV infections,"/>
   <result pre="and secondary DENV infections and assume that after two heterotypic" exact="DENV" post="infections, individuals become immune to further DENV infections. Homotypic"/>
   <result pre="after two heterotypic DENV infections, individuals become immune to further" exact="DENV" post="infections. Homotypic reinfections are not allowed in the model."/>
   <result pre="The human classes are further stratified depending on the individual’s" exact="ZIKV" post="status: either susceptible, infectious, cross-protected (from DENV), or recovered."/>
   <result pre="or cross-protection. The enhancement scenarios we considered included: no enhancement," exact="DENV" post="enhances DENV, DENV enhances DENV and ZIKV, and enhancement"/>
   <result pre="enhancement scenarios we considered included: no enhancement, DENV enhances DENV," exact="DENV" post="enhances DENV and ZIKV, and enhancement in all directions."/>
   <result pre="we considered included: no enhancement, DENV enhances DENV, DENV enhances" exact="DENV" post="and ZIKV, and enhancement in all directions. Enhancement was"/>
   <result pre="a dengue infection would reduce the hazard of a future" exact="Zika" post="infection and a Zika infection would reduce the hazard"/>
   <result pre="reduce the hazard of a future Zika infection and a" exact="Zika" post="infection would reduce the hazard of a future dengue"/>
   <result pre="dengue infection. Cross-serotype dengue protection (80% hazard reduction to other" exact="DENV" post="serotypes) was included in all scenarios. The average duration"/>
   <result pre="included in all scenarios. The average duration of cross-protection between" exact="DENV" post="serotypes was one year (γ = 1)46. We considered the case"/>
   <result pre="(γ = 1)46. We considered the case when cross-protection between dengue and" exact="Zika" post="also lasted one year on average. The scenarios without"/>
   <result pre="4 days (γ = 1/100). We considered two levels of cross-protection between" exact="DENV" post="and ZIKV. The high-level matched the level of cross-serotype"/>
   <result pre="only 20% (�? = 0.8). We did not incorporate seasonality in either" exact="DENV" post="or ZIKV transmission but expect simulations with seasonality to"/>
   <result pre="(�? = 0.8). We did not incorporate seasonality in either DENV or" exact="ZIKV" post="transmission but expect simulations with seasonality to be qualitatively"/>
   <result pre="using a tau-leap approximation of the Gillespie method in Fortran." exact="ZIKV" post="was introduced into the mosquito population after 100 years"/>
   <result pre="was introduced into the mosquito population after 100 years of" exact="DENV" post="only simulations. Numerical solutions for the corresponding deterministic system"/>
   <result pre="data was simulated after the introduction of ZIKV. We considered" exact="DENV" post="and ZIKV reproduction numbers for all combinations of 2"/>
   <result pre="simulated after the introduction of ZIKV. We considered DENV and" exact="ZIKV" post="reproduction numbers for all combinations of 2 and 4"/>
   <result pre="2 and 4 (see Fig. 4 for the case when" exact="DENV" post="and ZIKV reproduction numbers are 4 and 2 respectively),"/>
   <result pre="4 (see Fig. 4 for the case when DENV and" exact="ZIKV" post="reproduction numbers are 4 and 2 respectively), and for"/>
   <result pre="was performed in R. We also considered the case when" exact="ZIKV" post="was introduced after 40 years of DENV only simulations"/>
   <result pre="the case when ZIKV was introduced after 40 years of" exact="DENV" post="only simulations (see Supplementary Figs. 11 and 12). For"/>
   <result pre="are introduced each year for each serotype. Sample simulations displaying" exact="DENV" post="dynamics prior to the introduction of ZIKV under both"/>
   <result pre="Sample simulations displaying DENV dynamics prior to the introduction of" exact="ZIKV" post="under both stable and recently introduced DENV conditions are"/>
   <result pre="the introduction of ZIKV under both stable and recently introduced" exact="DENV" post="conditions are displayed in Supplementary Fig. 12. To evaluate"/>
   <result pre="by the scenario with no enhancement and no cross-protection between" exact="DENV" post="and ZIKV (see Fig. 4a). We define the trough"/>
   <result pre="scenario with no enhancement and no cross-protection between DENV and" exact="ZIKV" post="(see Fig. 4a). We define the trough duration to"/>
   <result pre="trough duration to be the length of time that aggregated" exact="DENV" post="prevalence is consecutively less than one half of the"/>
   <result pre="of ZIKV. Peak size is defined to be the maximum" exact="DENV" post="prevalence value, aggregated across all serotypes, in the 20"/>
   <result pre="ZIKV. Changes in peak size resulting from incorporating cross-protection between" exact="DENV" post="and ZIKV were evaluated by dividing the average peak"/>
   <result pre="in peak size resulting from incorporating cross-protection between DENV and" exact="ZIKV" post="were evaluated by dividing the average peak size for"/>
   <result pre="Report-Zika virus, microcephaly and Guillain-Barré syndrome. http://origin.searo.who.int/entity/bhutan/who-zika-28-7-16.pdf. (2016). 2.AyresCFJIdentification of" exact="Zika" post="virus vectors and implications for controlLancet Infect. Dis.20161627827910.1016/S1473-3099(16)00073-626852727 3.Chouin-Carneiro,"/>
   <result pre="(ed. Shields, V. D. C.) (InTech, 2017). 4.BardinaSVet al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunityScience201735617518010.1126/science.aal436528360135 5.DejnirattisaiWet al.Dengue virus"/>
   <result pre="5.DejnirattisaiWet al.Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with" exact="Zika" post="virusNat. Immunol.2016171102110810.1038/ni.351527339099 6.PaulLMet al.Dengue virus antibodies enhance Zika virus"/>
   <result pre="infection with Zika virusNat. Immunol.2016171102110810.1038/ni.351527339099 6.PaulLMet al.Dengue virus antibodies enhance" exact="Zika" post="virus infectionClin. Transl. Immunol.20165e11710.1038/cti.2016.72 7.StettlerKet al.Specificity, cross-reactivity, and function"/>
   <result pre="Immunol.20165e11710.1038/cti.2016.72 7.StettlerKet al.Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infectionScience201635382382610.1126/science.aaf850527417494 8.Barba-SpaethGet al.Structural basis of potent Zika–dengue virus"/>
   <result pre="potent Zika–dengue virus antibody cross-neutralizationNature20165364810.1038/nature1893827338953 9.Swanstrom, J. A. et al." exact="Dengue" post="virus envelope dimer epitope monoclonal antibodies isolated from dengue"/>
   <result pre="epitope monoclonal antibodies isolated from dengue patients are protective against" exact="Zika" post="virus. MBio7, e01123-16 (2016). 10.Rodriguez-BarraquerIet al.Impact of preexisting dengue"/>
   <result pre="MBio7, e01123-16 (2016). 10.Rodriguez-BarraquerIet al.Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic regionScience201936360761010.1126/science.aav661830733412 11.Badolato-CorrêaJet al.Human"/>
   <result pre="a dengue endemic regionScience201936360761010.1126/science.aav661830733412 11.Badolato-CorrêaJet al.Human T cell responses to" exact="Dengue" post="and Zika virus infection compared to Dengue/Zika coinfectionImmun. Inflamm."/>
   <result pre="endemic regionScience201936360761010.1126/science.aav661830733412 11.Badolato-CorrêaJet al.Human T cell responses to Dengue and" exact="Zika" post="virus infection compared to Dengue/Zika coinfectionImmun. Inflamm. Dis.2018619420610.1002/iid3.20329282904 12.VogelsCBFet"/>
   <result pre="co-transmission: a neglected public health concern?PLoS Biol.201917e300013010.1371/journal.pbio.300013030668574 13.ChavesBAet al.Coinfection with" exact="Zika" post="virus (ZIKV) and Dengue virus results in preferential ZIKV"/>
   <result pre="health concern?PLoS Biol.201917e300013010.1371/journal.pbio.300013030668574 13.ChavesBAet al.Coinfection with Zika virus (ZIKV) and" exact="Dengue" post="virus results in preferential ZIKV transmission by vector bite"/>
   <result pre="with Zika virus (ZIKV) and Dengue virus results in preferential" exact="ZIKV" post="transmission by vector bite to vertebrate hostJ. Infect. Dis.201821856357110.1093/infdis/jiy19629659904"/>
   <result pre="in BrazilLancet20163871052105310.1016/S0140-6736(16)00626-726944024 16.CaminadeCet al.Global risk model for vector-borne transmission of" exact="Zika" post="virus reveals the role of El Niño 2015Proc. Natl"/>
   <result pre="DataPLoS Negl. Trop. Dis.201610e000468710.1371/journal.pntd.000468727111294 19.FariaNRet al.Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the AmericasNature201754640641010.1038/nature2240128538727 20.World Health Organization."/>
   <result pre="http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf?ua=1 (2017). 21.ZambranaJVet al.Seroprevalence, risk factor, and spatial analyses of" exact="Zika" post="virus infection after the 2016 epidemic in Managua, NicaraguaProc."/>
   <result pre="Natl Acad. Sci. USA20181159294929910.1073/pnas.180467211530150394 22.Netto, E. M. et al. High" exact="Zika" post="Virus Seroprevalence in Salvador, Northeastern Brazil limits the potential"/>
   <result pre="Repository, 10.5281/zenodo.2566509 (2019). 26.RobbianiDFet al.Recurrent potent human neutralizing antibodies to" exact="Zika" post="virus in Brazil and MexicoCell2017169597609.e1110.1016/j.cell.2017.04.02428475892 27.SapparapuGet al.Neutralizing human antibodies"/>
   <result pre="virus in Brazil and MexicoCell2017169597609.e1110.1016/j.cell.2017.04.02428475892 27.SapparapuGet al.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature201654044344710.1038/nature2056427819683 28.MontoyaMet al.Longitudinal"/>
   <result pre="disease in miceNature201654044344710.1038/nature2056427819683 28.MontoyaMet al.Longitudinal analysis of antibody cross-neutralization following" exact="Zika" post="virus and Dengue virus infection in Asia and the"/>
   <result pre="28.MontoyaMet al.Longitudinal analysis of antibody cross-neutralization following Zika virus and" exact="Dengue" post="virus infection in Asia and the AmericasJ. Infect. Dis.201821853654510.1093/infdis/jiy16429618091"/>
   <result pre="American countries as a crucial factor in the spread of" exact="Chikungunya" post="virusJ. Virol.2014886294630610.1128/JVI.00370-1424672026 30.SabinABResearch on dengue during World War II1Am."/>
   <result pre="control of dengue virus infectionNat. Rev. Immunol.20151574575910.1038/nri391626603900 32.Halstead, S. B." exact="Dengue" post="antibody-dependent enhancement: knowns and unknowns. Microbiol. Spectr.2, 249–271 (2014)."/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52, 2015. Boletim Epidemiológico. http://portalms.saude.gov.br/boletins-epidemiologicos#."/>
   <result pre="mapping the 70 year historyTrends Microbiol.20142213814610.1016/j.tim.2013.12.01124468533 38.RibeiroGSet al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengue? LancetGlob. Health20186e140e141 39.Pan American"/>
   <result pre="Health Information Platform for the Americas (PLISA). Reported Cases of" exact="Dengue" post="Fever in The Americas. http://www.paho.org/data/index.php/en/mnu-topics/indicadores-dengue-en/dengue-nacional-en/252-dengue-pais-ano-en.html. 40.Ministerio da Saude Brasil."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6917977\results\search\tropicalVirus\results.xml">
   <result pre="non�?commercial and no modifications or adaptations are made.file:PBI-18-266.pdf Abstract Summary" exact="Chikungunya" post="virus (CHIKV) is a mosquito�?transmitted alphavirus, and its infection"/>
   <result pre="no licensed vaccines or therapeutics for human use to combat" exact="CHIKV" post="infections. In this study, we explored the feasibility of"/>
   <result pre="wild�?type (WT) and glycoengineered (∆XFT) Nicotiana benthamiana plants in treating" exact="CHIKV" post="infection in a mouse model. CHIKV mAb was efficiently"/>
   <result pre="benthamiana plants in treating CHIKV infection in a mouse model." exact="CHIKV" post="mAb was efficiently expressed and assembled in plant leaves"/>
   <result pre="plants as an effective platform for production of functionally active" exact="CHIKV" post="mAbs and implies optimization of in vivo activity by"/>
   <result pre="and Infectious Diseases 10.13039/100000060 R33AI101329R15A113706R15AI135893 fig-count: table-count: page-count: word-count: Introduction" exact="Chikungunya" post="virus (CHIKV) is a positive�?sense RNA virus belonging to"/>
   <result pre="2 (E1 and E2) (Voss et al., 2010). Infection of" exact="CHIKV" post="in humans can cause debilitating polyarthralgia that may persist"/>
   <result pre="knees, wrists and fingers (Schilte et al., 2013). Since 2004," exact="CHIKV" post="reemergence has resulted in millions of cases of severe"/>
   <result pre="2015). Currently, there are no licensed therapeutics or vaccines against" exact="CHIKV" post="for human use. Continued outbreaks of CHIKV and the"/>
   <result pre="or vaccines against CHIKV for human use. Continued outbreaks of" exact="CHIKV" post="and the risk of it spreading into new areas"/>
   <result pre="show evidence of protectivity, as these subjects are immune to" exact="CHIKV" post="reinfection (Kam et al., 2012; Yoon et al., 2015)."/>
   <result pre="2012; Yoon et al., 2015). Indeed, monoclonal antibodies (mAbs) against" exact="CHIKV" post="E1 and E2 have been shown to be protective"/>
   <result pre="E1 and E2 have been shown to be protective against" exact="CHIKV" post="infection in various mouse models. For example, anti�?E1 or"/>
   <result pre="protected immune compromised (Ifnar �?/�?) mice against lethal challenges of" exact="CHIKV" post="when given as post�?exposure therapy (Pal et al., 2013)."/>
   <result pre="candidates to treat various viral infections including those caused by" exact="West Nile" post="virus (WNV) (Sun et al., 2018), dengue virus (DENV)"/>
   <result pre="incompletely processed and oligomannosidic structures. Both mAb variants potently neutralized" exact="CHIKV" post="in vitro. Notably, both pCHKVmab glycoforms also showed efficacy"/>
   <result pre="pCHKVmab glycoforms also showed efficacy but with different potency against" exact="CHIKV" post="infection in a murine model. Results Expression and assembly"/>
   <result pre="Wiley &amp;amp; Sons, Ltd, Neutralization activity of plant�?derived CHKVmab against" exact="CHIKV" post="Plaque reduction neutralization test (PRNT) was used to evaluate"/>
   <result pre="used to evaluate the neutralization potential of plant�?produced mAbs against" exact="CHIKV" post="(Yang et al., 2017b). While the negative control mAb"/>
   <result pre="CHIKV, both WTpCHKVmab and ∆XFpCHKVmab showed strong neutralizing activity against" exact="CHIKV" post="with statistically similar potency (∆XFpCHKVmab EC50 = 130.5 ng/mL"/>
   <result pre="mAb (∆XFpWNVmab, negative control) were co�?incubated with 100 PFU of" exact="CHIKV" post="and Vero cells for 3 days. Plaques were counted,"/>
   <result pre="of the mean. In vivo efficacy of plant�?derived CHKVmab against" exact="CHIKV" post="infection Among mouse models of CHIKV infection, WT mice"/>
   <result pre="of plant�?derived CHKVmab against CHIKV infection Among mouse models of" exact="CHIKV" post="infection, WT mice (i.e. WT C57BL/6) develop arthritis symptoms"/>
   <result pre="in the right footpad with 1 × 105 PFU of" exact="CHIKV" post="and then treated at 12 h post�?infection with 50"/>
   <result pre="and post�?exposure therapeutics for CHIKV. Figure 4 Plant�?produced CHKVmabs reduce" exact="CHIKV" post="viraemia in mice. Wild�?type C57BL/6J mice (N = 6"/>
   <result pre="group) were subcutaneously infected with 1 × 105 PFUs of" exact="CHIKV" post="and treated intraperitoneally with 50 μg of indicated CHKVmab"/>
   <result pre="at day 2 dpi is presented as a ratio of" exact="CHIKV" post="E1 copy number per 1000 copy of cellular β�?actin."/>
   <result pre="determined by t�?tests. Antibody�?dependent enhancement activity of plant�?produced CHKVmab for" exact="DENV" post="infection One of the challenges for mAb therapeutics against"/>
   <result pre="For example, cross�?reactive but sub�?neutralizing antibodies against one serotype of" exact="DENV" post="from a previous infection can form complexes with another"/>
   <result pre="a previous infection can form complexes with another serotype of" exact="DENV" post="during a secondary infection to promote viral infection of"/>
   <result pre="ADE (Sun et al., 2018). Since the E proteins of" exact="CHIKV" post="and DENV are related and the two viruses co�?circulate"/>
   <result pre="et al., 2018). Since the E proteins of CHIKV and" exact="DENV" post="are related and the two viruses co�?circulate geographically (Kam"/>
   <result pre="cross�?reacts with E of most flaviviruses, efficiently caused ADE of" exact="DENV" post="infection in K562 cells that express the human FcγR"/>
   <result pre="In contrast, ∆XFpCHKVmab and WTpCHKVmab did not promote ADE for" exact="DENV" post="(Figure 5). These results indicate that plant�?produced CHKVmabs are"/>
   <result pre="not only efficacious but also safe as potential treatment against" exact="CHIKV" post="infection. Figure 5 Antibody�?dependent enhancement of CHKVmabs for DENV"/>
   <result pre="against CHIKV infection. Figure 5 Antibody�?dependent enhancement of CHKVmabs for" exact="DENV" post="infection. Serial dilutions of CHKVmabs or 4G2 (positive control"/>
   <result pre="and analysed by flow cytometry. Discussion The expanding epidemics of" exact="CHIKV" post="demand the development of efficacious therapeutics against this debilitating"/>
   <result pre="mouse anti�?CHIKV mAbs indicate that some of the antibodies against" exact="CHIKV" post="E1 and E2 have protective activity and their protectivity"/>
   <result pre="the feasibility of using plant�?produced mAbs against E1 in treating" exact="CHIKV" post="infection in a mouse model as a step towards"/>
   <result pre="mouse model as a step towards improving the efficacy of" exact="CHIKV" post="immunotherapy in humans. A prerequisite for plant�?made mAbs to"/>
   <result pre="manufacturing of CHKVmabs. Together, these results indicate that similar to" exact="CHIKV" post="vaccine development (Cardona�?Ospina et al., 2016; Salazar�?Gonzalez et al.,"/>
   <result pre="and cost, which will markedly increase the affordability of mAb�?based" exact="CHIKV" post="drugs to people in the developing world, where the"/>
   <result pre="to people in the developing world, where the majority of" exact="CHIKV" post="cases occurs. Another striking feature of the plant transient"/>
   <result pre="et al., 2013). Plant�?made CHKVmab exhibited strong neutralizing activity against" exact="CHIKV" post="with potencies similar to mammalian cell�?derived CHKVmab (Pal et"/>
   <result pre="compromised (Ifnar �?/�? or AG129) mice are subject to lethal" exact="CHIKV" post="infection, providing a convenient survival model (Pal et al.,"/>
   <result pre="do not develop the arthritis observed in humans. In contrast," exact="CHIKV" post="infection in WT C57BL/6 mice causes arthritis and swelling"/>
   <result pre="2017), presenting a more relevant animal model for studying human" exact="CHIKV" post="infection. CHIKV infection in WT C57BL/6 mice does not"/>
   <result pre="a more relevant animal model for studying human CHIKV infection." exact="CHIKV" post="infection in WT C57BL/6 mice does not cause lethal"/>
   <result pre="results showed that ∆XFpCHKVmab had better in vivo efficacy against" exact="CHIKV" post="than WTpCHKVmab. These results support our hypothesis that some"/>
   <result pre="addition, neither of the two mAb glycoforms promoted ADE for" exact="DENV" post="infection. These results suggest that mAbs have the potential"/>
   <result pre="to be used as effective and safe prophylaxis to prevent" exact="CHIKV" post="infection during outbreaks, especially for populations with high risk"/>
   <result pre="studies in mouse arthritis models that mimic symptoms of human" exact="CHIKV" post="infection. In the context of recent studies that demonstrate"/>
   <result pre="of recent studies that demonstrate broadly neutralizing human mAbs against" exact="CHIKV" post="E2 with therapeutic activity (Smith et al., 2015), our"/>
   <result pre="the development of a novel multi�?target therapy to combat sudden" exact="CHIKV" post="outbreaks. Materials and methods Ethics statement and biosafety All"/>
   <result pre="(USM). All in vitro experiments and animal studies involving live" exact="CHIKV" post="were performed by the certified personnel in the USM"/>
   <result pre="and purified with a method previously developed for anti�?WNV and" exact="DENV" post="mAbs (Dent et al., 2016; Lai et al., 2010,"/>
   <result pre="(http://www.proglycan.com) was used to annotate the glycans. Virus and cells" exact="CHIKV" post="(strain LR�?OPY1, kindly provided by Dr. Robert B. Tesh"/>
   <result pre="FBS at 37 °C in an incubation with 5% CO2." exact="CHIKV" post="neutralization and plaque assay Plaque reduction neutralization test (PRNT)"/>
   <result pre="Specifically, mAbs were serially diluted in phosphate�?buffered saline (PBS), while" exact="CHIKV" post="was diluted in serum�?free DMEM to a working concentration"/>
   <result pre="units (PFUs) per well. Following dilutions, mAbs were added to" exact="CHIKV" post="and incubated for 1 h at 37 °C. CHIKV�?mAb"/>
   <result pre="and counted. Percent (%) neutralization was calculated as: [(number of" exact="CHIKV" post="plaque per well with no mAb) − (number of"/>
   <result pre="CHIKV plaque per well with no mAb) − (number of" exact="CHIKV" post="plaque per well of diluted mAb)/(number of CHIKV plaque"/>
   <result pre="(number of CHIKV plaque per well of diluted mAb)/(number of" exact="CHIKV" post="plaque per well with no mAb) × 100]. Experiments"/>
   <result pre="side of the right hind footpad with 105 PFUs of" exact="CHIKV" post="as previously described (Acharya et al., 2015). Mice were"/>
   <result pre="was synthesized by using the iSCRIPT cDNA synthesis kit (Bio�?Rad)." exact="CHIKV" post="envelope protein 1 (CHIKV E1) and cellular β�?actin RNA"/>
   <result pre="(Bio�?Rad). Viral copy numbers were expressed as the ratio of" exact="CHIKV" post="E1 to cellular β�?actin. Primer sequences for mouse β�?actin"/>
   <result pre="E1 to cellular β�?actin. Primer sequences for mouse β�?actin and" exact="CHIKV" post="E1 gene were previously described (Acharya et al., 2015)."/>
   <result pre="assay The potential enhancing activities of the anti�?CHIKV mAbs for" exact="DENV" post="infection were examined by using FcγRIIa+ K562 cells (ATCC,"/>
   <result pre="B. Tesh at University of Texas Medical Branch for providing" exact="CHIKV" post="strain and Collin Jugler for the critical reading of"/>
   <result pre="Plant expression systems, a budding way to confront chikungunya and" exact="Zika" post="in developing countries?F1000Res, 5, 2121.27781090 Chen, Q. (2016) Glycoengineering"/>
   <result pre="M.S.et al (2010) Monoclonal antibody produced in plants efficiently treats" exact="West Nile" post="virus infection in mice. Proc. Natl. Acad. Sci. USA,"/>
   <result pre="Chen, Q. (2018) A plant�?produced vaccine protects mice against lethal" exact="West Nile" post="virus infection without enhancing Zika or dengue virus infectivity."/>
   <result pre="protects mice against lethal West Nile virus infection without enhancing" exact="Zika" post="or dengue virus infectivity. Vaccine, 36, 1846–1852.29490880 Leuzinger, K.,"/>
   <result pre="4, 419–425.22699226 Salazar�?Gonzalez, J.A., Angulo, C. and Rosales�?Mendoza, S. (2015)" exact="Chikungunya" post="virus vaccines: Current strategies and prospects for developing plant�?made"/>
   <result pre="Madec, Y., Carpentier, F., Kassab, S., Albert, M.L.et al (2013)" exact="Chikungunya" post="virus�?associated long�?term arthralgia: a 36�?month prospective longitudinal study. PLoS"/>
   <result pre="C., Crublet, E., Thompson, A.et al (2010) Glycoprotein organization of" exact="Chikungunya" post="virus particles revealed by X�?ray crystallography. Nature, 468, 709.21124458"/>
   <result pre="Lai, H., Sun, H. and Chen, Q. (2017a) Immunization of" exact="Zika" post="virus envelope protein domain III induces specific and neutralizing"/>
   <result pre="protein domain III induces specific and neutralizing immune responses against" exact="Zika" post="virus. Vaccine, 35, 4287–4294.28669618 Yang, M., Lai, H., Sun,"/>
   <result pre="Sun, H. and Chen, Q. (2017b) Virus�?like particles that display" exact="Zika" post="virus envelope protein domain III induce potent neutralizing immune"/>
   <result pre="H., Lai, H., Hurtado, J. and Chen, Q. (2018) Plant�?produced" exact="Zika" post="virus envelope protein elicits neutralizing immune responses that correlate"/>
   <result pre="elicits neutralizing immune responses that correlate with protective immunity against" exact="Zika" post="virus in mice. Plant Biotechnol. J.16, 572–580.28710796 Yoon, I.K.,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6920831\results\search\tropicalVirus\results.xml">
   <result pre="and hepatitides [15,16,17]. The additions to this list also include" exact="Dengue" post="fever virus (DENV) and HIV (which belong to Flavivirade"/>
   <result pre="pandemic influenza infection [5,14,108]. In one report, the incidence of" exact="DENV" post="infections seemed higher in obese patients, but needed more"/>
   <result pre="patientsPLoS ONE201813e020069810.1371/journal.pone.020069830016369 21.BadawiA.VelummailumR.RyooS.G.SenthinathanA.YaghoubiS.VasilevaD.OstermeierE.PlishkaM.SoosaipillaiM.AroraP.Prevalence of chronic comorbidities in dengue fever and" exact="West Nile" post="virus: A systematic review and meta-analysisPLoS ONE201813e020020010.1371/journal.pone.020020029990356 22.LakeJ.E.The fat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6921433\results\search\tropicalVirus\results.xml">
   <result pre="combat emerging infectious diseases? Lessons from the case of a" exact="Zika" post="virus human challenge trial PalaciosRicardoricardo.palacios@butantan.gov.br12ShahSeema K.SeShah@luriechildrens.org34[1], 0000 0001 1702"/>
   <result pre="part of epidemic preparedness, we use the case of a" exact="Zika" post="virus HCT to explore whether and when HCTs might"/>
   <result pre="acceptable. Keywords Human challenge trials Research ethics Ethics in emergencies" exact="Zika" post="virus Global Forum on Bioethics in Research GFBRBangkok, Thailand28-29"/>
   <result pre="virus, MERS-CoV, Lassa virus, Ebola virus disease, Marburg virus disease," exact="Zika" post="virus, and Rift Valley Fever [8]. These are serious"/>
   <result pre="currently unknown to cause human disease�? [8]. Notably, in 2013," exact="Zika" post="virus was a pathogen thought to cause only mild"/>
   <result pre="epidemic. In this paper, we consider the case of a" exact="Zika" post="virus HCT as a springboard to determine whether and"/>
   <result pre="might be useful in this scenario. The case of a" exact="Zika" post="virus HCT In 2015, Zika virus emerged as a"/>
   <result pre="scenario. The case of a Zika virus HCT In 2015," exact="Zika" post="virus emerged as a major public health crisis in"/>
   <result pre="countries. Although the WHO declared the state of emergency surrounding" exact="Zika" post="virus over in November 2016, it indicated that Zika"/>
   <result pre="surrounding Zika virus over in November 2016, it indicated that" exact="Zika" post="is likely to be a persistent and unpredictable public"/>
   <result pre="threat for years to come [9]. Some estimates indicate that" exact="Zika" post="virus is asymptomatic in the vast majority of people"/>
   <result pre="transient, but it can have potentially devastating consequences. In adults," exact="Zika" post="virus can cause neurological complications, including but not limited"/>
   <result pre="evidence is needed [12]. Perhaps of greatest concern, transmission of" exact="Zika" post="virus from a pregnant woman to a fetus can"/>
   <result pre="from a pregnant woman to a fetus can cause congenital" exact="Zika" post="syndrome. Congenital Zika syndrome typically involves microcephaly and potentially"/>
   <result pre="woman to a fetus can cause congenital Zika syndrome. Congenital" exact="Zika" post="syndrome typically involves microcephaly and potentially significant abnormalities in"/>
   <result pre="development, visual impairment, cardiac defects, and other complications [13, 14]." exact="Zika" post="virus is known to be transmissible through mosquito vectors,"/>
   <result pre="ways [15, 16]. Until recently, the duration of infectivity for" exact="Zika" post="virus was highly uncertain but is now thought to"/>
   <result pre="HCT in which healthy volunteers would be intentionally exposed to" exact="Zika" post="virus, which was a newly emerging public health threat"/>
   <result pre="publicly available, some of the details are widely known. The" exact="Zika" post="virus HCT was proposed to learn more about the"/>
   <result pre="was proposed to learn more about the early stages of" exact="Zika" post="infection and efficiently test whether vaccines can protect against"/>
   <result pre="Zika infection and efficiently test whether vaccines can protect against" exact="Zika" post="infection. The trial was to be conducted in the"/>
   <result pre="enroll healthy volunteers who would not otherwise be exposed to" exact="Zika" post="virus. Previous exposure to other viruses in the same"/>
   <result pre="the Walter Reed Army Institute of Research were concerned that" exact="Zika" post="virus HCTs were ethically complex. They therefore assembled an"/>
   <result pre="multidisciplinary expert panel to address the question of whether a" exact="Zika" post="virus HCT could be ethically justified, and if so,"/>
   <result pre="with making recommendations to NIH about the ethical considerations for" exact="Zika" post="HCTs in general. Unlike standard ethics review committee or"/>
   <result pre="the panel considered the latest scientific and epidemiological information about" exact="Zika" post="virus, existing ethical frameworks for HCTs, and ongoing research"/>
   <result pre="virus, existing ethical frameworks for HCTs, and ongoing research into" exact="Zika" post="vaccines. The panel held several teleconferences and one in-person"/>
   <result pre="drafted a report that was released in February 2017. The" exact="Zika" post="HCT ethics expert panel offered a preliminary ethical framework"/>
   <result pre="HCT ethics expert panel offered a preliminary ethical framework for" exact="Zika" post="HCTs and concluded that Zika virus HCTs could be"/>
   <result pre="a preliminary ethical framework for Zika HCTs and concluded that" exact="Zika" post="virus HCTs could be ethically justified in principle but"/>
   <result pre="[18]. The two main reasons that the panel concluded a" exact="Zika" post="HCT would be premature were that: (1) there was"/>
   <result pre="their consent to participation and not enough was known about" exact="Zika" post="transmission to ensure they could be protected; and (2)"/>
   <result pre="ongoing and the panel could not be confident that a" exact="Zika" post="HCT was needed to accelerate the course of vaccine"/>
   <result pre="needed to accelerate the course of vaccine development. First, although" exact="Zika" post="virus appears to be asymptomatic for most of those"/>
   <result pre="ongoing research, it was unclear at the time whether a" exact="Zika" post="HCT offered sufficient potential for societal benefit to justify"/>
   <result pre="Although these were the most critical and unresolved issues facing" exact="Zika" post="HCTs at the time, the panel also noted several"/>
   <result pre="research-related injury, and consultation with the community in which a" exact="Zika" post="HCT would be conducted—considerations which may be helpful for"/>
   <result pre="important to note that external conditions, the evidence available about" exact="Zika" post="virus, and the epidemiology of Zika virus have changed"/>
   <result pre="the evidence available about Zika virus, and the epidemiology of" exact="Zika" post="virus have changed since the panel submitted its recommendations."/>
   <result pre="its recommendations. The period of infectivity for those infected with" exact="Zika" post="virus is much better known; Zika virus can be"/>
   <result pre="for those infected with Zika virus is much better known;" exact="Zika" post="virus can be transmitted for roughly 30 days in individuals"/>
   <result pre="avoid unprotected sexual activity) [20]. Additionally, although a phase II" exact="Zika" post="vaccine trial is ongoing, enrollment is lower than projected,"/>
   <result pre="and some drug and vaccine developers have halted research on" exact="Zika" post="virus [21]. This suggests that a Zika HCT could"/>
   <result pre="halted research on Zika virus [21]. This suggests that a" exact="Zika" post="HCT could have clear and considerable value if conducted"/>
   <result pre="plan to protect bystanders and research participants. Application of the" exact="Zika" post="HCT case to other HCTs on emerging infectious diseases"/>
   <result pre="examination of the two major issues that arose in the" exact="Zika" post="HCT ethics consultation provides lessons for other potential HCTs"/>
   <result pre="in the United States. First, as was the case with" exact="Zika" post="virus, many stakeholders are likely to be interested in"/>
   <result pre="difficult to conduct giving the declining numbers and unpredictability of" exact="Zika" post="outbreaks, and the initial uncertainty about the value of"/>
   <result pre="outbreaks, and the initial uncertainty about the value of a" exact="Zika" post="HCT was resolved [17]. One possibility, then, is that"/>
   <result pre="uncertainty. For example, the modes and duration of transmission of" exact="Zika" post="virus were not known at the time of the"/>
   <result pre="at the time of the review of the ethics of" exact="Zika" post="HCTs, so the risks of transmission to people outside"/>
   <result pre="determine, let alone mitigate. As has been described elsewhere, the" exact="Zika" post="HCT ethics panel struggled with the question of how"/>
   <result pre="give consent to being exposed to risk of infection with" exact="Zika" post="virus, and there is limited guidance on how to"/>
   <result pre="will also have to be weighed in the balance. Although" exact="Zika" post="virus is asymptomatic in roughly half to three-quarters of"/>
   <result pre="were satisfied as well). Application to a &quot;Disease X�? Although" exact="Zika" post="virus was discovered in Uganda in 1947, it did"/>
   <result pre="concern until relatively recently. In 1956, Bearcroft inoculated himself with" exact="Zika" post="virus and noted only very mild, transient symptoms [32]."/>
   <result pre="[33], as seems to have occurred in recent years with" exact="Zika" post="virus. Recognizing that the world was not prepared for"/>
   <result pre="that the world was not prepared for the most recent" exact="Zika" post="epidemic, preparedness for the next &quot;Disease X�? is critically"/>
   <result pre="in an endemic setting. As with the example of the" exact="Zika" post="HCT, there are several other issues that should be"/>
   <result pre="public health emergency is overwhelming. The number of articles on" exact="Zika" post="virus registered in the National Center for Biotechnology Information’s"/>
   <result pre="more targeted fashion. Conclusion Examining the case of a potential" exact="Zika" post="virus HCT reveals that HCTs on emerging infectious diseases"/>
   <result pre="Authors’ information Both authors were not involved in any proposed" exact="Zika" post="virus human challenge trials as investigators or part of"/>
   <result pre="independent reviewers serving on a panel evaluating the ethics of" exact="Zika" post="virus human challenge trials. Funding Funds were provided by"/>
   <result pre="The authors participated in the independent panel that reviewed the" exact="Zika" post="virus human challenge trial but have no competing interests."/>
   <result pre="the International Health Regulations regarding microcephaly, other neurological disorders and" exact="Zika" post="virus (18 November 2016)2016GenevaWHO 10.MuñozLSBarrerasPPardoCAZika Virus-Associated Neurological Disease in"/>
   <result pre="Encephalitis, and MyelitisSemin Reprod Med201634527327910.1055/s-0036-159206627612158 11.ParraBLizarazoJJiménez-ArangoJAZea-VeraAFGonzález-ManriqueGVargasJet al.Guillain-Barre Syndrome Associated with" exact="Zika" post="Virus Infection in ColombiaN Engl J Med2016375161513152310.1056/NEJMoa160556427705091 12.AlettiMLecoulesSKanczugaVSolerCMaquartMSimonFet al.Transient"/>
   <result pre="ColombiaN Engl J Med2016375161513152310.1056/NEJMoa160556427705091 12.AlettiMLecoulesSKanczugaVSolerCMaquartMSimonFet al.Transient myocarditis associated with acute" exact="Zika" post="virus infectionClin Infect Dis201764567867927940942 13.de AraújoTVBRodriguesLCde Alencar XimenesRAde BarrosM-FDMontarroyosURde"/>
   <result pre="Professor Fernando Figueira; State Health Department of Pernambuco. Association between" exact="Zika" post="virus infection and microcephaly in Brazil, January to May,"/>
   <result pre="Infect Dis201616121356136310.1016/S1473-3099(16)30318-827641777 14.MooreCAStaplesJEDobynsWBPessoaAVenturaCVFonsecaEBet al.Characterizing the Pattern of Anomalies in Congenital" exact="Zika" post="Syndrome for Pediatric CliniciansJAMA Pediatr2017171328829510.1001/jamapediatrics.2016.398227812690 15.TurmelJMAbgueguenPHubertBVandammeYMMaquartMLe Guillou-GuillemetteHet al.Late sexual"/>
   <result pre="for Pediatric CliniciansJAMA Pediatr2017171328829510.1001/jamapediatrics.2016.398227812690 15.TurmelJMAbgueguenPHubertBVandammeYMMaquartMLe Guillou-GuillemetteHet al.Late sexual transmission of" exact="Zika" post="virus related to persistence in the semenLancet.201638710037250110.1016/S0140-6736(16)30775-927287833 16.SwaminathanSSchlabergRLewisJHansonKECouturierMRFatal Zika"/>
   <result pre="of Zika virus related to persistence in the semenLancet.201638710037250110.1016/S0140-6736(16)30775-927287833 16.SwaminathanSSchlabergRLewisJHansonKECouturierMRFatal" exact="Zika" post="Virus Infection with Secondary Nonsexual TransmissionN Engl J Med2016375191907190910.1056/NEJMc161061327681699"/>
   <result pre="Secondary Nonsexual TransmissionN Engl J Med2016375191907190910.1056/NEJMc161061327681699 17.Cohen, J. As massive" exact="Zika" post="vaccine trial struggles, researchers revive plan to intentionally infect"/>
   <result pre="HF, McCutchan F, Miller F, et al. Ethical considerations for" exact="Zika" post="virus human challenge trials. NIH. https://www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeStudiesReport2017.pdf. Accessed 15 Jun"/>
   <result pre="NIH. https://www.niaid.nih.gov/sites/default/files/EthicsZikaHumanChallengeStudiesReport2017.pdf. Accessed 15 Jun 2018. 19.CounotteMJKimCRWangJet al.Sexual transmission of" exact="Zika" post="virus and other flaviviruses: A living systematic reviewPLoS Med2018157e100261110.1371/journal.pmed.100261130040845"/>
   <result pre="Guidance for Preconception Counseling and Prevention of Sexual Transmission of" exact="Zika" post="Virus for Persons with Possible Zika Virus Exposure -"/>
   <result pre="of Sexual Transmission of Zika Virus for Persons with Possible" exact="Zika" post="Virus Exposure - United States, September 2016MMWR Morb Mortal"/>
   <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidatesVaccine.201937686386810.1016/j.vaccine.2018.12.04030639461 22.ShahSKKimmelmanJLyerlyADLynchHFMillerFGPalaciosRet al.Bystander risk, social value, and ethics"/>
   <result pre="research risksJ Med Ethics200935744544910.1136/jme.2008.02606219567696 31.MitchellPKMier-Y-Teran-RomeroLBiggerstaffBJet al.Reassessing Serosurvey-Based Estimates of the" exact="Zika" post="Symptomatic ProportionAm J Epidemiol201918820321310.1093/aje/kwy189 32.HoneinMADawsonALPetersonEEet al.Birth Defects Among Fetuses"/>
   <result pre="Fetuses and Infants of US Women with Evidence of Possible" exact="Zika" post="Virus Infection During PregnancyJAMA.20173171596810.1001/jama.2016.1900627960197 33.BearcroftWGZika virus infection experimentally induced"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6923192\results\search\tropicalVirus\results.xml">
   <result pre="available than human vaccines (41). Surveillance Japanese encephalitis virus (JEV)," exact="West Nile" post="virus (WNV), and St. Louis encephalitis virus (SLE) share"/>
   <result pre="of Culex mosquitoes and sentinel surveillance programs in place for" exact="WNV" post="could simultaneously also support vector surveillance for JEV through"/>
   <result pre="and DENV+ control serum and CSF with JE Detect and" exact="DENV" post="Detect InBios kits and developed a testing algorithm for"/>
   <result pre="Parasit Vectors. (2019) 12:244. 10.1186/s13071-019-3501-031101069 82.BuckleyADawsonAGouldEA. Detection of seroconversion to" exact="West Nile" post="virus, Usutu virus and Sindbis virus in UK sentinel"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6926201\results\search\tropicalVirus\results.xml">
   <result pre="for the early assessment of severe dengue. Keywords Early marker" exact="Dengue" post="fever Infection Serum neopterin 1 Introduction Dengue is an"/>
   <result pre="Keywords Early marker Dengue fever Infection Serum neopterin 1 Introduction" exact="Dengue" post="is an acute febrile illness caused by the Aedes"/>
   <result pre="eastern Mediterranean, South East Asia, and the western Pacific [4]." exact="Dengue" post="hemorrhagic fever (DHF) is a prominent reason for death"/>
   <result pre="victims are children under the age of 15 years [5]." exact="Dengue" post="virus infections can manifest as dengue fever or DHF/dengue"/>
   <result pre="and nonsevere dengue fever. [alt-text] Table 3 Neopterin Samples Nonsevere" exact="Dengue" post="Severe Dengue P value Mean Standard Deviation Mean Standard"/>
   <result pre="dengue fever. [alt-text] Table 3 Neopterin Samples Nonsevere Dengue Severe" exact="Dengue" post="P value Mean Standard Deviation Mean Standard Deviation First"/>
   <result pre="and nonsevere dengue The median raised neopterin levels in non-severe" exact="Dengue" post="and severe dengue were 4.20 nmol/l and 6.65 nmol/l, respectively. This"/>
   <result pre="clinical reviewOpen Med842014e10525426178 2Wilder-SmithA.SchwartzE.Dengue in travelersN Engl J Med3539200592493216135837 3PattersonJ.SammonM.GargM.Dengue," exact="Zika" post="and chikungunya: emerging arboviruses in the New WorldWest J"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6927920\results\search\tropicalVirus\results.xml">
   <result pre="influenza and bacterial super-infection.Front. Immunol.9:2151. 10.3389/fimmu.2018.0215130337919 GrantA.PoniaS. S.TripathiS.BalasubramaniamV.MiorinL.SourisseauM.et al. (2016)." exact="Zika" post="virus targets human STAT2 to inhibit type I interferon"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6935926\results\search\tropicalVirus\results.xml">
   <result pre="AndersenKG, LomanNJ2017Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nat"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948741\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Tropical Diseases"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : People and places : Geographical locations :"/>
   <result pre="outbreak in an upper medium class neighborhood in Northeast Brazil" exact="CHIKV" post="transmission in Bahia state, Northeast Brazil Goes de JesusJaquelineConceptualizationData"/>
   <result pre="(FS) by mid 2014. Following that, a large number of" exact="CHIKV" post="cases have been notified in FS, which is the"/>
   <result pre="conditions and the abundance of competent vectors. To better understand" exact="CHIKV" post="dynamics in Bahia state, we generated 5 complete genome"/>
   <result pre="a single strongly supported monophyletic clade that includes other older" exact="CHIKV" post="sequences from the same location, suggesting the persistence of"/>
   <result pre="genomic surveillance strategies to track viral adaptations and to monitor" exact="CHIKV" post="epidemics for improved public health control. Funding http://dx.doi.org/10.13039/501100003593Conselho Nacional"/>
   <result pre="GenBank under accession numbers: MK159123, MK159124, MK159125, MK159126, MK159127. Introduction" exact="Chikungunya" post="virus (CHIKV) has emerged as a public health concern"/>
   <result pre="spread causing epidemics in more than 100 countries [2]. Four" exact="CHIKV" post="lineages have been described: West African; East/Central/South African (ECSA);"/>
   <result pre="Lineage (IOL) [3–5]. In Brazil, the first autochthonous cases of" exact="CHIKV" post="were confirmed in September 2014 in the municipality of"/>
   <result pre="FS have reported a large number of positive cases for" exact="CHIKV" post="infection. Released data from the Brazilian surveillance health system"/>
   <result pre="habitants [9–10]. Here we report evidence of the persistence of" exact="CHIKV" post="ECSA genotype and shed light on a localized outbreak"/>
   <result pre="(n = 69) from 27 patients presenting symptoms consistent with" exact="CHIKV" post="infection from Serraria Brasil neighborhood were collected by active"/>
   <result pre="Time PCR Systems or a QuantStudio® Systems (Applied Biosystems). The" exact="CHIKV" post="non-structural protein 1 (nsp1) was targeted using the primers"/>
   <result pre="to 3’: AAAGGGCAAACTCAGCTTCAC), CHIKV-R (5’ to 3’: GCCCTGGGCTCATCGTTATTC) and the" exact="CHIKV" post="Probe (5’ to 3’: FAM-CGCTGTGATACAGTGGTTTCGTGTG), based on an assay"/>
   <result pre="online tool to amplify 400 bp overlapping amplicons of the" exact="CHIKV" post="complete genome (http://primal.zibraproject.org) [12]. All samples were subjected to"/>
   <result pre="Nucleotide sequences recovered from this study were first subtyped using" exact="Chikungunya" post="TypingTool (https://genomedetective.com/app/typingtool/chikungunya/) [13]. New sequences were aligned to complete"/>
   <result pre="New sequences were aligned to complete or almost complete reference" exact="CHIKV" post="genome sequences (&amp;gt;10,000 bp), retrieved from National Center for"/>
   <result pre="female and 26% (n = 7) male individuals, who exhibited" exact="CHIKV" post="symptoms as intense polyarthralgia with impaired walking (n ="/>
   <result pre="27), urine (n = 21) and saliva (n = 21)." exact="CHIKV" post="IgM serology was positive for 17 cases (73,91%; S1"/>
   <result pre="inference To investigate and to better understand the diversity of" exact="CHIKV" post="in some of most affected municipalities in Bahia state,"/>
   <result pre="of most affected municipalities in Bahia state, we generated 5" exact="CHIKV" post="near-complete genomes (coverage range 88.90%-99.82%, mean = 97,4%) (Table"/>
   <result pre="= 98%) (orange). 10.1371/journal.pone.0226098.t002Table 2 Statistics for the 5 new" exact="CHIKV" post="sequences generated in this study. ID Accession Number Average"/>
   <result pre="study, by performing Illumina approach sequencing, we generated 5 new" exact="CHIKV" post="near-complete genomic sequences from 2016, collected in a neighbourhood"/>
   <result pre="to ECSA genotype corroborating with previous studies [7, 23]. Although" exact="CHIKV" post="is related to explosive outbreaks around the world [24–25],"/>
   <result pre="the novel sequences do not represent a re-introduction of the" exact="CHIKV" post="into FS but confirm the basal circulation of the"/>
   <result pre="reported here were obtained from different cellular compartments of two" exact="CHIKV" post="infected patients (Table 1). As reported in a previous"/>
   <result pre="and urine may also be used for the diagnosis of" exact="CHIKV" post="infection, and the chances of detection are greatest when"/>
   <result pre="27 patients sampled in this study exhibited compatible symptoms for" exact="CHIKV" post="infection. Taken together, these findings corroborate to other studies"/>
   <result pre="findings corroborate to other studies that demonstrate that 70% of" exact="CHIKV" post="infection cases are symptomatic, since the virus rate of"/>
   <result pre="Culex quinquefasciatus and Aedes aegypti in the second, although no" exact="CHIKV" post="infected mosquito was reported. According to epidemiological surveillance data"/>
   <result pre="of transmission of dengue and other arbovirus infections such as" exact="CHIKV" post="[36] and may have had in impact on this"/>
   <result pre="may contribute to virus dispersion within the region and beyond." exact="CHIKV" post="infection in FS was characterized by two distinct epidemic"/>
   <result pre="related factors may have contributed for this epidemiological behaviour of" exact="CHIKV" post="in FS. When the virus was introduced in July"/>
   <result pre="vector proliferation and expansion of infection. Also, the sub-notification of" exact="CHIKV" post="cases by health care services may have masked the"/>
   <result pre="in George Americo neighborhood which reported the first cases of" exact="CHIKV" post="in FS. That location represents the epicenter of the"/>
   <result pre="conditions that might have favored the rapid dispersion of the" exact="CHIKV" post="infection. In contrast, Serraria Brasil neighborhood is placed far"/>
   <result pre="in our analysis, previous studies have reported the occurrence of" exact="CHIKV" post="mutations that modified its adaption to mosquito vectors such"/>
   <result pre="non-synonymous SNPs found here are not related to any known" exact="CHIKV" post="mutations that increase the virus replication and/or infectivity in"/>
   <result pre="virus adaptation to mosquitoes vectors, making possible the study of" exact="CHIKV" post="fitness and evolution in mosquito populations, foretelling increase in"/>
   <result pre="vector control [51]. Together, our results indicate the persistence of" exact="CHIKV" post="ECSA lineage in the municipality of Feira de Santana"/>
   <result pre="to track viral adaptations and to improve our understanding about" exact="CHIKV" post="circulation in FS and to prevent new epidemics. Supporting"/>
   <result pre="(TIF) LINK Click here for additional data file. S2 Fig" exact="Chikungunya" post="virus genetic statistics. (TIFF) LINK Click here for additional"/>
   <result pre="(TIFF) LINK Click here for additional data file. S3 Fig" exact="Chikungunya" post="notified cases by epidemiological week (SE) in Feira de"/>
   <result pre="laboratory and genome sequencing protocols. References References 1PathakH, MohanMC, RavindranV." exact="Chikungunya" post="arthritis. Clinical Medicine (London, England). 2019, 19(5):381–385. 10.7861/clinmed.2019-0035 2FuJYL,"/>
   <result pre="of General Virology. 10/201910.1099/jgv.0.001338. 3PowersAM, BraultAC, TeshRB, WeaverSC. Re-emergence of" exact="Chikungunya" post="and O'nyong-nyong viruses: evidence for distinct geographical lineages and"/>
   <result pre="PLoS Med. 2006;3(7):e26310.1371/journal.pmed.003026316700631 5PowersAM. Genomic evolution and phenotypic distinctions of" exact="Chikungunya" post="viruses causing the Indian Ocean outbreak. Exp Biol Med"/>
   <result pre="KraemerMUG, de OliveiraLF, et al.Emergence and potential for spread of" exact="Chikungunya" post="virus in Brazil. BMC Med. 2015;13: 10210.1186/s12916-015-0348-x25976325 7Rodrigues FariaN,"/>
   <result pre="CerqueiraE, Maia de LimaM, PybusO, Carlos Junior AlcantaraL. Epidemiology of" exact="Chikungunya" post="Virus in Bahia, Brazil, 2014–2015. PLoS Currents. 2016;8: ecurrents.outbreaks.c97507e3e48efb946401755d468c28."/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52, 2016. Secretaria de Vigilância"/>
   <result pre="et al.Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nature"/>
   <result pre="al. (2019) A computational method for the identification of Dengue," exact="Zika" post="and Chikungunya virus species and genotypes. PLOS Neglected Tropical"/>
   <result pre="A computational method for the identification of Dengue, Zika and" exact="Chikungunya" post="virus species and genotypes. PLOS Neglected Tropical Diseases13(5): e000723110.1371/journal.pntd.000723131067235"/>
   <result pre="Society for Clinical Virology. 2017;97: 44–49. 10.1016/j.jcv.2017.10.0152729100064 24MorrisonCR, PlanteKS, HeiseMT." exact="Chikungunya" post="Virus: Current Perspectives on a Reemerging Virus. Microbiol Spectr."/>
   <result pre="27Kariuki NjengaM, NderituL, LedermannJP, NdiranguA, LogueCH, KellyCHL, et al.Tracking epidemic" exact="Chikungunya" post="virus into the Indian Ocean from East Africa. The"/>
   <result pre="2008;89: 2754–2760. 10.1099/vir.0.2008/005413-018931072 28YactayoS, StaplesJE, MillotV, CibrelusL, Ramon-PardoP. Epidemiology of" exact="Chikungunya" post="in the Americas. The Journal of infectious diseases. 2016;214:"/>
   <result pre="GoodmanCH, HollowayK, de SalazarPM, ValadereAM, DrebotMA. Evaluation of Commercially Available" exact="Chikungunya" post="Virus Immunoglobulin M Detection Assays. The American journal of"/>
   <result pre="de Atenção Básica.–Brasília: Ministério da Saúde, 2017. 31GanesanVK, DuanB, ReidSP." exact="Chikungunya" post="Virus: Pathophysiology, Mechanism, and Modeling. Viruses. 2017;9: 36810.3390/v912036829194359 32RezzaG,"/>
   <result pre="and Modeling. Viruses. 2017;9: 36810.3390/v912036829194359 32RezzaG, NicolettiL, AngeliniRet al.Infection with" exact="Chikungunya" post="virus in Italy: an outbreak in a temperate region."/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 6, 2016. Ministério da Saúde."/>
   <result pre="CostaM da CN, CamposGS, PaixaoES, NatividadeMS, BarretoFR, et al.Seroprevalence of" exact="Chikungunya" post="Virus after Its Emergence in Brazil. Emerging infectious diseases."/>
   <result pre="CamachoE, PaterninaL, GuzmanH, DiazFJ, et al.Genetic Characterization of Northwestern Colombian" exact="Chikungunya" post="Virus Strains from the 2014–2015 Epidemic. The American journal"/>
   <result pre="BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by" exact="CHIKV" post="non-structural protein 1 (nsP1). Virology. 2013;438: 37–49. 10.1016/j.virol.2013.01.01023411007 46collab:"/>
   <result pre="IaniFC de M, et al.Genomic, epidemiological and digital surveillance of" exact="Chikungunya" post="virus in the Brazilian Amazon. PLoS neglected tropical diseases."/>
   <result pre="The´ze´J, de JesusJG, GiovanettiM, et al.Establishment and cryptic transmission of" exact="Zika" post="virus in Brazil and the Americas. Nature. 2017; 546(7658):406–10."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948816\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : People and places : Geographical locations :"/>
   <result pre="age-specific immunity on the timing and burden of the next" exact="Zika" post="virus outbreak Impact of age-specific immunity on the timing"/>
   <result pre="age-specific immunity on the timing and burden of the next" exact="Zika" post="virus outbreak http://orcid.org/0000-0003-1039-6873CounotteMichel J.ConceptualizationFormal analysisInvestigationMethodologyProject administrationSoftwareVisualizationWriting – original draft12*AlthausChristian"/>
   <result pre="author and source are credited.pntd.0007978.pdf Abstract The 2015–2017 epidemics of" exact="Zika" post="virus (ZIKV) in the Americas caused widespread infection, followed"/>
   <result pre="by protective immunity. The timing and burden of the next" exact="Zika" post="virus outbreak remains unclear. We used an agent-based model"/>
   <result pre="Managua, Nicaragua. We also investigated the potential impact of a" exact="ZIKV" post="vaccine. Assuming lifelong immunity, the risk of a ZIKV"/>
   <result pre="a ZIKV vaccine. Assuming lifelong immunity, the risk of a" exact="ZIKV" post="outbreak will remain low until 2035 and rise above"/>
   <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak, increasing the expected number of congenital abnormalities. ZIKV"/>
   <result pre="next ZIKV outbreak, increasing the expected number of congenital abnormalities." exact="ZIKV" post="vaccine development and licensure are urgent to attain the"/>
   <result pre="This urgency increases if immunity is not lifelong. Author summary" exact="Zika" post="virus (ZIKV) caused a major outbreak in the Americas"/>
   <result pre="long herd immunity can protect a population against a new" exact="ZIKV" post="outbreak. Data from Managua, Nicaragua showed an imbalance in"/>
   <result pre="from Managua, Nicaragua showed an imbalance in protective immunity after" exact="ZIKV" post="infection across different age-strata. We used this data to"/>
   <result pre="mathematical model to predict the future risk of a new" exact="ZIKV" post="outbreak and to evaluate the effect of loss of"/>
   <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak, increasing the expected number of congenital abnormalities. We"/>
   <result pre="Source code for the model is available from: https://github.com/ZikaProject/SeroProject. Introduction" exact="Zika" post="virus (ZIKV) is a flavivirus, which is transmitted primarily"/>
   <result pre="African and Asian countries [1, 2]. Between 2007 and 2013," exact="ZIKV" post="caused large-scale epidemics in the populations of Micronesia [3],"/>
   <result pre="Micronesia [3], French Polynesia [4] and other Pacific islands [1]." exact="ZIKV" post="probably became established in Aedes aegypti mosquitoes in the"/>
   <result pre="International Concern (PHEIC) [7]. WHO stated, in September 2016, that" exact="ZIKV" post="in pregnancy was the most likely cause of the"/>
   <result pre="By the beginning of 2018, over 220,000 confirmed cases of" exact="ZIKV" post="infection had been reported from Latin America and the"/>
   <result pre="lack of early recurrence [13], as has been seen with" exact="ZIKV" post="[14]. The duration of protective immunity induced by ZIKV"/>
   <result pre="with ZIKV [14]. The duration of protective immunity induced by" exact="ZIKV" post="infection remains uncertain, since immunity to ZIKV infection was"/>
   <result pre="immunity induced by ZIKV infection remains uncertain, since immunity to" exact="ZIKV" post="infection was not studied extensively before the 2013 outbreaks."/>
   <result pre="studies in French Polynesia and Fiji found that levels of" exact="ZIKV" post="neutralizing antibodies decrease with time [15]. If the fall"/>
   <result pre="means that people become susceptible to infection again, population level" exact="ZIKV" post="immunity might be declining already. Even if protective immunity"/>
   <result pre="if protective immunity is lifelong, the risk of a new" exact="ZIKV" post="outbreak will rise as susceptible newborns replace older individuals,"/>
   <result pre="data from the 2013 epidemic in French Polynesia, estimated that" exact="ZIKV" post="outbreaks are unlikely to occur for 12 to 20"/>
   <result pre="than older people [14]. That effect will be amplified if" exact="ZIKV" post="attack rates are lower in children than adults. Assessing"/>
   <result pre="are lower in children than adults. Assessing the risk of" exact="ZIKV" post="infection in women of reproductive age is essential because"/>
   <result pre="ZIKV infection in women of reproductive age is essential because" exact="ZIKV" post="infection in pregnancy, leading to adverse congenital outcomes, has"/>
   <result pre="is currently available against ZIKV. Phase I clinical trials of" exact="ZIKV" post="candidate vaccines have shown levels of neutralizing antibody titers"/>
   <result pre="Nicaragua were the first to report the age-stratified seroprevalence of" exact="ZIKV" post="antibodies in population-based surveys [23]. The first cases of"/>
   <result pre="antibodies in population-based surveys [23]. The first cases of autochthonous" exact="ZIKV" post="infection in Nicaragua were reported in January, 2016, and"/>
   <result pre="authorities of Nicaragua reported a total of 2,795 people with" exact="ZIKV" post="detected by reverse transcriptase (RT) PCR over this period"/>
   <result pre="symptomatic infections is likely much higher, owing to under-reporting. Furthermore," exact="ZIKV" post="infection is asymptomatic in 33 to 87% of cases"/>
   <result pre="in Managua to measure the prevalence of IgG antibodies against" exact="ZIKV" post="in 2- to 14-year olds (N = 3,740) and"/>
   <result pre="to 80-year olds (N = 2,147) [23]. The authors reported" exact="ZIKV" post="seroprevalence of 36.1% (95% confidence interval, CI: 34.5; 37.8%)"/>
   <result pre="In this study, we used published data from the 2016" exact="ZIKV" post="epidemic in Managua and developed an agent-based model (ABM)"/>
   <result pre="(ABM) to predict the evolution of age-specific protective immunity to" exact="ZIKV" post="infection in the population of Managua, Nicaragua during the"/>
   <result pre="period 2017–2097. We assessed: 1) the risk of a future" exact="ZIKV" post="outbreak; 2) the consequences of a future ZIKV outbreak"/>
   <result pre="a future ZIKV outbreak; 2) the consequences of a future" exact="ZIKV" post="outbreak on women of reproductive age; 3) the influence"/>
   <result pre="future attack rates; and 4) how vaccination could prevent future" exact="ZIKV" post="outbreaks. Materials and methods Modelling strategy We assessed the"/>
   <result pre="Modelling strategy We assessed the consequences of future outbreaks of" exact="ZIKV" post="infection in Managua, Nicaragua using a stochastic ABM. The"/>
   <result pre="a basic susceptible-infected-recovered (SIR) framework and integrates processes related to" exact="ZIKV" post="transmission, immunity, demography, adverse congenital outcomes and vaccination (Table"/>
   <result pre="on published estimates or inferences from data about the 2016" exact="ZIKV" post="epidemic (Table 1, Supporting information S1). We considered different"/>
   <result pre="about the duration of immunity, the timing and scale of" exact="ZIKV" post="reintroductions in the population, and the timing and scale"/>
   <result pre="10.1371/journal.pntd.0007978.t001Table 1 Parameterization of the agent-based model. Parameter Comment Source" exact="ZIKV" post="epidemic parameters  Transmission ratea Inferred from the 2016 epidemicb"/>
   <result pre="epidemicb [23]  Recovery rate Inferred from the 2016 epidemicb [23]" exact="ZIKV" post="immunity  Initial immunitya Inferred from the 2016 epidemicb [23]"/>
   <result pre="ratea – [29]  Ageing Linear ageing at each time-step –" exact="ZIKV" post="reintroduction  Delay until reintroduction 1 to 80 years 80"/>
   <result pre="individuals for 80 years (2017–2097). We assigned agents’ age and" exact="ZIKV" post="infection status (susceptible S, infected I or immune R)."/>
   <result pre="The model code and data are available from http://github.com/ZikaProject/SeroProject. Parameterization" exact="ZIKV" post="epidemic parameters We inferred the probability distributions for the"/>
   <result pre="and the recovery rate γ from data on the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. We used surveillance data [23],"/>
   <result pre="used surveillance data [23], which give weekly numbers of incident" exact="ZIKV" post="infections, confirmed by RT-PCR (dataset A, n = 1,165),"/>
   <result pre="(dataset A, n = 1,165), and survey data on age-stratified" exact="ZIKV" post="seroprevalence, measured among participants of pediatric and household cohort"/>
   <result pre="short time span. We recorded the overall cumulative incidence of" exact="ZIKV" post="cases using a dummy compartment: d C d t"/>
   <result pre="estimates inferred from incidence and sero-prevalence data on the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. Parameter Interpretation Prior Posterior (median"/>
   <result pre="Basic reproduction number – 1.58 (1.56; 1.59) CrI: Credible interval." exact="ZIKV" post="immunity We used the deterministic model, described in the"/>
   <result pre="ABM to allow the propagation of uncertainty. Protective immunity to" exact="ZIKV" post="after infection was lifelong in our first scenario, so"/>
   <result pre="each agent by 7 days at each 7-day time step." exact="ZIKV" post="reintroduction We reintroduced ZIKV in the population after a"/>
   <result pre="days at each 7-day time step. ZIKV reintroduction We reintroduced" exact="ZIKV" post="in the population after a delay of d ="/>
   <result pre="an extinction of the outbreak depends on the number of" exact="ZIKV" post="cases reintroduced in the population, we considered three different"/>
   <result pre="estimated number of microcephaly cases resulting from the reintroduction of" exact="ZIKV" post="depended on the exposure, i.e. the number of pregnant"/>
   <result pre="the exposure, i.e. the number of pregnant women infected by" exact="ZIKV" post="during their first trimester, to which we applied three"/>
   <result pre="on published estimates [10, 11]. We obtained the number of" exact="ZIKV" post="infections among women aged 15–49 years from ABM simulations."/>
   <result pre="of risk of microcephaly in births to pregnant woman with" exact="ZIKV" post="infection during the first trimester, as reported by Zhang"/>
   <result pre="10, 11]. Vaccination We examined the effects of a potential" exact="ZIKV" post="vaccine, given to 15-year-old-girls. This vaccination strategy was used"/>
   <result pre="the simulations, we collected 1) the evolution of the age-specific" exact="ZIKV" post="immunity in the population; 2) the attack rate resulting"/>
   <result pre="population; 2) the attack rate resulting from the reintroduction of" exact="ZIKV" post="at year d; 3) the age of newly infected"/>
   <result pre="vector density, of migration, and of an endemic circulation of" exact="ZIKV" post="on our predictions regarding the attack rate and the"/>
   <result pre="and assumptions are provided in Supporting information S2. Results 2016" exact="ZIKV" post="epidemic The fitted model (Fig 1), resulted in a"/>
   <result pre="≥15 age group. Fig 1 Model fit for the 2016" exact="ZIKV" post="epidemic. Model fit for (A) weekly incidence data and"/>
   <result pre="incidence data and (B) post-epidemic sero-prevalence data from the 2016" exact="ZIKV" post="epidemic in Managua, Nicaragua. Data points are in red"/>
   <result pre="by 42% between 2017 and 2097. Under the assumption that" exact="ZIKV" post="infection results in lifelong protective immunity, population renewal will"/>
   <result pre="old age group by 2046. Fig 2 Future risk of" exact="ZIKV" post="outbreaks. (A) The evolution of the immunity status per"/>
   <result pre="distribution of the attack rates resulting from the reintroduction of" exact="ZIKV" post="in the population at each year (1000 simulations for"/>
   <result pre="and effective reproduction number R e (purple). Future risk of" exact="ZIKV" post="outbreak Reintroductions of ZIKV in the population of Managua"/>
   <result pre="R e (purple). Future risk of ZIKV outbreak Reintroductions of" exact="ZIKV" post="in the population of Managua are unlikely to develop"/>
   <result pre="2016 (Fig 2B). After this point, attack rates resulting from" exact="ZIKV" post="reintroduction will rise steeply. By 2047, we predict that"/>
   <result pre="ZIKV reintroduction will rise steeply. By 2047, we predict that" exact="ZIKV" post="reintroductions will have a 50% probability of resulting in"/>
   <result pre="that the number of adverse congenital outcomes resulting from a" exact="ZIKV" post="outbreak during this period is likely to be higher"/>
   <result pre="different values for the added risk of microcephaly after a" exact="ZIKV" post="infection during the first trimester, we expect the mean"/>
   <result pre="expect the mean number of additional microcephaly cases due to" exact="ZIKV" post="infection resulting from the reintroduction of the virus in"/>
   <result pre="births in women of reproductive age. (A) Relative risk of" exact="ZIKV" post="infection during a ZIKV outbreak per age group compared"/>
   <result pre="reproductive age. (A) Relative risk of ZIKV infection during a" exact="ZIKV" post="outbreak per age group compared to the general population"/>
   <result pre="range). (B) Expected number of additional microcephaly events associated with" exact="ZIKV" post="infection during pregnancy per 100,000 total population according to"/>
   <result pre="different risk scenarios. Loss of immunity If protective immunity to" exact="ZIKV" post="is not lifelong, the time window before observing a"/>
   <result pre="before observing a rise in the attack rates resulting from" exact="ZIKV" post="reintroduction will shorten (Fig 4A). For instance, if 15%"/>
   <result pre="lifelong immunity (thick black line): (A) median attack rate of" exact="ZIKV" post="among reintroductions resulting in outbreaks (with a threshold of"/>
   <result pre="(with a threshold of 1%) and (B) relative risk of" exact="ZIKV" post="infection during an outbreak in the 15–29 year age"/>
   <result pre="and would also indirectly reduce the overall risk of a" exact="ZIKV" post="outbreak in the population (Fig 5). If effective vaccine"/>
   <result pre="herd immunity could effectively mitigate the overall risk of a" exact="ZIKV" post="outbreak in the population. The reduction in the number"/>
   <result pre="with no vaccination (thick black line). (A) relative risk of" exact="ZIKV" post="infection during an outbreak in the 15–29 year age"/>
   <result pre="compared with the general population and (B) attack rate of" exact="ZIKV" post="among reintroductions resulting in outbreaks (median, interquartile range, with"/>
   <result pre="shorter time window until a rise in the risk of" exact="ZIKV" post="outbreak, and higher overall attack rates. A future diminution"/>
   <result pre="the population, also lowering the time window before the next" exact="ZIKV" post="outbreak. Finally, a continuous endemic circulation of ZIKV in"/>
   <result pre="the next ZIKV outbreak. Finally, a continuous endemic circulation of" exact="ZIKV" post="in the region would increase the probability of an"/>
   <result pre="In this mathematical modelling study, we show that a new" exact="ZIKV" post="outbreak in Nicaragua would affect proportionally more women in"/>
   <result pre="infection pattern and population renewal. The risk of a new" exact="ZIKV" post="outbreak in Nicaragua, after reintroduction, will remain low before"/>
   <result pre="then rise to 50% in 2047. If protective immunity to" exact="ZIKV" post="decays with time, ZIKV recurrence could occur sooner. Timely"/>
   <result pre="in 2047. If protective immunity to ZIKV decays with time," exact="ZIKV" post="recurrence could occur sooner. Timely introduction of targeted vaccination,"/>
   <result pre="which is crucial when studying adverse congenital events caused by" exact="ZIKV" post="infection during pregnancy. We chose a simple approach based"/>
   <result pre="the human population. We acknowledge that the future occurrence of" exact="ZIKV" post="in the area also depends on the presence of"/>
   <result pre="superior to a simple SIR structure in describing the 2016" exact="ZIKV" post="epidemic of Managua (Supporting information S1). Similarly, Pandey et"/>
   <result pre="studies This study shows that the lower attack rate of" exact="ZIKV" post="in children than in adults will hasten the emergence"/>
   <result pre="the processes of ageing in relation to protective immunity to" exact="ZIKV" post="explicitly. Even with lifelong immunity, our model predicts that"/>
   <result pre="year olds, including women who will be at risk of" exact="ZIKV" post="infection in pregnancy. If immunity wanes, the time until"/>
   <result pre="in pregnancy. If immunity wanes, the time until the next" exact="ZIKV" post="outbreak will be reduced and, in that case, the"/>
   <result pre="4). Several authors have studied the time to a next" exact="ZIKV" post="outbreak, but none studied the effect of the loss"/>
   <result pre="et al. (2016) concluded that the age distribution of future" exact="ZIKV" post="outbreaks will likely differ and that a new large"/>
   <result pre="will be delayed for &quot;at least a decade�? [14]. Other" exact="ZIKV" post="vaccination studies confirm our findings. However, they do not"/>
   <result pre="[42]. Valega-Mackenzie et al. (2018) formulated a vaccination model for" exact="ZIKV" post="transmission that included mosquito and sexual transmission [43]. They"/>
   <result pre="we expect a higher number of congenital abnormalities due to" exact="ZIKV" post="infection. Thus, vaccine development efforts should be increased. Our"/>
   <result pre="documented high post-epidemic levels of seropositivity [25–27]. In regions where" exact="ZIKV" post="has not yet caused an epidemic but competent vectors"/>
   <result pre="with longitudinal follow-up, are needed to improve our understanding of" exact="ZIKV" post="antibody distribution in populations and to quantify the duration"/>
   <result pre="information will provide important information to improve mathematical modeling of" exact="ZIKV" post="risk. ZIKV vaccine development faces considerable hurdles. First, the"/>
   <result pre="provide important information to improve mathematical modeling of ZIKV risk." exact="ZIKV" post="vaccine development faces considerable hurdles. First, the evaluation of"/>
   <result pre="of vaccine efficacy has stalled because the reduced circulation of" exact="ZIKV" post="has reduced the visibility of ZIKV-associated disease [22]. Second,"/>
   <result pre="it is not clear whether or how vaccine-induced antibodies against" exact="ZIKV" post="will cross-react with other flaviviruses. To move vaccine development"/>
   <result pre="and implementing surveillance there. These can either be regions where" exact="ZIKV" post="is endemic, or where ZIKV outbreaks are likely to"/>
   <result pre="can either be regions where ZIKV is endemic, or where" exact="ZIKV" post="outbreaks are likely to occur; throughout the Americas, there"/>
   <result pre="is complex, but there are tools to facilitate planning [45]." exact="ZIKV" post="in an endemic setting, such as in Africa and"/>
   <result pre="and Asia, could prove a suitable setting as well. However," exact="ZIKV" post="circulation in endemic setting is not well described and"/>
   <result pre="gives us the opportunity to be prepared. The next sizeable" exact="ZIKV" post="outbreak in Nicaragua will likely not occur before 2035"/>
   <result pre="will be at highest risk of infection during the next" exact="ZIKV" post="outbreak. Vaccination targeted to young women could curb the"/>
   <result pre="the risk of a large outbreak and extend herd immunity." exact="ZIKV" post="vaccine development and licensure are urgent to attain the"/>
   <result pre="and the risk of adverse congenital outcomes. The urgency of" exact="ZIKV" post="vaccine development increases if immunity is not lifelong. Supporting"/>
   <result pre="cluster at the University of Bern. References References 1WikanN, SmithDR." exact="Zika" post="virus: History of a newly emerging arbovirus. Lancet Infect"/>
   <result pre="newly emerging arbovirus. Lancet Infect Dis. 2016;16(7):e119–e126. 10.1016/S1473-3099(16)30010-X27282424 2KohlA, GathererD." exact="Zika" post="virus: a previously slow pandemic spreads rapidly through the"/>
   <result pre="SunK, ChinazziM, Pastore Y PionttiA, DeanNE, RojasDP, et al.Spread of" exact="Zika" post="virus in the Americas. Proc Natl Acad Sci U"/>
   <result pre="the International Health Regulations (2005) (IHR 2005) Emergency Committee on" exact="Zika" post="virus and observed increase in neurological disorders and neonatal"/>
   <result pre="2018;7(196):19610.12688/f1000research.13704.130631437 10CauchemezS, BesnardM, BompardP, DubT, Guillemette-ArturP, Eyrolle-GuignotD, et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013-15: A retrospective"/>
   <result pre="retrospective study. Lancet. 2016;387(10033):2125–2132. 10.1016/S0140-6736(16)00651-626993883 11JohanssonMA, Mier-Y-Teran-RomeroL, ReefhuisJ, GilboaSM, HillsSL." exact="Zika" post="and the risk of Microcephaly. Obstet Gynecol Surv. 2016;71(11):635–636."/>
   <result pre="1975;104:104–121. 14FergusonNM, CucunubáZM, DorigattiI, Nedjati-GilaniGL, DonnellyCA, BasáñezMG, et al.Countering the" exact="Zika" post="epidemic in Latin America. Science. 2016;353(6297):353–354. 10.1126/science.aag021927417493 15HendersonAD, AubryM,"/>
   <result pre="578211. 16KucharskiAJ, FunkS, EggoRM, MalletHP, EdmundsWJ, NillesEJ. Transmission Dynamics of" exact="Zika" post="Virus in Island Populations: A Modelling Analysis of the"/>
   <result pre="Polynesia Outbreak. PLoS Negl Trop Dis. 2016;10(5):e000472610.1371/journal.pntd.000472627186984 17AbbinkP, StephensonKE, BarouchDH." exact="Zika" post="virus vaccines. Nat Rev Microbiol. 2018;16(10):594–600. 10.1038/s41579-018-0039-729921914 18World Health"/>
   <result pre="HuZ, YamshchikovG, RothwellRS, et al.Safety, tolerability, and immunogenicity of two" exact="Zika" post="virus DNA vaccine candidates in healthy adults: randomised, open-label,"/>
   <result pre="and immunogenicity results from three trials of a purified inactivated" exact="Zika" post="virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical"/>
   <result pre="21National Institute of Allergy and Infectious Diseases. VRC 705: A" exact="Zika" post="Virus DNA Vaccine in Healthy Adults and Adolescents (DNA);"/>
   <result pre="(DNA); 2018. [Online]. Available from: https://clinicaltrials.gov/ct2/show/NCT03110770. 22CohenJ. Steep drop in" exact="Zika" post="cases undermines vaccine trial. Science. 2018;361(6407):1055–1056. 10.1126/science.361.6407.105530213891 23ZambranaJV, Bustos"/>
   <result pre="SanchezN, OjedaS, et al.Seroprevalence, risk factor, and spatial analyses of" exact="Zika" post="virus infection after the 2016 epidemic in Managua, Nicaragua."/>
   <result pre="24BalmasedaA, StettlerK, Medialdea-CarreraR, ColladoD, JinX, ZambranaJV, et al.Antibody-based assay discriminates" exact="Zika" post="virus infection from other flaviviruses. Proc Natl Acad Sci."/>
   <result pre="2017;23(10):1751–1753. 10.3201/eid2310.17058328930020 26NettoEM, Moreira-SotoA, PedrosoC, HöserC, FunkS, KucharskiAJ, et al.High" exact="Zika" post="Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential"/>
   <result pre="in the variability of the basic reproductive number (R0) for" exact="Zika" post="epidemics in the Pacific islands. Elife. 2016;510.7554/eLife.1987427897973 38PandeyA, MubayiA,"/>
   <result pre="FariaNR, WalkerA, KraemerMUG, Villabona-ArenasCJ, et al.Epidemiological and ecological determinants of" exact="Zika" post="virus transmission in an urban setting. Elife. 2017;610.7554/eLife.2982028887877 41DurhamDP,"/>
   <result pre="DurhamDP, RandallS, HotezPJ, et al.What Is the Value of Different" exact="Zika" post="Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?J Infect"/>
   <result pre="Value of Different Zika Vaccination Strategies to Prevent and Mitigate" exact="Zika" post="Outbreaks?J Infect Dis. 2018. 43Valega-MackenzieW, Ríos-SotoKR. Can Vaccination Save"/>
   <result pre="Outbreaks?J Infect Dis. 2018. 43Valega-MackenzieW, Ríos-SotoKR. Can Vaccination Save a" exact="Zika" post="Virus Epidemic?Bull Math Biol. 2018;80(3):598–625. 10.1007/s11538-018-0393-729359251 44DiamondMS, LedgerwoodJE, PiersonTC."/>
   <result pre="Zika Virus Epidemic?Bull Math Biol. 2018;80(3):598–625. 10.1007/s11538-018-0393-729359251 44DiamondMS, LedgerwoodJE, PiersonTC." exact="Zika" post="Virus Vaccine Development: Progress in the Face of New"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6948821\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="surveillance strategies to detect arbovirus transmission: A simulation study for" exact="Zika" post="virus detection in Puerto Rico Comparing vector and human"/>
   <result pre="Public Health (Epidemiology), La Jolla, California, United States of America[3]," exact="Dengue" post="Branch, Centers for Disease Control and Prevention (CDC), San"/>
   <result pre="Background Detecting and monitoring the transmission of arboviruses such as" exact="Zika" post="virus (ZIKV), dengue virus, and chikungunya virus is critical"/>
   <result pre="compared the ability of different human-focused surveillance strategies to detect" exact="ZIKV" post="transmission in U.S. counties where no known transmission had"/>
   <result pre="human and virological surveillance in Ae. aegypti during the 2016" exact="ZIKV" post="epidemic in Caguas, Puerto Rico, to compare alternative strategies"/>
   <result pre="Puerto Rico, to compare alternative strategies for detecting and monitoring" exact="ZIKV" post="activity. Methods We developed a simulation model for mosquito"/>
   <result pre="in Ae. aegypti may be able to detect and monitor" exact="ZIKV" post="epidemic activity. However, surveillance for humans seeking care for"/>
   <result pre="of transmission intensity in most circumstances. Author summary Control of" exact="Zika" post="virus and other mosquito-borne viruses is dependent on timely"/>
   <result pre="found that testing people seeking medical care with signs of" exact="Zika" post="virus was a more effective strategy than testing blood"/>
   <result pre="we used data from human and mosquito surveillances during the" exact="Zika" post="epidemic of 2016 in Caguas, Puerto Rico to compare"/>
   <result pre="Puerto Rico to compare these strategies for detecting and monitoring" exact="Zika" post="virus activity. Using simulation models for human and mosquito"/>
   <result pre="mosquito surveillance strategies, we examined different transmission scenarios with varying" exact="Zika" post="virus infection rates. The results suggest that in high"/>
   <result pre="Zika virus infection rates. The results suggest that in high" exact="Zika" post="virus transmission scenarios, both approaches effectively identified transmission. In"/>
   <result pre="within the paper. Introduction First identified in Uganda in 1947," exact="Zika" post="virus (ZIKV) emerged in the Americas in 2015 [1,"/>
   <result pre="the Americas in 2015 [1, 2], with local transmission of" exact="ZIKV" post="first reported in December, 2015, in Puerto Rico [3]."/>
   <result pre="in December, 2015, in Puerto Rico [3]. The emergence of" exact="ZIKV" post="highlighted several challenges for arbovirus surveillance. Many infections do"/>
   <result pre="example, a previous assessment of human-based surveillance systems to detect" exact="ZIKV" post="transmission in U.S. counties found that despite low probabilities"/>
   <result pre="of detection than testing only patients with two or more" exact="Zika" post="symptoms. Effective prevention and control of arboviruses such as"/>
   <result pre="work suggested that testing clinical patients with at least two" exact="ZIKV" post="symptoms was a relatively effective strategy for detecting ZIKV"/>
   <result pre="two ZIKV symptoms was a relatively effective strategy for detecting" exact="ZIKV" post="transmission in humans, the probability of detection was &amp;lt;25%"/>
   <result pre="the surveillance strategies evaluated could detect even 5% of all" exact="ZIKV" post="infections. An alternative to detecting arboviruses in humans is"/>
   <result pre="which involves capturing and testing host seeking female mosquitoes. For" exact="West Nile" post="virus, which has a primary transmission cycle between infected"/>
   <result pre="of data from human and vector surveillance during the 2016" exact="ZIKV" post="epidemic in Caguas, Puerto Rico to compare strategies for"/>
   <result pre="arbovirus activity. Methods Ethics statement This study includes frequencies of" exact="ZIKV" post="cases in humans obtained from online weekly reports from"/>
   <result pre="for viral RNA using the Trioplex Real-time RT-PCR assay [16]." exact="ZIKV" post="may be detected in Ae. aegypti held in traps"/>
   <result pre="with subsequent confirmatory laboratory testing. We assessed the number of" exact="ZIKV" post="cases detected by RT-PCR (confirmed cases) compared with the"/>
   <result pre="humans considering the surveillance systems implemented in Caguas during the" exact="ZIKV" post="epidemic. We developed simulation models to estimate ZIKV transmission"/>
   <result pre="during the ZIKV epidemic. We developed simulation models to estimate" exact="ZIKV" post="transmission and detection in humans and mosquitoes at varying"/>
   <result pre="1. 10.1371/journal.pntd.0007988.t001Table 1 Parameter assumptions for Aedes aegypti surveillance for" exact="Zika" post="virus. Parameter Estimate Uncertainty distribution Source Duration of human"/>
   <result pre="fourth model used human surveillance for acutely ill patients with" exact="ZIKV" post="symptoms. The four surveillance strategies were evaluated at different"/>
   <result pre="assumed to be similar to previously published estimates for identifying" exact="ZIKV" post="cases from emergency departments in the continental United States"/>
   <result pre="of those patients have at least two of the following" exact="ZIKV" post="symptoms: arthralgia, conjunctivitis, fever, headache, or rash. Human surveillance"/>
   <result pre="acute illness with clinical suspicion of ZIKV. For reported suspect" exact="ZIKV" post="patients, we assumed all testing was performed with RT-PCR"/>
   <result pre="of 88.7% [25] and 96.1% [27] for RT-PCR detection of" exact="ZIKV" post="in mosquitoes. Based on those findings and studies of"/>
   <result pre="Based on those findings and studies of RT-PCR for detecting" exact="WNV" post="in mosquitoes [23, 24], we assumed the test has"/>
   <result pre="a specificity of 99.9–100%, which we approximated with uniform distributions." exact="ZIKV" post="RNA is stable enough to allow detection for up"/>
   <result pre="tested in the surveillance system for people not infected with" exact="ZIKV" post="and one minus the specificity of the human RT-PCR"/>
   <result pre="of greater than 78%. Fig 1 The total number of" exact="Zika" post="virus infections detected and probability of detecting local transmission"/>
   <result pre="virus infections detected and probability of detecting local transmission of" exact="Zika" post="virus by testing Aedes aegypti females collected from CDC"/>
   <result pre="ovitraps (SAGO) and emergency department patients with two or more" exact="Zika" post="virus symptoms. Panel A shows the expected number of"/>
   <result pre="by testing patients in emergency departments showing two or more" exact="ZIKV" post="symptoms (red). Panel C shows the weekly probability of"/>
   <result pre="symptoms (red). Panel C shows the weekly probability of detecting" exact="ZIKV" post="by testing mosquito pools. Panel D shows the weekly"/>
   <result pre="mosquito pools. Panel D shows the weekly probability of detecting" exact="ZIKV" post="by testing symptomatic emergency department patients. The bands represent"/>
   <result pre="intervals. 10.1371/journal.pntd.0007988.t002Table 2 The probability of detecting local transmission of" exact="Zika" post="virus and the total number of Zika virus infections"/>
   <result pre="local transmission of Zika virus and the total number of" exact="Zika" post="virus infections detected by testing Aedes aegypti pools collected"/>
   <result pre="gravid ovitraps and emergency department patients with two or more" exact="Zika" post="virus symptoms. Vector surveillance Human surveillance Strategy performance 180"/>
   <result pre="360 SAGO(95% UI) 720 SAGO(95% UI) Weekly probability of detection" exact="ZIKV" post="incidence of 1 per 100,000 per week 1.8% (0.4%,"/>
   <result pre="4.2%) 3.5% (0.8%, 8.2%) 6.9% (1.6%, 15.7%) 1.5% (0.3%, 4.7%)" exact="ZIKV" post="incidence of 1 per 10,000 per week 16.4% (4.0%,"/>
   <result pre="34.7%) 30.1% (7.9%, 57.4%) 51.2% (15.1%, 81.9%) 14.1% (2.7%, 38.0%)" exact="ZIKV" post="incidence of 1 per 1,000 per week 83.3% (33.6%,"/>
   <result pre="99.9%) 99.9% (80.6%, 100%) 78.0% (24.2%, 99.2%) Total number of" exact="ZIKV" post="infections detected per week ZIKV incidence of 1 per"/>
   <result pre="(24.2%, 99.2%) Total number of ZIKV infections detected per week" exact="ZIKV" post="incidence of 1 per 100,000 per week 0.02 (0.01,"/>
   <result pre="0.04) 0.04 (0.01, 0.09) 0.07 (0.02, 0.17) 0.02 (0.01, 0.05)" exact="ZIKV" post="incidence of 1 per 10,000 per week 0.18 (0.04,"/>
   <result pre="0.43) 0.36 (0.08, 0.85) 0.72 (0.16, 1.71) 0.15 (0.03, 0.40)" exact="ZIKV" post="incidence of 1 per 1,000 per week 1.79 (0.41,"/>
   <result pre="(Fig 2). In contrast, for human surveillance of patients with" exact="ZIKV" post="symptoms, the expected testing resources required were much lower"/>
   <result pre="tests per week were required for human surveillance with no" exact="ZIKV" post="transmission and 12 (95% UI: 8, 17) tests per"/>
   <result pre="of tests among emergency department patients with two or more" exact="ZIKV" post="symptoms given transmission scenarios of 0 (green), 1 (grey),"/>
   <result pre="(Fig 3B). Fig 3 Relationship between the number of simulated" exact="Zika" post="virus positive mosquito pools and human infections, and estimated"/>
   <result pre="incidence of human infections per week by the number of" exact="Zika" post="virus positive female Ae. aegypti pools per week. Panel"/>
   <result pre="of infections in emergency department patients with two or more" exact="Zika" post="virus symptoms per week. The lines are Bayesian negative"/>
   <result pre="16, 2017. Over this period, there were 127 confirmed human" exact="ZIKV" post="cases out of 452 suspect cases detected through passive"/>
   <result pre="(28.1% positive) in the entire municipality of Caguas and 49" exact="ZIKV" post="positive pools of female Ae. aegypti out of 8,518"/>
   <result pre="of human infections. Panel A shows the actual number of" exact="ZIKV" post="positive mosquito pools (navy bars) in the Caguas study"/>
   <result pre="in all of Caguas. Discussion Population-based surveillance and detection of" exact="ZIKV" post="is critical to guide timely public health and medical"/>
   <result pre="human population at risk. In a previous comparison of human-focused" exact="ZIKV" post="surveillance approaches, a strategy focusing on patients seeking emergency"/>
   <result pre="seeking care in an emergency department with two or more" exact="ZIKV" post="symptoms, whereas the actual surveillance data likely includes individuals"/>
   <result pre="includes individuals from other health facilities, those with only one" exact="ZIKV" post="symptom, patients suspected of having infection for other reasons,"/>
   <result pre="of Ae. aegypti, a finding substantiated by the detection of" exact="ZIKV" post="in mosquitoes in Mexico without reported human cases [34]."/>
   <result pre="S1 Fig Positive predictive value of testing mosquito pools for" exact="Zika" post="virus and emergency department patients with two or more"/>
   <result pre="Zika virus and emergency department patients with two or more" exact="Zika" post="virus symptoms. Panel A describes the positive predictive value"/>
   <result pre="PPV of a positive test over a range of possible" exact="ZIKV" post="incidences. (TIF) LINK Click here for additional data file."/>
   <result pre="Global Health. 2018;3(Suppl 1):e00053010.1136/bmjgh-2017-00053029435366 3Centers for Disease Control and Prevention." exact="Zika" post="infections increasing rapidly in Puerto Rico 2016 [cited 2019"/>
   <result pre="Cao-LormeauV-M, et al.Reassessing Serosurvey-Based Estimates of the Symptomatic Proportion of" exact="Zika" post="Virus Infections. American journal of epidemiology. 2018;188(1):206–13. 5RussellSP, RyffKR,"/>
   <result pre="of epidemiology. 2018;188(1):206–13. 5RussellSP, RyffKR, GouldCV, MartinSW, JohanssonMA. Detecting Local" exact="Zika" post="Virus Transmission In The Continental United States: A Comparison"/>
   <result pre="6ZhangQ, SunK, ChinazziM, y PionttiAP, DeanNE, RojasDP, et al.Spread of" exact="Zika" post="virus in the Americas. Proceedings of the National Academy"/>
   <result pre="MunjalA, KarthikK, TiwariR, et al.Prevention and Control Strategies to Counter" exact="Zika" post="Virus, a Special Focus on Intervention Approaches against Vector"/>
   <result pre="Frontiers in Microbiology. 2018;9:8710.3389/fmicb.2018.0008729472902 8collab: World Health Organization. Surveillance for" exact="Zika" post="virus infection, microcephaly and Guillain-Barré syndrome: Interim guidance: World"/>
   <result pre="Tropical Medicine and Hygiene. 2011;85(1):178–81. 10.4269/ajtmh.2011.11-004221734145 11DialloD, DialloM. Why is" exact="Zika" post="virus so rarely detected during outbreaks and how can"/>
   <result pre="al.Citywide Control of Aedes aegypti (Diptera: Culicidae) during the 2016" exact="Zika" post="Epidemic by Integrating Community Awareness, Education, Source Reduction, Larvicides,"/>
   <result pre="infection rates of Aedes aegypti during the first epidemics of" exact="Chikungunya" post="(2014) and Zika (2016) in areas with and without"/>
   <result pre="Aedes aegypti during the first epidemics of Chikungunya (2014) and" exact="Zika" post="(2016) in areas with and without vector control in"/>
   <result pre="de Puerto Rico: Departamento de Salud. Informe de Casos de" exact="Zika" post="por Municipios 2017 [cited 2019 August 9]. Available from:"/>
   <result pre="Entomology. 2000;37(1):89–101. 10.1603/0022-2585-37.1.8915218911 23HadfieldT, TurellM, DempseyM, DavidJ, ParkE. Detection of" exact="West Nile" post="virus in mosquitoes by RT-PCR. Molecular and Cellular Probes."/>
   <result pre="Molecular and Cellular Probes. 2001;15(3):147–50. 10.1006/mcpr.2001.035311352595 24SutherlandGL, NasciRS. Detection of" exact="West Nile" post="virus in large pools of mosquitoes. Journal of the"/>
   <result pre="of RT-PCR method in samples shown to be positive for" exact="Zika" post="virus by RT-qPCR in vector competence studies. Genetics and"/>
   <result pre="10.1590/1678-4685-GMB-2016-031228534930 26Paz-BaileyG, RosenbergES, DoyleK, Munoz-JordanJ, SantiagoGA, KleinL, et al.Persistence of" exact="Zika" post="Virus in Body Fluids. New England Journal of Medicine."/>
   <result pre="Journal of Clinical Microbiology. 2018:JCM. 01785–17. 28BurkhalterKL, SavageHM. Detection of" exact="Zika" post="virus in desiccated mosquitoes by real-time reverse transcription PCR"/>
   <result pre="KhandiaR, MunjalA, et al.Advances in diagnosis, surveillance, and monitoring of" exact="Zika" post="virus: an update. Frontiers in Microbiology. 2018;8:267710.3389/fmicb.2017.0267729403448 30Centers for"/>
   <result pre="Frontiers in Microbiology. 2018;8:267710.3389/fmicb.2017.0267729403448 30Centers for Disease Control and Prevention." exact="Zika" post="Virus: Information for Clinicians 2016 [cited 2019 February 17]."/>
   <result pre="[cited 2019 February 17]. Available from: https://www.cdc.gov/zika/pdfs/clinicianppt.pdf. 31DirlikovE. Update: ongoing" exact="Zika" post="virus transmission—Puerto Rico, November 1, 2015–April 14, 2016. MMWR"/>
   <result pre="2012;6(7):e173010.1371/journal.pntd.000173022816001 34HuertaH, González-RoldánJF, Sánchez-TejedaG, Correa-MoralesF, Romero-ContrerasFE, Cárdenas-FloresR, et al.Detection of" exact="Zika" post="virus in Aedes mosquitoes from Mexico. Transactions of The"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6949906\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.3390/v11121126viruses-11-01126 : Article Natural Infection of Aedes aegypti by" exact="Chikungunya" post="and Dengue type 2 Virus in a Transition Area"/>
   <result pre=": Article Natural Infection of Aedes aegypti by Chikungunya and" exact="Dengue" post="type 2 Virus in a Transition Area of North-Northeast"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Dengue" post="fever, chikungunya, and Zika are diseases caused by viruses"/>
   <result pre="Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Dengue fever, chikungunya, and" exact="Zika" post="are diseases caused by viruses transmitted by Aedes aegypti"/>
   <result pre="vectors. This study aimed to investigate the presence of Zika," exact="Dengue" post="and Chikungunya viruses in Ae. aegypti and Ae. albopictus"/>
   <result pre="study aimed to investigate the presence of Zika, Dengue and" exact="Chikungunya" post="viruses in Ae. aegypti and Ae. albopictus from the"/>
   <result pre="the only vector positive in two municipalities—Codó, with detection of" exact="Chikungunya" post="virus (CHIKV) belonging to the East-Central-South African genotype, and"/>
   <result pre="the East-Central-South African genotype, and in Caxias, with detection of" exact="Dengue" post="virus (DENV)-2 belonging to the Asian/American genotype. The detection"/>
   <result pre="virus (DENV)-2 belonging to the Asian/American genotype. The detection of" exact="CHIKV" post="and DENV-2 is evidence that those viruses are maintained"/>
   <result pre="cases, associated with the occurrence of dengue hemorrhagic fever. Aedes" exact="Chikungunya" post="virus Dengue virus arbovirus 1. Introduction Arboviral diseases are"/>
   <result pre="with the occurrence of dengue hemorrhagic fever. Aedes Chikungunya virus" exact="Dengue" post="virus arbovirus 1. Introduction Arboviral diseases are infections caused"/>
   <result pre="are records of a wide variety of arboviral diseases [1,4,5,6]." exact="Dengue" post="is the most important arboviral disease in the country"/>
   <result pre="January to September 2019 [7]. The disease is caused by" exact="Dengue" post="virus (DENV) (genus Flavivirus, family Flaviviridae), which has four"/>
   <result pre="more alarming with the introduction of two other important arboviruses:" exact="Zika" post="virus (ZIKV) and Chikungunya virus (CHIKV) [13,14,15]. The similar"/>
   <result pre="introduction of two other important arboviruses: Zika virus (ZIKV) and" exact="Chikungunya" post="virus (CHIKV) [13,14,15]. The similar pathogenicity shared by those"/>
   <result pre="as microcephaly and Guillain–Barré syndrome, were associated with infection by" exact="ZIKV" post="and CHIKV [16,17,18,19,20,21,22]. ZIKV also belongs to the Flavivirus"/>
   <result pre="and Guillain–Barré syndrome, were associated with infection by ZIKV and" exact="CHIKV" post="[16,17,18,19,20,21,22]. ZIKV also belongs to the Flavivirus genus in"/>
   <result pre="syndrome, were associated with infection by ZIKV and CHIKV [16,17,18,19,20,21,22]." exact="ZIKV" post="also belongs to the Flavivirus genus in the Flaviviridae"/>
   <result pre="number of notifications (9965 cases) was reported until August [7]." exact="CHIKV" post="belongs to the Alphavirus genus, Togaviridae family and it"/>
   <result pre="lineages were introduced in 2014 [15]. After the co-circulation with" exact="ZIKV" post="and DENV in 2016, a total of 185,593 chikungunya"/>
   <result pre="introduced in 2014 [15]. After the co-circulation with ZIKV and" exact="DENV" post="in 2016, a total of 185,593 chikungunya probable cases"/>
   <result pre="cases were reported [7]. The transmission of DENV, ZIKV, and" exact="CHIKV" post="occurs through the bite of infected mosquitoes, and Aedes"/>
   <result pre="of vector control strategies, minimizing the impact of the epidemics." exact="DENV" post="entomological surveillance has been performed on the island of"/>
   <result pre="the past, but no viral detection was reported [32]. Recently," exact="CHIKV" post="was detected in Ae. aegypti in two municipalities of"/>
   <result pre="study, we investigated the natural infection by DENV, ZIKV, and" exact="CHIKV" post="in Ae. aegypti and Ae. albopictus collected in urban"/>
   <result pre="primers and probes used for detection of DENV, ZIKV, and" exact="CHIKV" post="[49,50,51]. The reaction was performed on the 7500 Fast"/>
   <result pre="MA, USA) in a final volume of 25 μL. For" exact="DENV" post="detection, a multiplex assay for identification of the four"/>
   <result pre="Taq enzyme mix, and 5 μL of extracted RNA. For" exact="ZIKV" post="and CHIKV detection, singleplex assays were performed and the"/>
   <result pre="mix, and 5 μL of extracted RNA. For ZIKV and" exact="CHIKV" post="detection, singleplex assays were performed and the reaction consisted"/>
   <result pre="at 60 °C. Positive (RNA extracted from DENV, CHIKV, and" exact="ZIKV" post="infected mouse brains) and negative (nuclease-free water) controls were"/>
   <result pre="Hilden, Germany), following the manufacturer’s guidelines. 2.9.2. Genomic Sequencing The" exact="CHIKV" post="and DENV genomes were recovered by synthesizing the first"/>
   <result pre="following the manufacturer’s guidelines. 2.9.2. Genomic Sequencing The CHIKV and" exact="DENV" post="genomes were recovered by synthesizing the first and second"/>
   <result pre="and Ae. albopictus analyzed for detection of DENV, ZIKV, and" exact="CHIKV" post="by the RT-qPCR test, three were positive and were"/>
   <result pre="3.3. Viral Isolation Both AR849404 and AR849487 pools positive for" exact="CHIKV" post="and DENV-2, respectively, where further submitted to viral isolation"/>
   <result pre="of this species have already been found naturally infected by" exact="DENV" post="and ZIKV in Brazilian territory [66,67,68]. In addition, studies"/>
   <result pre="species have already been found naturally infected by DENV and" exact="ZIKV" post="in Brazilian territory [66,67,68]. In addition, studies indicate the"/>
   <result pre="of this mosquito in the transmission of DENV, ZIKV, and" exact="CHIKV" post="[69,70,71]. Another important fact is that Ae. albopictus is"/>
   <result pre="important arboviruses in different parts of the world, such as:" exact="DENV" post="in Hawaii [72], China [73,74], Reunión [75], Gabon [76],"/>
   <result pre="[72], China [73,74], Reunión [75], Gabon [76], and Mauritius [77];" exact="ZIKV" post="in Gabon [78]; and CHIKV in Reunión [75,79], Madagascar"/>
   <result pre="Gabon [76], and Mauritius [77]; ZIKV in Gabon [78]; and" exact="CHIKV" post="in Reunión [75,79], Madagascar [80], and Gabon [76,81]. In"/>
   <result pre="species collected were stored and are available for further investigations." exact="CHIKV" post="was detected in Ae. aegypti collected in Codó during"/>
   <result pre="state, entomovirological investigations play an important role in disease surveillance." exact="Chikungunya" post="fever in Maranhão was first reported in September of"/>
   <result pre="observed (6416 cases), possibly reflecting the disease control actions [86]." exact="CHIKV" post="had already been detected in Ae. aegypti in the"/>
   <result pre="Brazil are restricted to few groups. The available data about" exact="CHIKV" post="circulation are obtained from the human cases that show,"/>
   <result pre="incidence of dengue in the municipality. Due to the limited" exact="DENV" post="surveillance in vectors, information of the circulating DENV serotypes"/>
   <result pre="the limited DENV surveillance in vectors, information of the circulating" exact="DENV" post="serotypes is scarce. In official reports by the Brazilian"/>
   <result pre="the country for eight years, until 2016 [97]. All four" exact="DENV" post="serotypes have already been reported in the state of"/>
   <result pre="mechanisms and potential strategies for preventionTrends Microbiol.20132136036310.1016/j.tim.2013.03.00323910545 3.FigueiredoL.T.M.Large outbreaks of" exact="Chikungunya" post="virus in Brazil reveal uncommon clinical features and fatalitiesRev."/>
   <result pre="36Available online: https://portalarquivos2.saude.gov.br/images/pdf/2019/outubro/04/BE-multitematico-n28.pdf(accessed on 20 September 2019) 8.Villabona-ArenasC.J.ZanottoP.M.A.Worldwide Spread of" exact="Dengue" post="Virus Type 1PLoS ONE20138e6264910.1371/journal.pone.006264923675416 9.PykeA.T.MooreP.R.TaylorC.T.Hall-MendelinS.CameronJ.N.HewitsonG.R.PukallusD.S.HuangB.WarrilowD.Van Den HurkA.F.Highly divergent dengue"/>
   <result pre="A phylogenetic perspectiveMem. Inst. Oswaldo Cruz200910452652910.1590/S0074-0276200900030002119547883 12.GallichotteE.N.BaricT.J.NivarthiU.DelacruzM.J.GrahamR.WidmanD.G.YountB.L.DurbinA.P.WhiteheadS.S.SilvaA.M.et al.Genetic Variation between" exact="Dengue" post="Virus Type 4 Strains Impacts Human Antibody Binding and"/>
   <result pre="2017) 14.ZanlucaC.De MeloV.C.A.MosimannA.L.P.Dos SantosG.I.V.dos SantosC.N.D.LuzK.First report of autochthonous transmission of" exact="Zika" post="virus in BrazilMem. Inst. Oswaldo Cruz201511056957210.1590/0074-0276015019226061233 15.NunesM.R.T.FariaN.R.VasconcelosJ.M.GoldingN.KraemerM.U.OliveiraL.F.AzevedoR.d.S.d.S.SilvaD.E.A.SilvaE.V.P.SilvaS.P.et al.Emergence and"/>
   <result pre="Inst. Oswaldo Cruz201511056957210.1590/0074-0276015019226061233 15.NunesM.R.T.FariaN.R.VasconcelosJ.M.GoldingN.KraemerM.U.OliveiraL.F.AzevedoR.d.S.d.S.SilvaD.E.A.SilvaE.V.P.SilvaS.P.et al.Emergence and potential for spread of" exact="Chikungunya" post="virus in BrazilBMC Med.20151310210.1186/s12916-015-0348-x25976325 16.BandeiraA.C.CamposG.S.SardiS.I.RochaV.F.D.RochaG.C.M.Neonatal encephalitis due to Chikungunya"/>
   <result pre="of Chikungunya virus in BrazilBMC Med.20151310210.1186/s12916-015-0348-x25976325 16.BandeiraA.C.CamposG.S.SardiS.I.RochaV.F.D.RochaG.C.M.Neonatal encephalitis due to" exact="Chikungunya" post="vertical transmission: First report in BrazilIDCases20165575910.1016/j.idcr.2016.07.00827500084 17.RosárioM.S.JesusP.A.P.VasilakisN.FariasD.S.NovaesM.A.C.RodriguesS.G.MartinsL.C.VasconcelosP.F.d.C.KoA.I.AlcântaraL.C.J.et al.Case report:"/>
   <result pre="BrazilAm. J. Trop. Med. Hyg.2016951157116027645785 18.SilvaI.R.F.FronteraJ.A.FilippisA.M.B.NascimentoO.J.M.Neurologic complications associated with the" exact="Zika" post="virus in Brazilian adultsJAMA Neurol.2017741190119810.1001/jamaneurol.2017.170328806453 19.StyczynskiA.R.MaltaJ.M.A.S.Krow-LucalE.R.PercioJ.NóbregaM.E.VargasA.LanzieriT.M.LeiteP.L.StaplesJ.E.FischerM.X.et al.Increased rates of"/>
   <result pre="adultsJAMA Neurol.2017741190119810.1001/jamaneurol.2017.170328806453 19.StyczynskiA.R.MaltaJ.M.A.S.Krow-LucalE.R.PercioJ.NóbregaM.E.VargasA.LanzieriT.M.LeiteP.L.StaplesJ.E.FischerM.X.et al.Increased rates of Guillain-Barré syndrome associated with" exact="Zika" post="virus outbreak in the Salvador metropolitan area, BrazilPLoS Negl."/>
   <result pre="metropolitan area, BrazilPLoS Negl. Trop. Dis.201711e000586910.1371/journal.pntd.000586928854206 20.AraújoT.V.B.XimenesR.A.d.A.Miranda-FilhoD.d.B.SouzaW.V.MontarroyosU.R.MeloA.P.L.ValongueiroS.AlbuquerqueM.d.F.P.M.BragaC.FilhoS.P.B.et al.Association between microcephaly," exact="Zika" post="virus infection, and other risk factors in Brazil: final"/>
   <result pre="Infect. Dis.20181832833629242091 21.MehtaR.SoaresC.N.Medialdea-CarreraR.EllulM.SilvaM.T.T.Rosala-HallasA.JardimM.R.BurnsideG.PamplonaL.BhojakM.et al.The spectrum of neurological disease associated with" exact="Zika" post="and chikungunya viruses in adults in Rio de Janeiro,"/>
   <result pre="RielD.Van de PerreP.RockxB.SalinasS.Differential virulence between Asian and African lineages of" exact="Zika" post="virusPLoS Negl. Trop. Dis.201711e000582110.1371/journal.pntd.000582128934211 24.PetterssonJ.H.-O.EldholmV.SeligmanS.J.LundkvistÅ.FalconarA.K.GauntM.W.MussoD.NougairèdeA.CharrelR.GouldE.A.et al.How Did Zika Virus"/>
   <result pre="lineages of Zika virusPLoS Negl. Trop. Dis.201711e000582110.1371/journal.pntd.000582128934211 24.PetterssonJ.H.-O.EldholmV.SeligmanS.J.LundkvistÅ.FalconarA.K.GauntM.W.MussoD.NougairèdeA.CharrelR.GouldE.A.et al.How Did" exact="Zika" post="Virus Emerge in the Pacific Islands and Latin America?MBio20167e01239-1610.1128/mBio.01239-1627729507"/>
   <result pre="de dengue, febre de chikungunya e doença aguda pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52 de 2018Available online: http://portalarquivos2.saude.gov.br/images/pdf/2019/janeiro/28/2019-002.pdf(accessed"/>
   <result pre="to Brazil, the major vector of the dengue, chikungunya and" exact="Zika" post="virusesPLoS Negl. Trop. Dis.201711e000565310.1371/journal.pntd.000565328742801 29.collab: Instituto Brasileiro de Geografia"/>
   <result pre="Med. Trop.20124517417910.1590/S0037-8682201200020000722534987 32.BezerraJ.M.T.MirandaJ.P.Nunes-NetoJ.P.CruzA.C.R.TadeiW.P.PinheiroV.C.S.Occurrence of Aedes aegypti (Diptera, Culicidae) in a" exact="Dengue" post="Transmission Area at Coastal Maranhão State, BrazilOpen Trop. Med."/>
   <result pre="Estudos Superiores de Caxias (CESC)FonsecaR.S.BarrosM.C.UEMASão Luís, MA, Brasil20181351529788582271339 36.AragãoC.F.CruzA.C.R.Nunes-NetoJ.P.MonteiroH.A.d.O.SilvaE.V.P.SilvaS.P.AndradeA.T.d.S.TadeiW.P.PinheiroV.C.S.Circulation of" exact="Chikungunya" post="virus in Aedes aegypti in Maranhão, Northeast BrazilActa Trop.20181861429932932"/>
   <result pre="and Multiplex Real-Time PCR with Serotype-Specific Probes for Serotyping of" exact="Dengue" post="Virus InfectionsAdv. Virol.201120111910.1155/2011/51468122312344 49.SantiagoG.A.VergneE.QuilesY.CosmeJ.VazquezJ.MedinaJ.F.MedinaF.ColónC.MargolisH.Muñoz-JordánJ.L.Analytical and Clinical Performance of the"/>
   <result pre="CDC Real Time RT-PCR Assay for Detection and Typing of" exact="Dengue" post="VirusPLoS Negl. Trop. Dis.20137e231110.1371/annotation/ae27d48b-025f-47ce-8427-4af59f821ad723875046 50.FayeO.FayeO.DialloD.DialloM.WeidmannM.SallA.A.Quantitative real-time PCR detection of"/>
   <result pre="Dengue VirusPLoS Negl. Trop. Dis.20137e231110.1371/annotation/ae27d48b-025f-47ce-8427-4af59f821ad723875046 50.FayeO.FayeO.DialloD.DialloM.WeidmannM.SallA.A.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught MosquitoesVirol. J.201310110.1186/1743-422X-10-31123279912 51.LanciottiR.S.KosoyO.L.LavenJ.J.PanellaA.J.VelezJ.O.LambertA.J.CampbellG.L.Chikungunya virus"/>
   <result pre="53.GublerD.J.KunoG.SatherG.E.VelezM.OliverA.Mosquito Cell Cultures and Specific Monoclonal Antibodies in Surveillance for" exact="Dengue" post="VirusesAm. J. Trop. Med. Hyg.19843315816510.4269/ajtmh.1984.33.1586364855 54.PengY.LeungH.C.M.YiuS.M.ChinF.Y.L.IDBA-UD: a de novo"/>
   <result pre="Aedes albopictus in Fortaleza, Ceará, BrazilPLoS ONE201271910.1371/annotation/bc186d1e-f2fc-4dff-8084-a25cf32b9388 68.SmarttC.T.StennT.M.S.ChenT.TeixeiraM.G.QueirozE.P.SantosL.S.QueirozG.A.N.SouzaK.R.SilvaL.K.ShinD.et al.Evidence of" exact="Zika" post="Virus RNA Fragments in Aedes albopictus (Diptera: Culicidae) Field-Collected"/>
   <result pre="American Countries as a Crucial Factor in the Spread of" exact="Chikungunya" post="VirusJ. Virol.2014886294630610.1128/JVI.00370-1424672026 71.HonórioN.A.WigginsK.CâmaraD.C.P.EastmondB.AltoB.W.Chikungunya virus vector competency of Brazilian and"/>
   <result pre="Aedes albopictus (Diptera: Culicidae) in Macao, China, in Relation to" exact="Dengue" post="Virus TransmissionJ. Med. Entomol.20054241942810.1093/jmedent/42.3.41915962796 74.XuG.DongH.ShiN.LiuS.ZhouA.ChengZ.ChenG.LiuJ.FangT.ZhangH.et al.An outbreak os Dengue"/>
   <result pre="to Dengue Virus TransmissionJ. Med. Entomol.20054241942810.1093/jmedent/42.3.41915962796 74.XuG.DongH.ShiN.LiuS.ZhouA.ChengZ.ChenG.LiuJ.FangT.ZhangH.et al.An outbreak os" exact="Dengue" post="virus serotype 1 infection in Cixi, Ningbo, people’s republic"/>
   <result pre="infections during simultaneous outbreaks, Gabon, 2007Emerg. Infect. Dis.20091559159310.3201/eid1504.08066419331740 77.IssackM.I.PursemV.N.BarkhamT.M.S.NgL.InoueM.ManrajS.S.Reemergence of" exact="Dengue" post="in MauritiusEmerg. Infect. Dis.20101671671810.3201/eid1604.09158220350397 78.GrardG.CaronM.MomboI.M.NkogheD.OndoS.M.JiolleD.FontenilleD.PaupyC.LeroyE.M.Zika Virus in Gabon (Central"/>
   <result pre="of chikungunya virus: another emerging problem?Lancet Infect. Dis.2006646346410.1016/S1473-3099(06)70531-X16870524 80.RatsitorahinaM.HarisoaJ.RatovonjatoJ.BiacabeS.ReynesJ.-M.ZellerH.RaoelinaY.TalarminA.RichardV.SoaresJ.L.Outbreak of" exact="Dengue" post="and Chikungunya Fevers, Toamasina, Madagascar, 2006Emerg. Infect. Dis.2008141135113710.3201/eid1407.07152118598641 81.PagèsF.PeyrefitteC.N.MveM.T.JarjavalF.BrisseS.ItemanI.GravierP.NkogheD.GrandadamM.Aedes"/>
   <result pre="virus: another emerging problem?Lancet Infect. Dis.2006646346410.1016/S1473-3099(06)70531-X16870524 80.RatsitorahinaM.HarisoaJ.RatovonjatoJ.BiacabeS.ReynesJ.-M.ZellerH.RaoelinaY.TalarminA.RichardV.SoaresJ.L.Outbreak of Dengue and" exact="Chikungunya" post="Fevers, Toamasina, Madagascar, 2006Emerg. Infect. Dis.2008141135113710.3201/eid1407.07152118598641 81.PagèsF.PeyrefitteC.N.MveM.T.JarjavalF.BrisseS.ItemanI.GravierP.NkogheD.GrandadamM.Aedes albopictus Mosquito:"/>
   <result pre="Dis.2008141135113710.3201/eid1407.07152118598641 81.PagèsF.PeyrefitteC.N.MveM.T.JarjavalF.BrisseS.ItemanI.GravierP.NkogheD.GrandadamM.Aedes albopictus Mosquito: The Main Vector of the 2007" exact="Chikungunya" post="Outbreak in GabonPLoS Negl. Trop. Dis.20094e4691 82.LiY.KamaraF.ZhouG.PuthiyakunnonS.LiC.LiuY.ZhouY.YaoL.YanG.ChenX.Urbanization Increases Aedes"/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 72016Available online: http://portalarquivos2.saude.gov.br/images/pdf/2016/marco/23/2016-008---DengueSE8-publica----o.pdf(accessed on 13"/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 522017Available online: http://portalarquivos2.saude.gov.br/images/pdf/2018/janeiro/23/Boletim-2018-001-Dengue.pdf(accessed on 15"/>
   <result pre="ECSA in the AmericasPLoS Negl. Trop. Dis.201711e000563010.1371/journal.pntd.000563028614394 88.CostaA.C.d.ThézéJ.KomninakisS.C.V.Sanz-DuroR.L.FelintoM.R.L.MouraL.C.C.BarrosoI.M.d.O.SantosL.E.C.NunesM.A.d.L.MouraA.A.et al.Spread of" exact="Chikungunya" post="Virus East/Central/South African Genotype in Northeast BrazilEmerg. Infect. Dis.2017231742174410.3201/eid2310.17030728930031"/>
   <result pre="in Northeast BrazilEmerg. Infect. Dis.2017231742174410.3201/eid2310.17030728930031 89.TanabeE.L.d.L.TanabeI.S.B.SantosE.C.d.MarquesJ.P.d.S.BorgesA.A.LimaM.C.d.AndersonL.BassiÊ.J.Report of East-Central South African" exact="Chikungunya" post="virus genotype during the 2016 outbreak in the Alagoas"/>
   <result pre="Inst. Med. Trop. Sao Paulo201860e1910.1590/s1678-994620186001929694603 90.TauroL.B.CardosoC.W.SouzaR.L.NascimentoL.C.J.SantosD.R.CamposG.S.SardiS.ReisO.B.ReisM.G.KitronU.et al.A localized outbreak of" exact="Chikungunya" post="virus in Salvador, Bahia, BrazilMem. Inst. Oswaldo Cruz2019114e18059710.1590/0074-0276018059730843962 91.ContevilleL.C.ZanellaL.MarínM.A.de"/>
   <result pre="2014-2015Mem. Inst. Oswaldo Cruz201611134734810.1590/0074-0276016000427120007 92.CunhaM.S.CruzN.V.G.SchnellrathL.C.MedagliaM.L.G.CasottoM.E.AlbanoR.M.CostaL.J.DamasoC.R.Autochthonous Transmission of East/Central/South African Genotype" exact="Chikungunya" post="Virus, BrazilEmerg. Infect. Dis.2017231737173910.3201/eid2310.16185528930027 93.NavecaF.G.ClaroI.GiovanettiM.JesusJ.G.XavierJ.IaniF.C.d.M.NascimentoV.A.SouzaV.C.SilveiraP.P.LourençoJ.et al.Genomic, epidemiological and digital"/>
   <result pre="BrazilEmerg. Infect. Dis.2017231737173910.3201/eid2310.16185528930027 93.NavecaF.G.ClaroI.GiovanettiM.JesusJ.G.XavierJ.IaniF.C.d.M.NascimentoV.A.SouzaV.C.SilveiraP.P.LourençoJ.et al.Genomic, epidemiological and digital surveillance of" exact="Chikungunya" post="virus in the Brazilian AmazonPLoS Negl. Trop. Dis.201913e000706510.1371/journal.pntd.000706530845267 94.SouzaT.M.A.AzeredoE.L.Badolato-CorrêaJ.DamascoP.V.SantosC.Petitinga-PaivaF.NunesP.C.G.BarbosaL.S.CipitelliM.C.Chouin-CarneiroT.et"/>
   <result pre="94.SouzaT.M.A.AzeredoE.L.Badolato-CorrêaJ.DamascoP.V.SantosC.Petitinga-PaivaF.NunesP.C.G.BarbosaL.S.CipitelliM.C.Chouin-CarneiroT.et al.First Report of the East-Central South African Genotype of" exact="Chikungunya" post="Virus in Rio de Janeiro, BrazilPLOS Curr.2017910.1371/currents.outbreaks.4200119978d62ccaa454599cd2735727 95.Lessa-AquinoC.TrintaK.S.PestanaC.P.RibeiroM.O.SucupiraM.V.F.BoiaM.N.BaptistaP.A.CunhaR.V.MedeirosM.A.Detection of"/>
   <result pre="Rio de Janeiro, BrazilPLOS Curr.2017910.1371/currents.outbreaks.4200119978d62ccaa454599cd2735727 95.Lessa-AquinoC.TrintaK.S.PestanaC.P.RibeiroM.O.SucupiraM.V.F.BoiaM.N.BaptistaP.A.CunhaR.V.MedeirosM.A.Detection of East/Central/South African genotype" exact="Chikungunya" post="virus during an outbreak in a southeastern state of"/>
   <result pre="casos de dengue, febre de chikungunya e febre pelo vírus" exact="Zika" post="até a Semana Epidemiológica 5 de 2018Available online: http://portalarquivos2.saude.gov.br/images/pdf/2018/fevereiro/20/2018-007.pdf(accessed"/>
   <result pre="Outbreak in Piauí Caribbean Route of Introduction and Dissemination of" exact="Dengue" post="Virus in BrazilPLoS ONE20149e10451610.1371/journal.pone.010451625127366 103.OliveiraM.F.AraújoJ.M.G.JúniorO.C.F.FerreiraD.F.LimaD.B.m.SantosF.B.GonçalvesH.SchatzmayrA.T.NogueiraR.M.R.Two Lineages of Dengue Virus"/>
   <result pre="Dissemination of Dengue Virus in BrazilPLoS ONE20149e10451610.1371/journal.pone.010451625127366 103.OliveiraM.F.AraújoJ.M.G.JúniorO.C.F.FerreiraD.F.LimaD.B.m.SantosF.B.GonçalvesH.SchatzmayrA.T.NogueiraR.M.R.Two Lineages of" exact="Dengue" post="Virus Type 2, BrazilEmerg. Infect. Dis.20101657657810.3201/eid1603.09099620202456 104.RomanoC.M.MatosA.M.AraújoE.S.A.Villas-BoasL.S.SilvaW.C.OliveiraO.M.N.P.F.CarvalhoK.I.SouzaA.C.M.RodriguesC.L.LeviJ.E.et al.Characterization of"/>
   <result pre="Dengue Virus Type 2, BrazilEmerg. Infect. Dis.20101657657810.3201/eid1603.09099620202456 104.RomanoC.M.MatosA.M.AraújoE.S.A.Villas-BoasL.S.SilvaW.C.OliveiraO.M.N.P.F.CarvalhoK.I.SouzaA.C.M.RodriguesC.L.LeviJ.E.et al.Characterization of" exact="Dengue" post="Virus Type 2: New Insights on the 2010 Brazilian"/>
   <result pre="the 2010 Brazilian EpidemicPLoS ONE20105e1181110.1371/journal.pone.001181120676363 105.DrumondB.P.MondiniA.SchmidtD.J.BronzoniR.V.d.M.BoschI.NogueiraM.L.Circulation of Different Lineages of" exact="Dengue" post="Virus 2, Genotype American/Asian in Brazil: Dynamics and Molecular"/>
   <result pre="test using Alphavirus and Flavivirus specific polyclonal antibodies to identify" exact="Chikungunya" post="virus (CHIKV) and Dengue virus (DENV)-2 in C6/36 cell"/>
   <result pre="Flavivirus specific polyclonal antibodies to identify Chikungunya virus (CHIKV) and" exact="Dengue" post="virus (DENV)-2 in C6/36 cell cultures. It is possible"/>
   <result pre="increase in fluorescence (viral load) for both isolates. (A–C) for" exact="CHIKV" post="and (D–F) for DENV-2 (in the first, second, and"/>
   <result pre="of CHIKV. The strain AR849404 (in bold) clustered within the" exact="CHIKV" post="ECSA (East-Central-South African) genotype. Figure 4 Maximum likelihood phylogenetic"/>
   <result pre="of DENV-2. The strain AR849487 (in bold) clustered within the" exact="DENV" post="Asian/American genotype. viruses-11-01126-t001_Table 1Table 1 Distribution of insects of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6950258\results\search\tropicalVirus\results.xml">
   <result pre="Aedes mosquito is a well-established vector of several viruses, primarily" exact="Zika" post="(ZIKV), dengue (DENV) and chikungunya virus (CHIKV). Development and"/>
   <result pre="Diseases in the Pacific Region—A Review on DENV, ZIKV, and" exact="CHIKV" post="In the Pacific region, Aedes mosquitoes have been identified"/>
   <result pre="vector species. Mainly causing dengue epidemics linked to a single" exact="DENV" post="serotype throughout the past, recent research identified the co-circulation"/>
   <result pre="virus serotypes (types one to four), but newly emerging Aedes-borne" exact="Zika" post="and chikungunya transmission [28]. Regular DENV outbreaks had been"/>
   <result pre="but newly emerging Aedes-borne Zika and chikungunya transmission [28]. Regular" exact="DENV" post="outbreaks had been reported since 1960s from the Pacific"/>
   <result pre="been reported since 1960s from the Pacific region. Since then," exact="DENV" post="has established endemic and epidemic circulation. In the early"/>
   <result pre="established endemic and epidemic circulation. In the early 21st century," exact="ZIKV" post="(since 2007) and CHIKV (since 2011) epidemics occurred for"/>
   <result pre="circulation. In the early 21st century, ZIKV (since 2007) and" exact="CHIKV" post="(since 2011) epidemics occurred for the first time [21]."/>
   <result pre="(family Togaviridae), e.g., chikungunya virus, and Flaviviruses (family Flaviviridae), e.g.," exact="Zika" post="and dengue virus. Those viruses could primarily be linked"/>
   <result pre="found in peri-urban or rural areas [29]. DEN, ZIKV, and" exact="CHIKV" post="are tropical mosquito-borne viruses that share biological similarities with"/>
   <result pre="agents such as Ross River virus (closely related to CHIKV)," exact="West Nile" post="virus, and yellow fever virus (closely related to DENV"/>
   <result pre="West Nile virus, and yellow fever virus (closely related to" exact="DENV" post="and ZIKV). They primarily spread through the bite of"/>
   <result pre="africanus, Ae. hensilli, and Ae. albopictus [30]. Unlike other flaviviruses," exact="ZIKV" post="is known to further be passed from human to"/>
   <result pre="Blood-borne transmission and intrapartum transmission have also been reported for" exact="CHIKV" post="[32]. The main reservoir hosts include human and non-human"/>
   <result pre="2 describes the nature of some recent DENV, ZIKV, and" exact="CHIKV" post="outbreaks in different Pacific Island States, with an emphasis"/>
   <result pre="their epidemic potential, the clinical picture of DENV, ZIKV, and" exact="CHIKV" post="is often mild, and symptoms often go unrecognized [37]."/>
   <result pre="highly susceptible areas such as Pacific island nations. The 2016" exact="ZIKV" post="epidemic in the Americas fueled the debate how climate"/>
   <result pre="and Research (BMBF), aimed at investigating the outbreak of emerging" exact="ZIKV" post="disease in the Fiji Islands from an ecological perspective"/>
   <result pre="recent reports, 2019 has been an exceptionally active year of" exact="DENV" post="outbreaks worldwide [45]. As outlined, with increasing climate change"/>
   <result pre="approaches to cut off transmission routes for DENV, ZIKV, and" exact="CHIKV" post="disease gain increasing attention in public health. Control of"/>
   <result pre="September 2019) 17.AsadH.CarpenterD.O.Effects of climate change on the spread of" exact="Zika" post="Virus: A public health threatRev. Environ. Health201833314210.1515/reveh-2017-004229500926 18.ChangA.Y.FullerD.O.CarrasquilloO.BeierJ.C.Social justice,"/>
   <result pre="24.PazS.SemenzaJ.C.El Niño and climate change—Contributing factors in the dispersal of" exact="Zika" post="virus in the Americas?Lancet201638774510.1016/S0140-6736(16)00256-7 25.LeeS.H.NamK.W.JeongJ.Y.YooS.J.KohY.-S.LeeS.HeoS.T.SeongS.-Y.LeeK.H.The Effects of Climate Change"/>
   <result pre="Rep.2016444444610.1016/j.pmedr.2016.07.01127617189 27.MatysiakA.RoessA.Interrelationship between Climatic, Ecologic, Social, and Cultural Determinants Affecting" exact="Dengue" post="Emergence and Transmission in Puerto Rico and Their Implications"/>
   <result pre="Emergence and Transmission in Puerto Rico and Their Implications for" exact="Zika" post="ResponseJ. Trop. Med.2017201711410.1155/2017/894706728717366 28.Cao-LormeauV.-M.MussoD.Emerging arboviruses in the PacificLancet20143841571157210.1016/S0140-6736(14)61977-225443481 29.MavianC.DulceyM.MunozO.SalemiM.VittorA.Y.CapuaI.Islands"/>
   <result pre="of regional vectorsPLoS Negl. Trop. Dis.201812e000663710.1371/journal.pntd.000663730016372 31.AbushoukA.NegidaA.AhmedH.An updated review of" exact="Zika" post="virusJ. Clin. Virol.201684535810.1016/j.jcv.2016.09.01227721110 32.Contopoulos-IoannidisD.Newman-LindsayS.ChowC.LaBeaudA.D.Mother-to-child transmission of Chikungunya virus: A"/>
   <result pre="updated review of Zika virusJ. Clin. Virol.201684535810.1016/j.jcv.2016.09.01227721110 32.Contopoulos-IoannidisD.Newman-LindsayS.ChowC.LaBeaudA.D.Mother-to-child transmission of" exact="Chikungunya" post="virus: A systematic review and meta-analysisPLoS Negl. Trop. Dis.201812e000651010.1371/journal.pntd.000651029897898"/>
   <result pre="in French PolynesiaNew Microbes New Infect.20192910051310.1016/j.nmni.2019.01.00930899520 36.RiouJ.PolettoC.BoëlleP.-Y.A comparative analysis of" exact="Chikungunya" post="and Zika transmissionEpidemics201719435210.1016/j.epidem.2017.01.00128139388 37.PattersonJ.SammonM.GargM.Dengue, Zika and Chikungunya: Emerging Arboviruses"/>
   <result pre="PolynesiaNew Microbes New Infect.20192910051310.1016/j.nmni.2019.01.00930899520 36.RiouJ.PolettoC.BoëlleP.-Y.A comparative analysis of Chikungunya and" exact="Zika" post="transmissionEpidemics201719435210.1016/j.epidem.2017.01.00128139388 37.PattersonJ.SammonM.GargM.Dengue, Zika and Chikungunya: Emerging Arboviruses in the"/>
   <result pre="Infect.20192910051310.1016/j.nmni.2019.01.00930899520 36.RiouJ.PolettoC.BoëlleP.-Y.A comparative analysis of Chikungunya and Zika transmissionEpidemics201719435210.1016/j.epidem.2017.01.00128139388 37.PattersonJ.SammonM.GargM.Dengue," exact="Zika" post="and Chikungunya: Emerging Arboviruses in the New WorldWest. J."/>
   <result pre="Cross-Disciplinary ReviewClin. Microbiol. Rev.20011490993210.1128/CMR.14.4.909-932.200111585790 39.RothA.MercierA.LepersC.HoyD.DuituturagaS.BenyonE.GuillaumotL.SouarèsY.Concurrent outbreaks of dengue, chikungunya and" exact="Zika" post="virus infections—An unprecedented epidemic wave of mosquito-borne viruses in"/>
   <result pre="a large outbreak in FijiElife2018710.7554/eLife.34848 43.KamaM.AubryM.NaivaluT.VanhomwegenJ.Mariteragi-HelleT.TeissierA.PaoaafaiteT.HuéS.HibberdM.L.ManuguerraJ.-C.et al.Sustained Low-Level Transmission of" exact="Zika" post="and Chikungunya Viruses after Emergence in the Fiji IslandsEmerg."/>
   <result pre="outbreak in FijiElife2018710.7554/eLife.34848 43.KamaM.AubryM.NaivaluT.VanhomwegenJ.Mariteragi-HelleT.TeissierA.PaoaafaiteT.HuéS.HibberdM.L.ManuguerraJ.-C.et al.Sustained Low-Level Transmission of Zika and" exact="Chikungunya" post="Viruses after Emergence in the Fiji IslandsEmerg. Infect. Dis.2019251535153810.3201/eid2508.18052431310218"/>
   <result pre="of Climate Change ResilienceSpringerCham, Switzerland2019Volume 2 48.Chouin-CarneiroT.AntT.H.HerdC.LouisF.FaillouxA.B.SinkinsS.P.Wolbachia strain wAlbA blocks" exact="Zika" post="virus transmission in Aedes aegyptiMed. Vet. Entomol.201910.1111/mve.12384 49.RyanP.A.TurleyA.P.WilsonG.HurstT.P.RetzkiK.Brown-KenyonJ.HodgsonL.KennyN.CookH.MontgomeryB.L.et al.Establishment"/>
   <result pre="studies of recent Aedes-borne outbreaks in Pacific Island States. Pathogen." exact="ZIKV" post="[21,29,33] DENV (DENV-2) [21,29,34] CHIKV [35,36] Pacific Case Study"/>
   <result pre="recent Aedes-borne outbreaks in Pacific Island States. Pathogen. ZIKV [21,29,33]" exact="DENV" post="(DENV-2) [21,29,34] CHIKV [35,36] Pacific Case Study Yap Island,"/>
   <result pre="in Pacific Island States. Pathogen. ZIKV [21,29,33] DENV (DENV-2) [21,29,34]" exact="CHIKV" post="[35,36] Pacific Case Study Yap Island, Federate States of"/>
   <result pre="suspected cases PublicHealthChallenges Widespread mosquito vector; immunologically naïve population; co-circulating" exact="DENV" post="Widespread mosquito vector; endemic dengue virus (DENV) circulation; outbreak"/>
   <result pre="and clinical resources Widespread mosquito vector; immunologically naive population; co-circulating" exact="DENV" post="Mosquito-borne virus co-circulation DENV, zika virus (ZIKV) ZIKV DENV,"/>
   <result pre="population; co-circulating DENV Mosquito-borne virus co-circulation DENV, zika virus (ZIKV)" exact="ZIKV" post="DENV, ZIKV,Ross River virus (silent) PublicHealthImplications Development of robust"/>
   <result pre="the Pacific region. As a consequence, emerging diseases, such as" exact="ZIKV" post="disease, have successfully expanded to geographical areas where only"/>
   <result pre="ZIKV disease, have successfully expanded to geographical areas where only" exact="DENV" post="epidemics used to occur, including the Fiji Islands. The"/>
   <result pre="occur, including the Fiji Islands. The project aimed at exploring" exact="ZIKV" post="environmental suitability and potential of (re-)emergence in the Fiji"/>
   <result pre="temperature °C, total precipitation mm/km2, 1960–2018) and reports on confirmed" exact="DENV" post="and ZIKV infection (2007–2018) were acquired on a monthly"/>
   <result pre="total precipitation mm/km2, 1960–2018) and reports on confirmed DENV and" exact="ZIKV" post="infection (2007–2018) were acquired on a monthly basis in"/>
   <result pre="epidemiological trends in Viti Levu, Fiji. Additionally, evidence from recent" exact="ZIKV" post="serological studies was acquired to explore overall ZIKV susceptibility"/>
   <result pre="from recent ZIKV serological studies was acquired to explore overall" exact="ZIKV" post="susceptibility levels in the Fiji population. Environmental DENV and"/>
   <result pre="explore overall ZIKV susceptibility levels in the Fiji population. Environmental" exact="DENV" post="and ZIKV epidemic exposure was then assessed using pathogen-specific"/>
   <result pre="ZIKV susceptibility levels in the Fiji population. Environmental DENV and" exact="ZIKV" post="epidemic exposure was then assessed using pathogen-specific thermal thresholds"/>
   <result pre="thermal thresholds derived from laboratory studies (ZIKV = 22.6–34.8 °C," exact="DENV" post="= 17.8–34.6 °C) [41] looking at meteorological trends 1960–2018."/>
   <result pre="Key findings: Recent findings could only confirm low-level transmission of" exact="ZIKV" post="in Fiji during 2013–2017, indicating low-level herd immunity in"/>
   <result pre="to June (warm and wet season), with highest counts of" exact="DENV" post="and ZIKV infection recorded in Fiji’s densely populated areas,"/>
   <result pre="(warm and wet season), with highest counts of DENV and" exact="ZIKV" post="infection recorded in Fiji’s densely populated areas, mainly after"/>
   <result pre="Tmax = 29.1 [+0.3] °C) indicate suitable temperature conditions for" exact="DENV" post="year-round transmission since 1960, especially in Fiji’s main urban"/>
   <result pre="the South-East and North-West of Viti Levu, whereas only seasonal" exact="ZIKV" post="transmission risk could be identified, especially due to minimum"/>
   <result pre="identified, especially due to minimum temperature levels dropping beyond the" exact="ZIKV" post="transmission threshold levels. Pathogen Time Tmin suitability(1960–2018) Tmean suitability(1960–2018)"/>
   <result pre="threshold levels. Pathogen Time Tmin suitability(1960–2018) Tmean suitability(1960–2018) Tmax suitability(1960–2018)" exact="DENV" post="(17.8–34.6 °C) No months/year 11.2 (–0.4) 12.0 (+/–0) 11.8"/>
   <result pre="(17.8–34.6 °C) No months/year 11.2 (–0.4) 12.0 (+/–0) 11.8 (+0.2)" exact="ZIKV" post="(22.6–34.8 °C) No months/year 1.9 (+2.1) 10.6 (+0.4) 11.5"/>
   <result pre="No months/year 1.9 (+2.1) 10.6 (+0.4) 11.5 (+0.3) With endemic" exact="ZIKV" post="circulation in Southeast Asia [44], and as temperature rises,"/>
   <result pre="[44], and as temperature rises, there is a risk of" exact="ZIKV" post="re-emergence in Fiji, with potentially extended transmission season in"/>
   <result pre="transmission season in the near future. The findings demonstrate that" exact="ZIKV" post="must still be considered a potential health threat in"/>
   <result pre="Pacific region, aims to eradicate viruses like DENV, CHIKV, and" exact="ZIKV" post="by cutting of the transmission routes for mosquito-borne diseases."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6952674\results\search\tropicalVirus\results.xml">
   <result pre="pmcid: 6952674MRA01452-19 doi: 10.1128/MRA.01452-19 : Genome Sequences Genome Sequences of" exact="Chikungunya" post="Virus Strains from Bangladesh and Thailand Microbiology Resource Announcement"/>
   <result pre="Asia, and the Americas, affecting millions of people (1). Large-scale" exact="CHIKV" post="outbreaks were recently recorded in Dhaka, Bangladesh, in 2017"/>
   <result pre="Aedes aegypti and Aedes albopictus mosquitoes, are at risk of" exact="CHIKV" post="importation by viremic travelers and subsequent autochthonous transmission (1,"/>
   <result pre="travel in Thailand. Acute-phase sera were analyzed using a specific" exact="CHIKV" post="reverse-transcription real-time PCR assay (4) which detected CHIKV RNA"/>
   <result pre="a specific CHIKV reverse-transcription real-time PCR assay (4) which detected" exact="CHIKV" post="RNA in each patient sample. The same patient sera"/>
   <result pre="sera were inoculated onto A. albopictus C6/36 cell monolayers. Two" exact="CHIKV" post="isolates, namely, Bangladesh 2017 and Thail 2019, were recovered"/>
   <result pre="sequencing (WGS) and phylogenetic analysis. To support ongoing and enhanced" exact="CHIKV" post="surveillance within Australasia and provide contemporary sequences for continued"/>
   <result pre="genome sequence assembly was achieved by mapping to a reference" exact="CHIKV" post="genome sequence (strain CHIK31, GenBank accession number EU564335) that"/>
   <result pre="1). However, the E1-A226V mutation first detected during the 2005–2006" exact="CHIKV" post="epidemic on La Réunion Island (9) was not found"/>
   <result pre="tree (midpoint rooted for branch visibility only) inferred for 63" exact="CHIKV" post="genome sequences (excluding 5′ and 3′ untranslated regions) using"/>
   <result pre="version 7.450 and Geneious version 10.2.6 software. The three major" exact="CHIKV" post="genotypes (West African, Asian, and ECSA) are shown, including"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6955267\results\search\tropicalVirus\results.xml">
   <result pre="albopictus, a globally dispersed vector, allowing for the spread of" exact="CHIKV" post="to new regions following the 2006 Reunion Island CHIKV"/>
   <result pre="of CHIKV to new regions following the 2006 Reunion Island" exact="CHIKV" post="epidemic (30). Most amino acid transitions in our data"/>
   <result pre="observed in alphaviruses such as Semliki Forest virus (SFV) and" exact="CHIKV" post="to be able to withstand large nucleotide insertions and"/>
   <result pre="transition in RRV. Introduction of an arginine codon into a" exact="CHIKV" post="isolate significantly reduced joint morbidities in infected mice compared"/>
   <result pre="and P42214, respectively, has been described for other alphaviruses, including" exact="CHIKV" post="and SINV (34, 36), but this is the first"/>
   <result pre="Timescales have been estimated for other alphaviruses, including SINV (40)," exact="CHIKV" post="(28), Eastern equine encephalitis virus (EEEV) (41), and Venezuelan"/>
   <result pre="JadhavSM, GandheSS, HundekarSL, MishraAC, ArankalleVA2009Evolutionary rates and timescale comparison of" exact="Chikungunya" post="viruses inferred from the whole genome/E1 gene with special"/>
   <result pre="Trop Dis10:e0004511. doi:10.1371/journal.pntd.0004511.26977703 30.TsetsarkinKA, VanlandinghamDL, McGeeCE, HiggsS2007A single mutation in" exact="Chikungunya" post="virus affects vector specificity and epidemic potential. PLoS Pathog3:e201."/>
   <result pre="BrowningC, MoormanN, LimJK, HeiseMT2017Disruption of the opal stop codon attenuates" exact="Chikungunya" post="virus-induced arthritis and pathology. mBio8:e01456-17. doi:10.1128/mBio.01456-17.29138302 35.MylesKM, KellyCLH, LedermannJP,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6956279\results\search\tropicalVirus\results.xml">
   <result pre="two of the aforementioned single-target assays as recently described for" exact="Chikungunya" post="virus [6], and (iii) to attempt transferring this dual-target"/>
   <result pre="and (iii) frequently improves the sensitivity as previously shown with" exact="Chikungunya" post="virus [6]. Here, we selected four assays that were"/>
   <result pre="the Duo assay demonstrated higher RFU, as previously described with" exact="CHIKV" post="Duo [6], that warrants an easier interpretation of the"/>
   <result pre="ProceduresJ. Clin. Virol.20167791410.1016/j.jcv.2016.01.01726874083 6.ThirionL.PezziL.CorcosteguiI.Dubot-PérèsA.FalchiA.de LamballerieX.CharrelR.N.Development and Evaluation of a Duo" exact="Chikungunya" post="Virus Real-Time RT-PCR Assay Targeting Two Regions within the"/>
   <result pre="Lassa Virus, Crimean-Congo Hemorrhagic Fever Virus, Rift Valley Fever Virus," exact="Dengue" post="Virus, and Yellow Fever Virus by Real-Time Reverse Transcription-PCRJ."/>
   <result pre="encephalitis virus TBEV UVE/TBEV/2013/FR/32.11 WT-PCR (10 8,82) 001v-02352 West-Nile virus" exact="WNV" post="UVE/WNV/2008/US/R94224 (10 7,32) 001v-02224 Yellow Fever virus YFV UVE/YFV/UNK/XX/French"/>
   <result pre="West-Nile virus WNV UVE/WNV/2008/US/R94224 (10 7,32) 001v-02224 Yellow Fever virus" exact="YFV" post="UVE/YFV/UNK/XX/French neurotropic R94224 (10 7,32) 001v-02226 Usutu virus USUV"/>
   <result pre="5,32) 001v-EVA138 Murray Valley virus MVEV UVE/MVEV/UNK/AU/3329 (10 4,32) 001v-EVA145" exact="Zika" post="virus ZIKV UVE/ZIKV/1947/UG/MR766 (10 4,32) 001v-EVA143 Dengue virus DENV-1"/>
   <result pre="Murray Valley virus MVEV UVE/MVEV/UNK/AU/3329 (10 4,32) 001v-EVA145 Zika virus" exact="ZIKV" post="UVE/ZIKV/1947/UG/MR766 (10 4,32) 001v-EVA143 Dengue virus DENV-1 UVE/DENV-1/2013/NC/CNR_17132 (10"/>
   <result pre="(10 4,32) 001v-EVA145 Zika virus ZIKV UVE/ZIKV/1947/UG/MR766 (10 4,32) 001v-EVA143" exact="Dengue" post="virus DENV-1 UVE/DENV-1/2013/NC/CNR_17132 (10 7,57) 001v-03151 Alphavirus Venezuelan equine"/>
   <result pre="7,82) 001v-EVA1480 O’nyong-nyong virus ONNV UVE/ONNV/UNK/SN/Dakar 234 (10 4,22) 001v-EVA1044" exact="Chikungunya" post="virus CHIKV UVE/CHIKV/2017/FR/45625-26 (10 6,16) 001v-03433 Semliki Forest virus"/>
   <result pre="O’nyong-nyong virus ONNV UVE/ONNV/UNK/SN/Dakar 234 (10 4,22) 001v-EVA1044 Chikungunya virus" exact="CHIKV" post="UVE/CHIKV/2017/FR/45625-26 (10 6,16) 001v-03433 Semliki Forest virus SFV UVE/SFV/UNK/XX/1745"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958409\results\search\tropicalVirus\results.xml">
   <result pre="useful, for example, for proteins of Hepatitis B, HIV and" exact="West Nile" post="viruses [214,215,216]. Cells in cultures also served for large-scale"/>
   <result pre="and immune functionFish. Shellfish Immunol.20082534135010.1016/j.fsi.2008.05.00518640057 238.PalhaN.Guivel-BenhassineF.BriolatV.LutfallaG.SourisseauM.EllettF.WangC.-H.LieschkeG.J.HerbomelP.SchwartzO.et al.Real-Time Whole-Body Visualization of" exact="Chikungunya" post="Virus Infection and Host Interferon Response in ZebrafishPLoS Pathog.20139e100361910.1371/journal.ppat.100361924039582"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6958466\results\search\tropicalVirus\results.xml">
   <result pre="Approaches for Surveillance, Drug Discovery, and Vaccine Design for the" exact="Zika" post="Virus BasakSubhash C.1*https://orcid.org/0000-0003-3529-7820MajumdarSubhabrata2†https://orcid.org/0000-0002-1649-7731NandyAshesh3RoyProyasha3DuttaTathagata3VrackoMarjan4BhattacharjeeApurba K.5[1], [2], subho@research.att.com[3], anandy43@yahoo.comproyasha.roy@gmail.comtathagata.dk@gmail.com[4], marjan.vracko@ki.si[5], ab3094@georgetown.edu"/>
   <result pre="emerge and reemerge at random. The recent outbreak of the" exact="Zika" post="virus (ZIKV) is one such menace that shook the"/>
   <result pre="and discuss how they can work together to proactively combat" exact="ZIKV" post="or future emerging pathogens. viral epidemics Zika virus (ZIKV)"/>
   <result pre="to proactively combat ZIKV or future emerging pathogens. viral epidemics" exact="Zika" post="virus (ZIKV) SIR models 2D graphical method peptide vaccine"/>
   <result pre="Of the Black Death 1. Discovery and Brief History The" exact="Zika" post="Virus (ZIKV) was first isolated in 1947 from a"/>
   <result pre="first isolated in 1947 from a rhesus monkey in the" exact="Zika" post="forest of Uganda [1]. In 1952, the virus was"/>
   <result pre="Africa and Asia at first. The first major outbreak of" exact="ZIKV" post="infection was reported from the Yap Island in the"/>
   <result pre="the origin and spread of ZIKV. Serosurvey of humans found" exact="ZIKV" post="throughout Africa, Asia, and Oceania. In 1954, there was"/>
   <result pre="there was a report of the first three cases of" exact="ZIKV" post="infection in humans in Oyo state, Nigeria [2]. In"/>
   <result pre="antibodies of ZIKV. The first direct evidence of the presence" exact="ZIKV" post="in the Asian continent and the first proof of"/>
   <result pre="stomach ache, anorexia, and dizziness [6]. Regarding the spread of" exact="ZIKV" post="from Africa to Asia, Liang et al. [7] put"/>
   <result pre="on mathematical modeling. These authors carried out quantitative analysis of" exact="ZIKV" post="evolution, nucleotide substitution rate, and the time to the"/>
   <result pre="their results these authors concluded that a &quot;global dissemination of" exact="ZIKV" post="spread was likely to have originated from Africa, followed"/>
   <result pre="as a possible portal of entry for the transmission of" exact="ZIKV" post="from Africa to south-eastern Asia during that wartime period.�?"/>
   <result pre="from Africa to south-eastern Asia during that wartime period.�? The" exact="Zika" post="virus attracted a heightened international attention following huge incidence"/>
   <result pre="the Latin Americas in 2015 [8]. Historically, the spread of" exact="ZIKV" post="happened in two phases [9]: (a) Cases of ZIKV"/>
   <result pre="of ZIKV happened in two phases [9]: (a) Cases of" exact="ZIKV" post="detected during the pre-epidemic period (1947 to 1999), and"/>
   <result pre="pre-epidemic period (1947 to 1999), and (b) case history of" exact="ZIKV" post="during 2007 to 2017, respectively. On 2 March 2015"/>
   <result pre="these states. All cases were mild, with no reported deaths." exact="Zika" post="was not suspected at that stage, and no tests"/>
   <result pre="was not suspected at that stage, and no tests for" exact="Zika" post="were carried out. On 1 February 2016, WHO [1]"/>
   <result pre="February 2016, WHO [1] declared that the recent association of" exact="Zika" post="infection with clusters of microcephaly and other neurological disorders"/>
   <result pre="subsequently in the November of 2016. 2. Virology 2.1. Structure" exact="ZIKV" post="is a member of the Flavivirus genus that is"/>
   <result pre="Flaviviridae family. Some important disease-causing viruses of this genus are" exact="Dengue" post="fever virus, Tick-borne encephalitis virus, West Nile virus, Japanese"/>
   <result pre="of this genus are Dengue fever virus, Tick-borne encephalitis virus," exact="West Nile" post="virus, Japanese encephalitis virus, and Zika virus [10]. These"/>
   <result pre="Tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and" exact="Zika" post="virus [10]. These viruses possess a single stranded positive"/>
   <result pre="5′-UTR and 3′-UTR regions [1,9,10,11]. The 3′ terminal end of" exact="ZIKV" post="has a sub-genomic Flavivirus RNA (sfRNA) region that is"/>
   <result pre="viral-host cell binding and membrane fusion during replication. Replication of" exact="ZIKV" post="occurs in the cytoplasm of infected cells [15,16]. After"/>
   <result pre="Evolution and Spread From its initial stage in Uganda, the" exact="ZIKV" post="has numerous alterations. Figure 2 gives a phylogenetic tree"/>
   <result pre="numerous alterations. Figure 2 gives a phylogenetic tree of 22" exact="ZIKV" post="sequences [17]. There are two major groups: one with"/>
   <result pre="was first detected in 1947, the pre-epidemics period of the" exact="Zika" post="virus spanned till 1999. Table 2 provides a brief"/>
   <result pre="country-wise details of infection. Following this, a summary of the" exact="ZIKV" post="epidemics, from 2007 to the present time, is given"/>
   <result pre="detailed list of information about the clinical aspects of the" exact="Zika" post="virus infection. A majority of people infected with Zika"/>
   <result pre="the Zika virus infection. A majority of people infected with" exact="Zika" post="virus do not develop too many overt symptoms. Typical"/>
   <result pre="do not develop too many overt symptoms. Typical symptoms of" exact="Zika" post="virus infection include mild fever, rash, joint/muscle pain, headache,"/>
   <result pre="Most people recover from these symptoms in around a week." exact="ZIKV" post="infection during pregnancy has been linked to several complications,"/>
   <result pre="to several complications, which are collectively referred to as congenital" exact="Zika" post="syndrome. These include miscarriage, severe microcephaly, and other fetal"/>
   <result pre="tissue damage in brain, eye damage [20,21]. Another complication of" exact="ZIKV" post="infection is its association with the Guillain–Barré syndrome (GBS),"/>
   <result pre="website gives the following information regarding the transmission of the" exact="ZIKV" post="transmission [24]. (a)Through mosquito bites: ZIKV is transmitted to"/>
   <result pre="the transmission of the ZIKV transmission [24]. (a)Through mosquito bites:" exact="ZIKV" post="is transmitted to people primarily through the bite of"/>
   <result pre="bites. (b)From mother to child: A pregnant woman can pass" exact="ZIKV" post="to her fetus during pregnancy. (c)Through sex: ZIKV can"/>
   <result pre="can pass ZIKV to her fetus during pregnancy. (c)Through sex:" exact="ZIKV" post="can be transmitted through sex from a person who"/>
   <result pre="can be transmitted through sex from a person who has" exact="Zika" post="to his or her partners. The virus can be"/>
   <result pre="the time. It can be passed from a person with" exact="Zika" post="before their symptoms start, while they have symptoms, and"/>
   <result pre="have symptoms, and after their symptoms end. This scenario of" exact="ZIKV" post="disease transmission is not without precedents in the human"/>
   <result pre="is a new disease! 4. Mathematical/Computational Analysis and Results in" exact="ZIKV" post="Virology, Peptide Vaccine Design, and Anti-Zika Drug Design Currently,"/>
   <result pre="of the above-mentioned multidisciplinary approach for the management of the" exact="ZIKV" post="issues. 4.1. Quantitative Epidemiological Modelling Strategies to Prevent Zika"/>
   <result pre="the ZIKV issues. 4.1. Quantitative Epidemiological Modelling Strategies to Prevent" exact="Zika" post="The major approaches of quantitative modelling for prevention and"/>
   <result pre="major approaches of quantitative modelling for prevention and mitigation of" exact="ZIKV" post="can be broadly categorized into two parts: mathematical models"/>
   <result pre="accurately predict future disease incidences. Data-driven modelling strategies for countering" exact="Zika" post="have been explored keeping a diverse types of end"/>
   <result pre="epidemiological modelling, [37] attempted to predict new primate reservoirs of" exact="ZIKV" post="in the wild based on their phenotypical characteristics. This"/>
   <result pre="spreads of the virus through proactive surveillance and prevention of" exact="ZIKV" post="spread from the at-risk primate species. A number of"/>
   <result pre="novel compounds that are inhibitors of different enzymes present in" exact="ZIKV" post="[38,39,40], as well as repurposing existing drugs used in"/>
   <result pre="as repurposing existing drugs used in treating diseases similar to" exact="Zika" post="[41]. A more detailed list of such in-silico methods"/>
   <result pre="later in this review. 4.2. Computer-Assisted Peptide Vaccine Design for" exact="Zika" post="Virus Vaccination is the most effective way to induce"/>
   <result pre="look at the current methods of vaccine development and particularly," exact="Zika" post="virus vaccines that hopefully might reach the market within"/>
   <result pre="in which two surface proteins are recombined with a weakened" exact="YFV" post="strain [47]. None exist for the Zika or Dengue"/>
   <result pre="with a weakened YFV strain [47]. None exist for the" exact="Zika" post="or Dengue viruses. An important point to note is"/>
   <result pre="weakened YFV strain [47]. None exist for the Zika or" exact="Dengue" post="viruses. An important point to note is that vaccines,"/>
   <result pre="II [48]. They are either DNA-based vaccines or inactivated whole" exact="Zika" post="virus (ZIKV) vaccines. Additionally, there are two recombinant viral"/>
   <result pre="with ZIKV. However, one of the challenges faced in administering" exact="Zika" post="vaccines is a naturally occurring phenomenon called antibody dependent"/>
   <result pre="dependent enhancement or ADE. Reportedly, in cases of a secondary" exact="Dengue" post="infection, it has been seen that the disease severity"/>
   <result pre="probable cause is an abnormal behavior of the antibodies against" exact="Dengue" post="virus—they aid in the virulence of this arbovirus resulting"/>
   <result pre="virus—they aid in the virulence of this arbovirus resulting in" exact="Dengue" post="Shock Syndrome or Dengue Hemorrhagic Fever [49]. Since Zika"/>
   <result pre="virulence of this arbovirus resulting in Dengue Shock Syndrome or" exact="Dengue" post="Hemorrhagic Fever [49]. Since Zika is closely related to"/>
   <result pre="in Dengue Shock Syndrome or Dengue Hemorrhagic Fever [49]. Since" exact="Zika" post="is closely related to Dengue, an individual with a"/>
   <result pre="Zika is closely related to Dengue, an individual with a" exact="Zika" post="vaccination might be severely affected by ADE if she"/>
   <result pre="she or he is subsequently or naturally infected with the" exact="Zika" post="virus. Despite the advancement of vaccine over the last"/>
   <result pre="every year incurring massive production and distribution costs. Hypothetically, a" exact="Zika" post="virus would mutate at the rate of 0.12–0.25% [50]"/>
   <result pre="the capsid, envelope, NS2A, NS3, NS4B, and NS5 proteins of" exact="Zika" post="virus [51,52,53,54,55,56]. Addressing the issue of ADE, Dos Santos"/>
   <result pre="response by constructing a NS5-based peptide vaccines that targets both" exact="Zika" post="as well as Dengue viruses. Furthermore, Richner et al."/>
   <result pre="NS5-based peptide vaccines that targets both Zika as well as" exact="Dengue" post="viruses. Furthermore, Richner et al. (2017) [58] assembled modified"/>
   <result pre="Richner et al. (2017) [58] assembled modified prME mRNA of" exact="Zika" post="virus in lipid nanoparticles. The genetic modification allowed for"/>
   <result pre="VP7 surface glycoprotein and for more than 200 sequences of" exact="HPV" post="L1 capsid protein [61]. Subsequently, the conserved peptide regions"/>
   <result pre="al. (2017) [62] were able to identify and characterize four" exact="Zika" post="virus epitopes in the envelope protein for an effective"/>
   <result pre="AI may not be too far a goal [66]. The" exact="Zika" post="virus pandemic has eased considerably after the sudden eruption"/>
   <result pre="Principle and Alignment Free Sequence Descriptors in the Characterization of" exact="ZIKV" post="Sequences &quot;All cases are unique and very similar to"/>
   <result pre="The Cocktail Party As indicated in Section 1 above [1,9,17,27]," exact="Zika" post="virus is an evolving pathogen undergoing numerous changes during"/>
   <result pre="and gain new insights. For the comparison of sequences of" exact="ZIKV" post="we have used two classes of descriptors based on"/>
   <result pre="distribution in the sequence. Thus, a graphical representation of the" exact="Zika" post="virus whole genome sequence would look like the one"/>
   <result pre="gives an overview of the base distributions along the whole" exact="Zika" post="virus genome. It shows that while the structural genes"/>
   <result pre="the sequence. Table 4 shows the gR values of the" exact="Zika" post="virus genomic sequences in Africa, Asia, and South America"/>
   <result pre="more set and compact with time. A phylogenetic tree of" exact="Zika" post="virus sequences (Figure 2) also shows clear separation between"/>
   <result pre="the application are given in [78]. Clustering and Analysis of" exact="ZIKV" post="Sequences Clustering (grouping) and classification (categorization) of objects are"/>
   <result pre="areas of the globe (Africa, Asia, South America). Comparison of" exact="ZIKV" post="sequesters using calculated sequence descriptors follows the sequence (structure)-property"/>
   <result pre="PCA- and SOM-based clustering analysis using the orthogonal descriptors for" exact="ZIKV" post="sequences [81]. For PCA and SOM calculations, the standard"/>
   <result pre="[82]. The data set consists of 310 genome sequences of" exact="ZIKV" post="hosted in different species (83% in Homo sapiens, 17%"/>
   <result pre="inaccurate, and brilliant. Together they are powerful beyond imagination.�?Albert Einstein" exact="ZIKV" post="is a flavivirus family of infection transmitted by mosquitos."/>
   <result pre="concern for the infection heightened because of babies born from" exact="ZIKV" post="infected mothers showed microcephaly and neurological complications [84]. Since"/>
   <result pre="pharmacophores�?. Although no anti-Zika drug is currently available, several promising" exact="ZIKV" post="drug targets have been reported in recent years [90]."/>
   <result pre="[90]. These targets with compounds have shown potent activity against" exact="ZIKV" post="and its proteins. Non-structural (NS) flavivirus proteins are believed"/>
   <result pre="both replication and virion maturation [91]. Crystallographic structures of several" exact="ZIKV" post="related NS proteins are now available from protein structural"/>
   <result pre="and therapeutic antibodies have been identified and developed having anti-" exact="ZIKV" post="activity. However, most of these studies were in vitro"/>
   <result pre="nine vaccines reached phase I or II clinical trials against" exact="ZIKV" post="[97]. However, none of these compounds has yet been"/>
   <result pre="in recent years with the potential to be drugs for" exact="ZIKV" post="is presented in Table 6. In addition, the following"/>
   <result pre="targets that have been frequently implicated for potential discovery of" exact="ZIKV" post="drugs and are thus further discussed below. Viral proteins"/>
   <result pre="drugs and are thus further discussed below. Viral proteins as" exact="ZIKV" post="drug targets: Viral glycoproteins play important roles for virus"/>
   <result pre="In general, small molecules interfering with the function of any" exact="ZIKV" post="viral proteins should have the potential to restrict virus"/>
   <result pre="potential to restrict virus replication and prevent from progress of" exact="ZIKV" post="related pathogenesis and diseases. Envelope glycoprotein inhibitors too are"/>
   <result pre="in green tea has exhibited inhibition to the entry of" exact="ZIKV" post="into the host cell [114]. Protease inhibitors: ZIKV being"/>
   <result pre="entry of ZIKV into the host cell [114]. Protease inhibitors:" exact="ZIKV" post="being a flavivirus also possesses the NS2B-NS3 protease. Many"/>
   <result pre="protease and surprisingly, some of them were found to inhibit" exact="ZIKV" post="protease activity [108,115]. NS3 helicase inhibitors: These inhibitors bind"/>
   <result pre="are experimentally validated [116]. NS4B inhibitors: Very few studies on" exact="ZIKV" post="NS4B protein inhibition are performed so far, mainly because"/>
   <result pre="developing resistant viruses [117,118,119]. NS5 methyltransferase inhibitors: The structure of" exact="ZIKV" post="MTase with the S-adenosyl-L-methionine (SAM) analog, sinefungin was recently"/>
   <result pre="values &amp;lt;10 mM [110]. Host proteins as drug targets: Since" exact="ZIKV" post="like other flaviviruses contains a small genome, the host"/>
   <result pre="the viral protein functions could be an attractive target for" exact="ZIKV" post="drug discovery. Moreover, broad-spectrum strategy to target host cell"/>
   <result pre="inhibit the virus-induced cytopathic effects (CPE) of several flaviviruses, including" exact="ZIKV" post="(EC50 = 142.9 mg/mL) [126]. However, poor inhibition of"/>
   <result pre="indicates that it is not a suitable candidate as a" exact="ZIKV" post="drug [111]. Other tested nucleoside biosynthesis inhibitors showed better"/>
   <result pre="promising lead candidates for further development particularly as antivirals against" exact="ZIKV" post="[127]. BCX4430 an adenosine nucleoside analog has shown EC50"/>
   <result pre="from mortality induced by a Malaysian strain (P 6–740) of" exact="ZIKV" post="[128]. This protective efficacy of BCX4430 encourages its further"/>
   <result pre="an adenosine nucleoside analog, has also exhibited antiviral activity against" exact="ZIKV" post="in vitro with EC50 at the sub-micro molar range"/>
   <result pre="of a compound library of 100,000 small molecules based on" exact="Zika" post="RNA-dependent RNA polymerase (RdRp) structure, ten lead compounds were"/>
   <result pre="these compounds, 3-chloro-N-[(amino)carbonothioyl]-1-benzothiophene-2-carbox-amide (TPB), a non-nucleoside, was found to inhibit" exact="ZIKV" post="replication with an EC50 in submicromolar concentration (0.94 μM)"/>
   <result pre="that the compound binds to the catalytic site of the" exact="ZIKV" post="RdRp, acting as an allosteric agent to block the"/>
   <result pre="vivo studies (25 mg/kg) in animals (immunocompetent mice) infected with" exact="ZIKV" post="and treating with the compound, TPB showed a reduction"/>
   <result pre="h. Thus, TPB appears to be a promising compound against" exact="ZIKV" post="infection [130]. Another non-nucleoside inhibitor, emetine was reported to"/>
   <result pre="[130]. Another non-nucleoside inhibitor, emetine was reported to potently inhibit" exact="ZIKV" post="NS5 RNA polymerase activity by binding to its active"/>
   <result pre="and significantly reduced the levels of both NS1 protein and" exact="ZIKV" post="RNA in serum and liver, respectively [131]. Host cell"/>
   <result pre="Host cell lipid biosynthesis inhibitors: Viral infections including dengue and" exact="ZIKV" post="are known to be associated with alterations in the"/>
   <result pre="pathway of cholesterol could be an attractive therapeutic approach for" exact="ZIKV" post="drug discovery. As a part of cell-based screening of"/>
   <result pre="FDA-approved drugs, Lovastatin, an HMG-CoA reductase inhibitor was tested against" exact="ZIKV" post="and found to be potent through a dose–response assay"/>
   <result pre="discover PHA-690509, a cyclin- dependent kinase inhibitor (CDKi), that inhibited" exact="ZIKV" post="infection with an EC50 value of 1.72 mM [94]."/>
   <result pre="tested by the group to identify nine that could inhibit" exact="ZIKV" post="replication. Among these inhibitors, seliciclib (a purine analog, also"/>
   <result pre="also known as roscovitine) and RGB-286147 were found to inhibit" exact="ZIKV" post="infection at sub micro molar concentrations [95]. From these"/>
   <result pre="that one or more host CDKs might be important for" exact="ZIKV" post="replication process as flaviviruses are not known to encode"/>
   <result pre="uncontrolled) to be a target for discovery of compounds against" exact="ZIKV" post="infection [137]. The inhibitors for the receptor seem to"/>
   <result pre="only one known disruptor, celgosvir (6-O-buta-noyl castanospermine) was tested against" exact="ZIKV" post="that showed poor activity in a CPE- based assay"/>
   <result pre="yet fully understood [141]. It was identified through screening against" exact="ZIKV" post="in SNB-19 cells showing an EC50 value of 0.37"/>
   <result pre="has yet been approved by FDA for the treatment of" exact="ZIKV" post="infection, numerous small molecules have been identified that have"/>
   <result pre="which may provide completely new class of antiviral drugs including" exact="Zika" post="drugs. The approaches should include knowledge-based drug repurposing [143],"/>
   <result pre="against ZIKV. Pursuit of repurposing strategy on known drugs against" exact="ZIKV" post="revealed that a few antimalarial drugs do possess anti-ZIKV"/>
   <result pre="antimalarial aminoquinolines, Quinacrine (QC), Mefloquine (MQ), and GSK369796 active against" exact="ZIKV" post="in in vitro assay [41]. Activities against ZIKV of"/>
   <result pre="active against ZIKV in in vitro assay [41]. Activities against" exact="ZIKV" post="of the three aminoquinolines were found to be: EC50"/>
   <result pre="to reduce filovirus infections in vitro and in vivo, including" exact="DENV" post="infection [160]. Therefore, these novel host-based targets have the"/>
   <result pre="siRNA [144] and interacting peptides [147] could be useful for" exact="ZIKV" post="drug discovery. In silico structural-bioinformatics-based methodologies and frameworks have"/>
   <result pre="and frameworks have also been developed for the design of" exact="ZIKV" post="antibodies. One of these methodologies deals with RosettaAntibodyDesign (RAbD)"/>
   <result pre="we’ve got to think.�?Ernest Rutherford This review article on the" exact="Zika" post="virus covers the following stages of modern computer-assisted approaches"/>
   <result pre="following stages of modern computer-assisted approaches in the characterization of" exact="Zika" post="virus, risk assessment, and the prevention as well as"/>
   <result pre="characterization: modelling of disease spread mechanisms, vectors, and reservoirs of" exact="ZIKV" post="(and emerging pathogens in general); (b)Internal characterization: bioinformatics-based sequence"/>
   <result pre="stages provide a holistic and proactive step-by-step approach toward combating" exact="ZIKV" post="and potential future pathogens using computational methods. 5.1. Quantitative"/>
   <result pre="potential future pathogens using computational methods. 5.1. Quantitative Characterization of" exact="ZIKV" post="Infection In the realm of mathematical epidemiology discussed in"/>
   <result pre="the SIR model have been explored for the prediction of" exact="ZIKV" post="infection [30,31,32,33,34,35,36]. Besides SIR-type models, public health management in"/>
   <result pre="and associated computational tools. Because viruses are very complex (e.g.," exact="ZIKV" post="has around 11,000 bases in its RNA), the sequences"/>
   <result pre="5) the results on applications of alignment-free methods to the" exact="Zika" post="virus based on the structure (sequence)-property similarity principle [79]"/>
   <result pre="of the orthogonal variables or PCs derived from the calculated" exact="ZIKV" post="RNA sequence descriptors is evident from the PC1 versus"/>
   <result pre="plot in Figure 4 which can clearly separate the African" exact="ZIKV" post="sequences from those from Asia and South America. With"/>
   <result pre="the SOM approach (Figure 5) is even more interesting. Here" exact="ZIKV" post="sequences from various countries and regions are clearly separated"/>
   <result pre="and pathogenicity. 5.3. Computer-Assisted Vaccine Design Development of vaccines against" exact="ZIKV" post="is being attempted. But as of now, no vaccine"/>
   <result pre="as of now, no vaccine is available for use in" exact="Zika" post="Virus infected patients. Traditional vaccine development methods with its"/>
   <result pre="made to assist in this agenda, and designs for a" exact="Zika" post="virus vaccine have already been advanced using these procedures"/>
   <result pre="sphere. 5.4. Anti-Zika Drug Discovery Since a 3D structure of" exact="ZIKV" post="protein is now known, discovery for potential anti ZIKV"/>
   <result pre="of ZIKV protein is now known, discovery for potential anti" exact="ZIKV" post="drugs can be accomplished through a combination of structure-based"/>
   <result pre="important to note that even though the 3D structure of" exact="ZIKV" post="proteins are known, specific features, such as polarization factors,"/>
   <result pre="addition, alternative targets of established 3D protein structures implicated for" exact="ZIKV" post="proteins should also be explored for ZIKV drugs. Although"/>
   <result pre="structures implicated for ZIKV proteins should also be explored for" exact="ZIKV" post="drugs. Although pharmacophore modeling has demonstrated many successes in"/>
   <result pre="summary, it may be commented that for accomplishing a successful" exact="ZIKV" post="drug discovery program, the research team should have good"/>
   <result pre="review for vaccine design; T.D. did the computation of the" exact="Zika" post="genome data for the gR values for all 310"/>
   <result pre="for all 310 sequences available; M.V. performed clustering analysis of" exact="ZIKV" post="sequences; S.C.B., S.M., A.N., A.K.B. wrote the manuscript. Funding"/>
   <result pre="−0.07488 −0.03129 References References 1.World Health Organization (WHO) Report on" exact="Zika" post="VirusAvailable online: http://www.who.int/emergencies/zika-virus/mediacentre/press-releases/en/(accessed on 7 July 2019) 2.MacNamaraF.N.Zika virus:"/>
   <result pre="History, Emergence, Biology, and Prospects for ControlAntiviral Res.2016130698010.1016/j.antiviral.2016.03.01026996139 5.MarchetteN.J.GarciaR.RudnickA.Isolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm. J. Trop."/>
   <result pre="R. Soc. Trop. Med. Hyg.19817538939310.1016/0035-9203(81)90100-06275577 7.LiangD.LeungR.K.K.LeeS.S.KamK.M.Insights into intercontinental spread of" exact="Zika" post="virusPLoS ONE201712e017671010.1371/journal.pone.017671028448611 8.WHO Report on Zika VIRUS, Microcephaly and"/>
   <result pre="into intercontinental spread of Zika virusPLoS ONE201712e017671010.1371/journal.pone.017671028448611 8.WHO Report on" exact="Zika" post="VIRUS, Microcephaly and Guillain–Barré SyndromeAvailable online: http://apps.who.int/iris/bitstream/handle/10665/204609/zikasitrep_10Mar2016_eng.pdf;jsessionid=F9E4895E6176562081D34C0DED1A6550?sequence=1(accessed on 7"/>
   <result pre="on 7 July 2019) 9.NandyA.BasakS.C.The Epidemic that Shook the World—The" exact="Zika" post="Virus RampageExplor. Res. Hypothesis Med.20172435610.14218/ERHM.2017.00018 10.ArmstrongN.HouW.TangQ.Biological and historical overview"/>
   <result pre="Virus RampageExplor. Res. Hypothesis Med.20172435610.14218/ERHM.2017.00018 10.ArmstrongN.HouW.TangQ.Biological and historical overview of" exact="Zika" post="virusWorld J. Virol.201761810.5501/wjv.v6.i1.128239566 11.FayeO.FreireC.C.M.IamarinoA.FayeO.de OlivieraJ.V.C.DialloM.ZanottoP.M.A.SallA.A.Molecular Evolution of Zika Virus"/>
   <result pre="overview of Zika virusWorld J. Virol.201761810.5501/wjv.v6.i1.128239566 11.FayeO.FreireC.C.M.IamarinoA.FayeO.de OlivieraJ.V.C.DialloM.ZanottoP.M.A.SallA.A.Molecular Evolution of" exact="Zika" post="Virus during Its Emergence in the 20th CenturyPLoS Negl."/>
   <result pre="16.SutharM.S.DiamondM.S.GaleM.Jr.West Nile virus infection and immunityNat. Rev. Microbiol.20131111512810.1038/nrmicro295023321534 17.NandyA.DeyS.BasakS.C.Bielinska-WazD.WazP.Characterizing the" exact="Zika" post="Virus Genome—A Bioinformatics StudyCurr. Comp. Aided Drug Des.201612879710.2174/1573409912666160401115812 18.KindhauserM.K.AllenT.FrankV.SanthanaR.S.DyeC.Zika:"/>
   <result pre="a mosquito-borne virusBull. World Health Organ.20169467568610.2471/BLT.16.17108227708473 19.WHO Situation Report on" exact="Zika" post="Virus, 9th March 2017Available online: http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf(accessed on 7 July"/>
   <result pre="on 3 September 2019) 22.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 23.ParraB.LizarazoJ.JorgeA.Jimenez-ArangoJ.A.Zea-VaraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.et"/>
   <result pre="French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 23.ParraB.LizarazoJ.JorgeA.Jimenez-ArangoJ.A.Zea-VaraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.et al.Guillain–Barré Syndrome Associated with" exact="Zika" post="Virus Infection in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 24.Zika Virus"/>
   <result pre="29.HethcoteH.The Mathematics of Infectious DiseasesSIAM Rev.20004259965310.1137/S0036144500371907 30.SuparitP.WiratsudakulA.ModchangC.A mathematical model for" exact="Zika" post="virus transmission dynamics with a time-dependent mosquito biting rateTheor."/>
   <result pre="Med. Model.2018151110.1186/s12976-018-0083-z30064447 31.NishiuraH.MizumotoK.Villamil-GomezW.E.Rodriguez-MoralesA.J.Preliminary estimation of the basic reproduction number of" exact="Zika" post="virus infection during Colombia epidemic, 2015–2016Trav. Med. Infect. Dis.20161427427610.1016/j.tmaid.2016.03.01627060613"/>
   <result pre="virus associated with microcephalyN. Eng. J. Med.201637495195810.1056/NEJMoa160065126862926 33.AgustoF.B.BewickS.FaganW.F.Mathematical model of" exact="Zika" post="virus with vertical transmissionInfect. Dis. Model.20172324426710.1016/j.idm.2017.05.00329928740 34.PadmanabhanP.SeshaiyerP.Castillo-ChavezC.Mathematical modeling, analysis"/>
   <result pre="Model.20172324426710.1016/j.idm.2017.05.00329928740 34.PadmanabhanP.SeshaiyerP.Castillo-ChavezC.Mathematical modeling, analysis and simulation of the spread of" exact="Zika" post="with influence of sexual transmission and preventive measuresLett. Bioinform.2017414816610.1080/23737867.2017.1319746"/>
   <result pre="Strategies to Combat the MenaceBasakS.C.BhattacharjeeA.K.NandyA.NovaNew York, NY, USA2019129152 36.WiratsudakulA.SuparitP.ModchangC.Dynamics of" exact="Zika" post="virus outbreaks: An overview of mathematical modeling approachesPeerJ20186e452610.7717/peerj.452629593941 37.HanB.MajumdarS.CalmonF.P.GlicksbergB.S.HoreshR.KumarA.PererA.von"/>
   <result pre="37.HanB.MajumdarS.CalmonF.P.GlicksbergB.S.HoreshR.KumarA.PererA.von MarschallE.B.WeiD.MojsilovicA.et al.Confronting data sparsity to identify potential sources of" exact="Zika" post="virus spillover infection among primatesEpidemics201927596510.1016/j.epidem.2019.01.00530902616 38.SahooM.JenaL.DafS.KumarS.Virtual Screening for Potential"/>
   <result pre="primatesEpidemics201927596510.1016/j.epidem.2019.01.00530902616 38.SahooM.JenaL.DafS.KumarS.Virtual Screening for Potential Inhibitors of NS3 Protein of" exact="Zika" post="VirusGenomics Inform.20161410411110.5808/GI.2016.14.3.10427729840 39.SinghA.JanaN.K.Discovery of potential Zika virus RNA polymerase"/>
   <result pre="of NS3 Protein of Zika VirusGenomics Inform.20161410411110.5808/GI.2016.14.3.10427729840 39.SinghA.JanaN.K.Discovery of potential" exact="Zika" post="virus RNA polymerase inhibitors by docking-based virtual screeningComp. Biol."/>
   <result pre="activities of selected antimalarials against dengue virus type 2 and" exact="Zika" post="virusAntivir. Res.201713714115010.1016/j.antiviral.2016.11.01527889529 42.SinigagliaA.RiccettiS.TrevisanM.BarzonL.In silico approaches to Zika virus drug"/>
   <result pre="type 2 and Zika virusAntivir. Res.201713714115010.1016/j.antiviral.2016.11.01527889529 42.SinigagliaA.RiccettiS.TrevisanM.BarzonL.In silico approaches to" exact="Zika" post="virus drug discoveryExpert Opin. Drug Discov.20181382583510.1080/17460441.2018.151590930160181 43.LucaS.MihaescuT.History of BCG"/>
   <result pre="brief reviewInt. J. Gen. Med.2009219520010.2147/IJGM.S628120360904 47.GuyB.GuirakhooF.BarbanV.HiggsS.MonathT.P.LangJ.Preclinical and clinical development of" exact="YFV" post="17D-based chimeric vaccines against dengue, West Nile and Japanese"/>
   <result pre="and clinical development of YFV 17D-based chimeric vaccines against dengue," exact="West Nile" post="and Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 48.WHO Vaccine Pipeline TrackerAvailable online:"/>
   <result pre="al.Computational prediction and analysis of potential antigenic CTL epitopes in" exact="Zika" post="virus: A first step towards vaccine developmentInfect. Genet. Evol.20164518719710.1016/j.meegid.2016.08.03727590716"/>
   <result pre="and Immunoinformatics Probing Disclose the Epitope Based Peptide Vaccine Against" exact="Zika" post="Virus Envelope GlycoproteinInd. J. Pharma. Biol. Res.201424457 54.MirzaM.U.RafiqueS.AliA.MunirM.IkramN.MananA.Salo-AhenO.M.H.IdreesM.Towards peptide"/>
   <result pre="Envelope GlycoproteinInd. J. Pharma. Biol. Res.201424457 54.MirzaM.U.RafiqueS.AliA.MunirM.IkramN.MananA.Salo-AhenO.M.H.IdreesM.Towards peptide vaccines against" exact="Zika" post="virus: Immunoinformatics combined with molecular dynamics simulations to predict"/>
   <result pre="combined with molecular dynamics simulations to predict antigenic epitopes of" exact="Zika" post="viral proteinsSci. Rep.201663731310.1038/srep4463327934901 55.DeyS.DasS.NandyA.Characterization of Zika and Other Human"/>
   <result pre="predict antigenic epitopes of Zika viral proteinsSci. Rep.201663731310.1038/srep4463327934901 55.DeyS.DasS.NandyA.Characterization of" exact="Zika" post="and Other Human Infecting Flavivirus Envelope Proteins and Determination"/>
   <result pre="Epitope RegionsEC Microbiol.201782946 56.DarH.ZaheerT.RehmanM.T.AliA.JavedA.KhanG.A.BabarM.M.WaheedY.Prediction of promiscuous T-cell epitopes in the" exact="Zika" post="virus polyprotein: An in silico approachAsian Pac. J. Trop."/>
   <result pre="Trop. Med.2016984485010.1016/j.apjtm.2016.07.00427633296 57.Dos Santos FrancoL.Oliveira VidalP.AmorimJ.H.In silico design of a" exact="Zika" post="virus non-structural protein 5 aiming vaccine protection against zika"/>
   <result pre="human populationsJ. Biomed. Sci.2017248810.1186/s12929-017-0395-z29169357 58.RichnerJ.M.HimansuS.DowdK.A.ButlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.et al.Modified mRNA vaccines protect against" exact="Zika" post="virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 59.NandyA.GhoshA.NandyP.Numerical characterization of protein sequences and application"/>
   <result pre="of Human PapillomavirusCancer Inform.20161511610.4137/CIN.S39071 62.DeyS.NandyA.BasakS.C.NandyP.DasS.A Bioinformatics approach to designing a" exact="Zika" post="virus vaccineComput. Biol. Chem.20176814315210.1016/j.compbiolchem.2017.03.00228342423 63.CellisE.Getting peptide vaccines to work:"/>
   <result pre="ChoudhuryA.ZhukovN.VrackoM.Mathematical Characterization of Protein Transmembrane RegionsSci. World. J.2013201360783010.1155/2013/60783023690747 81.VrackoM.BasakS.C.NandyA.SenD.Clustering of" exact="Zika" post="viruses originating from different geographical regions using computational sequence"/>
   <result pre="drug development parametersCurr. Opin. Drug Discov.20011210210910.1124/pr.112.007336 90.MottinM.BorbaJ.V.V.B.BragaR.C.TorresP.H.M.MartiniM.C.Proenca-ModenaJ.L.JudiceC.C.CostaF.T.M.EkinsS.PerrymanA.L.et al.The A–Z of" exact="Zika" post="drug discoveryDrug Discov. Today20182310.1016/j.drudis.2018.06.01429935345 91.WattersonD.ModhiranN.YoungP.R.The many faces of the"/>
   <result pre="Res.20002823524210.1093/nar/28.1.23510592235 93.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MuñozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A screen of FDA-approved drugs for inhibitors of" exact="Zika" post="virus infectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 94.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors"/>
   <result pre="virus infectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 94.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
   <result pre="libraryF1000Research20165252310.12688/f1000research.9648.127909576 96.ZhuS.ZhangC.HuangL.S.ZhangX.Q.XuY.FangX.ZhouJ.WuM.SchooleyR.T.HuangZ.et al.Discovery and Computational Analyses of Novel Small Molecule" exact="Zika" post="Virus InhibitorsMolecules201924146510.3390/molecules24081465 97.Wilder-SmithA.VanniceK.DurbinA.HombachJ.ThomasS.J.ThevarjanI.SimmonsC.P.Zika vaccines and therapeutics: Landscape analysis and"/>
   <result pre="challenges aheadBMC Med.2018168410.1186/s12916-018-1067-x29871628 98.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.M.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v812032227916837 99.DevillersJ.Repurposing drugs for"/>
   <result pre="Infection in Different Cell ModelsViruses2016832210.3390/v812032227916837 99.DevillersJ.Repurposing drugs for use against" exact="Zika" post="virus infectionSAR QSAR Environ. Res.20182910311510.1080/1062936X.2017.141164229299939 100.OguntadeS.RamharackP.SolimanM.E.S.Characterizing the ligand-binding landscape"/>
   <result pre="virus infectionSAR QSAR Environ. Res.20182910311510.1080/1062936X.2017.141164229299939 100.OguntadeS.RamharackP.SolimanM.E.S.Characterizing the ligand-binding landscape of" exact="Zika" post="NS3 helicase-promising lead compounds as potential inhibitorsFuture Virol.20171226127310.2217/fvl-2017-0014 101.HercíkK.KozakJ.SalaM.DejmekM.XuL.BeiZ.ZhangD.DouY.WangH.Viral"/>
   <result pre="101.HercíkK.KozakJ.SalaM.DejmekM.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of" exact="Zika" post="virus replicationAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 102.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to"/>
   <result pre="virus replicationAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 102.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to Combat" exact="Zika" post="Virus: Current Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 103.EkinsS.MietchenD.CoffeeM.StrattonT.P.FreundlichJ.S.Freitas-JuniorL.MuratovE.Siqueira-NetoJ.WilliamsA.J.AndradeC.Open drug"/>
   <result pre="Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 103.EkinsS.MietchenD.CoffeeM.StrattonT.P.FreundlichJ.S.Freitas-JuniorL.MuratovE.Siqueira-NetoJ.WilliamsA.J.AndradeC.Open drug discovery fore the" exact="Zika" post="virusF1000Research2016515010.12688/f1000research.8013.127134728 104.MicewiczE.D.KhachatoorianR.FrenchS.W.RuchalaP.Identification of novel small-molecule inhibitors of Zika virus"/>
   <result pre="fore the Zika virusF1000Research2016515010.12688/f1000research.8013.127134728 104.MicewiczE.D.KhachatoorianR.FrenchS.W.RuchalaP.Identification of novel small-molecule inhibitors of" exact="Zika" post="virus infectionBioorg. Med. Chem. Lett.20182845245810.1016/j.bmcl.2017.12.01929258771 105.NcubeN.B.RamharackP.SolimanM.E.S.An &quot;All-In-One�? Pharmacophoric Architecture"/>
   <result pre="Biotechnol.201818579981410.1007/s12010-017-2690-229349531 106.SarukhanyanE.ShityakovS.DandekarT.In Silico Designed Axl Receptor Blocking Drug Candidates Against" exact="Zika" post="VirusACS Omega201835281529010.1021/acsomega.8b0022330023915 107.PanT.PengZ.TanL.ZouF.ZhouN.LiuB.LiangL.ChenC.LiuJ.WuL.Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication"/>
   <result pre="VirusACS Omega201835281529010.1021/acsomega.8b0022330023915 107.PanT.PengZ.TanL.ZouF.ZhouN.LiuB.LiangL.ChenC.LiuJ.WuL.Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication of" exact="Zika" post="Viruses by Inducing the Degradation of AXLJ. Virol.2018269210.1128/JVI.01018-1830068645 108.LimH.J.NguyenT.T.KimN.M.ParkJ.S.JangT.J.KimD.Inhibitory"/>
   <result pre="structure activity relationshipBiotechnol. Lett.20173941544210.1007/s10529-016-2261-627885509 109.JainR.ColomaJ.Garcia-SastreA.AggarwalA.K.Structure of the NS3 helicase from" exact="Zika" post="virusNat. Struct. Mol. Biol.20162375275410.1038/nsmb.325827399257 110.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RůžekD.Nucleoside Inhibitors of"/>
   <result pre="Zika virusNat. Struct. Mol. Biol.20162375275410.1038/nsmb.325827399257 110.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RůžekD.Nucleoside Inhibitors of" exact="Zika" post="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 111.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of Zika virus methyltransferase"/>
   <result pre="ClercqE.RůžekD.Nucleoside Inhibitors of Zika VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 111.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of" exact="Zika" post="virus methyltransferase inhibition by sinefunginArch. Virol.20171622091209610.1007/s00705-017-3345-x28357511 112.AdcockR.S.ChuY.K.GoldenJ.E.ChungD.H.Evaluation of anti-Zika"/>
   <result pre="high-throughput screen assayAntivir. Res.2017138475610.1016/j.antiviral.2016.11.01827919709 113.HanY.MesplèdeT.Investigational drugs for the treatment of" exact="Zika" post="virus infection: A preclinical and clinical updateExpert Opin. Investig."/>
   <result pre="updateExpert Opin. Investig. Drugs20182795196210.1080/13543784.2018.1548609 114.CarneiroB.M.BatistaM.N.BragaA.C.S.NogueiraM.L.RahalP.The green tea molecule EGCG inhibits" exact="Zika" post="virus entryVirology201649621521810.1016/j.virol.2016.06.01227344138 115.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of Zika NS2B-NS3pro and its"/>
   <result pre="tea molecule EGCG inhibits Zika virus entryVirology201649621521810.1016/j.virol.2016.06.01227344138 115.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
   <result pre="restricts genomic RNA replicationAntivir. Res.20139916517110.1016/j.antiviral.2013.05.01123735301 120.StephenP.BazM.BolvinG.LinS.X.Structural insight into NS5 of" exact="Zika" post="virus leading to the discovery of MTase inhibitorsJ. Am."/>
   <result pre="Targets2016171560157610.2174/138945011766615120912375126648061 128.JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.et al.Efficacy of the broad-spectrum antiviral compound BCX4430 against" exact="Zika" post="virus in cell culture and in a mouse modelAntivir."/>
   <result pre="modelAntivir. Res.2017137142210.1016/j.antiviral.2016.11.00327838352 129.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.-N.XieX.-P.ShiP.-Y.QinC.-F.Adenosine analog NITD008 is a potent inhibitor of" exact="Zika" post="virusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 130.PattnaikA.PalermoN.SahooB.R.YuanZ.HuD.AnnamalaiA.S.VuH.L.X.CorreasI.PrathipatiP.K.DestacheC.J.et al.Discovery of a non-nucleoside"/>
   <result pre="130.PattnaikA.PalermoN.SahooB.R.YuanZ.HuD.AnnamalaiA.S.VuH.L.X.CorreasI.PrathipatiP.K.DestacheC.J.et al.Discovery of a non-nucleoside RNA polymerase inhibitor for blocking" exact="Zika" post="virus replication through in silico screeningAntivir. Res.2018151788610.1016/j.antiviral.2017.12.01629274845 131.YangS.XuM.LeeE.M.ShiryaevS.A.HeS.SunW.ChengY.-S.HuX.TharappelA.M.LuB.et al.Emetine"/>
   <result pre="virus replication through in silico screeningAntivir. Res.2018151788610.1016/j.antiviral.2017.12.01629274845 131.YangS.XuM.LeeE.M.ShiryaevS.A.HeS.SunW.ChengY.-S.HuX.TharappelA.M.LuB.et al.Emetine inhibits" exact="Zika" post="and Ebola virus infections through two molecular mechanisms: Inhibiting"/>
   <result pre="response and autophagyFront. Microbiol.201451710.3389/fmicb.2014.0026624478763 140.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit" exact="Zika" post="virus infection in vitro and differentially affect cellular signaling,"/>
   <result pre="with broad antiviral effectsPLoS Pathog.20128e100297610.1371/journal.ppat.100297623133371 142.ChengF.MurrayJ.L.RubinD.H.Drug repurposing: New treatments for" exact="Zika" post="virus infection?Trends Mol. Med.20162291992110.1016/j.molmed.2016.09.00627692879 143.YangH.T.JuJ.H.WongY.T.ShmulevichI.ChiangJ.H.Literature-based discovery of new candidates"/>
   <result pre="of new candidates for drug repurposingBrief Bioinform.20171848849710.1093/bib/bbw03027113728 144.GiuliettiM.RighettiA.CianfrugliaL.ŠabanovićB.ArmeniT.PrincipatoG.PivaF.To accelerate the" exact="Zika" post="beat: Candidate design for RNA interference-based therapyVirus Res.201825513314010.1016/j.virusres.2018.07.01030031046 145.MengX.Y.LuoY.AnwarM.N.SunY.GaoY.ZhangH.MunirM.QiuH.-J.Long"/>
   <result pre="predicted human-Zika virus protein-protein interactionsComput. Biol. Chem.20177118018710.1016/j.compbiolchem.2017.10.01129112936 148.GoertzG.P.AbboS.R.FrosJ.J.PijlmanG.P.Functional RNA during" exact="Zika" post="virus 980 infectionVirus Res.2017254415310.1016/j.virusres.2017.08.01528864425 149.HermannT.Small molecules targeting viral RNAWiley"/>
   <result pre="by Flaviviridae virusesFront. Microbiol.20167123310.3389/fmicb.2016.0123327610098 155.LiC.ZhuX.JiX.QuanquinN.DengY.-Q.TianM.AliyariR.ZuoX.YuanL.AfridiS.K.et al.Chloroquine, a FDA-approved drug, prevents" exact="Zika" post="Virus infection and its associated congenital microcephaly in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372"/>
   <result pre="in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug chloroquine for" exact="Zika" post="virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial drug amodiaquine"/>
   <result pre="al.High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit" exact="Zika" post="virus infection in fetal-like organoids and adult brainCell Stem"/>
   <result pre="brainCell Stem Cell20172127428310.1016/j.stem.2017.06.01728736217 159.CaoB.ParnellL.A.DiamondM.S.MysorekarI.U.Inhibition of autophagy limits vertical transmission of" exact="Zika" post="virus in pregnant miceJ. Exp. Med.20172142303231310.1084/jem.2017095728694387 160.WarfieldK.L.WarrenT.K.QiuX.WellsJ.MireC.E.GeisbertJ.B.StuthmanK.S.GarzaN.L.Van TongerenS.A.ShurtleffA.C.et al.Assessment"/>
   <result pre="invertebrate hosts’Phil. Trans. R. Soc. B201437010.1098/rstb.2014.030725750231 168.GaoD.LouY.HeD.PorcoT.C.KuangY.ChowellG.RuanS.Prevention and Control of" exact="Zika" post="as a Mosquito-Borne and Sexually Transmitted Disease: A Mathematical"/>
   <result pre="Attribution License from [12]. Figure 2 Phylogenetic tree of 22" exact="ZIKV" post="genome sequences [17]. Each sequence is identified with its"/>
   <result pre="Publishers, www.benthamscience.com. Figure 3 The 2D graphical representation of the" exact="Zika" post="virus whole genome (GenBank Locus ID KY241706), methodology as"/>
   <result pre="y-axis. Figure 4 Principal component analysis (PCA) score plots of" exact="ZIKV" post="strains from different continents. Figure 5 Distribution of objects"/>
   <result pre="flavivirus genome including UTRs. Typical sequence length data taken from" exact="ZIKV" post="isolate ZIKV/H. sapiens/Brazil/PE243/2015 (GenBank Locus ID KX197192), complete genome."/>
   <result pre="and translation. pharmaceuticals-12-00157-t002_Table 2Table 2 The pre-epidemics period of the" exact="Zika" post="virus after its detection in 1947. A. africanus: Aedes"/>
   <result pre="after its detection in 1947. A. africanus: Aedes africanus; ZIKV:" exact="Zika" post="virus. Year Country Remarks 1947 Uganda First isolation and"/>
   <result pre="identification of ZIKV. Found in rhesus monkey, R766, caged in" exact="Zika" post="forest. 1948 Uganda Detected in A. africanus mosquitoes. Found"/>
   <result pre="forest. 1948 Uganda Detected in A. africanus mosquitoes. Found in" exact="Zika" post="forest. 1951 Nigeria First instance of ZIKV antibodies in"/>
   <result pre="mosquitoes. Found in Zika forest. 1951 Nigeria First instance of" exact="ZIKV" post="antibodies in human blood, found in children. 1952 Uganda,"/>
   <result pre="found in children. 1952 Uganda, Tanganyika First human cases of" exact="ZIKV" post="infection detected. India ZIKV antibodies found in human blood."/>
   <result pre="Uganda, Tanganyika First human cases of ZIKV infection detected. India" exact="ZIKV" post="antibodies found in human blood. 1953 Malaya, North Borneo,"/>
   <result pre="antibodies found in human blood. 1953 Malaya, North Borneo, Philippines" exact="ZIKV" post="antibodies found in residents. Nigeria ZIKV infection detected in"/>
   <result pre="Malaya, North Borneo, Philippines ZIKV antibodies found in residents. Nigeria" exact="ZIKV" post="infection detected in three persons. 1954 Egypt, Vietnam ZIKV"/>
   <result pre="Nigeria ZIKV infection detected in three persons. 1954 Egypt, Vietnam" exact="ZIKV" post="antibodies found in few residents. 1955 Nigeria ZIKV antibodies"/>
   <result pre="Egypt, Vietnam ZIKV antibodies found in few residents. 1955 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1957 Mozambique ZIKV antibodies"/>
   <result pre="1955 Nigeria ZIKV antibodies found in human blood. 1957 Mozambique" exact="ZIKV" post="antibodies found in human blood. 1958 Uganda Two strains"/>
   <result pre="antibodies found in human blood. 1958 Uganda Two strains of" exact="ZIKV" post="found in A. aegypti mosquitoes in Zika forest. 1960"/>
   <result pre="Two strains of ZIKV found in A. aegypti mosquitoes in" exact="Zika" post="forest. 1960 Angola ZIKV antibodies found in indigenous residents."/>
   <result pre="found in A. aegypti mosquitoes in Zika forest. 1960 Angola" exact="ZIKV" post="antibodies found in indigenous residents. 1961–1962 Central African Republic"/>
   <result pre="ZIKV antibodies found in indigenous residents. 1961–1962 Central African Republic" exact="ZIKV" post="antibodies found in human blood. 1961–1964 Ethiopia ZIKV antibodies"/>
   <result pre="African Republic ZIKV antibodies found in human blood. 1961–1964 Ethiopia" exact="ZIKV" post="antibodies found in human blood. 1962 Senegal ZIKV antibodies"/>
   <result pre="1961–1964 Ethiopia ZIKV antibodies found in human blood. 1962 Senegal" exact="ZIKV" post="antibodies found in human blood. 1963–1964 Central African Republic,"/>
   <result pre="antibodies found in human blood. 1963–1964 Central African Republic, Burkina-Faso" exact="ZIKV" post="antibodies found in human blood. 1963–1965 Ivory Coast ZIKV"/>
   <result pre="Burkina-Faso ZIKV antibodies found in human blood. 1963–1965 Ivory Coast" exact="ZIKV" post="antibodies found in human blood. 1964 Uganda First confirmation"/>
   <result pre="antibodies found in human blood. 1964 Uganda First confirmation that" exact="ZIKV" post="causes human disease.Clinical features reported. 1964–1965 Guinea-Bissau ZIKV antibodies"/>
   <result pre="confirmation that ZIKV causes human disease.Clinical features reported. 1964–1965 Guinea-Bissau" exact="ZIKV" post="antibodies found in human blood. 1964–1966 Togo, Cameroon ZIKV"/>
   <result pre="Guinea-Bissau ZIKV antibodies found in human blood. 1964–1966 Togo, Cameroon" exact="ZIKV" post="antibodies found in human blood. 1965 Niger ZIKV antibodies"/>
   <result pre="Togo, Cameroon ZIKV antibodies found in human blood. 1965 Niger" exact="ZIKV" post="antibodies found in human blood. 1965–1967 Nigeria ZIKV antibodies"/>
   <result pre="1965 Niger ZIKV antibodies found in human blood. 1965–1967 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1967 Benin, Gabon, Liberia"/>
   <result pre="ZIKV antibodies found in human blood. 1967 Benin, Gabon, Liberia" exact="ZIKV" post="antibodies found in human blood. 1966–1967 Uganda, Kenya, Somalia,"/>
   <result pre="antibodies found in human blood. 1966–1967 Uganda, Kenya, Somalia, Morocco" exact="ZIKV" post="antibodies found in human blood. 1967–1969 Uganda ZIKV antibodies"/>
   <result pre="Somalia, Morocco ZIKV antibodies found in human blood. 1967–1969 Uganda" exact="ZIKV" post="antibodies found in human blood. 1968 Kenya ZIKV antibodies"/>
   <result pre="1967–1969 Uganda ZIKV antibodies found in human blood. 1968 Kenya" exact="ZIKV" post="antibodies found in human blood. 1969–1972 Nigeria ZIKV antibodies"/>
   <result pre="1968 Kenya ZIKV antibodies found in human blood. 1969–1972 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1969 Malaysia ZIKV found"/>
   <result pre="1969–1972 Nigeria ZIKV antibodies found in human blood. 1969 Malaysia" exact="ZIKV" post="found in A. aegypti mosquitoes. 1969–1983 Indonesia, Malaysia, Pakistan"/>
   <result pre="ZIKV found in A. aegypti mosquitoes. 1969–1983 Indonesia, Malaysia, Pakistan" exact="ZIKV" post="found in mosquitoes.Sporadic human infections. 1970 Nigeria ZIKV antibodies"/>
   <result pre="Malaysia, Pakistan ZIKV found in mosquitoes.Sporadic human infections. 1970 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1971–1972 Angola ZIKV antibodies"/>
   <result pre="1970 Nigeria ZIKV antibodies found in human blood. 1971–1972 Angola" exact="ZIKV" post="antibodies found in human blood. 1972,1975, 1988,1990 Senegal ZIKV"/>
   <result pre="Angola ZIKV antibodies found in human blood. 1972,1975, 1988,1990 Senegal" exact="ZIKV" post="antibodies found in human blood. 1979 Central African Republic"/>
   <result pre="ZIKV antibodies found in human blood. 1979 Central African Republic" exact="ZIKV" post="antibodies found in human blood. 1980 Nigeria ZIKV antibodies"/>
   <result pre="African Republic ZIKV antibodies found in human blood. 1980 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1984 Uganda ZIKV antibodies"/>
   <result pre="1980 Nigeria ZIKV antibodies found in human blood. 1984 Uganda" exact="ZIKV" post="antibodies found in human blood. 1996–1997 Malaysia ZIKV antibodies"/>
   <result pre="1984 Uganda ZIKV antibodies found in human blood. 1996–1997 Malaysia" exact="ZIKV" post="antibodies found in human blood. 1999 Ivory Coast ZIKV"/>
   <result pre="Malaysia ZIKV antibodies found in human blood. 1999 Ivory Coast" exact="ZIKV" post="antibodies found in human blood. pharmaceuticals-12-00157-t003_Table 3Table 3 A"/>
   <result pre="in human blood. pharmaceuticals-12-00157-t003_Table 3Table 3 A brief summary of" exact="ZIKV" post="epidemics, 2007 to present. Data summarized from [18,19]. Year"/>
   <result pre="home country and passing infection through sexual contact. 2010 Cameroon" exact="ZIKV" post="antibodies found in human blood. 2010–2015 Cambodia, Indonesia, Malaysia,"/>
   <result pre="2010–2015 Cambodia, Indonesia, Malaysia, Philippines, Thailand, Maldives Mosquito transmission of" exact="ZIKV" post="in these countries to travelers who then carried the"/>
   <result pre="their home countries. 2011–2014 French Polynesia Second reported outbreak of" exact="ZIKV" post="infections. Connection with microcephaly and neurological disorders established later."/>
   <result pre="and neurological disorders established later. 2013–2014 Chile, Cook Islands,New Caledonia" exact="ZIKV" post="outbreak. 2013 Tahiti ZIKV isolated from patient’s semen showing"/>
   <result pre="later. 2013–2014 Chile, Cook Islands,New Caledonia ZIKV outbreak. 2013 Tahiti" exact="ZIKV" post="isolated from patient’s semen showing sexual transmissibility. 2014 Zambia"/>
   <result pre="ZIKV isolated from patient’s semen showing sexual transmissibility. 2014 Zambia" exact="ZIKV" post="antibodies found in human blood. 2015 April/May Brazil, Bahia"/>
   <result pre="Brazil, Bahia state National Reference Laboratory, Brazil confirmed, by PCR," exact="ZIKV" post="infections, for the first time in the Americas. 2015"/>
   <result pre="for the first time in the Americas. 2015 July Brazil" exact="Zika" post="cases confirmed by laboratory tests in 12 states. Neurological"/>
   <result pre="America Colombia, Republic of Cabo Verde report confirmed cases of" exact="ZIKV" post="infections.Brazil reported unusual increase in the number of cases"/>
   <result pre="declared a national public health emergency. Brazil reported detection of" exact="ZIKV" post="in amniotic fluid of fetuses with confirmed microcephaly. Suriname,"/>
   <result pre="Suriname, Panama, El Salvador, Guatemala, and Paraguay confirmed cases of" exact="ZIKV" post="infection. The Pan American Health Organization and WHO issued"/>
   <result pre="issued an epidemiological alert. 2015 November Mexico Three cases of" exact="ZIKV" post="infection confirmed by PCR. 2015 November French Polynesia Retrospective"/>
   <result pre="America Honduras, French Guiana, and Martinique reported confirmed cases of" exact="ZIKV" post="infections. 2015 December Puerto Rico First confirmed case of"/>
   <result pre="ZIKV infections. 2015 December Puerto Rico First confirmed case of" exact="Zika" post="infection reported. 2016 Maldives Finnish national working in Maldivestested"/>
   <result pre="reported. 2016 Maldives Finnish national working in Maldivestested positive for" exact="Zika" post="after return to Finland. 2016 January Americas Guyana reported"/>
   <result pre="Americas Guyana reported the first PCR-confirmed case of locally acquired" exact="Zika" post="infection.Ecuador, Bolivia, Barbados, Haiti, Dominican Republic, Nicaragua, Curacao and"/>
   <result pre="Nicaragua, Curacao and Jamaica reported the first confirmed cases of" exact="Zika" post="infections.First case of Zika in St. Martin reported. 2016"/>
   <result pre="reported the first confirmed cases of Zika infections.First case of" exact="Zika" post="in St. Martin reported. 2016 January US Virgin Islands"/>
   <result pre="reported. 2016 January US Virgin Islands First confirmed case of" exact="Zika" post="in St. Croix reported. 2016 February Americas First confirmed"/>
   <result pre="St. Croix reported. 2016 February Americas First confirmed case of" exact="ZIKV" post="infection in Chile reported.First case of sexually transmitted Zika"/>
   <result pre="of ZIKV infection in Chile reported.First case of sexually transmitted" exact="Zika" post="infection in Texas, USA reported. 2016 Various countries Angola,"/>
   <result pre="Papua New Guinea, and other countries report first cases of" exact="ZIKV" post="infections. 2016 Singapore ZIKV infection reported. 2016/2017 India Three"/>
   <result pre="other countries report first cases of ZIKV infections. 2016 Singapore" exact="ZIKV" post="infection reported. 2016/2017 India Three cases of ZIKV infection"/>
   <result pre="2016 Singapore ZIKV infection reported. 2016/2017 India Three cases of" exact="ZIKV" post="infection reported in Ahmedabad. 2017 Singapore Several cases of"/>
   <result pre="reported in Ahmedabad. 2017 Singapore Several cases of locally transmitted" exact="ZIKV" post="confirmed. pharmaceuticals-12-00157-t004_Table 4Table 4 gR values of all sequences"/>
   <result pre="pharmaceuticals-12-00157-t004_Table 4Table 4 gR values of all sequences of the" exact="Zika" post="virus genome with 10,272 identified bases and selected hosts"/>
   <result pre="compounds led to twenty compounds that were found to reduce" exact="ZIKV" post="infection [93] NIH clinical library of compounds By screening"/>
   <result pre="ibuprofen, naproxen, acetaminophen, and lornoxicam, potently inhibited the entry of" exact="Zika" post="virus Env/HIV-1-pseudotyped viruses Inhibited replication of wild-type ZIKV both"/>
   <result pre="entry of Zika virus Env/HIV-1-pseudotyped viruses Inhibited replication of wild-type" exact="ZIKV" post="both in cell lines and in primary human fetal"/>
   <result pre="favorable selective index (SI) values. In a mouse model of" exact="ZIKV" post="infection (300 mg/kg/d), treatment with BCX4430 showed promising results."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963280\results\search\tropicalVirus\results.xml">
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Dengue" post="virus (DENV) infections may result in asymptomatic cases or"/>
   <result pre="an increased mortality. Aiming to better understand the role of" exact="DENV" post="in renal injury observed in human fatal cases, post-mortem"/>
   <result pre="4 fatal case viremia histopathology cytokines inflammatory mediators 1. Introduction" exact="Dengue" post="virus (DENV) has four related but antigenically distinct serotypes"/>
   <result pre="Although there has been no definitive association of the different" exact="DENV" post="serotypes within the clinical course of the disease, it"/>
   <result pre="1 and Figure 2). Immunohistochemistry assay demonstrated the presence of" exact="DENV" post="NS3 protein in macrophages and mesangial cells in the"/>
   <result pre="expression in peritubular macrophages in the medullary region (Figure 3M)." exact="DENV" post="NS3 and CD68+ double-stained cells were also observed (Figure"/>
   <result pre="CD68+ double-stained cells were also observed (Figure 3O). 3. Discussion" exact="DENV" post="can infect several cell types in different tissues and"/>
   <result pre="liver, lung, spleen, brain, kidney, bone marrow, and heart [20,21,22,23,24]." exact="Dengue" post="renal involvement varies from elevated serum creatinine, acute tubular"/>
   <result pre="Analysis of autopsies or biopsies of human cells infected by" exact="DENV" post="using immunohistochemistry and in situ hybridization techniques detected viral"/>
   <result pre="reported immune complex-mediated lesion in the glomerulus in patients with" exact="DENV" post="infections, and have suggested this as a possible mechanism"/>
   <result pre="DENV-4 cases analyzed here, suggesting that renal damage caused by" exact="DENV" post="is not serotype-specific. In this study, we observed that"/>
   <result pre="DENV-4 infection and replication, demonstrated by the presence of the" exact="DENV" post="NS3 protein [20,42]. Arteriolar hyalinosis occurs by glomerular hyperfiltration"/>
   <result pre="in the medullary. CD68+ cells showed their co-expression with the" exact="DENV" post="NS3 protein, confirming the participation of those cells during"/>
   <result pre="identified in those tissues and the exacerbated host immune response." exact="Dengue" post="may cause vascular overload and reduction of intravascular volume."/>
   <result pre="of the Oswaldo Cruz Foundation, Ministry of Health, Brazil. 4.2." exact="Dengue" post="Fatal Cases Young adults (20–33 years old) fatal cases"/>
   <result pre="2013. Leptospirosis was investigated and presented a negative result. 4.3." exact="Dengue" post="Molecular Diagnosis, Histopathological Analysis, and Immunohistochemistry Kidney tissues samples"/>
   <result pre="USA). The conventional reverse transcriptase polymerase chain reaction (RT-PCR) for" exact="DENV" post="identification and serotyping was performed as described by Lanciotti"/>
   <result pre="Oliveira PintoL.M.KubelkaC.F.et al.Analysis of Clinical and Laboratory Alterations Related to" exact="Dengue" post="Case Severity: Comparison between Serotypes 2 and 4 in"/>
   <result pre="acute kidney injury in Thai childrenJ. Pediatr.201015730330910.1016/j.jpeds.2010.02.00820362302 19.PóvoaT.F.OliveiraE.R.A.Basílio-de-OliveiraC.A.NuovoG.J.ChagasV.L.A.SalomãoN.G.MotaE.M.PaesM.V.Peripheral Organs of" exact="Dengue" post="Fatal Cases Present Strong Pro-Inflammatory Response with Participation of"/>
   <result pre="32.MallhiT.H.KhanA.H.AdnanA.S.SarriffA.KhanY.H.JummaatF.Incidence, Characteristics and Risk Factors of Acute Kidney Injury among" exact="Dengue" post="Patients: A Retrospective AnalysisPLoS ONE201510e013846526421839 33.GlassockR.J.Immune complex-induced glomerular injury"/>
   <result pre="syndromeClin. Infect. Dis.20064380080110.1086/50711116912966 36.MohsinN.MohamedE.GaberM.ObaidaniI.BudruddinM.Al BusaidyS.Acute tubular necrosis associated with non-hemorrhagic" exact="Dengue" post="fever: A case reportRen. Fail.20093173673910.3109/0886022090300340419814641 37.UpadhayaB.K.SharmaA.KhairaA.DindaA.K.AgarwalS.K.TiwariS.C.Transient IgA nephropathy with"/>
   <result pre="and proximal contiguous tubules (PCT) and distal tubules (DCT). (B)" exact="Dengue" post="case showing the presence of inflammatory infiltrate (Ly), hyalinoses"/>
   <result pre="(RG), thickened Bowman’s capsule (BC) and damage (star) PCT. (C)" exact="Dengue" post="case showing tubular debris (D), edema (E), and pockets"/>
   <result pre="control without dengue virus (DENV) NS3 staining. (B,C) Detection of" exact="DENV" post="NS3 in the dengue case within macrophages (Mø), Mesenchymal"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963298\results\search\tropicalVirus\results.xml">
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Yellow fever" post="is a potentially fatal, mosquito-borne viral disease that appears"/>
   <result pre="yellow fever vaccine flavivirus mosquito-borne acute febrile illness 1. Background" exact="Yellow fever" post="(YF) is a potentially fatal disease caused by a"/>
   <result pre="Africa, tropical areas of South America, eastern Panama and Trinidad." exact="YFV" post="is transmitted to humans and non-human primates (NHP) by"/>
   <result pre="mosquitoes and humans in cities. While the sylvatic and intermediate" exact="YFV" post="transmission cycles account for most human disease, in the"/>
   <result pre="in Africa and Latin America and countries in Asia where" exact="YFV" post="is absent [23,24]. Factors that may favor the spread"/>
   <result pre="forested areas in equatorial Africa [24,30]. Low population immunity to" exact="YFV" post="in neighboring endemic areas due to under vaccination may"/>
   <result pre="surveillance and laboratory capacity to detect, monitor and respond to" exact="YFV" post="transmission. EYE built upon lessons learned from the WHO"/>
   <result pre="American countries where there is high to moderate risk of" exact="YFV" post="transmission [33]. While the last estimate of YF incidence"/>
   <result pre="against re-infection [45,46,47,48]. There are no documented cases of repeated" exact="YFV" post="infection, even in several historical cohorts [49]. Evidence also"/>
   <result pre="a broad range of RNA viruses, including Ebola, Marburg and" exact="YFV" post="[58,59]. A Phase 1 clinical trial to evaluate the"/>
   <result pre="used to treat hepatitis C, has shown antiviral activity against" exact="YFV" post="in cell-based assays and rodent infection models [54,57]. Further"/>
   <result pre="promise with many demonstrating broad cross-activity against multiple flaviviruses including" exact="YFV" post="[61,62,63,64,65,66]. One example of a promising, first-in-class monoclonal antibody"/>
   <result pre="Singapore [67]. TY014 was designed to neutralize multiple strains of" exact="YFV" post="by binding to an epitope on the E protein"/>
   <result pre="People living in or traveling to areas with risk for" exact="YFV" post="transmission should avoid mosquito bites whenever possible [69]. Those"/>
   <result pre="onset to avoid infecting naive mosquitoes that can then transmit" exact="YFV" post="to others. Persons ≥9 months old living in or"/>
   <result pre="old living in or traveling to areas with risk for" exact="YFV" post="transmission should be vaccinated unless they have a contraindication"/>
   <result pre="control program may be the most effective option to mitigate" exact="YFV" post="transmission in urban areas [74,75]. Third, the disease is"/>
   <result pre="population needs to be vaccinated in areas with risk for" exact="YFV" post="transmission to prevent outbreaks. This level of coverage requires"/>
   <result pre="vaccine was first developed in 1936 using an attenuated wild-type" exact="YFV" post="strain that was isolated in 1927 from a Ghanaian"/>
   <result pre="there are between 393.7 and 472.9 million people residing in" exact="YFV" post="transmission risk areas who need to be vaccinated to"/>
   <result pre="17D virus infection of the liver and visceral organs [98,100]." exact="Yellow fever" post="vaccine-associated viscerotropic disease (YEL-AVD) was first described in 2001,"/>
   <result pre="immune system may allow dissemination of the 17D strain [106,107]." exact="YFV" post="is a neurotropic virus and while YF vaccine is"/>
   <result pre="women should not receive YF vaccine except when exposure to" exact="YFV" post="cannot be avoided or travel cannot be postponed to"/>
   <result pre="found that vaccination protected NHPs against a lethal challenge of" exact="YFV" post="[43]. There is no evidence that vaccine effectiveness has"/>
   <result pre="the recent outbreaks as there is still only a single" exact="YFV" post="serotype and while the lineages between South America and"/>
   <result pre="the field support its effectiveness including the prevention of laboratory-acquired" exact="YFV" post="infections among vaccinated staff and the decline in YF"/>
   <result pre="beta-propiolactone (BPL) was shown to protect mice against a lethal" exact="YFV" post="challenge [129]. In a Phase 1 clinical trial, two"/>
   <result pre="to produce a safer YF vaccine is to express the" exact="YFV" post="pre-M and E proteins either as recombinant proteins or"/>
   <result pre="areas despite an effective vaccine. With increasing globalization and mobility," exact="YFV" post="has the potential to spread to YFV-naïve regions in"/>
   <result pre="in cell culture and replication-defective MVA vector vaccine expressing the" exact="YFV" post="pre-M and E proteins. Author Contributions All authors contributed"/>
   <result pre="July 2017 to March 2018Eurosurveillance20182310.2807/1560-7917.ES.2018.23.11.18-00106 22.DelatorreE.de AbreuF.V.S.RibeiroI.P.GomezM.M.Dos SantosA.A.C.Ferreira-de-BritoA.NevesM.BonellyI.de MirandaR.M.FurtadoN.D.et al.Distinct" exact="YFV" post="Lineages Co-circulated in the Central-Western and Southeastern Brazilian Regions"/>
   <result pre="2019Available online: http://ais.paho.org/phip/viz/ed_yellowfever.asp(accessed on 25 October 2019) 37.JohanssonM.A.Arana-VizcarrondoN.BiggerstaffB.J.StaplesJ.E.Incubation periods of" exact="Yellow fever" post="virusAm. J. Trop. Med. Hyg.20108318318810.4269/ajtmh.2010.09-078220595499 38.JohanssonM.A.VasconcelosP.F.StaplesJ.E.The whole iceberg: Estimating"/>
   <result pre="mortality during 19th century U.S. epidemicsmBio20145e01253-1410.1128/mBio.01253-1424895309 50.OliveiraR.A.de Oliveira-FilhoE.F.FernandesA.I.BritoC.A.MarquesE.T.TenorioM.C.GilL.H.Previous dengue or" exact="Zika" post="virus exposure can drive to infection enhancement or neutralisation"/>
   <result pre="passive therapy with a potently neutralizing humanized monoclonal antibody against" exact="West Nile" post="virusJ. Infect. Dis.200920020220510.1086/59979419527169 66.LongF.DoyleM.FernandezE.MillerA.S.KloseT.SevvanaM.BryanA.DavidsonE.DoranzB.J.KuhnR.J.et al.Structural basis of a potent"/>
   <result pre="66.LongF.DoyleM.FernandezE.MillerA.S.KloseT.SevvanaM.BryanA.DavidsonE.DoranzB.J.KuhnR.J.et al.Structural basis of a potent human monoclonal antibody against" exact="Zika" post="virus targeting a quaternary epitopeProc. Natl. Acad. Sci. USA20191161591159610.1073/pnas.181543211630642974"/>
   <result pre="Paulo state, Brazil, 2008-2009Rev. Inst. Med. Trop. Sao Paulo201355455010.1590/S0036-4665201300010000823328725 72.BowmanL.R.DoneganS.McCallP.J.Is" exact="Dengue" post="Vector Control Deficient in Effectiveness or Evidence?: Systematic Review"/>
   <result pre="17DJ. Virol.201387123921239710.1128/JVI.02149-1324027319 108.DhimanG.AbrahamR.GriffinD.E.Human Schwann cells are susceptible to infection with" exact="Zika" post="and yellow fever viruses, but not dengue virusSci. Rep.20199995110.1038/s41598-019-46389-031289325"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963661\results\search\tropicalVirus\results.xml">
   <result pre="Review Considering Genomic and Immunological Correlates of Protection for a" exact="Dengue" post="Intervention https://orcid.org/0000-0003-3624-7008BlightJoshua12AlvesEduardo12https://orcid.org/0000-0002-2648-1696Reyes-SandovalArturo2*[1], joshua.blight09@imperial.ac.ukeduardo.alves@imperial.ac.uk[2], *Correspondence: arturo.reyes@ndm.ox.ac.uk; Tel.: +44-1865-287811 epub: 2019-12-12collection:"/>
   <result pre="review discusses the roles of genomic and immunological aspects of" exact="DENV" post="infection, providing both a historical interpretation and fresh discussion"/>
   <result pre="be used for the next generation of dengue interventions. dengue" exact="DENV" post="genomic variation genomic diversity T-cell responses antibody responses vaccines"/>
   <result pre="key mosquito vectors, Aedes aegypti and Aedes albopictus [2,3]. The" exact="DENV" post="itself is a positive sense RNA flavivirus which exists"/>
   <result pre="which exists as four circulating serotypes [2]. The effects of" exact="DENV" post="infection are subclinical in approximately 75% of cases. However,"/>
   <result pre="of dengue infection they must target. 2. Viral Lifecycle The" exact="DENV" post="depends on both a human and mosquito host to"/>
   <result pre="NS4A, NS4B, and NS5; Figure 1) [15]. During human infection" exact="DENV" post="has an assorted cell tropism, with a particular preference"/>
   <result pre="DC-SIGN, mannose receptor, TIM/TAM receptors, laminin, HSP90/70) the receptor mediating" exact="DENV" post="entry remains elusive [15]. The virus enters host cells"/>
   <result pre="the presence of anti-prM antibodies, which may enable non-infectious immature" exact="DENV" post="particles with uncleaved M protein (prM) to infect host"/>
   <result pre="with uncleaved M protein (prM) to infect host cells [65,87,88]." exact="DENV" post="particles are also extremely dynamic, undergoing a process known"/>
   <result pre="1). Understanding the subtleties of the humoral response elicited by" exact="DENV" post="is therefore not only important to avoid detrimental enhancement"/>
   <result pre="to avoid detrimental enhancement effects but also to identify potential" exact="DENV" post="protein regions with the ability to generate autoreactive antibodies."/>
   <result pre="than one lineage is present in the same region [145]." exact="Dengue" post="dynamics in endemic regions are complex, characterised by continual"/>
   <result pre="and 2, and four genotypes in DENV3 and 4 [142,148]." exact="DENV" post="lineages have been associated with varying disease severity [149]"/>
   <result pre="virulent strains in mosquitoes co-infected with both [160]. Importantly, increased" exact="DENV" post="viral replication has been associated with more severe disease"/>
   <result pre="mutation per replication [142,150]. However, paradoxically and controversially, most the" exact="DENV" post="genome has been shown to be under purifying selection,"/>
   <result pre="serotypes has been reported for a short period after a" exact="DENV" post="infection [4,146,153]. In support of this hypothesis a study"/>
   <result pre="chimeric yellow fever viruses with the structural genes replaced by" exact="DENV" post="structural genes [18] and therefore aims to elicit neutralizing"/>
   <result pre="also in development, all of which contain regions of the" exact="DENV" post="proteome known to elicit robust antibody responses [105,141]. Two"/>
   <result pre="four serotypes but to avoid detrimental enhancement effects in subsequent" exact="DENV" post="infections or based on previous infections. Once such example"/>
   <result pre="a heterotypic infection which have low avidity. Heterotypic: A different" exact="DENV" post="serotype. Homotypic: The same DENV serotype. Cross-reactive: Immune cells"/>
   <result pre="low avidity. Heterotypic: A different DENV serotype. Homotypic: The same" exact="DENV" post="serotype. Cross-reactive: Immune cells which react to multiple serotypes."/>
   <result pre="Health (ODA), 16/107/05 (Design, development and GMP manufacture of a" exact="Zika" post="vaccine). This research is funded by the Department of"/>
   <result pre="The authors J.B. and A.R.-S. disclosed a patent application: WO2016181147A1;" exact="Dengue" post="Vaccines. References References 1.BhattS.GethingP.W.BradyO.J.MessinaJ.P.FarlowA.W.MoyesC.L.DrakeJ.M.BrownsteinJ.S.HoenA.G.SankohO.et al.The global distribution and burden"/>
   <result pre="Spread of a Mosquito-Borne DiseaseN. Engl. J. Med.20153721231123925806915 4.GuzmanM.G.HarrisE.DengueLancet201538545346510.1016/S0140-6736(14)60572-925230594 5.BowmanL.R.DoneganS.McCallP.J.Is" exact="Dengue" post="Vector Control Deficient in Effectiveness or Evidence? Systematic Review"/>
   <result pre="against flaviviruses: The case for the multifunctional NS3 protein from" exact="Dengue" post="virus as a targetAntiviral Res.2008809410110.1016/j.antiviral.2008.07.00118674567 8.NobleC.G.ChenY.-L.DongH.GuF.LimS.P.SchulW.WangQ.-Y.ShiP.-Y.Strategies for development of"/>
   <result pre="correlates for dengue vaccine developmentExpert Rev. Vaccines20161545546510.1586/14760584.2016.111694926560015 15.DiamondM.S.PiersonT.C.Molecular Insight into" exact="Dengue" post="Virus Pathogenesis and Its Implications for Disease ControlCell201516248849210.1016/j.cell.2015.07.00526232221 16.HalsteadS.B.RussellP.K.Protective"/>
   <result pre="3, randomised, observer-masked, placebo-controlled trialLancet20143841358136510.1016/S0140-6736(14)61060-625018116 18.VillarL.DayanG.H.Arredondo-GarcíaJ.L.RiveraD.M.CunhaR.DesedaC.ReynalesH.CostaM.S.Morales-RamírezJ.O.CarrasquillaG.et al.Efficacy of a Tetravalent" exact="Dengue" post="Vaccine in Children in Latin AmericaN. Engl. J. Med.201537211312310.1056/NEJMoa141103725365753"/>
   <result pre="Med.201537211312310.1056/NEJMoa141103725365753 19.HadinegoroS.R.Arredondo-GarcíaJ.L.CapedingM.R.DesedaC.ChotpitayasunondhT.DietzeR.Hj Muhammad IsmailH.I.ReynalesH.LimkittikulK.Rivera-MedinaD.M.et al.Efficacy and Long-Term Safety of a" exact="Dengue" post="Vaccine in Regions of Endemic DiseaseN. Engl. J. Med.20153731195120610.1056/NEJMoa150622326214039"/>
   <result pre="2 from a Sylvatic Lineage Isolated from a Patient with" exact="Dengue" post="Hemorrhagic FeverPLoS Negl. Trop. Dis.20093e42310.1371/journal.pntd.000042319399166 23.WichitS.FerrarisP.ChoumetV.MisséD.The effects of mosquito"/>
   <result pre="amino acids in vitroJ. Biol. Chem.20002759963996910.1074/jbc.275.14.996310744671 36.NobleC.G.SehC.C.ChaoA.T.ShiP.Y.Ligand-Bound Structures of the" exact="Dengue" post="Virus Protease Reveal the Active ConformationJ. Virol.20118643844610.1128/JVI.06225-1122031935 37.ClydeK.KyleJ.L.HarrisE.Recent advances"/>
   <result pre="Infectivity by Conserved Residues at Nonfurin Consensus Positions of the" exact="Dengue" post="Virus pr-M JunctionJ. Virol.200882107761079110.1128/JVI.01180-0818715923 44.MillerS.KastnerS.Krijnse-LockerJ.BühlerS.BartenschlagerR.The non-structural protein 4A of"/>
   <result pre="J. Trop. Med. Hyg.19521305010.4269/ajtmh.1952.1.3014903434 56.MontoyaM.GreshL.MercadoJ.C.WilliamsK.L.VargasM.J.GutierrezG.KuanG.GordonA.BalmasedaA.HarrisE.Symptomatic Versus Inapparent Outcome in Repeat" exact="Dengue" post="Virus Infections Is Influenced by the Time Interval between"/>
   <result pre="Dis.20137e235710.1371/journal.pntd.000235723951377 57.AndersonK.B.GibbonsR.V.CummingsD.A.T.NisalakA.GreenS.LibratyD.H.JarmanR.G.SrikiatkhachornA.MammenM.P.DaruneeB.et al.A Shorter Time Interval Between First and Second" exact="Dengue" post="Infections Is Associated With Protection From Clinical Illness in"/>
   <result pre="vitro infectionJ. Expe. Med.1977146218229 64.GuzmanM.G.VazquezS.The Complexity of Antibody-Dependent Enhancement of" exact="Dengue" post="Virus InfectionViruses201022649266210.3390/v212264921994635 65.DejnirattisaiW.JumnainsongA.OnsirisakulN.FittonP.VasanawathanaS.LimpitikulW.PuttikhuntC.EdwardsC.DuangchindaT.SupasaS.et al.Cross-reacting antibodies enhance dengue virus infection"/>
   <result pre="infection in humansScience201032874574810.1126/science.118518120448183 66.BeltramelloM.WilliamsK.L.SimmonsC.P.MacagnoA.SimonelliL.QuyenN.T.H.Sukupolvi-PettyS.Navarro-SanchezE.YoungP.R.de SilvaA.M.et al.The Human Immune Response to" exact="Dengue" post="Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with"/>
   <result pre="in children with dengueJ. Immunol.20101847281728710.4049/jimmunol.090326220483770 70.FlipseJ.Diosa-ToroM.A.HoornwegT.E.van de PolD.P.I.Urcuqui-InchimaS.SmitJ.M.Antibody-Dependent Enhancement of" exact="Dengue" post="Virus Infection in Primary Human Macrophages; Balancing Higher Fusion"/>
   <result pre="ResponsesSci. Rep.2016646510.1038/srep29201 71.ModhiranN.KalayanaroojS.UbolS.Subversion of Innate Defenses by the Interplay between" exact="DENV" post="and Pre-Existing Enhancing Antibodies: TLRs Signaling CollapsePLoS Negl. Trop."/>
   <result pre="Virol.20078836537510.1099/vir.0.82537-017251552 73.UbolS.PhukliaW.KalayanaroojS.ModhiranN.Mechanisms of Immune Evasion Induced by a Complex of" exact="Dengue" post="Virus and Preexisting Enhancing AntibodiesJ. Infect. Dis.201020192393510.1086/65101820158392 74.KouZ.LimJ.Y.H.BeltramelloM.QuinnM.ChenH.LiuS.-N.Martnez-SobridoL.DiamondM.S.SchlesingerJ.J.de SilvaA.et"/>
   <result pre="Type Specificity and Host Genetic Polymorphisms Influence Antibody-Dependent Enhancement of" exact="Dengue" post="Virus InfectionJ. Virol.2011851671168310.1128/JVI.00220-1021123382 76.ModhiranN.WattersonD.MullerD.A.PanettaA.K.SesterD.P.LiuL.HumeD.A.StaceyK.J.YoungP.R.Dengue virus NS1 protein activates cells"/>
   <result pre="vaccinationSci. Transl. Med.20157304ra14110.1126/scitranslmed.aaa3787 78.NgJ.K.W.ZhangS.L.TanH.C.YanB.GomezJ.M.M.TanW.Y.LamJ.H.TanG.K.X.OoiE.E.AlonsoS.First Experimental In Vivo Model of Enhanced" exact="Dengue" post="Disease Severity through Maternally Acquired Heterotypic Dengue AntibodiesPLoS Pathog201410e100403110.1371/journal.ppat.100403124699622"/>
   <result pre="Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic" exact="Dengue" post="AntibodiesPLoS Pathog201410e100403110.1371/journal.ppat.100403124699622 79.HoberD.PoliL.RoblinB.GestasP.ChungueE.GranicG.ImbertP.PecarereJ.L.Vergez-PascalR.WattreP.Serum levels of tumor necrosis factor-alpha (TNF-alpha),"/>
   <result pre="J. Trop. Med. Hyg.19934832433110.4269/ajtmh.1993.48.3248470771 80.GreenS.VaughnD.W.KalayanaroojS.NimmannityaS.SuntayakornS.NisalakA.LewR.InnisB.L.KuraneI.RothmanA.L.et al.Early Immune Activation in Acute" exact="Dengue" post="Illness Is Related to Development of Plasma Leakage and"/>
   <result pre="by monoclonal antibodiesJ. Immunol.1984132152915326607288 85.TsaiW.-Y.DurbinA.TsaiJ.-J.HsiehS.-C.WhiteheadS.WangW.-K.Complexity of Neutralizing Antibodies against Multiple" exact="Dengue" post="Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed"/>
   <result pre="Trop. Med. Hyg.19894044445110.4269/ajtmh.1989.40.4442712199 87.Rodenhuis-ZybertI.A.van der SchaarH.M.da Silva VoorhamJ.M.van der Ende-MetselaarH.LeiH.-Y.WilschutJ.SmitJ.M.Immature" exact="Dengue" post="Virus: A Veiled Pathogen?PLoS Pathog20106e100071810.1371/journal.ppat.100071820062797 88.Rodenhuis-ZybertI.A.MoeskerB.da Silva VoorhamJ.M.van der"/>
   <result pre="of immature flavivirus particlesJ. Virol.201185118001180810.1128/JVI.05237-1121880758 89.LaiC.Y.TsaiW.Y.LinS.R.KaoC.L.HuH.P.KingC.C.WuH.C.ChangG.J.WangW.K.Antibodies to Envelope Glycoprotein of" exact="Dengue" post="Virus during the Natural Course of Infection Are Predominantly"/>
   <result pre="Sci. USA20121097439744410.1073/pnas.120056610922499787 91.TeohE.P.KukkaroP.TeoE.W.LimA.P.C.TanT.T.YipA.SchulW.AungM.KostyuchenkoV.A.LeoY.S.et al.The Structural Basis for Serotype-Specific Neutralization of" exact="Dengue" post="Virus by a Human AntibodySci. Transl. Med.20124139ra8310.1126/scitranslmed.300388822723463 92.FibriansahG.TanJ.L.SmithS.A.de AlwisR.NgT.-S.KostyuchenkoV.A.JadiR.S.KukkaroP.de"/>
   <result pre="Analysis of the Antibody Response of Individuals Exposed to Primary" exact="Dengue" post="Virus InfectionPLoS Negl. Trop. Dis.20115e118810.1371/annotation/f585335f-ff77-40ae-a8b6-ad6019af31aa21713020 96.AvirutnanP.PunyadeeN.NoisakranS.KomoltriC.ThiemmecaS.AuethavornananK.JairungsriA.KanlayaR.TangthawornchaikulN.PuttikhuntC.et al.Vascular Leakage in"/>
   <result pre="Virus InfectionPLoS Negl. Trop. Dis.20115e118810.1371/annotation/f585335f-ff77-40ae-a8b6-ad6019af31aa21713020 96.AvirutnanP.PunyadeeN.NoisakranS.KomoltriC.ThiemmecaS.AuethavornananK.JairungsriA.KanlayaR.TangthawornchaikulN.PuttikhuntC.et al.Vascular Leakage in Severe" exact="Dengue" post="Virus Infections: A Potential Role for the Nonstructural Viral"/>
   <result pre="and secondary dengue hemorrhagic feverAm. J. Trop. Med. Hyg.19914448149310.4269/ajtmh.1991.44.4812063952 102.ValdésK.AlvarezM.PupoM.VázquezS.RodríguezR.GuzmánM.G.Human" exact="Dengue" post="antibodies against structural and nonstructural proteinsClin. Dia. Lab. Imm.2000785685710.1128/CDLI.7.5.856-857.200010973471"/>
   <result pre="dosesAm. J. Trop. Med. Hyg.20026626427210.4269/ajtmh.2002.66.26412139219 105.WeiskopfD.SetteA.T-Cell Immunity to Infection with" exact="Dengue" post="Virus in HumansFront. Immunol.2014557110.3389/fimmu.2014.0009325426120 106.WeiskopfD.AngeloM.A.de AzeredoE.L.SidneyJ.GreenbaumJ.A.FernandoA.N.BroadwaterA.KollaR.V.De SilvaA.D.de SilvaA.M.et al.Comprehensive"/>
   <result pre="HLA-Restricted T Cell Responses in a Novel Mouse Model of" exact="Dengue" post="Virus Infection Point toward New Implications for Vaccine DesignJ."/>
   <result pre="of Viral Components by CD4+ versus CD8+ T Lymphocytes in" exact="Dengue" post="Virus InfectionJ. Virol.2013872693270610.1128/JVI.02675-1223255803 111.TianY.GrifoniA.SetteA.WeiskopfD.Human T Cell Response to Dengue"/>
   <result pre="in Dengue Virus InfectionJ. Virol.2013872693270610.1128/JVI.02675-1223255803 111.TianY.GrifoniA.SetteA.WeiskopfD.Human T Cell Response to" exact="Dengue" post="Virus InfectionFront. Immunol.201910104310.3389/fimmu.2019.0212531143184 112.Cedillo-BarrónL.García-CorderoJ.Bustos-ArriagaJ.León-JuárezM.Gutiérrez-CastañedaB.Antibody response to dengue virusMicrobes Infect.20141671172010.1016/j.micinf.2014.07.01125124542"/>
   <result pre="RNA synthesis and viral replicationVirology200837417018510.1016/j.virol.2007.12.03518234265 114.AlvarezD.E.LodeiroM.F.LuduenaS.J.PietrasantaL.I.GamarnikA.V.Long-Range RNA-RNA Interactions Circularize the" exact="Dengue" post="Virus GenomeJ. Virol.2005796631664310.1128/JVI.79.11.6631-6643.200515890901 115.BykL.A.GamarnikA.V.Properties and Functions of the Dengue"/>
   <result pre="the Dengue Virus GenomeJ. Virol.2005796631664310.1128/JVI.79.11.6631-6643.200515890901 115.BykL.A.GamarnikA.V.Properties and Functions of the" exact="Dengue" post="Virus Capsid ProteinAnnu. Rev.2016326328110.1146/annurev-virology-110615-042334 116.WongS.-S.HaqshenasG.GowansE.J.MackenzieJ.The dengue virus M protein"/>
   <result pre="129.ZellwegerR.M.MillerR.EddyW.E.WhiteL.J.JohnstonR.E.ShrestaS.Role of Humoral versus Cellular Responses Induced by a Protective" exact="Dengue" post="Vaccine CandidatePLoS Pathog20139e100372310.1371/journal.ppat.100372324204271 130.HatchS.EndyT.P.ThomasS.MathewA.PottsJ.PazolesP.LibratyD.H.GibbonsR.RothmanA.L.Intracellular Cytokine Production by Dengue Virus-specific"/>
   <result pre="a Protective Dengue Vaccine CandidatePLoS Pathog20139e100372310.1371/journal.ppat.100372324204271 130.HatchS.EndyT.P.ThomasS.MathewA.PottsJ.PazolesP.LibratyD.H.GibbonsR.RothmanA.L.Intracellular Cytokine Production by" exact="Dengue" post="Virus-specific T cells Correlates with Subclinical Secondary InfectionJ. Infect."/>
   <result pre="with Subclinical Secondary InfectionJ. Infect. Dis.20112031282129110.1093/infdis/jir01221335561 131.YauchL.E.ZellwegerR.M.KotturiM.F.QutubuddinA.SidneyJ.PetersB.PrestwoodT.R.SetteA.ShrestaS.A Protective Role for" exact="Dengue" post="Virus-Specific CD8+ T CellsJ. Immunol.20091824865487310.4049/jimmunol.080197419342665 132.MongkolsapayaJ.DuangchindaT.DejnirattisaiW.VasanawathanaS.AvirutnanP.JairungsriA.KhemnuN.TangthawornchaikulN.ChotiyarnwongP.Sae-JangK.et al.T Cell Responses"/>
   <result pre="Virus-Specific CD8+ T CellsJ. Immunol.20091824865487310.4049/jimmunol.080197419342665 132.MongkolsapayaJ.DuangchindaT.DejnirattisaiW.VasanawathanaS.AvirutnanP.JairungsriA.KhemnuN.TangthawornchaikulN.ChotiyarnwongP.Sae-JangK.et al.T Cell Responses in" exact="Dengue" post="Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?J. Immunol.20061763821382910.4049/jimmunol.176.6.382116517753 133.MathewA.RothmanA.L.Understanding"/>
   <result pre="136.GreenS.PichyangkulS.VaughnD.W.KalayanaroojS.NimmannityaS.NisalakA.KuraneI.RothmanA.L.EnnisF.A.Early CD69 Expression on Peripheral Blood Lymphocytes from Children with" exact="Dengue" post="Hemorrhagic FeverJ. Infect. Dis.19991801429143510.1086/31507210515800 137.FribergH.BurnsL.WodaM.KalayanaroojS.EndyT.P.StephensH.A.F.GreenS.RothmanA.L.MathewA.Memory CD8+ T cells from"/>
   <result pre="selection pressures among genotypes of dengue-2 virusVirology2002298637210.1006/viro.2002.144712093174 144.ZhangC.MammenM.P.ChinnawirotpisanP.KlungthongC.RodpraditP.MonkongdeeP.NimmannityaS.KalayanaroojS.HolmesE.C.Clade Replacements in" exact="Dengue" post="Virus Serotypes 1 and 3 Are Associated with Changing"/>
   <result pre="to repeated introductions of different Asian strainsVirology200432950551210.1016/j.virol.2004.08.02915518827 146.OhAinleM.BalmasedaA.MacalaladA.R.TellezY.ZodyM.C.SaboríoS.NuñezA.LennonN.J.BirrenB.W.GordonA.et al.Dynamics of" exact="Dengue" post="Disease Severity Determined by the Interplay Between Viral Genetics"/>
   <result pre="Mosquito TransmissionJ. Virol.2012861853186110.1128/JVI.06458-1122130539 148.WittkeV.RobbT.E.ThuH.M.NisalakA.NimmannityaS.KalayanroojS.VaughnD.W.EndyT.P.HolmesE.C.AaskovJ.G.Extinction and Rapid Emergence of Strains of" exact="Dengue" post="3 Virus during an Interepidemic PeriodVirology200230114815610.1006/viro.2002.154912359455 149.Rico-HesseR.Dengue Virus Virulence"/>
   <result pre="Germany2009Volume 3384555 150.HangV.T.T.HolmesE.C.VeasnaD.QuyN.T.HienT.T.QuailM.ChurcherC.ParkhillJ.CardosaJ.FarrarJ.et al.Emergence of the Asian 1 Genotype of" exact="Dengue" post="Virus Serotype 2 in Viet Nam: In Vivo Fitness"/>
   <result pre="dengueProc. R. Soc. Lond. B Biol. Sci.20092762541254810.1098/rspb.2009.033119369266 158.ColognaR.ArmstrongP.M.Rico-HesseR.Selection for Virulent" exact="Dengue" post="Viruses Occurs in Humans and MosquitoesJ. Virol.20047985385910.1128/JVI.79.2.853-859.2005 159.ArmstrongP.M.Rico-HesseR.Efficiency of"/>
   <result pre="type 2 virusVector-Borne Zoonotic Dis.2001115916810.1089/15303660131697776912680353 161.LibratyD.H.YoungP.R.PickeringD.EndyT.P.KalayanaroojS.GreenS.VaughnD.W.NisalakA.EnnisF.A.RothmanA.L.High Circulating Levels of the" exact="Dengue" post="Virus Nonstructural Protein NS1 Early in Dengue Illness Correlate"/>
   <result pre="Levels of the Dengue Virus Nonstructural Protein NS1 Early in" exact="Dengue" post="Illness Correlate with the Development of Dengue Hemorrhagic FeverJ."/>
   <result pre="NS1 Early in Dengue Illness Correlate with the Development of" exact="Dengue" post="Hemorrhagic FeverJ. Infect. Dis.20021861165116810.1086/34381312355369 162.BennettS.N.Selection-Driven Evolution of Emergent Dengue"/>
   <result pre="of Dengue Hemorrhagic FeverJ. Infect. Dis.20021861165116810.1086/34381312355369 162.BennettS.N.Selection-Driven Evolution of Emergent" exact="Dengue" post="VirusMol. Biol. Evol.2003201650165810.1093/molbev/msg18212832629 163.VasilakisN.HolmesE.C.FokamE.B.FayeO.DialloM.SallA.A.WeaverS.C.Evolutionary Processes among Sylvatic Dengue Type"/>
   <result pre="of Emergent Dengue VirusMol. Biol. Evol.2003201650165810.1093/molbev/msg18212832629 163.VasilakisN.HolmesE.C.FokamE.B.FayeO.DialloM.SallA.A.WeaverS.C.Evolutionary Processes among Sylvatic" exact="Dengue" post="Type 2 VirusesJ. Virol.2007819591959510.1128/JVI.02776-0617553878 164.HolmesE.C.Patterns of intra- and interhost"/>
   <result pre="J. Tropical.19975710010810.4269/ajtmh.1997.57.100 169.HalsteadS.B.Dengue virus-mosquito interactionsAnnu. Rev. Entomol.20085327329110.1146/annurev.ento.53.103106.09332617803458 170.MorrisonA.C.MinnickS.L.RochaC.ForsheyB.M.StoddardS.T.GetisA.FocksD.A.RussellK.L.OlsonJ.G.BlairP.J.et al.Epidemiology of" exact="Dengue" post="Virus in Iquitos, Peru 1999 to 2005: Interepidemic and"/>
   <result pre="pathogenesis and application as a diagnostic biomarkerAntiviral Res.20139819220810.1016/j.antiviral.2013.03.00823523765 Figure 1" exact="Dengue" post="virus genome schematic. Figure 2 Dengue dynamics and its"/>
   <result pre="biomarkerAntiviral Res.20139819220810.1016/j.antiviral.2013.03.00823523765 Figure 1 Dengue virus genome schematic. Figure 2" exact="Dengue" post="dynamics and its implications for vaccine design. Lineage turnover"/>
   <result pre="severity [146]. ADE; antibody-dependent enhancement. Figure 3 A monovalent CD8" exact="Dengue" post="vaccine. CD8; cluster of differentiation 8. vaccines-07-00203-t001_Table 1Table 1"/>
   <result pre="Dengue vaccine. CD8; cluster of differentiation 8. vaccines-07-00203-t001_Table 1Table 1" exact="Dengue" post="virus genomic regions and their human immunological relevance. Region"/>
   <result pre="Response: +2° Response: +++ EEnvelope Key role in interaction of" exact="DENV" post="with host cells CD4 1° Response: +++2° Response: +++"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963678\results\search\tropicalVirus\results.xml">
   <result pre="PathogensPathogenspathogensPathogens2076-0817MDPI pmcid: 6963678 doi: 10.3390/pathogens8040193pathogens-08-00193 : Review Current Understanding of" exact="West Nile" post="Virus Clinical Manifestations, Immune Responses, Neuroinvasion, and Immunotherapeutic Implications"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="West Nile" post="virus (WNV) is the most common mosquito-borne virus in"/>
   <result pre="ages, although elderly and immunocompromised individuals are particularly at risk." exact="WNV" post="neuroinvasive disease has killed over 2300 Americans since WNV"/>
   <result pre="risk. WNV neuroinvasive disease has killed over 2300 Americans since" exact="WNV" post="entered into the United States in the New York"/>
   <result pre="progress has been made in both understanding the pathogenesis of" exact="WNV" post="and treatment in clinical practices. This review summarizes our"/>
   <result pre="in clinical practices. This review summarizes our current understanding of" exact="WNV" post="infection in terms of human clinical manifestations, host immune"/>
   <result pre="human clinical manifestations, host immune responses, neuroinvasion, and therapeutic interventions." exact="West Nile" post="virus immune response neuroinvasion clinical manifestation therapeutic implication 1."/>
   <result pre="immune response neuroinvasion clinical manifestation therapeutic implication 1. Introduction to" exact="West Nile" post="virus West Nile virus (WNV) belongs to the flavivirus"/>
   <result pre="clinical manifestation therapeutic implication 1. Introduction to West Nile virus" exact="West Nile" post="virus (WNV) belongs to the flavivirus genus in the"/>
   <result pre="the endosome into the cytoplasm after acidification-induced membrane fusion [1,2,3]." exact="WNV" post="has an approximately 11 kb long, single-stranded, positive sensed"/>
   <result pre="the prM, resulting in the release of mature virion [8]." exact="WNV" post="is cytolytic and induces apoptosis in a variety of"/>
   <result pre="hosts including humans, horses, and birds. In humans, infections with" exact="WNV" post="are either asymptomatic or can lead to life-threatening neuroinvasive"/>
   <result pre="remains the standard. Here, we review the current understanding of" exact="WNV" post="epidemiology, clinical manifestations, protective immune responses, mechanisms of neuroinvasion"/>
   <result pre="mechanisms of neuroinvasion and neuropathogenesis, and provide immunotherapeutic implications. 2." exact="WNV" post="Epidemiology In nature, WNV transmission is maintained in a"/>
   <result pre="neuropathogenesis, and provide immunotherapeutic implications. 2. WNV Epidemiology In nature," exact="WNV" post="transmission is maintained in a cycle between Culex mosquitoes,"/>
   <result pre="Humans, horses, and other vertebrate animals can be infected with" exact="WNV" post="through the bite of an infected mosquito, but are"/>
   <result pre="Disease Control and Prevention (CDC), most people (80%) infected with" exact="WNV" post="do not develop any symptoms, and about 20% infected"/>
   <result pre="rash. About 1 in 150 people who are infected with" exact="WNV" post="develop a severe illness affecting the central nervous system"/>
   <result pre="the Romania epidemic in 1996 marked the geographic transition of" exact="WNV" post="epidemics from rural areas to urban industrialized areas [11]."/>
   <result pre="from rural areas to urban industrialized areas [11]. In 1999," exact="WNV" post="gained entry into North America in New York City"/>
   <result pre="the neighboring countries in North America [13]. Phylogenetic analysis of" exact="WNV" post="isolated from the U.S. indicates that a single conserved"/>
   <result pre="since 2002, but is also found in old-world strains of" exact="WNV" post="[14]. This genotype has effectively displaced the genotype originally"/>
   <result pre="effectively displaced the genotype originally introduced to the U.S. [14]." exact="WNV" post="has now spread across six of seven continents, including"/>
   <result pre="important causative agents of human viral encephalitis worldwide. Since 1999," exact="WNV" post="has been estimated to cause more than 6 million"/>
   <result pre="is an urgent need to understand in-depth the pathogenesis of" exact="WNV" post="and develop specific treatment strategies. 3. Clinical Manifestations of"/>
   <result pre="WNV and develop specific treatment strategies. 3. Clinical Manifestations of" exact="WNV" post="Infection WNV fever and neuroinvasive disease: WNV infection in"/>
   <result pre="develop specific treatment strategies. 3. Clinical Manifestations of WNV Infection" exact="WNV" post="fever and neuroinvasive disease: WNV infection in humans can"/>
   <result pre="Clinical Manifestations of WNV Infection WNV fever and neuroinvasive disease:" exact="WNV" post="infection in humans can result in a spectrum of"/>
   <result pre="ranging from a febrile illness classified by the CDC as" exact="WNV" post="fever to severe neuroinvasive disease classified as meningitis, encephalitis,"/>
   <result pre="encephalitis, or acute flaccid paralysis (poliomyelitis variant) [16]. Before 1996," exact="WNV" post="was primarily known to cause febrile illness, now classified"/>
   <result pre="to cause febrile illness, now classified by the CDC as" exact="WNV" post="fever and often described as a &quot;summer flu�? associated"/>
   <result pre="rash. By definition, neurological symptoms (neuroinvasion) do not occur in" exact="WNV" post="fever patients and most recover completely, but fatigue and"/>
   <result pre="2002, approximately half of reported cases have been classified as" exact="WNV" post="fever and half as neuroinvasive disease. For example, in"/>
   <result pre="fever and half as neuroinvasive disease. For example, in the" exact="WNV" post="epidemic of 2012, of the 5387 reported WNV cases"/>
   <result pre="in the WNV epidemic of 2012, of the 5387 reported" exact="WNV" post="cases nationwide, 2734 (51%) were classified as neuroinvasive disease"/>
   <result pre="symptoms, including encephalitis, meningitis or acute flaccid paralysis [16]. Moreover," exact="WNV" post="infection has also been indicated to cause longitudinally extensive"/>
   <result pre="much more frequently, together with neuromuscular manifestations. Neuromuscular manifestations and" exact="WNV" post="poliomyelitis: In the 1999 New York City outbreak, more"/>
   <result pre="York City outbreak, more than 50% of patients with confirmed" exact="WNV" post="encephalitis had severe muscle weakness as a cardinal sign"/>
   <result pre="or severe axonal polyneuropathy [12,20,21]. In the 2002 and 2003" exact="WNV" post="epidemics, neuromuscular manifestations were a well-recognized feature associated with"/>
   <result pre="are now recognized as a prominent feature in patients with" exact="WNV" post="neuroinvasive disease [25]. Most physicians who are actively involved"/>
   <result pre="neuroinvasive disease [25]. Most physicians who are actively involved in" exact="WNV" post="clinical research now accept a poliomyelitis to be the"/>
   <result pre="most common cause of WNV-associated acute flaccid paralysis. Patients with" exact="WNV" post="poliomyelitis commonly have associated signs of meningitis, encephalitis, or"/>
   <result pre="on electrodiagnostic testing that occasionally are reported in patients with" exact="WNV" post="infection [24]. However, sensory loss attributed to WNV has"/>
   <result pre="patients with WNV infection [24]. However, sensory loss attributed to" exact="WNV" post="has not been a prominent clinical finding. WNV infection"/>
   <result pre="attributed to WNV has not been a prominent clinical finding." exact="WNV" post="infection and autonomic nervous system: To date, there are"/>
   <result pre="that dysautonomia plays in the morbidity and mortality of human" exact="WNV" post="infection. Yet, symptoms of dysautonomia are commonly observed during"/>
   <result pre="Yet, symptoms of dysautonomia are commonly observed during the acute" exact="WNV" post="infection and in WNV survivors recovered from the acute"/>
   <result pre="are commonly observed during the acute WNV infection and in" exact="WNV" post="survivors recovered from the acute illness. In one study"/>
   <result pre="recovered from the acute illness. In one study of 44" exact="WNV" post="patients that reported prolonged (&amp;gt; 6 months) post-infectious symptoms,"/>
   <result pre="in 9 (20%) [30]. In our initial series of 54" exact="WNV" post="patients from 2002 to 2006 who had extensive electrodiagnostic"/>
   <result pre="have also been observed by other clinicians [31,32]. In rodents," exact="WNV" post="can lead to autonomic dysfunction by infecting neurons controlling"/>
   <result pre="neurons in the brainstem were identified to be infected with" exact="WNV" post="[33]. The authors concluded that that infected neurons controlling"/>
   <result pre="identified in the sinoatrial (SA) and atrioventricular (AV) nodes [33]." exact="WNV" post="infection of hamsters has also been reported to cause"/>
   <result pre="changes in sweating, have also been observed in patients with" exact="WNV" post="infection [36]. Hence, both human and animal data suggest"/>
   <result pre="infection [36]. Hence, both human and animal data suggest that" exact="WNV" post="can cause dysautonomia, supporting the concept that the neurotropism"/>
   <result pre="can cause dysautonomia, supporting the concept that the neurotropism of" exact="WNV" post="may extend to autonomic neurons in the CNS and"/>
   <result pre="the CNS and autonomic ganglia. 4. Protective Immune Responses to" exact="WNV" post="Infection 4.1. Innate Immunity The innate immune system serves"/>
   <result pre="trigger the production of interferon I (FN) and other cytokines." exact="WNV" post="has an ssRNA genome but makes dsRNA intermediates while"/>
   <result pre="signaling of TLR3 in mice has been shown to facilitate" exact="WNV" post="infection by increasing the permeability of the blood-brain-barrier (BBB),"/>
   <result pre="while another report suggested that TLR3 might protect mice from" exact="WNV" post="infection [38,39,40]. Our research has demonstrated that TLR7 signaling"/>
   <result pre="has demonstrated that TLR7 signaling plays a protective role against" exact="WNV" post="infection in mouse models by triggering IL-23 mediated immune"/>
   <result pre="TLR8 in mice [42]. Although TLR8 may not directly sense" exact="WNV" post="RNA, it interacts with suppressor of cytokine signaling (SOCS)-1"/>
   <result pre="to confer CD8+ T cell-number expansion and effector functions against" exact="WNV" post="and other RNA viruses [53]. Mammalian cell PRRs recognize"/>
   <result pre="RNA viruses [53]. Mammalian cell PRRs recognize the PAMPs of" exact="WNV" post="and induce type I IFN productions during the early"/>
   <result pre="induce type I IFN productions during the early stages of" exact="WNV" post="infection. Experimental mice with genetic defects in the receptor"/>
   <result pre="tissues, leading to rapid lethality [54]. The induced IFN restricts" exact="WNV" post="viral replication, however, WNV has evolved to counter IFN"/>
   <result pre="lethality [54]. The induced IFN restricts WNV viral replication, however," exact="WNV" post="has evolved to counter IFN function at multiple steps"/>
   <result pre="inhibit type I IFN production or signaling [55,60,61,62,63]. In addition," exact="WNV" post="is resistant to the antiviral effects of IFN in"/>
   <result pre="has been observed in animal models or humans infected with" exact="WNV" post="[64]. Dendritic cell and macrophage: Mosquito transmitted WNV infection"/>
   <result pre="infected with WNV [64]. Dendritic cell and macrophage: Mosquito transmitted" exact="WNV" post="infection begins in the skin, and the virus replicates"/>
   <result pre="skin resident dendritic cells (DCs). After being activated by the" exact="WNV" post="antigens, LCs can migrate to the draining lymph node,"/>
   <result pre="leading to T-cell priming. In a murine model of dermal" exact="WNV" post="infection, bone marrow-derived monocytes infiltrate the skin, cluster near"/>
   <result pre="has been shown that human monocyte-derived DCs are permissive to" exact="WNV" post="infection, and secret high levels of type I IFN"/>
   <result pre="infected with WNV, which could partially explain the more severe" exact="WNV" post="infections in elderly patients [67]. However, type I IFN"/>
   <result pre="immunity in AXL receptor tyrosine kinase deficient (Axl−/−) mice during" exact="WNV" post="and influenza infection [70]. Recent studies showed that IL-1β,"/>
   <result pre="7 are important to induce DC-mediated antivirus IFN responses against" exact="WNV" post="infection [71,72,73]. Besides DCs, macrophages as specialized phagocytes and"/>
   <result pre="phagocytes and antigen-presenting cells are early responders to control initial" exact="WNV" post="replication and present the viral antigens to T cells."/>
   <result pre="present the viral antigens to T cells. Macrophages efficiently ingest" exact="WNV" post="through receptor-mediated endocytosis, then become activated to produce a"/>
   <result pre="I IFNs. These molecules are critical for the restriction of" exact="WNV" post="replication and the recruitment of more innate immune cells"/>
   <result pre="of infection [41]. The role of macrophages in resistance to" exact="WNV" post="infection has been shown in mice depleted of macrophages,"/>
   <result pre="of the CNS, become activated and produce proinflammatory molecules upon" exact="WNV" post="infection [40,41]. Recently, it has been shown that defective"/>
   <result pre="WNV infection [40,41]. Recently, it has been shown that defective" exact="WNV" post="replication in Peli1 (an E3 ubiquitin ligase)-deficient microglia and"/>
   <result pre="the pathogenesis of WNV. Neutrophils can serve as reservoirs for" exact="WNV" post="replication and dissemination in the early stages of infection"/>
   <result pre="dissemination in the early stages of infection but contribute to" exact="WNV" post="clearance later in the infection process [77]. In addition,"/>
   <result pre="[77]. In addition, neutrophils have also been documented to facilitate" exact="WNV" post="neuroinvasion via &quot;Trojan horse�? transport [78,79]. Natural Killer (NK)"/>
   <result pre="[80]. However, the reported roles of NK cells in controlling" exact="WNV" post="infection in mice are complex. Although NK cells can"/>
   <result pre="cells can be activated and recruited in the CNS following" exact="WNV" post="infection in mice, and they have been shown to"/>
   <result pre="strain of mice also failed to alter the susceptibility to" exact="WNV" post="infection, suggesting NK cells may not have a primary"/>
   <result pre="NK cells may not have a primary role in controlling" exact="WNV" post="infection and disease in mice [82]. In contrast, human"/>
   <result pre="human NK cells can be activated and able to inhibit" exact="WNV" post="infection of Vero cells through both cytolytic and noncytolytic"/>
   <result pre="cells have been shown to mount a robust response to" exact="WNV" post="infection, resulting in cytolytic activity, cytokine secretion, and chemokine"/>
   <result pre="lack of NK protection in mice may be due to" exact="WNV" post="suppressing or bypassing the NK response. Therefore, it is"/>
   <result pre="The detailed roles of NK cells in the pathogenesis of" exact="WNV" post="need to be further investigated. Gamma-Delta T cell: γδ"/>
   <result pre="pathogenic roles of γδ T cells have been indicated during" exact="WNV" post="infection. In mouse models, both γδ T cell-deficient (TCRδ−/−)"/>
   <result pre="been suggested to contribute to regulate intracellular perforin levels against" exact="WNV" post="in the periphery αβ T cells [86]. In contrast,"/>
   <result pre="peripheral γδ T cells have been implied to contribute to" exact="WNV" post="pathogenesis in mice. Depletion of Vγ4+ cells in mice"/>
   <result pre="in lower levels of viremia, encephalitis, and mortality rates following" exact="WNV" post="infection. The pathogenic effects of Vγ4+ cells are mediated"/>
   <result pre="shown to compromise the integrity of the BBB and facilitate" exact="WNV" post="entry into the brain [40]. Anti-inflammatory cytokine IL-10 has"/>
   <result pre="has been shown to play a negative role in controlling" exact="WNV" post="infection in mice [88]. Vγ4+ cell-depleted mice had reduced"/>
   <result pre="load in the brain and a lower mortality rate to" exact="WNV" post="encephalitis [89]. In addition, Vγ4+ cells negatively regulate Vγ1+"/>
   <result pre="Vγ1+ T cell responses via the production of TGF-β during" exact="WNV" post="infection [89]. 4.2. Complement The complement system consists of"/>
   <result pre="C3. The complement system has a protective role in controlling" exact="WNV" post="infection. WNV infection in mice deficient in complement receptor"/>
   <result pre="complement system has a protective role in controlling WNV infection." exact="WNV" post="infection in mice deficient in complement receptor 1 (CR1)"/>
   <result pre="factor D all resulted in increased mortality in mice following" exact="WNV" post="infection. Furthermore, the lack of complement functions might also"/>
   <result pre="in the deficiency of B and T cell responses to" exact="WNV" post="[91]. MBL recognizes N-linked glycans on the structural proteins"/>
   <result pre="[91]. MBL recognizes N-linked glycans on the structural proteins of" exact="WNV" post="and DENV, resulting in neutralization through a C3- and"/>
   <result pre="canonical and bypass lectin activation pathways [92]. Soluble and cell-surface-associated" exact="WNV" post="NS1 has been shown to bind to and recruit"/>
   <result pre="The complement component C1q increases the potency of antibodies against" exact="WNV" post="by modulating the stoichiometric requirements for neutralization [96]. However,"/>
   <result pre="in MBL-A and MBL-C or MASP-2 were more vulnerable to" exact="WNV" post="infection than WT mice, they had comparable kinetics of"/>
   <result pre="pathway might have important yet subordinate functions in protecting against" exact="WNV" post="infection [97]. In addition, using C5-depleted or -deficient human"/>
   <result pre="suggested that C5 might not either contribute to protection against" exact="WNV" post="pathogenesis or augment the neutralizing efficacy of complement-fixing anti-WNV"/>
   <result pre="Antibody and B cells are essential in the defense against" exact="WNV" post="infection in that mice deficient in B cells and"/>
   <result pre="WT, μMT and RAG1 (T and B cell-deficient) mice from" exact="WNV" post="infection. Antibody by itself did not eliminate viral reservoirs"/>
   <result pre="IgM and secreting other antibody isotypes, are vulnerable to lethal" exact="WNV" post="infection [101]. These results demonstrated that the early anti-WNV"/>
   <result pre="demonstrated that the early anti-WNV IgM in the course of" exact="WNV" post="infection limits viremia and dissemination into the CNS. The"/>
   <result pre="this, mice deficient in interferon-induced transmembrane protein, Ifitm3, infected with" exact="WNV" post="showed decreases in the total number of B cells,"/>
   <result pre="mice deficient in interferon regulatory factor 5 (Irf5−/−) infected with" exact="WNV" post="exhibited small differences in the type I IFN response"/>
   <result pre="these mice [105]. Furthermore, B cell and humoral responses to" exact="WNV" post="infection have been suggested to be regulated by many"/>
   <result pre="and TNF-α). CD8+ T cells are essential in protecting from" exact="WNV" post="infection. Early studies using rag-deficient mice that lack all"/>
   <result pre="MHC class Ia-deficient mice demonstrated a protective role in clearing" exact="WNV" post="infection in the CNS and peripheral tissues [100,111]. In"/>
   <result pre="infection in the CNS and peripheral tissues [100,111]. In addition," exact="WNV" post="infection of mice deficient in perforin, fas ligand and"/>
   <result pre="been shown to increase the survival of the mice from" exact="WNV" post="infection [118]. Collectively, the results from these studies indicated"/>
   <result pre="CD8+ T cells play an important protective role in controlling" exact="WNV" post="infection. However, studies also showed a potential pathogenic role"/>
   <result pre="showed a potential pathogenic role for CD8+ T cells in" exact="WNV" post="infection. High doses (108 PFU) of Sarafend strain of"/>
   <result pre="WNV infection. High doses (108 PFU) of Sarafend strain of" exact="WNV" post="infection in CD8−/− mice lead to the increased survival,"/>
   <result pre="T cells are involved in both recovery and immunopathology in" exact="WNV" post="infection [119]. Additionally, when mice lacking the interferon-stimulated gene"/>
   <result pre="survived better than the isotype control mice following a mutant" exact="WNV" post="(E218A) infection, in which NS5 lacks 2′-O methyltransferase activity,"/>
   <result pre="Therefore, while CD8 T cells are required for control of" exact="WNV" post="infection, they may also contribute to immunopathogenesis in some"/>
   <result pre="to have both indirect and direct roles in defense against" exact="WNV" post="infection. Infection of mice that lack CD4+ T cells"/>
   <result pre="T cells and MHC class II resulted in a prolonged" exact="WNV" post="infection in the CNS that culminated in uniform lethality"/>
   <result pre="an indirect protective role of CD4+ T cell during primary" exact="WNV" post="infection by sustaining antibody production and effector CD8+ T"/>
   <result pre="T cells may also play a direct role in limiting" exact="WNV" post="replication by producing IFN-γ, IL-2 and granzyme B, and"/>
   <result pre="that Tregs appeared to play a protective role in limiting" exact="WNV" post="disease. Tregs expanded significantly in the peripheral after WNV"/>
   <result pre="limiting WNV disease. Tregs expanded significantly in the peripheral after" exact="WNV" post="infection in both humans and mice. In humans, the"/>
   <result pre="with asymptomatic mice after infection and Treg-deficient mice developed lethal" exact="WNV" post="infection at a higher rate than the controls [124]."/>
   <result pre="RIG-I, was dispensable for Treg proliferation and suppressive capacity during" exact="WNV" post="infection in mice [126,127]. 5. WNV Neuroinvasion and Neuropathogenesis"/>
   <result pre="and suppressive capacity during WNV infection in mice [126,127]. 5." exact="WNV" post="Neuroinvasion and Neuropathogenesis Neuroinvasion: WNV can enter the CNS"/>
   <result pre="infection in mice [126,127]. 5. WNV Neuroinvasion and Neuropathogenesis Neuroinvasion:" exact="WNV" post="can enter the CNS and cause neuroinvasive diseases with"/>
   <result pre="[128,129]. Although the detailed mechanisms are still not well understood," exact="WNV" post="has been suggested to enter the CNS through multiple"/>
   <result pre="microvasculature, infection of olfactory neurons, infected leukocytes that &quot;Trojan horse�?" exact="WNV" post="to the CNS, and/or direct axonal retrograde transport from"/>
   <result pre="axonal retrograde transport from infected peripheral nerves [87,91,92,93,94,95,96,97] (Figure 1)." exact="WNV" post="replication in the peripheral organs and the blood cells,"/>
   <result pre="blood circulation that may lead to infection in the CNS." exact="WNV" post="infection in the CNS can result in meningitis, encephalitis,"/>
   <result pre="can result in meningitis, encephalitis, and acute flaccid paralysis, including" exact="WNV" post="poliomyelitis. The possible mechanisms by which WNV enters the"/>
   <result pre="flaccid paralysis, including WNV poliomyelitis. The possible mechanisms by which" exact="WNV" post="enters the CNS include: ① WNV infection induces the"/>
   <result pre="possible mechanisms by which WNV enters the CNS include: ①" exact="WNV" post="infection induces the expression of TNF-α, MIF, MMP9, ICAM-1"/>
   <result pre="BBB allowing the virus to penetrate to the CNS; ②" exact="WNV" post="may infect endothelial cells in the cerebral microvasculature, from"/>
   <result pre="which progeny viruses may be released into the CNS; ③" exact="WNV" post="may enter the CNS from infected olfactory bulbs via"/>
   <result pre="leukocytes, such as neutrophils via a &quot;Trojan horse�? transport of" exact="WNV" post="to the CNS; and ⑤ WNV may be transported"/>
   <result pre="&quot;Trojan horse�? transport of WNV to the CNS; and ⑤" exact="WNV" post="may be transported to the CNS through the infected"/>
   <result pre="the CNS through the infected peripheral nerves. In the CNS," exact="WNV" post="may infect neurons, microglia, and astrocytes producing cytokines and"/>
   <result pre="persistently elevated in the blood for months after clearance of" exact="WNV" post="from the body, which can lead to a post-infectious"/>
   <result pre="causing inflammation and neuronal death in the CNS. In mice," exact="WNV" post="induces systemic infection and then crosses the BBB, leading"/>
   <result pre="factor (MIF) are vital for the transient BBB permeabilization upon" exact="WNV" post="infection [40,131,132,133]. In addition, a study on Venezuelan equine"/>
   <result pre="to enter the brain [134]. While the initial site of" exact="WNV" post="entry into the CNS is still debatable, the rostral-caudal"/>
   <result pre="into the CNS is still debatable, the rostral-caudal spread of" exact="WNV" post="antigen from the olfactory bulb to the remaining structures"/>
   <result pre="notion because olfactory bulbs have been observed to have more" exact="WNV" post="antigens than other brain regions by immunostaining in the"/>
   <result pre="infection [41,88,137], suggesting olfactory bulbs are a possible route of" exact="WNV" post="entry into the CNS bypassing the BBB. In contrast,"/>
   <result pre="WNV entry into the CNS bypassing the BBB. In contrast," exact="WNV" post="antigen localizing to the olfactory lobes in horses and"/>
   <result pre="infected T cells and macrophages have been suggested carriers of" exact="WNV" post="into the CNS [141,142,143], however, our results demonstrated that"/>
   <result pre="WNV into the CNS [141,142,143], however, our results demonstrated that" exact="WNV" post="replicates more efficiently in human and mouse polymorphonuclear neutrophils"/>
   <result pre="are recruited into the brain at an early stage of" exact="WNV" post="infection [144]. In addition, clinical data also showed that"/>
   <result pre="into the CNS of patients at the early stage of" exact="WNV" post="neuroinvasive disease [145,146]. Our recent results show that WNV-infected"/>
   <result pre="neutrophils could play a major &quot;Trojan horse�? role in transporting" exact="WNV" post="into the CNS [78]. However, it is possible that"/>
   <result pre="neurons through the activation of mitochondrial/caspase-9 and caspase-3 pathways during" exact="WNV" post="infection [82,113,147]. In WNV-infected mice, apoptotic neurons are prominent"/>
   <result pre="but rare in the brain, suggesting that the mechanisms of" exact="WNV" post="induced cell death may differ within specific regions of"/>
   <result pre="within specific regions of the CNS [128]. In the CNS," exact="WNV" post="infects neurons, basal ganglia, brainstem and spinal cord [140],"/>
   <result pre="ganglia, brainstem and spinal cord [140], while in cell culture" exact="WNV" post="infects both neurons and astrocytes, although with differing kinetics"/>
   <result pre="courses [153]. Examination of sera and cerebrospinal fluid (CSF) from" exact="WNV" post="patients who had symptoms between 2–18 days showed elevated"/>
   <result pre="products (RAGE) could also be activated by HMGB1 released from" exact="WNV" post="infected cells undergoing necrotic cell death [157,158]. The spinal"/>
   <result pre="and showed an overall increase in S100B immunoreactivity in the" exact="WNV" post="compared to the control specimens, which may lead to"/>
   <result pre="RAGE mediated damage at other unaffected regions [156]. In addition," exact="WNV" post="infection could result in a focal loss of ganglionic"/>
   <result pre="may be severe enough to produce sensory deficits in some" exact="WNV" post="patients [29]. Post-infectious CNS symptoms: Human acute WNV infection"/>
   <result pre="in some WNV patients [29]. Post-infectious CNS symptoms: Human acute" exact="WNV" post="infection induces a significant upregulation of various proinflammatory proteins"/>
   <result pre="post-infectious proinflammatory state that may contribute to long-term neuroinflammation in" exact="WNV" post="survivors [30,78,118]. Among a large cohort of participants with"/>
   <result pre="Among a large cohort of participants with a history of" exact="WNV" post="infection in Houston, TX, USA, approximately 40% of those"/>
   <result pre="3/11) and meningitis (36%, 5/14) cases during 1–3 years following" exact="WNV" post="infection. At the second assessment between 8–11 years post-infection,"/>
   <result pre="the second assessment between 8–11 years post-infection, 57% (4/7) of" exact="West Nile" post="fever, 33% (2/6) of West Nile meningitis, and 36%"/>
   <result pre="post-infection, 57% (4/7) of West Nile fever, 33% (2/6) of" exact="West Nile" post="meningitis, and 36% (5/14) of West Nile encephalitis had"/>
   <result pre="33% (2/6) of West Nile meningitis, and 36% (5/14) of" exact="West Nile" post="encephalitis had developed new neurological complications [163]. Importantly, MRI"/>
   <result pre="MRI findings provide valuable evidence regarding the neurologic outcomes following" exact="WNV" post="CNS infection. Post-infectious CNS symptoms included post-exertion fatigue, dizziness,"/>
   <result pre="depression, anxiety, sleep disruption, and recurrent headaches [30]. Moreover, numerous" exact="WNV" post="patients have developed autoinflammatory or autoimmune-related diseases, including myasthenia"/>
   <result pre="or autoimmune-related diseases, including myasthenia gravis (MG) [165,166], suggesting that" exact="WNV" post="infection may promote or amplify underlying autoimmunity. Interestingly, RAGE"/>
   <result pre="MG [170]. These results indicate that over-expression of IL-17 following" exact="WNV" post="infection could contribute to the development of MG, although"/>
   <result pre="development of MG, although it can be beneficial in clearing" exact="WNV" post="by promoting CD8+ T cell cytotoxicity [118]. Furthermore, WNV"/>
   <result pre="clearing WNV by promoting CD8+ T cell cytotoxicity [118]. Furthermore," exact="WNV" post="infection has also been suggested to induce other autoimmune"/>
   <result pre="evidence are still needed to establish the cause-effective relationship of" exact="WNV" post="infection with autoimmune diseases. 6. Immunotherapeutic Intervention Despite the"/>
   <result pre="6. Immunotherapeutic Intervention Despite the development of four licensed veterinary" exact="WNV" post="vaccines, there are still no approved vaccines or antivirals"/>
   <result pre="difficulties in clinical study design (due to lack of enough" exact="WNV" post="cases for a phase III vaccine efficacy study), and"/>
   <result pre="high dose steroids may result in marked clinical improvement in" exact="WNV" post="patients who suffer severe neuroinflammation. Both experimental and clinical"/>
   <result pre="suggest that pro-inflammatory mediators may contribute to the pathogenesis of" exact="WNV" post="in the CNS. Treatment of infected neuronal cells with"/>
   <result pre="However, an in-depth understanding of the immune-mediated post-infectious pathogenesis of" exact="WNV" post="infection has direct therapeutic implications and treatment strategies that"/>
   <result pre="has been documented to improve the outcomes of patients with" exact="WNV" post="neuroinvasive disease. In 14 patients with acute WNV meningoencephalitis,"/>
   <result pre="patients with WNV neuroinvasive disease. In 14 patients with acute" exact="WNV" post="meningoencephalitis, intravenous dexamethasone injection was suggested to play a"/>
   <result pre="play a critical role in shortening the acute phase of" exact="WNV" post="disease and hastening patient recovery [176]. In addition, high-dose"/>
   <result pre="effect’ of high dose corticosteroids in a semi-comatose woman with" exact="WNV" post="encephalitis highlights the success of this therapeutic approach [178]."/>
   <result pre="approach [178]. Although the use of steroids in patients with" exact="WNV" post="neuroinvasive disease seems counterintuitive, with concern that immunosuppressive effects"/>
   <result pre="promote viremia and worsen outcome, the evidence is compelling that" exact="WNV" post="is rapidly cleared by immune responses in immunocompetent patients"/>
   <result pre="steroids and possibly other immunosuppressive drugs in the treatment of" exact="WNV" post="infection. The clinical experience warrants appropriate large-scale clinical trials"/>
   <result pre="of corticosteroids and other immunosuppressive drugs in the treatment of" exact="WNV" post="disease. This is particularly pertinent in light of the"/>
   <result pre="has been no successful development or marketing of a human" exact="WNV" post="vaccine. 7. Concluding Remarks WNV has become a major"/>
   <result pre="or marketing of a human WNV vaccine. 7. Concluding Remarks" exact="WNV" post="has become a major global health concern in the"/>
   <result pre="Basic and clinical research has made great progress in understanding" exact="WNV" post="biology, transmission, host immune responses, neuroinvasion, and immunopathogenesis. However,"/>
   <result pre="still be directed at further understanding of the pathogenesis of" exact="WNV" post="infection, both in animal models and humans, that will"/>
   <result pre="under Award Number R15AI135893 to F.B. P.J.S.V. was supported by" exact="West Nile" post="Research Fund administered by The Wilson Research Foundation, Jackson,"/>
   <result pre="Genet.2018959510.3389/fgene.2018.0059530564270 6.EFirthA.AtkinsJ.F.A conserved predicted pseudoknot in the NS2A-encoding sequence of" exact="West Nile" post="and Japanese encephalitis flaviviruses suggests NS1’ may derive from"/>
   <result pre="derive from ribosomal frameshiftingVirol. J.200961410.1186/1743-422X-6-1419196463 7.YoungL.B.MelianE.B.SetohY.X.YoungP.R.KhromykhA.A.Last 20 aa of the" exact="West Nile" post="virus NS1′ protein are responsible for its retention in"/>
   <result pre="Microbiol. Rev.20122563564810.1128/CMR.00045-1223034323 9.SpiglandI.Jasinska-KlingbergW.HofshiE.GoldblumN.Clinical and laboratory observations in an outbreak of" exact="West Nile" post="fever in Israel in 1957Harefuah19585427528013562703 10.WeinbergerM.PitlikS.D.GandacuD.LangR.NassarF.Ben DavidD.RubinsteinE.IzthakiA.MishalJ.KitzesR.et al.West Nile"/>
   <result pre="Dis.2001768669110.3201/eid0704.01741611585533 11.CampbellG.L.MarfinA.A.LanciottiR.S.GublerD.J.West Nile virusLancet Infect. Dis.2002251952910.1016/S1473-3099(02)00368-712206968 12.MostashariF.FineA.O’LearyD.HuangA.ShermanM.WongS.CampbellG.L.ShiehW.-J.SmithP.GreenbergA.et al.The Outbreak of" exact="West Nile" post="Virus Infection in the New York City Area in"/>
   <result pre="1999N. Engl. J. Med.20013441807181411407341 13.ChanceyC.GrinevA.VolkovaE.RiosM.The Global Ecology and Epidemiology of" exact="West Nile" post="VirusBiomed Res. Int.2015201512010.1155/2015/376230 14.KramerL.D.LiJ.ShiP.Y.West Nile virusLancet. Neurol.2007617118110.1016/S1474-4422(07)70030-317239804 15.KaiserJ.A.BarrettA.D.Twenty Years"/>
   <result pre="Int.2015201512010.1155/2015/376230 14.KramerL.D.LiJ.ShiP.Y.West Nile virusLancet. Neurol.2007617118110.1016/S1474-4422(07)70030-317239804 15.KaiserJ.A.BarrettA.D.Twenty Years of Progress toward" exact="West Nile" post="Virus Vaccine DevelopmentViruses20191182310.3390/v11090823 16.collab: CDCWest Nile VirusAvailable online: https://www.cdc.gov/westnile/healthcareproviders/healthcareproviders-diagnostic.html(accessed"/>
   <result pre="2018) 17.MartinovicV.Kisic-TepavcevicD.KacarA.MesarosS.PekmezovicT.DrulovicJ.Longitudinally extensive transverse myelitis in a patient infected with" exact="West Nile" post="virusMult. Scler. Relat. Disord.201932192210.1016/j.msard.2019.04.00731005826 18.PradhanS.AnandS.ChoudhuryS.S.Cognitive behavioural impairment with irreversible"/>
   <result pre="behavioural impairment with irreversible sensorineural deafness as a complication of" exact="West Nile" post="encephalitisJ. Neurovirol.20192542943310.1007/s13365-019-00733-230903400 19.BurdmannE.A.Flaviviruses and Kidney DiseasesAdv. Chronic Kidney Dis.20192619820610.1053/j.ackd.2019.01.00231202392"/>
   <result pre="encephalitisJ. Neurovirol.20192542943310.1007/s13365-019-00733-230903400 19.BurdmannE.A.Flaviviruses and Kidney DiseasesAdv. Chronic Kidney Dis.20192619820610.1053/j.ackd.2019.01.00231202392 20.ConettaR.TeixeiraA.A.WaldmanG.SampsonB.A.AsnisD.S.The" exact="West Nile" post="Virus Outbreak of 1999 in New York: The Flushing"/>
   <result pre="The Flushing Hospital ExperienceClin. Infect. Dis.20003041341810722421 21.SampsonB.A.AmbrosiC.CharlotA.ReiberK.VeressJ.F.ArmbrustmacherV.The pathology of human" exact="West Nile" post="virus infectionHum. Pathol.20003152753110.1053/hp.2000.804710836291 22.LeisA.A.PolkJ.L.DostrowV.WinkelmannM.StokicD.S.A Poliomyelitis-like Syndrome from West Nile"/>
   <result pre="human West Nile virus infectionHum. Pathol.20003152753110.1053/hp.2000.804710836291 22.LeisA.A.PolkJ.L.DostrowV.WinkelmannM.StokicD.S.A Poliomyelitis-like Syndrome from" exact="West Nile" post="Virus InfectionN. Engl. J. Med.20023471279128010.1056/NEJM2002c02158712270971 23.LiJ.LoebJ.A.ShyM.E.ShahA.K.TselisA.C.KupskiW.J.LewisR.A.Asymmetric flaccid paralysis: A"/>
   <result pre="Engl. J. Med.20023471279128010.1056/NEJM2002c02158712270971 23.LiJ.LoebJ.A.ShyM.E.ShahA.K.TselisA.C.KupskiW.J.LewisR.A.Asymmetric flaccid paralysis: A neuromuscular presentation of" exact="West Nile" post="virus infectionAnn. Neurol.20035370371010.1002/ana.1057512783415 24.JehaL.E.SilaC.A.LedermanR.J.PraysonR.A.IsadaC.M.GordonS.M.West Nile virus infection: A new"/>
   <result pre="virus infection: A new acute paralytic illnessNeurology200361555910.1212/01.WNL.0000073617.08185.0A12847156 25.LeisA.A.StokicD.S.Neuromuscular Manifestations of" exact="West Nile" post="Virus InfectionFront. Neurol.201233710.3389/fneur.2012.0003722461779 26.LeisA.A.StokicD.S.WebbR.M.SlavinskiS.A.FratkinJ.Clinical spectrum of muscle weakness in"/>
   <result pre="Virus InfectionFront. Neurol.201233710.3389/fneur.2012.0003722461779 26.LeisA.A.StokicD.S.WebbR.M.SlavinskiS.A.FratkinJ.Clinical spectrum of muscle weakness in human" exact="West Nile" post="virus infectionMuscle Nerve20032830230810.1002/mus.1044012929189 27.SejvarJ.J.LeisA.A.StokicD.S.Van GerpenJ.A.MarfinA.A.WebbR.HaddadM.B.TierneyB.C.SlavinskiS.A.PolkJ.L.et al.Acute Flaccid Paralysis and"/>
   <result pre="Nile virus infectionMuscle Nerve20032830230810.1002/mus.1044012929189 27.SejvarJ.J.LeisA.A.StokicD.S.Van GerpenJ.A.MarfinA.A.WebbR.HaddadM.B.TierneyB.C.SlavinskiS.A.PolkJ.L.et al.Acute Flaccid Paralysis and" exact="West Nile" post="Virus InfectionEmerg. Infect. Dis.2003978879310.3201/eid0907.03012912890318 28.JohnstoneJ.HannaS.E.NicolleL.E.DrebotM.A.NeupaneB.MahonyJ.B.LoebM.B.Prognosis of West Nile virus"/>
   <result pre="Paralysis and West Nile Virus InfectionEmerg. Infect. Dis.2003978879310.3201/eid0907.03012912890318 28.JohnstoneJ.HannaS.E.NicolleL.E.DrebotM.A.NeupaneB.MahonyJ.B.LoebM.B.Prognosis of" exact="West Nile" post="virus associated acute flaccid paralysis: A case seriesJ. Med."/>
   <result pre="case seriesJ. Med. Case Rep.2011539510.1186/1752-1947-5-39521854567 29.FratkinJ.D.LeisA.A.StokicD.S.SlavinskiS.A.GeissR.W.Spinal cord neuropathology in human" exact="West Nile" post="virus infectionArch. Pathol. Lab. Med.200412853353715086282 30.GarciaM.N.HauseA.M.WalkerC.M.OrangeJ.S.HasbunR.MurrayK.O.Evaluation of Prolonged Fatigue"/>
   <result pre="J.20031681399140512771068 32.LindseyN.P.SejvarJ.J.BodeA.V.PapeW.J.CampbellG.L.Delayed Mortality in a Cohort of Persons Hospitalized with" exact="West Nile" post="Virus Disease in Colorado in 2003Vector Borne Zoonotic Dis.20121223023510.1089/vbz.2011.072122022816"/>
   <result pre="Borne Zoonotic Dis.20121223023510.1089/vbz.2011.072122022816 33.WangH.SiddharthanV.HallJ.O.MorreyJ.D.Autonomic Nervous Dysfunction in Hamsters Infected with" exact="West Nile" post="VirusPLoS ONE20116e1957510.1371/journal.pone.001957521573009 34.MorreyJ.D.SiddharthanV.WangH.HallJ.O.MotterN.E.SkinnerR.D.SkirpstunasR.T.Neurological suppression of diaphragm electromyographs in hamsters"/>
   <result pre="ONE20116e1957510.1371/journal.pone.001957521573009 34.MorreyJ.D.SiddharthanV.WangH.HallJ.O.MotterN.E.SkinnerR.D.SkirpstunasR.T.Neurological suppression of diaphragm electromyographs in hamsters infected with" exact="West Nile" post="virusJ. Neurovirol.20101631832910.3109/13550284.2010.50184720632796 35.ZukorK.WangH.HurstB.L.SiddharthanV.Van WettereA.PilowskyP.M.MorreyJ.D.Phrenic nerve deficits and neurological immunopathology"/>
   <result pre="35.ZukorK.WangH.HurstB.L.SiddharthanV.Van WettereA.PilowskyP.M.MorreyJ.D.Phrenic nerve deficits and neurological immunopathology associated with acute" exact="West Nile" post="virus infection in mice and hamstersJ. Neurovirol.20172318620410.1007/s13365-016-0488-627761801 36.BudhramA.SharmaM.ShettarB.Hosseini-MoghaddamS.M.KhawA.V.Sensory and"/>
   <result pre="in mice and hamstersJ. Neurovirol.20172318620410.1007/s13365-016-0488-627761801 36.BudhramA.SharmaM.ShettarB.Hosseini-MoghaddamS.M.KhawA.V.Sensory and autonomic involvement in" exact="West Nile" post="virus-associated acute flaccid paralysisNeurol. Clin. Pract.2017739439710.1212/CPJ.000000000000037329620087 37.TownT.JengD.AlexopoulouL.TanJ.FlavellR.A.Microglia recognize double-stranded"/>
   <result pre="TLR3J. Immunol.20061763804381210.4049/jimmunol.176.6.380416517751 38.DaffisS.SamuelM.A.SutharM.S.GaleM.DiamondM.S.Toll-Like Receptor 3 Has a Protective Role against" exact="West Nile" post="Virus InfectionJ. Virol.200882103491035810.1128/JVI.00935-0818715906 39.ScholleF.MasonP.W.West Nile virus replication interferes with"/>
   <result pre="transcription and response to interferon treatmentVirology2005342778710.1016/j.virol.2005.07.02116111732 40.WangT.TownT.AlexopoulouL.AndersonJ.F.FikrigE.FlavellR.A.Toll-like receptor 3 mediates" exact="West Nile" post="virus entry into the brain causing lethal encephalitisNat. Med.2004101366137310.1038/nm114015558055"/>
   <result pre="brain causing lethal encephalitisNat. Med.2004101366137310.1038/nm114015558055 41.TownT.BaiF.WangT.KaplanA.T.QianF.MontgomeryR.R.AndersonJ.F.FlavellR.A.FikrigE.Toll-like receptor 7 mitigates lethal" exact="West Nile" post="encephalitis via interleukin 23-dependent immune cell infiltration and homingImmunity20093024225310.1016/j.immuni.2008.11.01219200759"/>
   <result pre="43.PaulA.M.AcharyaD.LeL.WangP.StokicD.S.LeisA.A.AlexopoulouL.TownT.FlavellR.A.FikrigE.et al.TLR8 Couples SOCS-1 and Restrains TLR7-Mediated Antiviral Immunity, Exacerbating" exact="West Nile" post="Virus Infection in MiceJ. Immunol.20161974425443510.4049/jimmunol.160090227798161 44.KatoH.TakeuchiO.Mikamo-SatohE.HiraiR.KawaiT.MatsushitaK.HiiragiA.DermodyT.S.FujitaT.AkiraS.Length-dependent recognition of double-stranded"/>
   <result pre="T cell survival and fitnessImmunity20123723524810.1016/j.immuni.2012.07.00422841161 54.SamuelM.A.DiamondM.S.Alpha/Beta Interferon Protects against Lethal" exact="West Nile" post="Virus Infection by Restricting Cellular Tropism and Enhancing Neuronal"/>
   <result pre="Neuronal SurvivalJ. Virol.200579133501336110.1128/JVI.79.21.13350-13361.200516227257 55.LiuW.J.WangX.J.ClarkD.C.LobigsM.HallR.A.KhromykhA.A.A Single Amino Acid Substitution in the" exact="West Nile" post="Virus Nonstructural Protein NS2A Disables Its Ability To Inhibit"/>
   <result pre="Inhibition of Beta Interferon Promoter-Driven TranscriptionJ. Virol.200478122251223510.1128/JVI.78.22.12225-12235.200415507609 61.SetohY.X.PeriasamyP.PengN.Y.G.AmarillaA.A.SlonchakA.KhromykhA.A.Helicase Domain of" exact="West Nile" post="Virus NS3 Protein Plays a Role in Inhibition of"/>
   <result pre="immune evasionJ. Virol.2011852723273210.1128/JVI.02050-1021191014 63.Laurent-RolleM.BoerE.F.LubickK.J.WolfinbargerJ.B.CarmodyA.B.RockxB.LiuW.AshourJ.ShupertW.L.HolbrookM.R.et al.The NS5 Protein of the Virulent" exact="West Nile" post="Virus NY99 Strain Is a Potent Antagonist of Type"/>
   <result pre="SignalingJ. Virol.2010843503351510.1128/JVI.01161-0920106931 64.Chan-TackK.M.ForrestG.Failure of interferon alpha-2b in a patient with" exact="West Nile" post="virus meningoencephalitis and acute flaccid paralysisScand. J. Infect. Dis.20053794494610.1080/0036554050026269016308241"/>
   <result pre="differentiation from migrating Ly6C(lo) bone marrow monocytes in early dermal" exact="West Nile" post="virus infectionJ. Immunol.20111862382239610.4049/jimmunol.100268221248254 66.KovatsS.TurnerS.SimmonsA.PoweT.ChakravartyE.Alberola-IlaJ.West Nile virus-infected human dendritic cells"/>
   <result pre="in Dendritic Cells From Older Donors Infected In Vitro With" exact="West Nile" post="VirusJ. Infect. Dis.20112031415142410.1093/infdis/jir04821398396 68.MartinaB.E.KorakaP.van den DoelP.RimmelzwaanG.F.HaagmansB.L.OsterhausA.D.DC-SIGN enhances infection of"/>
   <result pre="Dis.20112031415142410.1093/infdis/jir04821398396 68.MartinaB.E.KorakaP.van den DoelP.RimmelzwaanG.F.HaagmansB.L.OsterhausA.D.DC-SIGN enhances infection of cells with glycosylated" exact="West Nile" post="virus in vitro and virus replication in human dendritic"/>
   <result pre="69.SilvaM.C.Guerrero-PlataA.GilfoyF.D.GarofaloR.P.MasonP.W.Differential Activation of Human Monocyte-Derived and Plasmacytoid Dendritic Cells by" exact="West Nile" post="Virus Generated in Different Host CellsJ. Virol.200781136401364810.1128/JVI.00857-0717913823 70.SchmidE.T.PangI.K.SilvaE.A.C.BosurgiL.MinerJ.J.DiamondM.S.IwasakiA.RothlinC.V.AXL receptor"/>
   <result pre="72.ChowK.T.DriscollC.LooY.M.KnollM.GaleM.Jr.IRF5 regulates unique subset of genes in dendritic cells during" exact="West Nile" post="virus infectionJ. Leukoc. Biol.201910541142510.1002/JLB.MA0318-136RRR30457675 73.LazearH.M.LancasterA.WilkinsC.SutharM.S.HuangA.VickS.C.ClepperL.ThackrayL.BrassilM.M.VirginH.W.et al.IRF-3, IRF-5, and IRF-7"/>
   <result pre="Virol.199614145946910.1007/BF017183108645088 75.LuoH.WinkelmannE.R.ZhuS.RuW.MaysE.SilvasJ.A.VollmerL.L.GaoJ.PengB.-H.BoppN.E.et al.Peli1 facilitates virus replication and promotes neuroinflammation during" exact="West Nile" post="virus infectionJ. Clin. Investig.20181284980499110.1172/JCI9990230247157 76.DrescherB.BaiF.Neutrophil in viral infections, friend"/>
   <result pre="Res.20131711710.1016/j.virusres.2012.11.00223178588 77.BaiF.KongK.DaiJ.QianF.ZhangL.BrownC.R.FikrigE.MontgometryR.R.A Paradoxical Role for Neutrophils in the Pathogenesis of" exact="West Nile" post="VirusJ. Infect. Dis.20102021804181210.1086/65741621050124 78.PaulA.M.AcharyaD.DutyL.ThompsonE.A.LeL.StokicD.S.LeisA.A.BaiF.Osteopontin facilitates West Nile virus neuroinvasion"/>
   <result pre="the Pathogenesis of West Nile VirusJ. Infect. Dis.20102021804181210.1086/65741621050124 78.PaulA.M.AcharyaD.DutyL.ThompsonE.A.LeL.StokicD.S.LeisA.A.BaiF.Osteopontin facilitates" exact="West Nile" post="virus neuroinvasion via neutrophil &quot;Trojan horse�? transportSci. Rep.20177472210.1038/s41598-017-04839-728680095 79.WangP.BaiF.ZenewiczL.A.DaiJ.GateD.ChengG.YangL.QianF.YuanX.MontgomeryR.R.et"/>
   <result pre="neutrophil &quot;Trojan horse�? transportSci. Rep.20177472210.1038/s41598-017-04839-728680095 79.WangP.BaiF.ZenewiczL.A.DaiJ.GateD.ChengG.YangL.QianF.YuanX.MontgomeryR.R.et al.IL-22 Signaling Contributes to" exact="West Nile" post="Encephalitis PathogenesisPLoS ONE20127e4415310.1371/journal.pone.004415322952908 80.VivierE.TomaselloE.BaratinM.WalzerT.UgoliniS.Functions of natural killer cellsNat. Immunol.2008950351010.1038/ni158218425107"/>
   <result pre="killer cellsJ. Neuroimmunol.19881910111010.1016/0165-5728(88)90039-23397404 82.ShresthaB.SamuelM.A.DiamondM.S.CD8+ T cells require perforin to clear" exact="West Nile" post="virus from infected neuronsJ. Virol.20068011912910.1128/JVI.80.1.119-129.200616352536 83.ZhangM.DanielS.HuangY.ChanceyC.HuangQ.LeiY.F.GrinevA.MostowskiH.RiosM.DaytonA.Anti-West Nile virus activity"/>
   <result pre="natural killer cellsBMC Immunol.201011310.1186/1471-2172-11-320089143 84.YaoY.Strauss-AlbeeD.M.ZhouJ.Q.MalawistaA.GarciaM.N.MurrayK.O.BlishC.A.MontgomeryR.R.The natural killer cell response to" exact="West Nile" post="virus in young and old individuals with or without"/>
   <result pre="Interferon Plays a Crucial Early Antiviral Role in Protection against" exact="West Nile" post="Virus InfectionJ. Virol.2006805338534810.1128/JVI.00274-0616699014 86.WangT.ScullyE.YinZ.KimJ.H.WangS.YanJ.MamulaM.AndersonJ.F.CraftJ.FikrigE.IFN-gamma-producing gamma delta T cells help"/>
   <result pre="InfectionJ. Virol.2006805338534810.1128/JVI.00274-0616699014 86.WangT.ScullyE.YinZ.KimJ.H.WangS.YanJ.MamulaM.AndersonJ.F.CraftJ.FikrigE.IFN-gamma-producing gamma delta T cells help control murine" exact="West Nile" post="virus infectionJ. Immunol.20031712524253110.4049/jimmunol.171.5.252412928402 87.WelteT.LambJ.AndersonJ.F.BornW.K.O’BrienR.L.WangT.Role of two distinct gammadelta T"/>
   <result pre="Immunol.20031712524253110.4049/jimmunol.171.5.252412928402 87.WelteT.LambJ.AndersonJ.F.BornW.K.O’BrienR.L.WangT.Role of two distinct gammadelta T cell subsets during" exact="West Nile" post="virus infectionFEMS Immunol. Med. Microbiol.20085327528310.1111/j.1574-695X.2008.00430.x18513355 88.BaiF.TownT.QianF.WangP.KamanakaM.ConnollyT.M.GateD.MontgomeryR.R.FlavellR.A.FikrigE.IL-10 Signaling Blockade Controls"/>
   <result pre="virus infectionFEMS Immunol. Med. Microbiol.20085327528310.1111/j.1574-695X.2008.00430.x18513355 88.BaiF.TownT.QianF.WangP.KamanakaM.ConnollyT.M.GateD.MontgomeryR.R.FlavellR.A.FikrigE.IL-10 Signaling Blockade Controls Murine" exact="West Nile" post="Virus InfectionPLoS Pathog.20095e100061010.1371/journal.ppat.100061019816558 89.WelteT.AronsonJ.GongB.RachamalluA.MendellN.TeshR.PaesslerS.BornW.K.O’BrienR.L.WangT.Vgamma4+ T cells regulate host immune"/>
   <result pre="InfectionPLoS Pathog.20095e100061010.1371/journal.ppat.100061019816558 89.WelteT.AronsonJ.GongB.RachamalluA.MendellN.TeshR.PaesslerS.BornW.K.O’BrienR.L.WangT.Vgamma4+ T cells regulate host immune response to" exact="West Nile" post="virus infectionFEMS Immunol. Med. Microbiol.20116318319210.1111/j.1574-695X.2011.00840.x22077221 90.MehlhopE.WhitbyK.OliphantT.MarriA.EngleM.DiamondM.S.Complement Activation Is Required"/>
   <result pre="Is Required for Induction of a Protective Antibody Response against" exact="West Nile" post="Virus InfectionJ. Virol.2005797466747710.1128/JVI.79.12.7466-7477.200515919902 91.MehlhopE.DiamondM.S.Protective immune responses against West Nile"/>
   <result pre="against West Nile Virus InfectionJ. Virol.2005797466747710.1128/JVI.79.12.7466-7477.200515919902 91.MehlhopE.DiamondM.S.Protective immune responses against" exact="West Nile" post="virus are primed by distinct complement activation pathwaysJ. Exp."/>
   <result pre="protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of" exact="West Nile" post="virusCell Host Microbe2009638139110.1016/j.chom.2009.09.00319837377 97.FuchsA.PintoA.K.SchwaebleW.J.DiamondM.S.The lectin pathway of complement activation"/>
   <result pre="97.FuchsA.PintoA.K.SchwaebleW.J.DiamondM.S.The lectin pathway of complement activation contributes to protection from" exact="West Nile" post="virus infectionVirology201141210110910.1016/j.virol.2011.01.00321269656 98.MehlhopE.FuchsA.EngleM.DiamondM.S.Complement modulates pathogenesis and antibody-dependent neutralization of"/>
   <result pre="Nile virus infectionVirology201141210110910.1016/j.virol.2011.01.00321269656 98.MehlhopE.FuchsA.EngleM.DiamondM.S.Complement modulates pathogenesis and antibody-dependent neutralization of" exact="West Nile" post="virus infection through a C5-independent mechanismVirology2009393111510.1016/j.virol.2009.08.01919744691 99.DiamondM.S.ShresthaB.MarriA.MahanD.EngleM.B Cells and"/>
   <result pre="Critical Roles in the Immediate Defense of Disseminated Infection by" exact="West Nile" post="Encephalitis VirusJ. Virol.2003772578258610.1128/JVI.77.4.2578-2586.200312551996 100.EngleM.J.DiamondM.S.Antibody Prophylaxis and Therapy against West"/>
   <result pre="West Nile Encephalitis VirusJ. Virol.2003772578258610.1128/JVI.77.4.2578-2586.200312551996 100.EngleM.J.DiamondM.S.Antibody Prophylaxis and Therapy against" exact="West Nile" post="Virus Infection in Wild-Type and Immunodeficient MiceJ. Virol.200377129411294910.1128/JVI.77.24.12941-12949.200314645550 101.DiamondM.S.SitatiE.M.FriendL.D.HiggsS.ShresthaB.EngleM.A"/>
   <result pre="101.DiamondM.S.SitatiE.M.FriendL.D.HiggsS.ShresthaB.EngleM.A Critical Role for Induced IgM in the Protection against" exact="West Nile" post="Virus InfectionJ. Exp. Med.20031981853186210.1084/jem.2003122314662909 102.XiaJ.WinkelmannE.R.GorderS.R.MasonP.W.MilliganG.N.TLR3- and MyD88-Dependent Signaling Differentially"/>
   <result pre="Med.20031981853186210.1084/jem.2003122314662909 102.XiaJ.WinkelmannE.R.GorderS.R.MasonP.W.MilliganG.N.TLR3- and MyD88-Dependent Signaling Differentially Influences the Development of" exact="West Nile" post="Virus-Specific B Cell Responses in Mice following Immunization with"/>
   <result pre="a Single-Cycle Flavivirus Vaccine CandidateJ. Virol.201387120901210110.1128/JVI.01469-1323986602 103.PurthaW.E.ChachuK.A.VirginH.W.DiamondM.S.Early B-Cell Activation after" exact="West Nile" post="Virus Infection Requires Alpha/Beta Interferon but Not Antigen Receptor"/>
   <result pre="Not Antigen Receptor SignalingJ. Virol.200882109641097410.1128/JVI.01646-0818786989 104.GormanM.J.PoddarS.FarzanM.DiamondM.S.The Interferon-Stimulated Gene Ifitm3 Restricts" exact="West Nile" post="Virus Infection and PathogenesisJ. Virol.2016908212822510.1128/JVI.00581-1627384652 105.ThackrayL.B.ShresthaB.RichnerJ.M.MinerJ.J.PintoA.K.LaZearH.M.GaleM.DiamondM.S.Interferon Regulatory Factor 5-Dependent"/>
   <result pre="5-Dependent Immune Responses in the Draining Lymph Node Protect against" exact="West Nile" post="Virus InfectionJ. Virol.201488110071102110.1128/JVI.01545-1425031348 106.GiordanoD.DravesK.E.YoungL.B.RoeK.BryanM.A.DreschC.RichnerJ.M.DiamondM.S.GaleM.ClarkE.A.Protection of mice deficient in mature"/>
   <result pre="Virol.201488110071102110.1128/JVI.01545-1425031348 106.GiordanoD.DravesK.E.YoungL.B.RoeK.BryanM.A.DreschC.RichnerJ.M.DiamondM.S.GaleM.ClarkE.A.Protection of mice deficient in mature B cells from" exact="West Nile" post="virus infection by passive and active immunizationPLoS Pathog.201713e100674310.1371/journal.ppat.100674329176765 107.MehlhopE.Ansarah-SobrinhoC.JohnsonS.EngleM.FremontD.H.PiersonT.C.DiamondM.S.Complement"/>
   <result pre="mannerCell Host Microbe2007241742610.1016/j.chom.2007.09.01518078693 108.RoeK.GiordanoD.YoungL.B.DravesK.E.HolderU.SutharM.S.GaleM.ClarkE.A.Dendritic cell-associated MAVS is required to control" exact="West Nile" post="virus replication and ensuing humoral immune responsesPLoS ONE201914e021892810.1371/journal.pone.021892831242236 109.SitatiE.McCandlessE.E.KleinR.S.DiamondM.S.CD40-CD40"/>
   <result pre="of CD8+ T cells into the brain and protection against" exact="West Nile" post="virus encephalitisJ. Virol.2007819801981110.1128/JVI.00941-0717626103 110.SitatiE.M.DiamondM.S.CD4+ T-cell responses are required for"/>
   <result pre="encephalitisJ. Virol.2007819801981110.1128/JVI.00941-0717626103 110.SitatiE.M.DiamondM.S.CD4+ T-cell responses are required for clearance of" exact="West Nile" post="virus from the central nervous systemJ. Virol.200680120601206910.1128/JVI.01650-0617035323 111.ShresthaB.DiamondM.S.Role of"/>
   <result pre="systemJ. Virol.200680120601206910.1128/JVI.01650-0617035323 111.ShresthaB.DiamondM.S.Role of CD8+ T cells in control of" exact="West Nile" post="virus infectionJ. Virol.2004788312832110.1128/JVI.78.15.8312-8321.200415254203 112.ShresthaB.DiamondM.S.Fas ligand interactions contribute to CD8+"/>
   <result pre="Virol.2004788312832110.1128/JVI.78.15.8312-8321.200415254203 112.ShresthaB.DiamondM.S.Fas ligand interactions contribute to CD8+ T-cell-mediated control of" exact="West Nile" post="virus infection in the central nervous systemJ. Virol.200781117491175710.1128/JVI.01136-0717804505 113.ShresthaB.PintoA.K.GreenS.BoschI.DiamondM.S.CD8+"/>
   <result pre="nervous systemJ. Virol.200781117491175710.1128/JVI.01136-0717804505 113.ShresthaB.PintoA.K.GreenS.BoschI.DiamondM.S.CD8+ T cells use TRAIL to restrict" exact="West Nile" post="virus pathogenesis by controlling infection in neuronsJ. Virol.2012868937894810.1128/JVI.00673-1222740407 114.KleinR.S.LinE.ZhangB.LusterA.D.TollettJ.SamuelM.A.EngleM.DiamondM.S.Neuronal"/>
   <result pre="Virol.2012868937894810.1128/JVI.00673-1222740407 114.KleinR.S.LinE.ZhangB.LusterA.D.TollettJ.SamuelM.A.EngleM.DiamondM.S.Neuronal CXCL10 directs CD8+ T-cell recruitment and control of" exact="West Nile" post="virus encephalitisJ. Virol.200579114571146610.1128/JVI.79.17.11457-11466.200516103196 115.ZhangB.ChanY.K.LuB.DiamondM.S.KleinR.S.CXCR3 mediates region-specific antiviral T cell"/>
   <result pre="antiviral T cell trafficking within the central nervous system during" exact="West Nile" post="virus encephalitisJ. Immunol.20081802641264910.4049/jimmunol.180.4.264118250476 116.McCandlessE.E.WangQ.WoernerB.M.HarperJ.M.KleinR.S.CXCL12 limits inflammation by localizing mononuclear"/>
   <result pre="trafficking in the central nervous system and improves survival from" exact="West Nile" post="virus encephalitisProc. Natl. Acad. Sci. USA2008105112701127510.1073/pnas.080089810518678898 118.AcharyaD.WangP.PaulA.M.DaiJ.GateD.LoweryJ.E.StokicD.S.LeisA.A.FlavellR.A.TownT.et al.Interleukin-17A Promotes"/>
   <result pre="USA2008105112701127510.1073/pnas.080089810518678898 118.AcharyaD.WangP.PaulA.M.DaiJ.GateD.LoweryJ.E.StokicD.S.LeisA.A.FlavellR.A.TownT.et al.Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate" exact="West Nile" post="Virus ClearanceJ. Virol.201791e01529-1610.1128/JVI.01529-1627795421 119.WangY.LobigsM.LeeE.MullbacherA.CD8+ T cells mediate recovery and"/>
   <result pre="ClearanceJ. Virol.201791e01529-1610.1128/JVI.01529-1627795421 119.WangY.LobigsM.LeeE.MullbacherA.CD8+ T cells mediate recovery and immunopathology in" exact="West Nile" post="virus encephalitisJ. Virol.200377133231333410.1128/JVI.77.24.13323-13334.200314645588 120.SzretterK.J.DanielsB.P.ChoH.GaineyM.D.YokoyamaW.M.GaleM.VirginH.W.KleinR.S.SenG.C.DiamondM.S.2′-O Methylation of the Viral mRNA"/>
   <result pre="encephalitisJ. Virol.200377133231333410.1128/JVI.77.24.13323-13334.200314645588 120.SzretterK.J.DanielsB.P.ChoH.GaineyM.D.YokoyamaW.M.GaleM.VirginH.W.KleinR.S.SenG.C.DiamondM.S.2′-O Methylation of the Viral mRNA Cap by" exact="West Nile" post="Virus Evades Ifit1-Dependent and -Independent Mechanisms of Host Restriction"/>
   <result pre="for dendritic cell–mediated T cell reactivation within the CNS during" exact="West Nile" post="virus encephalitisJ. Exp. Med.201321050351610.1084/jem.2012189723460727 123.ShresthaB.NgT.ChuH.J.NollM.DiamondM.S.The relative contribution of antibody"/>
   <result pre="of antibody and CD8+ T cells to vaccine immunity against" exact="West Nile" post="encephalitis virusVaccine2008262020203310.1016/j.vaccine.2008.02.00918339459 124.LanteriM.C.O’BrienK.M.PurthaW.E.CameronM.J.LundJ.M.OwenR.E.HeitmanJ.W.CusterB.HirschkornD.F.ToblerL.H.et al.Tregs control the development of symptomatic"/>
   <result pre="Nile encephalitis virusVaccine2008262020203310.1016/j.vaccine.2008.02.00918339459 124.LanteriM.C.O’BrienK.M.PurthaW.E.CameronM.J.LundJ.M.OwenR.E.HeitmanJ.W.CusterB.HirschkornD.F.ToblerL.H.et al.Tregs control the development of symptomatic" exact="West Nile" post="virus infection in humans and miceJ. Clin. Investig.20091193266327710.1172/JCI3938719855131 125.GrahamJ.B.Da"/>
   <result pre="Adaptive T Cell Responses and Host Resistance to an Attenuated" exact="West Nile" post="Virus Infection in Old MiceJ. Virol.2016901333134410.1128/JVI.02488-1526581984 128.ShresthaB.GottliebD.DiamondM.S.Infection and Injury"/>
   <result pre="in Old MiceJ. Virol.2016901333134410.1128/JVI.02488-1526581984 128.ShresthaB.GottliebD.DiamondM.S.Infection and Injury of Neurons by" exact="West Nile" post="Encephalitis VirusJ. Virol.200377132031321310.1128/JVI.77.24.13203-13213.200314645577 129.PhilpottD.C.E.NolanM.S.EvertN.MayesB.HesalroadD.FonkenE.MurrayK.O.Acute and Delayed Deaths after West"/>
   <result pre="West Nile Encephalitis VirusJ. Virol.200377132031321310.1128/JVI.77.24.13203-13213.200314645577 129.PhilpottD.C.E.NolanM.S.EvertN.MayesB.HesalroadD.FonkenE.MurrayK.O.Acute and Delayed Deaths after" exact="West Nile" post="Virus Infection, Texas, USA, 2002–2012Emerg. Infect. Dis.20192510.3201/eid2502.181250 130.DiamondM.S.KleinR.S.West Nile"/>
   <result pre="the blood-brain barrierNat. Med.2004101294129510.1038/nm1204-129415580248 131.DaiJ.WangP.BaiF.TownT.FikrigE.ICAM-1 participates in the entry of" exact="West Nile" post="virus into the central nervous systemJ. Virol.2008824164416810.1128/JVI.02621-0718256150 132.WangP.DaiJ.BaiF.KongK.-F.WongS.J.MontgomeryR.R.MadriJ.A.FikrigE.Matrix Metalloproteinase"/>
   <result pre="into the central nervous systemJ. Virol.2008824164416810.1128/JVI.02621-0718256150 132.WangP.DaiJ.BaiF.KongK.-F.WongS.J.MontgomeryR.R.MadriJ.A.FikrigE.Matrix Metalloproteinase 9 Facilitates" exact="West Nile" post="Virus Entry into the BrainJ. Virol.2008828978898510.1128/JVI.00314-0818632868 133.ArjonaA.FoellmerH.G.TownT.LengL.McDonaldC.WangT.WongS.J.MontgomeryR.R.FikrigE.BucalaR.Abrogation of macrophage"/>
   <result pre="the BrainJ. Virol.2008828978898510.1128/JVI.00314-0818632868 133.ArjonaA.FoellmerH.G.TownT.LengL.McDonaldC.WangT.WongS.J.MontgomeryR.R.FikrigE.BucalaR.Abrogation of macrophage migration inhibitory factor decreases" exact="West Nile" post="virus lethality by limiting viral neuroinvasionJ. Clin. Investig.20071173059306610.1172/JCI3221817909632 134.SchäferA.BrookeC.B.WhitmoreA.C.JohnstonR.E.The"/>
   <result pre="Equine Encephalitis Virus InfectionJ. Virol.201185106821069010.1128/JVI.05032-1121849461 135.BrownA.N.KentK.A.BennettC.J.BernardK.A.Tissue tropism and neuroinvasion of" exact="West Nile" post="virus do not differ for two mouse strains with"/>
   <result pre="targeting the west nile virus envelope proteinJ. Virol.2007812047205510.1128/JVI.01840-0617151121 138.SuenW.W.ProwN.A.HallR.A.Bielefeldt-OhmannH.Mechanism of" exact="West Nile" post="Virus Neuroinvasion: A Critical AppraisalViruses201462796282510.3390/v607279625046180 139.CantileC.Del PieroF.Di GuardoG.ArispiciM.Pathologic and"/>
   <result pre="AppraisalViruses201462796282510.3390/v607279625046180 139.CantileC.Del PieroF.Di GuardoG.ArispiciM.Pathologic and immunohistochemical findings in naturally occuring" exact="West Nile" post="virus infection in horsesVet. Pathol.20013841443110.1354/vp.38-4-41411467475 140.GuarnerJ.ShiehW.-J.HunterS.PaddockC.D.MorkenT.CampbellG.L.MarfinA.A.ZakiS.R.Clinicopathologic study and laboratory"/>
   <result pre="Pathol.20013841443110.1354/vp.38-4-41411467475 140.GuarnerJ.ShiehW.-J.HunterS.PaddockC.D.MorkenT.CampbellG.L.MarfinA.A.ZakiS.R.Clinicopathologic study and laboratory diagnosis of 23 cases with" exact="West Nile" post="virus encephalomyelitisHum. Pathol.20043598399010.1016/j.humpath.2004.04.00815297965 141.WangS.WelteT.McGargillM.TownT.ThompsonJ.AndersonJ.F.FlavellR.A.FikrigE.HedrickS.M.WangT.Drak2 contributes to West Nile virus"/>
   <result pre="cases with West Nile virus encephalomyelitisHum. Pathol.20043598399010.1016/j.humpath.2004.04.00815297965 141.WangS.WelteT.McGargillM.TownT.ThompsonJ.AndersonJ.F.FlavellR.A.FikrigE.HedrickS.M.WangT.Drak2 contributes to" exact="West Nile" post="virus entry into the brain and lethal encephalitisJ. Immunol.20081812084209110.4049/jimmunol.181.3.208418641347"/>
   <result pre="mediates enhanced flavivirus replication in macrophagesJ. Exp. Med.198315825826310.1084/jem.158.1.2586864163 143.SamuelM.A.DiamondM.S.Pathogenesis of" exact="West Nile" post="Virus Infection: A Balance between Virulence, Innate and Adaptive"/>
   <result pre="and Viral EvasionJ. Virol.2006809349936010.1128/JVI.01122-0616973541 144.BrehinA.C.MouriesJ.FrenkielM.P.DadaglioG.DespresP.LafonM.CoudercT.Dynamics of immune cell recruitment during" exact="West Nile" post="encephalitis and identification of a new CD19+B220-BST-2+ leukocyte populationJ."/>
   <result pre="CD19+B220-BST-2+ leukocyte populationJ. Immunol.20081806760676710.4049/jimmunol.180.10.676018453596 145.RawalA.GavinP.J.SturgisC.D.Cerebrospinal fluid cytology in seasonal epidemic" exact="West Nile" post="virus meningo-encephalitisDiagn. Cytopathol.20063412712910.1002/dc.2041016511849 146.TylerK.L.PapeJ.GoodyR.J.CorkillM.Kleinschmidt-DeMastersB.K.CSF findings in 250 patients with"/>
   <result pre="meningo-encephalitisDiagn. Cytopathol.20063412712910.1002/dc.2041016511849 146.TylerK.L.PapeJ.GoodyR.J.CorkillM.Kleinschmidt-DeMastersB.K.CSF findings in 250 patients with serologically confirmed" exact="West Nile" post="virus meningitis and encephalitisNeurology20066636136510.1212/01.wnl.0000195890.70898.1f16382032 147.YangJ.-S.RamanathanM.P.MuthumaniK.ChooA.Y.JinS.-H.YuQ.-C.HwangD.S.ChooD.K.LeeM.D.DangK.et al.Induction of Inflammation by"/>
   <result pre="Nile virus meningitis and encephalitisNeurology20066636136510.1212/01.wnl.0000195890.70898.1f16382032 147.YangJ.-S.RamanathanM.P.MuthumaniK.ChooA.Y.JinS.-H.YuQ.-C.HwangD.S.ChooD.K.LeeM.D.DangK.et al.Induction of Inflammation by" exact="West Nile" post="virus Capsid through the Caspase-9 Apoptotic PathwayEmerg. Infect. Dis.200281379138410.3201/eid0812.02022412498651"/>
   <result pre="bax-dependent apoptosisFEBS Lett.2001500172410.1016/S0014-5793(01)02573-X11434919 149.CheeranM.C.-J.HuS.ShengW.S.RashidA.PetersonP.K.LokensgardJ.R.Differential responses of human brain cells to" exact="West Nile" post="virus infectionJ. Neurovirol.20051151252410.1080/1355028050038498216338745 150.QuickE.D.LeserJ.S.ClarkeP.TylerK.L.Activation of Intrinsic Immune Responses and"/>
   <result pre="in an Ex Vivo Spinal Cord Slice Culture Model of" exact="West Nile" post="Virus InfectionJ. Virol.201488130051301410.1128/JVI.01994-1425165111 151.GlassW.G.LimJ.K.CholeraR.PletnevA.G.GaoJ.-L.MurphyP.M.Chemokine receptor CCR5 promotes leukocyte trafficking"/>
   <result pre="CCR5 promotes leukocyte trafficking to the brain and survival in" exact="West Nile" post="virus infectionJ. Exp. Med.20052021087109810.1084/jem.2004253016230476 152.VigP.J.S.LuD.PaulA.M.KuwarR.LopezM.StokicD.S.LeisA.A.GarrettM.R.BaiF.Differential Expression of Genes Related"/>
   <result pre="Ex Vivo Spinal Cord and Cerebellar Slice Cultures Infected with" exact="West Nile" post="VirusBrain Sci.20189110.3390/brainsci901000130586874 153.ArmahH.B.WangG.OmaluB.I.TeshR.B.GyureK.A.ChuteD.J.SmithR.D.DulaiP.VintersH.V.Kleinschmidt-DeMastersB.K.et al.Systemic Distribution of West Nile Virus"/>
   <result pre="Infected with West Nile VirusBrain Sci.20189110.3390/brainsci901000130586874 153.ArmahH.B.WangG.OmaluB.I.TeshR.B.GyureK.A.ChuteD.J.SmithR.D.DulaiP.VintersH.V.Kleinschmidt-DeMastersB.K.et al.Systemic Distribution of" exact="West Nile" post="Virus Infection: Postmortem Immunohistochemical Study of Six CasesBrain Pathol.20071735436210.1111/j.1750-3639.2007.00080.x17610522"/>
   <result pre="155.PetzoldA.GrovesM.LeisA.ScaravilliF.StokicD.StokicD.Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after" exact="West Nile" post="Virus infectionMuscle Nerve201041424910.1002/mus.2144819790244 156.KuwarR.StokicD.LeisA.BaiF.PaulA.FratkinJ.VigP.PaulA.Does astroglial protein S100B contribute to"/>
   <result pre="Nile Virus infectionMuscle Nerve201041424910.1002/mus.2144819790244 156.KuwarR.StokicD.LeisA.BaiF.PaulA.FratkinJ.VigP.PaulA.Does astroglial protein S100B contribute to" exact="West Nile" post="neuro-invasive syndrome?J. Neurol. Sci.201535824325210.1016/j.jns.2015.09.00326382833 157.ChuJ.J.H.NgM.L.The mechanism of cell death"/>
   <result pre="neuro-invasive syndrome?J. Neurol. Sci.201535824325210.1016/j.jns.2015.09.00326382833 157.ChuJ.J.H.NgM.L.The mechanism of cell death during" exact="West Nile" post="virus infection is dependent on initial infectious doseJ. Gen."/>
   <result pre="glycation end-products in neurodegenerative diseasesRev. Neurosci.20152669169810.1515/revneuro-2015-000326226128 160.KumarM.VermaS.NerurkarV.R.Pro-inflammatory cytokines derived from" exact="West Nile" post="virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal"/>
   <result pre="and neuronal deathJ. Neuroinflamm.201077310.1186/1742-2094-7-73 161.VermaS.KumarM.NerurkarV.R.Cyclooxygenase-2 inhibitor blocks the production of" exact="West Nile" post="virus-induced neuroinflammatory markers in astrocytesJ. Gen. Virol.20119250751510.1099/vir.0.026716-021106803 162.MurrayK.O.GarciaM.N.RahbarM.H.MartínezD.KhuwajaS.A.ArafatR.R.RossmannS.Survival Analysis,"/>
   <result pre="of Recovery up to 8 Years Post-Infection among the Houston" exact="West Nile" post="Virus CohortPLoS ONE20149e10295310.1371/journal.pone.010295325054656 163.WeatherheadJ.E.MillerV.E.GarciaM.N.HasbunR.SalazarL.DimachkieM.M.MurrayK.O.Long-term neurological outcomes in West Nile"/>
   <result pre="Houston West Nile Virus CohortPLoS ONE20149e10295310.1371/journal.pone.010295325054656 163.WeatherheadJ.E.MillerV.E.GarciaM.N.HasbunR.SalazarL.DimachkieM.M.MurrayK.O.Long-term neurological outcomes in" exact="West Nile" post="virus-infected patients: An observational studyAm. J. Trop. Med. Hyg.2015921006101210.4269/ajtmh.14-061625802426"/>
   <result pre="J. Trop. Med. Hyg.2015921006101210.4269/ajtmh.14-061625802426 164.MurrayK.O.NolanM.S.RoncaS.E.DattaS.GovindarajanK.NarayanaP.A.SalazarL.WoodsS.P.HasbunR.The Neurocognitive and MRI Outcomes of" exact="West Nile" post="Virus Infection: Preliminary Analysis Using an External Control GroupFront."/>
   <result pre="myasthenia gravisEur. J. Immunol.2015451339134710.1002/eji.20144506425676041 171.AhmedS.LibmanR.WessonK.AhmedF.EinbergK.Guillain-Barre syndrome: An unusual presentation of" exact="West Nile" post="virus infectionNeurology20005514414610.1212/WNL.55.1.14410891928 172.AlmhannaK.PalanichamyN.SharmaM.HobbsR.SilA.Unilateral Brachial Plexopathy Associated with West Nile"/>
   <result pre="of West Nile virus infectionNeurology20005514414610.1212/WNL.55.1.14410891928 172.AlmhannaK.PalanichamyN.SharmaM.HobbsR.SilA.Unilateral Brachial Plexopathy Associated with" exact="West Nile" post="Virus MeningoencephalitisClin. Infect. Dis.2003361629163010.1086/37523112802774 173.Hassin-BaerS.KirsonE.D.ShulmanL.BuchmanA.S.BinH.HindiyehM.MarkevichL.MendelsonE.Stiff-Person Syndrome Following West Nile"/>
   <result pre="with West Nile Virus MeningoencephalitisClin. Infect. Dis.2003361629163010.1086/37523112802774 173.Hassin-BaerS.KirsonE.D.ShulmanL.BuchmanA.S.BinH.HindiyehM.MarkevichL.MendelsonE.Stiff-Person Syndrome Following" exact="West Nile" post="FeverArch. Neurol.20046193894110.1001/archneur.61.6.93815210535 174.KaragianniP.AlexopoulosH.SourdiA.PapadimitriouD.DimitrakopoulosA.MoutsopoulosH.West Nile Virus infection triggering autoimmune encephalitis:"/>
   <result pre="steroids in the management of acute flaccid paralysis due to" exact="West Nile" post="virus infectionScand. J. Infect. Dis.20043650951210.1080/0036554041002065915307586 178.LeisA.A.SinclairD.J.Lazarus Effect of High"/>
   <result pre="178.LeisA.A.SinclairD.J.Lazarus Effect of High Dose Corticosteroids in a Patient with" exact="West Nile" post="Virus Encephalitis: A Coincidence or a Clue?Front. Med.201968110.3389/fmed.2019.00081 179.HuangC.SlaterB.RuddR.ParchuriN.HullR.DupuisM.HindenburgA.First"/>
   <result pre="Encephalitis: A Coincidence or a Clue?Front. Med.201968110.3389/fmed.2019.00081 179.HuangC.SlaterB.RuddR.ParchuriN.HullR.DupuisM.HindenburgA.First Isolation of" exact="West Nile" post="virus from a Patient with Encephalitis in the United"/>
   <result pre="corticosteroid in the treatment of dengue—A systemic reviewHeliyon20184e0081610.1016/j.heliyon.2018.e0081630258999 Figure 1" exact="West Nile" post="virus (WNV) neuroinvasion and neuropathogenesis."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963679\results\search\tropicalVirus\results.xml">
   <result pre="10.3390/pathogens8040216pathogens-08-00216 : Article Assessment of Immunogenicity and Efficacy of a" exact="Zika" post="Vaccine Using Modified Vaccinia Ankara Virus as Carriers https://orcid.org/0000-0001-7932-2341López-CamachoCésar1†https://orcid.org/0000-0003-2847-9407KimYoung"/>
   <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Zika" post="virus (ZIKV) is an emerging mosquito-borne flavivirus that has"/>
   <result pre="stimulate effective immunity in mice and provide protection upon a" exact="ZIKV" post="challenge model, using a non-adjuvanted single vaccination approach. In"/>
   <result pre="constructed various modified vaccinia Ankara (MVA) viruses to express the" exact="ZIKV" post="Envelope (E) with modifications on the precursor membrane (prM)"/>
   <result pre="were evaluated as a non-adjuvanted single vaccination regimen against a" exact="ZIKV" post="Brazilian isolate, using viraemia as the correlate of protection."/>
   <result pre="by all MVA vectored vaccines and sub-optimal efficacy in a" exact="ZIKV" post="challenge model. Our results indicate the requirement of additional"/>
   <result pre="afford sterile protection upon a non-adjuvanted and single vaccination regime." exact="Zika" post="virus MVA envelope proteins vaccines immunogenicity efficacy mice 1."/>
   <result pre="virus MVA envelope proteins vaccines immunogenicity efficacy mice 1. Introduction" exact="Zika" post="virus (ZIKV) is a mosquito-borne flavivirus virus that belongs"/>
   <result pre="discovery in 1947 from a sentinel rhesus monkey in Uganda," exact="ZIKV" post="caused sporadic outbreaks in Africa and South Asia until"/>
   <result pre="in Micronesia in 2007 and French Polynesia in 2013 [2,3]." exact="ZIKV" post="has spread rapidly throughout the Americas since its first"/>
   <result pre="in 2015 [4], affecting more than 70 countries worldwide [5]." exact="ZIKV" post="is classified into two lineages: African (AF) and Asian"/>
   <result pre="outbreaks occurring worldwide. The main vector for urban transmission of" exact="ZIKV" post="is the Aedes mosquito, although sexual contact and vertical"/>
   <result pre="are also responsible for the virus dissemination [7]. Infection by" exact="ZIKV" post="is associated with neurological complications, such as microcephaly in"/>
   <result pre="licensed vaccines are yet available against ZIKV. There are many" exact="ZIKV" post="vaccine candidates, such as inactivated virus, based on DNA,"/>
   <result pre="vectors encoding the precursor membrane (prM) and the envelope (E)" exact="ZIKV" post="proteins, which are currently in phase I or II"/>
   <result pre="[12,13,14,15,16]. We have previously reported the development of four ChAdOx1" exact="ZIKV" post="vaccine candidates and their protective efficacy in a homologous"/>
   <result pre="ZIKV vaccine candidates and their protective efficacy in a homologous" exact="ZIKV" post="challenge model [17]. All four ChAdOx1 ZIKV vaccine candidates"/>
   <result pre="in a homologous ZIKV challenge model [17]. All four ChAdOx1" exact="ZIKV" post="vaccine candidates (prME, prME ΔTM, Env, and Env ΔTM)"/>
   <result pre="Env ΔTM) were shown to stimulate the production of anti-E" exact="ZIKV" post="antibodies and demonstrated protective efficacy in a homologous ZIKV-lineage"/>
   <result pre="transmembrane domain (prME ΔTM) induced the highest titres of anti-envelope" exact="ZIKV" post="antibodies that provided 100% efficacy against ZIKV infection, with"/>
   <result pre="titres of anti-envelope ZIKV antibodies that provided 100% efficacy against" exact="ZIKV" post="infection, with only a single and non-adjuvanted vaccination. Here,"/>
   <result pre="measured at 4 weeks and 12 weeks post-immunisation. In a" exact="ZIKV" post="mice challenge model, two MVA-ZIKV vaccine candidates (Env ΔTM"/>
   <result pre="in viral load in mice. This study reports that MVA" exact="ZIKV" post="vaccine candidates may be a limited candidate for further"/>
   <result pre="single-vaccination approach. 2. Results 2.1. Modified Vaccinia Ankara (MVA) Expressing" exact="ZIKV" post="Antigens To generate MVA-based ZIKV vaccine candidates, we sub-cloned"/>
   <result pre="Modified Vaccinia Ankara (MVA) Expressing ZIKV Antigens To generate MVA-based" exact="ZIKV" post="vaccine candidates, we sub-cloned each of the ZIKV transgenes"/>
   <result pre="generate MVA-based ZIKV vaccine candidates, we sub-cloned each of the" exact="ZIKV" post="transgenes (prME, prME ΔTM, Env, Env ΔTM) with parental"/>
   <result pre="as described elsewhere [18] (Figure 1c). The expression of the" exact="ZIKV" post="immunogens was confirmed by western blot in cells extracts"/>
   <result pre="showed that MVA viral vectors are correctly packaged, carrying the" exact="ZIKV" post="transgenes in their genome and more importantly, that they"/>
   <result pre="that they are capable of inducing the expression of the" exact="ZIKV" post="E in transduced cells. 2.2. Assessment of Immunogenicity We"/>
   <result pre="of cellular responses were detected at 4 weeks post-immunisation. 2.3." exact="ZIKV" post="Challenge in BALB/c Mice To assess the efficacy of"/>
   <result pre="at four-weeks post-immunisation (n = 5) were intravenously challenged with" exact="ZIKV" post="(strain Brazil ZKV2015; ZIKV-BR), as previously described [17]. Vaccine"/>
   <result pre="(qPCR); at 0, 1, 2, 3, 4, and 7-days post" exact="ZIKV" post="challenge (Figure 3). The naïve control group challenged with"/>
   <result pre="ZIKV challenge (Figure 3). The naïve control group challenged with" exact="ZIKV" post="displayed the expected viraemia kinetics, comprising a viral load"/>
   <result pre="a single dose of MVA-ZIKV vaccines conferred partial protection against" exact="ZIKV" post="challenge. For the MVA prME vaccinated group, all mice"/>
   <result pre="the rest of the MVA-ZIKV vaccines, by substantially reducing the" exact="ZIKV" post="loads in blood, such protection did not reach 100%"/>
   <result pre="protection in BALB/c mice challenged with ZIKV. 3. Discussion A" exact="ZIKV" post="vaccine target product profile [20] indicates that a preferred"/>
   <result pre="profile [20] indicates that a preferred dose regimen in a" exact="Zika" post="vaccine development is a single immunisation, although a minimal"/>
   <result pre="We have previously demonstrated that a non-replicative adenoviral-vectored vaccine expressing" exact="ZIKV" post="antigens induces high levels of immunity and protective efficacy"/>
   <result pre="induces high levels of immunity and protective efficacy in a" exact="ZIKV" post="mice challenge model against a ZIKV-BR strain, all upon"/>
   <result pre="Particles (VLPs) and inducing partial protection in mice after a" exact="ZIKV" post="challenge, upon a homologous prime-boost approach [21]. Of particular"/>
   <result pre="an MVA vaccine expressing the non-structural protein 1 (NS1) of" exact="ZIKV" post="has been demonstrated to be 100% effective in both"/>
   <result pre="a BALB/c mouse strain that had no lethal outcome upon" exact="ZIKV" post="infection. Hence, we measured vaccine efficacy by means of"/>
   <result pre="further studies, such as the use of a highly susceptible" exact="ZIKV" post="challenge model in A129, mice would be helpful to"/>
   <result pre="model in A129, mice would be helpful to explore the" exact="ZIKV" post="presence in key organs, such as the brain, spleen,"/>
   <result pre="of MVA-ZIKV vaccines in preventing viraemia, it is expected that" exact="ZIKV" post="viral loads may be found in those organs. Lastly,"/>
   <result pre="single immunisation in inbred and outbred mice, respectively [17]. Various" exact="ZIKV" post="vaccine platforms based on the ZIKV envelope have been"/>
   <result pre="mice, respectively [17]. Various ZIKV vaccine platforms based on the" exact="ZIKV" post="envelope have been reported, which consist of DNA, mRNA,"/>
   <result pre="and using different routes of administrations. Therefore, levels of immunogenicity," exact="ZIKV" post="neutralisation, or in vivo efficacy outcomes are still a"/>
   <result pre="development of an efficacious vaccine development that could prevent future" exact="ZIKV" post="outbreaks. 4. Materials and Methods Female inbred BALB/c mice"/>
   <result pre="BALB/c mice were used for the assessment of immunogenicity and" exact="ZIKV" post="challenge. Mice were purchased from either Envigo (Bicester, UK)"/>
   <result pre="Review Committee (P9804B4F1). Animal experiments performed at Harvard (immunisation and" exact="ZIKV" post="challenge) were approved by the BIDMC Institutional Animal Care"/>
   <result pre="plasmid was used as template to further generate the four" exact="ZIKV" post="antigens (prME, prME ΔTM, Env, and Env ∆TM) as"/>
   <result pre="prME ΔTM, Env, and Env ∆TM) as previously described ([17])." exact="ZIKV" post="antigens were used to generate MVA viruses as previously"/>
   <result pre="infected with MVA for homologous recombination and insertion of the" exact="ZIKV" post="ORF and GFP marker gene at a TK locus"/>
   <result pre="microscope (FEI, Eindhoven, The Netherlands). To test the expression of" exact="ZIKV" post="antigens, BHK-21 cells were transfected with rMVA. At 24"/>
   <result pre="incubated with 1:1000 anti-Zika Env monoclonal antibody (mouse mAb to" exact="Zika" post="Env protein, AZ1176, Aalto BioReagents, Dublin, Republic of Ireland)."/>
   <result pre="dose of new recombinant modified vaccinia ankara (MVA) encoding the" exact="ZIKV" post="antigens at a dose of 1 × 106 PFU."/>
   <result pre="(IM) and diluted in endotoxin-free PBS. Enzyme-linked immunosorbent assay (ELISA)-recombinant" exact="ZIKV" post="Envelope protein was used to measure anti-ZIKV envelope antibody"/>
   <result pre="[19]. Briefly, Nunc Maxisorp Immuno ELISA plates were coated with" exact="Zika" post="virus envelope antigen (Env-CD4) diluted in PBS to a"/>
   <result pre="after single immunisation with MVA-ZIKV vaccine. Mice sera reactive to" exact="ZIKV" post="E was serially diluted three-fold down in PBS/T with"/>
   <result pre="Spot forming cells (SFC)/106 PBMCs producing IFNγ were calculated. The" exact="ZIKV" post="challenge was performed as described [26]. Briefly, naïve and"/>
   <result pre="plaque-forming units (PFU)) of the ZIKV-BR strain. Viral loads following" exact="ZIKV" post="challenge were quantitated by RT-PCR at day 1, 2,"/>
   <result pre="in a blind experiment. After the experimental outcome of the" exact="ZIKV" post="challenge, samples were decoded. Viral loads were assessed as"/>
   <result pre="per mL. The infectivity of virus in peripheral blood from" exact="ZIKV" post="challenged mice was confirmed by PFU assays. Specific primers"/>
   <result pre="to amplify a region contained in the Capsid of the" exact="ZIKV" post="genome. Acknowledgments We would like to thank the Jenner"/>
   <result pre="and performed the animal experiments. P.A. and R.A.L. performed the" exact="ZIKV" post="challenge model and the RT-PCR viral loads. C.L.-C., Y.C.K.,"/>
   <result pre="C.L.-C., Y.C.K., P.A. and R.A.L. performed ELISA assays and analysed" exact="ZIKV" post="challenge data. Y.C.K. produced the ZIKV envelope protein. Y.C.K."/>
   <result pre="ELISA assays and analysed ZIKV challenge data. Y.C.K. produced the" exact="ZIKV" post="envelope protein. Y.C.K. performed ELISPOT, cell culture, transfections and"/>
   <result pre="Health (ODA), 16/107/05 (Design, development and GMP manufacture of a" exact="Zika" post="vaccine). Conflicts of Interest A.R.-S. and C.L.-C. are co-inventors"/>
   <result pre="Conflicts of Interest A.R.-S. and C.L.-C. are co-inventors of the" exact="Zika" post="vaccines described in this manuscript, filed by Oxford University"/>
   <result pre="University Innovation Limited in the International Patent Application No. PCR/GB2017/052220" exact="Zika" post="Vaccine. The remaining authors declare no competing interests. References"/>
   <result pre="https://www.who.int/emergencies/zika-virus/situation-report/10-march-2017/en/(accessed on 25 July 2019) 6.FayeO.FayeO.DialloD.DialloM.WeidmannM.SallA.A.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught MosquitoesVirol. J.20131031110.1186/1743-422X-10-31124148652 7.PetersenL.R.JamiesonD.J.PowersA.M.HoneinM.A.Zika VirusN."/>
   <result pre="J.20131031110.1186/1743-422X-10-31124148652 7.PetersenL.R.JamiesonD.J.PowersA.M.HoneinM.A.Zika VirusN. Engl. J. Med.20163741552156310.1056/NEJMra160211327028561 8.CauchemezS.BesnardM.BompardP.DubT.Guillemette-ArturP.Eyrolle-GuignotD.SaljeH.Van KerkhoveM.D.AbadieV.GarelC.et al.Association between" exact="Zika" post="virus and microcephaly in French Polynesia, 2013–2015: A retrospective"/>
   <result pre="MicrocephalyN. Engl. J. Med.201637495195810.1056/NEJMoa160065126862926 10.Cao-LormeauV.-M.BlakeA.MonsS.LastèreS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 11.DiamondM.S.LedgerwoodJ.E.PiersonT.C.Zika"/>
   <result pre="multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidatePLoS ONE20105e1398310.1371/journal.pone.001398321085591 17.López-CamachoC.AbbinkP.LaroccaR.A.DejnirattisaiW.BoydM.Badamchi-ZadehA.WallaceZ.R.DoigJ.VelazquezR.S.NetoR.D.L.et al.Rational" exact="Zika" post="vaccine design via the modulation of antigen membrane anchors"/>
   <result pre="Vaccinia Virus in Infected Human CellsJ. Virol.200377106061062210.1128/JVI.77.19.10606-10622.200312970445 19.KimY.C.Lopez-CamachoC.NettleshipJ.E.RahmanN.HillM.L.Silva-ReyesL.Ortiz-MartinezG.Figueroa-AguilarG.MarM.A.Vivanco-CidH.et al.Optimization of" exact="Zika" post="virus envelope protein production for ELISA and correlation of"/>
   <result pre="Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing" exact="Zika" post="Virus Structural Proteins Controls Zika Virus Replication in MiceSci."/>
   <result pre="Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls" exact="Zika" post="Virus Replication in MiceSci. Rep.201881738510.1038/s41598-018-35724-630478418 22.BraultA.C.DomiA.McDonaldE.M.Talmi-FrankD.McCurleyN.BasuR.RobinsonH.L.HellersteinM.DuggalN.K.BowenR.A.et al.A Zika Vaccine"/>
   <result pre="Proteins Controls Zika Virus Replication in MiceSci. Rep.201881738510.1038/s41598-018-35724-630478418 22.BraultA.C.DomiA.McDonaldE.M.Talmi-FrankD.McCurleyN.BasuR.RobinsonH.L.HellersteinM.DuggalN.K.BowenR.A.et al.A" exact="Zika" post="Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in"/>
   <result pre="cellular immune responses in miceVaccine2017353780378810.1016/j.vaccine.2017.05.03228579232 26.LaroccaR.A.AbbinkP.PeronJ.P.S.de ZanottoP.M.A.IampietroM.J.Badamchi-ZadehA.BoydM.Ng’ang’aD.KirilovaM.NityanandamR.et al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 Figure 1 MVA-ZIKV vaccine designs. (a)"/>
   <result pre="cassette used to produce the recombinant MVA vectors, containing the" exact="ZIKV" post="structural genes shown in blue box. ((b), left panel)"/>
   <result pre="sequence (red box in Figure 1a) plus each of the" exact="ZIKV" post="transgenes. Asterisks denote the MVA backbone plasmid. ((b), right"/>
   <result pre="particles were detected [18]. Bar, 500 nm. (d) Expression of" exact="ZIKV" post="immunogens by western blot of BHK21 cell extracts transduced"/>
   <result pre="in size can be appreciated in the monomeric form of" exact="ZIKV" post="E (around 45 kDa for full length E, in"/>
   <result pre="were intramuscularly immunised with a single dose of MVA encoding" exact="ZIKV" post="antigens at 1 × 106 plaque forming units (PFU)/mouse."/>
   <result pre="immunisation were quantified by ELISA in plates coated with a" exact="ZIKV" post="E protein [19]. (c) Cellular immune responses to MVA-ZIKV"/>
   <result pre="by (IFNγ) ex vivo ELISPOT, and 20-mer peptides spanning the" exact="ZIKV" post="prME proteins at 10 μg/mL were used for stimulation."/>
   <result pre="PFU of ZIKV-BR strain, at four weeks post immunisation. After" exact="ZIKV" post="challenge, viral loads were monitored for seven days. (b)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6963926\results\search\tropicalVirus\results.xml">
   <result pre="TLR3 signaling genes affecting viral infections. For instance, susceptibility to" exact="Chikungunya" post="virus (CHIKV) infection is highly increased in human and"/>
   <result pre="unknown functional consequences, were associated with an increased risk of" exact="CHIKV" post="disease occurrence [101]. Patients with impaired TLR3-mediated responses show"/>
   <result pre="cell surface, and is linked with an elevated susceptibility to" exact="West Nile" post="virus (WNV) [134] and with increased severity of illness"/>
   <result pre="With H7N9/H1N1pdm09 InfluenzaJ. Infect. Dis.20172169710410.1093/infdis/jix23528510725 101.HerZ.TengT.S.TanJ.J.TeoT.H.KamY.W.LumF.M.LeeW.W.GabrielC.MelchiottiR.AndiappanA.K.et al.Loss of TLR3 aggravates" exact="CHIKV" post="replication and pathology due to an altered virus-specific neutralizing"/>
   <result pre="virus infection in ChinaPathology20104267468010.3109/00313025.2010.52369621080879 134.GlassW.G.McDermottD.H.LimJ.K.LekhongS.YuS.F.FrankW.A.PapeJ.CheshierR.C.MurphyP.M.CCR5 deficiency increases risk of symptomatic" exact="West Nile" post="virus infectionJ. Exp. Med.2006203354010.1084/jem.2005197016418398 135.KeynanY.JunoJ.MeyersA.BallT.B.KumarA.RubinsteinE.FowkeK.R.Chemokine receptor 5 big up"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6964091\results\search\tropicalVirus\results.xml">
   <result pre="to Cholera, Measles, Meningitis and Viral Haemorrhagic Diseases (Crimean Congo," exact="Dengue" post="Fever, Ebola Virus Disease, Lassa Fever, Marburg Virus Disease,"/>
   <result pre="Viral Haemorrhagic Diseases, such as Ebola Virus Disease, Yellow Fever," exact="Dengue" post="Fever, Lassa Fever, and Rift Valley Fever. Other causes"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6964813\results\search\tropicalVirus\results.xml">
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus Broad dengue neutralization in mosquitoes expressing an engineered"/>
   <result pre="an engineered single-chain variable fragment derived from a broadly neutralizing" exact="DENV" post="human monoclonal antibody and have significantly reduced viral infection,"/>
   <result pre="dissemination, and transmission rates for all four major antigenically distinct" exact="DENV" post="serotypes. Importantly, this is the first engineered approach that"/>
   <result pre="Importantly, this is the first engineered approach that targets all" exact="DENV" post="serotypes, which is crucial for effective disease suppression. These"/>
   <result pre="These results provide a compelling route for developing effective genetic-based" exact="DENV" post="control strategies, which could be extended to curtail other"/>
   <result pre="the transgene throughout wild disease-transmitting mosquito populations and preventing further" exact="DENV" post="transmission. Since a number of diverse and well-characterized antibodies"/>
   <result pre="are within the manuscript and its Supporting Information files Introduction" exact="Dengue" post="fever is a devastating viral disease caused by several"/>
   <result pre="readily controlled using broad-spectrum techniques [1,2]. Transmitted by infected mosquitoes," exact="DENV" post="infection typically manifests as severe fever, headaches, and myalgia[3]"/>
   <result pre="dengue hemorrhagic fever and dengue shock syndrome[4]. Global incidences of" exact="DENV" post="and its associated economic burden have increased dramatically in"/>
   <result pre="the disease-spreading mosquitoes is currently the best option for preventing" exact="DENV" post="transmission [13]. Aedes aegypti [16], the main vector of"/>
   <result pre="DENV transmission [13]. Aedes aegypti [16], the main vector of" exact="DENV" post="and other epidemiologically significant viruses such as chikungunya (CHIKV),"/>
   <result pre="significant viruses such as chikungunya (CHIKV), yellow fever (YFV), and" exact="Zika" post="(ZIKV), is a domestic endophilic mosquito[17] that has expanded"/>
   <result pre="manner and can inhibit mosquito infection with pathogens such as" exact="DENV" post="and ZIKV[28,29], have also been carried out. These have"/>
   <result pre="genes, and several approaches for engineering Ae. aegypti resistance to" exact="DENV" post="have been attempted. For example, one study used RNA"/>
   <result pre="their ability to target only one or two—not all four—major" exact="DENV" post="serotypes. Because hyperendemicity of DENV in tropical areas is"/>
   <result pre="one or two—not all four—major DENV serotypes. Because hyperendemicity of" exact="DENV" post="in tropical areas is frequent[5] and secondary DENV infection"/>
   <result pre="hyperendemicity of DENV in tropical areas is frequent[5] and secondary" exact="DENV" post="infection has been linked to severe dengue disease (SDD),"/>
   <result pre="studies demonstrated that this antibody neutralized viruses from all major" exact="DENV" post="serotypes and was capable of significantly reducing viremia in"/>
   <result pre="variable fragment (scFv) that is capable of neutralizing all four" exact="DENV" post="serotypes[44]. Crucially, we demonstrate that mosquitoes expressing this anti-DENV"/>
   <result pre="cannot be infected with or transmit any of the four" exact="DENV" post="serotypes and have few significant fitness costs conferred by"/>
   <result pre="antibody. These results provide a promising route for developing effective" exact="DENV" post="control strategies using genetically engineered mosquitoes. Materials and methods"/>
   <result pre="the chemiluminescent HRP substrate (Millipore, Cat. No#WBKLS0500) to the blots." exact="DENV" post="infection of mosquitoes and virus determination All experiments were"/>
   <result pre="the insectary at the Australian Animal Health Laboratory. The following" exact="DENV" post="strains were used for all viral challenge experiments: DENV-1"/>
   <result pre="by red fluorescence in the eye) mosquitoes were exposed to" exact="DENV" post="as described previously [61]. Briefly, female mosquitoes were challenged"/>
   <result pre="infection and dissemination were carried out as previously described [61]." exact="DENV" post="infection frequency was defined by the number of midguts"/>
   <result pre="the WT line, and the resulting offspring were used for" exact="DENV" post="infection experiments. At the end of the experiment, the"/>
   <result pre="as our model due to its ability to cross-neutralize multiple" exact="DENV" post="serotypes in humans[44]. As it is a human monoclonal"/>
   <result pre="Effect of anti-dengue virus (DENV) single-chain variable fragment (scFv) on" exact="DENV" post="titers of TADV-A, Wolbachia-infected (wMel), and wildtype (WT) mosquitoes."/>
   <result pre="challenged with a blood meal infected with one of four" exact="DENV" post="serotypes (DENV-1, isolate ET243; DENV-2, isolate ET300; DENV-3, isolate"/>
   <result pre="determine if the anti-DENV transgene confers resistance to all four" exact="DENV" post="serotypes, we determined viral titers in extracted midguts, carcasses,"/>
   <result pre="context (i.e., in the midgut following a blood meal) for" exact="DENV" post="suppression. Engineered mosquitoes are resistant to infection with all"/>
   <result pre="suppression. Engineered mosquitoes are resistant to infection with all four" exact="DENV" post="serotypes To determine the functional significance of anti-DENV 1C19"/>
   <result pre="post infection (dpi), midguts from blood-fed mosquitoes were dissected, and" exact="DENV" post="RNA copies were measured using RT-qPCR. All three lines"/>
   <result pre="comprehensive characterization. For a more detailed study of the TADV-A" exact="DENV" post="vector competence, the effect of transgene zygosity on the"/>
   <result pre="(Fig 1B, Table 1). 10.1371/journal.ppat.1008103.t001Table 1 Anti-DENV scFv effect on" exact="DENV" post="infection, dissemination, and transmission rates. DENV titers in WT,"/>
   <result pre="Anti-DENV scFv effect on DENV infection, dissemination, and transmission rates." exact="DENV" post="titers in WT, heterozygous and homozygous TADV-A (TADV-AHt and"/>
   <result pre="mosquitoes following a blood meal infected with one of four" exact="DENV" post="serotypes are shown. DENV GE from mosquito midguts (at"/>
   <result pre="meal infected with one of four DENV serotypes are shown." exact="DENV" post="GE from mosquito midguts (at 4 or 14 dpi)"/>
   <result pre="at 14 dpi were determined using TCID50 on Vero cells." exact="DENV" post="GE or viral titer on indicated dpi from specified"/>
   <result pre="mosquitoes with detected virus; percentage of mosquitoes with detected virus)" exact="DENV" post="Serotype Strain 4 dpi 14 dpi Midgut–GE Midgut–GE Carcass–GE"/>
   <result pre="whether the anti-DENV 1C19 scFv is broadly inhibitory for other" exact="DENV" post="serotypes, the vector competence of TADV-A mosquitoes was assessed"/>
   <result pre="positive for the virus in most specimens, though the overall" exact="DENV" post="titers were significantly lower than compared to the WT"/>
   <result pre="compare the inhibitory effect of the anti-DENV 1C19 scFv to" exact="DENV" post="inhibition through Wolbachia[65–67] infection, we challenged WT mosquitoes infected"/>
   <result pre="reduced (p &amp;lt; 0.001) in wMel mosquitoes (~3 log10), and" exact="DENV" post="titers in mosquito saliva at 14 dpi were significantly"/>
   <result pre="effective as homozygotes, and similarly effective as heterozygotes, at blocking" exact="DENV" post="infection as Wolbachia-infected mosquitoes. Transgene impact on fitness To"/>
   <result pre="assessed. Transgenic, WT, or wMel mosquitoes were infected with four" exact="DENV" post="serotypes and their survivorship was assessed 14 dpi (Table"/>
   <result pre="and the percent of surviving mosquitoes separately infected by four" exact="DENV" post="serotypes was assessed at 14 dpi. Strain Fitness Parameter"/>
   <result pre="anti-DENV 1C19 scFv renders mosquitoes refractory to all four major" exact="DENV" post="serotypes and therefore appears to be a potent viral"/>
   <result pre="homozygous for the anti-DENV 1C19 scFv showed complete refractoriness to" exact="DENV" post="infection, heterozygous mosquitoes were still partially refractory to DENV"/>
   <result pre="to DENV infection, heterozygous mosquitoes were still partially refractory to" exact="DENV" post="infection, dissemination, and transmission, with significant, several orders-of-magnitude reductions"/>
   <result pre="mosquitoes [63], it binds to the exposed fusion loop of" exact="DENV" post="and inhibits the virus particle from releasing its genome"/>
   <result pre="would be sufficient to render heterozygous mosquitoes unable to transmit" exact="DENV" post="to a susceptible host[68]. Though this remains to be"/>
   <result pre="more efficient than—Wolbachia-infected mosquitoes, which are currently being released for" exact="DENV" post="control because they are known to be refractory to"/>
   <result pre="a gene-drive system to reduce or eliminate the risk of" exact="DENV" post="transmission by mosquitoes. In fact, previous efforts have demonstrated"/>
   <result pre="populations into transgenic homozygotes that would be completely resistant to" exact="DENV" post="transmission. Of paramount importance to the viability of such"/>
   <result pre="evolution. Indeed, several studies have shown that, in some contexts," exact="DENV" post="can rapidly evolve resistance in response to neutralizing antibodies"/>
   <result pre="as well as a combination of antibody and non-antibody based" exact="DENV" post="refractoriness transgenes (e.g., [36,37]; [38]; [39])). The deployment of"/>
   <result pre="far-reaching consequences for rendering mosquitoes resistant to other arboviruses like" exact="ZIKV" post="and CHIKV by using similar genetic engineering strategies to"/>
   <result pre="for rendering mosquitoes resistant to other arboviruses like ZIKV and" exact="CHIKV" post="by using similar genetic engineering strategies to develop scFv-based"/>
   <result pre="data file. S3 Fig Effect of the anti-DENV scFv on" exact="DENV" post="GE in three independent transgenic mosquito lines. DENV GE"/>
   <result pre="scFv on DENV GE in three independent transgenic mosquito lines." exact="DENV" post="GE in WT and transgenic mosquito lines (TADV-A, TADV-B,"/>
   <result pre="a blood meal infected with DENV-2 (ET300 strain) are shown." exact="DENV" post="GE from mosquito midguts (at 4 dpi) of WT"/>
   <result pre="dengue control. Armed Forces Med J India. 2015;71: 67–70. 3WhitehornJ." exact="Dengue" post="Fever Viruses. eLS. John Wiley &amp;amp; Sons, Ltd; 2001."/>
   <result pre="Fever Viruses. eLS. John Wiley &amp;amp; Sons, Ltd; 2001. 4RajapakseS." exact="Dengue" post="shock. J Emerg Trauma Shock. 2011;4: 120–127. 10.4103/0974-2700.7683521633580 5MessinaJP,"/>
   <result pre="DesedaC, ChotpitayasunondhT, DietzeR, et al.Efficacy and Long-Term Safety of a" exact="Dengue" post="Vaccine in Regions of Endemic Disease. N Engl J"/>
   <result pre="PLoS Negl Trop Dis. 2017;11: e000563210.1371/journal.pntd.000563228749942 21HaugCJ, KienyMP, MurgueB. The" exact="Zika" post="Challenge. N Engl J Med. 2016;374: 1801–1803. 10.1056/NEJMp160373427028782 22GattonML,"/>
   <result pre="VelezID, OsorioJE. The wMel strain of Wolbachia Reduces Transmission of" exact="Zika" post="virus by Aedes aegypti. Sci Rep. 2016;6: 2879210.1038/srep2879227364935 29WalkerT,"/>
   <result pre="DasS, PotiKE, et al.Engineered Aedes aegypti JAK/STAT Pathway-Mediated Immunity to" exact="Dengue" post="Virus. PLoS Negl Trop Dis. 2017;11: e000518710.1371/journal.pntd.000518728081143 40BurtonDR, PoignardP,"/>
   <result pre="Proteins. CSH Protoc. 2006;200610.1101/pdb.prot431322485689 61DucheminJ-B, MeePT, LynchSE, VedururuR, TrinidadL, ParadkarP." exact="Zika" post="vector transmission risk in temperate Australia: a vector competence"/>
   <result pre="Transmission of Aedes aegypti Transmitted Viruses In: HilgenfeldR, VasudevanSG, editors." exact="Dengue" post="and Zika: Control and Antiviral Treatment Strategies. Singapore: Springer"/>
   <result pre="et al.Structural basis of a potent human monoclonal antibody against" exact="Zika" post="virus targeting a quaternary epitope. Proc Natl Acad Sci"/>
   <result pre="Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against" exact="Chikungunya" post="Virus. Cell Host Microbe. 2015;18: 382. 81GooL, DebbinkK, KoseN,"/>
   <result pre="DoyleMP, WesselAW, et al.A protective human monoclonal antibody targeting the" exact="West Nile" post="virus E protein preferentially recognizes mature virions. Nat Microbiol."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968261\results\search\tropicalVirus\results.xml">
   <result pre="Increased temperatures reduce the vectorial capacity of Aedes mosquitoes for" exact="Zika" post="virus Emerging Microbes &amp;amp; Infections M. G. Onyango et"/>
   <result pre="cited.TEMI_9_1707125.pdf Abstract ABSTRACT Rapid and significant range expansion of both" exact="Zika" post="virus (ZIKV) and its Aedes vector species has resulted"/>
   <result pre="virus (ZIKV) and its Aedes vector species has resulted in" exact="ZIKV" post="being declared a global health threat. Mean temperatures are"/>
   <result pre="&amp;lt; 0.001]. Temperature had a population and species-specific impact on" exact="ZIKV" post="infection rates. Overall, Ae. albopictus reared at the lowest"/>
   <result pre="Aedes mosquitoes in the Americas. KEYWORDS Climate change Aedes mosquitoes" exact="Zika" post="virus vectorial capacity transmission potential Funding Centers for Disease"/>
   <result pre="[Cooperative Agreement Number U01CK000509]. fig-count: table-count: equation-count: ref-count: page-count: Background" exact="Zika" post="virus (ZIKV; Flavivirus, Flaviviridae), which prior to 2007 was"/>
   <result pre="in recent years and evolved into a global health threat." exact="ZIKV" post="was first identified in Brazil in May 2015 and"/>
   <result pre="subsequently spread throughout the Americas [3–7]. The explosive spread of" exact="ZIKV" post="from Asia to the Americas and the association with"/>
   <result pre="the virus and the potential impact of temperature increases on" exact="ZIKV" post="transmission. Increases in average and maximum temperatures have been"/>
   <result pre="viral strain affect the vector competence of Aedes mosquitoes for" exact="ZIKV" post="[1,7,26,27]. A recent study by [2] showed that a"/>
   <result pre="non-structural protein 1 (NS1) may have enhanced the infectivity of" exact="ZIKV" post="and facilitated transmission by Aedes aegypti in the Americas."/>
   <result pre="temperature and demonstrated high infection rates but low transmission of" exact="ZIKV" post="for all populations. While a study by [29] reared"/>
   <result pre="blood feeding. Despite progress made to understand the biology of" exact="ZIKV" post="infection and its interactions with its vectors, questions remain"/>
   <result pre="of unique populations of Ae. aegypti and Ae. albopictus for" exact="ZIKV" post="held under diurnal, fluctuating temperature regimes mimicking field conditions"/>
   <result pre="impact of future increase in temperature in the Americas on" exact="ZIKV" post="transmission dynamics of Ae. aegypti and Ae. albopictus will"/>
   <result pre="standard operating procedure (SOP) for rearing mosquitoes in our insectary." exact="Zika" post="virus vector competence To test for the effect of"/>
   <result pre="mosquitoes were orally exposed to bloodmeal containing 8.3 log10 PFU/ml" exact="ZIKV" post="HND (2016-19563, GenBank accession no. KX906952) [7]. The virus"/>
   <result pre="and stored at −80°C to allow for the determination of" exact="ZIKV" post="titres. The engorged females were maintained on 10% sucrose"/>
   <result pre="competence Ae. aegypti and Ae. albopictus were equally susceptible to" exact="ZIKV" post="infection [Fisher’s exact test P = .44]. Overall, temperature influenced infection"/>
   <result pre="population and species-specific manner. Higher temperatures were associated with lower" exact="ZIKV" post="infection rates of AEG MI population, i.e. the individuals"/>
   <result pre="3). Figure 3. Vector competence of Aedes mosquitoes infected with" exact="Zika" post="virus and reared at different temperature regimes. Note: The"/>
   <result pre="plot represents the proportion of blood-fed individuals successfully infected with" exact="Zika" post="virus. Above each bar plot, the total number of"/>
   <result pre="1. Vector competence of Aedes mosquitoes in this study following" exact="ZIKV" post="exposure. Species Geographical origin Temp. regime % Infection (whole"/>
   <result pre="on viral load was measured. Figure 4. Viral load of" exact="ZIKV" post="in Aedes mosquitoes at 4 and 14 days post-infection"/>
   <result pre="(DPI). Note: The plot represents the absolute viral load of" exact="ZIKV" post="in individuals of different populations of Aedes mosquitoes utilized"/>
   <result pre="on species, population and temperature regime, an overall decrease in" exact="ZIKV" post="transmissibility was measured with all three populations evaluated following"/>
   <result pre="2°C rise in diurnal temperature cycle. A larger decrease in" exact="ZIKV" post="transmission was measured for Ae. aegypti mosquitoes when modelling"/>
   <result pre="shift in the suitability of Aedes populations for transmission of" exact="ZIKV" post="and other invasive arboviruses. Higher temperatures decreased the blood-feeding"/>
   <result pre="demonstrated a unimodal effect of temperature on the EIP of" exact="ZIKV" post="on Ae. aegypti across eight constant temperatures (16–38°C), with"/>
   <result pre="studies have demonstrated Ae. albopictus is a competent vector for" exact="ZIKV" post="in the laboratory [1,7]. However, the vector competence has"/>
   <result pre="vector competence has been shown to be influenced by the" exact="ZIKV" post="strain and the geographic origin of the mosquito population"/>
   <result pre="origin of the mosquito population [1]. The explosive spread of" exact="ZIKV" post="in the Americas raised concerns that another vector in"/>
   <result pre="vector in addition to Ae. aegypti might be involved in" exact="ZIKV" post="transmission [52]. Our study confirms the potential for Ae."/>
   <result pre="the potential for Ae. albopictus to play a role in" exact="ZIKV" post="epidemics in the Americas, although they have not been"/>
   <result pre="in temperature would require additional studies with multiple populations and" exact="ZIKV" post="strains. There are two important caveats to this study."/>
   <result pre="arboviral infections in mosquitoes are persistent, these data suggest that" exact="ZIKV" post="infected individuals were less likely to survive the experimental"/>
   <result pre="these data demonstrate that temperature is a significant component of" exact="ZIKV" post="transmission; and defining optimum conditions for individual populations and"/>
   <result pre="will have negative fitness cost on Aedes aegypti mosquitoes for" exact="ZIKV" post="and could significantly alter their vector competence. Further, the"/>
   <result pre="assisted in mosquito manipulation exercises. KL: Generated and propagated the" exact="ZIKV" post="infectious clone utilized in this study. AV: Designed the"/>
   <result pre="vector competency of Aedes albopictus populations from the Americas for" exact="Zika" post="virus. Am J Trop Med Hyg. 2017;97(2):330–339. doi: 10.4269/ajtmh.16-096928829735"/>
   <result pre="2017;97(2):330–339. doi: 10.4269/ajtmh.16-096928829735 2LiuY, LiuJ, DuS, et al.Evolutionary enhancement of" exact="Zika" post="virus infectivity in Aedes aegypti mosquitoes. Nature[Internet]2017;545(May):482–486. Available from:"/>
   <result pre="3BoyerS, CalvezE, Chouin-CarneiroT, et al.An overview of mosquito vectors of" exact="Zika" post="virus. Microbes Infect. 2018;20:1–15. doi: 10.1016/j.micinf.2018.01.00628986306 4BogochII, BradyOJ, KraemerMUG,"/>
   <result pre="10.1016/j.micinf.2018.01.00628986306 4BogochII, BradyOJ, KraemerMUG, et al.Anticipating the international spread of" exact="Zika" post="virus from Brazil. Lancet. 2016;387(10016):335–336. doi: 10.1016/S0140-6736(16)00080-526777915 5HennesseyM, FicherM,"/>
   <result pre="2016;65(3):55–58. doi: 10.15585/mmwr.mm6503e1 6PetersenE, WilsonME, TouchS, et al.Rapid spread of" exact="Zika" post="virus in the Americas – implications for public health"/>
   <result pre="Dis. 2016;44(May):11–15. doi: 10.1016/j.ijid.2016.02.00126854199 7CiotaA, BialosukniaS, ZinkS, et al.Effects of" exact="Zika" post="virus strain and Aedes mosquito species on vector competence."/>
   <result pre="MeolaMA, MoudyRM, et al.Temperature, viral genetics, and the transmission of" exact="West Nile" post="virus by Culex pipiens mosquitoes. PLoS Pathog. 2008;4(6):e1000092. doi:"/>
   <result pre="Pathog. 2008;4(6):e1000092. doi: 10.1371/journal.ppat.100009218584026 24TeslaB, DemakovskyLR, MordecaiEA, et al.Temperature drives" exact="Zika" post="virus transmission: evidence from empirical and mathematical models. Proc"/>
   <result pre="et al.Vector competence of American mosquitoes for three strains of" exact="Zika" post="virus. PLoS Negl Trop Dis. 2016;10(10):e0005101. doi: 10.1371/journal.pntd.000510127783679 27MuttisE,"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="virus. PLoS Negl Trop Dis. 2016;10(3):e0004543. doi: 10.1371/journal.pntd.000454326938868 29TramonteAR,"/>
   <result pre="2016;10(3):e0004543. doi: 10.1371/journal.pntd.000454326938868 29TramonteAR, ChristoffersonRC.Investigating the probability of establishment of" exact="Zika" post="virus and detection through mosquito surveillance under different temperature"/>
   <result pre="p. 34CiotaA, EhrbarD, MatacchieroA, et al.The evolution of virulence of" exact="West Nile" post="virus in a mosquito vector: implications for arbovirus adaptation"/>
   <result pre="Trop Med Public Health. 2009;40(5):942–950.19842378 52GardnerLM, ChenN, SarkarS.Global risk of" exact="Zika" post="virus depends critically on vector status of Aedes albopictus."/>
   <result pre="et al.The costs of infection and resistance as determinants of" exact="West Nile" post="virus susceptibility in Culex mosquitoes. BMC Ecol. 2011;11(23):1–8.21211032"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968431\results\search\tropicalVirus\results.xml">
   <result pre="doi: 10.1080/22221751.2019.1701954 : Indeed Category: Letter Return of the founder" exact="Chikungunya" post="virus to its place of introduction into Brazil is"/>
   <result pre="epidemic seasons and sampled locations. Estimated climate-driven transmission potential of" exact="CHIKV" post="remained at similar levels throughout the years, such that"/>
   <result pre="2014. Bahia remains a reservoir of the genetic diversity of" exact="CHIKV" post="in the Americas, and genomic surveillance strategies are essential"/>
   <result pre="transmission and persistence both locally and over large distances. KEYWORDS" exact="Chikungunya" post="East-Central-South-African genotype Northeast Brazil surveillance portable genome sequencing Funding"/>
   <result pre="Pessoal de Nível Superior. fig-count: table-count: equation-count: ref-count: page-count: Text" exact="Chikungunya" post="virus (CHIKV) is an emerging mosquito-borne virus belonging to"/>
   <result pre="significant public health problem in tropical and subtropical regions [1]." exact="CHIKV" post="infection results in an acute, debilitating febrile illness, but"/>
   <result pre="Ocean Lineage (IOL) [1]. In September 2014, the first autochthonous" exact="CHIKV" post="infections were confirmed in Brazil. They were characterized by"/>
   <result pre="in Brazil. They were characterized by two distinct genotypes: the" exact="CHIKV" post="Asian genotype was found in Oiapoque, a city in"/>
   <result pre="the left. (B) Molecular clock phylogeny obtained using 20 new" exact="CHIKV" post="near-complete genome sequences from the 2017–2018 epidemic in the"/>
   <result pre="different locations. (C) Weekly number of laboratory confirmed cases of" exact="CHIKV" post="between 2016 and 2018, superimposed with daily mean index"/>
   <result pre="submitted to real time RT-qPCR protocols for the detection of" exact="Zika" post="virus (ZIKV), dengue virus (DENV 1-4), mayaro virus (MAYV),"/>
   <result pre="virus (DENV 1-4), mayaro virus (MAYV), oropouche virus (OROV) and" exact="CHIKV" post="as previously described [6–9]. Samples were selected for sequencing"/>
   <result pre="High Fidelity Hot-Start DNA Polymerase (New England Biolabs) and the" exact="CHIKV" post="primers scheme, as previously described [10]. DNA library preparation"/>
   <result pre="Maximum Likelihood (ML) phylogeny. To investigate the dynamics of the" exact="CHIKV" post="infection at a larger spatial scale, we generated a"/>
   <result pre="phylogenetic analysis using BEAST 1.10.4 [13]. Data of weekly confirmed" exact="CHIKV" post="cases in Bahia were supplied by the Brazilian Ministry"/>
   <result pre="the viruses tested, all the samples were positive only for" exact="CHIKV" post="infection. From serum sampled during the two outbreaks in"/>
   <result pre="showed that since 2014, Bahia has experienced different events of" exact="CHIKV" post="re-introduction and epidemic spread (Figure 1 panel B). The"/>
   <result pre="Salvador at 2 m, above sea level. Confirmed cases presented three" exact="CHIKV" post="epidemic waves, characterized by a continuous reduction in total"/>
   <result pre="introduction in 2014; similarly to what has been described for" exact="ZIKV" post="in Feira de Santana [5]. In this study, we"/>
   <result pre="of Bahia, we also revealed the reconstructed transmission potential of" exact="CHIKV" post="has remained reasonably stable throughout the years, such that"/>
   <result pre="FariaNR, de VasconcelosJM, et al.Emergence and potential for spread of" exact="Chikungunya" post="virus in Brazil. BMC Med. 2015;13:102–103. doi: 10.1186/s12916-015-0348-x25976325 2NavecaFG,"/>
   <result pre="2NavecaFG, ClaroI, GiovanettiM, et al.Genomic, epidemiological and digital surveillance of" exact="Chikungunya" post="virus in the Brazilian Amazon. PLoS Negl Trop Dis."/>
   <result pre="Negl Trop Dis. 2019;7:13–13. 3XavierJ, GiovanettiM, FonsecaV, et al.Circulation of" exact="Chikungunya" post="virus East/Central/South African lineage in Rio de Janeiro, Brazil."/>
   <result pre="de dengue, febre de chikungunya e doença aguda pelo vírus" exact="Zika" post="até a Semana Epidemiológica 52 de 2018. Ministério da"/>
   <result pre="de Lima MM, FariaNR, et al.Epidemiological and ecological determinants of" exact="Zika" post="virus transmission in an urban setting. Elife. 2017;9:6–29. 6LanciottiRS,"/>
   <result pre="2017;9:6–29. 6LanciottiRS, KosoyOL, LavenJJ, et al.Genetic and serologic properties of" exact="Zika" post="virus associated with an epidemic, Yap state, Micronesia, 2007."/>
   <result pre="et al.Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nat"/>
   <result pre="TheysK, et al.A computational method for the identification of Dengue," exact="Zika" post="and Chikungunya virus species and genotypes. PLoS Negl Trop"/>
   <result pre="al.A computational method for the identification of Dengue, Zika and" exact="Chikungunya" post="virus species and genotypes. PLoS Negl Trop Dis. 2019;8:13–15."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6968865\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Molecular Biology"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Anatomy :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Microbiology :"/>
   <result pre="Medical microbiology : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Medicine and health sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial pathogens : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : Viral pathogens : Flaviviruses:" exact="West Nile" post="virus : Biology and Life Sciences : Biochemistry: Nucleic"/>
   <result pre="(YFV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV) and" exact="West Nile" post="virus (WNV) cause significant morbidity and mortality worldwide. DENV"/>
   <result pre="West Nile virus (WNV) cause significant morbidity and mortality worldwide." exact="DENV" post="is a major public health concern on a global"/>
   <result pre="Year Location Virus Cases Death rate complications Reference 2011 Uganda" exact="YFV" post="181 45 (24.9%) [11] 2012 Texas, USA WNV 1,868"/>
   <result pre="2011 Uganda YFV 181 45 (24.9%) [11] 2012 Texas, USA" exact="WNV" post="1,868 89 (5%) [12] 2015 India DENV 99,913 200"/>
   <result pre="2012 Texas, USA WNV 1,868 89 (5%) [12] 2015 India" exact="DENV" post="99,913 200 (0.2%) [13] 2016–2017 Latin America Caribean ZIKV"/>
   <result pre="India DENV 99,913 200 (0.2%) [13] 2016–2017 Latin America Caribean" exact="ZIKV" post="217,000 3,400 associated congenital syndrome [14] 2016 Taiwan DENV"/>
   <result pre="Caribean ZIKV 217,000 3,400 associated congenital syndrome [14] 2016 Taiwan" exact="DENV" post="22,777 182 (0.8%) [15] 2016 Odisha JEV 336 103"/>
   <result pre="[15] 2016 Odisha JEV 336 103 (30.6%) [16] 2017 Bangladesh" exact="CHIKV" post="13,176 N/A [17] 2017 Australia RRV &amp;gt;1,000 N/A [18]"/>
   <result pre="the genus and species level. An example of this is" exact="DENV" post="that contains four serotypes, each being quite diverse at"/>
   <result pre="for each type [20]. Assays that can universally detect all" exact="DENV" post="serotypes have been described but these assays still employ"/>
   <result pre="been used to successfully detect the presence of high risk" exact="HPV" post="in clinical samples [23] and the presence of pathogens,"/>
   <result pre="used in cross-reactivity studies Virus Supplier Catalogue# Virus Supplier Catalogue#" exact="CHIKV" post="Vircell MBC099 adenovirus Vircell MBC001 CHIKV Zeptometrix NATCHIKV-ST BK"/>
   <result pre="Catalogue# Virus Supplier Catalogue# CHIKV Vircell MBC099 adenovirus Vircell MBC001" exact="CHIKV" post="Zeptometrix NATCHIKV-ST BK Vircell MBC051 DENV1-4, CHIKV, ZIKV Amplirun"/>
   <result pre="Vircell MBC001 CHIKV Zeptometrix NATCHIKV-ST BK Vircell MBC051 DENV1-4, CHIKV," exact="ZIKV" post="Amplirun total Vircell MBT023 coronavirus Vircell MBC090 DENV-1 Vircell"/>
   <result pre="H3 Vircell MBC029 WEEV Vircell MBC098 influenza B Vircell MBC03" exact="WNV" post="Vircell MBC069 parainfluenza-1 Vircell MBC037 WNV Zeptometrix NATWNV-0005 parainfluenza-2"/>
   <result pre="influenza B Vircell MBC03 WNV Vircell MBC069 parainfluenza-1 Vircell MBC037" exact="WNV" post="Zeptometrix NATWNV-0005 parainfluenza-2 Vircell MBC038 YFV Vircell MBC100 parainfluenza-3"/>
   <result pre="MBC069 parainfluenza-1 Vircell MBC037 WNV Zeptometrix NATWNV-0005 parainfluenza-2 Vircell MBC038" exact="YFV" post="Vircell MBC100 parainfluenza-3 Vircell MBC039 ZIKV (Asian) Vircell MBC103"/>
   <result pre="NATWNV-0005 parainfluenza-2 Vircell MBC038 YFV Vircell MBC100 parainfluenza-3 Vircell MBC039" exact="ZIKV" post="(Asian) Vircell MBC103 parainfluenza-4A Vircell MBC050 ZIKV Vircell MBC072"/>
   <result pre="parainfluenza-3 Vircell MBC039 ZIKV (Asian) Vircell MBC103 parainfluenza-4A Vircell MBC050" exact="ZIKV" post="Vircell MBC072 rhinovirus Vircell MBC091 ZIKV Zeptometrix NATZIKV-ST RSV"/>
   <result pre="MBC103 parainfluenza-4A Vircell MBC050 ZIKV Vircell MBC072 rhinovirus Vircell MBC091" exact="ZIKV" post="Zeptometrix NATZIKV-ST RSV (subtype A) Vircell MBC041 ZIKV range"/>
   <result pre="Vircell MBC091 ZIKV Zeptometrix NATZIKV-ST RSV (subtype A) Vircell MBC041" exact="ZIKV" post="range validation Zeptometrix NATZIKV-RV RSV (subtype B) Vircell MBC083"/>
   <result pre="MBC048 Validation panels In addition, quality assurance panels for DENV," exact="CHIKV" post="and ZIKV were obtained from QCMD (Quality Controls for"/>
   <result pre="panels In addition, quality assurance panels for DENV, CHIKV and" exact="ZIKV" post="were obtained from QCMD (Quality Controls for Molecular Diagnostics,"/>
   <result pre="Clinical samples Serum or plasma samples from patient with suspected" exact="DENV" post="infection were collected at Port Vila Central Hospital, Efate,"/>
   <result pre="are available from Genetic Signatures: pan-flavivirus, pan-alphavirus and pan-dengue (FA001)," exact="Zika" post="virus (FA002-A), West Nile virus (FA002-B), Yellow Fever Virus"/>
   <result pre="Genetic Signatures: pan-flavivirus, pan-alphavirus and pan-dengue (FA001), Zika virus (FA002-A)," exact="West Nile" post="virus (FA002-B), Yellow Fever Virus (FA002-C), Tick-borne encephalitis virus"/>
   <result pre="the combined PCR mastermix and components using the EasyScreen Flavivirus" exact="Dengue" post="Alphavirus Detection Kit. (Genetic Signatures, Sydney, Australia). Thermocycling consisted"/>
   <result pre="a primary sample, fresh urine was spiked with both NATtrol" exact="Zika" post="Stock (Qualitative) (Manufacturer, CATALOG# NATZIKV-ST) and NATtrol Zika Virus"/>
   <result pre="both NATtrol Zika Stock (Qualitative) (Manufacturer, CATALOG# NATZIKV-ST) and NATtrol" exact="Zika" post="Virus Range Verification Panel (Manufacturer, CATALOG# NATZIKV-RV). The whole"/>
   <result pre="inactivated viruses containing a mixture of DENV-1, DENV-2, DENV-3, DENV-4," exact="CHIKV" post="and ZIKV in a plasma matrix) and genomic RNA"/>
   <result pre="containing a mixture of DENV-1, DENV-2, DENV-3, DENV-4, CHIKV and" exact="ZIKV" post="in a plasma matrix) and genomic RNA from DENV-1,"/>
   <result pre="matrix) and genomic RNA from DENV-1, DENV-2, DENV-3, DENV-4 and" exact="CHIKV" post="(Vircell, Valencia, Spain) and were used. Samples were diluted"/>
   <result pre="LLOD Studies copies per reaction (10 replicates) Virus Flavivirus Alphavirus" exact="Dengue" post="Run Control* 0.63 1.25 2.18 DENV1 14 N/A 56.25"/>
   <result pre="N/A 81.25 DENV3 39 N/A 39 DENV4 56.25 N/A 112.5" exact="CHIKV" post="N/A 20.3 N/A *Whole inactivated virus material in a"/>
   <result pre="the 2016–2018 QCMD proficiency panels. QCMD proficiency panel data 2016–2018" exact="Dengue" post="panels Zika panels Chikungunya panels Year Core Educational Core"/>
   <result pre="QCMD proficiency panels. QCMD proficiency panel data 2016–2018 Dengue panels" exact="Zika" post="panels Chikungunya panels Year Core Educational Core Educational Core"/>
   <result pre="panels. QCMD proficiency panel data 2016–2018 Dengue panels Zika panels" exact="Chikungunya" post="panels Year Core Educational Core Educational Core Educational 2016"/>
   <result pre="as mouth swabs or urine samples from patients suspected of" exact="DENV" post="infection could be used as a less invasive alternative"/>
   <result pre="taken and these extracted using standard procedures as described. Although" exact="DENV" post="RNA could be detected in all three sample types,"/>
   <result pre="Immuno Assays. It is well established that EIA assays for" exact="ZIKV" post="virus show a high degree of cross reactivity with"/>
   <result pre="Enzyme Immuno Assays are unable to differentiate between the individual" exact="DENV" post="serotypes and are generally less sensitive than molecular assays."/>
   <result pre="alphaviruses show a different global distribution with viruses such as" exact="YFV" post="endemic in Africa, TBEV endemic in Eurasia, JEV in"/>
   <result pre="was able to detect DENV-1, DENV-2, DENV-3, DENV-4, ZIKV, YFV," exact="WNV" post="and TBEV down to 13 copies per reaction, which"/>
   <result pre="The results shown demonstrate that when DENV-1, DENV-2, DENV-3, DENV-4," exact="ZIKV" post="and CHIKV inactivated whole virus particles were pooled in"/>
   <result pre="shown demonstrate that when DENV-1, DENV-2, DENV-3, DENV-4, ZIKV and" exact="CHIKV" post="inactivated whole virus particles were pooled in a serum"/>
   <result pre="signals thus confirming the negative results. QCMD panels for DENV," exact="ZIKV" post="virus and CHIKV from 2016–2018 were obtained to monitor"/>
   <result pre="the negative results. QCMD panels for DENV, ZIKV virus and" exact="CHIKV" post="from 2016–2018 were obtained to monitor the performance of"/>
   <result pre="was reported that between 2012 and 2014, dengue (serotypes 1–4)," exact="CHIKV" post="and ZIKV viruses were circulating in the region with"/>
   <result pre="that between 2012 and 2014, dengue (serotypes 1–4), CHIKV and" exact="ZIKV" post="viruses were circulating in the region with over 120,000"/>
   <result pre="28 outbreaks of disease were reported. These numbers include 18" exact="DENV" post="(serotypes 1–4), 7 CHIKV and 3 ZIKV outbreaks [30]."/>
   <result pre="were reported. These numbers include 18 DENV (serotypes 1–4), 7" exact="CHIKV" post="and 3 ZIKV outbreaks [30]. These outbreaks result in"/>
   <result pre="numbers include 18 DENV (serotypes 1–4), 7 CHIKV and 3" exact="ZIKV" post="outbreaks [30]. These outbreaks result in a heavy toll"/>
   <result pre="management. Furthermore, there have been no Chickungunya and only one" exact="Zika" post="case recorded on the islands (Kalkie Sero, personal communication)."/>
   <result pre="IgM serological tests. In order to confirm the presence of" exact="DENV" post="samples had to be sent to New Zealand in"/>
   <result pre="time RT–PCR or nested RT–PCR are widely used to detect" exact="DENV" post="genes in acute-phase serum samples. This detection coincides with"/>
   <result pre="samples from patients attending Port Vila Central Hospital with suspected" exact="DENV" post="infection. Prior to testing, a preliminary study was undertaken"/>
   <result pre="and serum or plasma samples were obtained and processed. Although" exact="DENV" post="RNA could be detected in both urine and mouth"/>
   <result pre="subsequent patient testing. In total, 187 patient samples with suspected" exact="DENV" post="infection were processed using the system (Table 5). Of"/>
   <result pre="weak PCR signals with Ct values greater than 40. Thus" exact="DENV" post="RNA may have been present below the LLOD of"/>
   <result pre="there were 61 female cases and 59 male cases of" exact="DENV" post="infection in the patient cohort. Anker and Arima previously"/>
   <result pre="and Arima previously found an excess of males among reported" exact="DENV" post="cases ≥ 15 years of age [34] however this"/>
   <result pre="small sample set. Fig 5 shows the weekly prevalence of" exact="DENV" post="infection from December 2016 to March 24th 2017. The"/>
   <result pre="testing of patients attending the Port Vila Central Hospital with" exact="DENV" post="like symptoms using the pan-flavivirus/pan-alphavirus/pan-dengue molecular assays. The increase"/>
   <result pre="methods compared to conventional EIA. Fig 6 shows age related" exact="DENV" post="infections. As can be seen from the data the"/>
   <result pre="islands of Vanuatu [35]. Fig 7 shows the number of" exact="DENV" post="dengue cases by island of residence with the incidence"/>
   <result pre="expected also has the highest number of residents with confirmed" exact="DENV" post="infection, with 26 cases over the period of testing."/>
   <result pre="as 229 or less. In general, the number of positive" exact="DENV" post="cases can be correlated with the island population, where"/>
   <result pre="the island population, where for most islands, the incidence of" exact="DENV" post="infection was not significantly different to the average national"/>
   <result pre="Tongoa and Ambae had a higher number of mosquitoes harbouring" exact="DENV" post="thus leading to the increased number of positive cases"/>
   <result pre="observed in residents of the island (Fig 7). Fig 7" exact="Dengue" post="positive samples per 1000. The figure shows the population"/>
   <result pre="Public Health Surveillance Unit, Ministry of Health for data on" exact="Zika" post="and Chikungunya prevalence. Finally, we thank Dr. John Waitumbi,"/>
   <result pre="Surveillance Unit, Ministry of Health for data on Zika and" exact="Chikungunya" post="prevalence. Finally, we thank Dr. John Waitumbi, Lab Research"/>
   <result pre="2FayeOumar, FayeOusmane, DialloDiawo, DialloMawlouth, WeidmannManfredet al.Quantitative real-time PCR detection of" exact="Zika" post="virus and evaluation with field-caught Mosquitoes. Virology Journal2013; 10:31110.1186/1743-422X-10-31124148652"/>
   <result pre="MuchiriEM, MungaiPL, MutukuFM, et al.High rates of o'nyong nyong and" exact="Chikungunya" post="virus transmission in coastal Kenya. PLoS Negl Trop Dis."/>
   <result pre="J Infect Dis. 2012; 7;16(7) 12MurrayKO, RuktanonchaiD, HesalroadD, FonkenE, NolanMS." exact="West Nile" post="virus, Texas, USA, 2012. Emerg Infect Dis. 201311; 19(11):"/>
   <result pre="Control Programme (NVBDCP), Directorate-General of Health Services, Government of India." exact="Dengue" post="cases and deaths in the country since. 2010. accessed"/>
   <result pre="14Colón-GonzálezFJ, PeresCA, Steiner São BernardoC, HunterPR, LakeIR. After the epidemic:" exact="Zika" post="virus projections for Latin America and the Caribbean. PLoS"/>
   <result pre="23BaleriolaC, MillarD, MelkiJ, CoulstonN, AltmanP, RismantoNet al.Comparison of a novel" exact="HPV" post="test with the Hybrid Capture II (hcII) and a"/>
   <result pre="LyS, CappelleJ, KimKS, Lorn TryP, RosS, et al.Value of Routine" exact="Dengue" post="Diagnostic Tests in Urine and Saliva Specimens. PLoS Negl"/>
   <result pre="MengelleC.; Chapuy-RegaudS.; PaviliL.; Prisant, et al.Kinetics of anti-ZIKV antibodies after" exact="Zika" post="infection using two commercial enzyme-linked immunoassays. Diagn Microbiol Infect"/>
   <result pre="routine dengue virus serology in travelers in the era of" exact="Zika" post="virus emergence. J Clin Virol. 20177; 92:25–31. 10.1016/j.jcv.2017.05.00128505571 28A"/>
   <result pre="HoyD, DuituturagaS, BenyonE, et al.Concurrent outbreaks of dengue, chikungunya and" exact="Zika" post="virus infections–an unprecedented epidemic wave of mosquito-borne viruses in"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6969489\results\search\tropicalVirus\results.xml">
   <result pre="new epidemics, such as the zoonotic H5N1 pandemic (5, 6)," exact="Zika" post="(7), and the recent Ebola outbreaks (8, 9). Studies"/>
   <result pre="humans. N. Engl. J. Med.353, 1374–1385 (2005).16192482 7AliotaM. T.et al.," exact="Zika" post="in the Americas, year 2: What have we learned?"/>
   <result pre="al., Multiplex PCR method for MinION and Illumina sequencing of" exact="Zika" post="and other virus genomes directly from clinical samples. Nat."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6971842\results\search\tropicalVirus\results.xml">
   <result pre="medium, provided the original work is properly cited.wellcomeopenres-4-17060.pdf Abstract Introduction:" exact="Yellow fever" post="is endemic in specific regions of sub-Saharan Africa and"/>
   <result pre="preparation of the manuscript. KEY QUESTIONS What is already known?" exact="Yellow fever" post="vaccines should contain a minimum of 1,000 international units"/>
   <result pre="provided by the reduced doses of yellow fever vaccine? Introduction" exact="Yellow fever" post="(YF) is caused by a mosquito-borne flavivirus that is"/>
   <result pre="post-vaccination. To measure neutralising antibody to other flaviviruses (including dengue," exact="West Nile" post="and zika viruses) on the baseline sample and determine"/>
   <result pre="evaluated for presence of antibodies to other flaviviruses (including dengue," exact="West Nile" post="and Zika virus) and their association with YF vaccine"/>
   <result pre="of antibodies to other flaviviruses (including dengue, West Nile and" exact="Zika" post="virus) and their association with YF vaccine immunogenicity assessed."/>
   <result pre="and neural or extraneural inoculation.Am J Epidemiol.1943;38(2):152–172. Reference Source 15BarrettADT:" exact="Yellow fever" post="live attenuated vaccine: A very successful live attenuated vaccine"/>
   <result pre="al.: Seroprevalence of Infections with Dengue, Rift Valley Fever and" exact="Chikungunya" post="Viruses in Kenya, 2007.PLoS One.2015;10(7):e0132645. 10.1371/journal.pone.013264526177451 48KamauEAgotiCNNgoiJMet al.: Complete"/>
   <result pre="Kenya, 2007.PLoS One.2015;10(7):e0132645. 10.1371/journal.pone.013264526177451 48KamauEAgotiCNNgoiJMet al.: Complete Genome Sequences of" exact="Dengue" post="Virus Type 2 Strains from Kilifi, Kenya.Microbiol Resour Announc.2019;8(4):pii:"/>
   <result pre="antibody repertoire to Flaviviruses in the endemic population of the" exact="Zika" post="forest in Uganda.J Immunol.2017;198(1 Supplement). 10.13140/RG.2.2.20146.40649"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6971860\results\search\tropicalVirus\results.xml">
   <result pre="made available in this article, unless otherwise stated. Abstract Background" exact="Dengue" post="hemorrhagic fever is an acute viral infection transmitted by"/>
   <result pre="evidence to elucidate the origin, circulation, and genetic evolution of" exact="DENV" post="in Vietnam. Keywords Dengue virus (DENV) Full-length genome Dengue"/>
   <result pre="origin, circulation, and genetic evolution of DENV in Vietnam. Keywords" exact="Dengue" post="virus (DENV) Full-length genome Dengue virus type 1 (DENV-1)"/>
   <result pre="of DENV in Vietnam. Keywords Dengue virus (DENV) Full-length genome" exact="Dengue" post="virus type 1 (DENV-1) Genetic variants Dengue epidemic Funding"/>
   <result pre="(DENV) Full-length genome Dengue virus type 1 (DENV-1) Genetic variants" exact="Dengue" post="epidemic Funding http://dx.doi.org/10.13039/100007225Ministry of Science and Technology KC.10.22/16–20BuiHuy Vu"/>
   <result pre="epidemic Funding http://dx.doi.org/10.13039/100007225Ministry of Science and Technology KC.10.22/16–20BuiHuy Vu Background" exact="Dengue" post="hemorrhagic fever is a mosquito-borne acute infection caused by"/>
   <result pre="fatal if not diagnosed and treated promptly and effectively [2]." exact="Dengue" post="hemorrhagic fever can result in major epidemics; these often"/>
   <result pre="DENV–1, DENV–2, DENV–3, and DENV–4 [5]. The genome structure of" exact="DENV" post="has positive sense RNA genome of 10.6 to 11.0 kb"/>
   <result pre="proportion of cases with more severe disease [4, 11]. Thus," exact="DENV" post="is classified as being of low, medium and high"/>
   <result pre="of low, medium and high epidemiological impact. In which, several" exact="DENV" post="may be retained in sylvatic cycles with little transmissibility"/>
   <result pre="dengue fever only [4, 11]. In contrast, many genotypes of" exact="DENV" post="may be associated with the potential to also cause"/>
   <result pre="severe dengue hemorrhagic fever and dengue shock syndrome [4, 11]." exact="DENV" post="has been known for over 200 years [12]. The first"/>
   <result pre="and regions around the world [13]. The disease caused by" exact="DENV" post="is most often benign, non-fatal, with main manifestations of"/>
   <result pre="50 million cases occur per year [17]. The rise of" exact="DENV" post="accompanied by increasing severity is thought to have occurred"/>
   <result pre="as well as poor health infrastructure in most affected countries." exact="Dengue" post="in Vietnam has a year-round occurrence, usually increasing in"/>
   <result pre="of vectors, and the circulation of all four types of" exact="DENV" post="[19]. The habit of hoarding domestic water at home"/>
   <result pre="DENV-1 genome over time and the genetic diversity of the" exact="DENV" post="resulting due to synonymous and non-synonymous mutations that make"/>
   <result pre="resulting due to synonymous and non-synonymous mutations that make the" exact="DENV" post="adaptable under selective pressure. Moreover, the construction of the"/>
   <result pre="our knowledge on the circulation and genetic evolutionary characteristics of" exact="DENV" post="in Vietnam. Methods Patients and samples setting A total"/>
   <result pre="by ethical board of the National Hospital of Tropical Diseases." exact="Dengue" post="serotyping and quantification DENV were typed and quantified using"/>
   <result pre="the National Hospital of Tropical Diseases. Dengue serotyping and quantification" exact="DENV" post="were typed and quantified using Real-time One-Step Reverse Transcription"/>
   <result pre="at 60 °C for 30 s, followed by reading the fluorescence. The" exact="DENV" post="serotypes were determined by specific fluorescence and viral load"/>
   <result pre="data to obtain the best sequences. The completed sequence of" exact="DENV" post="type 1 was then assembled from the reads using"/>
   <result pre="of NS1 plays an important role in the replication of" exact="DENV" post="RNA with wide repeatability, ranging from 800 to 8000 × ."/>
   <result pre="the disease Discussion Previous studies involving genome analysis on the" exact="DENV" post="revealed that genetic alteration may lead to a change"/>
   <result pre="investigate the amino acid substitutions in the genome of the" exact="DENV" post="that caused the large and unusual dengue outbreak that"/>
   <result pre="infected with DENV3 and 4. Thus, the serotype distribution of" exact="DENV" post="in the epidemic of 2017 was different from the"/>
   <result pre="in dengue outbreaks [5, 16, 36, 37]. The distribution of" exact="DENV" post="types in each of the different epidemics may have"/>
   <result pre="is dominant [5, 38–40]. Other studies on the epidemiology of" exact="DENV" post="causing outbreaks in Vietnam have been recorded as iendemic"/>
   <result pre="some other geographical areas. Therefore, studying the genome characteristics of" exact="DENV" post="strains will help to trace the origins of the"/>
   <result pre="NS4B, NS5 genes. These changes may be related to the" exact="DENV" post="virulence, but further studies are needed to clarify the"/>
   <result pre="to clarify the influence of the amino acid substitution of" exact="DENV" post="and dengue hemorrhagic fever severe. Studies on the genetic"/>
   <result pre="dengue hemorrhagic fever severe. Studies on the genetic evolution of" exact="DENV" post="shows that the average mutation rate of DENV is"/>
   <result pre="evolution of DENV shows that the average mutation rate of" exact="DENV" post="is approximately 7.5 × 10− 4 mutations/position/year, this mutation speed compared to"/>
   <result pre="only slower than the HIV and influenza viruses. In nature," exact="DENV" post="exists in two forms, sylvatic and urban. Studies on"/>
   <result pre="were many mutations that occurred in the genome of the" exact="DENV" post="that caused outbreak in 2017. Comparison of genetic mutation"/>
   <result pre="exist many different forms of DENV, the emergence of new" exact="DENV" post="forms in a geographical area may be due to"/>
   <result pre="suggest an introduction of genetic transfer or the spread of" exact="DENV" post="from one geographic region to another. This, in turn,"/>
   <result pre="variant strains. Previous studies on the phylogenetic tree construction of" exact="DENV" post="often used the nucleotide sequence of E gene. In"/>
   <result pre="of dengue in Vietnam in 2017 and originated from the" exact="DENV" post="that was previously distributed in Vietnam. In addition, the"/>
   <result pre="a close relationship between these DENV1 strains and two other" exact="DENV" post="type 1 strains from Cambodia (2006 and 2008). These"/>
   <result pre="and 2008). These findings confirmed the origin and circulation of" exact="DENV" post="in Vietnam. There exists no report of any intrusion"/>
   <result pre="in Vietnam. There exists no report of any intrusion of" exact="DENV" post="from other geographical areas. However, several studies in China,"/>
   <result pre="its kind to describe the complete genome sequence of 72" exact="DENV" post="type 1 viruses circulating in the unusual dengue outbreak"/>
   <result pre="in Northern Vietnam and their genome characteristics compared to several" exact="DENV" post="type 1 strains distributed in Vietnam and other parts"/>
   <result pre="two sets of primers. Table S2. Genetic variations in the" exact="Dengue" post="type 1 genome circulated in Unusual Dengue Epidemic of"/>
   <result pre="variations in the Dengue type 1 genome circulated in Unusual" exact="Dengue" post="Epidemic of 2017 in Vietnam. Description of amino acid"/>
   <result pre="to more than 20.000x. Figure S2. The distance estimation between" exact="Dengue" post="type 1 samples and references. The box chart depicts"/>
   <result pre="D1 samples with each of 47 references. The distance between" exact="Dengue" post="type 1 sample and references was measure by Mash-distance."/>
   <result pre="1 sample and references was measure by Mash-distance. Abbreviations DENV1" exact="DENV" post="type 1 MAFFT Multiple Alignment using Fast Fourier Transform"/>
   <result pre="that they have no competing interests. References References 1.Organization. WWH." exact="Dengue" post="and Severe Dengue. Fact Sheet. Updated April 2017. 2017"/>
   <result pre="and treatment - a reviewMem Inst Oswaldo Cruz2017112852353110.1590/0074-0276017004428767976 15.Organization WWH." exact="Dengue" post="guideline for dignosis, treatment, prevention and control https://www.who.int/tdr/publications/documents/dengue-diagnosis.pdfWHO. 2009."/>
   <result pre="and the Health-Related Quality of Life of Patients in the" exact="Dengue" post="Fever Outbreak in Hanoi in 2017International Journal of Environmental"/>
   <result pre="Public Health2018156117410.3390/ijerph15061174 24.Huong Van NguyenPQTTNguyenTHVuGTTTTCLHTruongNTNguyenSHDoHPHLTNGHHDangAKDoCDTranTHCALBXTHoCSHRogerCMHo Knowledge, Attitude and Practice about" exact="Dengue" post="Fever among Patients Experiencing the 2017 Outbreak in VietnamInt"/>
   <result pre="VietnamInfect Ecol Epidemiol201991166012931528273 26.Huong Van NguyenPQTTNguyenTHVuGTHoangCLTranTTTruongNTNguyenSHDoHPHaGHNguyenHLTDangAKDoCDTranTHTranBXLatkinCAHoCSHHoRCMKnowledge, Attitude and Practice about" exact="Dengue" post="Fever among Patients Experiencing the 2017 Outbreak in VietnamInt"/>
   <result pre="ThamNguyen ThiLanhMai NgocFarrarJeremy J.WhiteheadStephen S.SimmonsCameron P.Clinical and Virological Features of" exact="Dengue" post="in Vietnamese InfantsPLoS Neglected Tropical Diseases201044e65710.1371/journal.pntd.000065720405057 30.Le VietTChoisyMBryantJEVu TrongDPham"/>
   <result pre="IndonesiaPLoS Negl Trop Dis2018126e000661610.1371/journal.pntd.000661629953438 38.CaoJDengHYeLMaXChenSSunXet al.Epidemiological and clinical characteristics of" exact="Dengue" post="virus outbreaks in two regions of China, 2014–2015PLoS One2019143e021335310.1371/journal.pone.021335330835769"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6976597\results\search\tropicalVirus\results.xml">
   <result pre="induce polyarthritis1. The members of the old world viruses include" exact="Chikungunya" post="Virus (CHIKV), Ross River Virus (RRV), Mayaro Virus (MAYV),"/>
   <result pre="strains are also associated with large epidemics such as the" exact="Chikungunya" post="virus (CHIKV) out-break which was spread across 40 countries"/>
   <result pre="components of the inflammatory cellular infiltrate in animal models of" exact="CHIKV" post="and RRV infections8–10. Production of a broad range of"/>
   <result pre="reported by Lidbury et al.11. Interestingly, a comparative study between" exact="CHIKV" post="infection induced gene expression and rheumatoid arthritis induced gene"/>
   <result pre="epitopes and host proteins. Results Arthritogenic alpha viruses such as" exact="Chikungunya" post="virus (CHIKV), Ross river virus (RRV), Semiliki forest virus"/>
   <result pre="depicted in Fig. 2 using the structural polyprotein of the" exact="Chikungunya" post="virus as a representative model. Figure 2 Domain diagram"/>
   <result pre="polyprotein of the alphaviruses. The regions have been depicted using" exact="Chikungunya" post="virus (strain S27 African prototype) structural polyprotein as a"/>
   <result pre="as plausible B cell epitopes also at a conformational level," exact="CHIKV" post="structural polyprotein was used as a model to locate"/>
   <result pre="6 Epitopes predicted based on the 3D structure of the" exact="Chikungunya" post="virus structural polyprotein (PDB ID: 3J2W) using ElliPro. The"/>
   <result pre="B cell epitope prediction analysis based on the structure of" exact="CHIKV" post="structural polyprotein concurred with some of the conserved regions"/>
   <result pre="in the literature29. Structural polyproteins of the six arthritogenic alphaviruses:" exact="Chikungunya" post="virus (strain S2-African prototype)(UniProt ID: Q8JUX5), the Ross river"/>
   <result pre="epitopes. Full length amino acid sequence of structural polyprotein of" exact="Chikungunya" post="virus (strain S27-African prototype) (UniProt ID: Q8JUX5) was subjected"/>
   <result pre="to predict the regions on the structural polyprotein of the" exact="Chikungunya" post="virus (PDB ID: 3J2W). ElliPro accepts a PDB structure"/>
   <result pre="arthrogenic alphavirusThe Journal of infectious diseases2008197111585159310.1086/58784118433328 12.NakayaHIet al.Gene profiling of" exact="Chikungunya" post="virus arthritis in a mouse model reveals significant overlap"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6977312\results\search\tropicalVirus\results.xml">
   <result pre="Reduced or lost vision Measles, rubella, influenza, CMV, HSV, VZV," exact="West Nile," post="chikungunya, dengue and various encephalitis viruses Rickettsia spp., Borrelia"/>
   <result pre="to moderate vitreous reaction No No – Doxycycline Systemic corticosteroids" exact="Dengue" post="virus Maculopathy with macular edema, focal chorioretinitis, yellow subretinal"/>
   <result pre="– 1 week after the onset of the fever No" exact="Chikungunya" post="virus Multifocal choroiditis, retinal whitening with retinal and macular"/>
   <result pre="uveitis Keratitis 1 month to 1 year after diagnosis No" exact="West Nile" post="Virus Multifocal chorioretinitis, linear clusters of circular deep yellowish"/>
   <result pre="lesions of other mosquito-transmitted viral disease notably chikungunya, dengue and" exact="West Nile" post="(Table 2) [112]. Other antiviral drugs (e.g. ganciclovir, foscarnet)"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6979359\results\search\tropicalVirus\results.xml">
   <result pre="data made available in this article, unless otherwise stated. Abstract" exact="Yellow fever" post="(YF) is an acute viral disease, affecting humans and"/>
   <result pre="epidemiological aspects, new clinical findings in humans, and issues regarding" exact="YFV" post="infection in vectors and NHP in Brazil. The 2016–2019"/>
   <result pre="higher than total cases in the previous 36 years. A new" exact="YFV" post="lineage was associated with the recent outbreaks, with persistent"/>
   <result pre="human case suggested the occurrence of the urban transmission cycle." exact="YFV" post="was detected in a variety of NHP specimens presenting"/>
   <result pre="YF surveillance, control, and future strategies for NHP conservation. Keywords" exact="Yellow fever" post="virus Yellow fever Arbovirus Flavivirus Non-human primate Epizootic Outbreak"/>
   <result pre="and future strategies for NHP conservation. Keywords Yellow fever virus" exact="Yellow fever" post="Arbovirus Flavivirus Non-human primate Epizootic Outbreak Epidemiology Vector Pathogenesis"/>
   <result pre="Funding National Council for Scientific and Technological Development (CNPq)440593/2016-6 Background" exact="Yellow fever" post="virus (YFV) causes yellow fever (YF), an acute disease"/>
   <result pre="and NHP [2, 7–9]. Most of the experimental studies with" exact="YFV" post="were performed with Old World NHP, but little is"/>
   <result pre="in Neotropical NHP. Neotropical NHP are considered highly susceptible to" exact="YFV" post="infection [10], which may be related to the recent"/>
   <result pre="in the country. Main text The virus and transmission cycle" exact="YFV" post="is the prototype member of the genus Flavivirus (family"/>
   <result pre="NS2B, NS3, NS4A, NS4B, and NS5) [11]. Until now, one" exact="YFV" post="serotype and seven genotypes have been described in Africa"/>
   <result pre="and Aedes bromeliae as vectors [12, 13]. In South America," exact="YFV" post="is endemic in the Amazon Basin (Brazil, Peru, Bolivia,"/>
   <result pre="mosquitoes primarily belonging to the genera Haemagogus and Sabethes [15]." exact="YFV" post="South American I and II genotypes are derived from"/>
   <result pre="African genotype [16, 17]. South American I is the predominant" exact="YFV" post="genotype in Brazil, possessing five distinct lineages 1A-1E [17,"/>
   <result pre="endemic areas in North Brazil [20, 21]. Genomic analyses of" exact="YFV" post="causing the recent outbreaks revealed unique mutations leading to"/>
   <result pre="of hospitalization, the child died, and postmortem analysis showed wild-type" exact="YFV" post="RNA in the cerebrospinal fluid [29]. The persistence of"/>
   <result pre="in the cerebrospinal fluid [29]. The persistence of the wild-type" exact="YFV" post="genome has been demonstrated in serum [28] and in"/>
   <result pre="after the onset of symptoms, respectively. These findings indicate that" exact="YFV" post="might persist in the host for more extended periods"/>
   <result pre="factors related to the host and the phase of infection." exact="Yellow fever" post="surveillance and control Since all South American NHP are"/>
   <result pre="control Since all South American NHP are highly susceptible to" exact="YFV" post="infection, and epizootics often precede human cases, NHP can"/>
   <result pre="tests [33]. Immunohistochemistry and histopathology analyses allow the detection of" exact="YFV" post="antigens and the identification of histological alterations observed in"/>
   <result pre="infection of monkeys by other flaviviruses, some studies have detected" exact="Zika" post="virus RNA in NHP, during the latest YFV outbreaks"/>
   <result pre="have detected Zika virus RNA in NHP, during the latest" exact="YFV" post="outbreaks in Brazil [34, 35]. Faced with this, molecular"/>
   <result pre="the most reliable and specific tool to diagnose and confirm" exact="YFV" post="infection. YF laboratory diagnosis is performed through virologic or"/>
   <result pre="Reference Laboratories linked to the MOH. For molecular detection of" exact="YFV" post="RNA by RT-qPCR, sera collected from the first up"/>
   <result pre="onset of symptoms is recommended, and the positive result confirms" exact="YFV" post="infection. Serological tests, especially MAC-ELISA to detect IgM antibodies,"/>
   <result pre="other flaviviruses, which are widespread throughout the same regions of" exact="YFV" post="occurrence, the detection of IgM anti-YFV is only presumptive"/>
   <result pre="Finally, epizootics surveillance programs could fail in early detection of" exact="YFV" post="circulation, due to the loss of naïve sentinel NHP."/>
   <result pre="yellow fever in Brazil During the 18th and 19th centuries," exact="YFV" post="caused devastating urban outbreaks in the Americas, and it"/>
   <result pre="de Janeiro, and Bahia states in 2017 [4, 5]. The" exact="YFV" post="lineage causing this outbreak was estimated to exist for"/>
   <result pre="in the Southeast region, which was later confirmed [54, 57]." exact="YFV" post="cases occurred until 2018 [53, 54] in Minas Gerais,"/>
   <result pre="males aged 14 to 35, who are more exposed to" exact="YFV" post="by occupational or ecotourism activities in rural and sylvatic"/>
   <result pre="Brazilian Ministry of Health Brazil and State Health Departments [60–73]" exact="Yellow fever" post="virus vectors in Brazil Unlike NHP and humans, which"/>
   <result pre="heal by developing long-term immunity, mosquitoes are considered reservoirs of" exact="YFV" post="since they remain infected and can transmit the virus"/>
   <result pre="cyaneus, S. glaucodaemon, and S. albiprivus) are the primary sylvatic" exact="YFV" post="vectors [2, 33, 75]. YFV-naturally infected specimens of Aedes"/>
   <result pre="reported in Brazil, however, these mosquitoes are not considered primary" exact="YFV" post="vectors [75–79]. H. janthinomys and H. leucocelaenus have a"/>
   <result pre="in the South American continent and are considered the main" exact="YFV" post="vectors in the Americas and South/Southeast Brazil, respectively [80,"/>
   <result pre="chloropterus is limited to forest areas and considered the primary" exact="YFV" post="sylvatic vector. Their eggs can persist through the dry"/>
   <result pre="the dry season, which is probably a key factor in" exact="YFV" post="maintenance through unfavorable dry periods [86]. Sylvatic YFV vectors"/>
   <result pre="factor in YFV maintenance through unfavorable dry periods [86]. Sylvatic" exact="YFV" post="vectors are abundant in the treetops, with daytime activity"/>
   <result pre="93]. Experimental studies have demonstrated that A. albopictus can transmit" exact="YFV" post="[77, 94–96], and it was found naturally infected with"/>
   <result pre="anthropophilic and endophilic habits and is the urban vector of" exact="YFV" post="[81]. Despite the sensitivity to YFV infection and the"/>
   <result pre="the urban vector of YFV [81]. Despite the sensitivity to" exact="YFV" post="infection and the high infestation indices of A. aegypti"/>
   <result pre="Brazil [75, 77, 98, 99], there is no evidence of" exact="YFV" post="transmission by A. aegypti, since the eradication of urban"/>
   <result pre="degraded habitats [104, 105]. Neotropical NHP are potential hosts for" exact="YFV" post="due to their ecological and behavioral patterns and their"/>
   <result pre="favor of hematophagous mosquitoes and, consequently, the transmission of viruses." exact="Yellow fever" post="in non-human primates Old World NHP are sensitive to"/>
   <result pre="fever in non-human primates Old World NHP are sensitive to" exact="YFV" post="and develop enough viremia to reinfect mosquitoes but rarely"/>
   <result pre="they show clinical signs or die. In Africa, the primary" exact="YFV" post="amplifier hosts are Cercopithecus spp. (with viremia lasting for"/>
   <result pre="and possibly Galago senegalensis could be infected and contribute to" exact="YFV" post="transmission [7]. Serological and clinical findings related to YFV"/>
   <result pre="to YFV transmission [7]. Serological and clinical findings related to" exact="YFV" post="infection are described in many Neotropical NHP [112–114]. All"/>
   <result pre="NHP [112–114]. All Neotropical NHP genera are considered susceptible to" exact="YFV" post="infection with differing degrees of sensitivity [115, 116]. Early"/>
   <result pre="sensitivity [115, 116]. Early reports in Brazil showed antibodies against" exact="YFV" post="in specimens of Cebus, Callithrix, and Leontopithecus, in Mato"/>
   <result pre="states [117–119]. An extensive immunological survey detected humoral immunity against" exact="YFV" post="in Alouatta, Ateles, Aotus, Callicebus, Callithrix, Cebus, Brachyteles, Leontopithecus,"/>
   <result pre="[121]. Alouatta is described as the most susceptible genus to" exact="YFV" post="infection, developing clinical illness and fatal disease [114, 122,"/>
   <result pre="123], even when infected with low virus inoculum [2]. However," exact="YFV" post="antibodies have been detected in some specimens of Alouatta,"/>
   <result pre="sudden silence is considered a signal for the circulation of" exact="YFV" post="[33, 89]. High numbers of NHP deaths, especially of"/>
   <result pre="of Callithrix are also involved in the sylvatic cycle of" exact="YFV" post="in Brazil. Experimental studies demonstrated the susceptibility of Callithrix"/>
   <result pre="susceptibility of Callithrix albicolis, Callithrix penicillata, and hybrids marmosets to" exact="YFV" post="[113]. Wild specimens of C. penicillata presenting histopathological findings"/>
   <result pre="Wild specimens of C. penicillata presenting histopathological findings suggestive of" exact="YFV" post="infection, and marmosets showing anti-YFV antibodies have been reported"/>
   <result pre="states [53]. From 2017 on, genomic and epidemiological studies described" exact="YFV" post="infection in NHP in the Southeast region of Brazil."/>
   <result pre="that some species of Callithrix may have different sensitivity to" exact="YFV" post="when compared to Alouatta spp. and Sapajus spp. [20]."/>
   <result pre="Basin, a YF endemic region, could be more resistant to" exact="YFV" post="compared to NHP from YFV-free areas. Besides other ecological"/>
   <result pre="139]. The first successful infection of a rhesus monkey with" exact="YFV" post="was demonstrated in 1928, by Stokes and colleagues (1928)."/>
   <result pre="cells [141]. In general, NHP exhibit the viscerotropic disease, and" exact="YFV" post="can be found in the liver, kidneys, bone marrow,"/>
   <result pre="edema in lungs and eyelid, and hyperemia of the eyelid." exact="YFV" post="RNA was detected in the lungs, liver, kidneys, bladder,"/>
   <result pre="intestine, suggesting that the pathological picture was probably caused by" exact="YFV" post="[137]. Fernandes and colleagues (2017) performed histologic analyses of"/>
   <result pre="latest YF outbreak in Brazil are an alert. A new" exact="YFV" post="lineage was associated with the 2016–2019 outbreaks. However, whether"/>
   <result pre="Genomic surveillance and evolutionary studies demonstrated the sustained circulation of" exact="YFV" post="before December 2016 until 2019, reaching extensive YF-free areas"/>
   <result pre="was described in Leontopithecus rosalia. NHP are amplifier hosts for" exact="YFV" post="but are not viral reservoirs since they die or"/>
   <result pre="studies to better understand the duration of protective immunity against" exact="YFV" post="in NHP are required. Further investigation of viremia in"/>
   <result pre="Neotropical NHP could contribute to the assessment of sensitivity to" exact="YFV" post="and the potential for vector infection. This information is"/>
   <result pre="cycle. Further studies to understand the role of NHP in" exact="YFV" post="circulation in different environments are needed, as well as"/>
   <result pre="Ministry of Health TCID50 Median tissue culture infectious dose YF" exact="Yellow fever" post="YFV Yellow fever virus Publisher’s Note Springer Nature remains"/>
   <result pre="Health TCID50 Median tissue culture infectious dose YF Yellow fever" exact="YFV" post="Yellow fever virus Publisher’s Note Springer Nature remains neutral"/>
   <result pre="TCID50 Median tissue culture infectious dose YF Yellow fever YFV" exact="Yellow fever" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
   <result pre="2.VasconcelosPFCYellow feverRev Soc Bras Med Trop20033627529310.1590/S0037-8682200300020001212806465 3.Maguire HCF, Heymann DL." exact="Yellow fever" post="in Africa. BMJ. 2016:i3764. 4.MS-BR. Centro de Operações de"/>
   <result pre="N, Mesquita F, Zanotto P, et al. First detection of" exact="Zika" post="virus in neotropical primates in Brazil: a possible new"/>
   <result pre="Parra MCP, Del Sarto JL, et al. Evidence of natural" exact="Zika" post="virus infection in neotropical non-human primates in Brazil. Sci"/>
   <result pre="from: http://portalarquivos.saude.gov.br/images/pdf/2017/outubro/06/Volume-Unico-2017.pdf [cited 2019 Jul 18] 53.DelatorreEde AbreuFVSRibeiroIPGómezMMdos SantosAACFerreira-de-BritoAet al.Distinct" exact="YFV" post="lineages co-circulated in the Central-Western and southeastern Brazilian regions"/>
   <result pre="SoaresDutraMaria Rita TeixeiraRamalhoDario Brockde ThoisyBenoitKroonErna GeessienTrindadeGiliane de SouzaDrumondBetânia PaivaPersistence of" exact="Yellow fever" post="virus outside the Amazon Basin, causing epidemics in Southeast"/>
   <result pre="E, da Fonseca DF, Sallum MAM, Noll CA, et al." exact="Yellow fever" post="virus in Haemagogus leucocelaenus and Aedes serratus mosquitoes, southern"/>
   <result pre="PL, Pinheiro FP, Pissinatti A, da Cunha RV, et al." exact="Yellow fever" post="outbreak in Brazil: the puzzle of rapid viral spread"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6986714\results\search\tropicalVirus\results.xml">
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Mathematics : Statistics : Statistical methods: Monte Carlo method Modeling" exact="Chikungunya" post="control strategies and Mayaro potential outbreak in the city"/>
   <result pre="potential outbreak in the city of Rio de Janeiro Modeling" exact="Chikungunya" post="control strategies and Mayaro potential outbreak in Rio de"/>
   <result pre="In this work, we perform data analysis of the last" exact="Chikungunya" post="epidemics in the city of Rio de Janeiro by"/>
   <result pre="example, around 300.000 people were infected by Dengue, Zika, or" exact="Chikungunya" post="by the end of the 11th week of 2019"/>
   <result pre="apply a compartmental mathematical model to investigate the dynamics of" exact="Chikungunya" post="outbreaks in the city of Rio de Janeiro in"/>
   <result pre="these parameters, we estimate the basic reproduction number Ro for" exact="Chikungunya" post="outbreaks in those years. We also simulate a scenario"/>
   <result pre="and methods In this work, we perform mathematical modeling of" exact="Chikungunya" post="outbreaks in Rio de Janeiro for the years 2016,"/>
   <result pre="Janeiro for the years 2016, 2017 and 2019 [12]. The" exact="Chikungunya" post="virus infects humans through mosquitoes as the disease vector."/>
   <result pre="the application of the SEIR model in the data of" exact="Chikungunya" post="in Rio de Janeiro—Brazil in different years (2016, 2018"/>
   <result pre="data which contains the weekly number of infected people of" exact="Chikungunya" post="outbreak in Rio de Janeiro was obtained from the"/>
   <result pre="year. Fig 2 The number of infected people distribution by" exact="Chikungunya" post="in Rio de Janeiro for 2016, 2018 and 2019,"/>
   <result pre="10.1371/journal.pone.0222900.t003Table 3 Best fitted parameter values in different years for" exact="Chikungunya" post="(CHKV) in Rio de Janeiro. Estimated parameter are also"/>
   <result pre="row shows the values of the estimated Ro for both" exact="Chikungunya" post="and Mayaro. Parameter CHKV—2016 CHKV—2018 CHKV—2019 Mayaro βh 0.1"/>
   <result pre=". Considering other epidemic diseases in Rio de Janeiro as" exact="Dengue" post="and Zika, which are transmitted by the same vector,"/>
   <result pre="estimated parameters for Mayaro virus using the data for the" exact="Chikungunya" post="outbreak in 2018, which is the most recent complete"/>
   <result pre="the ±5% range from the best fit value of the" exact="Chikungunya" post="epidemic data of 2018. From these simulations, the time-shift"/>
   <result pre="spreading [13, 23]. The simulations were carried out using the" exact="Chikungunya" post="epidemic outbreak data from Rio de Janeiro in 2018."/>
   <result pre="for ω, ωo, ϵ = 0.5. Conclusion The last three" exact="Chikungunya" post="outbreaks in the city of Rio de Janeiro, Brazil,"/>
   <result pre="[37, 39, 41]. Based on the assumption that Mayaro and" exact="Chikungunya" post="viruses have a similar spreading mechanism [37], since both"/>
   <result pre="[31, 36, 42, 43], we used parameters fitted from the" exact="Chikungunya" post="outbreak from 2018 to estimate the R o M"/>
   <result pre="Aedes albopictus. Nature microbiology. 2019;4(5):85410.1038/s41564-019-0376-y30833735 2PazS. Climate change impacts on" exact="West Nile" post="virus transmission in a global context. Philosophical Transactions of"/>
   <result pre="diseases. 2009;3(5):e44810.1371/journal.pntd.000044819478848 8BonyahE, KhanMA, OkosunK, IslamS. A theoretical model for" exact="Zika" post="virus transmission. PloS one. 2017;12(10):e018554010.1371/journal.pone.018554028977007 9DelamaterPL, StreetEJ, LeslieTF, YangYT,"/>
   <result pre="Control of Malaria. 1957. 11YakobL, ClementsACA. A Mathematical Model of" exact="Chikungunya" post="Dynamics and Control: The Major Epidemic on Réunion Island."/>
   <result pre="in Singapore. Epidemiology &amp;amp; Infection. 2008;136(3):309–319. 10.1017/S095026880700866717540051 14WearingHJ, RobertMA, ChristoffersonRC." exact="Dengue" post="and chikungunya: modelling the expansion of mosquito-borne viruses into"/>
   <result pre="the reproductive number, total outbreak size, and reporting rates for" exact="Zika" post="epidemics in South and Central America. Epidemics. 2017;21:63–79. 10.1016/j.epidem.2017.06.00528803069"/>
   <result pre="therapy. Antiviral research. 2013;99(3):345–370. 10.1016/j.antiviral.2013.06.00923811281 18DubrulleM, MoussonL, MoutaillerS, VazeilleM, FaillouxAB." exact="Chikungunya" post="virus and Aedes mosquitoes: saliva is infectious as soon"/>
   <result pre="one. 2009;4(6):e589510.1371/journal.pone.000589519521520 19VazeilleM, MoutaillerS, CoudrierD, RousseauxC, KhunH, HuerreM, et al.Two" exact="Chikungunya" post="isolates from the outbreak of La Reunion (Indian Ocean)"/>
   <result pre="An outbreak vector-host epidemic model with spatial structure: the 2015–2016" exact="Zika" post="outbreak in Rio De Janeiro. Theoretical Biology and Medical"/>
   <result pre="Tropical Medicine and Hygiene. 2001;95(4):370–374. 10.1016/s0035-9203(01)90184-111579875 35MassadE, BurattiniMN, CoutinhoFAB, LopezLF." exact="Dengue" post="and the risk of urban yellow fever reintroduction in"/>
   <result pre="and Transmission Potential of the Virus in Mixed Infections With" exact="Chikungunya" post="Virus. Journal of medical entomology. 2019;56(3):832–843. 10.1093/jme/tjy24130668762 37FigueiredoMLGd, FigueiredoLTM."/>
   <result pre="entomology. 2019;56(3):832–843. 10.1093/jme/tjy24130668762 37FigueiredoMLGd, FigueiredoLTM. Emerging alphaviruses in the Americas:" exact="Chikungunya" post="and Mayaro. Revista da Sociedade Brasileira de Medicina Tropical."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6986850\results\search\tropicalVirus\results.xml">
   <result pre="2014;69:351–82. 10.1093/jhmas/jrs06123090980 16. CovelloVT, PetersRG, WojteckiJG, HydeRC. Risk communication, the" exact="West Nile" post="virus epidemic, and bioterrorism: responding to the communication challenges"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6987159\results\search\tropicalVirus\results.xml">
   <result pre="Reports2045-2322Nature Publishing Group UKLondon pmcid: 698715958135 doi: 10.1038/s41598-020-58135-y : Article" exact="Zika" post="virus targets the human thymic epithelium MessiasCarolina V.12Loss-MoraisGuilherme3CarvalhoJoseane Biso"/>
   <result pre="hypothesized that the thymus might also be infected by the" exact="Zika" post="virus (ZIKV). Herein we provide compelling evidence that ZIKV"/>
   <result pre="the Zika virus (ZIKV). Herein we provide compelling evidence that" exact="ZIKV" post="targets human thymic epithelial cells (TEC) in vivo and"/>
   <result pre="a decrease in proliferation and increase in cell death. Moreover," exact="ZIKV" post="modulates a high amount of coding RNAs with upregulation"/>
   <result pre="thymus, particularly the thymic epithelium, is a target for the" exact="ZIKV" post="with changes in the expression of molecules that are"/>
   <result pre="Mercosur #03/11) and the Program of Preventing and Combating the" exact="Zika" post="Virus, MCTIC/FNDCT - CNPq/MEC-CAPES/MS-Decit (Grants 426767/2018-7 and 88881.130684/2016-01); Brazilian"/>
   <result pre="Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM) #465489/2014-1. Introduction" exact="Zika" post="virus (ZIKV) epidemics in 2015-2016 resulted in devastating effects,"/>
   <result pre="born from mothers infected by the virus during pregnancy1–4. Additionally," exact="ZIKV" post="infection in adults correlated with a rise in the"/>
   <result pre="knowledge on the cellular and molecular alterations caused by the" exact="ZIKV" post="in the nervous tissue largely increased in the last"/>
   <result pre="are much less defined. In terms of secondary lymphoid organs," exact="ZIKV" post="RNA and protein have been described in lymph nodes"/>
   <result pre="non-human primate. However, in the same study, the presence of" exact="ZIKV" post="RNA in T-cells was observed only in axillary lymph"/>
   <result pre="that the thymic epithelium might also be infected by the" exact="Zika" post="virus. Herein we provide compelling evidence that ZIKV targets"/>
   <result pre="by the Zika virus. Herein we provide compelling evidence that" exact="ZIKV" post="targets human TEC both in vivo and in vitro."/>
   <result pre="alterations in the thymic microenvironment from babies prenatally infected by" exact="ZIKV" post="were observed, as well as the presence of the"/>
   <result pre="data reveal that the thymus is a target for the" exact="ZIKV" post="and may function as a reservoir of the virus"/>
   <result pre="infection. Results Cultured human TEC can be infected by the" exact="Zika" post="virus We first investigated the infectivity and growth capacity"/>
   <result pre="on the envelope protein conserved in the flavivirus family, including" exact="Dengue" post="virus, West Nile virus, Japanese Encephalitis virus and Zika"/>
   <result pre="envelope protein conserved in the flavivirus family, including Dengue virus," exact="West Nile" post="virus, Japanese Encephalitis virus and Zika virus19. As shown"/>
   <result pre="including Dengue virus, West Nile virus, Japanese Encephalitis virus and" exact="Zika" post="virus19. As shown in Fig. 1a,b, we found a"/>
   <result pre="on adhered cells (Fig. 1c,d), and the presence of the" exact="ZIKV" post="envelope protein could be detected in the cytoplasm -"/>
   <result pre="1 Human TEC can be infected in vitro by the" exact="Zika" post="virus. (a) TEC were infected with ZIKV (MOI = 0.1 or"/>
   <result pre="vitro by the Zika virus. (a) TEC were infected with" exact="ZIKV" post="(MOI = 0.1 or 1) and the relative expression of 4G2+"/>
   <result pre="isotype controls, blue curves represent MOCK and red curves represent" exact="ZIKV" post="(n = 3). TEC were infected with ZIKV (MOI = 1) and (c)"/>
   <result pre="and red curves represent ZIKV (n = 3). TEC were infected with" exact="ZIKV" post="(MOI = 1) and (c) the percentage of 4G2+ cells were"/>
   <result pre="(f) Representative images of TEC culture 72 hpi (n = 3). (g)" exact="ZIKV" post="growth curve in TEC culture. Supernatant of ZIKV-infected TEC"/>
   <result pre="t-test or one-way ANOVA, followed by Tukey multiple comparison test)." exact="ZIKV" post="infection induced cytopathic effects in TEC with the presence"/>
   <result pre="(Fig. 1g). Furthermore, infected TEC-derived supernatants were able to convey" exact="ZIKV" post="to uninfected TEC cultures (Fig. 1h). Since human TEC"/>
   <result pre="by ZIKV, we searched for the membrane expression of well-known" exact="ZIKV" post="receptors, namely TIM1, TIM4, TYRO3, and AXL. Actually, cultured"/>
   <result pre="with the corresponding neutralizing antibody completely prevented TEC infection by" exact="ZIKV" post="(Fig. 1j,k), showing that ZIKV uses the AXL receptor"/>
   <result pre="completely prevented TEC infection by ZIKV (Fig. 1j,k), showing that" exact="ZIKV" post="uses the AXL receptor to invade human TEC. Zika"/>
   <result pre="that ZIKV uses the AXL receptor to invade human TEC." exact="Zika" post="virus infection disturbs cell growth in cultured human TEC"/>
   <result pre="cultured human TEC Considering that human TEC were sensitive to" exact="ZIKV" post="infection, we wondered whether such an infection could also"/>
   <result pre="The TEC counting in infected versus uninfected cultures showed that" exact="ZIKV" post="infection induced a progressive reduction in the numbers of"/>
   <result pre="HTLV-1 neither in cell proliferation nor cell death16. Figure 2" exact="Zika" post="virus infection down modulates the growth of cultured human"/>
   <result pre="of cultured human thymic epithelial cells. TECs were infected with" exact="ZIKV" post="(MOI = 1) and the (a) numbers of cells in culture"/>
   <result pre="hpi. Values represent the mean ± SEM (n = 3). **p &amp;lt; 0.01, ***p &amp;lt; 0.001 (unpaired t-test)." exact="Zika" post="infection induces major changes in human TEC gene expression"/>
   <result pre="Enrichment Analyses of upregulated and downregulated genes from transcriptome of" exact="Zika" post="virus-infected TEC. (a) Top 10 significant terms from the"/>
   <result pre="and cell division, with a slight increase of apoptosis after" exact="ZIKV" post="infection (Supplemental Table 2 and Fig. 2). The Enrichment"/>
   <result pre="4 Non-coding genes response in human TEC infected with the" exact="Zika" post="virus. (a) Expression of Long non-coding genes related to"/>
   <result pre="The hsa-miR-7-3-3p was the most upregulated miRNA (log2 FC = 5.16) after" exact="ZIKV" post="infection. The majority of miRNAs presented a slightly upregulation"/>
   <result pre="analyses revealed complex molecular responses of TEC in response to" exact="ZIKV" post="infection, showing an intricate regulatory network, including different layers"/>
   <result pre="distinct clusters of genes whose expression was altered secondary to" exact="ZIKV" post="infection. Co-cultures of ZIKV-infected TEC with lymphoblastic T cells"/>
   <result pre="the cells expressing high amounts of ICAM-1 (5.2% (±1.2) of" exact="ZIKV" post="infected cells and 2.6% (±0.5) for controls (p = 0.05). As"/>
   <result pre="although the differences were not statistically significant (p-value = 0.1). Figure 5" exact="Zika" post="virus infection in human cultured epithelial cells enhances cell"/>
   <result pre="to lymphoblastic T cells. (a) Human TEC were infected with" exact="ZIKV" post="(MOI = 1) and 72 hpi the expression of ICAM-1 (CD54)"/>
   <result pre="of the control group (n = 3). Human TEC were infected with" exact="ZIKV" post="(MOI = 1) and 72 hpi uninfected CEM acute T-cell leukemia"/>
   <result pre="in duplicate). (e) CEM cells were not directly infected by" exact="ZIKV" post="(MOI = 1). CEM cells were infected with ZIKV (MOI = 1) for"/>
   <result pre="directly infected by ZIKV (MOI = 1). CEM cells were infected with" exact="ZIKV" post="(MOI = 1) for 2 h and 72 hpi 4G2+ cells were"/>
   <result pre="Interestingly enough, we could not directly infect CEM cells with" exact="ZIKV" post="(Fig. 5e) or with Zika virus-infected TEC supernatant (data"/>
   <result pre="directly infect CEM cells with ZIKV (Fig. 5e) or with" exact="Zika" post="virus-infected TEC supernatant (data not shown). The human thymic"/>
   <result pre="The human thymic epithelium is altered after congenital in vivo" exact="ZIKV" post="infection We also studied sections of six thymuses from"/>
   <result pre="that died in postnatal life born from mothers infected by" exact="ZIKV" post="during pregnancy. The histological profile of these specimens varied"/>
   <result pre="the cortical/medullary distinction (Fig. 6b, case 2). Figure 6 Congenital" exact="Zika" post="virus infection induces major changes in the human thymic"/>
   <result pre="network are represented (n = 2 for controls and n = 6 for congenital" exact="ZIKV" post="infection). Arrows show some of the Hassal’s corpuscles. C:"/>
   <result pre="These data are summarized in Fig. 7. Figure 7 Congenital" exact="Zika" post="virus infection induces changes in the human thymic extracellular"/>
   <result pre="in the images. (n = 2 for controls and n = 6 for congenital" exact="ZIKV" post="infection). We also searched for the presence of the"/>
   <result pre="out that one thymus was positive for the presence of" exact="ZIKV" post="ascertained by the RT-PCR (case 4 - Supplemental Table"/>
   <result pre="of the thymus preparations were positive for the presence of" exact="Dengue" post="as well as Chikungunya viruses (Supplemental Table 4). Secondary"/>
   <result pre="were positive for the presence of Dengue as well as" exact="Chikungunya" post="viruses (Supplemental Table 4). Secondary antibodies were used as"/>
   <result pre="not generate any significant labeling (Supplemental Fig. 2b). Figure 8" exact="ZIKV" post="envelope protein is found in human thymus of babies"/>
   <result pre="protein is found in human thymus of babies with congenital" exact="Zika" post="virus infection. Representative images of immunofluorescence staining of 4G2"/>
   <result pre="human thymus sections (n = 2 for controls and n = 6 for congenital" exact="ZIKV" post="infection). First column shows the merge of the three"/>
   <result pre="immune system secondary to a congenital syndrome caused by the" exact="ZIKV" post="remains largely unknown, although there is evidence that innate"/>
   <result pre="TEC is permissive to different types of RNA viruses. Importantly," exact="ZIKV" post="did trigger an antiviral machinery response in human TEC,"/>
   <result pre="changes in TEC growth were also found after in vitro" exact="ZIKV" post="infection, including a decrease in proliferation and increase in"/>
   <result pre="cell numbers after 3-day TEC cultures. RNA viruses such as" exact="ZIKV" post="use strategies to modulate cell-cycle control and cell proliferation"/>
   <result pre="higher levels of VCAM1 and ICAM-1 expression in TEC after" exact="ZIKV" post="infection. Enhanced expression of some matrix metalloproteinase genes, such"/>
   <result pre="the ECM-related metabolism of TEC is altered by ZIKV. Moreover," exact="ZIKV" post="augmented the gene expression of various chemokines; some of"/>
   <result pre="other human viruses such as HBV, HCV, and EMCV40. Following" exact="ZIKV" post="infection in TEC, we also detected an upregulation of"/>
   <result pre="findings highlight a high complexity in the intracellular circuitry controlling" exact="ZIKV" post="replication within human TEC. In addition to extended in"/>
   <result pre="who died early in life, whose mothers were infected with" exact="ZIKV" post="during pregnancy. Although the number of specimens was low,"/>
   <result pre="conceivable that the human thymic epithelium is a target for" exact="ZIKV" post="infection, with general but also specific consequences, as for"/>
   <result pre="intrathymic T-cell development. Methods and Patients Human TEC line and" exact="Zika" post="virus infection The human postnatal TEC line17 was maintained"/>
   <result pre="(InvivoGen) at 37 °C, in an atmosphere containing 5% CO2. The" exact="ZIKV" post="strain used in this study was RIO-U1, which was"/>
   <result pre="(GenBank Accession number: KU926309), as described elsewhere49. Viral stocks of" exact="ZIKV" post="Rio-U1 were prepared by infecting Vero cell monolayers. The"/>
   <result pre="conditions but not infected by ZIKV. CEM cell line and" exact="ZIKV" post="infection CEM is an acute T-cell lymphoblastic leukemia cell"/>
   <result pre="that was maintained in RPMI-1640 medium supplemented as described above." exact="ZIKV" post="Infection was performed with 1.0 MOI, as described previously"/>
   <result pre="Our experiments on the role of the AXL receptor in" exact="ZIKV" post="entry in TECs were based on the paper of"/>
   <result pre="exposure of the human skin fibroblast cell line HFF1 to" exact="ZIKV" post="(and to Dengue virus, used as a positive control)"/>
   <result pre="human skin fibroblast cell line HFF1 to ZIKV (and to" exact="Dengue" post="virus, used as a positive control) resulted in comparable"/>
   <result pre="6 months after birth, and whose mothers were infected with" exact="ZIKV" post="during pregnancy. The clinical features of these newborns are"/>
   <result pre="Mercosur #03/11) and the Program of Preventing and Combating the" exact="Zika" post="Virus, MCTIC/FNDCT - CNPq/MEC-CAPES/MS-Decit (Grants 426767/2018-7 and 88881.130684/2016-01 for"/>
   <result pre="declare no competing interests. References References 1.MartinesRBet al.Pathology of congenital" exact="Zika" post="syndrome in Brazil: a case seriesLancet201638889890410.1016/S0140-6736(16)30883-227372395 2.Carod-ArtalFJNeurological complications of"/>
   <result pre="Zika syndrome in Brazil: a case seriesLancet201638889890410.1016/S0140-6736(16)30883-227372395 2.Carod-ArtalFJNeurological complications of" exact="Zika" post="virus infectionExpert Rev. Anti. Infect. Ther.20181639941010.1080/14787210.2018.146670229668332 3.Lopes MoreiraMEet al.Neurodevelopment"/>
   <result pre="Anti. Infect. Ther.20181639941010.1080/14787210.2018.146670229668332 3.Lopes MoreiraMEet al.Neurodevelopment in Infants Exposed to" exact="Zika" post="Virus In UteroN. Engl. J. Med.20183792377237910.1056/NEJMc180009830575464 4.Nielsen-SainesKet al.Delayed childhood"/>
   <result pre="childrenNat. Med.2019251213121710.1038/s41591-019-0496-131285631 5.Da SilvaIRFFronteraJADe FilippisAMBDo NascimentoOJMNeurologic complications associated with the" exact="Zika" post="virus in Brazilian adultsJAMA Neurol.2017741190119810.1001/jamaneurol.2017.170328806453 6.SavinoWet al.Zika Virus Infection"/>
   <result pre="selection along with survival of selected thymocytesMol. Immunol.20084542810.1016/j.molimm.2007.05.01617604837 21.FooSSet al.Asian" exact="Zika" post="virus strains target CD14+blood monocytes and induce M2-skewed immunosuppression"/>
   <result pre="immunosuppression during pregnancyNat. Microbiol.201721558157010.1038/s41564-017-0016-328827581 22.MichlmayrDAndradePGonzalezKBalmasedaAHarrisECD14+CD16+monocytes are the main target of" exact="Zika" post="virus infection in peripheral blood mononuclear cells in a"/>
   <result pre="of MitosisJ. Virol.2011857989800110.1128/JVI.00280-1121680513 24.StrangeDPGreenRSiemannDNGaleMVermaSImmunoprofiles of human Sertoli cells infected with" exact="Zika" post="virus reveals unique insights into host-pathogen crosstalkSci. Rep.2018811510.1038/s41598-018-27027-729311619 25.LimontaDet"/>
   <result pre="al.Determination of system level alterations in host transcriptome due to" exact="Zika" post="virus (ZIKV) Infection in retinal pigment epitheliumSci. Rep.2018811610.1038/s41598-017-17765-529311619 27.LiuLingChenZhenyuZhangXinLiShunHuiYiFengHexiDuYanhuaJinGuohuaZhouXiaohuiZhangXiaoqingProtection"/>
   <result pre="virus (ZIKV) Infection in retinal pigment epitheliumSci. Rep.2018811610.1038/s41598-017-17765-529311619 27.LiuLingChenZhenyuZhangXinLiShunHuiYiFengHexiDuYanhuaJinGuohuaZhouXiaohuiZhangXiaoqingProtection of" exact="ZIKV" post="infection-induced neuropathy by abrogation of acute antiviral response in"/>
   <result pre="subset characterized by high molecular weight cytokeratin expressionEndocrinology198812325576410.1210/endo-123-5-25572458915 48.Valdespino-VázquezMYet al.Congenital" exact="Zika" post="Syndrome and Extra-Central Nervous System Detection of Zika Virus"/>
   <result pre="48.Valdespino-VázquezMYet al.Congenital Zika Syndrome and Extra-Central Nervous System Detection of" exact="Zika" post="Virus in a Pre-term Newborn in MexicoClin. Infect. Dis.20196890391210.1093/cid/ciy61630188990"/>
   <result pre="Pre-term Newborn in MexicoClin. Infect. Dis.20196890391210.1093/cid/ciy61630188990 49.BonaldoMCet al.Isolation of Infective" exact="Zika" post="Virus from Urine and Saliva of Patients in BrazilPLoS"/>
   <result pre="infects human blood mononuclear cellsBMC Infect. Dis.20191998610.1186/s12879-019-4622-y31752731 51.HamelRet al.Biology of" exact="Zika" post="Virus Infection in Human Skin CellsJ. Virol.2015898880889610.1128/JVI.00354-1526085147 52.Ribeiro-CarvalhoMMFarias-de-OliveiraDAVilla-VerdeDMSSavinoWTriiodothyronine modulates"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6988203\results\search\tropicalVirus\results.xml">
   <result pre="has been used in arbovirus surveillance and during Ebola and" exact="Zika" post="outbreaks [34, 129]. This technology is non-PCR-based tool for"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6988270\results\search\tropicalVirus\results.xml">
   <result pre="assays.Viruses. 2015;7(6):3130-54. 10.3390/v706276326090727 11CormanVMRascheABarontiCAldabbaghSCadarDReuskenCBet al.Assay optimization for molecular detection of" exact="Zika" post="virus.Bull World Health Organ. 2016;94(12):880-92. 10.2471/BLT.16.17595027994281 12FischerCde LamballerieXDrexlerJFEnhanced molecular"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6989424\results\search\tropicalVirus\results.xml">
   <result pre="10.3389/fimmu.2020.00016 : Immunology: Original Research CD4 T Cell Determinants in" exact="West Nile" post="Virus Disease and Asymptomatic Infection KoblischkeMaximilian1SpitzerFelicia S.1FlorianDavid M.1AberleStephan W.1MalafaStefan1FaeIngrid2CassanitiIrene34JungbauerChristof5KnappBernhard6LaferlHermann7FischerGottfried2BaldantiFausto34StiasnyKarin1HeinzFranz"/>
   <result pre="is permitted which does not comply with these terms. Abstract" exact="West Nile" post="(WN) virus infection of humans is frequently asymptomatic, but"/>
   <result pre="targeted in other mosquito-borne flaviviruses, including dengue, yellow fever, and" exact="Zika" post="viruses. Together, these findings indicate a strong impact of"/>
   <result pre="is an important issue to consider in future vaccine design." exact="West Nile" post="virus flavivirus CD4 T cell immunodominance epitope West Nile"/>
   <result pre="design. West Nile virus flavivirus CD4 T cell immunodominance epitope" exact="West Nile" post="patients Funding Austrian Science Fund10.13039/501100002428P29881-B30 fig-count: table-count: equation-count: ref-count:"/>
   <result pre="Austrian Science Fund10.13039/501100002428P29881-B30 fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="West Nile" post="(WN) virus is a mosquito-borne flavivirus that has caused"/>
   <result pre="virus infection. By measuring responses in 29 individuals with either" exact="West Nile" post="virus disease (WND) or asymptomatic infection, we identified 67"/>
   <result pre="San Matteo Pavia) in northern Italy. Table 1 Characteristics of" exact="West Nile" post="virus-infected subjects. Diagnosis of WNV infection IL-2 ELISPOT result"/>
   <result pre="Table 1 Characteristics of West Nile virus-infected subjects. Diagnosis of" exact="WNV" post="infection IL-2 ELISPOT result Patient Symptoms WNV RNAa WNVIgM"/>
   <result pre="subjects. Diagnosis of WNV infection IL-2 ELISPOT result Patient Symptoms" exact="WNV" post="RNAa WNVIgM E prM C 501 Asymptomatic pos Pos"/>
   <result pre="the time of diagnosis, all 29 participants were negative in" exact="Zika" post="neutralization tests. In addition, previous DEN virus infection was"/>
   <result pre="accordance with biosecurity regulations and institutional safety procedures. Detection of" exact="West Nile" post="Virus RNA WN virus PCR was performed as described"/>
   <result pre="conserved WN virus 3′-noncoding region was used (32). Detection of" exact="West Nile" post="Virus IgM WN virus-specific IgM antibodies were detected in"/>
   <result pre="virus-induced cytopathic effects. Virus NT titers ≥20 were considered positive." exact="Zika" post="virus-specific neutralizing antibodies were determined in Vero cells (23)."/>
   <result pre="dilutions of heat-inactivated serum samples were incubated with 30–60 TCID50" exact="Zika" post="virus (strain H/PF 2013) for 1 h at 37°C."/>
   <result pre="of experimentally identified epitopes were KUN virus C (PDB 1SFK)," exact="Zika" post="sE (5LBV) (26), DEN-2 sE (PDB 1OAN) (27), and"/>
   <result pre="of C and E, multiple sequence alignments were performed (GenBank:" exact="Zika" post="virus KJ776791; DEN 1–4 viruses AF226687, M29095, DQ863638, GQ398256;"/>
   <result pre="of the WN virus (PDB 2I69), YF virus (PDB 6EPK)," exact="Zika" post="virus (PDB 5LBV), and DEN virus sE proteins (PDB"/>
   <result pre="II (E245), or III (E381), respectively onto those of YF," exact="Zika" post="and DEN viruses was performed using the PyMOL algorithms"/>
   <result pre="C protein (PDB 1SFK) (36) highlighting epitopes recognized in WN," exact="Zika" post="(23), DEN (40, 41), and YF viruses (22). (B)"/>
   <result pre="(B) Envelope protein structure alignment of WN (PDB 2I69) (25)," exact="Zika" post="(PDB 5LBV) (26), DEN (PDB 1OAN) (27), and YF"/>
   <result pre="of WN virus sE protein domains with those of YF," exact="Zika" post="and DEN viruses, respectively. The analysis included epitope regions"/>
   <result pre="the upper part of E DI, which is absent in" exact="Zika" post="and DEN viruses (Figure 4). It is notable that"/>
   <result pre="WN virus (PDB 2I69) (25) and YF (PDB 6EPK) (28)," exact="Zika" post="(PDB 5LBV) (26), or DEN (PDB 1OAN) (27) viruses."/>
   <result pre="Figure 5 Peptide-MHC II Binding Prediction and HLA Association of" exact="West Nile" post="Virus Epitopes. (A) Predicted IC50 values for experimentally tested"/>
   <result pre="similar to those previously identified for distantly related flaviviruses, including" exact="Zika" post="(23), DEN (40, 41), and YF (22) viruses. Especially"/>
   <result pre="from other flaviviruses, included an α-helix that is absent from" exact="Zika" post="and DEN viruses. Its protrusion from the upper part"/>
   <result pre="in other clinically relevant flaviviruses, including yellow fever, dengue and" exact="Zika" post="viruses. Together, these data provide novel insights into a"/>
   <result pre="development. Viruses. (2019) 11:E823. 10.3390/v1109082331491885 2.AberleSWKolodziejekJJungbauerCStiasnyKAberleJHZoufalyAet al.. Increase in human" exact="West Nile" post="and Usutu virus infections, Austria, 2018. Eurosurveillance. (2018) 23:7–12."/>
   <result pre="Usutu virus infections, Austria, 2018. Eurosurveillance. (2018) 23:7–12. 10.2807/1560-7917.ES.2018.23.43.180054530376913 3.BarrettADT." exact="West Nile" post="in Europe: an increasing public health problem. J Travel"/>
   <result pre="public health problem. J Travel Med. (2018) 25:1–2. 10.1093/jtm/tay09630289526 4.GouldLHFikrigE." exact="West Nile" post="virus: a growing concern?J Clin Invest. (2004) 113:1102–7. 10.1172/JCI2162315085186"/>
   <result pre="8, 2019). 6.DiamondMSPiersonTCFremontDH. The structural immunology of antibody protection against" exact="West Nile" post="virus. Immunol Rev. (2008) 225:212–25. 10.1111/j.1600-065X.2008.00676.x18837784 7.MehlhopEDiamondMS. The molecular"/>
   <result pre="225:212–25. 10.1111/j.1600-065X.2008.00676.x18837784 7.MehlhopEDiamondMS. The molecular basis of antibody protection against" exact="West Nile" post="Virus. Hum Antibody Therapeut Viral Disease. (2008) 317:125–53. 10.1007/978-3-540-72146-8_517990792"/>
   <result pre="for vaccine development. Cell Host Microbe. (2008) 4:229–38. 10.1016/j.chom.2008.08.00418779049 9.BrienJDUhrlaubJLNikolich-ZugichJ." exact="West Nile" post="virus-specific CD4 T cells exhibit direct antiviral cytokine secretion"/>
   <result pre="10.4049/jimmunol.181.12.856819050276 10.SitatiEMDiamondMS. CD4(+) T-cell responses are required for clearance of" exact="West Nile" post="virus from the central nervous system. J Virol. (2006)"/>
   <result pre="on the dominance of virus-specific CD4 T cell epitopes in" exact="Zika" post="virus infection. Front Immunol. (2018) 9:208310.3389/fimmu.2018.0208330254648 24.SchwaigerJAberleJHStiasnyKKnappBSchreinerWFaeIet al.. Specificities"/>
   <result pre="J Virol. (2014) 88:7828–42. 10.1128/JVI.00196-1424789782 25.KanaiRKarKAnthonyKGouldLHLedizetMFikrigEet al.. Crystal structure of" exact="West Nile" post="virus envelope glycoprotein reveals viral surface epitopes. J Virol."/>
   <result pre="(1995) 375:291–8. 10.1038/375291a07753193 31.StiasnyKAberleSWHeinzFX. Retrospective identification of human cases of" exact="West Nile" post="virus infection in Austria (2009 to 2010) by serological"/>
   <result pre="RT-PCR assay for detection and quantification of both lineages of" exact="West Nile" post="virus RNA. J Clin Virol. (2006) 36:177–82. 10.1016/j.jcv.2006.02.00816675298 33.NybakkenGEOliphantTJohnsonSBurkeSDiamondMSFremontDH."/>
   <result pre="J Clin Virol. (2006) 36:177–82. 10.1016/j.jcv.2006.02.00816675298 33.NybakkenGEOliphantTJohnsonSBurkeSDiamondMSFremontDH. Structural basis of" exact="West Nile" post="virus neutralization by a therapeutic antibody. Nature. (2005) 437:764–8."/>
   <result pre="to tick-borne encephalitis vaccination. NPJ Vaccines. (2019) 4:38. 10.1038/s41541-019-0133-531508246 36.DoklandTWalshMMackenzieJMKhromykhAAEeKHWangS." exact="West Nile" post="virus core protein; tetramer structure and ribbon formation. Structure."/>
   <result pre="7:539. 10.1038/msb.2011.7521988835 44.SirohiDChenZGSunLKloseTPiersonTCRossmannMGet al.The 3.8 angstrom resolution cryo-EM structure of" exact="Zika" post="virus. Science. (2016) 352:467–70. 10.1126/science.aaf531627033547 45.AngeloMAGrifoniAO'RourkePHSidneyJPaulSPetersBet al.. Human CD4(+)"/>
   <result pre="in proteins. Embo J. (1986) 5:823–6. 10.1002/j.1460-2075.1986.tb04288.x3709526 60.JamesEAGatesTJLaFondREYamamotoSNiCMaiDet al.. Neuroinvasive" exact="West Nile" post="infection elicits elevated and atypically polarized t cell responses"/>
   <result pre="Development of a humanized monoclonal antibody with therapeutic potential against" exact="West Nile" post="virus. Nat Med. (2005) 11:522–30. 10.1038/nm124015852016 67.KaufmannBVogtMRGoudsmitJHoldawayHAAksyukAAChipmanPRet al.. Neutralization"/>
   <result pre="virus. Nat Med. (2005) 11:522–30. 10.1038/nm124015852016 67.KaufmannBVogtMRGoudsmitJHoldawayHAAksyukAAChipmanPRet al.. Neutralization of" exact="West Nile" post="virus by cross-linking of its surface proteins with Fab"/>
   <result pre="Nat Med. (2015) 21:1216–22. 10.1038/nm.395826413780 73.MurrayKWalkerCHerringtonELewisJAMcCormickJBeasleyDWCet al.. Persistent Infection with" exact="West Nile" post="Virus Years after Initial Infection. J Infect Diseases. (2010)"/>
   <result pre="201:2–4. 10.1086/64873119961306 74.LanteriMCO'BrienKMPurthaWECameronMJLundJMOwenREet al.. Tregs control the development of symptomatic" exact="West Nile" post="virus infection in humans and mice. J Clin Invest."/>
   <result pre="Genetic contribution of MHC Class II genes in susceptibility to" exact="West Nile" post="virus infection. PLoS ONE. (2016) 11:e165952. 10.1371/journal.pone.016595227812212 77.SarriCAPapadopoulosGEPapaATsakrisAPervanidouDBakaAet al.."/>
   <result pre="class II peptide-binding region associated with protection/susceptibility to the severe" exact="West Nile" post="Virus disease. PLoS ONE. (2018) 13:e205557. 10.1371/journal.pone.020555730379846 Abbreviations C"/>
   <result pre="disease. PLoS ONE. (2018) 13:e205557. 10.1371/journal.pone.020555730379846 Abbreviations C capsid DEN" exact="Dengue" post="E envelope HLA human leukocyte antigen JE Japanese encephalitis"/>
   <result pre="peripheral blood mononuclear cells prM pre-membrane TBE Tick-borne encephalitis WN" exact="West Nile" post="WND West Nile virus disease YF Yellow fever."/>
   <result pre="cells prM pre-membrane TBE Tick-borne encephalitis WN West Nile WND" exact="West Nile" post="virus disease YF Yellow fever."/>
   <result pre="encephalitis WN West Nile WND West Nile virus disease YF" exact="Yellow fever." post=""/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6991954\results\search\tropicalVirus\results.xml">
   <result pre="diseases discussed in this Review. Disease Vaccine Highest discovery status" exact="Dengue" post="CYD-TDV/Dengvaxia: Efficacy 60%–70%, but only given to persons with"/>
   <result pre="immunity and for manipulating it to tackle life-threatening fungal infections." exact="Dengue" post="Dengue fever is a mosquito-borne viral infection found in"/>
   <result pre="and for manipulating it to tackle life-threatening fungal infections. Dengue" exact="Dengue" post="fever is a mosquito-borne viral infection found in tropical"/>
   <result pre="virus, and all serotypes are presently circulating in endemic areas." exact="DENV" post="infects cells of the human immune system and other"/>
   <result pre="in domain II showed strong neutralizing activity against all 4" exact="DENV" post="serotypes [46]. However, at subneutralizing concentrations, it also elicited"/>
   <result pre="PeerJ. 2017;5:e402110.7717/peerj.402129152418 49SimmonsM, PutnakR, SunP, BurgessT, MarascoWA. Antibody Prophylaxis Against" exact="Dengue" post="Virus 2 Infection in Non-Human Primates. Am J Trop"/>
   <result pre=".26475445 122AguiarM, StollenwerkN, HalsteadSB. The Impact of the Newly Licensed" exact="Dengue" post="Vaccine in Endemic Countries. PLoS Negl Trop Dis. 2016;10(12):e000517910.1371/journal.pntd.000517928002420"/>
   <result pre="infection in primate leukocytes. Nature. 1977;265(5596):739–41. 10.1038/265739a0 .404559 124collab: Live" exact="Dengue" post="Vaccines Technical Consultation Reporting G, Bentsi-EnchillAD, SchmitzJ, EdelmanR, DurbinA,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6993835\results\search\tropicalVirus\results.xml">
   <result pre="• Japanese encephalitis virus • St Louis encephalitis virus •" exact="West Nile" post="virus • Murray Valley encephalitis virus • Non-arthropod-borne togavirus"/>
   <result pre="disorders IV.Infectious encephalopathy • Cerebral malaria • Shigella encephalopathy •" exact="Dengue" post="encephalopathy • Sepsis syndrome • Enteric encephalopathy V. Structural"/>
   <result pre="of encephalitis in the southern state of Kerela 19, 20." exact="Dengue" post="infection was known to produce neurologic manifestations, including encephalopathy,"/>
   <result pre="worldwide with little seasonal or age and sex predilection 4." exact="West Nile" post="encephalitis virus was introduced in the US in the"/>
   <result pre="in India.PLoS Negl Trop Dis.2019;13(6):e0007393. 10.1371/journal.pntd.000739331246966 F1000 Recommendation 21LumLCLamSKChoyYSet al.:" exact="Dengue" post="encephalitis: a true entity?Am J Trop Med Hyg.1996;54(3):256–9. 10.4269/ajtmh.1996.54.2568600761"/>
   <result pre="a true entity?Am J Trop Med Hyg.1996;54(3):256–9. 10.4269/ajtmh.1996.54.2568600761 22KumarRTripathiSTambeJJet al.:" exact="Dengue" post="encephalopathy in children in Northern India: clinical features and"/>
   <result pre="10.1186/s13071-019-3515-731133059 F1000 Recommendation 26YeungMWShingENelderMet al.: Epidemiologic and clinical parameters of" exact="West Nile" post="virus infections in humans: a scoping review.BMC Infect Dis.2017;17(1):"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6995199\results\search\tropicalVirus\results.xml">
   <result pre="500 U/mL penicillin (Cristalia), and 50 μg/mL streptomycin (Schering-Plough, São Paulo, Brazil)." exact="YFV" post="(vaccine strain 17DD), MAYV (Strain BeAr20290), CHIKV (Genotype ECSA"/>
   <result pre="São Paulo, Brazil). YFV (vaccine strain 17DD), MAYV (Strain BeAr20290)," exact="CHIKV" post="(Genotype ECSA – Strain BHI3762/H804917, kindly provided by Dr."/>
   <result pre="plaques generated by arbovirus infection in the Vero cell monolayers." exact="YFV" post="generated largely undefined edge lysis plaques that included numerous"/>
   <result pre="edge lysis plaques that included numerous stretched cells (Fig. 3)." exact="CHIKV" post="presented large circular plaques, while MAYV showed small undefined"/>
   <result pre="Virus Goes Viral educational kit. Abbreviations APMV Acanthamoeba polyphaga mimivirus" exact="CHIKV" post="Chikungunya virus CPEs Cytopathic effects CPXV Cowpoxvirus CVG Cedratvirus"/>
   <result pre="Goes Viral educational kit. Abbreviations APMV Acanthamoeba polyphaga mimivirus CHIKV" exact="Chikungunya" post="virus CPEs Cytopathic effects CPXV Cowpoxvirus CVG Cedratvirus DNA"/>
   <result pre="PYG Peptone-yeast extract with glucose TPV Tupanvirus VACV Vaccinia virus" exact="YFV" post="Yellow fever virus Publisher’s Note Springer Nature remains neutral"/>
   <result pre="Peptone-yeast extract with glucose TPV Tupanvirus VACV Vaccinia virus YFV" exact="Yellow fever" post="virus Publisher’s Note Springer Nature remains neutral with regard"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6996800\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Tropical Diseases"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : People and places : Geographical locations :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Research and Analysis Methods : Mathematical and"/>
   <result pre="Interdependence between confirmed and discarded cases of dengue, chikungunya and" exact="Zika" post="viruses in Brazil: A multivariate time-series analysis Interdependence between"/>
   <result pre="time-series analysis Interdependence between reported cases of dengue, chikungunya and" exact="Zika" post="viruses in Brazil http://orcid.org/0000-0002-7167-8754OliveiraJuliane F.ConceptualizationData curationFormal analysisInvestigationMethodologySoftwareValidationVisualizationWriting – original"/>
   <result pre="interrelationships between discarded and confirmed cases of dengue, chikungunya, and" exact="Zika" post="in Brazil. We used data from the Brazilian National"/>
   <result pre="and in 2016. The series of reported cases of both" exact="Zika" post="and chikungunya reached their peak in late 2015 and"/>
   <result pre="2015 and early 2016. The VAR model shows that the" exact="Zika" post="series have a significant impact on the dengue series"/>
   <result pre="of Data and Knowledge Integration for Health (CIDACS) through the" exact="Zika" post="Platform- a long-term surveillance platform for the Zika virus"/>
   <result pre="through the Zika Platform- a long-term surveillance platform for the" exact="Zika" post="virus and microcephaly, Unified Health System (SUS) - Brazilian"/>
   <result pre="with the emergence and dissemination of chikungunya virus (CHIKV) and" exact="Zika" post="virus (ZIKV), transmitted by Aedes mosquitoes (mainly Aedes aegypti),"/>
   <result pre="the demand on health and other support services. From the" exact="DENV" post="introduction, in 1986, to until arrival and subsequent spread"/>
   <result pre="introduction, in 1986, to until arrival and subsequent spread of" exact="CHIKV" post="and ZIKV, dengue was the most important vector-borne disease"/>
   <result pre="in cities of Brazil, [3, 4]. In September of 2014," exact="CHIKV" post="was detected in cities of the states of Amapá"/>
   <result pre="Norte, in the northeast of Brazil, while in April 2015," exact="ZIKV" post="was identified as its aetiologic agent [6]. Patients infected"/>
   <result pre="was identified as its aetiologic agent [6]. Patients infected with" exact="ZIKV" post="typically presented low (or no) fever and skin rash"/>
   <result pre="within the first 24 hours of the disease onset, while" exact="DENV" post="and CHIKV cause high fever immediately. Also, CHIKV causes"/>
   <result pre="first 24 hours of the disease onset, while DENV and" exact="CHIKV" post="cause high fever immediately. Also, CHIKV causes more intense"/>
   <result pre="onset, while DENV and CHIKV cause high fever immediately. Also," exact="CHIKV" post="causes more intense arthralgia than DENV. However, the other"/>
   <result pre="were impacted by the introduction and spread of chikungunya and" exact="Zika" post="virus in Brazil. Materials and methods We used a"/>
   <result pre="how the classification of notified cases of dengue, chikungunya and" exact="Zika" post="affected each other in Brazil from 2015 to 2017."/>
   <result pre="2010 to 2017), chikungunya (from 2014 up to 2017), and" exact="Zika" post="(from 2015 up to 2017) viruses. We only considered"/>
   <result pre="cases) were excluded from the analyses. However inconclusive cases of" exact="Zika" post="represented about 30% (110,656/361,396 registered cases) of all notified"/>
   <result pre="2017, accounting for about 56% (33,863/60,972 registered cases) of the" exact="Zika" post="notifications in 2015. Once specific Zika laboratory tests were"/>
   <result pre="registered cases) of the Zika notifications in 2015. Once specific" exact="Zika" post="laboratory tests were unavailable in that period, for the"/>
   <result pre="for the purpose of the carried analyses, we considered inconclusive" exact="Zika" post="cases as confirmed Zika cases. To perform the study"/>
   <result pre="the carried analyses, we considered inconclusive Zika cases as confirmed" exact="Zika" post="cases. To perform the study of time series analyses,"/>
   <result pre="cases) and in 2016 (with 1,101,228 registered confirmed cases). Confirmed" exact="Zika" post="and chikungunya cases reached their peaks in late 2015"/>
   <result pre="plots of confirmed and discarded cases of dengue, chikungunya and" exact="Zika" post="by epidemiological week. Brazil, January 2015 to December 2017."/>
   <result pre="week, during the whole corresponding periods, for dengue, chikungunya and" exact="Zika" post="in the country, we see that the slope aD"/>
   <result pre="confirmed and discarded cases, per semester, of dengue, chikungunya and" exact="Zika" post="in Brazil. Proportions of dengue (from 2010 up to"/>
   <result pre="2010 up to 2017); chikungunya (from 2014 up to 2017);" exact="Zika" post="(from 2015 up to 2017). We can see that"/>
   <result pre="2014 and 2017. Although chikungunya presents lower incidence compared with" exact="Zika" post="and dengue, in 2015 we notice an inverted pattern"/>
   <result pre="dengue affect the series of confirmed and discarded cases of" exact="Zika" post="and vice-versa. On the other hand, no associations were"/>
   <result pre="found between the series of confirmed and discaded cases of" exact="Zika" post="and chikungunya. The series of confirmed Zika and confirmed"/>
   <result pre="discaded cases of Zika and chikungunya. The series of confirmed" exact="Zika" post="and confirmed (0.63) and discarded (0.70) dengue, as well"/>
   <result pre="discarded (0.70) dengue, as well as, the series of discarded" exact="Zika" post="and confirmed (0.66) dengue present a positive strong linear"/>
   <result pre="Confirmed cases of dengue do not affect confirmed cases of" exact="Zika" post="3.836 &amp;lt; 0.001 Reject Confirmed cases of Zika do"/>
   <result pre="cases of Zika 3.836 &amp;lt; 0.001 Reject Confirmed cases of" exact="Zika" post="do not affect confirmed cases of dengue 5.363 &amp;lt;"/>
   <result pre="Discarded cases of dengue do not affect confirmed cases of" exact="Zika" post="3.836 &amp;lt; 0.001 Reject Confirmed cases of Zika do"/>
   <result pre="cases of Zika 3.836 &amp;lt; 0.001 Reject Confirmed cases of" exact="Zika" post="do not affect discarded cases of dengue 4.112 &amp;lt;"/>
   <result pre="Confirmed cases of dengue do not affect discarded cases of" exact="Zika" post="4.567 &amp;lt; 0.001 Reject Discarded cases of Zika do"/>
   <result pre="cases of Zika 4.567 &amp;lt; 0.001 Reject Discarded cases of" exact="Zika" post="do not affect confirmed cases of dengue 3.417 &amp;lt;"/>
   <result pre="Confirmed cases of chikungunya do not affect confirmed cases of" exact="Zika" post="1.128 0.333 Do not reject Confirmed cases of Zika"/>
   <result pre="of Zika 1.128 0.333 Do not reject Confirmed cases of" exact="Zika" post="do not affect confirmed chikungunya 0.9064 0.547 Do not"/>
   <result pre="Discarded cases of chikungunya do not affect confirmed cases of" exact="Zika" post="0.9579 0.493 Do not reject Confirmed cases of Zika"/>
   <result pre="of Zika 0.9579 0.493 Do not reject Confirmed cases of" exact="Zika" post="do not affect discarded cases of chikungunya 0.9339 0.518"/>
   <result pre="Confirmed cases of chikungunya do not affect discarded cases of" exact="Zika" post="1.010 0.440 Do not reject Discarded cases of Zika"/>
   <result pre="of Zika 1.010 0.440 Do not reject Discarded cases of" exact="Zika" post="do not affect confirmed cases of chikungunya 0.8859 0.568"/>
   <result pre="confirmed and discarded cases of either dengue or chikungunya or" exact="Zika" post="are not included. Additionally, we show the results of"/>
   <result pre="it is clear a mutual influence of the cases of" exact="Zika" post="and dengue, we also performed an analysis of the"/>
   <result pre="an analysis of the restricted models between the cases of" exact="Zika" post="and chikungunya and the cases of dengue and chikungunya."/>
   <result pre="and the cases of dengue and chikungunya. The analysis between" exact="Zika" post="and chikungunya also presents a better AIC value 41.67"/>
   <result pre="Granger tests shows three different results: i) confirmed cases of" exact="Zika" post="affect discarded cases of chikungunya (Test statistic = 2.206,"/>
   <result pre="statistic = 2.206, p-value = 0.011); ii) discarded cases of" exact="Zika" post="affect confirmed cases of chikungunya (Test statistic = 2.447,"/>
   <result pre="0.004); and iii) a borderline result where confirmed cases of" exact="Zika" post="affect confirmed cases of chikungunya (Test statistic = 1.761,"/>
   <result pre="reasonable interpretation is that an increase of individuals notified as" exact="Zika" post="contributes to an increase of wrong notification of dengue"/>
   <result pre="wrong notification of dengue cases within two scenario: people with" exact="Zika" post="were wrongly classified as dengue (and vice-versa), or perhaps"/>
   <result pre="individuals. The results also indicate that the series of confirmed" exact="Zika" post="cases increased the series of discarded dengue cases and"/>
   <result pre="cases and that, among those discarded, there were indeed confirmed" exact="Zika" post="cases. The series of confirmed cases of dengue affects"/>
   <result pre="be explained by the awareness of the consequences accounted by" exact="Zika" post="at the end of 2015. The notifications of Zika"/>
   <result pre="by Zika at the end of 2015. The notifications of" exact="Zika" post="and dengue had overall weaker effects on the notification"/>
   <result pre="the 12 possible combinations. Considering confirmed and discarded cases of" exact="Zika" post="and chikungunya, the unrestricted model was not able to"/>
   <result pre="the null hypothesis, as in the result for chikungunya and" exact="Zika" post="cases, or a very small correlation value, as for"/>
   <result pre="also support the conclusion that the notifications of dengue and" exact="Zika" post="happened independently of the notification of chikungunya. Regarding the"/>
   <result pre="of each viruses, although chikungunya presents lower incidence compared with" exact="Zika" post="and dengue, in 2015 we notice an inverted pattern"/>
   <result pre="chikungunya cases in opposition to the decrease of dengue and" exact="Zika" post="cases in this population, may suggest that it was"/>
   <result pre="notifications of confirmed and discarded cases of dengue, chikungunya and" exact="Zika" post="presented, in most of the cases, linear dependence. This"/>
   <result pre="semester of 2014 on, when the simultaneous circulation of DENV," exact="ZIKV" post="and CHIKV in densely populated urban spaces greatly hampered"/>
   <result pre="2014 on, when the simultaneous circulation of DENV, ZIKV and" exact="CHIKV" post="in densely populated urban spaces greatly hampered the correct"/>
   <result pre="record of each case of these diseases [9, 18]. Although" exact="CHIKV" post="and ZIKV emerged almost simultaneously in cities in the"/>
   <result pre="each case of these diseases [9, 18]. Although CHIKV and" exact="ZIKV" post="emerged almost simultaneously in cities in the same region"/>
   <result pre="are scarce, we see that the notification of dengue and" exact="Zika" post="are shown to be independent of the notification of"/>
   <result pre="notification of chikungunya. These findings are plausible, since dengue and" exact="Zika" post="present more similar clinical manifestations to each other as"/>
   <result pre="compared to chikungunya [7]. The expressive joint manifestations produced by" exact="CHIKV" post="infections allow a more accurate clinical diagnosis, even when"/>
   <result pre="use of discarded cases of chikungunya as complementary cases of" exact="Zika" post="infection, as suggested by Oliveira et al [18]. However,"/>
   <result pre="thus contribute to construct more accurate prediction models of future" exact="Zika" post="epidemics, using only possible cases of dengue. Another point"/>
   <result pre="cases of dengue and confirmed chikungunya, and confirmed cases of" exact="Zika" post="and confirmed chikungunya might be due to spatial factors"/>
   <result pre="providing good evaluation indicators [19]. However, with the emergence of" exact="CHIKV" post="and ZIKAV in the period 2014-2015, which have clinical"/>
   <result pre="series of confirmed and discarded cases of dengue, chikungunya and" exact="Zika" post="before and after differentiation. Brazil, January 2015 to December"/>
   <result pre="S2 Fig Probability plot and histograms for confirmed and discarded" exact="Zika" post="model’s residuals. The probability plot shows the unscaled quantiles"/>
   <result pre="2014. Emerging infectious diseases, 2015, 215: 90610.3201/eid2105.14172725898939 6CamposGS, BandeiraAC, SardiSI." exact="Zika" post="virus outbreak, bahia, brazil. Emerging infectious diseases, 2015, 2110:"/>
   <result pre="2015, 2110: 188510.3201/eid2110.15084726401719 7IoosS, MalletHP, GoffartIL, GauthierV, CardosoT, and HeridaMCurrent" exact="Zika" post="virus epidemiology and recent epidemics. Medecine et maladies infectieuses,"/>
   <result pre="et al.Viremia and clinical presentation in Nicaraguan patients infected with" exact="Zika" post="virus, chikungunya virus, and dengue virus. Clinical Infectious Diseases."/>
   <result pre="Clarendon press, 1990. 13Oliveira JF. Multivariate time series analiysis of" exact="Zika" post="dengue and chikungunya viruses in Brazil. GitHub repository. https://github.com/Julian-sun/Multivariate-time-series-analiysis-of-Zika-dengue-and-chikungunya-viruses-in-Brazil.git."/>
   <result pre="Python in Science Conference, 2010. https://www.statsmodels.org/stable/index.html. 15NimmannityaS, HalsteadSB, CohenSN, MargiottaMR." exact="Dengue" post="and chikungunya virus infection in man in Thailand. 1962–1964."/>
   <result pre="of tropical medicine and hygiene. 1969111;18(6):954–71. 10.4269/ajtmh.1969.18.9545355242 16StaplesJE, BreimanRF, PowersAM." exact="Chikungunya" post="fever: an epidemiological review of a re-emerging infectious disease."/>
   <result pre="17RibeiroGS, KikutiM, TauroLB, NascimentoLC, CardosoCW, CamposGS, et al.Does immunity after" exact="Zika" post="virus infection cross-protect against dengue?. The Lancet Global health."/>
   <result pre="Souza KuchenbeckerR, SchmidtMI. Infection-related microcephaly after the 2015 and 2016" exact="Zika" post="virus outbreaks in Brazil: a surveillance-based analysis. The Lancet."/>
   <result pre="TauroLB, KikutiM, AnjosRO, SantosVC, GonçalvesTS, et al.Concomitant transmission of Dengue," exact="Chikungunya" post="and Zika viruses in Brazil: clinical and epidemiological findings"/>
   <result pre="AnjosRO, SantosVC, GonçalvesTS, et al.Concomitant transmission of Dengue, Chikungunya and" exact="Zika" post="viruses in Brazil: clinical and epidemiological findings from surveillance"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC6996850\results\search\tropicalVirus\results.xml">
   <result pre="respiratory syndrome. J.Clin. Virol2006; 35: 179–84. 10.1016/j.jcv.2005.07.00516112612 52ChareonsirisuthigulT, KalayanaroojS, UbolS." exact="Dengue" post="virus (DENV) antibody-dependent enhancement of infection upregulates the production"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7000767\results\search\tropicalVirus\results.xml">
   <result pre="Association of past dengue fever epidemics with the risk of" exact="Zika" post="microcephaly at the population level in Brazil http://orcid.org/0000-0002-9566-0284CarvalhoMarilia Sámarilia.carvalho@fiocruz.br1http://orcid.org/0000-0001-9012-9382FreitasLaís"/>
   <result pre="http://creativecommons.org/licenses/by/4.0/. Abstract Despite all the research done on the first" exact="Zika" post="virus (ZIKV) epidemics, it was only after the Brazilian"/>
   <result pre="it was only after the Brazilian epidemic that the Congenital" exact="Zika" post="Syndrome was described. This was made possible due to"/>
   <result pre="is partially an effect of the population prior immunity against" exact="Dengue" post="viruses (DENV), that cross-react with ZIKV. In this ecological"/>
   <result pre="an effect of herd immunity and of multiple exposures to" exact="DENV" post="that could boost immunity. Subject terms Viral infection Epidemiology"/>
   <result pre="epidemic in the Northeast (NE) region of Brazil with the" exact="Zika" post="virus (ZIKV) was the high rate of dispersion of"/>
   <result pre="Despite all the research done on the first epidemics of" exact="ZIKV" post="in Yap Islands and later in French Polynesia2–4, it"/>
   <result pre="Polynesia2–4, it was only after the Brazilian epidemic that Congenital" exact="Zika" post="Syndrome (CZS) was described5. This could be due to"/>
   <result pre="any other region in the world that had undergone a" exact="Zika" post="epidemic7–9. Several reasons for this discrepancy were suggested –"/>
   <result pre="women postponing pregnancy or having abortions18–20. The antigenic similarity between" exact="ZIKV" post="and dengue virus (DENV), sharing approximately 54% of their"/>
   <result pre="have shown that anti-DENV antibodies can both enhance and neutralize" exact="ZIKV" post="infection22–26. In animal models, mice that received plasma with"/>
   <result pre="level of anti-DENV antibodies had a higher mortality rate after" exact="ZIKV" post="infection than mice that received plasma without antibodies. However,"/>
   <result pre="plasma with a high level of anti-DENV antibodies survived after" exact="ZIKV" post="challenge and presented milder symptoms22. Human plasma collected ≤100"/>
   <result pre="presented milder symptoms22. Human plasma collected ≤100 days after PCR-confirmed" exact="DENV" post="infection binds and cross-neutralizes ZIKV in vitro. On the"/>
   <result pre="collected ≤100 days after PCR-confirmed DENV infection binds and cross-neutralizes" exact="ZIKV" post="in vitro. On the other hand, late-convalescent-phase plasma does"/>
   <result pre="the understanding of cross-neutralizing antibody responses among individuals with prior" exact="DENV" post="exposure, particularly how these responses evolve over time and"/>
   <result pre="countries is quite unknown28. In summary, it is known that" exact="ZIKV" post="shares structural similarities with other flaviviruses, especially DENV, and"/>
   <result pre="with other flaviviruses, especially DENV, and co-circulates in dengue-endemic regions." exact="ZIKV" post="and DENV cross-immunity can be either protective or enhancing"/>
   <result pre="flaviviruses, especially DENV, and co-circulates in dengue-endemic regions. ZIKV and" exact="DENV" post="cross-immunity can be either protective or enhancing in experimental"/>
   <result pre="2014 data, both in the exploratory analysis and the maps." exact="Dengue" post="data are collected by the Brazilian Information System for"/>
   <result pre="cases decreased first in the NE, the dispersion centre of" exact="Zika" post="epidemic, followed by the SE and CW regions. Table"/>
   <result pre="of microcephaly rate among live-born neonates in 2014, before the" exact="Zika" post="epidemic. Among the 400 microregions included in the analysis,"/>
   <result pre="described. It should be noted that the notification system for" exact="Zika" post="was only implemented in February 2016, when the Zika"/>
   <result pre="for Zika was only implemented in February 2016, when the" exact="Zika" post="epidemic was decreasing in the NE region. Therefore, we"/>
   <result pre="in the NE region. Therefore, we could not control for" exact="Zika" post="incidence in the models. It is possible that the"/>
   <result pre="the differences in microcephaly rates were a consequence of different" exact="ZIKV" post="attack rates across the regions, as suggested in a"/>
   <result pre="paper37. In this study, after testing for other concurrent factors," exact="ZIKV" post="was assumed to be the only cause of the"/>
   <result pre="epidemic, with no unmeasured confounders or effect modifiers. However, if" exact="Zika" post="incidence alone explains the excess microcephaly rates, then microcephaly"/>
   <result pre="to why the NE region would have presented with a" exact="Zika" post="incidence more than ten times larger than anywhere else"/>
   <result pre="interval between infections changes the role of anti-DENV antibodies on" exact="ZIKV" post="infection, either to protect or to increase the risk"/>
   <result pre="hypothesis is based on what is described for sequential heterotypic" exact="DENV" post="infections (there are four DENV serotypes). It has been"/>
   <result pre="is described for sequential heterotypic DENV infections (there are four" exact="DENV" post="serotypes). It has been established that a narrow range"/>
   <result pre="over time, there is a window of cross-protection between the" exact="DENV" post="serotypes. A previous study found that a shorter interval"/>
   <result pre="seems to play a role against ZIKV. Mice primed with" exact="DENV" post="and 30 days later challenged with ZIKV during pregnancy"/>
   <result pre="Mice primed with DENV and 30 days later challenged with" exact="ZIKV" post="during pregnancy presented reduced burden in maternal and fetal"/>
   <result pre="required for this cross-protection. However, mice challenged 80 days after" exact="DENV" post="priming were not protected, indicating the transient nature of"/>
   <result pre="of cross-protection again40. Figure 7 Hypothesized interaction between dengue and" exact="Zika" post="infections on the development of microcephaly. Most research on"/>
   <result pre="of previous DENV-immunity on the severity of clinical symptoms of" exact="ZIKV" post="infection is based on experimental models41,42. Cohort studies are"/>
   <result pre="give the most reliable understanding of the role of previous" exact="DENV" post="exposure on ZIKV infection. However, the reduction in the"/>
   <result pre="reliable understanding of the role of previous DENV exposure on" exact="ZIKV" post="infection. However, the reduction in the incidence of Zika"/>
   <result pre="on ZIKV infection. However, the reduction in the incidence of" exact="Zika" post="after the last epidemic in Brazil in 2016 limits"/>
   <result pre="study dengue and that have been adapted to also study" exact="Zika" post="are of great value. For example, a recent study"/>
   <result pre="Brazil, found that the titres of DENV-antibodies measured before the" exact="Zika" post="epidemic were inversely associated with the risk of ZIKV"/>
   <result pre="the Zika epidemic were inversely associated with the risk of" exact="ZIKV" post="infection46. In a paediatric cohort in Nicaragua, prior DENV"/>
   <result pre="of ZIKV infection46. In a paediatric cohort in Nicaragua, prior" exact="DENV" post="infection was inversely associated with the risk of symptomatic"/>
   <result pre="DENV infection was inversely associated with the risk of symptomatic" exact="ZIKV" post="infection47. In a cohort of ZIKV-infected pregnant women, previous"/>
   <result pre="ZIKV infection47. In a cohort of ZIKV-infected pregnant women, previous" exact="DENV" post="infection was not associated with disease severity and abnormal"/>
   <result pre="human immune sera, which showed a cross-neutralizing antibody response to" exact="ZIKV" post="on DENV-immune subjects 1–3 years after DENV infection28. The"/>
   <result pre="antibody response to ZIKV on DENV-immune subjects 1–3 years after" exact="DENV" post="infection28. The larger window at the ecological level is"/>
   <result pre="an effect of herd immunity and of multiple exposures to" exact="DENV" post="that would boost immunity. This is consistent with a"/>
   <result pre="This is consistent with a case-control study in which the" exact="DENV" post="seroprevalence and the mean number of neutralized serotypes (indicative"/>
   <result pre="led to the early discovery of the causal link between" exact="Zika" post="and microcephaly may have generated a hyper-awareness of the"/>
   <result pre="surveillance system for neonatal malformation clustered in space and time." exact="Dengue" post="epidemics in the previous 15 years were used as"/>
   <result pre="published since 2002. Other possible factors in the pathway between" exact="Zika" post="infection and microcephaly have been suggested, the most important"/>
   <result pre="limitations of this study, in addition to not controlling for" exact="Zika" post="incidence, are well known: accuracy of microcephaly classification and"/>
   <result pre="our results. The detection of either ADE or cross-protection between" exact="DENV" post="and ZIKV is not a trivial task, either in"/>
   <result pre="The detection of either ADE or cross-protection between DENV and" exact="ZIKV" post="is not a trivial task, either in animal models"/>
   <result pre="contribute to building the knowledge regarding the relationship between DENV," exact="ZIKV" post="and congenital Zika syndrome. Supplementary information LINK Supplementary information"/>
   <result pre="the knowledge regarding the relationship between DENV, ZIKV and congenital" exact="Zika" post="syndrome. Supplementary information LINK Supplementary information Publisher’s note Springer"/>
   <result pre="The authors declare no competing interests. References References 1.LoweRet al.The" exact="Zika" post="Virus Epidemic in Brazil: From Discovery to Future ImplicationsInt."/>
   <result pre="in French PolynesiaLancet20163871051105210.1016/S0140-6736(16)00625-5 5.Miranda-FilhoDEBet al.Initial Description of the Presumed Congenital" exact="Zika" post="SyndromeAm. J. Public. Health201610659860010.2105/AJPH.2016.30311526959258 6.de OliveiraWKet al.Infection-related microcephaly after"/>
   <result pre="Health201610659860010.2105/AJPH.2016.30311526959258 6.de OliveiraWKet al.Infection-related microcephaly after the 2015 and 2016" exact="Zika" post="virus outbreaks in Brazil: a surveillance-based analysisLancet201739086187010.1016/S0140-6736(17)31368-528647172 7.CoelhoACrovellaSMicrocephaly Prevalence"/>
   <result pre="Brazil: a surveillance-based analysisLancet201739086187010.1016/S0140-6736(17)31368-528647172 7.CoelhoACrovellaSMicrocephaly Prevalence in Infants Born to" exact="Zika" post="Virus-Infected Women: A Systematic Review and Meta-AnalysisInt. J. Mol."/>
   <result pre="in Rio de JaneiroN. Engl. J. Med.20163752321233410.1056/NEJMoa160241226943629 9.VogelGOne year later," exact="Zika" post="scientists prepare for a long warSci.20163541088108910.1126/science.354.6316.1088 10.Albuquerque, M. de"/>
   <result pre="Microcephaly at Birth in Brazil in 2010Pediatrics2018141e2017058910.1542/peds.2017-058929305391 12.RodriguesLaura CMicrocephaly and" exact="Zika" post="virus infectionThe Lancet2016387100332070207210.1016/S0140-6736(16)00742-X 13.ButlerDMicrocephaly surge in doubtNat.2016530131410.1038/nature.2016.19259 14.Lopez-Camelo, J."/>
   <result pre="I. M. &amp;amp; Castilla, E. ECLAMC FINAL DOCUMENT (2015). 15.RossiSLEbelGDShanCShiP-YVasilakisNDid" exact="Zika" post="Virus Mutate to Cause Severe Outbreaks?Trends Microbiology20182687788510.1016/j.tim.2018.05.007 16.Souza, W."/>
   <result pre="W. V. de et al. Microcephaly epidemic related to the" exact="Zika" post="virus and living conditions in Recife, Northeast Brazil. BMC"/>
   <result pre="Northeast Brazil. BMC Public Health18 (2018). 17.HalsteadSBBiologic Evidence Required for" exact="Zika" post="Disease Enhancement by Dengue AntibodiesEmerg. Infect. Dis.20172356957310.3201/eid2304.16187928322690 18.AikenARAet al.Requests"/>
   <result pre="Health18 (2018). 17.HalsteadSBBiologic Evidence Required for Zika Disease Enhancement by" exact="Dengue" post="AntibodiesEmerg. Infect. Dis.20172356957310.3201/eid2304.16187928322690 18.AikenARAet al.Requests for Abortion in Latin"/>
   <result pre="al.Requests for Abortion in Latin America in the Wake of" exact="Zika" post="VirusN. Engl. J. Med.201637539639810.1056/NEJMc160538927331661 19.Diaz-QuijanoFAPelissariDMChiavegatto FilhoADPZika-Associated Microcephaly Epidemic and"/>
   <result pre="Rate Reduction in Brazilian CitiesAm. J. Public. Health201810851451610.2105/AJPH.2017.30426029470110 20.CastroMCHanQCCarvalhoLRVictoraCGFrançaGVAImplications of" exact="Zika" post="virus and congenital Zika syndrome for the number of"/>
   <result pre="CitiesAm. J. Public. Health201810851451610.2105/AJPH.2017.30426029470110 20.CastroMCHanQCCarvalhoLRVictoraCGFrançaGVAImplications of Zika virus and congenital" exact="Zika" post="syndrome for the number of live births in BrazilProc."/>
   <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virusProc. Natl Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 22.BardinaSVet al.Enhancement of Zika"/>
   <result pre="to Zika virusProc. Natl Acad. Sci. USA20161137852785710.1073/pnas.160793111327354515 22.BardinaSVet al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunitySci.201735617518010.1126/science.aal4365 23.DurbinAPDengue Antibody and"/>
   <result pre="Sequence in MiceImmun.20174677177310.1016/j.immuni.2017.04.023 25.RobbianiDFet al.Recurrent Potent Human Neutralizing Antibodies to" exact="Zika" post="Virus in Brazil and MexicoCell2017169597609.e1110.1016/j.cell.2017.04.02428475892 26.WenJShrestaSADE-ing and Abetting ZikaCell"/>
   <result pre="ZikaCell Host Microbe20172155755810.1016/j.chom.2017.04.00628494235 27.CollinsMHet al.Lack of Durable Cross-Neutralizing Antibodies Against" exact="Zika" post="Virus from Dengue Virus InfectionEmerg. Infect. Dis.20172377378110.3201/eid2305.16163028418292 28.MontoyaMageldaCollinsMatthewDejnirattisaiWanwisaKatzelnickLeah CPuerta-GuardoHenryJadiRameshSchildhauerSamuelSupasaPiyadaVasanawathanaSirijittMalasitPridaMongkolsapayaJuthathipde"/>
   <result pre="27.CollinsMHet al.Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from" exact="Dengue" post="Virus InfectionEmerg. Infect. Dis.20172377378110.3201/eid2305.16163028418292 28.MontoyaMageldaCollinsMatthewDejnirattisaiWanwisaKatzelnickLeah CPuerta-GuardoHenryJadiRameshSchildhauerSamuelSupasaPiyadaVasanawathanaSirijittMalasitPridaMongkolsapayaJuthathipde SilvaAruna DTisseraHasithaBalmasedaAngelScreatonGavinde SilvaAravinda"/>
   <result pre="CPuerta-GuardoHenryJadiRameshSchildhauerSamuelSupasaPiyadaVasanawathanaSirijittMalasitPridaMongkolsapayaJuthathipde SilvaAruna DTisseraHasithaBalmasedaAngelScreatonGavinde SilvaAravinda MHarrisEvaLongitudinal Analysis of Antibody Cross-neutralization Following" exact="Zika" post="Virus and Dengue Virus Infection in Asia and the"/>
   <result pre="SilvaAravinda MHarrisEvaLongitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and" exact="Dengue" post="Virus Infection in Asia and the AmericasThe Journal of"/>
   <result pre="30.AndradeDaniela V.HarrisEvaRecent advances in understanding the adaptive immune response to" exact="Zika" post="virus and the effect of previous flavivirus exposureVirus Research2018254273310.1016/j.virusres.2017.06.01928655548"/>
   <result pre="‘Tidyverse’ (2017). 36.The R-INLA project http://www.r-inla.org/home. 37.BradyOJet al.The association between" exact="Zika" post="virus infection and microcephaly in Brazil 2015–2017: An observational"/>
   <result pre="Med.197042311328 39.AndersonKBet al.A Shorter Time Interval Between First and Second" exact="Dengue" post="Infections Is Associated With Protection From Clinical Illness in"/>
   <result pre="in ThailandJ. Infect. Dis.201420936036810.1093/infdis/jit43623964110 40.Regla-Nava, J. A. et al. Cross-reactive" exact="Dengue" post="virus-specific CD8+ T cells protect against Zika virus during"/>
   <result pre="et al. Cross-reactive Dengue virus-specific CD8+ T cells protect against" exact="Zika" post="virus during pregnancy. Nature Communications9 (2018). 41.Martín-Acebes, M. A.,"/>
   <result pre="by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in" exact="Zika" post="Virus Infection. Front Immunol9 (2018). 43.CohenJWhere has all the"/>
   <result pre="Zika Virus Infection. Front Immunol9 (2018). 43.CohenJWhere has all the" exact="Zika" post="gone?Sci.201735763163210.1126/science.357.6352.631 44.SiednerMJRyanETBogochIIGone or forgotten? The rise and fall of"/>
   <result pre="Zika gone?Sci.201735763163210.1126/science.357.6352.631 44.SiednerMJRyanETBogochIIGone or forgotten? The rise and fall of" exact="Zika" post="virusLancet Public. Health20183e109e11010.1016/S2468-2667(18)30029-X29519697 45.Netto, E. M. et al. High"/>
   <result pre="Zika virusLancet Public. Health20183e109e11010.1016/S2468-2667(18)30029-X29519697 45.Netto, E. M. et al. High" exact="Zika" post="Virus Seroprevalence in Salvador, Northeastern Brazil Limits the Potential"/>
   <result pre="46.Rodriguez-Barraquer, I. et al. Impact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region. 5 (2019)."/>
   <result pre="of Zika: A pediatric cohort in NicaraguaPLOS Med.201916e100272610.1371/journal.pmed.100272630668565 48.HalaiU-Aet al.Maternal" exact="Zika" post="Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and"/>
   <result pre="Med.201916e100272610.1371/journal.pmed.100272630668565 48.HalaiU-Aet al.Maternal Zika Virus Disease Severity, Virus Load, Prior" exact="Dengue" post="Antibodies, and Their Relationship to Birth OutcomesClin. Infect. Dis.20176587788310.1093/cid/cix47228535184"/>
   <result pre="to Birth OutcomesClin. Infect. Dis.20176587788310.1093/cid/cix47228535184 49.PedrosoCeliaFischerCarloFeldmannMarieSarnoManoelLuzEstelaMoreira-SotoAndrésCabralRenataNettoEduardo MartinsBritesCarlosKümmererBeate M.DrexlerJan FelixCross-Protection of" exact="Dengue" post="Virus Infection against Congenital Zika Syndrome, Northeastern BrazilEmerging Infectious"/>
   <result pre="49.PedrosoCeliaFischerCarloFeldmannMarieSarnoManoelLuzEstelaMoreira-SotoAndrésCabralRenataNettoEduardo MartinsBritesCarlosKümmererBeate M.DrexlerJan FelixCross-Protection of Dengue Virus Infection against Congenital" exact="Zika" post="Syndrome, Northeastern BrazilEmerging Infectious Diseases20192581485149310.3201/eid2508.19011331075077 50.VictoraCGet al.Microcephaly in Brazil:"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002134\results\search\tropicalVirus\results.xml">
   <result pre="pathogens such as dengue virus (DENV), Japanese encephalitis virus (JEV)," exact="Zika" post="virus (ZIKV), West Nile virus (WNV), yellow fever virus"/>
   <result pre="dengue virus (DENV), Japanese encephalitis virus (JEV), Zika virus (ZIKV)," exact="West Nile" post="virus (WNV), yellow fever virus (YFV), etc. (1). These"/>
   <result pre="various emerging and re-emerging infectious diseases worldwide (2). Among them," exact="DENV" post="causes about 390 million human infections and 20,000 deaths"/>
   <result pre="have caused numerous epidemics across the globe, as the recent" exact="ZIKV" post="outbreaks in Americas and the spread of JEV and"/>
   <result pre="ZIKV outbreaks in Americas and the spread of JEV and" exact="WNV" post="into new geographic territories have become serious threats to"/>
   <result pre="16–18). For flaviviruses, previous studies have revealed, as expected, that" exact="DENV" post="and ZIKV can induce the production of vsiRNAs in"/>
   <result pre="flaviviruses, previous studies have revealed, as expected, that DENV and" exact="ZIKV" post="can induce the production of vsiRNAs in infected Aedes"/>
   <result pre="by the deficiency of RNAi. In addition, NS2As of other" exact="DENV" post="serotypes and mosquito-borne flaviviruses, including JEV, WNV, and ZIKV,"/>
   <result pre="lanes 4, 6, and 7; and fig. S1D). Fig. 1" exact="DENV" post="NS2A suppresses Dicer-mediated siRNA biogenesis. (A) S2 cells were"/>
   <result pre="dose dependently (lanes 5 to 8). Together, we conclude that" exact="DENV" post="NS2A suppresses RNAi by sequestrating dsRNA from Dicer cleavage"/>
   <result pre="the positively charged residues of NS2As encoded by the four" exact="DENV" post="serotypes, ZIKV, JEV, and WNV (fig. S2C) and then"/>
   <result pre="NS2As encoded by the four DENV serotypes, ZIKV, JEV, and" exact="WNV" post="(fig. S2C) and then examined the single-point mutations of"/>
   <result pre="3A). Fig. 3 NS2A works as a potent VSR during" exact="DENV" post="infection in human 293T cells. (A) 293T, 293T-NoDice, 293T-IFNAR1-KO,"/>
   <result pre="C and D), implying that RNAi is fully suppressed during" exact="DENV" post="infection in differentiated mammalian cells. Moreover, in the absence"/>
   <result pre="works as a bona fide VSR in the context of" exact="DENV" post="infection in differentiated mammalian cells, we sought to examine"/>
   <result pre="cells. Fig. 6 NS2A works as a potent VSR during" exact="DENV" post="infection in mosquito cells. (A) Northern blotting of vsiRNAs"/>
   <result pre="previous sequence analysis revealed that NS2As from all the four" exact="DENV" post="serotypes (DENV1-4) and multiple other flaviviruses share high homology"/>
   <result pre="commonalities in functions. Thus, we first examined whether NS2As from" exact="DENV" post="serotype-1 to serotype-4 have the same VSR activities. Our"/>
   <result pre="the VSR activity of NS2A encoded by ZIKV, JEV, or" exact="WNV" post="in 293T cells, in which RNAi is induced by"/>
   <result pre="role of NS2A as a potential VSR for all the" exact="DENV" post="serotypes as well as multiple other flaviviruses. It would"/>
   <result pre="replication and virion assembly, and antagonizes IFN response (25–31); and" exact="ZIKV" post="NS2A has been recently found to interact with and"/>
   <result pre="flaviviruses to evade antiviral RNAi. Previous studies have found that" exact="DENV" post="NS2A is associated with endoplasmic reticulum (ER) and contains"/>
   <result pre="that the intermolecular interactions between pTMSs are critical in a" exact="DENV" post="life cycle (25, 33). Mutations of multiple conserved residues"/>
   <result pre="another VSR(s). Previous studies have identified some flaviviral factors, including" exact="WNV" post="subgenomic flavivirus RNA (sfRNA) and DENV NS4B, that suppressed"/>
   <result pre="some flaviviral factors, including WNV subgenomic flavivirus RNA (sfRNA) and" exact="DENV" post="NS4B, that suppressed synthetic dsRNA- or shRNA-induced RNAi via"/>
   <result pre="assays (34, 35). Besides, Myles and colleagues genetically added a" exact="YFV" post="capsid gene into the genome of Sindbis virus (SINV)"/>
   <result pre="Sindbis virus (SINV) and observed that the mutant SINV overexpressing" exact="YFV" post="capsid exhibited enhanced viral replication and virulence in mosquito,"/>
   <result pre="replication and virulence in mosquito, while the mutant SINV overexpressing" exact="DENV" post="NS4B or WNV sfRNA failed to do so (36),"/>
   <result pre="in mosquito, while the mutant SINV overexpressing DENV NS4B or" exact="WNV" post="sfRNA failed to do so (36), suggesting that flaviviral"/>
   <result pre="A recent study by us uncovered that infection with WT" exact="ZIKV" post="could induce the production of abundant vsiRNAs in hNPCs,"/>
   <result pre="among different AGO proteins. Fig. S6. NS2As from the four" exact="DENV" post="serotypes suppress RNAi in S2 and Aag2 cells. Fig."/>
   <result pre="R., Emerging flaviviruses: The spread and resurgence of Japanese encephalitis," exact="West Nile" post="and dengue viruses. Nat. Med.10, S98–S109 (2004).15577938 2XiaH., WangY.,"/>
   <result pre="4BaudD., GublerD. J., SchaubB., LanteriM. C., MussoD., An update on" exact="Zika" post="virus infection. Lancet390, 2099–2109 (2017).28647173 5DaepC. A., Muñoz-JordánJ. L.,"/>
   <result pre="Flaviviruses, an expanding threat in public health: Focus on dengue," exact="West Nile," post="and Japanese encephalitis virus. J. Neurovirol.20, 539–560 (2014).25287260 6PangX.,"/>
   <result pre="ManJ. H., LiX. F., CuiJ., XuZ., HuB., ZhouX., QinC. F.," exact="Zika" post="virus infection induces RNAi-mediated antiviral immunity in human neural"/>
   <result pre="J., SreenuV. B., MeritsA., MaringerK., SchnettlerE., KohlA., Characterization of the" exact="Zika" post="virus induced small RNA response in Aedes aegypti cells."/>
   <result pre="HartC. E., WidenS. G., WoodT. G., ThangamaniS., AsgariS., HughesG. L.," exact="Zika" post="virus alters the microRNA expression profile and elicits an"/>
   <result pre="WeaverS. C., WangT., RajsbaumR., ShiP.-Y., An evolutionary NS1 mutation enhances" exact="Zika" post="virus evasion of host interferon induction. Nat. Commun.9, 414"/>
   <result pre="A., KhromykhA. A., A single amino acid substitution in the" exact="West Nile" post="virus nonstructural protein NS2A disables its ability to inhibit"/>
   <result pre="XiaH., ShanC., ChenX., ShiP. Y., Genetic and biochemical characterizations of" exact="Zika" post="virus NS2A protein. Emerg. Microbes Infect.8, 585–602 (2019).30958095 32YoonK."/>
   <result pre="(2013).23741001 36SamuelG. H., WileyM. R., BadawiA., AdelmanZ. N., MylesK. M.," exact="Yellow fever" post="virus capsid protein is a potent suppressor of RNA"/>
   <result pre="Poole-SmithB. K., FranzA. W., Barbosa-SolomieuV., WiluszJ., OlsonK. E., BlairC. D.," exact="Dengue" post="virus type 2 infections of Aedes aegypti are modulated"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002310\results\search\tropicalVirus\results.xml">
   <result pre="rapid genomic surveillance data on-site during outbreaks of Ebola (1)," exact="Zika" post="(2), and Lassa (3) viruses. These studies relied on"/>
   <result pre="doi:10.1038/nature16996.26840485 2.FariaNR, SabinoEC, NunesMRT, AlcantaraLCJ, LomanNJ, PybusOG2016Mobile real-time surveillance of" exact="Zika" post="virus in Brazil. Genome Med8:97. doi:10.1186/s13073-016-0356-2.27683027 3.KafetzopoulouLE, PullanST, LemeyP,"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7002824\results\search\tropicalVirus\results.xml">
   <result pre="their possible molecular mechanisms against Influenza virus, HIV, Hepatitis virus," exact="Dengue" post="virus and Chikungunya virus. Microbiology; Pharmaceutical science; Health sciences;"/>
   <result pre="mechanisms against Influenza virus, HIV, Hepatitis virus, Dengue virus and" exact="Chikungunya" post="virus. Microbiology; Pharmaceutical science; Health sciences; Public health; Pharmacology;"/>
   <result pre="and pandemics worldwide (Table 1), like Swine Influenza, Avian Influenza," exact="Dengue" post="fever. Even though various types of treatment methods are"/>
   <result pre="&amp;amp;C Annually 1.4 million [83] HIV 1981–2018 32 million [84]" exact="Dengue" post="Annually 25,000 [85] Various natural compounds including herbal products"/>
   <result pre="Anti-dengue virus Coumarin has the potential to significantly suppress the" exact="Dengue" post="and chikungunya viral infections in vitro. However, the need"/>
   <result pre="and other effects on in vivo model [68]. Flaviviruses like" exact="Dengue" post="virus need their polyprotein processing by viral NS3 protease"/>
   <result pre="haplopin) were extracted and their inhibitory activities were checked against" exact="Dengue" post="infection. They exhibited weak anti-dengue activity when used separately,"/>
   <result pre="coumarin) against dengue viral infection were investigated. In case of" exact="Dengue" post="infection, a DNA binding protein namely, high mobility group"/>
   <result pre="from the seeds of Mammea americana and Tabernaemontana cymosa on" exact="Dengue" post="and Chikungunya virus infectionsBMC Complement Altern. Med.201711228049463 69ErbelP.SchieringN.ArcyA.D.RenatusM.KroemerM.LimS.P.YinZ.KellerT.H.VasudevanS.G.HommelU.Structural basis"/>
   <result pre="seeds of Mammea americana and Tabernaemontana cymosa on Dengue and" exact="Chikungunya" post="virus infectionsBMC Complement Altern. Med.201711228049463 69ErbelP.SchieringN.ArcyA.D.RenatusM.KroemerM.LimS.P.YinZ.KellerT.H.VasudevanS.G.HommelU.Structural basis for the"/>
   <result pre="for the activation of flaviviral NS3 proteases from dengue and" exact="West Nile" post="virusNat. Struct. Mol. Biol.13200620052006 70YusufzaiS.K.OsmanH.KhanM.S.RazikB.M.A.4 - thiazolidinone coumarin derivatives"/>
   <result pre="70YusufzaiS.K.OsmanH.KhanM.S.RazikB.M.A.4 - thiazolidinone coumarin derivatives as two - component NS2B/NS3" exact="DENV" post="flavivirus serine protease inhibitors: synthesis, molecular docking, biological evaluation"/>
   <result pre="dengue virus infectionNat. Publ. Gr.2017112 73RuJ.HuangW.LinS.TanK.European Journal of Medicinal Chemistry" exact="Chikungunya" post="virus inhibition by synthetic coumarin e guanosine conjugatesEur. J."/>
   <result pre="V. AIDS Statistics–2018 Fact Sheet2019UNAIDS 85World Health OrganizationGlobal Strategy for" exact="Dengue" post="Prevention and Control: 2012–20202018Avilable from:http://www.who.int/denguecontrol/9789241504034/en/Accessed, 18"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7003685\results\search\tropicalVirus\results.xml">
   <result pre="up essential move intend to shorten the spread of dengue." exact="Dengue" post="Epidemiological Manipur ELISA Funding Department of Health Research-Indian Council"/>
   <result pre="analysis, decision to publish, or preparation of the manuscript. Introduction" exact="Dengue" post="is a mosquito borne flavivirus belonging to the family"/>
   <result pre="no incidence of dengue (Fig. 1, Table 2). Figure 1" exact="Dengue" post="positive cases distribution month wise over a three year"/>
   <result pre="females (Anker &amp;amp; Arima, 2011; Arima, Chiew &amp;amp; Matsui, 2015)." exact="Dengue" post="infection was found in all the age groups in"/>
   <result pre="(2015), Paul et al. (2018) and Gupta et al. (2016)." exact="Dengue" post="infection is not age specific and not only children"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="2-part\PMC7004335\results\search\tropicalVirus\results.xml">
   <result pre="Organisms : Viruses : RNA viruses : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Microbial Pathogens : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Organisms : Viruses : Viral Pathogens : Togaviruses : Alphaviruses:" exact="Chikungunya" post="Virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Zika" post="Virus : Biology and life sciences : Organisms :"/>
   <result pre="sciences : Organisms : Viruses : RNA viruses : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Microbiology :"/>
   <result pre="Medical Microbiology : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Pathology and"/>
   <result pre=": Pathogens : Microbial Pathogens : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Biology and Life Sciences : Organisms :"/>
   <result pre="Sciences : Organisms : Viruses : Viral Pathogens : Flaviviruses:" exact="Dengue" post="Virus : Medicine and Health Sciences : Tropical Diseases"/>
   <result pre="and Health Sciences : Tropical Diseases : Neglected Tropical Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="Medicine and Health Sciences : Infectious Diseases : Viral Diseases:" exact="Chikungunya" post="Infection : Medicine and Health Sciences : Infectious Diseases"/>
   <result pre="published from January 2017 to March 2018. Interestingly, information on" exact="Zika" post="virus vector species composition was abundant, but sparse on"/>
   <result pre="Zika virus vector species composition was abundant, but sparse on" exact="Zika" post="virus transmission dynamics. Few studies examined natural infection rates"/>
   <result pre="virus transmission dynamics. Few studies examined natural infection rates of" exact="Zika" post="virus, vertical transmission, or co-infection with other viruses. This"/>
   <result pre="International Development Research Centre (IDRC)’s CIHR-IDRC Canada-Latin America and Caribbean" exact="Zika" post="Virus Research Program to the RADAM-LAC Research Team, and"/>
   <result pre="of the others. Since its identification in Uganda in 1947," exact="Zika" post="virus (Flavivirus, Flaviviridae) has been, until recently, confined only"/>
   <result pre="[2]. To date, 86 countries have reported evidence of mosquito-transmitted" exact="Zika" post="virus infection. [3] Brazil currently faces the greatest burden"/>
   <result pre="virus infection. [3] Brazil currently faces the greatest burden of" exact="Zika" post="virus infections [4]. Dengue fever, caused by four different"/>
   <result pre="currently faces the greatest burden of Zika virus infections [4]." exact="Dengue" post="fever, caused by four different serotypes of dengue virus"/>
   <result pre="year, and an estimated 22,000 die from severe dengue [5]." exact="Dengue" post="is hyperendemic in the Americas, with cyclic epidemics occurring"/>
   <result pre="with cyclic epidemics occurring every three to five years [6]." exact="Chikungunya" post="virus (Alphavirus, Togoviridae) was first isolated in Tanzania in"/>
   <result pre="children and/or older age groups at higher risk. Symptoms of" exact="Zika" post="viral infection include rash, fever, arthralgia, and conjunctivitis [11]."/>
   <result pre="[11]. More importantly, since its initial emergence in the Americas," exact="Zika" post="virus has been confirmed as a cause of congenital"/>
   <result pre="of congenital abnormalities (in infants born to women infected with" exact="Zika" post="virus during pregnancy) and as a trigger of Guillain-Barré"/>
   <result pre="et al. [17] conducted a comprehensive scoping review of the" exact="Zika" post="virus literature in 2016. However, the authors identified a"/>
   <result pre="of chikungunya in 2013. This timeframe includes the introduction of" exact="Zika" post="virus and the ongoing co-circulation of three globally spreading"/>
   <result pre="chikungunya virus spread to the Americas, followed in 2014 by" exact="Zika" post="virus. These years are thus characterized by co-circulation of"/>
   <result pre="were the most numerous, followed by studies focusing exclusively on" exact="Zika" post="virus, while studies focusing on chikungunya virus or on"/>
   <result pre="2018 (Fig 2), closely reflecting the introductions of chikungunya and" exact="Zika" post="viruses in the Americas and subsequent epidemics, respectively. Fig"/>
   <result pre="and Modelling 3 Laboratory and Modelling 1 Virus of interest" exact="Zika" post="30 Dengue 45 Chikungunya 10 Multiple 11 Mosquito species"/>
   <result pre="3 Laboratory and Modelling 1 Virus of interest Zika 30" exact="Dengue" post="45 Chikungunya 10 Multiple 11 Mosquito species of interest"/>
   <result pre="and Modelling 1 Virus of interest Zika 30 Dengue 45" exact="Chikungunya" post="10 Multiple 11 Mosquito species of interest Ae. aegypti"/>
   <result pre="quinquefasciatus 1 Others 12 None specifically 2 Vector species composition" exact="Zika" post="virus There is extensive evidence that Ae. aegypti mosquitoes"/>
   <result pre="extensive evidence that Ae. aegypti mosquitoes are able to transmit" exact="Zika" post="virus in both the laboratory [19–29] and in the"/>
   <result pre="field [30–32]. Ae. albopictus mosquitoes were also able to transmit" exact="Zika" post="virus in experimental studies [22,23], but studies in which"/>
   <result pre="both Ae. aegypti and Ae. albopictus were captured found no" exact="Zika" post="virus-infected Ae. albopictus [31,32]. Gendernalik et al. [33] and"/>
   <result pre="that Ae. vexans mosquitoes are also experimentally competent vectors of" exact="Zika" post="virus, but no studies indicated natural Ae. vexans infection"/>
   <result pre="virus, but no studies indicated natural Ae. vexans infection with" exact="Zika" post="virus. Cx. quinquefasciatus has been identified by predictive models"/>
   <result pre="been identified by predictive models as a potential vector for" exact="Zika" post="virus [34], as have Sabethes and Haemagogus spp. [35]."/>
   <result pre="Seven studies found that Cx. quinquefasciatus mosquitoes were refractory to" exact="Zika" post="virus when exposed to infectious blood meals [29,36–42]. Ferreira-de-Brito"/>
   <result pre="that no Cx. quinquefasciatus captured in Brazil were positive for" exact="Zika" post="virus. In contrast, Guedes et al. [43] detected Zika"/>
   <result pre="for Zika virus. In contrast, Guedes et al. [43] detected" exact="Zika" post="virus in the midgut, salivary glands and saliva of"/>
   <result pre="RT-PCR and transmission electron microscopy. The same study also reported" exact="Zika" post="virus isolated from two field-caught Cx. quinquefasciatus in Brazil."/>
   <result pre="Zika virus isolated from two field-caught Cx. quinquefasciatus in Brazil." exact="Dengue" post="virus Ae. albopictus [44–47] and Ae. aegypti [27,45,46,48–50] are"/>
   <result pre="latter was not identified as a competent vector species experimentally." exact="Chikungunya" post="virus Ae. aegypti [46,63–68], Ae. albopictus [46,64,66–69], Aedes terrens"/>
   <result pre="leucocelaenus [70] are all experimentally competent to transmit chikungunya virus." exact="Chikungunya" post="virus transmission in Ae. aegypti has also been observed"/>
   <result pre="Two studies conducted in Brazil exclusively examined infection rates by" exact="Zika" post="virus in wild mosquito populations (Table 2). Ferreira-de-Brito et"/>
   <result pre="species of interest. Authors Year Location Mosquito species Pools tested" exact="Zika" post="rate (%) Dengue rate (%) Chikungunya rate (%) Ferreira-de-Brito"/>
   <result pre="Authors Year Location Mosquito species Pools tested Zika rate (%)" exact="Dengue" post="rate (%) Chikungunya rate (%) Ferreira-de-Brito et al. 2016"/>
   <result pre="Mosquito species Pools tested Zika rate (%) Dengue rate (%)" exact="Chikungunya" post="rate (%) Ferreira-de-Brito et al. 2016 Brazil Aedes sp."/>
   <result pre="A study reported on the prevalence of both chikungunya and" exact="Zika" post="viruses among Ae. aegypti in Ecuador (Table 2) [30]."/>
   <result pre="[58,60,80], and one [81] reported on the vertical transmission of" exact="Zika" post="virus. Buckner et al. [80] found a vertical transmission"/>
   <result pre="in Argentina. Thangamani et al. [81] experimentally injected mosquitoes with" exact="Zika" post="virus and observed Zika virus infection in Ae. aegypti"/>
   <result pre="al. [81] experimentally injected mosquitoes with Zika virus and observed" exact="Zika" post="virus infection in Ae. aegypti offspring, but not Ae."/>
   <result pre="aegypti pools out of 69 tested were found positive for" exact="Zika" post="virus [81]. Transmission risk modelling Seven studies modelled transmission"/>
   <result pre="[81]. Transmission risk modelling Seven studies modelled transmission dynamics for" exact="Zika" post="virus [40,82–87]. Lourenço et al. [40] used vectorial capacity"/>
   <result pre="and precipitation were more conducive to Ae. aegypti presence and" exact="Zika" post="virus cases. Da Cruz Ferreira et al. [112] found"/>
   <result pre="laboratory-based or modelling-based study framework, and focused exclusively on either" exact="Zika" post="or dengue. One limitation of our study is the"/>
   <result pre="vector species in disease maintenance and/or transmission. Vector competence for" exact="Zika" post="virus has been well established for Ae. aegypti [19–32]"/>
   <result pre="a growing consensus that Cx. quinquefasciatus is not a competent" exact="Zika" post="virus vector, and no consensus has been reached regarding"/>
   <result pre="number of studies report that Cx. quinquefasciatus is refractory to" exact="Zika" post="virus [29,36–39,41,116]. While Zika virus has been detected in"/>
   <result pre="that Cx. quinquefasciatus is refractory to Zika virus [29,36–39,41,116]. While" exact="Zika" post="virus has been detected in a small number of"/>
   <result pre="indicate their ability to transmit the virus. Interestingly, information on" exact="Zika" post="virus vector species composition was abundant, but sparse on"/>
   <result pre="Zika virus vector species composition was abundant, but sparse on" exact="Zika" post="virus transmission dynamics. Few studies examined natural infection rates"/>
   <result pre="virus transmission dynamics. Few studies examined natural infection rates of" exact="Zika" post="virus [31,32], vertical transmission [81], or co-infection with other"/>
   <result pre="three viruses [46,50,58,77,80,101,102]. Based on the internationally recognized urgency of" exact="Zika" post="virus infection as a public health concern, and potential"/>
   <result pre="and other emerging arboviruses in the future, further research on" exact="Zika" post="virus transmission dynamics is of pressing need. Also, given"/>
   <result pre="Mauricio Espinel and Varsovia Cevallos. References References 1DickGWA, KitchenSF, HaddowAJ." exact="Zika" post="virus. I. Isolations and serological specificity. Trans R Soc"/>
   <result pre="for control. Antiviral Res. 2016;130: 69–80. 10.1016/j.antiviral.2016.03.01026996139 3World Health Organization." exact="Zika" post="virus. 2018. Available: https://www.who.int/news-room/fact-sheets/detail/zika-virus 4HillsSL, FischerM, PetersenLR. Epidemiology of"/>
   <result pre="Zika virus. 2018. Available: https://www.who.int/news-room/fact-sheets/detail/zika-virus 4HillsSL, FischerM, PetersenLR. Epidemiology of" exact="Zika" post="virus infection. J Infect Dis. 2017;216: S868–S874. 10.1093/infdis/jix43429267914 5KamgangB,"/>
   <result pre="2016;214: S441–S445. 10.1093/infdis/jiw39027920170 9Centre for Disease Control. Clinical Guidance |" exact="Dengue" post="| CDC. 2019. Available: https://www.cdc.gov/dengue/clinicallab/clinical.html 10NakkharaP, ChongsuvivatwongV, ThammapaloS. Risk"/>
   <result pre="2013;107: 789–796. 10.1093/trstmh/trt08324052594 11HabyMM, PinartM, EliasV, ReveizL. Prevalence of asymptomatic" exact="Zika" post="virus infection: a systematic review. Bull World Health Organ."/>
   <result pre="Trop Dis. 2015;9: e000338310.1371/journal.pntd.000338325569303 17WaddellLA, GreigJD. Scoping review of the" exact="Zika" post="virus literature. PloS One. 2016;11: e015637610.1371/journal.pone.015637627244249 18TriccoAC, LillieE, ZarinW,"/>
   <result pre="vector competency of Aedes albopictus populations from the Americas for" exact="Zika" post="virus. Am J Trop Med Hyg. 2017;97: 330–339. 10.4269/ajtmh.16-096928829735"/>
   <result pre="al.Correction: laboratory strains of Aedes aegypti are competent to Brazilian" exact="Zika" post="virus. PloS One. 2017;12: e017408110.1371/journal.pone.017408128288192 22Chouin-CarneiroT, Vega-RuaA, VazeilleM, YebakimaA,"/>
   <result pre="of Aedes aegypti and Aedes albopictus from the Americas to" exact="Zika" post="virus. PLoS Negl Trop Dis. 2016;10: e000454310.1371/journal.pntd.000454326938868 23CiotaAT, BialosukniaSM,"/>
   <result pre="e000454310.1371/journal.pntd.000454326938868 23CiotaAT, BialosukniaSM, ZinkSD, BrecherM, EhrbarDJ, MorrissetteMN, et al.Effects of" exact="Zika" post="virus strain and Aedes Mosquito species on vector competence."/>
   <result pre="10.3201/eid2307.16163328430564 24HuangY-JS, LyonsAC, HsuW-W, ParkSL, HiggsS, VanlandinghamDL. Differential outcomes of" exact="Zika" post="virus infection in Aedes aegypti orally challenged with infectious"/>
   <result pre="a northern population of Aedes vexans (Diptera: Culicidae) to transmit" exact="Zika" post="virus. J Med Entomol. 2017;54: 1354–1359. 10.1093/jme/tjx08728499036 26RoundyCM, AzarSR,"/>
   <result pre="LealG, YunR, et al.Variation in Aedes aegypti mosquito competence for" exact="Zika" post="virus transmission. Emerg Infect Dis. 2017;23: 625–632. 10.3201/eid2304.16148428287375 27RückertC,"/>
   <result pre="et al.Vector competence of American mosquitoes for three strains of" exact="Zika" post="virus. PLoS Negl Trop Dis. 2016;10: e000510110.1371/journal.pntd.000510127783679 30CevallosV, PonceP,"/>
   <result pre="et al.First detection of natural infection of Aedes aegypti with" exact="Zika" post="virus in Brazil and throughout South America. Mem Inst"/>
   <result pre="R deM, BrasilP, MoroneFC, CâmaraDCP, MeiraGLS, et al.Early evidence for" exact="Zika" post="virus circulation among Aedes aegypti mosquitoes, Rio de Janeiro,"/>
   <result pre="MurrietaRA, et al.American Aedes vexans mosquitoes are competent vectors of" exact="Zika" post="virus. Am J Trop Med Hyg. 2017;96: 1338–1340. 10.4269/ajtmh.16-096328719283"/>
   <result pre="10.4269/ajtmh.16-096328719283 34EvansMV, DallasTA, HanBA, MurdockCC, DrakeJM. Data-driven identification of potential" exact="Zika" post="virus vectors. eLife. 2017;610.7554/eLife.2205328244371 35AlthouseBM, VasilakisN, SallAA, DialloM, WeaverSC,"/>
   <result pre="eLife. 2017;610.7554/eLife.2205328244371 35AlthouseBM, VasilakisN, SallAA, DialloM, WeaverSC, HanleyKA. Potential for" exact="Zika" post="virus to establish a sylvatic transmission cycle in the"/>
   <result pre="from areas with the highest incidence of microcephaly associated with" exact="Zika" post="virus infections in the Northeast Region of Brazil are"/>
   <result pre="Rio de Janeiro is not competent to transmit the local" exact="Zika" post="virus. PLoS Negl Trop Dis. 2016;10: e000499310.1371/journal.pntd.000499327598421 38HartCE, RoundyCM,"/>
   <result pre="Culex quinquefasciatus and Culex pipiens pipiens from North America for" exact="Zika" post="virus. Am J Trop Med Hyg. 2017;96: 1235–1240. 10.4269/ajtmh.16-086528500817"/>
   <result pre="FariaNR, WalkerA, KraemerMU, Villabona-ArenasCJ, et al.Epidemiological and ecological determinants of" exact="Zika" post="virus transmission in an urban setting. eLife. 2017;610.7554/eLife.2982028887877 41DodsonBL,"/>
   <result pre="41DodsonBL, RasgonJL. Vector competence of Anopheles and Culex mosquitoes for" exact="Zika" post="virus. PeerJ. 2017;5: e309610.7717/peerj.309628316896 42AliotaMT, PeinadoSA, OsorioJE, BartholomayLC. Culex"/>
   <result pre="OsorioJE, BartholomayLC. Culex pipiens and Aedes triseriatus mosquito susceptibility to" exact="Zika" post="virus. Emerg Infect Dis. 2016;22: 1857–1859. 10.3201/eid2210.16108227434194 43GuedesDR, PaivaMH,"/>
   <result pre="LimaJBP, RoqueRA, de Souza SampaioV, CampolinaTB, et al.Transovarial transmission of" exact="DENV" post="in Aedes aegypti in the Amazon basin: a local"/>
   <result pre="e5993310.1371/journal.pone.005993323555838 77CecílioSG, JúniorWFS, TótolaAH, de Brito MagalhãesCL, FerreiraJMS, de MagalhãesJC." exact="Dengue" post="virus detection in Aedes aegypti larvae from southeastern Brazil."/>
   <result pre="Vector Ecol. 2015;40: 71–74. 10.1111/jvec.1213426047186 78Calderón-ArguedasO, TroyoA, Moreira-SotoRD, MarínR, TaylorL." exact="Dengue" post="viruses in Aedes albopictus Skuse from a pineapple plantation"/>
   <result pre="Florida. J Med Entomol. 2013;50: 1291–1297. 10.1603/me1304724843934 81ThangamaniS.Vertical transmission of" exact="Zika" post="virus in Aedes aegypti mosquitoes. Am J Trop Med"/>
   <result pre="2016;95: 1169–1173. 10.4269/ajtmh.16-044827573623 82MariniG, GuzzettaG, RosàR, MerlerS. First outbreak of" exact="Zika" post="virus in the continental United States: a modelling analysis."/>
   <result pre="near real-time estimation of transmission dynamics during the 2015–2016 Colombian" exact="Zika" post="virus disease outbreak. JMIR Public Health Surveill. 2016;2: e3010.2196/publichealth.581427251981"/>
   <result pre="MolinaA, RúaG, PájaroD, et al.Stratifying the potential local transmission of" exact="Zika" post="in municipalities of Antioquia, Colombia. Trop Med Int Health"/>
   <result pre="YangY, KenahE, QuinteroJ, TomasiS, et al.The epidemiology and transmissibility of" exact="Zika" post="virus in Girardot and San Andres island, Colombia, September"/>
   <result pre="An outbreak vector-host epidemic model with spatial structure: the 2015–2016" exact="Zika" post="outbreak in Rio De Janeiro. Theor Biol Med Model."/>
   <result pre="QuattrochiDA, et al.On the seasonal occurrence and abundance of the" exact="Zika" post="virus vector mosquito Aedes aegypti in the contiguous United"/>
   <result pre="PLoS Curr. 2016;810.1371/currents.outbreaks.50dfc7f46798675fc63e7d7da563da7627066299 111LoD, ParkB. Modeling the spread of the" exact="Zika" post="virus using topological data analysis. PloS One. 2018;13: e019212010.1371/journal.pone.019212029438377"/>
   <result pre="VarjakM, et al.Culex quinquefasciatus mosquitoes do not support replication of" exact="Zika" post="virus. J Gen Virol. 2018;99: 258–264. 10.1099/jgv.0.00094929076805"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
